ID   STK19_HUMAN             Reviewed;         368 AA.
AC   P49842; A6NF95; A6NFW8; B0QZR5; Q13159; Q31617; Q5JP77; Q5ST72; Q5ST75;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   18-OCT-2001, sequence version 2.
DT   02-DEC-2020, entry version 171.
DE   RecName: Full=Serine/threonine-protein kinase 19 {ECO:0000305};
DE            EC=2.7.11.1 {ECO:0000305|PubMed:9812991};
DE   AltName: Full=Protein G11 {ECO:0000303|PubMed:8012361};
DE   AltName: Full=Protein RP1 {ECO:0000303|PubMed:8132574};
GN   Name=STK19 {ECO:0000303|PubMed:30712867, ECO:0000312|HGNC:HGNC:11398};
GN   Synonyms=G11 {ECO:0000303|PubMed:8012361},
GN   RP1 {ECO:0000303|PubMed:8132574};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 3 AND 4), AND TISSUE
RP   SPECIFICITY.
RX   PubMed=8012361; DOI=10.1093/hmg/3.3.481;
RA   Sargent C.A., Anderson M.J., Hsieh S.-L., Kendall E., Gomez-Escobar N.,
RA   Campbell R.D.;
RT   "Characterisation of the novel gene G11 lying adjacent to the complement
RT   C4A gene in the human major histocompatibility complex.";
RL   Hum. Mol. Genet. 3:481-488(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 2).
RX   PubMed=8132574;
RA   Liming S., Wu L., Sanlioglu S., Chen R., Mendoza A.R., Dangel A.W.,
RA   Carroll M.C., Zipf W.B., Yu C.;
RT   "Structure and genetics of the partially duplicated gene RP located
RT   immediately upstream of the complement C4A and the C4B genes in the HLA
RT   class III region. Molecular cloning, exon-intron structure, composite
RT   retroposon, and breakpoint of gene duplication.";
RL   J. Biol. Chem. 269:8466-8476(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14656967; DOI=10.1101/gr.1736803;
RA   Xie T., Rowen L., Aguado B., Ahearn M.E., Madan A., Qin S., Campbell R.D.,
RA   Hood L.;
RT   "Analysis of the gene-dense major histocompatibility complex class III
RT   region and its comparison to mouse.";
RL   Genome Res. 13:2621-2636(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT GLY-311.
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   PARTIAL NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING
RP   (ISOFORM 4).
RC   TISSUE=Blood;
RX   PubMed=8575831; DOI=10.1007/bf00587313;
RA   Ulgiati D., Townend D.C., Christiansen F.T., Dawkins R.L., Abraham L.J.;
RT   "Complete sequence of the complement C4 gene from the HLA-A1, B8, C4AQ0,
RT   C4B1, DR3 haplotype.";
RL   Immunogenetics 43:250-252(1996).
RN   [7]
RP   COFACTOR, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-300; LYS-315 AND
RP   LYS-317.
RX   PubMed=9812991; DOI=10.1074/jbc.273.47.30954;
RA   Gomez-Escobar N., Chou C.-F., Lin W.-W., Hsieh S.-L., Campbell R.D.;
RT   "The G11 gene located in the major histocompatibility complex encodes a
RT   novel nuclear serine/threonine protein kinase.";
RL   J. Biol. Chem. 273:30954-30960(1998).
RN   [8]
RP   INTERACTION WITH BAG1.
RC   TISSUE=T-cell;
RX   PubMed=15986447; DOI=10.1002/ijc.21259;
RA   Wadle A., Mischo A., Henrich P.P., Stenner-Lieven F., Scherer C., Imig J.,
RA   Petersen G., Pfreundschuh M., Renner C.;
RT   "Characterization of Hap/BAG-1 variants as RP1 binding proteins with
RT   antiapoptotic activity.";
RL   Int. J. Cancer 117:896-904(2005).
RN   [9]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASN-89; GLY-311 AND VAL-331.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [10]
RP   VARIANT ASN-89, CHARACTERIZATION OF VARIANT ASN-89, FUNCTION, CATALYTIC
RP   ACTIVITY, ACTIVITY REGULATION, AND MUTAGENESIS OF VAL-134 AND LEU-139.
RX   PubMed=30712867; DOI=10.1016/j.cell.2019.01.002;
RA   Yin C., Zhu B., Zhang T., Liu T., Chen S., Liu Y., Li X., Miao X., Li S.,
RA   Mi X., Zhang J., Li L., Wei G., Xu Z.X., Gao X., Huang C., Wei Z.,
RA   Goding C.R., Wang P., Deng X., Cui R.;
RT   "Pharmacological targeting of STK19 inhibits oncogenic NRAS-driven
RT   melanomagenesis.";
RL   Cell 176:1113-1127(2019).
CC   -!- FUNCTION: Serine/threonine-protein kinase that acts as a key regulator
CC       of NRAS signaling by mediating phosphorylation of NRAS at 'Ser-89',
CC       thereby enhancing NRAS-binding to its downstream effectors.
CC       {ECO:0000269|PubMed:30712867}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:30712867, ECO:0000305|PubMed:9812991};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990;
CC         Evidence={ECO:0000269|PubMed:30712867, ECO:0000305|PubMed:9812991};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000305|PubMed:9812991};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609;
CC         Evidence={ECO:0000305|PubMed:9812991};
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000269|PubMed:9812991};
CC       Note=Divalent metal cations. Has a preference for Mn(2+).
CC       {ECO:0000269|PubMed:9812991};
CC   -!- ACTIVITY REGULATION: Specifically inhibited by ZT-12-037-01 (1a) (N2-
CC       cyclopropyl-N4-(1-isopropylpiperidin-4-yl)- 6,7-dimethoxyquinazoline-
CC       2,4-diamine) (PubMed:30712867). Inhibition by ZT-12-037-01 (1a) blocks
CC       oncogenic NRAS-driven melanocyte malignant transformation and melanoma
CC       growth (PubMed:30712867). {ECO:0000269|PubMed:30712867}.
CC   -!- SUBUNIT: Interacts (via N-terminus) with BAG1.
CC       {ECO:0000269|PubMed:15986447}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9812991}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=G11-Z;
CC         IsoId=P49842-1; Sequence=Displayed;
CC       Name=2; Synonyms=G11-Z-short;
CC         IsoId=P49842-2; Sequence=VSP_004433;
CC       Name=3; Synonyms=G11-Y {ECO:0000303|PubMed:8012361};
CC         IsoId=P49842-3; Sequence=VSP_004432;
CC       Name=4; Synonyms=G11-Y-short {ECO:0000303|PubMed:8012361};
CC         IsoId=P49842-4; Sequence=VSP_004432, VSP_004433;
CC   -!- TISSUE SPECIFICITY: Monocytes, hepatocytes, epithelial cells, T- and B-
CC       lymphocytes. {ECO:0000269|PubMed:8012361}.
CC   -!- DISEASE: Note=Gain-of-function variants in STK19 are involved in NRAS-
CC       driven melanomagenesis (PubMed:30712867). Melanoma are malignant
CC       neoplasm of melanocytes, arising de novo or from a pre-existing benign
CC       nevus, which occurs most often in the skin but also may involve other
CC       sites (PubMed:30712867). Conditional knockin mice overexpressing Asn-89
CC       variant exhibit hyperpigmentation of the skin, ears, and tail, and the
CC       melanin content in skin was significantly increased after tamoxifen
CC       induction (PubMed:30712867). Moreover, knockin mice overexpressing Asn-
CC       89 variant promote NRAS 'Arg-61'-driven melanomagenesis
CC       (PubMed:30712867). {ECO:0000269|PubMed:30712867}.
CC   -!- SIMILARITY: Belongs to the STK19 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X77474; CAA54622.1; -; Genomic_DNA.
DR   EMBL; X77489; CAA54622.1; JOINED; Genomic_DNA.
DR   EMBL; X77490; CAA54622.1; JOINED; Genomic_DNA.
DR   EMBL; X77491; CAA54622.1; JOINED; Genomic_DNA.
DR   EMBL; X77474; CAA54623.1; -; Genomic_DNA.
DR   EMBL; X77489; CAA54623.1; JOINED; Genomic_DNA.
DR   EMBL; X77490; CAA54623.1; JOINED; Genomic_DNA.
DR   EMBL; X77491; CAA54623.1; JOINED; Genomic_DNA.
DR   EMBL; X77386; CAA54565.1; -; mRNA.
DR   EMBL; L26261; AAA20120.1; -; Genomic_DNA.
DR   EMBL; L26260; AAA20122.1; -; mRNA.
DR   EMBL; AF019413; AAB67976.1; -; Genomic_DNA.
DR   EMBL; AL049547; CAB89303.1; -; Genomic_DNA.
DR   EMBL; AL049547; CAB89304.1; -; Genomic_DNA.
DR   EMBL; AL645922; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL662849; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL844853; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BX679671; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CR753822; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CR753845; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CR759782; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471081; EAX03566.1; -; Genomic_DNA.
DR   EMBL; CH471081; EAX03567.1; -; Genomic_DNA.
DR   EMBL; U24578; AAA99716.1; -; Genomic_DNA.
DR   CCDS; CCDS4733.1; -. [P49842-1]
DR   PIR; B53439; A53439.
DR   RefSeq; NP_004188.1; NM_004197.1. [P49842-4]
DR   RefSeq; NP_115830.1; NM_032454.1. [P49842-1]
DR   BioGRID; 114383; 15.
DR   IntAct; P49842; 7.
DR   STRING; 9606.ENSP00000364482; -.
DR   iPTMnet; P49842; -.
DR   PhosphoSitePlus; P49842; -.
DR   BioMuta; STK19; -.
DR   DMDM; 19860281; -.
DR   EPD; P49842; -.
DR   jPOST; P49842; -.
DR   MassIVE; P49842; -.
DR   MaxQB; P49842; -.
DR   PaxDb; P49842; -.
DR   PeptideAtlas; P49842; -.
DR   PRIDE; P49842; -.
DR   ProteomicsDB; 56153; -. [P49842-1]
DR   ProteomicsDB; 56154; -. [P49842-2]
DR   ProteomicsDB; 56155; -. [P49842-3]
DR   ProteomicsDB; 56156; -. [P49842-4]
DR   Antibodypedia; 28162; 190 antibodies.
DR   DNASU; 8859; -.
DR   Ensembl; ENST00000375331; ENSP00000364480; ENSG00000204344. [P49842-2]
DR   Ensembl; ENST00000375333; ENSP00000364482; ENSG00000204344. [P49842-1]
DR   Ensembl; ENST00000383327; ENSP00000372817; ENSG00000206342.
DR   Ensembl; ENST00000424104; ENSP00000393272; ENSG00000236250. [P49842-2]
DR   Ensembl; ENST00000425138; ENSP00000395028; ENSG00000234947. [P49842-2]
DR   Ensembl; ENST00000426802; ENSP00000389352; ENSG00000226257. [P49842-2]
DR   Ensembl; ENST00000431383; ENSP00000403479; ENSG00000226033. [P49842-1]
DR   Ensembl; ENST00000433397; ENSP00000395864; ENSG00000234947. [P49842-1]
DR   Ensembl; ENST00000438256; ENSP00000391798; ENSG00000236250. [P49842-1]
DR   Ensembl; ENST00000444147; ENSP00000399915; ENSG00000226033. [P49842-2]
DR   Ensembl; ENST00000452688; ENSP00000413766; ENSG00000226257. [P49842-1]
DR   GeneID; 8859; -.
DR   KEGG; hsa:8859; -.
DR   UCSC; uc003nyv.4; human. [P49842-1]
DR   CTD; 8859; -.
DR   DisGeNET; 8859; -.
DR   EuPathDB; HostDB:ENSG00000204344.14; -.
DR   GeneCards; STK19; -.
DR   HGNC; HGNC:11398; STK19.
DR   HPA; ENSG00000204344; Low tissue specificity.
DR   MIM; 604977; gene.
DR   neXtProt; NX_P49842; -.
DR   OpenTargets; ENSG00000204344; -.
DR   PharmGKB; PA36206; -.
DR   eggNOG; ENOG502RDW5; Eukaryota.
DR   GeneTree; ENSGT00390000018295; -.
DR   HOGENOM; CLU_064399_0_0_1; -.
DR   InParanoid; P49842; -.
DR   OMA; SQVKFHM; -.
DR   OrthoDB; 1329271at2759; -.
DR   PhylomeDB; P49842; -.
DR   TreeFam; TF105332; -.
DR   PathwayCommons; P49842; -.
DR   BioGRID-ORCS; 8859; 1 hit in 874 CRISPR screens.
DR   ChiTaRS; STK19; human.
DR   GeneWiki; STK19; -.
DR   GenomeRNAi; 8859; -.
DR   Pharos; P49842; Tbio.
DR   PRO; PR:P49842; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; P49842; protein.
DR   Bgee; ENSG00000204344; Expressed in left adrenal gland and 124 other tissues.
DR   ExpressionAtlas; P49842; baseline and differential.
DR   Genevisible; P49842; HS.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; TAS:ProtInc.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0017016; F:Ras GTPase binding; IPI:UniProtKB.
DR   GO; GO:0046579; P:positive regulation of Ras protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   InterPro; IPR018865; Ser/Thr_kinase_19.
DR   PANTHER; PTHR15243; PTHR15243; 1.
DR   Pfam; PF10494; Stk19; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Kinase; Manganese; Nucleotide-binding;
KW   Nucleus; Polymorphism; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase.
FT   CHAIN           1..368
FT                   /note="Serine/threonine-protein kinase 19"
FT                   /id="PRO_0000072275"
FT   VAR_SEQ         1..110
FT                   /note="Missing (in isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:8012361"
FT                   /id="VSP_004432"
FT   VAR_SEQ         222..225
FT                   /note="Missing (in isoform 2 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:8012361,
FT                   ECO:0000303|PubMed:8132574"
FT                   /id="VSP_004433"
FT   VARIANT         39
FT                   /note="A -> D (in dbSNP:rs34843142)"
FT                   /id="VAR_051387"
FT   VARIANT         89
FT                   /note="D -> N (recurrent gain-of-function variant found in
FT                   metastatic melanoma; promotes NRAS signaling; somatic
FT                   mutation; dbSNP:rs267600971)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:30712867"
FT                   /id="VAR_042361"
FT   VARIANT         311
FT                   /note="S -> G (in dbSNP:rs616634)"
FT                   /evidence="ECO:0000269|PubMed:14574404,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042362"
FT   VARIANT         331
FT                   /note="A -> V (in dbSNP:rs7743647)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042363"
FT   MUTAGEN         134
FT                   /note="V->Y: Prevents inhition by ZT-12-037-01 (1a) without
FT                   affecting much the serine/threonine-protein kinase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:30712867"
FT   MUTAGEN         139
FT                   /note="L->V: Prevents inhition by ZT-12-037-01 (1a) without
FT                   affecting much the serine/threonine-protein kinase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:30712867"
FT   MUTAGEN         300
FT                   /note="K->P: Partial loss of activity."
FT                   /evidence="ECO:0000269|PubMed:9812991"
FT   MUTAGEN         315
FT                   /note="K->P: Partial loss of activity."
FT                   /evidence="ECO:0000269|PubMed:9812991"
FT   MUTAGEN         317
FT                   /note="K->P: Complete loss of activity."
FT                   /evidence="ECO:0000269|PubMed:9812991"
FT   CONFLICT        195..197
FT                   /note="QGE -> GQR (in Ref. 6; AAA99716)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   368 AA;  40916 MW;  A05AC847081DE8F8 CRC64;
     MQKWFSAFDD AIIQRQWRAN PSRGGGGVSF TKEVDTNVAT GAPPRRQRVP GRACPWREPI
     RGRRGARPGG GDAGGTPGET VRHCSAPEDP IFRFSSLHSY PFPGTIKSRD MSWKRHHLIP
     ETFGVKRRRK RGPVESDPLR GEPGSARAAV SELMQLFPRG LFEDALPPIV LRSQVYSLVP
     DRTVADRQLK ELQEQGEIRI VQLGFDLDAH GIIFTEDYRT RVCDCVLKAC DGRPYAGAVQ
     KFLASVLPAC GDLSFQQDQM TQTFGFRDSE ITHLVNAGVL TVRDAGSWWL AVPGAGRFIK
     YFVKGRQAVL SMVRKAKYRE LLLSELLGRR APVVVRLGLT YHVHDLIGAQ LVDCISTTSG
     TLLRLPET
//
ID   TERT_HUMAN              Reviewed;        1132 AA.
AC   O14746; O14783; Q2XS35; Q8N6C3; Q8NG38; Q8NG46;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   02-DEC-2020, entry version 193.
DE   RecName: Full=Telomerase reverse transcriptase;
DE            EC=2.7.7.49 {ECO:0000269|PubMed:21602826, ECO:0000269|PubMed:29695869};
DE   AltName: Full=HEST2;
DE   AltName: Full=Telomerase catalytic subunit;
DE   AltName: Full=Telomerase-associated protein 2;
DE            Short=TP2;
GN   Name=TERT; Synonyms=EST2, TCS1, TRT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9288757; DOI=10.1016/s0092-8674(00)80538-3;
RA   Meyerson M., Counter C.M., Eaton E.N., Ellisen L.W., Steiner P.,
RA   Caddle S.D., Ziaugra L., Beijersbergen R.L., Davidoff M.J., Liu Q.,
RA   Bacchetti S., Haber D.A., Weinberg R.A.;
RT   "hEST2, the putative human telomerase catalytic subunit gene, is up-
RT   regulated in tumor cells and during immortalization.";
RL   Cell 90:785-795(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Embryonic kidney;
RX   PubMed=9252327; DOI=10.1126/science.277.5328.955;
RA   Nakamura T.M., Morin G.B., Chapman K.B., Weinrich S.L., Andrews W.H.,
RA   Lingner J., Harley C.B., Cech T.R.;
RT   "Telomerase catalytic subunit homologs from fission yeast and human.";
RL   Science 277:955-959(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10333526; DOI=10.1016/s0378-1119(99)00108-0;
RA   Wick M., Zubov D., Hagen G.;
RT   "Genomic organization and promoter characterization of the gene encoding
RT   the human telomerase reverse transcriptase (hTERT).";
RL   Gene 232:97-106(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=12869302; DOI=10.1016/s1476-5586(03)80051-9;
RA   Hisatomi H., Ohyashiki K., Ohyashiki J.H., Nagao K., Kanamaru T.,
RA   Hirata H., Hibi N., Tsukada Y.;
RT   "Expression profile of a gamma-deletion variant of the human telomerase
RT   reverse transcriptase gene.";
RL   Neoplasia 5:193-197(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 4).
RC   TISSUE=Stomach cancer;
RX   PubMed=14654914;
RA   Nagao K., Katsumata K., Aizawa Y., Saito N., Hirata H., Sasaki H.,
RA   Yamamoto S., Hikiji K., Koiwa T., Hisatomi H.;
RT   "Differential alternative splicing expressions of telomerase reverse
RT   transcriptase in gastrointestinal cell lines.";
RL   Oncol. Rep. 11:127-131(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Londono-Vallejo J.A.;
RT   "Sequence of a BAC carrying the entire hTERT gene.";
RL   Submitted (OCT-2001) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS TYR-412 AND THR-1062.
RG   NIEHS SNPs program;
RL   Submitted (OCT-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=8676067; DOI=10.1084/jem.183.6.2471;
RA   Weng N.P., Levine B.L., June C.H., Hodes R.J.;
RT   "Regulated expression of telomerase activity in human T lymphocyte
RT   development and activation.";
RL   J. Exp. Med. 183:2471-2479(1996).
RN   [11]
RP   FUNCTION IN TELOMERASE ACTIVITY, TISSUE SPECIFICITY, ASSOCIATION WITH TEP1,
RP   AND MUTAGENESIS OF ASP-712; ASP-868 AND ASP-869.
RX   PubMed=9389643; DOI=10.1101/gad.11.23.3109;
RA   Harrington L., Zhou W., McPhail T., Oulton R., Yeung D.S., Mar V.,
RA   Bass M.B., Robinson M.O.;
RT   "Human telomerase contains evolutionarily conserved catalytic and
RT   structural subunits.";
RL   Genes Dev. 11:3109-3115(1997).
RN   [12]
RP   RECONSTITUTION OF THE TELOMERASE COMPLEX, AND MUTAGENESIS OF ASP-712;
RP   ASP-868 AND ASP-869.
RX   PubMed=9443919; DOI=10.1016/s0960-9822(98)70067-3;
RA   Beattie T.L., Zhou W., Robinson M.O., Harrington L.;
RT   "Reconstitution of human telomerase activity in vitro.";
RL   Curr. Biol. 8:177-180(1998).
RN   [13]
RP   ASSOCIATION WITH TEP1.
RX   PubMed=11029039; DOI=10.1091/mbc.11.10.3329;
RA   Beattie T.L., Zhou W., Robinson M.O., Harrington L.;
RT   "Polymerization defects within human telomerase are distinct from
RT   telomerase RNA and TEP1 binding.";
RL   Mol. Biol. Cell 11:3329-3340(2000).
RN   [14]
RP   INTERACTION WITH HSPA1A; HSP90A AND PTGES3.
RX   PubMed=11274138; DOI=10.1074/jbc.c100055200;
RA   Forsythe H.L., Jarvis J.L., Turner J.W., Elmore L.W., Holt S.E.;
RT   "Stable association of hsp90 and p23, but Not hsp70, with active human
RT   telomerase.";
RL   J. Biol. Chem. 276:15571-15574(2001).
RN   [15]
RP   PHOSPHORYLATION AT TYR-707, SUBCELLULAR LOCATION, INTERACTION WITH RAN AND
RP   XP01, AND MUTAGENESIS OF TYR-707.
RX   PubMed=12808100; DOI=10.1128/mcb.23.13.4598-4610.2003;
RA   Haendeler J., Hoffmann J., Brandes R.P., Zeiher A.M., Dimmeler S.;
RT   "Hydrogen peroxide triggers nuclear export of telomerase reverse
RT   transcriptase via Src kinase family-dependent phosphorylation of tyrosine
RT   707.";
RL   Mol. Cell. Biol. 23:4598-4610(2003).
RN   [16]
RP   INTERACTION WITH MCRS1.
RX   PubMed=15044100; DOI=10.1016/j.bbrc.2004.02.166;
RA   Song H., Li Y., Chen G., Xing Z., Zhao J., Yokoyama K.K., Li T., Zhao M.;
RT   "Human MCRS2, a cell-cycle-dependent protein, associates with LPTS/PinX1
RT   and reduces the telomere length.";
RL   Biochem. Biophys. Res. Commun. 316:1116-1123(2004).
RN   [17]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=14963003; DOI=10.1161/01.res.0000121104.05977.f3;
RA   Haendeler J., Hoffmann J., Diehl J.F., Vasa M., Spyridopoulos I.,
RA   Zeiher A.M., Dimmeler S.;
RT   "Antioxidants inhibit nuclear export of telomerase reverse transcriptase
RT   and delay replicative senescence of endothelial cells.";
RL   Circ. Res. 94:768-775(2004).
RN   [18]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15138842; DOI=10.1007/s00418-004-0645-5;
RA   Yan P., Benhattar J., Seelentag W., Stehle J.C., Bosman F.T.;
RT   "Immunohistochemical localization of hTERT protein in human tissues.";
RL   Histochem. Cell Biol. 121:391-397(2004).
RN   [19]
RP   INTERACTION WITH NCL, AND SUBCELLULAR LOCATION.
RX   PubMed=15371412; DOI=10.1074/jbc.m407643200;
RA   Khurts S., Masutomi K., Delgermaa L., Arai K., Oishi N., Mizuno H.,
RA   Hayashi N., Hahn W.C., Murakami S.;
RT   "Nucleolin interacts with telomerase.";
RL   J. Biol. Chem. 279:51508-51515(2004).
RN   [20]
RP   FUNCTIONAL DOMAINS, AND MUTAGENESIS OF TRP-547 AND ASP-868.
RX   PubMed=15082768; DOI=10.1128/mcb.24.9.3720-3733.2004;
RA   Moriarty T.J., Marie-Egyptienne D.T., Autexier C.;
RT   "Functional organization of repeat addition processivity and DNA synthesis
RT   determinants in the human telomerase multimer.";
RL   Mol. Cell. Biol. 24:3720-3733(2004).
RN   [21]
RP   INTERACTION WITH MKRN1, AND UBIQUITINATION.
RX   PubMed=15805468; DOI=10.1101/gad.1289405;
RA   Kim J.H., Park S.-M., Kang M.R., Oh S.-Y., Lee T.H., Muller M.T.,
RA   Chung I.K.;
RT   "Ubiquitin ligase MKRN1 modulates telomere length homeostasis through a
RT   proteolysis of hTERT.";
RL   Genes Dev. 19:776-781(2005).
RN   [22]
RP   FUNCTION, AND MUTAGENESIS OF ASP-868.
RX   PubMed=15857955; DOI=10.1091/mbc.e05-02-0148;
RA   Moriarty T.J., Ward R.J., Taboski M.A., Autexier C.;
RT   "An anchor site-type defect in human telomerase that disrupts telomere
RT   length maintenance and cellular immortalization.";
RL   Mol. Biol. Cell 16:3152-3161(2005).
RN   [23]
RP   FUNCTION, AND MUTAGENESIS OF ARG-631; ASP-712 AND ASP-868.
RX   PubMed=17026956; DOI=10.1016/j.bbrc.2006.09.125;
RA   Rahman R., Mo L., Cui W.;
RT   "Telomerase with mutated catalytic motifs has dominant negative effects on
RT   telomerase activity and inhibits cell growth.";
RL   Biochem. Biophys. Res. Commun. 350:796-802(2006).
RN   [24]
RP   PHOSPHORYLATION, AND FUNCTION.
RX   PubMed=17548608; DOI=10.4049/jimmunol.178.12.7710;
RA   Plunkett F.J., Franzese O., Finney H.M., Fletcher J.M., Belaramani L.L.,
RA   Salmon M., Dokal I., Webster D., Lawson A.D., Akbar A.N.;
RT   "The loss of telomerase activity in highly differentiated CD8+CD28-CD27- T
RT   cells is associated with decreased Akt (Ser473) phosphorylation.";
RL   J. Immunol. 178:7710-7719(2007).
RN   [25]
RP   INTERACTION WITH NAT10.
RX   PubMed=18082603; DOI=10.1016/j.molcel.2007.09.023;
RA   Fu D., Collins K.;
RT   "Purification of human telomerase complexes identifies factors involved in
RT   telomerase biogenesis and telomere length regulation.";
RL   Mol. Cell 28:773-785(2007).
RN   [26]
RP   FUNCTION, DNA-BINDING, AND MUTAGENESIS OF 137-TRP--LEU-141; ASP-712 AND
RP   930-TRP--LEU-934.
RX   PubMed=17296728; DOI=10.1128/mcb.02368-06;
RA   Wyatt H.D., Lobb D.A., Beattie T.L.;
RT   "Characterization of physical and functional anchor site interactions in
RT   human telomerase.";
RL   Mol. Cell. Biol. 27:3226-3240(2007).
RN   [27]
RP   FUNCTION, AND MUTAGENESIS OF LEU-866 AND VAL-867.
RX   PubMed=17264120; DOI=10.1093/nar/gkm002;
RA   Drosopoulos W.C., Prasad V.R.;
RT   "The active site residue Valine 867 in human telomerase reverse
RT   transcriptase influences nucleotide incorporation and fidelity.";
RL   Nucleic Acids Res. 35:1155-1168(2007).
RN   [28]
RP   INTERACTION WITH PTPN11, PHOSPHORYLATION AT TYR-707, SUBCELLULAR LOCATION,
RP   AND MUTAGENESIS OF TYR-707.
RX   PubMed=18829466; DOI=10.1074/jbc.m805138200;
RA   Jakob S., Schroeder P., Lukosz M., Buchner N., Spyridopoulos I.,
RA   Altschmied J., Haendeler J.;
RT   "Nuclear protein tyrosine phosphatase Shp-2 is one important negative
RT   regulator of nuclear export of telomerase reverse transcriptase.";
RL   J. Biol. Chem. 283:33155-33161(2008).
RN   [29]
RP   PHOSPHORYLATION, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=19188162; DOI=10.1158/1078-0432.ccr-08-0792;
RA   Ram R., Uziel O., Eldan O., Fenig E., Beery E., Lichtenberg S.,
RA   Nordenberg Y., Lahav M.;
RT   "Ionizing radiation up-regulates telomerase activity in cancer cell lines
RT   by post-translational mechanism via ras/phosphatidylinositol 3-kinase/Akt
RT   pathway.";
RL   Clin. Cancer Res. 15:914-923(2009).
RN   [30]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PML.
RX   PubMed=19567472; DOI=10.1242/jcs.048066;
RA   Oh W., Ghim J., Lee E.W., Yang M.R., Kim E.T., Ahn J.H., Song J.;
RT   "PML-IV functions as a negative regulator of telomerase by interacting with
RT   TERT.";
RL   J. Cell Sci. 122:2613-2622(2009).
RN   [31]
RP   INTERACTION WITH SMARCA4, AND FUNCTION.
RX   PubMed=19571879; DOI=10.1038/nature08137;
RA   Park J.I., Venteicher A.S., Hong J.Y., Choi J., Jun S., Shkreli M.,
RA   Chang W., Meng Z., Cheung P., Ji H., McLaughlin M., Veenstra T.D.,
RA   Nusse R., McCrea P.D., Artandi S.E.;
RT   "Telomerase modulates Wnt signalling by association with target gene
RT   chromatin.";
RL   Nature 460:66-72(2009).
RN   [32]
RP   FUNCTION, DNA-BINDING, AND MUTAGENESIS OF GLN-169.
RX   PubMed=19777057; DOI=10.1371/journal.pone.0007176;
RA   Wyatt H.D., Tsang A.R., Lobb D.A., Beattie T.L.;
RT   "Human telomerase reverse transcriptase (hTERT) Q169 is essential for
RT   telomerase function in vitro and in vivo.";
RL   PLoS ONE 4:E7176-E7176(2009).
RN   [33]
RP   IDENTIFICATION IN THE TELOMERASE HOLOENZYME COMPLEX.
RX   PubMed=19179534; DOI=10.1126/science.1165357;
RA   Venteicher A.S., Abreu E.B., Meng Z., McCann K.E., Terns R.M.,
RA   Veenstra T.D., Terns M.P., Artandi S.E.;
RT   "A human telomerase holoenzyme protein required for Cajal body localization
RT   and telomere synthesis.";
RL   Science 323:644-648(2009).
RN   [34]
RP   IDENTIFICATION IN THE TELOMERASE HOLOENZYME COMPLEX.
RX   PubMed=20351177; DOI=10.1128/mcb.00151-10;
RA   Egan E.D., Collins K.;
RT   "Specificity and stoichiometry of subunit interactions in the human
RT   telomerase holoenzyme assembled in vivo.";
RL   Mol. Cell. Biol. 30:2775-2786(2010).
RN   [35]
RP   INTERACTION WITH DHX36.
RX   PubMed=21846770; DOI=10.1093/nar/gkr630;
RA   Lattmann S., Stadler M.B., Vaughn J.P., Akman S.A., Nagamine Y.;
RT   "The DEAH-box RNA helicase RHAU binds an intramolecular RNA G-quadruplex in
RT   TERC and associates with telomerase holoenzyme.";
RL   Nucleic Acids Res. 39:9390-9404(2011).
RN   [36]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH NVL.
RX   PubMed=22226966; DOI=10.1016/j.bbrc.2011.12.101;
RA   Her J., Chung I.K.;
RT   "The AAA-ATPase NVL2 is a telomerase component essential for holoenzyme
RT   assembly.";
RL   Biochem. Biophys. Res. Commun. 417:1086-1092(2012).
RN   [37]
RP   PHOSPHORYLATION AT SER-227, SUBCELLULAR LOCATION, AND NUCLEAR LOCALIZATION
RP   SIGNAL.
RX   PubMed=22366458; DOI=10.1242/jcs.099267;
RA   Chung J., Khadka P., Chung I.K.;
RT   "Nuclear import of hTERT requires a bipartite nuclear localization signal
RT   and Akt-mediated phosphorylation.";
RL   J. Cell Sci. 125:2684-2697(2012).
RN   [38]
RP   PHOSPHORYLATION AT SER-457, UBIQUITINATION, AND MUTAGENESIS OF SER-457.
RX   PubMed=23362280; DOI=10.1074/jbc.m112.416792;
RA   Jung H.Y., Wang X., Jun S., Park J.I.;
RT   "Dyrk2-associated EDD-DDB1-VprBP E3 ligase inhibits telomerase by TERT
RT   degradation.";
RL   J. Biol. Chem. 288:7252-7262(2013).
RN   [39]
RP   UBIQUITINATION.
RX   PubMed=23612978; DOI=10.1074/jbc.m112.416735;
RA   Wang X., Singh S., Jung H.Y., Yang G., Jun S., Sastry K.J., Park J.I.;
RT   "HIV-1 Vpr protein inhibits telomerase activity via the EDD-DDB1-VPRBP E3
RT   ligase complex.";
RL   J. Biol. Chem. 288:15474-15480(2013).
RN   [40]
RP   INVOLVEMENT IN CMM9.
RX   PubMed=23348503; DOI=10.1126/science.1230062;
RA   Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A.,
RA   Kadel S., Moll I., Nagore E., Hemminki K., Schadendorf D., Kumar R.;
RT   "TERT promoter mutations in familial and sporadic melanoma.";
RL   Science 339:959-961(2013).
RN   [41]
RP   INTERACTION WITH ATF7.
RX   PubMed=29490055; DOI=10.1093/nar/gky155;
RA   Maekawa T., Liu B., Nakai D., Yoshida K., Nakamura K.I., Yasukawa M.,
RA   Koike M., Takubo K., Chatton B., Ishikawa F., Masutomi K., Ishii S.;
RT   "ATF7 mediates TNF-alpha-induced telomere shortening.";
RL   Nucleic Acids Res. 46:4487-4504(2018).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 461-469 IN COMPLEX WITH CLASS I
RP   MAJOR HISTOCOMPATIBILITY COMPLEX (MHC).
RX   PubMed=16323248; DOI=10.1002/eji.200535424;
RA   Cole D.K., Rizkallah P.J., Gao F., Watson N.I., Boulter J.M., Bell J.I.,
RA   Sami M., Gao G.F., Jakobsen B.K.;
RT   "Crystal structure of HLA-A*2402 complexed with a telomerase peptide.";
RL   Eur. J. Immunol. 36:170-179(2006).
RN   [43]
RP   STRUCTURE BY ELECTRON MICROSCOPY (7.7 ANGSTROMS) OF THE TELOMERASE
RP   HOLOENZYME COMPLEX, AND CATALYTIC ACTIVITY.
RX   PubMed=29695869; DOI=10.1038/s41586-018-0062-x;
RA   Nguyen T.H.D., Tam J., Wu R.A., Greber B.J., Toso D., Nogales E.,
RA   Collins K.;
RT   "Cryo-EM structure of substrate-bound human telomerase holoenzyme.";
RL   Nature 557:190-195(2018).
RN   [44]
RP   VARIANT AA THR-202, VARIANTS DKCA2 TRP-979 AND LEU-1127, CHARACTERIZATION
RP   OF VARIANT AA THR-202, AND CHARACTERIZATION OF VARIANTS DKCA2 TRP-979 AND
RP   LEU-1127.
RX   PubMed=15885610; DOI=10.1016/j.bcmd.2004.12.008;
RA   Vulliamy T.J., Walne A., Baskaradas A., Mason P.J., Marrone A., Dokal I.;
RT   "Mutations in the reverse transcriptase component of telomerase (TERT) in
RT   patients with bone marrow failure.";
RL   Blood Cells Mol. Dis. 34:257-263(2005).
RN   [45]
RP   VARIANTS PFBMFT1 THR-202; TYR-412; MET-694; CYS-772 AND MET-1090, AND
RP   VARIANTS THR-279; GLU-441 DEL AND THR-1062.
RX   PubMed=15814878; DOI=10.1056/nejmoa042980;
RA   Yamaguchi H., Calado R.T., Ly H., Kajigaya S., Baerlocher G.M.,
RA   Chanock S.J., Lansdorp P.M., Young N.S.;
RT   "Mutations in TERT, the gene for telomerase reverse transcriptase, in
RT   aplastic anemia.";
RL   N. Engl. J. Med. 352:1413-1424(2005).
RN   [46]
RP   VARIANT DKCA2 ASN-902, AND CHARACTERIZATION OF VARIANT DKCA2 ASN-902.
RX   PubMed=16247010; DOI=10.1073/pnas.0508124102;
RA   Armanios M., Chen J.-L., Chang Y.-P.C., Brodsky R.A., Hawkins A.,
RA   Griffin C.A., Eshleman J.R., Cohen A.R., Chakravarti A., Hamosh A.,
RA   Greider C.W.;
RT   "Haploinsufficiency of telomerase reverse transcriptase leads to
RT   anticipation in autosomal dominant dyskeratosis congenita.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:15960-15964(2005).
RN   [47]
RP   INVOLVEMENT IN CAD SUSCEPTIBILITY.
RX   PubMed=16890917; DOI=10.1016/j.bbrc.2006.07.103;
RA   Matsubara Y., Murata M., Watanabe K., Saito I., Miyaki K., Omae K.,
RA   Ishikawa M., Matsushita K., Iwanaga S., Ogawa S., Ikeda Y.;
RT   "Coronary artery disease and a functional polymorphism of hTERT.";
RL   Biochem. Biophys. Res. Commun. 348:669-672(2006).
RN   [48]
RP   VARIANT DKCB4 ARG-721.
RX   PubMed=16332973; DOI=10.1182/blood-2005-07-2622;
RA   Vulliamy T.J., Marrone A., Knight S.W., Walne A., Mason P.J., Dokal I.;
RT   "Mutations in dyskeratosis congenita: their impact on telomere length and
RT   the diversity of clinical presentation.";
RL   Blood 107:2680-2685(2006).
RN   [49]
RP   VARIANTS AA ASP-682 AND MET-726, AND CHARACTERIZATION OF VARIANT AA
RP   MET-726.
RX   PubMed=16627250;
RA   Liang J., Yagasaki H., Kamachi Y., Hama A., Matsumoto K., Kato K., Kudo K.,
RA   Kojima S.;
RT   "Mutations in telomerase catalytic protein in Japanese children with
RT   aplastic anemia.";
RL   Haematologica 91:656-658(2006).
RN   [50]
RP   VARIANT AA ASN-570, AND CHARACTERIZATION OF VARIANTS ASN-570; ASP-682;
RP   ARG-721; MET-726; ASN-902; TRP-979 AND LEU-1127.
RX   PubMed=16990594; DOI=10.1182/blood-2006-07-035089;
RA   Xin Z.T., Beauchamp A.D., Calado R.T., Bradford J.W., Regal J.A.,
RA   Shenoy A., Liang Y., Lansdorp P.M., Young N.S., Ly H.;
RT   "Functional characterization of natural telomerase mutations found in
RT   patients with hematologic disorders.";
RL   Blood 109:524-532(2007).
RN   [51]
RP   VARIANTS DKCB4 CYS-811 AND TRP-901, AND CHARACTERIZATION OF VARIANTS DKCB4
RP   CYS-811 AND TRP-901.
RX   PubMed=17785587; DOI=10.1182/blood-2006-12-062851;
RA   Marrone A., Walne A., Tamary H., Masunari Y., Kirwan M., Beswick R.,
RA   Vulliamy T., Dokal I.;
RT   "Telomerase reverse-transcriptase homozygous mutations in autosomal
RT   recessive dyskeratosis congenita and Hoyeraal-Hreidarsson syndrome.";
RL   Blood 110:4198-4205(2007).
RN   [52]
RP   VARIANTS IDIOPATHIC PULMONARY FIBROSIS SUSCEPTIBILITY GLN-55 AND MET-1110,
RP   AND CHARACTERIZATION OF VARIANTS GLN-55 AND MET-1110.
RX   PubMed=17392301; DOI=10.1056/nejmoa066157;
RA   Armanios M.Y., Chen J.J., Cogan J.D., Alder J.K., Ingersoll R.G.,
RA   Markin C., Lawson W.E., Xie M., Vulto I., Phillips J.A., Lansdorp P.M.,
RA   Greider C.W., Loyd J.E.;
RT   "Telomerase mutations in families with idiopathic pulmonary fibrosis.";
RL   N. Engl. J. Med. 356:1317-1326(2007).
RN   [53]
RP   VARIANT PFBMFT1 HIS-865.
RX   PubMed=17460043; DOI=10.1073/pnas.0701009104;
RA   Tsakiri K.D., Cronkhite J.T., Kuan P.J., Xing C., Raghu G., Weissler J.C.,
RA   Rosenblatt R.L., Shay J.W., Garcia C.K.;
RT   "Adult-onset pulmonary fibrosis caused by mutations in telomerase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:7552-7557(2007).
RN   [54]
RP   VARIANTS DKCB4 TYR-412 AND SER-704, AND CHARACTERIZATION OF VARIANTS DKCB4
RP   TYR-412 AND SER-704.
RX   PubMed=18042801; DOI=10.1182/blood-2007-10-120907;
RA   Du H.Y., Pumbo E., Manley P., Field J.J., Bayliss S.J., Wilson D.B.,
RA   Mason P.J., Bessler M.;
RT   "Complex inheritance pattern of dyskeratosis congenita in two families with
RT   2 different mutations in the telomerase reverse transcriptase gene.";
RL   Blood 111:1128-1130(2008).
RN   [55]
RP   VARIANTS ALA-65; MET-299; LYS-522 AND THR-1062, AND VARIANTS AA THR-202;
RP   TYR-412; GLU-441 DEL; ASN-570; GLN-631; MET-694 AND LEU-785.
RX   PubMed=19760749; DOI=10.1002/humu.21115;
RA   Kirwan M., Vulliamy T., Marrone A., Walne A.J., Beswick R., Hillmen P.,
RA   Kelly R., Stewart A., Bowen D., Schonland S.O., Whittle A.M., McVerry A.,
RA   Gilleece M., Dokal I.;
RT   "Defining the pathogenic role of telomerase mutations in myelodysplastic
RT   syndrome and acute myeloid leukemia.";
RL   Hum. Mutat. 30:1567-1573(2009).
RN   [56]
RP   VARIANTS ALA-65; MET-299; TYR-412; GLU-441 DEL; LYS-522 AND THR-1062.
RX   PubMed=19147845; DOI=10.1073/pnas.0807057106;
RA   Calado R.T., Regal J.A., Hills M., Yewdell W.T., Dalmazzo L.F., Zago M.A.,
RA   Lansdorp P.M., Hogge D., Chanock S.J., Estey E.H., Falcao R.P., Young N.S.;
RT   "Constitutional hypomorphic telomerase mutations in patients with acute
RT   myeloid leukemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:1187-1192(2009).
RN   [57]
RP   VARIANTS PFBMFT1 MET-170; THR-716; PHE-841; ARG-902 AND PHE-1025, AND
RP   CHARACTERIZATION OF VARIANTS PFBMFT1 MET-170; THR-716; PHE-841 AND
RP   PHE-1025.
RX   PubMed=21436073; DOI=10.1182/blood-2010-11-322149;
RA   Parry E.M., Alder J.K., Qi X., Chen J.J., Armanios M.;
RT   "Syndrome complex of bone marrow failure and pulmonary fibrosis predicts
RT   germline defects in telomerase.";
RL   Blood 117:5607-5611(2011).
RN   [58]
RP   VARIANT DKCB4 SER-704, VARIANT DKCA2 TRP-979, CHARACTERIZATION OF VARIANT
RP   DKCB4 SER-704, CHARACTERIZATION OF VARIANT DKCA2 TRP-979, AND CATALYTIC
RP   ACTIVITY.
RX   PubMed=21602826; DOI=10.1038/nature10084;
RA   Batista L.F., Pech M.F., Zhong F.L., Nguyen H.N., Xie K.T., Zaug A.J.,
RA   Crary S.M., Choi J., Sebastiano V., Cherry A., Giri N., Wernig M.,
RA   Alter B.P., Cech T.R., Savage S.A., Reijo Pera R.A., Artandi S.E.;
RT   "Telomere shortening and loss of self-renewal in dyskeratosis congenita
RT   induced pluripotent stem cells.";
RL   Nature 474:399-402(2011).
RN   [59]
RP   VARIANTS PFBMFT1 ILE-791 AND MET-867, AND CHARACTERIZATION OF VARIANTS
RP   PFBMFT1 ILE-791 AND MET-867.
RX   PubMed=21483807; DOI=10.1371/journal.pgen.1001352;
RA   Alder J.K., Cogan J.D., Brown A.F., Anderson C.J., Lawson W.E.,
RA   Lansdorp P.M., Phillips J.A. III, Loyd J.E., Chen J.J., Armanios M.;
RT   "Ancestral mutation in telomerase causes defects in repeat addition
RT   processivity and manifests as familial pulmonary fibrosis.";
RL   PLoS Genet. 7:E1001352-E1001352(2011).
RN   [60]
RP   VARIANT PFBMFT1 LEU-923.
RX   PubMed=22512499; DOI=10.1056/nejmc1200999;
RA   Gansner J.M., Rosas I.O., Ebert B.L.;
RT   "Pulmonary fibrosis, bone marrow failure, and telomerase mutation.";
RL   N. Engl. J. Med. 366:1551-1553(2012).
CC   -!- FUNCTION: Telomerase is a ribonucleoprotein enzyme essential for the
CC       replication of chromosome termini in most eukaryotes. Active in
CC       progenitor and cancer cells. Inactive, or very low activity, in normal
CC       somatic cells. Catalytic component of the teleromerase holoenzyme
CC       complex whose main activity is the elongation of telomeres by acting as
CC       a reverse transcriptase that adds simple sequence repeats to chromosome
CC       ends by copying a template sequence within the RNA component of the
CC       enzyme. Catalyzes the RNA-dependent extension of 3'-chromosomal termini
CC       with the 6-nucleotide telomeric repeat unit, 5'-TTAGGG-3'. The
CC       catalytic cycle involves primer binding, primer extension and release
CC       of product once the template boundary has been reached or nascent
CC       product translocation followed by further extension. More active on
CC       substrates containing 2 or 3 telomeric repeats. Telomerase activity is
CC       regulated by a number of factors including telomerase complex-
CC       associated proteins, chaperones and polypeptide modifiers. Modulates
CC       Wnt signaling. Plays important roles in aging and antiapoptosis.
CC       {ECO:0000269|PubMed:14963003, ECO:0000269|PubMed:15082768,
CC       ECO:0000269|PubMed:15857955, ECO:0000269|PubMed:17026956,
CC       ECO:0000269|PubMed:17264120, ECO:0000269|PubMed:17296728,
CC       ECO:0000269|PubMed:17548608, ECO:0000269|PubMed:19188162,
CC       ECO:0000269|PubMed:19567472, ECO:0000269|PubMed:19571879,
CC       ECO:0000269|PubMed:19777057, ECO:0000269|PubMed:9389643}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 2'-deoxyribonucleoside 5'-triphosphate + DNA(n) =
CC         diphosphate + DNA(n+1); Xref=Rhea:RHEA:22508, Rhea:RHEA-COMP:11130,
CC         Rhea:RHEA-COMP:11131, ChEBI:CHEBI:33019, ChEBI:CHEBI:61560,
CC         ChEBI:CHEBI:83828; EC=2.7.7.49;
CC         Evidence={ECO:0000269|PubMed:21602826, ECO:0000269|PubMed:29695869};
CC   -!- SUBUNIT: Catalytic component of the telomerase holoenzyme complex
CC       composed of one molecule of TERT, one molecule of WRAP53/TCAB1, two
CC       molecules of H/ACA ribonucleoprotein complex subunits DKC1, NOP10, NHP2
CC       and GAR1, and a telomerase RNA template component (TERC)
CC       (PubMed:19179534, PubMed:20351177, PubMed:29695869). The telomerase
CC       holoenzyme complex is associated with TEP1, SMG6/EST1A and POT1
CC       (PubMed:19179534). The molecular chaperone HSP90/P23 complex is
CC       required for correct assembly and stabilization of the active
CC       telomerase (PubMed:11274138). Interacts directly with HSP90A and PTGES3
CC       (PubMed:11274138). Interacts with HSPA1A; the interaction occurs in the
CC       absence of TERC and dissociates once the complex has formed
CC       (PubMed:11274138). Interacts with RAN; the interaction promotes nuclear
CC       export of TERT (PubMed:12808100). Interacts with XPO1
CC       (PubMed:12808100). Interacts with PTPN11; the interaction retains TERT
CC       in the nucleus (PubMed:18829466). Interacts with NCL (via RRM1 and C-
CC       terminal RRM4/Arg/Gly-rich domains); the interaction is important for
CC       nucleolar localization of TERT (PubMed:15371412). Interacts with
CC       SMARCA4 (via the bromodomain); the interaction regulates Wnt-mediated
CC       signaling (By similarity). Interacts with MCRS1 (isoform MCRS2); the
CC       interaction inhibits in vitro telomerase activity (PubMed:15044100).
CC       Interacts with PIF1; the interaction has no effect on the elongation
CC       activity of TERT (By similarity). Interacts with PML; the interaction
CC       recruits TERT to PML bodies and inhibits telomerase activity
CC       (PubMed:19567472). Interacts with GNL3L (By similarity). Interacts with
CC       isoform 1 and isoform 2 of NVL (PubMed:22226966). Interacts with DHX36
CC       (PubMed:21846770). Interacts with ATF7 (PubMed:29490055).
CC       {ECO:0000250|UniProtKB:O70372, ECO:0000269|PubMed:11274138,
CC       ECO:0000269|PubMed:12808100, ECO:0000269|PubMed:15044100,
CC       ECO:0000269|PubMed:15371412, ECO:0000269|PubMed:18829466,
CC       ECO:0000269|PubMed:19179534, ECO:0000269|PubMed:19567472,
CC       ECO:0000269|PubMed:20351177, ECO:0000269|PubMed:21846770,
CC       ECO:0000269|PubMed:22226966, ECO:0000269|PubMed:29490055,
CC       ECO:0000269|PubMed:29695869}.
CC   -!- INTERACTION:
CC       O14746; P35222: CTNNB1; NbExp=2; IntAct=EBI-1772203, EBI-491549;
CC       O14746; Q9BVP2: GNL3; NbExp=3; IntAct=EBI-1772203, EBI-641642;
CC       O14746; P06748: NPM1; NbExp=5; IntAct=EBI-1772203, EBI-78579;
CC       O14746; Q96BK5: PINX1; NbExp=6; IntAct=EBI-1772203, EBI-721782;
CC       O14746; P29590-5: PML; NbExp=7; IntAct=EBI-1772203, EBI-304008;
CC       O14746; Q9Y265: RUVBL1; NbExp=11; IntAct=EBI-1772203, EBI-353675;
CC       O14746; P51532: SMARCA4; NbExp=8; IntAct=EBI-1772203, EBI-302489;
CC       O14746; O14746: TERT; NbExp=3; IntAct=EBI-1772203, EBI-1772203;
CC       O14746; O14773-1: TPP1; NbExp=2; IntAct=EBI-1772203, EBI-15619703;
CC       O14746; Q92900: UPF1; NbExp=3; IntAct=EBI-1772203, EBI-373471;
CC       O14746; P03126: E6; Xeno; NbExp=7; IntAct=EBI-1772203, EBI-1177242;
CC   -!- SUBCELLULAR LOCATION: Nucleus, nucleolus {ECO:0000269|PubMed:22226966}.
CC       Nucleus, nucleoplasm. Nucleus. Chromosome, telomere. Cytoplasm.
CC       Nucleus, PML body. Note=Shuttling between nuclear and cytoplasm depends
CC       on cell cycle, phosphorylation states, transformation and DNA damage.
CC       Diffuse localization in the nucleoplasm. Enriched in nucleoli of
CC       certain cell types. Translocated to the cytoplasm via nuclear pores in
CC       a CRM1/RAN-dependent manner involving oxidative stress-mediated
CC       phosphorylation at Tyr-707. Dephosphorylation at this site by SHP2
CC       retains TERT in the nucleus. Translocated to the nucleus by
CC       phosphorylation by AKT.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=O14746-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O14746-2; Sequence=VSP_019587, VSP_019588;
CC       Name=3;
CC         IsoId=O14746-3; Sequence=VSP_021727;
CC       Name=4;
CC         IsoId=O14746-4; Sequence=VSP_053369, VSP_019587, VSP_019588;
CC   -!- TISSUE SPECIFICITY: Expressed at a high level in thymocyte
CC       subpopulations, at an intermediate level in tonsil T-lymphocytes, and
CC       at a low to undetectable level in peripheral blood T-lymphocytes.
CC       {ECO:0000269|PubMed:8676067, ECO:0000269|PubMed:9389643}.
CC   -!- INDUCTION: Activated by cytotoxic events and down-regulated during
CC       aging. In peripheral T-lymphocytes, induced By CD3 and by
CC       PMA/ionomycin. Inhibited by herbimycin B. {ECO:0000269|PubMed:8676067}.
CC   -!- DOMAIN: The primer grip sequence in the RT domain is required for
CC       telomerase activity and for stable association with short telomeric
CC       primers.
CC   -!- DOMAIN: The RNA-interacting domain 1 (RD1)/N-terminal extension (NTE)
CC       is required for interaction with the pseudoknot-template domain of each
CC       of TERC dimers. It contains anchor sites that bind primer nucleotides
CC       upstream of the RNA-DNA hybrid and is thus an essential determinant of
CC       repeat addition processivity.
CC   -!- DOMAIN: The RNA-interacting domain 2 (RD2) is essential for both
CC       interaction with the CR4-CR5 domain of TERC and for DNA synthesis.
CC   -!- PTM: Phosphorylation at Tyr-707 under oxidative stress leads to
CC       translocation of TERT to the cytoplasm and reduces its antiapoptotic
CC       activity. Dephosphorylated by SHP2/PTPN11 leading to nuclear retention.
CC       Phosphorylation at Ser-227 by the AKT pathway promotes nuclear
CC       location. Phosphorylation at the G2/M phase at Ser-457 by DYRK2
CC       promotes ubiquitination by the EDVP complex and degradation.
CC       {ECO:0000269|PubMed:12808100, ECO:0000269|PubMed:18829466,
CC       ECO:0000269|PubMed:22366458, ECO:0000269|PubMed:23362280}.
CC   -!- PTM: Ubiquitinated by the EDVP complex, a E3 ligase complex following
CC       phosphorylation at Ser-457 by DYRK2. Ubiquitinated leads to proteasomal
CC       degradation. {ECO:0000269|PubMed:23362280}.
CC   -!- PTM: (Microbial infection) In case of infection by HIV-1, the EDVP
CC       complex is hijacked by HIV-1 via interaction between HIV-1 Vpr and
CC       DCAF1/VPRBP, leading to ubiquitination and degradation.
CC       {ECO:0000269|PubMed:23362280}.
CC   -!- DISEASE: Note=Activation of telomerase has been implicated in cell
CC       immortalization and cancer cell pathogenesis.
CC   -!- DISEASE: Aplastic anemia (AA) [MIM:609135]: A form of anemia in which
CC       the bone marrow fails to produce adequate numbers of peripheral blood
CC       elements. It is characterized by peripheral pancytopenia and marrow
CC       hypoplasia. {ECO:0000269|PubMed:15885610, ECO:0000269|PubMed:16627250,
CC       ECO:0000269|PubMed:16990594, ECO:0000269|PubMed:19760749}. Note=Disease
CC       susceptibility is associated with variations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Note=Genetic variations in TERT are associated with coronary
CC       artery disease (CAD).
CC   -!- DISEASE: Dyskeratosis congenita, autosomal dominant, 2 (DKCA2)
CC       [MIM:613989]: A rare multisystem disorder caused by defective telomere
CC       maintenance. It is characterized by progressive bone marrow failure,
CC       and the clinical triad of reticulated skin hyperpigmentation, nail
CC       dystrophy, and mucosal leukoplakia. Common but variable features
CC       include premature graying, aplastic anemia, low platelets,
CC       osteoporosis, pulmonary fibrosis, and liver fibrosis among others.
CC       Early mortality is often associated with bone marrow failure,
CC       infections, fatal pulmonary complications, or malignancy.
CC       {ECO:0000269|PubMed:15885610, ECO:0000269|PubMed:16247010,
CC       ECO:0000269|PubMed:21602826}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Pulmonary fibrosis, and/or bone marrow failure, telomere-
CC       related, 1 (PFBMFT1) [MIM:614742]: A disease associated with shortened
CC       telomeres. Pulmonary fibrosis is the most common manifestation. Other
CC       manifestations include aplastic anemia due to bone marrow failure,
CC       hepatic fibrosis, and increased cancer risk, particularly
CC       myelodysplastic syndrome and acute myeloid leukemia. Phenotype, age at
CC       onset, and severity are determined by telomere length.
CC       {ECO:0000269|PubMed:15814878, ECO:0000269|PubMed:17460043,
CC       ECO:0000269|PubMed:21436073, ECO:0000269|PubMed:21483807,
CC       ECO:0000269|PubMed:22512499}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Dyskeratosis congenita, autosomal recessive, 4 (DKCB4)
CC       [MIM:613989]: A severe form of dyskeratosis congenita, a rare
CC       multisystem disorder caused by defective telomere maintenance. It is
CC       characterized by progressive bone marrow failure, and the clinical
CC       triad of reticulated skin hyperpigmentation, nail dystrophy, and
CC       mucosal leukoplakia. Common but variable features include premature
CC       graying, aplastic anemia, low platelets, osteoporosis, pulmonary
CC       fibrosis, and liver fibrosis among others. Early mortality is often
CC       associated with bone marrow failure, infections, fatal pulmonary
CC       complications, or malignancy. {ECO:0000269|PubMed:16332973,
CC       ECO:0000269|PubMed:17785587, ECO:0000269|PubMed:18042801,
CC       ECO:0000269|PubMed:21602826}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Pulmonary fibrosis, idiopathic (IPF) [MIM:178500]: A lung
CC       disease characterized by shortness of breath, radiographically evident
CC       diffuse pulmonary infiltrates, and varying degrees of inflammation and
CC       fibrosis on biopsy. In some cases, the disorder can be rapidly
CC       progressive and characterized by sequential acute lung injury with
CC       subsequent scarring and end-stage lung disease. Note=Disease
CC       susceptibility is associated with variations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Melanoma, cutaneous malignant 9 (CMM9) [MIM:615134]: A
CC       malignant neoplasm of melanocytes, arising de novo or from a pre-
CC       existing benign nevus, which occurs most often in the skin but also may
CC       involve other sites. {ECO:0000269|PubMed:23348503}. Note=Disease
CC       susceptibility is associated with variations affecting the gene
CC       represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 3]: May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the reverse transcriptase family. Telomerase
CC       subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/tert/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF018167; AAC51724.1; -; mRNA.
DR   EMBL; AF015950; AAC51672.1; -; mRNA.
DR   EMBL; AF128894; AAD30037.1; -; Genomic_DNA.
DR   EMBL; AF128893; AAD30037.1; JOINED; Genomic_DNA.
DR   EMBL; AB085628; BAC11010.1; -; mRNA.
DR   EMBL; AB086379; BAC11014.1; -; mRNA.
DR   EMBL; AB086950; BAC11015.1; -; mRNA.
DR   EMBL; AY007685; AAG23289.1; -; Genomic_DNA.
DR   EMBL; DQ264729; ABB72674.1; -; Genomic_DNA.
DR   EMBL; AC114291; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471102; EAX08167.1; -; Genomic_DNA.
DR   CCDS; CCDS3861.2; -. [O14746-1]
DR   CCDS; CCDS54831.1; -. [O14746-3]
DR   PIR; T03844; T03844.
DR   RefSeq; NP_001180305.1; NM_001193376.1. [O14746-3]
DR   RefSeq; NP_937983.2; NM_198253.2. [O14746-1]
DR   PDB; 2BCK; X-ray; 2.80 A; C/F=461-469.
DR   PDB; 4B18; X-ray; 2.52 A; B=222-240.
DR   PDB; 4MNQ; X-ray; 2.74 A; C=540-548.
DR   PDB; 5MEN; X-ray; 2.81 A; C=540-548.
DR   PDB; 5MEO; X-ray; 1.77 A; C=540-548.
DR   PDB; 5MEP; X-ray; 2.71 A; C/F=540-548.
DR   PDB; 5MEQ; X-ray; 2.27 A; C=540-546.
DR   PDB; 5MER; X-ray; 1.88 A; C/F=540-546.
DR   PDB; 5UGW; X-ray; 2.31 A; A=961-1132.
DR   PDBsum; 2BCK; -.
DR   PDBsum; 4B18; -.
DR   PDBsum; 4MNQ; -.
DR   PDBsum; 5MEN; -.
DR   PDBsum; 5MEO; -.
DR   PDBsum; 5MEP; -.
DR   PDBsum; 5MEQ; -.
DR   PDBsum; 5MER; -.
DR   PDBsum; 5UGW; -.
DR   SMR; O14746; -.
DR   BioGRID; 112874; 98.
DR   ComplexPortal; CPX-17; Telomerase catalytic core complex.
DR   ComplexPortal; CPX-20; TERT-RMRP complex.
DR   ComplexPortal; CPX-265; Telomerase holoenzyme complex.
DR   CORUM; O14746; -.
DR   DIP; DIP-40646N; -.
DR   ELM; O14746; -.
DR   IntAct; O14746; 24.
DR   MINT; O14746; -.
DR   STRING; 9606.ENSP00000309572; -.
DR   BindingDB; O14746; -.
DR   ChEMBL; CHEMBL2916; -.
DR   DrugBank; DB05036; Grn163l.
DR   DrugBank; DB12747; Tertomotide.
DR   DrugBank; DB00495; Zidovudine.
DR   DrugCentral; O14746; -.
DR   iPTMnet; O14746; -.
DR   PhosphoSitePlus; O14746; -.
DR   BioMuta; TERT; -.
DR   EPD; O14746; -.
DR   MassIVE; O14746; -.
DR   PaxDb; O14746; -.
DR   PeptideAtlas; O14746; -.
DR   PRIDE; O14746; -.
DR   ProteomicsDB; 48203; -. [O14746-1]
DR   ProteomicsDB; 48204; -. [O14746-2]
DR   ProteomicsDB; 48205; -. [O14746-3]
DR   ProteomicsDB; 73418; -.
DR   ABCD; O14746; 9 sequenced antibodies.
DR   Antibodypedia; 8998; 949 antibodies.
DR   DNASU; 7015; -.
DR   Ensembl; ENST00000310581; ENSP00000309572; ENSG00000164362. [O14746-1]
DR   Ensembl; ENST00000334602; ENSP00000334346; ENSG00000164362. [O14746-3]
DR   Ensembl; ENST00000460137; ENSP00000425003; ENSG00000164362. [O14746-4]
DR   GeneID; 7015; -.
DR   KEGG; hsa:7015; -.
DR   UCSC; uc003jcb.2; human. [O14746-1]
DR   CTD; 7015; -.
DR   DisGeNET; 7015; -.
DR   EuPathDB; HostDB:ENSG00000164362.18; -.
DR   GeneCards; TERT; -.
DR   GeneReviews; TERT; -.
DR   HGNC; HGNC:11730; TERT.
DR   HPA; ENSG00000164362; Group enriched (bone marrow, lymphoid tissue, testis).
DR   MalaCards; TERT; -.
DR   MIM; 178500; phenotype.
DR   MIM; 187270; gene+phenotype.
DR   MIM; 609135; phenotype.
DR   MIM; 613989; phenotype.
DR   MIM; 614742; phenotype.
DR   MIM; 615134; phenotype.
DR   neXtProt; NX_O14746; -.
DR   OpenTargets; ENSG00000164362; -.
DR   Orphanet; 457246; Clear cell sarcoma of kidney.
DR   Orphanet; 146; Differentiated thyroid carcinoma.
DR   Orphanet; 1775; Dyskeratosis congenita.
DR   Orphanet; 618; Familial melanoma.
DR   Orphanet; 3322; Hoyeraal-Hreidarsson syndrome.
DR   Orphanet; 88; Idiopathic aplastic anemia.
DR   Orphanet; 2032; Idiopathic pulmonary fibrosis.
DR   Orphanet; 2495; Meningioma.
DR   PharmGKB; PA36447; -.
DR   eggNOG; KOG1005; Eukaryota.
DR   GeneTree; ENSGT00390000018531; -.
DR   HOGENOM; CLU_001996_2_0_1; -.
DR   InParanoid; O14746; -.
DR   OMA; HCAPHRV; -.
DR   OrthoDB; 1297956at2759; -.
DR   PhylomeDB; O14746; -.
DR   TreeFam; TF329048; -.
DR   PathwayCommons; O14746; -.
DR   Reactome; R-HSA-171319; Telomere Extension By Telomerase.
DR   Reactome; R-HSA-201722; Formation of the beta-catenin:TCF transactivating complex.
DR   SIGNOR; O14746; -.
DR   BioGRID-ORCS; 7015; 16 hits in 850 CRISPR screens.
DR   EvolutionaryTrace; O14746; -.
DR   GeneWiki; Telomerase_reverse_transcriptase; -.
DR   GenomeRNAi; 7015; -.
DR   Pharos; O14746; Tchem.
DR   PRO; PR:O14746; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; O14746; protein.
DR   Bgee; ENSG00000164362; Expressed in stromal cell of endometrium and 152 other tissues.
DR   Genevisible; O14746; HS.
DR   GO; GO:0000781; C:chromosome, telomeric region; IC:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0042645; C:mitochondrial nucleoid; IDA:BHF-UCL.
DR   GO; GO:0000784; C:nuclear chromosome, telomeric region; IDA:BHF-UCL.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0000783; C:nuclear telomere cap complex; IC:BHF-UCL.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IEA:Ensembl.
DR   GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell.
DR   GO; GO:0031379; C:RNA-directed RNA polymerase complex; IPI:BHF-UCL.
DR   GO; GO:0000333; C:telomerase catalytic core complex; IDA:BHF-UCL.
DR   GO; GO:0005697; C:telomerase holoenzyme complex; IDA:UniProtKB.
DR   GO; GO:1990572; C:TERT-RMRP complex; IDA:BHF-UCL.
DR   GO; GO:0051087; F:chaperone binding; IPI:BHF-UCL.
DR   GO; GO:0003677; F:DNA binding; IDA:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:BHF-UCL.
DR   GO; GO:0003723; F:RNA binding; IPI:BHF-UCL.
DR   GO; GO:0003968; F:RNA-directed 5'-3' RNA polymerase activity; IDA:BHF-UCL.
DR   GO; GO:0003964; F:RNA-directed DNA polymerase activity; IDA:BHF-UCL.
DR   GO; GO:0003720; F:telomerase activity; IDA:UniProtKB.
DR   GO; GO:0070034; F:telomerase RNA binding; IDA:BHF-UCL.
DR   GO; GO:0003721; F:telomerase RNA reverse transcriptase activity; IDA:BHF-UCL.
DR   GO; GO:0042162; F:telomeric DNA binding; IBA:GO_Central.
DR   GO; GO:0098680; F:template-free RNA nucleotidyltransferase; IDA:BHF-UCL.
DR   GO; GO:0001223; F:transcription coactivator binding; IPI:BHF-UCL.
DR   GO; GO:0000049; F:tRNA binding; IDA:BHF-UCL.
DR   GO; GO:1904837; P:beta-catenin-TCF complex assembly; TAS:Reactome.
DR   GO; GO:0071456; P:cellular response to hypoxia; IMP:BHF-UCL.
DR   GO; GO:0071897; P:DNA biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0022616; P:DNA strand elongation; IDA:BHF-UCL.
DR   GO; GO:0062103; P:double-stranded RNA biosynthetic process; IDA:ARUK-UCL.
DR   GO; GO:0070200; P:establishment of protein localization to telomere; IDA:BHF-UCL.
DR   GO; GO:0007005; P:mitochondrion organization; IDA:BHF-UCL.
DR   GO; GO:2000773; P:negative regulation of cellular senescence; IDA:BHF-UCL.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IEA:Ensembl.
DR   GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; IMP:BHF-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:BHF-UCL.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:1903799; P:negative regulation of production of miRNAs involved in gene silencing by miRNA; TAS:ARUK-UCL.
DR   GO; GO:1903704; P:negative regulation of production of siRNA involved in RNA interference; IDA:BHF-UCL.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:1900087; P:positive regulation of G1/S transition of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0046326; P:positive regulation of glucose import; IEA:Ensembl.
DR   GO; GO:0042635; P:positive regulation of hair cycle; ISS:BHF-UCL.
DR   GO; GO:0051000; P:positive regulation of nitric-oxide synthase activity; IDA:BHF-UCL.
DR   GO; GO:1902895; P:positive regulation of pri-miRNA transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:0032092; P:positive regulation of protein binding; IDA:BHF-UCL.
DR   GO; GO:1904751; P:positive regulation of protein localization to nucleolus; IDA:BHF-UCL.
DR   GO; GO:2000648; P:positive regulation of stem cell proliferation; ISS:BHF-UCL.
DR   GO; GO:1903620; P:positive regulation of transdifferentiation; IEA:Ensembl.
DR   GO; GO:1904754; P:positive regulation of vascular associated smooth muscle cell migration; IEA:Ensembl.
DR   GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0030177; P:positive regulation of Wnt signaling pathway; IGI:BHF-UCL.
DR   GO; GO:0030422; P:production of siRNA involved in RNA interference; IDA:BHF-UCL.
DR   GO; GO:0031647; P:regulation of protein stability; IDA:BHF-UCL.
DR   GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL.
DR   GO; GO:0046686; P:response to cadmium ion; IEA:Ensembl.
DR   GO; GO:0006278; P:RNA-dependent DNA biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0000723; P:telomere maintenance; TAS:UniProtKB.
DR   GO; GO:0007004; P:telomere maintenance via telomerase; IDA:UniProtKB.
DR   GO; GO:0001172; P:transcription, RNA-templated; IDA:BHF-UCL.
DR   InterPro; IPR043502; DNA/RNA_pol_sf.
DR   InterPro; IPR000477; RT_dom.
DR   InterPro; IPR021891; Telomerase_RBD.
DR   InterPro; IPR003545; Telomerase_RT.
DR   PANTHER; PTHR12066; PTHR12066; 1.
DR   Pfam; PF00078; RVT_1; 1.
DR   Pfam; PF12009; Telomerase_RBD; 1.
DR   PRINTS; PR01365; TELOMERASERT.
DR   SMART; SM00975; Telomerase_RBD; 1.
DR   SUPFAM; SSF56672; SSF56672; 1.
DR   PROSITE; PS50878; RT_POL; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Chromosome; Cytoplasm;
KW   Disease mutation; DNA-binding; Dyskeratosis congenita; Magnesium;
KW   Metal-binding; Nucleotidyltransferase; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Ribonucleoprotein;
KW   RNA-directed DNA polymerase; Telomere; Transferase; Ubl conjugation.
FT   CHAIN           1..1132
FT                   /note="Telomerase reverse transcriptase"
FT                   /id="PRO_0000054925"
FT   DOMAIN          605..935
FT                   /note="Reverse transcriptase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00405"
FT   REGION          1..230
FT                   /note="RNA-interacting domain 1"
FT   REGION          58..197
FT                   /note="GQ motif"
FT   REGION          137..141
FT                   /note="Required for regulating specificity for telomeric
FT                   DNA and for processivity for primer elongation"
FT   REGION          231..324
FT                   /note="Linker"
FT   REGION          301..538
FT                   /note="Required for oligomerization"
FT   REGION          325..550
FT                   /note="RNA-interacting domain 2"
FT   REGION          376..521
FT                   /note="QFP motif"
FT   REGION          397..417
FT                   /note="CP motif"
FT   REGION          914..928
FT                   /note="Required for oligomerization"
FT   REGION          930..934
FT                   /note="Primer grip sequence"
FT   REGION          936..1132
FT                   /note="CTE"
FT   MOTIF           222..240
FT                   /note="Bipartite nuclear localization signal"
FT   MOTIF           328..333
FT                   /note="TFLY; involved in RNA binding"
FT                   /evidence="ECO:0000250|UniProtKB:Q4KTA7"
FT   METAL           712
FT                   /note="Magnesium; catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00405"
FT   METAL           868
FT                   /note="Magnesium; catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00405"
FT   METAL           869
FT                   /note="Magnesium; catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00405"
FT   SITE            169
FT                   /note="Required for optimal binding of telomeric ssDNA and
FT                   incorporation of nucleotides at the second position of the
FT                   template"
FT   SITE            867
FT                   /note="Required for nucleotide incorporation and primer
FT                   extension rate"
FT   MOD_RES         227
FT                   /note="Phosphoserine; by PKB/AKT1"
FT                   /evidence="ECO:0000269|PubMed:22366458"
FT   MOD_RES         457
FT                   /note="Phosphoserine; by DYRK2"
FT                   /evidence="ECO:0000269|PubMed:23362280"
FT   MOD_RES         707
FT                   /note="Phosphotyrosine; by SRC-type Tyr-kinases"
FT                   /evidence="ECO:0000269|PubMed:12808100,
FT                   ECO:0000269|PubMed:18829466"
FT   VAR_SEQ         711..722
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14654914"
FT                   /id="VSP_053369"
FT   VAR_SEQ         764..807
FT                   /note="STLTDLQPYMRQFVAHLQETSPLRDAVVIEQSSSLNEASSGLFD -> LRPV
FT                   PGDPAGLHPLHAALQPVLRRHGEQAVCGDSAGRAAPAFGG (in isoform 2 and
FT                   isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:12869302,
FT                   ECO:0000303|PubMed:14654914"
FT                   /id="VSP_019587"
FT   VAR_SEQ         808..1132
FT                   /note="Missing (in isoform 2 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:12869302,
FT                   ECO:0000303|PubMed:14654914"
FT                   /id="VSP_019588"
FT   VAR_SEQ         885..947
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14654914"
FT                   /id="VSP_021727"
FT   VARIANT         55
FT                   /note="L -> Q (in idiopathic pulmonary fibrosis
FT                   susceptibility; impaired telomerase activity;
FT                   dbSNP:rs387907247)"
FT                   /evidence="ECO:0000269|PubMed:17392301"
FT                   /id="VAR_062535"
FT   VARIANT         65
FT                   /note="P -> A (associated with acute myeloid leukemia;
FT                   dbSNP:rs544215765)"
FT                   /evidence="ECO:0000269|PubMed:19147845,
FT                   ECO:0000269|PubMed:19760749"
FT                   /id="VAR_062780"
FT   VARIANT         170
FT                   /note="V -> M (in PFBMFT1; the mutant protein is
FT                   demonstrated to cause decreased telomerase activity;
FT                   dbSNP:rs387907248)"
FT                   /evidence="ECO:0000269|PubMed:21436073"
FT                   /id="VAR_068792"
FT   VARIANT         202
FT                   /note="A -> T (in PFBMFT1 and AA; severe and moderate;
FT                   associated with disease susceptibility; shorter telomeres;
FT                   dbSNP:rs121918661)"
FT                   /evidence="ECO:0000269|PubMed:15814878,
FT                   ECO:0000269|PubMed:15885610, ECO:0000269|PubMed:19760749"
FT                   /id="VAR_036863"
FT   VARIANT         279
FT                   /note="A -> T (in dbSNP:rs61748181)"
FT                   /evidence="ECO:0000269|PubMed:15814878"
FT                   /id="VAR_036864"
FT   VARIANT         299
FT                   /note="V -> M (associated with acute myeloid leukemia;
FT                   dbSNP:rs756624928)"
FT                   /evidence="ECO:0000269|PubMed:19147845,
FT                   ECO:0000269|PubMed:19760749"
FT                   /id="VAR_062781"
FT   VARIANT         412
FT                   /note="H -> Y (in PFBMFT1, AA and DKCB4; severe and
FT                   moderate; associated with susceptibility to acute
FT                   myelogenous leukemia; the mutant protein has 36% residual
FT                   activity; dbSNP:rs34094720)"
FT                   /evidence="ECO:0000269|PubMed:15814878,
FT                   ECO:0000269|PubMed:18042801, ECO:0000269|PubMed:19147845,
FT                   ECO:0000269|PubMed:19760749, ECO:0000269|Ref.7"
FT                   /id="VAR_025149"
FT   VARIANT         441
FT                   /note="Missing (in AA; associated with susceptibility to
FT                   acute myeloid leukemia)"
FT                   /evidence="ECO:0000269|PubMed:15814878,
FT                   ECO:0000269|PubMed:19147845, ECO:0000269|PubMed:19760749"
FT                   /id="VAR_036865"
FT   VARIANT         522
FT                   /note="R -> K (associated with acute myeloid leukemia)"
FT                   /evidence="ECO:0000269|PubMed:19147845,
FT                   ECO:0000269|PubMed:19760749"
FT                   /id="VAR_062782"
FT   VARIANT         570
FT                   /note="K -> N (in AA; abolishes telomerase catalytic
FT                   activity but no effect on binding to TERC)"
FT                   /evidence="ECO:0000269|PubMed:16990594,
FT                   ECO:0000269|PubMed:19760749"
FT                   /id="VAR_062536"
FT   VARIANT         631
FT                   /note="R -> Q (in AA; dbSNP:rs199422294)"
FT                   /evidence="ECO:0000269|PubMed:19760749"
FT                   /id="VAR_062783"
FT   VARIANT         682
FT                   /note="G -> D (in AA; non-severe; abolishes telomerase
FT                   catalytic activity but little effect on binding to TERC;
FT                   dbSNP:rs199422295)"
FT                   /evidence="ECO:0000269|PubMed:16627250,
FT                   ECO:0000269|PubMed:16990594"
FT                   /id="VAR_062537"
FT   VARIANT         694
FT                   /note="V -> M (in PFBMFT1 and AA; moderate;
FT                   dbSNP:rs121918662)"
FT                   /evidence="ECO:0000269|PubMed:15814878,
FT                   ECO:0000269|PubMed:19760749"
FT                   /id="VAR_036866"
FT   VARIANT         704
FT                   /note="P -> S (in DKCB4; the mutant protein has 13%
FT                   residual activity; dbSNP:rs199422297)"
FT                   /evidence="ECO:0000269|PubMed:18042801,
FT                   ECO:0000269|PubMed:21602826"
FT                   /id="VAR_068793"
FT   VARIANT         716
FT                   /note="A -> T (in PFBMFT1; the mutant protein is
FT                   demonstrated to cause severely compromised telomerase
FT                   activity; dbSNP:rs387907249)"
FT                   /evidence="ECO:0000269|PubMed:21436073"
FT                   /id="VAR_068794"
FT   VARIANT         721
FT                   /note="P -> R (in DKCB4; no effect on telomerase catalytic
FT                   activity and little effect on binding to TERC;
FT                   dbSNP:rs199422299)"
FT                   /evidence="ECO:0000269|PubMed:16332973,
FT                   ECO:0000269|PubMed:16990594"
FT                   /id="VAR_062538"
FT   VARIANT         726
FT                   /note="T -> M (in AA; very severe; no effect on telomerase
FT                   catalytic activity but shortened telomeres;
FT                   dbSNP:rs149566858)"
FT                   /evidence="ECO:0000269|PubMed:16627250,
FT                   ECO:0000269|PubMed:16990594"
FT                   /id="VAR_062539"
FT   VARIANT         772
FT                   /note="Y -> C (in PFBMFT1; moderate; dbSNP:rs121918663)"
FT                   /evidence="ECO:0000269|PubMed:15814878"
FT                   /id="VAR_036867"
FT   VARIANT         785
FT                   /note="P -> L (in AA; dbSNP:rs483352771)"
FT                   /evidence="ECO:0000269|PubMed:19760749"
FT                   /id="VAR_062784"
FT   VARIANT         791
FT                   /note="V -> I (in PFBMFT1; associated with Met-867 in cis
FT                   on the same allele; the double mutant shows severe defects
FT                   in telomere repeat addition processivity;
FT                   dbSNP:rs141425941)"
FT                   /evidence="ECO:0000269|PubMed:21483807"
FT                   /id="VAR_068795"
FT   VARIANT         811
FT                   /note="R -> C (in DKCB4; 50% reduction in telomerase
FT                   activity; dbSNP:rs199422301)"
FT                   /evidence="ECO:0000269|PubMed:17785587"
FT                   /id="VAR_062540"
FT   VARIANT         841
FT                   /note="L -> F (in PFBMFT1)"
FT                   /evidence="ECO:0000269|PubMed:21436073"
FT                   /id="VAR_068796"
FT   VARIANT         865
FT                   /note="R -> H (in PFBMFT1; dbSNP:rs121918666)"
FT                   /evidence="ECO:0000269|PubMed:17460043"
FT                   /id="VAR_036868"
FT   VARIANT         867
FT                   /note="V -> M (in PFBMFT1; associated with Ile-791 in cis
FT                   on the same allele; the double mutant shows severe defects
FT                   in telomere repeat addition processivity; this mutation
FT                   causes most if not all of the functional defects;
FT                   dbSNP:rs201159197)"
FT                   /evidence="ECO:0000269|PubMed:21483807"
FT                   /id="VAR_068797"
FT   VARIANT         901
FT                   /note="R -> W (in DKCB4; severe phenotype overlapping with
FT                   Hoyeraal-Hreidarsson syndrome; very short telomeres and
FT                   greatly reduced telomerase activity; dbSNP:rs199422304)"
FT                   /evidence="ECO:0000269|PubMed:17785587"
FT                   /id="VAR_062541"
FT   VARIANT         902
FT                   /note="K -> N (in DKCA2; abolishes telomerase catalytic
FT                   activity but no effect on binding to TERC;
FT                   dbSNP:rs121918665)"
FT                   /evidence="ECO:0000269|PubMed:16247010,
FT                   ECO:0000269|PubMed:16990594"
FT                   /id="VAR_036869"
FT   VARIANT         902
FT                   /note="K -> R (in PFBMFT1; dbSNP:rs387907250)"
FT                   /evidence="ECO:0000269|PubMed:21436073"
FT                   /id="VAR_068798"
FT   VARIANT         923
FT                   /note="P -> L (in PFBMFT1; dbSNP:rs387907251)"
FT                   /evidence="ECO:0000269|PubMed:22512499"
FT                   /id="VAR_068799"
FT   VARIANT         948
FT                   /note="S -> R (in dbSNP:rs34062885)"
FT                   /id="VAR_053726"
FT   VARIANT         979
FT                   /note="R -> W (in DKCA2; shortened telomeres but no effect
FT                   on telomerase catalytic activity nor on binding to TERC;
FT                   dbSNP:rs199422305)"
FT                   /evidence="ECO:0000269|PubMed:15885610,
FT                   ECO:0000269|PubMed:16990594, ECO:0000269|PubMed:21602826"
FT                   /id="VAR_062542"
FT   VARIANT         1025
FT                   /note="V -> F (in PFBMFT1)"
FT                   /evidence="ECO:0000269|PubMed:21436073"
FT                   /id="VAR_068800"
FT   VARIANT         1062
FT                   /note="A -> T (increased incidence in sporadic acute
FT                   myeloid leukemia; dbSNP:rs35719940)"
FT                   /evidence="ECO:0000269|PubMed:15814878,
FT                   ECO:0000269|PubMed:19147845, ECO:0000269|PubMed:19760749,
FT                   ECO:0000269|Ref.7"
FT                   /id="VAR_025150"
FT   VARIANT         1090
FT                   /note="V -> M (in PFBMFT1; severe; dbSNP:rs121918664)"
FT                   /evidence="ECO:0000269|PubMed:15814878"
FT                   /id="VAR_036870"
FT   VARIANT         1110
FT                   /note="T -> M (in idiopathic pulmonary fibrosis
FT                   susceptibility; impaired telomerase activity;
FT                   dbSNP:rs199422306)"
FT                   /evidence="ECO:0000269|PubMed:17392301"
FT                   /id="VAR_062543"
FT   VARIANT         1127
FT                   /note="F -> L (in DKCA2; severe; shortened telomeres but no
FT                   effect on telomerase catalytic activity nor on binding to
FT                   TERC; dbSNP:rs1176273130)"
FT                   /evidence="ECO:0000269|PubMed:15885610,
FT                   ECO:0000269|PubMed:16990594"
FT                   /id="VAR_062544"
FT   MUTAGEN         137..141
FT                   /note="WGLLL->AAAAA: Reduced catalytic activity and repeat
FT                   addition processivity. Complete loss of catalytic activity
FT                   but no loss of binding to telomeric primers; when
FT                   associated with 930-A--A-934."
FT                   /evidence="ECO:0000269|PubMed:17296728"
FT   MUTAGEN         169
FT                   /note="Q->A: About 80% loss of enzymatic activity. Greatly
FT                   reduced incorporation of second nucleotide. Altered
FT                   strength of binding to ssDNA. Little effect on repeat
FT                   addition processivity, nor on TR interaction nor on protein
FT                   levels."
FT                   /evidence="ECO:0000269|PubMed:19777057"
FT   MUTAGEN         169
FT                   /note="Q->N: About 85% loss of enzymatic activity. Greatly
FT                   reduced incorporation of second nucleotide. Altered
FT                   strength of binding to ssDNA. No effect on protein levels
FT                   nor on TR interaction."
FT                   /evidence="ECO:0000269|PubMed:19777057"
FT   MUTAGEN         169
FT                   /note="Q->T: About 90% loss of enzymatic activity. Greatly
FT                   reduced incorporation of second nucleotide. Altered
FT                   strength of binding to ssDNA. No effect on protein levels
FT                   nor on TR interaction."
FT                   /evidence="ECO:0000269|PubMed:19777057"
FT   MUTAGEN         457
FT                   /note="S->A: Abolishes phosphorylation by DYRK2."
FT                   /evidence="ECO:0000269|PubMed:23362280"
FT   MUTAGEN         547
FT                   /note="W->A: Defective in high-affinity TERC interactions."
FT                   /evidence="ECO:0000269|PubMed:15082768"
FT   MUTAGEN         631
FT                   /note="R->A: Abolishes telomerase catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:17026956"
FT   MUTAGEN         707
FT                   /note="Y->F: Abolishes oxidative stress-induced
FT                   phosphorylation and RAN binding. Impaired nuclear export
FT                   and enhanced antiapoptotic activity against ROS-dependent
FT                   apoptosis induction. Impaired interaction with PTPN11. No
FT                   dephosphorylation by PTPN11."
FT                   /evidence="ECO:0000269|PubMed:12808100,
FT                   ECO:0000269|PubMed:18829466"
FT   MUTAGEN         712
FT                   /note="D->A: Loss of telomerase activity. In the absence of
FT                   TR, no loss of binding to telomeric primers."
FT                   /evidence="ECO:0000269|PubMed:17026956,
FT                   ECO:0000269|PubMed:17296728, ECO:0000269|PubMed:9389643,
FT                   ECO:0000269|PubMed:9443919"
FT   MUTAGEN         866
FT                   /note="L->Y: Moderate reduction in telomerase activity, no
FT                   change in repeat extension rate nor on nucleotide
FT                   incorporation fidelity. Little further reduction in
FT                   activity but 13.5-fold increase in nucleotide incorporation
FT                   fidelity; when associated with M-867."
FT                   /evidence="ECO:0000269|PubMed:17264120"
FT   MUTAGEN         867
FT                   /note="V->A: About 75% reduction in telomerase activity,
FT                   about 80% reduction in repeat reduction rate and 3.9-fold
FT                   increase in nucleotide incorporation fidelity."
FT                   /evidence="ECO:0000269|PubMed:17264120"
FT   MUTAGEN         867
FT                   /note="V->M: About 75% reduction in telomerase activity,
FT                   about 50% reduction in repeat extension rate and 5.2-fold
FT                   increase in nucleotide incorporation fidelity. Little
FT                   further reduction in activity and 13.5-fold increase in
FT                   nucleotide incorporation fidelity; when associated with Y-
FT                   866."
FT                   /evidence="ECO:0000269|PubMed:17264120"
FT   MUTAGEN         867
FT                   /note="V->T: Severe reduction in telomerase activity, about
FT                   50% reduction in repeat extension rate and 2.2-fold
FT                   increase in nucleotide incorporation fidelity. No further
FT                   reduction in activity but 2.8-fold increase in nucleotide
FT                   incorporation fidelity; when associated with Y-866."
FT                   /evidence="ECO:0000269|PubMed:17264120"
FT   MUTAGEN         868..869
FT                   /note="DD->AA: Loss of telomerase activity."
FT   MUTAGEN         868
FT                   /note="D->A: Loss of telomerase activity."
FT                   /evidence="ECO:0000269|PubMed:15082768,
FT                   ECO:0000269|PubMed:15857955, ECO:0000269|PubMed:17026956,
FT                   ECO:0000269|PubMed:9389643, ECO:0000269|PubMed:9443919"
FT   MUTAGEN         869
FT                   /note="D->A: Loss of telomerase activity."
FT                   /evidence="ECO:0000269|PubMed:9389643,
FT                   ECO:0000269|PubMed:9443919"
FT   MUTAGEN         930..934
FT                   /note="WCGLL->AAAAA: Completely abolishes telomerase-
FT                   mediated primer extension and reduced binding to short
FT                   telomeric primers. Complete loss of catalytic activity but
FT                   no further loss of binding to telomeric primers; when
FT                   associated with 137-A--A-141."
FT                   /evidence="ECO:0000269|PubMed:17296728"
FT   CONFLICT        516
FT                   /note="D -> G (in Ref. 1; AAC51724)"
FT                   /evidence="ECO:0000305"
FT   HELIX           966..983
FT                   /evidence="ECO:0000244|PDB:5UGW"
FT   HELIX           984..986
FT                   /evidence="ECO:0000244|PDB:5UGW"
FT   TURN            989..991
FT                   /evidence="ECO:0000244|PDB:5UGW"
FT   HELIX           994..1017
FT                   /evidence="ECO:0000244|PDB:5UGW"
FT   HELIX           1025..1027
FT                   /evidence="ECO:0000244|PDB:5UGW"
FT   HELIX           1029..1050
FT                   /evidence="ECO:0000244|PDB:5UGW"
FT   TURN            1051..1053
FT                   /evidence="ECO:0000244|PDB:5UGW"
FT   HELIX           1067..1082
FT                   /evidence="ECO:0000244|PDB:5UGW"
FT   HELIX           1083..1085
FT                   /evidence="ECO:0000244|PDB:5UGW"
FT   HELIX           1086..1104
FT                   /evidence="ECO:0000244|PDB:5UGW"
FT   HELIX           1111..1118
FT                   /evidence="ECO:0000244|PDB:5UGW"
SQ   SEQUENCE   1132 AA;  126997 MW;  94E35469C4CA33A0 CRC64;
     MPRAPRCRAV RSLLRSHYRE VLPLATFVRR LGPQGWRLVQ RGDPAAFRAL VAQCLVCVPW
     DARPPPAAPS FRQVSCLKEL VARVLQRLCE RGAKNVLAFG FALLDGARGG PPEAFTTSVR
     SYLPNTVTDA LRGSGAWGLL LRRVGDDVLV HLLARCALFV LVAPSCAYQV CGPPLYQLGA
     ATQARPPPHA SGPRRRLGCE RAWNHSVREA GVPLGLPAPG ARRRGGSASR SLPLPKRPRR
     GAAPEPERTP VGQGSWAHPG RTRGPSDRGF CVVSPARPAE EATSLEGALS GTRHSHPSVG
     RQHHAGPPST SRPPRPWDTP CPPVYAETKH FLYSSGDKEQ LRPSFLLSSL RPSLTGARRL
     VETIFLGSRP WMPGTPRRLP RLPQRYWQMR PLFLELLGNH AQCPYGVLLK THCPLRAAVT
     PAAGVCAREK PQGSVAAPEE EDTDPRRLVQ LLRQHSSPWQ VYGFVRACLR RLVPPGLWGS
     RHNERRFLRN TKKFISLGKH AKLSLQELTW KMSVRDCAWL RRSPGVGCVP AAEHRLREEI
     LAKFLHWLMS VYVVELLRSF FYVTETTFQK NRLFFYRKSV WSKLQSIGIR QHLKRVQLRE
     LSEAEVRQHR EARPALLTSR LRFIPKPDGL RPIVNMDYVV GARTFRREKR AERLTSRVKA
     LFSVLNYERA RRPGLLGASV LGLDDIHRAW RTFVLRVRAQ DPPPELYFVK VDVTGAYDTI
     PQDRLTEVIA SIIKPQNTYC VRRYAVVQKA AHGHVRKAFK SHVSTLTDLQ PYMRQFVAHL
     QETSPLRDAV VIEQSSSLNE ASSGLFDVFL RFMCHHAVRI RGKSYVQCQG IPQGSILSTL
     LCSLCYGDME NKLFAGIRRD GLLLRLVDDF LLVTPHLTHA KTFLRTLVRG VPEYGCVVNL
     RKTVVNFPVE DEALGGTAFV QMPAHGLFPW CGLLLDTRTL EVQSDYSSYA RTSIRASLTF
     NRGFKAGRNM RRKLFGVLRL KCHSLFLDLQ VNSLQTVCTN IYKILLLQAY RFHACVLQLP
     FHQQVWKNPT FFLRVISDTA SLCYSILKAK NAGMSLGAKG AAGPLPSEAV QWLCHQAFLL
     KLTRHRVTYV PLLGSLRTAQ TQLSRKLPGT TLTALEAAAN PALPSDFKTI LD
//
ID   TRRAP_HUMAN             Reviewed;        3859 AA.
AC   Q9Y4A5; A4D265; O75218; Q9Y631; Q9Y6H4;
DT   28-NOV-2003, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 3.
DT   02-DEC-2020, entry version 202.
DE   RecName: Full=Transformation/transcription domain-associated protein;
DE   AltName: Full=350/400 kDa PCAF-associated factor;
DE            Short=PAF350/400;
DE   AltName: Full=STAF40;
DE   AltName: Full=Tra1 homolog;
GN   Name=TRRAP; Synonyms=PAF400;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), PARTIAL PROTEIN SEQUENCE, FUNCTION,
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH MYC AND E2F1.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=9708738; DOI=10.1016/s0092-8674(00)81479-8;
RA   McMahon S.B., Van Buskirk H.A., Dugan K.A., Copeland T.D., Cole M.D.;
RT   "The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc
RT   and E2F oncoproteins.";
RL   Cell 94:363-374(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 41-90; 337-344;
RP   369-387; 879-892; 997-1005; 1171-1184; 1237-1247; 1545-1560; 1815-1820;
RP   1922-1934; 2211-2218; 2260-2275; 2534-2547; 2583-2594; 2706-2726;
RP   2830-2844; 3567-3573; 3583-3598; 3604-3614; 3712-3730 AND 3822-3834, AND
RP   IDENTIFICATION IN THE PCAF COMPLEX WITH TADA2L; TADA3L; TAF5L; TAF6L;
RP   TAF10; SUPT3H; TAF12 AND TAF9.
RC   TISSUE=Fetal heart;
RX   PubMed=9885574; DOI=10.1016/s1097-2765(00)80301-9;
RA   Vassilev A., Yamauchi J., Kotani T., Prives C., Avantaggiati M.L., Qin J.,
RA   Nakatani Y.;
RT   "The 400 kDa subunit of the PCAF histone acetylase complex belongs to the
RT   ATM superfamily.";
RL   Mol. Cell 2:869-875(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S.,
RA   Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E.,
RA   Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W.,
RA   Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A.,
RA   Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X.,
RA   Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E.,
RA   Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [6]
RP   SUBCELLULAR LOCATION, IDENTIFICATION IN THE STAGA COMPLEX WITH SUPT3H;
RP   GCN5L2; KIAA0764; TAF5L; TAF6L; TADA3L; TAF10; TAF12 AND TAF9, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=11564863; DOI=10.1128/mcb.21.20.6782-6795.2001;
RA   Martinez E., Palhan V.B., Tjernberg A., Lymar E.S., Gamper A.M.,
RA   Kundu T.K., Chait B.T., Roeder R.G.;
RT   "Human STAGA complex is a chromatin-acetylating transcription coactivator
RT   that interacts with pre-mRNA splicing and DNA damage-binding factors in
RT   vivo.";
RL   Mol. Cell. Biol. 21:6782-6795(2001).
RN   [7]
RP   IDENTIFICATION IN THE TFTC-HAT COMPLEX WITH TAF5L; TAF6L; TADA3L; SUPT3H;
RP   TAF2; TAF4; TAF5; GCN5L2 AND TAF10.
RX   PubMed=10373431; DOI=10.1074/jbc.274.26.18285;
RA   Brand M., Yamamoto K., Staub A., Tora L.;
RT   "Identification of TATA-binding protein-free TAFII-containing complex
RT   subunits suggests a role in nucleosome acetylation and signal
RT   transduction.";
RL   J. Biol. Chem. 274:18285-18289(1999).
RN   [8]
RP   IDENTIFICATION IN THE TIP60 HAT COMPLEX WITH KAT5; RUVBL1 AND RUVBL2.
RX   PubMed=10966108; DOI=10.1016/s0092-8674(00)00051-9;
RA   Ikura T., Ogryzko V.V., Grigoriev M., Groisman R., Wang J., Horikoshi M.,
RA   Scully R., Qin J., Nakatani Y.;
RT   "Involvement of the TIP60 histone acetylase complex in DNA repair and
RT   apoptosis.";
RL   Cell 102:463-473(2000).
RN   [9]
RP   INTERACTION WITH GCN5L2.
RX   PubMed=10611234; DOI=10.1128/mcb.20.2.556-562.2000;
RA   McMahon S.B., Wood M.A., Cole M.D.;
RT   "The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5
RT   to c-Myc.";
RL   Mol. Cell. Biol. 20:556-562(2000).
RN   [10]
RP   INTERACTION WITH E2F1 AND E2F4, AND FUNCTION.
RX   PubMed=11418595; DOI=10.1074/jbc.m102067200;
RA   Lang S.E., McMahon S.B., Cole M.D., Hearing P.;
RT   "E2F transcriptional activation requires TRRAP and GCN5 cofactors.";
RL   J. Biol. Chem. 276:32627-32634(2001).
RN   [11]
RP   DOMAIN.
RX   PubMed=11445536; DOI=10.1101/gad.900101;
RA   Park J., Kunjibettu S., McMahon S.B., Cole M.D.;
RT   "The ATM-related domain of TRRAP is required for histone acetyltransferase
RT   recruitment and Myc-dependent oncogenesis.";
RL   Genes Dev. 15:1619-1624(2001).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH TP53.
RX   PubMed=12138177; DOI=10.1128/mcb.22.16.5650-5661.2002;
RA   Ard P.G., Chatterjee C., Kunjibettu S., Adside L.R., Gralinski L.E.,
RA   McMahon S.B.;
RT   "Transcriptional regulation of the mdm2 oncogene by p53 requires TRRAP
RT   acetyltransferase complexes.";
RL   Mol. Cell. Biol. 22:5650-5661(2002).
RN   [13]
RP   IDENTIFICATION IN THE BAF53 COMPLEX WITH BAF53A; RUVBL1 AND SMARCA4.
RX   PubMed=11839798; DOI=10.1128/mcb.22.5.1307-1316.2002;
RA   Park J., Wood M.A., Cole M.D.;
RT   "BAF53 forms distinct nuclear complexes and functions as a critical c-Myc-
RT   interacting nuclear cofactor for oncogenic transformation.";
RL   Mol. Cell. Biol. 22:1307-1316(2002).
RN   [14]
RP   FUNCTION.
RX   PubMed=12743606; DOI=10.1038/sj.onc.1206376;
RA   Lang S.E., Hearing P.;
RT   "The adenovirus E1A oncoprotein recruits the cellular TRRAP/GCN5 histone
RT   acetyltransferase complex.";
RL   Oncogene 22:2836-2841(2003).
RN   [15]
RP   FUNCTION.
RX   PubMed=12660246; DOI=10.1074/jbc.m211795200;
RA   Liu X., Tesfai J., Evrard Y.A., Dent S.Y.R., Martinez E.;
RT   "c-Myc transformation domain recruits the human STAGA complex and requires
RT   TRRAP and GCN5 acetylase activity for transcription activation.";
RL   J. Biol. Chem. 278:20405-20412(2003).
RN   [16]
RP   FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE
RP   NUA4 COMPLEX.
RX   PubMed=14966270; DOI=10.1128/mcb.24.5.1884-1896.2004;
RA   Doyon Y., Selleck W., Lane W.S., Tan S., Cote J.;
RT   "Structural and functional conservation of the NuA4 histone
RT   acetyltransferase complex from yeast to humans.";
RL   Mol. Cell. Biol. 24:1884-1896(2004).
RN   [17]
RP   IDENTIFICATION IN STAGA COMPLEX.
RX   PubMed=18206972; DOI=10.1016/j.molcel.2007.12.011;
RA   Zhao Y., Lang G., Ito S., Bonnet J., Metzger E., Sawatsubashi S.,
RA   Suzuki E., Le Guezennec X., Stunnenberg H.G., Krasnov A., Georgieva S.G.,
RA   Schuele R., Takeyama K., Kato S., Tora L., Devys D.;
RT   "A TFTC/STAGA module mediates histone H2A and H2B deubiquitination,
RT   coactivates nuclear receptors, and counteracts heterochromatin silencing.";
RL   Mol. Cell 29:92-101(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2051, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [19]
RP   FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, AND INTERACTION WITH NPAT.
RX   PubMed=17967892; DOI=10.1128/mcb.00607-07;
RA   DeRan M., Pulvino M., Greene E., Su C., Zhao J.;
RT   "Transcriptional activation of histone genes requires NPAT-dependent
RT   recruitment of TRRAP-Tip60 complex to histone promoters during the G1/S
RT   phase transition.";
RL   Mol. Cell. Biol. 28:435-447(2008).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2051 AND SER-2077, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [21]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-3078, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [22]
RP   INTERACTION WITH TELO2 AND TTI1.
RX   PubMed=20427287; DOI=10.1074/jbc.m110.121699;
RA   Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K.,
RA   Iemura S., Natsume T., Mizushima N.;
RT   "Tti1 and Tel2 are critical factors in mammalian target of rapamycin
RT   complex assembly.";
RL   J. Biol. Chem. 285:20109-20116(2010).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   PROBABLE INVOLVEMENT IN MELANOMA, VARIANT PHE-722, AND CHARACTERIZATION OF
RP   VARIANT PHE-722.
RX   PubMed=21499247; DOI=10.1038/ng.810;
RA   Wei X., Walia V., Lin J.C., Teer J.K., Prickett T.D., Gartner J., Davis S.,
RA   Stemke-Hale K., Davies M.A., Gershenwald J.E., Robinson W., Robinson S.,
RA   Rosenberg S.A., Samuels Y.;
RT   "Exome sequencing identifies GRIN2A as frequently mutated in melanoma.";
RL   Nat. Genet. 43:442-446(2011).
RN   [26]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1628; SER-2051 AND SER-2077,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [29]
RP   FUNCTION, AND IDENTIFICATION IN THE SWR1-LIKE COMPLEX.
RX   PubMed=24463511; DOI=10.1038/nature12922;
RA   Obri A., Ouararhni K., Papin C., Diebold M.L., Padmanabhan K., Marek M.,
RA   Stoll I., Roy L., Reilly P.T., Mak T.W., Dimitrov S., Romier C.,
RA   Hamiche A.;
RT   "ANP32E is a histone chaperone that removes H2A.Z from chromatin.";
RL   Nature 505:648-653(2014).
RN   [30]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-2543, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [31]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-893; GLY-1070; HIS-1669; HIS-1724;
RP   VAL-1925; LEU-1932; LEU-1947; GLY-2139; TRP-2302; GLY-2433; LEU-2690;
RP   ASP-2750; GLU-2801 AND MET-2931.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [32]
RP   INVOLVEMENT IN DEDDFA, AND VARIANT DEDDFA GLN-2004.
RX   PubMed=30424743; DOI=10.1186/s12881-018-0711-9;
RA   Mavros C.F., Brownstein C.A., Thyagrajan R., Genetti C.A., Tembulkar S.,
RA   Graber K., Murphy Q., Cabral K., VanNoy G.E., Bainbridge M., Shi J.,
RA   Agrawal P.B., Beggs A.H., D'Angelo E., Gonzalez-Heydrich J.;
RT   "De novo variant of TRRAP in a patient with very early onset psychosis in
RT   the context of non-verbal learning disability and obsessive-compulsive
RT   disorder: a case report.";
RL   BMC Med. Genet. 19:197-197(2018).
RN   [33]
RP   VARIANTS DEDDFA PHE-805; LEU-860; LEU-893; MET-1031; GLN-1035; ARG-1037;
RP   THR-1043; GLY-1104; LYS-1106; TRP-1111; ARG-1159; CYS-1859; CYS-1866;
RP   ARG-1866; ARG-1883; LEU-1932 AND GLN-3757.
RX   PubMed=30827496; DOI=10.1016/j.ajhg.2019.01.010;
RG   CAUSES Study;
RG   Deciphering Developmental Disorders study;
RA   Cogne B., Ehresmann S., Beauregard-Lacroix E., Rousseau J., Besnard T.,
RA   Garcia T., Petrovski S., Avni S., McWalter K., Blackburn P.R.,
RA   Sanders S.J., Uguen K., Harris J., Cohen J.S., Blyth M., Lehman A.,
RA   Berg J., Li M.H., Kini U., Joss S., von der Lippe C., Gordon C.T.,
RA   Humberson J.B., Robak L., Scott D.A., Sutton V.R., Skraban C.M.,
RA   Johnston J.J., Poduri A., Nordenskjoeld M., Shashi V., Gerkes E.H.,
RA   Bongers E.M.H.F., Gilissen C., Zarate Y.A., Kvarnung M., Lally K.P.,
RA   Kulch P.A., Daniels B., Hernandez-Garcia A., Stong N., McGaughran J.,
RA   Retterer K., Tveten K., Sullivan J., Geisheker M.R., Stray-Pedersen A.,
RA   Tarpinian J.M., Klee E.W., Sapp J.C., Zyskind J., Holla O.L., Bedoukian E.,
RA   Filippini F., Guimier A., Picard A., Busk O.L., Punetha J., Pfundt R.,
RA   Lindstrand A., Nordgren A., Kalb F., Desai M., Ebanks A.H., Jhangiani S.N.,
RA   Dewan T., Coban Akdemir Z.H., Telegrafi A., Zackai E.H., Begtrup A.,
RA   Song X., Toutain A., Wentzensen I.M., Odent S., Bonneau D., Latypova X.,
RA   Deb W., Redon S., Bilan F., Legendre M., Troyer C., Whitlock K.,
RA   Caluseriu O., Murphree M.I., Pichurin P.N., Agre K., Gavrilova R.,
RA   Rinne T., Park M., Shain C., Heinzen E.L., Xiao R., Amiel J., Lyonnet S.,
RA   Isidor B., Biesecker L.G., Lowenstein D., Posey J.E., Denomme-Pichon A.S.,
RA   Ferec C., Yang X.J., Rosenfeld J.A., Gilbert-Dussardier B.,
RA   Audebert-Bellanger S., Redon R., Stessman H.A.F., Nellaker C., Yang Y.,
RA   Lupski J.R., Goldstein D.B., Eichler E.E., Bolduc F., Bezieau S., Kuery S.,
RA   Campeau P.M.;
RT   "Missense Variants in the Histone Acetyltransferase Complex Component Gene
RT   TRRAP Cause Autism and Syndromic Intellectual Disability.";
RL   Am. J. Hum. Genet. 104:530-541(2019).
RN   [34]
RP   VARIANTS DFNA75 CYS-171 AND ASN-394, VARIANT ASP-2750, AND INVOLVEMENT IN
RP   DFNA75.
RX   PubMed=31231791; DOI=10.1111/cge.13590;
RA   Xia W., Hu J., Ma J., Huang J., Wang X., Jiang N., Zhang J., Ma Z., Ma D.;
RT   "Novel TRRAP mutation causes autosomal dominant non-syndromic hearing
RT   loss.";
RL   Clin. Genet. 96:300-308(2019).
CC   -!- FUNCTION: Adapter protein, which is found in various multiprotein
CC       chromatin complexes with histone acetyltransferase activity (HAT),
CC       which gives a specific tag for epigenetic transcription activation.
CC       Component of the NuA4 histone acetyltransferase complex which is
CC       responsible for acetylation of nucleosomal histones H4 and H2A. Plays a
CC       central role in MYC transcription activation, and also participates in
CC       cell transformation by MYC. Required for p53/TP53-, E2F1- and E2F4-
CC       mediated transcription activation. Also involved in transcription
CC       activation mediated by the adenovirus E1A, a viral oncoprotein that
CC       deregulates transcription of key genes. Probably acts by linking
CC       transcription factors such as E1A, MYC or E2F1 to HAT complexes such as
CC       STAGA thereby allowing transcription activation. Probably not required
CC       in the steps following histone acetylation in processes of
CC       transcription activation. May be required for the mitotic checkpoint
CC       and normal cell cycle progression. Component of a SWR1-like complex
CC       that specifically mediates the removal of histone H2A.Z/H2AZ1 from the
CC       nucleosome. May play a role in the formation and maintenance of the
CC       auditory system (By similarity). {ECO:0000250|UniProtKB:A0A0R4ITC5,
CC       ECO:0000269|PubMed:11418595, ECO:0000269|PubMed:12138177,
CC       ECO:0000269|PubMed:12660246, ECO:0000269|PubMed:12743606,
CC       ECO:0000269|PubMed:14966270, ECO:0000269|PubMed:17967892,
CC       ECO:0000269|PubMed:24463511, ECO:0000269|PubMed:9708738}.
CC   -!- SUBUNIT: Interacts with MYC, E2F1 and E2F4 transcription factors.
CC       Interacts directly with p53/TP53. Interacts with GCN5L2. Component of
CC       various HAT complexes. Component of the PCAF complex, at least composed
CC       of TADA2L/ADA2, SUPT3H, TADA3L/ADA3, TAF5L/PAF65-beta, TAF6L/PAF65-
CC       alpha, TAF10/TAFII30, TAF12/TAFII20, TAF9/TAFII31 and TRRAP. Component
CC       of the TFTC-HAT complex, at least composed of TAF5L, TAF6L, TADA3L,
CC       SUPT3H/SPT3, TAF2/TAFII150, TAF4/TAFII135, TAF5/TAFII100, GCN5L2/GCN5,
CC       TAF10 and TRRAP. Component of the NuA4 histone acetyltransferase
CC       complex which contains the catalytic subunit KAT5/TIP60 and the
CC       subunits EP400, TRRAP/PAF400, BRD8/SMAP, EPC1, DMAP1/DNMAP1,
CC       RUVBL1/TIP49, RUVBL2, ING3, actin, ACTL6A/BAF53A, MORF4L1/MRG15,
CC       MORF4L2/MRGX, MRGBP, YEATS4/GAS41, VPS72/YL1 and MEAF6. Component of
CC       the STAGA complex, at least composed of SUPT3H, GCN5L2, SUPT7L, TAF5L,
CC       TAF6L, TADA3L, TAD1L, TAF10, TAF12, TRRAP and TAF9. The STAGA core
CC       complex is associated with a subcomplex required for histone
CC       deubiquitination composed of ATXN7L3, ENY2 and USP22. Component of the
CC       BAF53 complex, at least composed of BAF53A, RUVBL1, SMARCA4/BRG1, and
CC       TRRAP, which preferentially acetylates histone H4 (and H2A) within
CC       nucleosomes. Interacts with NPAT. Interaction with TELO2 AND TTI1.
CC       Component of a SWR1-like complex. {ECO:0000269|PubMed:10373431,
CC       ECO:0000269|PubMed:10611234, ECO:0000269|PubMed:10966108,
CC       ECO:0000269|PubMed:11418595, ECO:0000269|PubMed:11564863,
CC       ECO:0000269|PubMed:11839798, ECO:0000269|PubMed:12138177,
CC       ECO:0000269|PubMed:14966270, ECO:0000269|PubMed:17967892,
CC       ECO:0000269|PubMed:18206972, ECO:0000269|PubMed:20427287,
CC       ECO:0000269|PubMed:24463511, ECO:0000269|PubMed:9708738,
CC       ECO:0000269|PubMed:9885574}.
CC   -!- INTERACTION:
CC       Q9Y4A5; O15265: ATXN7; NbExp=6; IntAct=EBI-399128, EBI-708350;
CC       Q9Y4A5; P01106: MYC; NbExp=4; IntAct=EBI-399128, EBI-447544;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11564863,
CC       ECO:0000269|PubMed:9708738}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9Y4A5-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9Y4A5-2; Sequence=VSP_009102, VSP_009103;
CC   -!- DOMAIN: The PI3K/PI4K domain is required for the recruitment of HAT
CC       complexes, and the MYC-dependent transactivation. Although it is
CC       strongly related to the PI3/PI4-kinase family, it lacks the typical
CC       motifs that constitute the catalytic site of PI3/PI4-kinase proteins,
CC       and lacks such activity. {ECO:0000269|PubMed:11445536}.
CC   -!- DISEASE: Note=TRRAP mutation Phe-722 has been frequently found in
CC       cutaneous malignant melanoma, suggesting that TRRAP may play a role in
CC       the pathogenesis of melanoma. {ECO:0000269|PubMed:21499247}.
CC   -!- DISEASE: Developmental delay with or without dysmorphic facies and
CC       autism (DEDDFA) [MIM:618454]: An autosomal dominant neurodevelopmental
CC       disorder apparent from infancy or early childhood. Some patients
CC       present with intellectual disability and renal, cardiac, genitourinary
CC       systems, as well as structural brain abnormalities. In some cases, the
CC       phenotype is less severe, has no systemic involvement and is
CC       characterized by autism spectrum disorder and/or intellectual
CC       disability, sometimes associated with epilepsy. Affected individuals
CC       manifest variable dysmorphic features. {ECO:0000269|PubMed:30424743,
CC       ECO:0000269|PubMed:30827496}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Deafness, autosomal dominant, 75 (DFNA75) [MIM:618778]: A form
CC       of non-syndromic deafness characterized by late-onset hearing loss that
CC       involves mid and high frequencies, and progresses to encompass all
CC       frequencies. {ECO:0000269|PubMed:31231791}. Note=The disease may be
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. TRA1 subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC62433.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF076974; AAD09420.1; -; mRNA.
DR   EMBL; AF110377; AAD04629.1; -; mRNA.
DR   EMBL; AC004893; AAC62433.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AC004991; AAC27675.2; -; Genomic_DNA.
DR   EMBL; CH471091; EAW76694.1; -; Genomic_DNA.
DR   EMBL; CH236956; EAL23887.1; -; Genomic_DNA.
DR   CCDS; CCDS5659.1; -. [Q9Y4A5-2]
DR   CCDS; CCDS59066.1; -. [Q9Y4A5-1]
DR   PIR; T02632; T02632.
DR   RefSeq; NP_001231509.1; NM_001244580.1. [Q9Y4A5-1]
DR   RefSeq; NP_003487.1; NM_003496.3. [Q9Y4A5-2]
DR   BioGRID; 113900; 154.
DR   ComplexPortal; CPX-900; SAGA complex.
DR   ComplexPortal; CPX-903; TFTC histone acetylation complex.
DR   ComplexPortal; CPX-978; NuA4 histone acetyltransferase complex.
DR   ComplexPortal; CPX-989; PCAF histone acetylase complex.
DR   CORUM; Q9Y4A5; -.
DR   DIP; DIP-28149N; -.
DR   IntAct; Q9Y4A5; 69.
DR   MINT; Q9Y4A5; -.
DR   STRING; 9606.ENSP00000352925; -.
DR   iPTMnet; Q9Y4A5; -.
DR   MetOSite; Q9Y4A5; -.
DR   PhosphoSitePlus; Q9Y4A5; -.
DR   BioMuta; TRRAP; -.
DR   DMDM; 116242829; -.
DR   EPD; Q9Y4A5; -.
DR   jPOST; Q9Y4A5; -.
DR   MassIVE; Q9Y4A5; -.
DR   PaxDb; Q9Y4A5; -.
DR   PeptideAtlas; Q9Y4A5; -.
DR   PRIDE; Q9Y4A5; -.
DR   ProteomicsDB; 86142; -. [Q9Y4A5-1]
DR   ProteomicsDB; 86143; -. [Q9Y4A5-2]
DR   Antibodypedia; 16027; 180 antibodies.
DR   Ensembl; ENST00000355540; ENSP00000347733; ENSG00000196367. [Q9Y4A5-2]
DR   Ensembl; ENST00000359863; ENSP00000352925; ENSG00000196367. [Q9Y4A5-1]
DR   GeneID; 8295; -.
DR   KEGG; hsa:8295; -.
DR   UCSC; uc003upp.3; human. [Q9Y4A5-1]
DR   CTD; 8295; -.
DR   DisGeNET; 8295; -.
DR   EuPathDB; HostDB:ENSG00000196367.12; -.
DR   GeneCards; TRRAP; -.
DR   HGNC; HGNC:12347; TRRAP.
DR   HPA; ENSG00000196367; Low tissue specificity.
DR   MalaCards; TRRAP; -.
DR   MIM; 603015; gene.
DR   MIM; 618454; phenotype.
DR   MIM; 618778; phenotype.
DR   neXtProt; NX_Q9Y4A5; -.
DR   OpenTargets; ENSG00000196367; -.
DR   PharmGKB; PA37020; -.
DR   eggNOG; KOG0889; Eukaryota.
DR   GeneTree; ENSGT00390000017961; -.
DR   InParanoid; Q9Y4A5; -.
DR   OMA; HLSYLMR; -.
DR   OrthoDB; 7189at2759; -.
DR   PhylomeDB; Q9Y4A5; -.
DR   TreeFam; TF106414; -.
DR   PathwayCommons; Q9Y4A5; -.
DR   Reactome; R-HSA-201722; Formation of the beta-catenin:TCF transactivating complex.
DR   Reactome; R-HSA-3214847; HATs acetylate histones.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   SIGNOR; Q9Y4A5; -.
DR   BioGRID-ORCS; 8295; 695 hits in 872 CRISPR screens.
DR   ChiTaRS; TRRAP; human.
DR   GenomeRNAi; 8295; -.
DR   Pharos; Q9Y4A5; Tbio.
DR   PRO; PR:Q9Y4A5; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; Q9Y4A5; protein.
DR   Bgee; ENSG00000196367; Expressed in sural nerve and 197 other tissues.
DR   ExpressionAtlas; Q9Y4A5; baseline and differential.
DR   Genevisible; Q9Y4A5; HS.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0035267; C:NuA4 histone acetyltransferase complex; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0000125; C:PCAF complex; NAS:UniProtKB.
DR   GO; GO:0000124; C:SAGA complex; IBA:GO_Central.
DR   GO; GO:0030914; C:STAGA complex; IDA:UniProtKB.
DR   GO; GO:0000812; C:Swr1 complex; IDA:UniProtKB.
DR   GO; GO:0033276; C:transcription factor TFTC complex; IDA:UniProtKB.
DR   GO; GO:0003712; F:transcription coregulator activity; IDA:UniProtKB.
DR   GO; GO:1904837; P:beta-catenin-TCF complex assembly; TAS:Reactome.
DR   GO; GO:0006281; P:DNA repair; IBA:GO_Central.
DR   GO; GO:0016573; P:histone acetylation; NAS:UniProtKB.
DR   GO; GO:0016578; P:histone deubiquitination; IDA:UniProtKB.
DR   GO; GO:0043968; P:histone H2A acetylation; IDA:UniProtKB.
DR   GO; GO:0043967; P:histone H4 acetylation; IDA:UniProtKB.
DR   GO; GO:0016310; P:phosphorylation; IEA:GOC.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IBA:GO_Central.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR003152; FATC_dom.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000403; PI3/4_kinase_cat_dom.
DR   InterPro; IPR003151; PIK-rel_kinase_FAT.
DR   InterPro; IPR014009; PIK_FAT.
DR   InterPro; IPR033317; TRA1/TRRAP.
DR   PANTHER; PTHR11139:SF1; PTHR11139:SF1; 1.
DR   Pfam; PF02259; FAT; 1.
DR   Pfam; PF00454; PI3_PI4_kinase; 1.
DR   SMART; SM01343; FATC; 1.
DR   SMART; SM00146; PI3Kc; 1.
DR   SUPFAM; SSF48371; SSF48371; 3.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51189; FAT; 1.
DR   PROSITE; PS51190; FATC; 1.
DR   PROSITE; PS50290; PI3_4_KINASE_3; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Activator; Alternative splicing; Autism spectrum disorder;
KW   Chromatin regulator; Deafness; Direct protein sequencing; Disease mutation;
KW   Isopeptide bond; Mental retardation; Non-syndromic deafness; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000244|PubMed:22223895"
FT   CHAIN           2..3859
FT                   /note="Transformation/transcription domain-associated
FT                   protein"
FT                   /id="PRO_0000088851"
FT   DOMAIN          2692..3275
FT                   /note="FAT"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00534"
FT   DOMAIN          3528..3826
FT                   /note="PI3K/PI4K"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   DOMAIN          3827..3859
FT                   /note="FATC"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00534,
FT                   ECO:0000255|PROSITE-ProRule:PRU00535"
FT   REGION          2010..2388
FT                   /note="Interaction with TP53"
FT                   /evidence="ECO:0000269|PubMed:12138177"
FT   MOTIF           2047..2062
FT                   /note="Bipartite nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        485..526
FT                   /note="Pro-rich"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000244|PubMed:22223895"
FT   MOD_RES         1628
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         2051
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:18691976, ECO:0000244|PubMed:23186163"
FT   MOD_RES         2077
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         3078
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   CROSSLNK        2543
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   VAR_SEQ         1492..1509
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9708738"
FT                   /id="VSP_009102"
FT   VAR_SEQ         3001..3012
FT                   /note="GKPTWSGMHSSS -> A (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9708738"
FT                   /id="VSP_009103"
FT   VARIANT         171
FT                   /note="R -> C (in DFNA75; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:31231791"
FT                   /id="VAR_083794"
FT   VARIANT         394
FT                   /note="D -> N (in DFNA75; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:31231791"
FT                   /id="VAR_083795"
FT   VARIANT         722
FT                   /note="S -> F (found in a cutaneous malignant melanoma
FT                   sample; somatic mutation; induces cell transformation and
FT                   confers resistance to apoptosis; dbSNP:rs147405090)"
FT                   /evidence="ECO:0000269|PubMed:21499247"
FT                   /id="VAR_067754"
FT   VARIANT         805
FT                   /note="L -> F (in DEDDFA; unknown pathological
FT                   significance; dbSNP:rs1562940289)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082969"
FT   VARIANT         860
FT                   /note="F -> L (in DEDDFA; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082970"
FT   VARIANT         878
FT                   /note="R -> L (in dbSNP:rs17161510)"
FT                   /id="VAR_028359"
FT   VARIANT         893
FT                   /note="R -> C (in an ovarian serous carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041658"
FT   VARIANT         893
FT                   /note="R -> L (in DEDDFA; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082971"
FT   VARIANT         1031
FT                   /note="I -> M (in DEDDFA)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082972"
FT   VARIANT         1035
FT                   /note="R -> Q (in DEDDFA; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082973"
FT   VARIANT         1037
FT                   /note="S -> R (in DEDDFA; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082974"
FT   VARIANT         1043
FT                   /note="A -> T (in DEDDFA; dbSNP:rs1562945106)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082975"
FT   VARIANT         1070
FT                   /note="S -> G (in dbSNP:rs55920979)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041659"
FT   VARIANT         1104
FT                   /note="E -> G (in DEDDFA)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082976"
FT   VARIANT         1106
FT                   /note="E -> K (in DEDDFA)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082977"
FT   VARIANT         1111
FT                   /note="G -> W (in DEDDFA; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082978"
FT   VARIANT         1159
FT                   /note="G -> R (in DEDDFA)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082979"
FT   VARIANT         1669
FT                   /note="R -> H (in a colorectal adenocarcinoma sample;
FT                   somatic mutation; dbSNP:rs373632999)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041660"
FT   VARIANT         1724
FT                   /note="R -> H (in a gastric adenocarcinoma sample; somatic
FT                   mutation; dbSNP:rs782203759)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041661"
FT   VARIANT         1859
FT                   /note="R -> C (in DEDDFA)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082980"
FT   VARIANT         1866
FT                   /note="W -> C (in DEDDFA; unknown pathological
FT                   significance; dbSNP:rs1562957576)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082981"
FT   VARIANT         1866
FT                   /note="W -> R (in DEDDFA; dbSNP:rs1562957569)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082982"
FT   VARIANT         1883
FT                   /note="G -> R (in DEDDFA)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082983"
FT   VARIANT         1925
FT                   /note="A -> V (in dbSNP:rs56197298)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041662"
FT   VARIANT         1932
FT                   /note="P -> L (in DEDDFA; unknown pathological
FT                   significance; also found in a colorectal adenocarcinoma
FT                   sample; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:30827496"
FT                   /id="VAR_041663"
FT   VARIANT         1947
FT                   /note="R -> L (in an ovarian mucinous carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041664"
FT   VARIANT         2004
FT                   /note="R -> Q (in DEDDFA; unknown pathological
FT                   significance; dbSNP:rs1562959030)"
FT                   /evidence="ECO:0000269|PubMed:30424743"
FT                   /id="VAR_082984"
FT   VARIANT         2139
FT                   /note="W -> G (in dbSNP:rs34185633)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041665"
FT   VARIANT         2302
FT                   /note="R -> W (in a colorectal adenocarcinoma sample;
FT                   somatic mutation; dbSNP:rs528967912)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041666"
FT   VARIANT         2433
FT                   /note="S -> G (in dbSNP:rs35634065)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041667"
FT   VARIANT         2690
FT                   /note="P -> L (in a lung large cell carcinoma sample;
FT                   somatic mutation; dbSNP:rs753661271)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041668"
FT   VARIANT         2750
FT                   /note="E -> D (in dbSNP:rs55755466)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:31231791"
FT                   /id="VAR_041669"
FT   VARIANT         2801
FT                   /note="K -> E (in dbSNP:rs56341061)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041670"
FT   VARIANT         2931
FT                   /note="T -> M (in a colorectal adenocarcinoma sample;
FT                   somatic mutation; dbSNP:rs1294404368)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041671"
FT   VARIANT         3757
FT                   /note="R -> Q (in DEDDFA; unknown pathological
FT                   significance; dbSNP:rs987263983)"
FT                   /evidence="ECO:0000269|PubMed:30827496"
FT                   /id="VAR_082985"
FT   CONFLICT        660
FT                   /note="E -> D (in Ref. 2; AAD04629)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   3859 AA;  437600 MW;  391E467C0047B00B CRC64;
     MAFVATQGAT VVDQTTLMKK YLQFVAALTD VNTPDETKLK MMQEVSENFE NVTSSPQYST
     FLEHIIPRFL TFLQDGEVQF LQEKPAQQLR KLVLEIIHRI PTNEHLRPHT KNVLSVMFRF
     LETENEENVL ICLRIIIELH KQFRPPITQE IHHFLDFVKQ IYKELPKVVN RYFENPQVIP
     ENTVPPPEMV GMITTIAVKV NPEREDSETR THSIIPRGSL SLKVLAELPI IVVLMYQLYK
     LNIHNVVAEF VPLIMNTIAI QVSAQARQHK LYNKELYADF IAAQIKTLSF LAYIIRIYQE
     LVTKYSQQMV KGMLQLLSNC PAETAHLRKE LLIAAKHILT TELRNQFIPC MDKLFDESIL
     IGSGYTARET LRPLAYSTLA DLVHHVRQHL PLSDLSLAVQ LFAKNIDDES LPSSIQTMSC
     KLLLNLVDCI RSKSEQESGN GRDVLMRMLE VFVLKFHTIA RYQLSAIFKK CKPQSELGAV
     EAALPGVPTA PAAPGPAPSP APVPAPPPPP PPPPPATPVT PAPVPPFEKQ GEKDKEDKQT
     FQVTDCRSLV KTLVCGVKTI TWGITSCKAP GEAQFIPNKQ LQPKETQIYI KLVKYAMQAL
     DIYQVQIAGN GQTYIRVANC QTVRMKEEKE VLEHFAGVFT MMNPLTFKEI FQTTVPYMVE
     RISKNYALQI VANSFLANPT TSALFATILV EYLLDRLPEM GSNVELSNLY LKLFKLVFGS
     VSLFAAENEQ MLKPHLHKIV NSSMELAQTA KEPYNYFLLL RALFRSIGGG SHDLLYQEFL
     PLLPNLLQGL NMLQSGLHKQ HMKDLFVELC LTVPVRLSSL LPYLPMLMDP LVSALNGSQT
     LVSQGLRTLE LCVDNLQPDF LYDHIQPVRA ELMQALWRTL RNPADSISHV AYRVLGKFGG
     SNRKMLKESQ KLHYVVTEVQ GPSITVEFSD CKASLQLPME KAIETALDCL KSANTEPYYR
     RQAWEVIKCF LVAMMSLEDN KHALYQLLAH PNFTEKTIPN VIISHRYKAQ DTPARKTFEQ
     ALTGAFMSAV IKDLRPSALP FVASLIRHYT MVAVAQQCGP FLLPCYQVGS QPSTAMFHSE
     ENGSKGMDPL VLIDAIAICM AYEEKELCKI GEVALAVIFD VASIILGSKE RACQLPLFSY
     IVERLCACCY EQAWYAKLGG VVSIKFLMER LPLTWVLQNQ QTFLKALLFV MMDLTGEVSN
     GAVAMAKTTL EQLLMRCATP LKDEERAEEI VAAQEKSFHH VTHDLVREVT SPNSTVRKQA
     MHSLQVLAQV TGKSVTVIME PHKEVLQDMV PPKKHLLRHQ PANAQIGLME GNTFCTTLQP
     RLFTMDLNVV EHKVFYTELL NLCEAEDSAL TKLPCYKSLP SLVPLRIAAL NALAACNYLP
     QSREKIIAAL FKALNSTNSE LQEAGEACMR KFLEGATIEV DQIHTHMRPL LMMLGDYRSL
     TLNVVNRLTS VTRLFPNSFN DKFCDQMMQH LRKWMEVVVI THKGGQRSDG NESISECGRC
     PLSPFCQFEE MKICSAIINL FHLIPAAPQT LVKPLLEVVM KTERAMLIEA GSPFREPLIK
     FLTRHPSQTV ELFMMEATLN DPQWSRMFMS FLKHKDARPL RDVLAANPNR FITLLLPGGA
     QTAVRPGSPS TSTMRLDLQF QAIKIISIIV KNDDSWLASQ HSLVSQLRRV WVSENFQERH
     RKENMAATNW KEPKLLAYCL LNYCKRNYGD IELLFQLLRA FTGRFLCNMT FLKEYMEEEI
     PKNYSIAQKR ALFFRFVDFN DPNFGDELKA KVLQHILNPA FLYSFEKGEG EQLLGPPNPE
     GDNPESITSV FITKVLDPEK QADMLDSLRI YLLQYATLLV EHAPHHIHDN NKNRNSKLRR
     LMTFAWPCLL SKACVDPACK YSGHLLLAHI IAKFAIHKKI VLQVFHSLLK AHAMEARAIV
     RQAMAILTPA VPARMEDGHQ MLTHWTRKII VEEGHTVPQL VHILHLIVQH FKVYYPVRHH
     LVQHMVSAMQ RLGFTPSVTI EQRRLAVDLS EVVIKWELQR IKDQQPDSDM DPNSSGEGVN
     SVSSSIKRGL SVDSAQEVKR FRTATGAISA VFGRSQSLPG ADSLLAKPID KQHTDTVVNF
     LIRVACQVND NTNTAGSPGE VLSRRCVNLL KTALRPDMWP KSELKLQWFD KLLMTVEQPN
     QVNYGNICTG LEVLSFLLTV LQSPAILSSF KPLQRGIAAC MTCGNTKVLR AVHSLLSRLM
     SIFPTEPSTS SVASKYEELE CLYAAVGKVI YEGLTNYEKA TNANPSQLFG TLMILKSACS
     NNPSYIDRLI SVFMRSLQKM VREHLNPQAA SGSTEATSGT SELVMLSLEL VKTRLAVMSM
     EMRKNFIQAI LTSLIEKSPD AKILRAVVKI VEEWVKNNSP MAANQTPTLR EKSILLVKMM
     TYIEKRFPED LELNAQFLDL VNYVYRDETL SGSELTAKLE PAFLSGLRCA QPLIRAKFFE
     VFDNSMKRRV YERLLYVTCS QNWEAMGNHF WIKQCIELLL AVCEKSTPIG TSCQGAMLPS
     ITNVINLADS HDRAAFAMVT HVKQEPRERE NSESKEEDVE IDIELAPGDQ TSTPKTKELS
     EKDIGNQLHM LTNRHDKFLD TLREVKTGAL LSAFVQLCHI STTLAEKTWV QLFPRLWKIL
     SDRQQHALAG EISPFLCSGS HQVQRDCQPS ALNCFVEAMS QCVPPIPIRP CVLKYLGKTH
     NLWFRSTLML EHQAFEKGLS LQIKPKQTTE FYEQESITPP QQEILDSLAE LYSLLQEEDM
     WAGLWQKRCK YSETATAIAY EQHGFFEQAQ ESYEKAMDKA KKEHERSNAS PAIFPEYQLW
     EDHWIRCSKE LNQWEALTEY GQSKGHINPY LVLECAWRVS NWTAMKEALV QVEVSCPKEM
     AWKVNMYRGY LAICHPEEQQ LSFIERLVEM ASSLAIREWR RLPHVVSHVH TPLLQAAQQI
     IELQEAAQIN AGLQPTNLGR NNSLHDMKTV VKTWRNRLPI VSDDLSHWSS IFMWRQHHYQ
     GKPTWSGMHS SSIVTAYENS SQHDPSSNNA MLGVHASASA IIQYGKIARK QGLVNVALDI
     LSRIHTIPTV PIVDCFQKIR QQVKCYLQLA GVMGKNECMQ GLEVIESTNL KYFTKEMTAE
     FYALKGMFLA QINKSEEANK AFSAAVQMHD VLVKAWAMWG DYLENIFVKE RQLHLGVSAI
     TCYLHACRHQ NESKSRKYLA KVLWLLSFDD DKNTLADAVD KYCIGVPPIQ WLAWIPQLLT
     CLVGSEGKLL LNLISQVGRV YPQAVYFPIR TLYLTLKIEQ RERYKSDPGP IRATAPMWRC
     SRIMHMQREL HPTLLSSLEG IVDQMVWFRE NWHEEVLRQL QQGLAKCYSV AFEKSGAVSD
     AKITPHTLNF VKKLVSTFGV GLENVSNVST MFSSAASESL ARRAQATAQD PVFQKLKGQF
     TTDFDFSVPG SMKLHNLISK LKKWIKILEA KTKQLPKFFL IEEKCRFLSN FSAQTAEVEI
     PGEFLMPKPT HYYIKIARFM PRVEIVQKHN TAARRLYIRG HNGKIYPYLV MNDACLTESR
     REERVLQLLR LLNPCLEKRK ETTKRHLFFT VPRVVAVSPQ MRLVEDNPSS LSLVEIYKQR
     CAKKGIEHDN PISRYYDRLA TVQARGTQAS HQVLRDILKE VQSNMVPRSM LKEWALHTFP
     NATDYWTFRK MFTIQLALIG FAEFVLHLNR LNPEMLQIAQ DTGKLNVAYF RFDINDATGD
     LDANRPVPFR LTPNISEFLT TIGVSGPLTA SMIAVARCFA QPNFKVDGIL KTVLRDEIIA
     WHKKTQEDTS SPLSAAGQPE NMDSQQLVSL VQKAVTAIMT RLHNLAQFEG GESKVNTLVA
     AANSLDNLCR MDPAWHPWL
//
ID   XRCC3_HUMAN             Reviewed;         346 AA.
AC   O43542; O43568; Q9BU18;
DT   03-APR-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1998, sequence version 1.
DT   02-DEC-2020, entry version 176.
DE   RecName: Full=DNA repair protein XRCC3;
DE   AltName: Full=X-ray repair cross-complementing protein 3;
GN   Name=XRCC3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND VARIANT MET-241.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=9660962; DOI=10.1016/s1097-2765(00)80078-7;
RA   Liu N., Lamerdin J.E., Tebbs R.S., Schild D., Tucker J.D., Shen M.R.,
RA   Brookman K.W., Siciliano M.J., Walter C.A., Fan W., Narayana L.S.,
RA   Zhou Z.-Q., Adamson A.W., Sorensen K.J., Chen D.J., Jones N.J.,
RA   Thompson L.H.;
RT   "XRCC2 and XRCC3, new human Rad51-family members, promote chromosome
RT   stability and protect against DNA cross-links and other damages.";
RL   Mol. Cell 1:783-793(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS HIS-94 AND MET-241.
RG   NIEHS SNPs program;
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lymph, Muscle, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   IDENTIFICATION IN THE CX3 COMPLEX WITH XRCC3.
RX   PubMed=11751635; DOI=10.1101/gad.947001;
RA   Masson J.Y., Tarsounas M.C., Stasiak A.Z., Stasiak A., Shah R.,
RA   McIlwraith M.J., Benson F.E., West S.C.;
RT   "Identification and purification of two distinct complexes containing the
RT   five RAD51 paralogs.";
RL   Genes Dev. 15:3296-3307(2001).
RN   [5]
RP   INVOLVEMENT IN BC SUSCEPTIBILITY.
RX   PubMed=12023982; DOI=10.1093/hmg/11.12.1399;
RA   Kuschel B., Auranen A., McBride S., Novik K.L., Antoniou A.,
RA   Lipscombe J.M., Day N.E., Easton D.F., Ponder B.A., Pharoah P.D.,
RA   Dunning A.;
RT   "Variants in DNA double-strand break repair genes and breast cancer
RT   susceptibility.";
RL   Hum. Mol. Genet. 11:1399-1407(2002).
RN   [6]
RP   IDENTIFICATION IN THE CX3 COMPLEX WITH XRCC3.
RX   PubMed=11744692; DOI=10.1074/jbc.m108306200;
RA   Miller K.A., Yoshikawa D.M., McConnell I.R., Clark R., Schild D.,
RA   Albala J.S.;
RT   "RAD51C interacts with RAD51B and is central to a larger protein complex in
RT   vivo exclusive of RAD51.";
RL   J. Biol. Chem. 277:8406-8411(2002).
RN   [7]
RP   INTERACTION WITH RAD51 AND RAD51C.
RX   PubMed=11842113; DOI=10.1093/nar/30.4.1009;
RA   Liu N., Schild D., Thelen M.P., Thompson L.H.;
RT   "Involvement of Rad51C in two distinct protein complexes of Rad51 paralogs
RT   in human cells.";
RL   Nucleic Acids Res. 30:1009-1015(2002).
RN   [8]
RP   INTERACTION WITH RAD51C.
RX   PubMed=14704354; DOI=10.1093/nar/gkg925;
RA   Miller K.A., Sawicka D., Barsky D., Albala J.S.;
RT   "Domain mapping of the Rad51 paralog protein complexes.";
RL   Nucleic Acids Res. 32:169-178(2004).
RN   [9]
RP   FUNCTION.
RX   PubMed=14716019; DOI=10.1126/science.1093037;
RA   Liu Y., Masson J.Y., Shah R., O'Regan P., West S.C.;
RT   "RAD51C is required for Holliday junction processing in mammalian cells.";
RL   Science 303:243-246(2004).
RN   [10]
RP   SUBCELLULAR LOCATION.
RX   PubMed=16215984; DOI=10.1002/jcb.20640;
RA   Bennett B.T., Knight K.L.;
RT   "Cellular localization of human Rad51C and regulation of ubiquitin-mediated
RT   proteolysis of Rad51.";
RL   J. Cell. Biochem. 96:1095-1109(2005).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INDUCTION.
RX   PubMed=20413593; DOI=10.1074/jbc.m109.099846;
RA   Sage J.M., Gildemeister O.S., Knight K.L.;
RT   "Discovery of a novel function for human Rad51: maintenance of the
RT   mitochondrial genome.";
RL   J. Biol. Chem. 285:18984-18990(2010).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   INTERACTION WITH SWSAP1 AND ZSWIM7.
RX   PubMed=21965664; DOI=10.1074/jbc.m111.271080;
RA   Liu T., Wan L., Wu Y., Chen J., Huang J.;
RT   "hSWS1.SWSAP1 is an evolutionarily conserved complex required for efficient
RT   homologous recombination repair.";
RL   J. Biol. Chem. 286:41758-41766(2011).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [16]
RP   FUNCTION IN HOLLIDAY JUNCTION RESOLUTION.
RX   PubMed=23108668; DOI=10.1242/jcs.114595;
RA   Rodrigue A., Coulombe Y., Jacquet K., Gagne J.P., Roques C., Gobeil S.,
RA   Poirier G., Masson J.Y.;
RT   "The RAD51 paralogs ensure cellular protection against mitotic defects and
RT   aneuploidy.";
RL   J. Cell Sci. 126:348-359(2013).
RN   [17]
RP   FUNCTION OF THE CX3 COMPLEX.
RX   PubMed=23149936; DOI=10.1128/mcb.00465-12;
RA   Chun J., Buechelmaier E.S., Powell S.N.;
RT   "Rad51 paralog complexes BCDX2 and CX3 act at different stages in the
RT   BRCA1-BRCA2-dependent homologous recombination pathway.";
RL   Mol. Cell. Biol. 33:387-395(2013).
RN   [18]
RP   INTERACTION WITH PALB2, AND IDENTIFICATION IN A PALB2-CONTAINING HR
RP   COMPLEX.
RX   PubMed=24141787; DOI=10.1038/onc.2013.421;
RA   Park J.Y., Singh T.R., Nassar N., Zhang F., Freund M., Hanenberg H.,
RA   Meetei A.R., Andreassen P.R.;
RT   "Breast cancer-associated missense mutants of the PALB2 WD40 domain, which
RT   directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair.";
RL   Oncogene 33:4803-4812(2014).
RN   [19]
RP   ELECTRON MICROSCOPY OF THE CX3 COMPLEX, AND DNA-BINDING OF THE CX3 COMPLEX.
RX   PubMed=20207730; DOI=10.1074/jbc.m109.074286;
RA   Compton S.A., Ozgur S., Griffith J.D.;
RT   "Ring-shaped Rad51 paralog protein complexes bind Holliday junctions and
RT   replication forks as visualized by electron microscopy.";
RL   J. Biol. Chem. 285:13349-13356(2010).
RN   [20]
RP   VARIANT CMM6 MET-241.
RX   PubMed=11059748;
RA   Winsey S.L., Haldar N.A., Marsh H.P., Bunce M., Marshall S.E., Harris A.L.,
RA   Wojnarowska F., Welsh K.I.;
RT   "A variant within the DNA repair gene XRCC3 is associated with the
RT   development of melanoma skin cancer.";
RL   Cancer Res. 60:5612-5616(2000).
CC   -!- FUNCTION: Involved in the homologous recombination repair (HRR) pathway
CC       of double-stranded DNA, thought to repair chromosomal fragmentation,
CC       translocations and deletions. Part of the RAD21 paralog protein complex
CC       CX3 which acts in the BRCA1-BRCA2-dependent HR pathway. Upon DNA
CC       damage, CX3 acts downstream of RAD51 recruitment; the complex binds
CC       predominantly to the intersection of the four duplex arms of the
CC       Holliday junction (HJ) and to junctions of replication forks. Involved
CC       in HJ resolution and thus in processing HR intermediates late in the
CC       DNA repair process; the function may be linked to the CX3 complex and
CC       seems to involve GEN1 during mitotic cell cycle progression. Part of a
CC       PALB2-scaffolded HR complex containing BRCA2 and RAD51C and which is
CC       thought to play a role in DNA repair by HR. Plays a role in regulating
CC       mitochondrial DNA copy number under conditions of oxidative stress in
CC       the presence of RAD51 and RAD51C. {ECO:0000269|PubMed:14716019,
CC       ECO:0000269|PubMed:20413593, ECO:0000269|PubMed:23108668,
CC       ECO:0000269|PubMed:23149936}.
CC   -!- SUBUNIT: Interacts with RAD51C and RAD51. Part of the CX3 complex
CC       consisting of RAD51C and XRCC3; the complex has a ring-like structure
CC       arranged into a flat disc around a central channel; CX3 can interact
CC       with RAD51 in vitro. Forms a complex with FANCD2, BRCA2 and
CC       phosphorylated FANCG. Interacts with SWSAP1 and ZSWIM7; involved in
CC       homologous recombination repair. Interacts directly with PALB2 which
CC       may serve as a scaffold for a HR complex containing PALB2, BRCA2,
CC       RAD51C, RAD51 and XRCC3. {ECO:0000269|PubMed:11744692,
CC       ECO:0000269|PubMed:11751635, ECO:0000269|PubMed:11842113,
CC       ECO:0000269|PubMed:14704354, ECO:0000269|PubMed:21965664,
CC       ECO:0000269|PubMed:24141787}.
CC   -!- INTERACTION:
CC       O43542; Q86YC2: PALB2; NbExp=3; IntAct=EBI-2849976, EBI-1222653;
CC       O43542; Q06609: RAD51; NbExp=5; IntAct=EBI-2849976, EBI-297202;
CC       O43542; O43502: RAD51C; NbExp=11; IntAct=EBI-2849976, EBI-2267048;
CC       O43542; Q6NVH7: SWSAP1; NbExp=2; IntAct=EBI-2849976, EBI-5281637;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Cytoplasm, perinuclear
CC       region. Mitochondrion. Note=Accumulates in discrete nuclear foci prior
CC       to DNA damage, and these foci persist throughout the time course of DNA
CC       repair.
CC   -!- INDUCTION: Stress-induced increase in the mitochondrial levels is seen.
CC       {ECO:0000269|PubMed:20413593}.
CC   -!- DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancy
CC       originating from breast epithelial tissue. Breast neoplasms can be
CC       distinguished by their histologic pattern. Invasive ductal carcinoma is
CC       by far the most common type. Breast cancer is etiologically and
CC       genetically heterogeneous. Important genetic factors have been
CC       indicated by familial occurrence and bilateral involvement. Mutations
CC       at more than one locus can be involved in different families or even in
CC       the same case. {ECO:0000269|PubMed:12023982}. Note=Disease
CC       susceptibility is associated with variations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Melanoma, cutaneous malignant 6 (CMM6) [MIM:613972]: A
CC       malignant neoplasm of melanocytes, arising de novo or from a pre-
CC       existing benign nevus, which occurs most often in the skin but also may
CC       involve other sites. {ECO:0000269|PubMed:11059748}. Note=Disease
CC       susceptibility is associated with variations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the RecA family. RAD51 subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/XRCC3ID335ch14q32.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/xrcc3/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF035586; AAC05368.1; -; mRNA.
DR   EMBL; AF037222; AAC04805.1; -; Genomic_DNA.
DR   EMBL; AF508041; AAM23015.1; -; Genomic_DNA.
DR   EMBL; BC001036; AAH01036.1; -; mRNA.
DR   EMBL; BC002949; AAH02949.1; -; mRNA.
DR   EMBL; BC011725; AAH11725.1; -; mRNA.
DR   CCDS; CCDS9984.1; -.
DR   RefSeq; NP_001093588.1; NM_001100118.1.
DR   RefSeq; NP_001093589.1; NM_001100119.1.
DR   RefSeq; NP_005423.1; NM_005432.3.
DR   RefSeq; XP_005268103.1; XM_005268046.2.
DR   RefSeq; XP_011535440.1; XM_011537138.2.
DR   SMR; O43542; -.
DR   BioGRID; 113351; 164.
DR   CORUM; O43542; -.
DR   DIP; DIP-42016N; -.
DR   IntAct; O43542; 147.
DR   MINT; O43542; -.
DR   STRING; 9606.ENSP00000451974; -.
DR   iPTMnet; O43542; -.
DR   PhosphoSitePlus; O43542; -.
DR   BioMuta; XRCC3; -.
DR   EPD; O43542; -.
DR   jPOST; O43542; -.
DR   MassIVE; O43542; -.
DR   PaxDb; O43542; -.
DR   PeptideAtlas; O43542; -.
DR   PRIDE; O43542; -.
DR   ProteomicsDB; 49041; -.
DR   Antibodypedia; 14778; 577 antibodies.
DR   DNASU; 7517; -.
DR   Ensembl; ENST00000352127; ENSP00000343392; ENSG00000126215.
DR   Ensembl; ENST00000553264; ENSP00000451974; ENSG00000126215.
DR   Ensembl; ENST00000554913; ENSP00000451362; ENSG00000126215.
DR   Ensembl; ENST00000555055; ENSP00000452598; ENSG00000126215.
DR   GeneID; 7517; -.
DR   KEGG; hsa:7517; -.
DR   CTD; 7517; -.
DR   DisGeNET; 7517; -.
DR   EuPathDB; HostDB:ENSG00000126215.13; -.
DR   GeneCards; XRCC3; -.
DR   HGNC; HGNC:12830; XRCC3.
DR   HPA; ENSG00000126215; Tissue enhanced (skin).
DR   MalaCards; XRCC3; -.
DR   MIM; 114480; phenotype.
DR   MIM; 600675; gene.
DR   MIM; 613972; phenotype.
DR   neXtProt; NX_O43542; -.
DR   OpenTargets; ENSG00000126215; -.
DR   PharmGKB; PA37422; -.
DR   eggNOG; KOG1564; Eukaryota.
DR   GeneTree; ENSGT00930000151053; -.
DR   HOGENOM; CLU_041732_1_0_1; -.
DR   InParanoid; O43542; -.
DR   OMA; PCLGLQW; -.
DR   OrthoDB; 1341207at2759; -.
DR   PhylomeDB; O43542; -.
DR   TreeFam; TF101203; -.
DR   PathwayCommons; O43542; -.
DR   Reactome; R-HSA-5685942; HDR through Homologous Recombination (HRR).
DR   Reactome; R-HSA-5693554; Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA).
DR   Reactome; R-HSA-5693568; Resolution of D-loop Structures through Holliday Junction Intermediates.
DR   Reactome; R-HSA-5693579; Homologous DNA Pairing and Strand Exchange.
DR   BioGRID-ORCS; 7517; 468 hits in 848 CRISPR screens.
DR   ChiTaRS; XRCC3; human.
DR   GeneWiki; XRCC3; -.
DR   GenomeRNAi; 7517; -.
DR   Pharos; O43542; Tbio.
DR   PRO; PR:O43542; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; O43542; protein.
DR   Bgee; ENSG00000126215; Expressed in left lobe of thyroid gland and 131 other tissues.
DR   ExpressionAtlas; O43542; baseline and differential.
DR   Genevisible; O43542; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0000784; C:nuclear chromosome, telomeric region; IC:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0033065; C:Rad51C-XRCC3 complex; IDA:UniProtKB.
DR   GO; GO:0005657; C:replication fork; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0008094; F:DNA-dependent ATPase activity; IEA:InterPro.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; TAS:ProtInc.
DR   GO; GO:0006310; P:DNA recombination; TAS:ProtInc.
DR   GO; GO:0006281; P:DNA repair; IGI:BHF-UCL.
DR   GO; GO:0000724; P:double-strand break repair via homologous recombination; IMP:UniProtKB.
DR   GO; GO:0045003; P:double-strand break repair via synthesis-dependent strand annealing; IBA:GO_Central.
DR   GO; GO:0036297; P:interstrand cross-link repair; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0090267; P:positive regulation of mitotic cell cycle spindle assembly checkpoint; IMP:UniProtKB.
DR   GO; GO:0010824; P:regulation of centrosome duplication; IMP:UniProtKB.
DR   GO; GO:0071140; P:resolution of mitotic recombination intermediates; IMP:UniProtKB.
DR   GO; GO:0010033; P:response to organic substance; IEA:Ensembl.
DR   GO; GO:0090656; P:t-circle formation; IMP:BHF-UCL.
DR   GO; GO:0000722; P:telomere maintenance via recombination; IMP:BHF-UCL.
DR   GO; GO:0090737; P:telomere maintenance via telomere trimming; IGI:BHF-UCL.
DR   GO; GO:0090657; P:telomeric loop disassembly; TAS:BHF-UCL.
DR   CDD; cd01123; Rad51_DMC1_radA; 1.
DR   InterPro; IPR013632; DNA_recomb/repair_Rad51_C.
DR   InterPro; IPR016467; DNA_recomb/repair_RecA-like.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR033925; Rad51_DMC1_RadA.
DR   InterPro; IPR020588; RecA_ATP-bd.
DR   Pfam; PF08423; Rad51; 1.
DR   PIRSF; PIRSF005856; Rad51; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   PROSITE; PS50162; RECA_2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; ATP-binding; Cytoplasm; Disease mutation; DNA damage;
KW   DNA recombination; DNA repair; DNA-binding; Mitochondrion;
KW   Nucleotide-binding; Nucleus; Polymorphism; Reference proteome.
FT   CHAIN           1..346
FT                   /note="DNA repair protein XRCC3"
FT                   /id="PRO_0000122951"
FT   NP_BIND         107..114
FT                   /note="ATP"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000244|PubMed:22814378"
FT   VARIANT         94
FT                   /note="R -> H (in dbSNP:rs3212057)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_020405"
FT   VARIANT         241
FT                   /note="T -> M (in CMM6; risk factor for disease
FT                   development; dbSNP:rs861539)"
FT                   /evidence="ECO:0000269|PubMed:11059748,
FT                   ECO:0000269|PubMed:9660962, ECO:0000269|Ref.2"
FT                   /id="VAR_013006"
FT   VARIANT         271
FT                   /note="G -> R (in dbSNP:rs28903080)"
FT                   /id="VAR_029295"
FT   VARIANT         302
FT                   /note="R -> H (in dbSNP:rs28903081)"
FT                   /id="VAR_029296"
SQ   SEQUENCE   346 AA;  37850 MW;  4DDF3B163C3B3332 CRC64;
     MDLDLLDLNP RIIAAIKKAK LKSVKEVLHF SGPDLKRLTN LSSPEVWHLL RTASLHLRGS
     SILTALQLHQ QKERFPTQHQ RLSLGCPVLD ALLRGGLPLD GITELAGRSS AGKTQLALQL
     CLAVQFPRQH GGLEAGAVYI CTEDAFPHKR LQQLMAQQPR LRTDVPGELL QKLRFGSQIF
     IEHVADVDTL LECVNKKVPV LLSRGMARLV VIDSVAAPFR CEFDSQASAP RARHLQSLGA
     TLRELSSAFQ SPVLCINQVT EAMEEQGAAH GPLGFWDERV SPALGITWAN QLLVRLLADR
     LREEEAALGC PARTLRVLSA PHLPPSSCSY TISAEGVRGT PGTQSH
//
ID   P53_HUMAN               Reviewed;         393 AA.
AC   P04637; Q15086; Q15087; Q15088; Q16535; Q16807; Q16808; Q16809; Q16810;
AC   Q16811; Q16848; Q2XN98; Q3LRW1; Q3LRW2; Q3LRW3; Q3LRW4; Q3LRW5; Q86UG1;
AC   Q8J016; Q99659; Q9BTM4; Q9HAQ8; Q9NP68; Q9NPJ2; Q9NZD0; Q9UBI2; Q9UQ61;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   24-NOV-2009, sequence version 4.
DT   02-DEC-2020, entry version 289.
DE   RecName: Full=Cellular tumor antigen p53;
DE   AltName: Full=Antigen NY-CO-13;
DE   AltName: Full=Phosphoprotein p53;
DE   AltName: Full=Tumor suppressor p53;
GN   Name=TP53; Synonyms=P53;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=4006916; DOI=10.1002/j.1460-2075.1985.tb03768.x;
RA   Zakut-Houri R., Bienz-Tadmor B., Givol D., Oren M.;
RT   "Human p53 cellular tumor antigen: cDNA sequence and expression in COS
RT   cells.";
RL   EMBO J. 4:1251-1255(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT GLY-76.
RX   PubMed=2946935; DOI=10.1128/mcb.6.5.1379;
RA   Lamb P., Crawford L.;
RT   "Characterization of the human p53 gene.";
RL   Mol. Cell. Biol. 6:1379-1385(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3894933; DOI=10.1128/mcb.5.7.1601;
RA   Harlow E., Williamson N.M., Ralston R., Helfman D.M., Adams T.E.;
RT   "Molecular cloning and in vitro expression of a cDNA clone for human
RT   cellular tumor antigen p53.";
RL   Mol. Cell. Biol. 5:1601-1610(1985).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3025664; DOI=10.1128/mcb.6.12.4650;
RA   Harris N., Brill E., Shohat O., Prokocimer M., Wolf D., Arai N., Rotter V.;
RT   "Molecular basis for heterogeneity of the human p53 protein.";
RL   Mol. Cell. Biol. 6:4650-4656(1986).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2905688; DOI=10.1016/0378-1119(88)90196-5;
RA   Buchman V.L., Chumakov P.M., Ninkina N.N., Samarina O.P., Georgiev G.P.;
RT   "A variation in the structure of the protein-coding region of the human p53
RT   gene.";
RL   Gene 70:245-252(1988).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS SPORADIC CANCERS.
RX   PubMed=1915267; DOI=10.1002/j.1460-2075.1991.tb07837.x;
RA   Farrell P.J., Allan G., Shanahan F., Vousden K.H., Crook T.;
RT   "p53 is frequently mutated in Burkitt's lymphoma cell lines.";
RL   EMBO J. 10:2879-2887(1991).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286.
RX   PubMed=8316628; DOI=10.2307/3578196;
RA   Allalunis-Turner M.J., Barron G.M., Day R.S. III, Dobler K.D.,
RA   Mirzayans R.;
RT   "Isolation of two cell lines from a human malignant glioma specimen
RT   differing in sensitivity to radiation and chemotherapeutic drugs.";
RL   Radiat. Res. 134:349-354(1993).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH WWOX.
RX   PubMed=11058590; DOI=10.1074/jbc.m007140200;
RA   Chang N.-S., Pratt N., Heath J., Schultz L., Sleve D., Carey G.B.,
RA   Zevotek N.;
RT   "Hyaluronidase induction of a WW domain-containing oxidoreductase that
RT   enhances tumor necrosis factor cytotoxicity.";
RL   J. Biol. Chem. 276:3361-3370(2001).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 7; 8 AND 9), SUBCELLULAR
RP   LOCATION, TISSUE SPECIFICITY, ALTERNATIVE PROMOTER USAGE, ALTERNATIVE
RP   SPLICING, INDUCTION, AND VARIANT ARG-72.
RC   TISSUE=Colon;
RX   PubMed=16131611; DOI=10.1101/gad.1339905;
RA   Bourdon J.C., Fernandes K., Murray-Zmijewski F., Liu G., Diot A.,
RA   Xirodimas D.P., Saville M.K., Lane D.P.;
RT   "p53 isoforms can regulate p53 transcriptional activity.";
RL   Genes Dev. 19:2122-2137(2005).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Chumakov P.M., Almazov V.P., Jenkins J.R.;
RL   Submitted (JUN-1991) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Rozemuller E.H., Tilanus M.G.J.;
RT   "P53 genomic sequence. Corrections and polymorphism.";
RL   Submitted (MAR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-47; LYS-339 AND
RP   ALA-366.
RG   NIEHS SNPs program;
RL   Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286.
RX   PubMed=11023613; DOI=10.1667/0033-7587(2000)154[0473:htftmg]2.0.co;2;
RA   Anderson C.W., Allalunis-Turner M.J.;
RT   "Human TP53 from the malignant glioma-derived cell lines M059J and M059K
RT   has a cancer-associated mutation in exon 8.";
RL   Radiat. Res. 154:473-476(2000).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS HIS-273 AND SER-309.
RA   Azuma K., Shichijo S., Itoh K.;
RT   "Identification of a tumor-rejection antigen recognized by HLA-B46
RT   restricted CTL.";
RL   Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-72.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ARG-72.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [18]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ALA-278.
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-379 (ISOFORM 1), AND VARIANTS ASN-139 AND
RP   PRO-155.
RC   TISSUE=Lung carcinoma;
RX   PubMed=14660794; DOI=10.1073/pnas.2536558100;
RA   Kanashiro C.A., Schally A.V., Groot K., Armatis P., Bernardino A.L.,
RA   Varga J.L.;
RT   "Inhibition of mutant p53 expression and growth of DMS-153 small cell lung
RT   carcinoma by antagonists of growth hormone-releasing hormone and
RT   bombesin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:15836-15841(2003).
RN   [20]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 101-393.
RX   PubMed=6396087; DOI=10.1002/j.1460-2075.1984.tb02287.x;
RA   Matlashewski G., Lamb P., Pim D., Peacock J., Crawford L., Benchimol S.;
RT   "Isolation and characterization of a human p53 cDNA clone: expression of
RT   the human p53 gene.";
RL   EMBO J. 3:3257-3262(1984).
RN   [21]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 126-185.
RA   Pan X.L., Zhang A.H.;
RT   "Study on the effect of tumor suppressor gene p53 in arsenism patients.";
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN   [22]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 261-298, AND VARIANT GLN-282.
RC   TISSUE=Blood;
RA   Nimri L.F., Owais W., Momani E.;
RT   "Detection of P53 gene mutations and serum p53 antibodies associated with
RT   cigarette smoking.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [23]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 262-306, AND VARIANT VAL-262.
RC   TISSUE=Ovarian adenocarcinoma;
RA   Filippini G., Soldati G.;
RL   Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases.
RN   [24]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260.
RC   TISSUE=Glial cell, and Glial tumor;
RA   Thompson-Hehir J., Davies M.P.A., Green J.A., Halliwell N., Joyce K.A.,
RA   Salisbury J., Sibson D.R., Vergote I., Walker C.;
RT   "Mutation detection utilizing a novel PCR approach for amplification of the
RT   p53 gene from microdissected tissue: application to archival tumor
RT   samples.";
RL   Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
RN   [25]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260.
RA   Yavuz A.S., Farner N.L., Yavuz S., Grammer A.C., Girschick H.J.,
RA   Lipsky P.E.;
RT   "Bcl6 and P53 gene mutations in tonsillar B cells.";
RL   Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [26]
RP   PROTEIN SEQUENCE OF 320-337, SUBUNIT, INTERACTION WITH PRMT5, SUBCELLULAR
RP   LOCATION, METHYLATION AT ARG-333; ARG-335 AND ARG-337 BY PRMT5,
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND MUTAGENESIS OF 333-ARG--ARG-337.
RX   PubMed=19011621; DOI=10.1038/ncb1802;
RA   Jansson M., Durant S.T., Cho E.C., Sheahan S., Edelmann M., Kessler B.,
RA   La Thangue N.B.;
RT   "Arginine methylation regulates the p53 response.";
RL   Nat. Cell Biol. 10:1431-1439(2008).
RN   [27]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 332-366.
RA   Pinto E.M., Mendonca B.B., Latronico A.C.;
RT   "Allelic variant in intron 9 of TP53 gene.";
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [28]
RP   INTERACTION WITH HUMAN PAPILLOMAVIRUS TYPE 6 AND 11 PROTEIN E6 (MICROBIAL
RP   INFECTION).
RX   PubMed=2175676; DOI=10.1016/0092-8674(90)90409-8;
RA   Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M.;
RT   "The E6 oncoprotein encoded by human papillomavirus types 16 and 18
RT   promotes the degradation of p53.";
RL   Cell 63:1129-1136(1990).
RN   [29]
RP   NUCLEAR LOCALIZATION SIGNAL, AND MUTAGENESIS OF LYS-319; LYS-320 AND
RP   LYS-321.
RX   PubMed=2156209;
RA   Addison C., Jenkins J.R., Sturzbecher H.-W.;
RT   "The p53 nuclear localisation signal is structurally linked to a p34cdc2
RT   kinase motif.";
RL   Oncogene 5:423-426(1990).
RN   [30]
RP   PHOSPHORYLATION BY P60/CDC2 AND CYCLIN B/CDC2.
RX   PubMed=2141171; DOI=10.1073/pnas.87.12.4766;
RA   Bischoff J.R., Friedman P.N., Marshak D.R., Prives C., Beach D.;
RT   "Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:4766-4770(1990).
RN   [31]
RP   PHOSPHORYLATION.
RX   PubMed=1705009; DOI=10.1128/mcb.11.3.1598;
RA   Samad A., Carroll R.B.;
RT   "The tumor suppressor p53 is bound to RNA by a stable covalent linkage.";
RL   Mol. Cell. Biol. 11:1598-1606(1991).
RN   [32]
RP   DEPHOSPHORYLATION BY PP2A.
RX   PubMed=1848668; DOI=10.1128/mcb.11.4.1996;
RA   Scheidtmann K.H., Mumby M.C., Rundell K., Walter G.;
RT   "Dephosphorylation of simian virus 40 large-T antigen and p53 protein by
RT   protein phosphatase 2A: inhibition by small-t antigen.";
RL   Mol. Cell. Biol. 11:1996-2003(1991).
RN   [33]
RP   ALTERNATIVE SPLICING.
RX   PubMed=8632903;
RA   Flaman J.-M., Waridel F., Estreicher A., Vannier A., Limacher J.-M.,
RA   Gilbert D., Iggo R., Frebourg T.;
RT   "The human tumour suppressor gene p53 is alternatively spliced in normal
RT   cells.";
RL   Oncogene 12:813-818(1996).
RN   [34]
RP   GLYCOSYLATION.
RX   PubMed=8632915;
RA   Shaw P., Freeman J., Bovey R., Iggo R.;
RT   "Regulation of specific DNA binding by p53: evidence for a role for O-
RT   glycosylation and charged residues at the carboxy-terminus.";
RL   Oncogene 12:921-930(1996).
RN   [35]
RP   PHOSPHORYLATION AT SER-33.
RX   PubMed=9372954; DOI=10.1128/mcb.17.12.7220;
RA   Ko L.J., Shieh S.-Y., Chen X., Jayaraman L., Tamai K., Taya Y., Prives C.,
RA   Pan Z.-Q.;
RT   "p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner.";
RL   Mol. Cell. Biol. 17:7220-7229(1997).
RN   [36]
RP   FUNCTION, AND IDENTIFICATION IN COMPLEX WITH CAK.
RX   PubMed=9840937; DOI=10.1038/sj.onc.1202504;
RA   Schneider E., Montenarh M., Wagner P.;
RT   "Regulation of CAK kinase activity by p53.";
RL   Oncogene 17:2733-2741(1998).
RN   [37]
RP   SUMOYLATION AT LYS-386, AND MUTAGENESIS OF LYS-386.
RA   Gostissa M., Hengstermann A., Fogal V., Sandy P., Schwarz S.E.,
RA   Scheffner M., Del Sal G.;
RT   "Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1.";
RL   EMBO J. 18:6462-6471(1999).
RN   [38]
RP   PHOSPHORYLATION AT THR-18 BY CSNK1D/CK1.
RX   PubMed=10606744; DOI=10.1016/s0014-5793(99)01647-6;
RA   Dumaz N., Milne D.M., Meek D.W.;
RT   "Protein kinase CK1 is a p53-threonine 18 kinase which requires prior
RT   phosphorylation of serine 15.";
RL   FEBS Lett. 463:312-316(1999).
RN   [39]
RP   BIPARTITE NUCLEAR LOCALIZATION SIGNAL, AND CHARACTERIZATION OF VARIANT
RP   ASN-305.
RX   PubMed=10551826; DOI=10.1074/jbc.274.46.32699;
RA   Liang S.H., Clarke M.F.;
RT   "A bipartite nuclear localization signal is required for p53 nuclear import
RT   regulated by a carboxyl-terminal domain.";
RL   J. Biol. Chem. 274:32699-32703(1999).
RN   [40]
RP   PHOSPHORYLATION AT SER-15 AND SER-20, INDUCTION BY DNA DAMAGE,
RP   CHARACTERIZATION OF LFS VARIANT HIS-273, MUTAGENESIS OF THR-18; SER-20 AND
RP   22-LEU-TRP-23, SUBCELLULAR LOCATION, AND INTERACTION WITH PML AND MDM2.
RX   PubMed=10570149; DOI=10.1073/pnas.96.24.13777;
RA   Chehab N.H., Malikzay A., Stavridi E.S., Halazonetis T.D.;
RT   "Phosphorylation of Ser-20 mediates stabilization of human p53 in response
RT   to DNA damage.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:13777-13782(1999).
RN   [41]
RP   UBIQUITINATION.
RX   PubMed=10722742; DOI=10.1074/jbc.275.12.8945;
RA   Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., Weissman A.M.;
RT   "Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and
RT   p53.";
RL   J. Biol. Chem. 275:8945-8951(2000).
RN   [42]
RP   ACETYLATION AT LYS-373 AND LYS-382.
RX   PubMed=10656795; DOI=10.1006/jmbi.1999.3415;
RA   Abraham J., Kelly J., Thibault P., Benchimol S.;
RT   "Post-translational modification of p53 protein in response to ionizing
RT   radiation analyzed by mass spectrometry.";
RL   J. Mol. Biol. 295:853-864(2000).
RN   [43]
RP   PHOSPHORYLATION AT SER-315 AND SER-392 BY CDK2, AND MUTAGENESIS OF LYS-382;
RP   LEU-383 AND PHE-385.
RX   PubMed=10884347; DOI=10.1006/jmbi.2000.3830;
RA   Luciani M.G., Hutchins J.R.A., Zheleva D., Hupp T.R.;
RT   "The C-terminal regulatory domain of p53 contains a functional docking site
RT   for cyclin A.";
RL   J. Mol. Biol. 300:503-518(2000).
RN   [44]
RP   FUNCTION, INTERACTION WITH PML, AND SUBCELLULAR LOCATION.
RX   PubMed=11025664; DOI=10.1038/35036365;
RA   Guo A., Salomoni P., Luo J., Shih A., Zhong S., Gu W., Pandolfi P.P.;
RT   "The function of PML in p53-dependent apoptosis.";
RL   Nat. Cell Biol. 2:730-736(2000).
RN   [45]
RP   INTERACTION WITH E4F1.
RX   PubMed=10644996; DOI=10.1038/sj.onc.1203250;
RA   Sandy P., Gostissa M., Fogal V., Cecco L.D., Szalay K., Rooney R.J.,
RA   Schneider C., Del Sal G.;
RT   "p53 is involved in the p120E4F-mediated growth arrest.";
RL   Oncogene 19:188-199(2000).
RN   [46]
RP   PHOSPHORYLATION AT THR-18.
RX   PubMed=10951572; DOI=10.1038/sj.onc.1203709;
RA   Lopez-Borges S., Lazo P.A.;
RT   "The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18
RT   within the mdm-2 binding site of the p53 tumour suppressor protein.";
RL   Oncogene 19:3656-3664(2000).
RN   [47]
RP   REVIEW ON ZINC-BINDING PROPERTIES.
RX   PubMed=11554448; DOI=10.1089/15230860152542961;
RA   Hainaut P., Mann K.;
RT   "Zinc binding and redox control of p53 structure and function.";
RL   Antioxid. Redox Signal. 3:611-623(2001).
RN   [48]
RP   PHOSPHORYLATION AT SER-15.
RX   PubMed=11554766; DOI=10.1006/bbrc.2001.5627;
RA   Imamura K., Ogura T., Kishimoto A., Kaminishi M., Esumi H.;
RT   "Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated
RT   protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D-
RT   ribofuranoside, in a human hepatocellular carcinoma cell line.";
RL   Biochem. Biophys. Res. Commun. 287:562-567(2001).
RN   [49]
RP   DEACETYLATION AT LYS-382 BY SIRT1.
RX   PubMed=11672523; DOI=10.1016/s0092-8674(01)00527-x;
RA   Vaziri H., Dessain S.K., Ng Eaton E., Imai S., Frye R.A., Pandita T.K.,
RA   Guarente L., Weinberg R.A.;
RT   "hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.";
RL   Cell 107:149-159(2001).
RN   [50]
RP   MINIMAL REPRESSION DOMAIN.
RX   PubMed=11007800; DOI=10.1074/jbc.m008231200;
RA   Hong T.M., Chen J.J., Peck K., Yang P.C., Wu C.W.;
RT   "p53 amino acids 339-346 represent the minimal p53 repression domain.";
RL   J. Biol. Chem. 276:1510-1515(2001).
RN   [51]
RP   PHOSPHORYLATION AT SER-20 BY PLK3.
RX   PubMed=11447225; DOI=10.1074/jbc.m104157200;
RA   Xie S., Wang Q., Wu H., Cogswell J., Lu L., Jhanwar-Uniyal M., Dai W.;
RT   "Reactive oxygen species-induced phosphorylation of p53 on serine 20 is
RT   mediated in part by polo-like kinase-3.";
RL   J. Biol. Chem. 276:36194-36199(2001).
RN   [52]
RP   PHOSPHORYLATION AT SER-20 BY PLK3.
RX   PubMed=11551930; DOI=10.1074/jbc.m106050200;
RA   Xie S., Wu H., Wang Q., Cogswell J.P., Husain I., Conn C., Stambrook P.,
RA   Jhanwar-Uniyal M., Dai W.;
RT   "Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at
RT   least in part via the p53 pathway.";
RL   J. Biol. Chem. 276:43305-43312(2001).
RN   [53]
RP   SUMOYLATION AT LYS-386, SUBCELLULAR LOCATION, AND MUTAGENESIS OF PHE-385;
RP   LYS-386; THR-387 AND GLU-388.
RX   PubMed=11124955; DOI=10.1074/jbc.m009476200;
RA   Rodriguez M.S., Dargemont C., Hay R.T.;
RT   "SUMO-1 conjugation in vivo requires both a consensus modification motif
RT   and nuclear targeting.";
RL   J. Biol. Chem. 276:12654-12659(2001).
RN   [54]
RP   PHOSPHORYLATION BY PRPK.
RX   PubMed=11546806; DOI=10.1074/jbc.m105669200;
RA   Abe Y., Matsumoto S., Wei S., Nezu K., Miyoshi A., Kito K., Ueda N.,
RA   Shigemoto K., Hitsumoto Y., Nikawa J., Enomoto Y.;
RT   "Cloning and characterization of a p53-related protein kinase expressed in
RT   interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, and
RT   the testes.";
RL   J. Biol. Chem. 276:44003-44011(2001).
RN   [55]
RP   PHOSPHORYLATION AT SER-392.
RX   PubMed=11239457; DOI=10.1016/s1097-2765(01)00176-9;
RA   Keller D.M., Zeng X., Wang Y., Zhang Q.H., Kapoor M., Shu H., Goodman R.,
RA   Lozano G., Zhao Y., Lu H.;
RT   "A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16,
RT   and SSRP1.";
RL   Mol. Cell 7:283-292(2001).
RN   [56]
RP   INTERACTION WITH USP7.
RX   PubMed=12507430; DOI=10.1016/s0092-8674(02)01199-6;
RA   Hu M., Li P., Li M., Li W., Yao T., Wu J.-W., Gu W., Cohen R.E., Shi Y.;
RT   "Crystal structure of a UBP-family deubiquitinating enzyme in isolation and
RT   in complex with ubiquitin aldehyde.";
RL   Cell 111:1041-1054(2002).
RN   [57]
RP   IDENTIFICATION IN A COMPLEX WITH CABLES1 AND TP73.
RX   PubMed=11706030; DOI=10.1074/jbc.m108535200;
RA   Tsuji K., Mizumoto K., Yamochi T., Nishimoto I., Matsuoka M.;
RT   "Differential effect of ik3-1/cables on p53- and p73-induced cell death.";
RL   J. Biol. Chem. 277:2951-2957(2002).
RN   [58]
RP   INTERACTION WITH HIPK2.
RX   PubMed=11925430; DOI=10.1074/jbc.m200153200;
RA   Kim E.-J., Park J.-S., Um S.-J.;
RT   "Identification and characterization of HIPK2 interacting with p73 and
RT   modulating functions of the p53 family in vivo.";
RL   J. Biol. Chem. 277:32020-32028(2002).
RN   [59]
RP   INTERACTION WITH HIPK2, PHOSPHORYLATION AT SER-46, AND MUTAGENESIS OF
RP   SER-46 AND LYS-382.
RX   PubMed=11740489; DOI=10.1038/ncb715;
RA   Hofmann T.G., Moeller A., Sirma H., Zentgraf H., Taya Y., Droege W.,
RA   Will H., Schmitz M.L.;
RT   "Regulation of p53 activity by its interaction with homeodomain-interacting
RT   protein kinase-2.";
RL   Nat. Cell Biol. 4:1-10(2002).
RN   [60]
RP   INTERACTION WITH HIPK2, AND PHOSPHORYLATION AT SER-46.
RX   PubMed=11780126; DOI=10.1038/ncb714;
RA   D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y., Saito S.,
RA   Gostissa M., Coen S., Marchetti A., Del Sal G., Piaggio G., Fanciulli M.,
RA   Appella E., Soddu S.;
RT   "Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and
RT   mediates apoptosis.";
RL   Nat. Cell Biol. 4:11-19(2002).
RN   [61]
RP   INTERACTION WITH ING4.
RX   PubMed=12750254;
RA   Shiseki M., Nagashima M., Pedeux R.M., Kitahama-Shiseki M., Miura K.,
RA   Okamura S., Onogi H., Higashimoto Y., Appella E., Yokota J., Harris C.C.;
RT   "p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity.";
RL   Cancer Res. 63:2373-2378(2003).
RN   [62]
RP   ACETYLATION AT LYS-305.
RX   PubMed=12724314; DOI=10.1074/jbc.m212574200;
RA   Wang Y.H., Tsay Y.G., Tan B.C., Lo W.Y., Lee S.C.;
RT   "Identification and characterization of a novel p300-mediated p53
RT   acetylation site, lysine 305.";
RL   J. Biol. Chem. 278:25568-25576(2003).
RN   [63]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH CHEK2 AND PML,
RP   UBIQUITINATION BY MDM2, AND PHOSPHORYLATION AT SER-20.
RX   PubMed=12810724; DOI=10.1074/jbc.m301264200;
RA   Louria-Hayon I., Grossman T., Sionov R.V., Alsheich O., Pandolfi P.P.,
RA   Haupt Y.;
RT   "The promyelocytic leukemia protein protects p53 from Mdm2-mediated
RT   inhibition and degradation.";
RL   J. Biol. Chem. 278:33134-33141(2003).
RN   [64]
RP   INTERACTION WITH TP53INP1.
RX   PubMed=12851404; DOI=10.1074/jbc.m301979200;
RA   Tomasini R., Samir A.A., Carrier A., Isnardon D., Cecchinelli B., Soddu S.,
RA   Malissen B., Dagorn J.-C., Iovanna J.L., Dusetti N.J.;
RT   "TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are
RT   partners in regulating p53 activity.";
RL   J. Biol. Chem. 278:37722-37729(2003).
RN   [65]
RP   NUCLEOCYTOPLASMIC SHUTTLING, AND NUCLEAR EXPORT SIGNAL.
RX   PubMed=12944468; DOI=10.1128/mcb.23.18.6396-6405.2003;
RA   O'Keefe K., Li H., Zhang Y.;
RT   "Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated
RT   cytoplasmic degradation but not ubiquitination.";
RL   Mol. Cell. Biol. 23:6396-6405(2003).
RN   [66]
RP   FUNCTION, AND INTERACTION WITH PPP1R13L; PPP1R13B AND TP53BP2.
RX   PubMed=12524540; DOI=10.1038/ng1070;
RA   Bergamaschi D., Samuels Y., O'Neil N.J., Trigiante G., Crook T.,
RA   Hsieh J.-K., O'Connor D.J., Zhong S., Campargue I., Tomlinson M.L.,
RA   Kuwabara P.E., Lu X.;
RT   "iASPP oncoprotein is a key inhibitor of p53 conserved from worm to
RT   human.";
RL   Nat. Genet. 33:162-167(2003).
RN   [67]
RP   INTERACTION WITH HIPK1.
RX   PubMed=12702766; DOI=10.1073/pnas.0530308100;
RA   Kondo S., Lu Y., Debbas M., Lin A.W., Sarosi I., Itie A., Wakeham A.,
RA   Tuan J., Saris C., Elliott G., Ma W., Benchimol S., Lowe S.W., Mak T.W.,
RA   Thukral S.K.;
RT   "Characterization of cells and gene-targeted mice deficient for the p53-
RT   binding kinase homeodomain-interacting protein kinase 1 (HIPK1).";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:5431-5436(2003).
RN   [68]
RP   INTERACTION WITH CDKN2AIP.
RX   PubMed=15109303; DOI=10.1042/bj20040337;
RA   Hasan M.K., Yaguchi T., Minoda Y., Hirano T., Taira K., Wadhwa R.,
RA   Kaul S.C.;
RT   "Alternative reading frame protein (ARF)-independent function of CARF
RT   (collaborator of ARF) involves its interactions with p53: evidence for a
RT   novel p53-activation pathway and its negative feedback control.";
RL   Biochem. J. 380:605-610(2004).
RN   [69]
RP   INTERACTION WITH HRMT1L2; EP300 AND CARM1, AND FUNCTION.
RX   PubMed=15186775; DOI=10.1016/j.cell.2004.05.009;
RA   An W., Kim J., Roeder R.G.;
RT   "Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional
RT   activation by p53.";
RL   Cell 117:735-748(2004).
RN   [70]
RP   INTERACTION WITH ANKRD2.
RX   PubMed=15136035; DOI=10.1016/j.jmb.2004.03.071;
RA   Kojic S., Medeot E., Guccione E., Krmac H., Zara I., Martinelli V.,
RA   Valle G., Faulkner G.;
RT   "The Ankrd2 protein, a link between the sarcomere and the nucleus in
RT   skeletal muscle.";
RL   J. Mol. Biol. 339:313-325(2004).
RN   [71]
RP   PHOSPHORYLATION AT THR-55, MUTAGENESIS OF THR-55, AND INTERACTION WITH
RP   TAF1.
RX   PubMed=15053879; DOI=10.1016/s1097-2765(04)00123-6;
RA   Li H.-H., Li A.G., Sheppard H.M., Liu X.;
RT   "Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for
RT   TAF1 in cell G1 progression.";
RL   Mol. Cell 13:867-878(2004).
RN   [72]
RP   DEUBIQUITINATION BY USP7.
RX   PubMed=15053880; DOI=10.1016/s1097-2765(04)00157-1;
RA   Li M., Brooks C.L., Kon N., Gu W.;
RT   "A dynamic role of HAUSP in the p53-Mdm2 pathway.";
RL   Mol. Cell 13:879-886(2004).
RN   [73]
RP   ALTERNATIVE SPLICING (ISOFORM 4), FUNCTION, SUBCELLULAR LOCATION, AND
RP   UBIQUITINATION.
RX   PubMed=15340061; DOI=10.1128/mcb.24.18.7987-7997.2004;
RA   Ghosh A., Stewart D., Matlashewski G.;
RT   "Regulation of human p53 activity and cell localization by alternative
RT   splicing.";
RL   Mol. Cell. Biol. 24:7987-7997(2004).
RN   [74]
RP   METHYLATION AT LYS-372, AND MUTAGENESIS OF LYS-372.
RX   PubMed=15525938; DOI=10.1038/nature03117;
RA   Chuikov S., Kurash J.K., Wilson J.R., Xiao B., Justin N., Ivanov G.S.,
RA   McKinney K., Tempst P., Prives C., Gamblin S.J., Barlev N.A., Reinberg D.;
RT   "Regulation of p53 activity through lysine methylation.";
RL   Nature 432:353-360(2004).
RN   [75]
RP   INTERACTION WITH AURKA, AND PHOSPHORYLATION AT SER-315.
RX   PubMed=14702041; DOI=10.1038/ng1279;
RA   Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F.,
RA   Fujii S., Arlinghaus R.B., Czerniak B.A., Sen S.;
RT   "Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization
RT   and inhibition of p53.";
RL   Nat. Genet. 36:55-62(2004).
RN   [76]
RP   INTERACTION WITH NOC2L.
RX   PubMed=16322561; DOI=10.1101/gad.351205;
RA   Hublitz P., Kunowska N., Mayer U.P., Muller J.M., Heyne K., Yin N.,
RA   Fritzsche C., Poli C., Miguet L., Schupp I.W., van Grunsven L.A.,
RA   Potiers N., van Dorsselaer A., Metzger E., Roemer K., Schule R.;
RT   "NIR is a novel INHAT repressor that modulates the transcriptional activity
RT   of p53.";
RL   Genes Dev. 19:2912-2924(2005).
RN   [77]
RP   INTERACTION WITH BANP, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT SER-15.
RX   PubMed=15701641; DOI=10.1074/jbc.m413200200;
RA   Jalota-Badhwar A., Singh K., Pavithra L., Kaul-Ghanekar R., Jameel S.,
RA   Chattopadhyay S.;
RT   "Tumor suppressor SMAR1 activates and stabilizes p53 through its arginine-
RT   serine-rich motif.";
RL   J. Biol. Chem. 280:16019-16029(2005).
RN   [78]
RP   INTERACTION WITH PTK2/FAK1.
RX   PubMed=15855171; DOI=10.1074/jbc.m414172200;
RA   Golubovskaya V.M., Finch R., Cance W.G.;
RT   "Direct interaction of the N-terminal domain of focal adhesion kinase with
RT   the N-terminal transactivation domain of p53.";
RL   J. Biol. Chem. 280:25008-25021(2005).
RN   [79]
RP   INTERACTION WITH WWOX, AND MUTAGENESIS OF SER-46.
RX   PubMed=16219768; DOI=10.1074/jbc.m505590200;
RA   Chang N.-S., Doherty J., Ensign A., Schultz L., Hsu L.-J., Hong Q.;
RT   "WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-,
RT   and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds
RT   and stabilizes serine 46-phosphorylated p53.";
RL   J. Biol. Chem. 280:43100-43108(2005).
RN   [80]
RP   PHOSPHORYLATION AT SER-15.
RX   PubMed=15866171; DOI=10.1016/j.molcel.2005.03.027;
RA   Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M.J.,
RA   Thompson C.B.;
RT   "AMP-activated protein kinase induces a p53-dependent metabolic
RT   checkpoint.";
RL   Mol. Cell 18:283-293(2005).
RN   [81]
RP   INTERACTION WITH STK11/LKB1, AND PHOSPHORYLATION AT SER-15 AND SER-392.
RX   PubMed=17108107; DOI=10.1158/0008-5472.can-06-0999;
RA   Zeng P.Y., Berger S.L.;
RT   "LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate
RT   transcriptional activation.";
RL   Cancer Res. 66:10701-10708(2006).
RN   [82]
RP   PHOSPHORYLATION AT THR-18.
RX   PubMed=16704422; DOI=10.1111/j.1742-4658.2006.05256.x;
RA   Blanco S., Klimcakova L., Vega F.M., Lazo P.A.;
RT   "The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms
RT   determines their different effect on p53 stability in tumour cell lines.";
RL   FEBS J. 273:2487-2504(2006).
RN   [83]
RP   INTERACTION WITH YWHAZ.
RX   PubMed=16376338; DOI=10.1016/j.febslet.2005.12.024;
RA   Gu Y.-M., Jin Y.-H., Choi J.-K., Baek K.-H., Yeo C.-Y., Lee K.-Y.;
RT   "Protein kinase A phosphorylates and regulates dimerization of 14-3-3
RT   epsilon.";
RL   FEBS Lett. 580:305-310(2006).
RN   [84]
RP   PHOSPHORYLATION AT SER-46, AND INTERACTION WITH PRKCG.
RX   PubMed=16377624; DOI=10.1074/jbc.m512074200;
RA   Yoshida K., Liu H., Miki Y.;
RT   "Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor
RT   suppressor in the apoptotic response to DNA damage.";
RL   J. Biol. Chem. 281:5734-5740(2006).
RN   [85]
RP   METHYLATION AT LYS-370, AND MUTAGENESIS OF LYS-370.
RX   PubMed=17108971; DOI=10.1038/nature05287;
RA   Huang J., Perez-Burgos L., Placek B.J., Sengupta R., Richter M.,
RA   Dorsey J.A., Kubicek S., Opravil S., Jenuwein T., Berger S.L.;
RT   "Repression of p53 activity by Smyd2-mediated methylation.";
RL   Nature 444:629-632(2006).
RN   [86]
RP   INTERACTION WITH DAXX.
RX   PubMed=16845383; DOI=10.1038/ncb1442;
RA   Tang J., Qu L.K., Zhang J., Wang W., Michaelson J.S., Degenhardt Y.Y.,
RA   El-Deiry W.S., Yang X.;
RT   "Critical role for Daxx in regulating Mdm2.";
RL   Nat. Cell Biol. 8:855-862(2006).
RN   [87]
RP   MOTIF, AND METHYLATION AT LYS-372.
RX   PubMed=16415881; DOI=10.1038/nsmb1045;
RA   Couture J.-F., Collazo E., Hauk G., Trievel R.C.;
RT   "Structural basis for the methylation site specificity of SET7/9.";
RL   Nat. Struct. Mol. Biol. 13:140-146(2006).
RN   [88]
RP   INTERACTION WITH POU4F2.
RX   PubMed=17145718; DOI=10.1093/nar/gkl878;
RA   Budhram-Mahadeo V.S., Bowen S., Lee S., Perez-Sanchez C., Ensor E.,
RA   Morris P.J., Latchman D.S.;
RT   "Brn-3b enhances the pro-apoptotic effects of p53 but not its induction of
RT   cell cycle arrest by cooperating in trans-activation of bax expression.";
RL   Nucleic Acids Res. 34:6640-6652(2006).
RN   [89]
RP   PHOSPHORYLATION AT SER-37, AND MUTAGENESIS OF SER-37.
RX   PubMed=17254968; DOI=10.1016/j.cell.2006.11.050;
RA   Sun P., Yoshizuka N., New L., Moser B.A., Li Y., Liao R., Xie C., Chen J.,
RA   Deng Q., Yamout M., Dong M.Q., Frangou C.G., Yates J.R. III, Wright P.E.,
RA   Han J.;
RT   "PRAK is essential for ras-induced senescence and tumor suppression.";
RL   Cell 128:295-308(2007).
RN   [90]
RP   INTERACTION WITH ZNF385A, AND CHARACTERIZATION OF VARIANTS ALA-143; HIS-175
RP   AND PRO-175.
RX   PubMed=17719541; DOI=10.1016/j.cell.2007.06.013;
RA   Das S., Raj L., Zhao B., Kimura Y., Bernstein A., Aaronson S.A., Lee S.W.;
RT   "Hzf Determines cell survival upon genotoxic stress by modulating p53
RT   transactivation.";
RL   Cell 130:624-637(2007).
RN   [91]
RP   UBIQUITINATION, INTERACTION WITH SYVN1, AND SUBCELLULAR LOCATION.
RX   PubMed=17170702; DOI=10.1038/sj.emboj.7601490;
RA   Yamasaki S., Yagishita N., Sasaki T., Nakazawa M., Kato Y., Yamadera T.,
RA   Bae E., Toriyama S., Ikeda R., Zhang L., Fujitani K., Yoo E.,
RA   Tsuchimochi K., Ohta T., Araya N., Fujita H., Aratani S., Eguchi K.,
RA   Komiya S., Maruyama I., Higashi N., Sato M., Senoo H., Ochi T.,
RA   Yokoyama S., Amano T., Kim J., Gay S., Fukamizu A., Nishioka K., Tanaka K.,
RA   Nakajima T.;
RT   "Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident
RT   ubiquitin ligase 'Synoviolin'.";
RL   EMBO J. 26:113-122(2007).
RN   [92]
RP   INTERACTION WITH PPP2CA; PPP2R1A; PPP2R2A AND PPP2R5C.
RX   PubMed=17245430; DOI=10.1038/sj.emboj.7601519;
RA   Li H.H., Cai X., Shouse G.P., Piluso L.G., Liu X.;
RT   "A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced
RT   dephosphorylation of p53 at Thr55.";
RL   EMBO J. 26:402-411(2007).
RN   [93]
RP   INTERACTION WITH ARMC10.
RX   PubMed=17904127; DOI=10.1016/j.febslet.2007.09.025;
RA   Zhou X., Yang G., Huang R., Chen X., Hu G.;
RT   "SVH-B interacts directly with p53 and suppresses the transcriptional
RT   activity of p53.";
RL   FEBS Lett. 581:4943-4948(2007).
RN   [94]
RP   PHOSPHORYLATION AT SER-9.
RX   PubMed=18022393; DOI=10.1016/j.febslet.2007.11.022;
RA   Arai S., Matsushita A., Du K., Yagi K., Okazaki Y., Kurokawa R.;
RT   "Novel homeodomain-interacting protein kinase family member, HIPK4,
RT   phosphorylates human p53 at serine 9.";
RL   FEBS Lett. 581:5649-5657(2007).
RN   [95]
RP   DOMAIN.
RX   PubMed=17467953; DOI=10.1016/j.ygeno.2007.02.003;
RA   Piskacek S., Gregor M., Nemethova M., Grabner M., Kovarik P., Piskacek M.;
RT   "Nine-amino-acid transactivation domain: establishment and prediction
RT   utilities.";
RL   Genomics 89:756-768(2007).
RN   [96]
RP   INTERACTION WITH RFFL AND RNF34.
RX   PubMed=17121812; DOI=10.1074/jbc.m610793200;
RA   Yang W., Rozan L.M., McDonald E.R. III, Navaraj A., Liu J.J., Matthew E.M.,
RA   Wang W., Dicker D.T., El-Deiry W.S.;
RT   "CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-
RT   p53ser20 degradation.";
RL   J. Biol. Chem. 282:3273-3281(2007).
RN   [97]
RP   FUNCTION, AND INTERACTION WITH MAML1.
RX   PubMed=17317671; DOI=10.1074/jbc.m608974200;
RA   Zhao Y., Katzman R.B., Delmolino L.M., Bhat I., Zhang Y., Gurumurthy C.B.,
RA   Germaniuk-Kurowska A., Reddi H.V., Solomon A., Zeng M.S., Kung A., Ma H.,
RA   Gao Q., Dimri G., Stanculescu A., Miele L., Wu L., Griffin J.D.,
RA   Wazer D.E., Band H., Band V.;
RT   "The notch regulator MAML1 interacts with p53 and functions as a
RT   coactivator.";
RL   J. Biol. Chem. 282:11969-11981(2007).
RN   [98]
RP   PHOSPHORYLATION AT SER-15; SER-33 AND SER-46, INTERACTION WITH CDK5, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=17591690; DOI=10.1242/jcs.03468;
RA   Lee J.-H., Kim H.-S., Lee S.-J., Kim K.-T.;
RT   "Stabilization and activation of p53 induced by Cdk5 contributes to
RT   neuronal cell death.";
RL   J. Cell Sci. 120:2259-2271(2007).
RN   [99]
RP   INTERACTION WITH MORC3.
RX   PubMed=17332504; DOI=10.1091/mbc.e06-08-0747;
RA   Takahashi K., Yoshida N., Murakami N., Kawata K., Ishizaki H.,
RA   Tanaka-Okamoto M., Miyoshi J., Zinn A.R., Shime H., Inoue N.;
RT   "Dynamic regulation of p53 subnuclear localization and senescence by
RT   MORC3.";
RL   Mol. Biol. Cell 18:1701-1709(2007).
RN   [100]
RP   FUNCTION, PHOSPHORYLATION AT SER-46, AND MUTAGENESIS OF SER-46.
RX   PubMed=17349958; DOI=10.1016/j.molcel.2007.02.007;
RA   Taira N., Nihira K., Yamaguchi T., Miki Y., Yoshida K.;
RT   "DYRK2 is targeted to the nucleus and controls p53 via Ser46
RT   phosphorylation in the apoptotic response to DNA damage.";
RL   Mol. Cell 25:725-738(2007).
RN   [101]
RP   DEMETHYLATION BY KDM1A.
RX   PubMed=17805299; DOI=10.1038/nature06092;
RA   Huang J., Sengupta R., Espejo A.B., Lee M.G., Dorsey J.A., Richter M.,
RA   Opravil S., Shiekhattar R., Bedford M.T., Jenuwein T., Berger S.L.;
RT   "p53 is regulated by the lysine demethylase LSD1.";
RL   Nature 449:105-108(2007).
RN   [102]
RP   METHYLATION AT LYS-382, AND MUTAGENESIS OF LYS-382.
RX   PubMed=17707234; DOI=10.1016/j.molcel.2007.07.012;
RA   Shi X., Kachirskaia I., Yamaguchi H., West L.E., Wen H., Wang E.W.,
RA   Dutta S., Appella E., Gozani O.;
RT   "Modulation of p53 function by SET8-mediated methylation at lysine 382.";
RL   Mol. Cell 27:636-646(2007).
RN   [103]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [104]
RP   ACETYLATION, AND DEACETYLATION BY SIRT2.
RX   PubMed=18249187; DOI=10.1016/j.bbrc.2008.01.114;
RA   Jin Y.H., Kim Y.J., Kim D.W., Baek K.H., Kang B.Y., Yeo C.Y., Lee K.Y.;
RT   "Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of
RT   p53.";
RL   Biochem. Biophys. Res. Commun. 368:690-695(2008).
RN   [105]
RP   INTERACTION WITH SETD2.
RX   PubMed=18585004; DOI=10.1016/j.cellsig.2008.05.012;
RA   Xie P., Tian C., An L., Nie J., Lu K., Xing G., Zhang L., He F.;
RT   "Histone methyltransferase protein SETD2 interacts with p53 and selectively
RT   regulates its downstream genes.";
RL   Cell. Signal. 20:1671-1678(2008).
RN   [106]
RP   INTERACTION WITH NUPR1.
RX   PubMed=18690848; DOI=10.2174/156800908785133196;
RA   Clark D.W., Mitra A., Fillmore R.A., Jiang W.G., Samant R.S., Fodstad O.,
RA   Shevde L.A.;
RT   "NUPR1 interacts with p53, transcriptionally regulates p21 and rescues
RT   breast epithelial cells from doxorubicin-induced genotoxic stress.";
RL   Curr. Cancer Drug Targets 8:421-430(2008).
RN   [107]
RP   UBIQUITINATION, AND SUBCELLULAR LOCATION.
RX   PubMed=18206965; DOI=10.1016/j.molcel.2007.11.031;
RA   Lim S.T., Chen X.L., Lim Y., Hanson D.A., Vo T.T., Howerton K.,
RA   Larocque N., Fisher S.J., Schlaepfer D.D., Ilic D.;
RT   "Nuclear FAK promotes cell proliferation and survival through FERM-enhanced
RT   p53 degradation.";
RL   Mol. Cell 29:9-22(2008).
RN   [108]
RP   INTERACTION WITH KAT7.
RX   PubMed=17954561; DOI=10.1128/mcb.00662-07;
RA   Iizuka M., Sarmento O.F., Sekiya T., Scrable H., Allis C.D., Smith M.M.;
RT   "Hbo1 Links p53-dependent stress signaling to DNA replication licensing.";
RL   Mol. Cell. Biol. 28:140-153(2008).
RN   [109]
RP   INTERACTION WITH PPP2CA; PPP2R1A AND PPP2R5C, PHOSPHORYLATION AT SER-15 BY
RP   ATM, AND MUTAGENESIS OF SER-15.
RX   PubMed=17967874; DOI=10.1128/mcb.00983-07;
RA   Shouse G.P., Cai X., Liu X.;
RT   "Serine 15 phosphorylation of p53 directs its interaction with B56gamma and
RT   the tumor suppressor activity of B56gamma-specific protein phosphatase
RT   2A.";
RL   Mol. Cell. Biol. 28:448-456(2008).
RN   [110]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [111]
RP   INTERACTION WITH MKRN1, MUTAGENESIS OF 291-LYS-LYS-292, AND UBIQUITINATION
RP   AT LYS-291 AND LYS-292 BY MKRN1.
RX   PubMed=19536131; DOI=10.1038/emboj.2009.164;
RA   Lee E.-W., Lee M.-S., Camus S., Ghim J., Yang M.-R., Oh W., Ha N.-C.,
RA   Lane D.P., Song J.;
RT   "Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell
RT   cycle arrest and apoptosis.";
RL   EMBO J. 28:2100-2113(2009).
RN   [112]
RP   UBIQUITINATION BY TOPORS.
RX   PubMed=19473992; DOI=10.1074/jbc.c109.001560;
RA   Yang X., Li H., Zhou Z., Wang W.H., Deng A., Andrisani O., Liu X.;
RT   "Plk1-mediated phosphorylation of Topors regulates p53 stability.";
RL   J. Biol. Chem. 284:18588-18592(2009).
RN   [113]
RP   INTERACTION WITH MTA1 AND COP1, AND UBIQUITINATION.
RX   PubMed=19837670; DOI=10.1074/jbc.m109.056499;
RA   Li D.Q., Divijendra Natha Reddy S., Pakala S.B., Wu X., Zhang Y.,
RA   Rayala S.K., Kumar R.;
RT   "MTA1 coregulator regulates p53 stability and function.";
RL   J. Biol. Chem. 284:34545-34552(2009).
RN   [114]
RP   INTERACTION WITH HHV-5 PROTEIN UL123 (MICROBIAL INFECTION).
RX   PubMed=19776115; DOI=10.1128/jvi.00304-09;
RA   Hwang E.S., Zhang Z., Cai H., Huang D.Y., Huong S.M., Cha C.Y., Huang E.S.;
RT   "Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits p53-
RT   dependent transactivation by a mechanism different from that of IE2-86
RT   protein.";
RL   J. Virol. 83:12388-12398(2009).
RN   [115]
RP   INTERACTION WITH FBXO42.
RX   PubMed=19509332; DOI=10.1073/pnas.0901864106;
RA   Sun L., Shi L., Li W., Yu W., Liang J., Zhang H., Yang X., Wang Y., Li R.,
RA   Yao X., Yi X., Shang Y.;
RT   "JFK, a Kelch domain-containing F-box protein, links the SCF complex to p53
RT   regulation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:10195-10200(2009).
RN   [116]
RP   FUNCTION, UBIQUITINATION, AND INTERACTION WITH TRIM24.
RX   PubMed=19556538; DOI=10.1073/pnas.0813177106;
RA   Allton K., Jain A.K., Herz H.M., Tsai W.W., Jung S.Y., Qin J., Bergmann A.,
RA   Johnson R.L., Barton M.C.;
RT   "Trim24 targets endogenous p53 for degradation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:11612-11616(2009).
RN   [117]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-381 AND LYS-382, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [118]
RP   INTERACTION WITH TAF6 ISOFORMS 1 AND 4.
RX   PubMed=20096117; DOI=10.1186/1471-2199-11-10;
RA   Wilhelm E., Kornete M., Targat B., Vigneault-Edwards J., Frontini M.,
RA   Tora L., Benecke A., Bell B.;
RT   "TAF6delta orchestrates an apoptotic transcriptome profile and interacts
RT   functionally with p53.";
RL   BMC Mol. Biol. 11:10-10(2010).
RN   [119]
RP   UBIQUITINATION, AND DEUBIQUITINATION BY USP10.
RX   PubMed=20096447; DOI=10.1016/j.cell.2009.12.032;
RA   Yuan J., Luo K., Zhang L., Cheville J.C., Lou Z.;
RT   "USP10 regulates p53 localization and stability by deubiquitinating p53.";
RL   Cell 140:384-396(2010).
RN   [120]
RP   FUNCTION.
RX   PubMed=20673990; DOI=10.1016/j.cell.2010.06.040;
RA   Huarte M., Guttman M., Feldser D., Garber M., Koziol M.J.,
RA   Kenzelmann-Broz D., Khalil A.M., Zuk O., Amit I., Rabani M., Attardi L.D.,
RA   Regev A., Lander E.S., Jacks T., Rinn J.L.;
RT   "A large intergenic noncoding RNA induced by p53 mediates global gene
RT   repression in the p53 response.";
RL   Cell 142:409-419(2010).
RN   [121]
RP   PHOSPHORYLATION AT SER-20 BY CSNK1D/CK1.
RX   PubMed=20041275; DOI=10.1007/s00018-009-0236-7;
RA   Venerando A., Marin O., Cozza G., Bustos V.H., Sarno S., Pinna L.A.;
RT   "Isoform specific phosphorylation of p53 by protein kinase CK1.";
RL   Cell. Mol. Life Sci. 67:1105-1118(2010).
RN   [122]
RP   INTERACTION WITH SNAI1, CHARACTERIZATION OF VARIANTS LEU-110; PRO-155;
RP   HIS-175; SER-232; SER-249; HIS-273 AND TRP-282, AND MUTAGENESIS OF ARG-248.
RX   PubMed=20385133; DOI=10.1016/j.febslet.2010.04.006;
RA   Lim S.O., Kim H., Jung G.;
RT   "p53 inhibits tumor cell invasion via the degradation of snail protein in
RT   hepatocellular carcinoma.";
RL   FEBS Lett. 584:2231-2236(2010).
RN   [123]
RP   INTERACTION WITH PTK2B/PYK2 AND MDM2, UBIQUITINATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=19880522; DOI=10.1074/jbc.m109.064212;
RA   Lim S.T., Miller N.L., Nam J.O., Chen X.L., Lim Y., Schlaepfer D.D.;
RT   "Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating
RT   cell proliferation and survival.";
RL   J. Biol. Chem. 285:1743-1753(2010).
RN   [124]
RP   METHYLATION AT LYS-373, AND MUTAGENESIS OF LYS-373.
RX   PubMed=20118233; DOI=10.1074/jbc.m109.062588;
RA   Huang J., Dorsey J., Chuikov S., Perez-Burgos L., Zhang X., Jenuwein T.,
RA   Reinberg D., Berger S.L.;
RT   "G9a and Glp methylate lysine 373 in the tumor suppressor p53.";
RL   J. Biol. Chem. 285:9636-9641(2010).
RN   [125]
RP   ERRATUM OF PUBMED:20118233.
RA   Huang J., Dorsey J., Chuikov S., Perez-Burgos L., Zhang X., Jenuwein T.,
RA   Reinberg D., Berger S.L.;
RL   J. Biol. Chem. 285:18122-18122(2010).
RN   [126]
RP   PHOSPHORYLATION AT THR-55, AND INTERACTION WITH GRK5.
RX   PubMed=20124405; DOI=10.1074/jbc.m109.094243;
RA   Chen X., Zhu H., Yuan M., Fu J., Zhou Y., Ma L.;
RT   "G-protein-coupled receptor kinase 5 phosphorylates p53 and inhibits DNA
RT   damage-induced apoptosis.";
RL   J. Biol. Chem. 285:12823-12830(2010).
RN   [127]
RP   INTERACTION WITH BRD7, AND ACETYLATION AT LYS-382.
RX   PubMed=20228809; DOI=10.1038/ncb2038;
RA   Drost J., Mantovani F., Tocco F., Elkon R., Comel A., Holstege H.,
RA   Kerkhoven R., Jonkers J., Voorhoeve P.M., Agami R., Del Sal G.;
RT   "BRD7 is a candidate tumour suppressor gene required for p53 function.";
RL   Nat. Cell Biol. 12:380-389(2010).
RN   [128]
RP   UBIQUITINATION BY RFWD3.
RX   PubMed=20173098; DOI=10.1073/pnas.0912094107;
RA   Fu X., Yucer N., Liu S., Li M., Yi P., Mu J.J., Yang T., Chu J., Jung S.Y.,
RA   O'Malley B.W., Gu W., Qin J., Wang Y.;
RT   "RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53 stability in
RT   response to DNA damage.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:4579-4584(2010).
RN   [129]
RP   INTERACTION WITH BRD7.
RX   PubMed=20660729; DOI=10.1073/pnas.1009559107;
RA   Burrows A.E., Smogorzewska A., Elledge S.J.;
RT   "Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are
RT   critical regulators of p53 required for induction of replicative
RT   senescence.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:14280-14285(2010).
RN   [130]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [131]
RP   INTERACTION WITH UHRF2.
RX   PubMed=21952639; DOI=10.4161/cc.10.19.17176;
RA   Mori T., Ikeda D.D., Fukushima T., Takenoshita S., Kochi H.;
RT   "NIRF constitutes a nodal point in the cell cycle network and is a
RT   candidate tumor suppressor.";
RL   Cell Cycle 10:3284-3299(2011).
RN   [132]
RP   FUNCTION, INTERACTION WITH AURKB AND NOC2L, PHOSPHORYLATION AT SER-183;
RP   SER-269 AND THR-284, CHARACTERIZATION OF VARIANT ALA-284, MUTAGENESIS OF
RP   SER-183 AND SER-269, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=20959462; DOI=10.1074/jbc.m110.174755;
RA   Wu L., Ma C.A., Zhao Y., Jain A.;
RT   "Aurora B interacts with NIR-p53, leading to p53 phosphorylation in its
RT   DNA-binding domain and subsequent functional suppression.";
RL   J. Biol. Chem. 286:2236-2244(2011).
RN   [133]
RP   INVOLVEMENT IN BCC7.
RX   PubMed=21946351; DOI=10.1038/ng.926;
RA   Stacey S.N., Sulem P., Jonasdottir A., Masson G., Gudmundsson J.,
RA   Gudbjartsson D.F., Magnusson O.T., Gudjonsson S.A., Sigurgeirsson B.,
RA   Thorisdottir K., Ragnarsson R., Benediktsdottir K.R., Nexo B.A.,
RA   Tjonneland A., Overvad K., Rudnai P., Gurzau E., Koppova K., Hemminki K.,
RA   Corredera C., Fuentelsaz V., Grasa P., Navarrete S., Fuertes F.,
RA   Garcia-Prats M.D., Sanambrosio E., Panadero A., De Juan A., Garcia A.,
RA   Rivera F., Planelles D., Soriano V., Requena C., Aben K.K.,
RA   van Rossum M.M., Cremers R.G., van Oort I.M., van Spronsen D.J.,
RA   Schalken J.A., Peters W.H., Helfand B.T., Donovan J.L., Hamdy F.C.,
RA   Badescu D., Codreanu O., Jinga M., Csiki I.E., Constantinescu V., Badea P.,
RA   Mates I.N., Dinu D.E., Constantin A., Mates D., Kristjansdottir S.,
RA   Agnarsson B.A., Jonsson E., Barkardottir R.B., Einarsson G.V.,
RA   Sigurdsson F., Moller P.H., Stefansson T., Valdimarsson T.,
RA   Johannsson O.T., Sigurdsson H., Jonsson T., Jonasson J.G.,
RA   Tryggvadottir L., Rice T., Hansen H.M., Xiao Y., Lachance D.H.,
RA   O'Neill B.P., Kosel M.L., Decker P.A., Thorleifsson G., Johannsdottir H.,
RA   Helgadottir H.T., Sigurdsson A., Steinthorsdottir V., Lindblom A.,
RA   Sandler R.S., Keku T.O., Banasik K., Jorgensen T., Witte D.R., Hansen T.,
RA   Pedersen O., Jinga V., Neal D.E., Catalona W.J., Wrensch M., Wiencke J.,
RA   Jenkins R.B., Nagore E., Vogel U., Kiemeney L.A., Kumar R., Mayordomo J.I.,
RA   Olafsson J.H., Kong A., Thorsteinsdottir U., Rafnar T., Stefansson K.;
RT   "A germline variant in the TP53 polyadenylation signal confers cancer
RT   susceptibility.";
RL   Nat. Genet. 43:1098-1103(2011).
RN   [134]
RP   INTERACTION WITH NUAK1, AND PHOSPHORYLATION AT SER-15 AND SER-392.
RX   PubMed=21317932; DOI=10.1038/onc.2011.19;
RA   Hou X., Liu J.E., Liu W., Liu C.Y., Liu Z.Y., Sun Z.Y.;
RT   "A new role of NUAK1: directly phosphorylating p53 and regulating cell
RT   proliferation.";
RL   Oncogene 30:2933-2942(2011).
RN   [135]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PPIF.
RX   PubMed=22726440; DOI=10.1016/j.cell.2012.05.014;
RA   Vaseva A.V., Marchenko N.D., Ji K., Tsirka S.E., Holzmann S., Moll U.M.;
RT   "p53 opens the mitochondrial permeability transition pore to trigger
RT   necrosis.";
RL   Cell 149:1536-1548(2012).
RN   [136]
RP   INTERACTION WITH UBC9, PHOSPHORYLATION AT SER-392, AND SUMOYLATION AT
RP   LYS-386.
RX   PubMed=22214662; DOI=10.4161/cc.11.2.18999;
RA   Bennett R.L., Pan Y., Christian J., Hui T., May W.S. Jr.;
RT   "The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and
RT   activation, leading to G(1) arrest.";
RL   Cell Cycle 11:407-417(2012).
RN   [137]
RP   INTERACTION WITH NOP53.
RX   PubMed=22522597; DOI=10.1038/cdd.2012.40;
RA   Lee S., Kim J.Y., Kim Y.J., Seok K.O., Kim J.H., Chang Y.J., Kang H.Y.,
RA   Park J.H.;
RT   "Nucleolar protein GLTSCR2 stabilizes p53 in response to ribosomal
RT   stresses.";
RL   Cell Death Differ. 19:1613-1622(2012).
RN   [138]
RP   INTERACTION WITH ZNF385B.
RX   PubMed=22945289; DOI=10.1002/eji.201242530;
RA   Iijima K., Yamada H., Miharu M., Imadome K., Miyagawa Y., Akimoto S.,
RA   Kobayashi K., Okita H., Nakazawa A., Fujiwara S., Fujimoto J., Kiyokawa N.;
RT   "ZNF385B is characteristically expressed in germinal center B cells and
RT   involved in B-cell apoptosis.";
RL   Eur. J. Immunol. 42:3405-3415(2012).
RN   [139]
RP   METHYLATION AT LYS-370 AND LYS-382.
RX   PubMed=22864287; DOI=10.1038/nsmb.2353;
RA   Cui G., Park S., Badeaux A.I., Kim D., Lee J., Thompson J.R., Yan F.,
RA   Kaneko S., Yuan Z., Botuyan M.V., Bedford M.T., Cheng J.Q., Mer G.;
RT   "PHF20 is an effector protein of p53 double lysine methylation that
RT   stabilizes and activates p53.";
RL   Nat. Struct. Mol. Biol. 19:916-924(2012).
RN   [140]
RP   FUNCTION.
RX   PubMed=24051492; DOI=10.1038/ncomms3444;
RA   Miki T., Matsumoto T., Zhao Z., Lee C.C.;
RT   "p53 regulates Period2 expression and the circadian clock.";
RL   Nat. Commun. 4:2444-2444(2013).
RN   [141]
RP   INTERACTION WITH KAT6A, AND ACETYLATION AT LYS-120 AND LYS-382.
RX   PubMed=23431171; DOI=10.1073/pnas.1300490110;
RA   Rokudai S., Laptenko O., Arnal S.M., Taya Y., Kitabayashi I., Prives C.;
RT   "MOZ increases p53 acetylation and premature senescence through its complex
RT   formation with PML.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:3895-3900(2013).
RN   [142]
RP   INTERACTION WITH UBD.
RX   PubMed=25422469; DOI=10.1073/pnas.1403383111;
RA   Theng S.S., Wang W., Mah W.C., Chan C., Zhuo J., Gao Y., Qin H., Lim L.,
RA   Chong S.S., Song J., Lee C.G.;
RT   "Disruption of FAT10-MAD2 binding inhibits tumor progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:E5282-E5291(2014).
RN   [143]
RP   UBIQUITINATION.
RX   PubMed=25591766; DOI=10.1159/000369691;
RA   Yang L., Zhou B., Li X., Lu Z., Li W., Huo X., Miao Z.;
RT   "RNF125 is a ubiquitin-protein ligase that promotes p53 degradation.";
RL   Cell. Physiol. Biochem. 35:237-245(2015).
RN   [144]
RP   INTERACTION WITH HADV5 E1B-55K (MICROBIAL INFECTION).
RX   PubMed=25772236; DOI=10.1038/onc.2015.63;
RA   Wimmer P., Berscheminski J., Blanchette P., Groitl P., Branton P.E.,
RA   Hay R.T., Dobner T., Schreiner S.;
RT   "PML isoforms IV and V contribute to adenovirus-mediated oncogenic
RT   transformation by functionally inhibiting the tumor-suppressor p53.";
RL   Oncogene 35:69-82(2016).
RN   [145]
RP   INTERACTION WITH AFG1L, AND SUBCELLULAR LOCATION.
RX   PubMed=27323408; DOI=10.18632/oncotarget.9959;
RA   Cesnekova J., Spacilova J., Hansikova H., Houstek J., Zeman J.,
RA   Stiburek L.;
RT   "LACE1 interacts with p53 and mediates its mitochondrial translocation and
RT   apoptosis.";
RL   Oncotarget 7:47687-47698(2016).
RN   [146]
RP   INTERACTION WITH DDX3X AND GAMMA-TUBULIN, SUBCELLULAR LOCATION, AND
RP   PHOSPHORYLATION AT SER-15.
RX   PubMed=28842590; DOI=10.1038/s41598-017-09779-w;
RA   Chen W.J., Wang W.T., Tsai T.Y., Li H.K., Lee Y.W.;
RT   "DDX3 localizes to the centrosome and prevents multipolar mitosis by
RT   epigenetically and translationally modulating p53 expression.";
RL   Sci. Rep. 7:9411-9411(2017).
RN   [147]
RP   INVOLVEMENT IN BMFS5.
RX   PubMed=30146126; DOI=10.1016/j.ajhg.2018.07.020;
RA   Toki T., Yoshida K., Wang R., Nakamura S., Maekawa T., Goi K., Katoh M.C.,
RA   Mizuno S., Sugiyama F., Kanezaki R., Uechi T., Nakajima Y., Sato Y.,
RA   Okuno Y., Sato-Otsubo A., Shiozawa Y., Kataoka K., Shiraishi Y., Sanada M.,
RA   Chiba K., Tanaka H., Terui K., Sato T., Kamio T., Sakaguchi H., Ohga S.,
RA   Kuramitsu M., Hamaguchi I., Ohara A., Kanno H., Miyano S., Kojima S.,
RA   Ishiguro A., Sugita K., Kenmochi N., Takahashi S., Eto K., Ogawa S.,
RA   Ito E.;
RT   "De novo mutations activating germline TP53 in an inherited bone-marrow-
RT   failure syndrome.";
RL   Am. J. Hum. Genet. 103:440-447(2018).
RN   [148]
RP   STRUCTURE BY NMR OF 319-360.
RX   PubMed=8023159; DOI=10.1126/science.8023159;
RA   Clore G.M., Omichinski J.G., Sakaguchi K., Zambrano N., Sakamoto H.,
RA   Appella E., Gronenborn A.M.;
RT   "High-resolution structure of the oligomerization domain of p53 by
RT   multidimensional NMR.";
RL   Science 265:386-391(1994).
RN   [149]
RP   STRUCTURE BY NMR OF 325-355.
RX   PubMed=7773777; DOI=10.1038/nsb1294-877;
RA   Lee W., Harvey T.S., Yin Y., Yau P., Litchfield D., Arrowsmith C.H.;
RT   "Solution structure of the tetrameric minimum transforming domain of p53.";
RL   Nat. Struct. Biol. 1:877-890(1994).
RN   [150]
RP   STRUCTURE BY NMR OF 326-354.
RX   PubMed=9321402; DOI=10.1093/emboj/16.20.6230;
RA   McCoy M., Stavridi E.S., Waterman J.L., Wieczorek A.M., Opella S.J.,
RA   Halazonetis T.D.;
RT   "Hydrophobic side-chain size is a determinant of the three-dimensional
RT   structure of the p53 oligomerization domain.";
RL   EMBO J. 16:6230-6236(1997).
RN   [151]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 94-289.
RX   PubMed=8023157; DOI=10.1126/science.8023157;
RA   Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P.;
RT   "Crystal structure of a p53 tumor suppressor-DNA complex: understanding
RT   tumorigenic mutations.";
RL   Science 265:346-355(1994).
RN   [152]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 325-356.
RX   PubMed=7878469; DOI=10.1126/science.7878469;
RA   Jeffrey P.D., Gorina S., Pavletich N.P.;
RT   "Crystal structure of the tetramerization domain of the p53 tumor
RT   suppressor at 1.7 angstroms.";
RL   Science 267:1498-1502(1995).
RN   [153]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 13-29 IN COMPLEX WITH MDM2.
RX   PubMed=8875929; DOI=10.1126/science.274.5289.948;
RA   Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J.,
RA   Pavletich N.P.;
RT   "Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor
RT   transactivation domain.";
RL   Science 274:948-953(1996).
RN   [154]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 97-287 IN COMPLEX WITH 53BP2.
RX   PubMed=8875926; DOI=10.1126/science.274.5289.1001;
RA   Gorina S., Pavletich N.P.;
RT   "Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains
RT   of 53BP2.";
RL   Science 274:1001-1005(1996).
RN   [155]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 94-312 IN COMPLEX WITH ZINC IONS,
RP   AND SUBUNIT.
RX   PubMed=14534297; DOI=10.1074/jbc.m309732200;
RA   Joerger A.C., Allen M.D., Fersht A.R.;
RT   "Crystal structure of a superstable mutant of human p53 core domain.
RT   Insights into the mechanism of rescuing oncogenic mutations.";
RL   J. Biol. Chem. 279:1291-1296(2004).
RN   [156]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 94-293 IN COMPLEX WITH DNA AND
RP   ZINC IONS, AND SUBUNIT.
RX   PubMed=16793544; DOI=10.1016/j.molcel.2006.05.015;
RA   Kitayner M., Rozenberg H., Kessler N., Rabinovich D., Shaulov L.,
RA   Haran T.E., Shakked Z.;
RT   "Structural basis of DNA recognition by p53 tetramers.";
RL   Mol. Cell 22:741-753(2006).
RN   [157]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 358-367 IN COMPLEX WITH USP7, AND
RP   INTERACTION WITH USP7.
RX   PubMed=16474402; DOI=10.1038/nsmb1067;
RA   Sheng Y., Saridakis V., Sarkari F., Duan S., Wu T., Arrowsmith C.H.,
RA   Frappier L.;
RT   "Molecular recognition of p53 and MDM2 by USP7/HAUSP.";
RL   Nat. Struct. Mol. Biol. 13:285-291(2006).
RN   [158]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 360-368 IN COMPLEX WITH USP7,
RP   MUTAGENESIS OF PRO-359; GLY-361 AND SER-362, AND INTERACTION WITH USP7.
RX   PubMed=16402859; DOI=10.1371/journal.pbio.0040027;
RA   Hu M., Gu L., Li M., Jeffrey P.D., Gu W., Shi Y.;
RT   "Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7:
RT   implications for the regulation of the p53-MDM2 pathway.";
RL   PLoS Biol. 4:228-239(2006).
RN   [159]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 377-386, METHYLATION AT LYS-382,
RP   MUTAGENESIS OF LYS-382, AND INTERACTION WITH L3MBTL1.
RX   PubMed=20870725; DOI=10.1074/jbc.m110.139527;
RA   West L.E., Roy S., Lachmi-Weiner K., Hayashi R., Shi X., Appella E.,
RA   Kutateladze T.G., Gozani O.;
RT   "The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at lysine
RT   382 to target gene repression.";
RL   J. Biol. Chem. 285:37725-37732(2010).
RN   [160]
RP   REVIEW.
RX   PubMed=8266092; DOI=10.1126/science.8266092;
RA   Harris C.C.;
RT   "p53: at the crossroads of molecular carcinogenesis and risk assessment.";
RL   Science 262:1980-1981(1993).
RN   [161]
RP   REVIEW ON VARIANTS.
RX   PubMed=1905840; DOI=10.1126/science.1905840;
RA   Hoolstein M., Sidransky D., Vogelstein B., Harris C.C.;
RT   "p53 mutations in human cancers.";
RL   Science 253:49-53(1991).
RN   [162]
RP   REVIEW ON VARIANTS.
RX   PubMed=8829653;
RX   DOI=10.1002/(sici)1098-1004(1996)7:3<202::aid-humu4>3.0.co;2-c;
RA   de Vries E.M.G., Ricke D.O., de Vries T.N., Hartmann A., Blaszyk H.,
RA   Liao D., Soussi T., Kovach J.S., Sommer S.S.;
RT   "Database of mutations in the p53 and APC tumor suppressor genes designed
RT   to facilitate molecular epidemiological analyses.";
RL   Hum. Mutat. 7:202-213(1996).
RN   [163]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 94-312 IN COMPLEX WITH ZINC IONS.
RX   PubMed=17015838; DOI=10.1073/pnas.0607286103;
RA   Joerger A.C., Ang H.C., Fersht A.R.;
RT   "Structural basis for understanding oncogenic p53 mutations and designing
RT   rescue drugs.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:15056-15061(2006).
RN   [164]
RP   X-RAY CRYSTALLOGRAPHY (1.54 ANGSTROMS) OF 94-292 OF VARIANT GLN-282.
RX   PubMed=18453682; DOI=10.1107/s0907444908003338;
RA   Tu C., Tan Y.H., Shaw G., Zhou Z., Bai Y., Luo R., Ji X.;
RT   "Impact of low-frequency hotspot mutation R282Q on the structure of p53
RT   DNA-binding domain as revealed by crystallography at 1.54 angstroms
RT   resolution.";
RL   Acta Crystallogr. D 64:471-477(2008).
RN   [165]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 94-312 OF VARIANT CYS-202 IN
RP   COMPLEX WITH ZINC IONS AND PHIKAN083.
RX   PubMed=18650397; DOI=10.1073/pnas.0805326105;
RA   Boeckler F.M., Joerger A.C., Jaggi G., Rutherford T.J., Veprintsev D.B.,
RA   Fersht A.R.;
RT   "Targeted rescue of a destabilized mutant of p53 by an in silico screened
RT   drug.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10360-10365(2008).
RN   [166]
RP   X-RAY CRYSTALLOGRAPHY (1.2 ANGSTROMS) OF 94-293 OF VARIANT SER-249 IN
RP   COMPLEX WITH DNA.
RX   PubMed=18996393; DOI=10.1016/j.jmb.2008.10.063;
RA   Suad O., Rozenberg H., Brosh R., Diskin-Posner Y., Kessler N., Shimon L.J.,
RA   Frolow F., Liran A., Rotter V., Shakked Z.;
RT   "Structural basis of restoring sequence-specific DNA binding and
RT   transactivation to mutant p53 by suppressor mutations.";
RL   J. Mol. Biol. 385:249-265(2009).
RN   [167]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 94-310 IN COMPLEX WITH ZINC IONS.
RX   PubMed=19515728; DOI=10.1093/protein/gzp018;
RA   Khoo K.H., Joerger A.C., Freund S.M., Fersht A.R.;
RT   "Stabilising the DNA-binding domain of p53 by rational design of its
RT   hydrophobic core.";
RL   Protein Eng. Des. Sel. 22:421-430(2009).
RN   [168]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 94-312 OF VARIANT CYS-220 IN
RP   COMPLEX WITH ZINC IONS.
RX   PubMed=20142040; DOI=10.1016/j.chembiol.2009.12.011;
RA   Basse N., Kaar J.L., Settanni G., Joerger A.C., Rutherford T.J.,
RA   Fersht A.R.;
RT   "Toward the rational design of p53-stabilizing drugs: probing the surface
RT   of the oncogenic Y220C mutant.";
RL   Chem. Biol. 17:46-56(2010).
RN   [169]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 94-293 IN COMPLEX WITH DNA AND
RP   ZINC IONS, AND SUBUNIT.
RX   PubMed=20364130; DOI=10.1038/nsmb.1800;
RA   Kitayner M., Rozenberg H., Rohs R., Suad O., Rabinovich D., Honig B.,
RA   Shakked Z.;
RT   "Diversity in DNA recognition by p53 revealed by crystal structures with
RT   Hoogsteen base pairs.";
RL   Nat. Struct. Mol. Biol. 17:423-429(2010).
RN   [170]
RP   VARIANT ARG-72.
RX   PubMed=1999338; DOI=10.1007/bf00201836;
RA   Olschwang S., Laurent-Puig P., Vassal A., Salmon R.-J., Thomas G.;
RT   "Characterization of a frequent polymorphism in the coding sequence of the
RT   Tp53 gene in colonic cancer patients and a control population.";
RL   Hum. Genet. 86:369-370(1991).
RN   [171]
RP   VARIANT LFS THR-133.
RX   PubMed=1933902;
RA   Law J.C., Strong L.C., Chidambaram A., Ferrell R.E.;
RT   "A germ line mutation in exon 5 of the p53 gene in an extended cancer
RT   family.";
RL   Cancer Res. 51:6385-6387(1991).
RN   [172]
RP   VARIANTS LFS CYS-245; TRP-248; PRO-252 AND LYS-258.
RX   PubMed=1978757; DOI=10.1126/science.1978757;
RA   Malkin D., Li F.P., Strong L.C., Fraumeni J.F. Jr., Nelson C.E., Kim D.H.,
RA   Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A., Friend S.H.;
RT   "Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas,
RT   and other neoplasms.";
RL   Science 250:1233-1238(1990).
RN   [173]
RP   VARIANT LFS ASP-245.
RX   PubMed=2259385; DOI=10.1038/348747a0;
RA   Srivastava S., Zou Z., Pirollo K., Blattner W., Chang E.H.;
RT   "Germ-line transmission of a mutated p53 gene in a cancer-prone family with
RT   Li-Fraumeni syndrome.";
RL   Nature 348:747-749(1990).
RN   [174]
RP   VARIANT LFS LEU-272.
RX   PubMed=1737852; DOI=10.1172/jci115630;
RA   Felix C.A., Nau M.M., Takahashi T., Mitsudomi T., Chiba I., Poplack D.G.,
RA   Reaman G.H., Cole D.E., Letterio J.J., Whang-Peng J., Knutsen T.,
RA   Minna J.D.;
RT   "Hereditary and acquired p53 gene mutations in childhood acute
RT   lymphoblastic leukemia.";
RL   J. Clin. Invest. 89:640-647(1992).
RN   [175]
RP   VARIANTS LFS HIS-273 AND VAL-325.
RX   PubMed=1565144; DOI=10.1056/nejm199205143262002;
RA   Malkin D., Jolly K.W., Barbier N., Look A.T., Friend S.H., Gebhardt M.C.,
RA   Andersen T.I., Boerresen A.-L., Li F.P., Garber J., Strong L.C.;
RT   "Germline mutations of the p53 tumor-suppressor gene in children and young
RT   adults with second malignant neoplasms.";
RL   N. Engl. J. Med. 326:1309-1315(1992).
RN   [176]
RP   VARIANTS SPORADIC CANCERS GLN-132; SER-249; LYS-280 AND LYS-285.
RX   PubMed=1694291;
RA   Bartek J., Iggo R., Gannon J., Lane D.P.;
RT   "Genetic and immunochemical analysis of mutant p53 in human breast cancer
RT   cell lines.";
RL   Oncogene 5:893-899(1990).
RN   [177]
RP   VARIANTS SPORADIC CANCERS PHE-241 AND HIS-273.
RX   PubMed=1699228; DOI=10.1073/pnas.87.19.7555;
RA   Rodrigues N.R., Rowan A., Smith M.E.F., Kerr I.B., Bodmer W.F.,
RA   Gannon J.V., Lane D.P.;
RT   "p53 mutations in colorectal cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:7555-7559(1990).
RN   [178]
RP   VARIANTS SPORADIC CANCER VAL-154; VAL-245; GLN-248; LEU-278 AND SER-278.
RX   PubMed=2263646; DOI=10.1073/pnas.87.24.9958;
RA   Hollstein M.C., Metcalf R.A., Welsh J.A., Montesano R., Harris C.C.;
RT   "Frequent mutation of the p53 gene in human esophageal cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:9958-9961(1990).
RN   [179]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=1647768; DOI=10.1016/0006-291x(91)90623-f;
RA   Ishioka C., Sato T., Gamoh M., Suzuki T., Shibata H., Kanamaru R.,
RA   Wakui A., Yamazaki T.;
RT   "Mutations of the P53 gene, including an intronic point mutation, in
RT   colorectal tumors.";
RL   Biochem. Biophys. Res. Commun. 177:901-906(1991).
RN   [180]
RP   VARIANTS SPORADIC CANCERS LEU-152; ALA-155; HIS-175; PHE-176 AND HIS-273.
RX   PubMed=1868473;
RA   Casson A.G., Mukhopadhyay T., Cleary K.R., Ro J.Y., Levin B., Roth J.A.;
RT   "p53 gene mutations in Barrett's epithelium and esophageal cancer.";
RL   Cancer Res. 51:4495-4499(1991).
RN   [181]
RP   VARIANTS SPORADIC CANCERS IN CHINA.
RX   PubMed=1849234; DOI=10.1038/350427a0;
RA   Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C.;
RT   "Mutational hotspot in the p53 gene in human hepatocellular carcinomas.";
RL   Nature 350:427-428(1991).
RN   [182]
RP   VARIANTS SPORADIC CANCERS IN SOUTH AFRICA.
RX   PubMed=1672732; DOI=10.1038/350429a0;
RA   Bressac B., Kew M., Wands J., Ozturk M.;
RT   "Selective G to T mutations of p53 gene in hepatocellular carcinoma from
RT   southern Africa.";
RL   Nature 350:429-431(1991).
RN   [183]
RP   VARIANTS SPORADIC CANCERS PHE-176; PHE-242; CYS-245; LEU-248 AND HIS-273.
RX   PubMed=1394225;
RA   Somers K.D., Merrick M.A., Lopez M.E., Incognito L.S., Schechter G.L.,
RA   Casey G.;
RT   "Frequent p53 mutations in head and neck cancer.";
RL   Cancer Res. 52:5997-6000(1992).
RN   [184]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=1327751; DOI=10.1002/j.1460-2075.1992.tb05487.x;
RA   Crook T., Vousden K.H.;
RT   "Properties of p53 mutations detected in primary and secondary cervical
RT   cancers suggest mechanisms of metastasis and involvement of environmental
RT   carcinogens.";
RL   EMBO J. 11:3935-3940(1992).
RN   [185]
RP   VARIANTS SPORADIC CANCERS CYS-205; GLU-281 AND LYS-285.
RX   PubMed=1459726; DOI=10.1002/ijc.2910520606;
RA   Sakai E., Rikimaru K., Ueda M., Matsumoto Y., Ishii N., Enomoto S.,
RA   Yamamoto H., Tsuchida N.;
RT   "The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous-
RT   cell carcinoma.";
RL   Int. J. Cancer 52:867-872(1992).
RN   [186]
RP   VARIANT PRO-HIS-PRO-178 INS.
RX   PubMed=1303181; DOI=10.1093/hmg/1.3.207;
RA   Bhatia K., Guiterrez M.I., Magrath I.T.;
RT   "A novel mutation in the p53 gene in a Burkitt's lymphoma cell line.";
RL   Hum. Mol. Genet. 1:207-208(1992).
RN   [187]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=1437144;
RA   Duthu A., Debuire B., Romano J.W., Ehrhart J.C., Fiscella M., May E.,
RA   Appella E., May P.;
RT   "p53 mutations in Raji cells: characterization and localization relative to
RT   other Burkitt's lymphomas.";
RL   Oncogene 7:2161-2167(1992).
RN   [188]
RP   VARIANT SPORADIC CANCER THR-280.
RX   PubMed=1631151; DOI=10.1073/pnas.89.14.6516;
RA   Sun Y., Hegamyer G., Heng Y.-J., Hildesheim A., Chen J.-Y., Chen I.-H.,
RA   Cao Y., Yao K.-T., Colburn N.H.;
RT   "An infrequent point mutation of the p53 gene in human nasopharyngeal
RT   carcinoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:6516-6520(1992).
RN   [189]
RP   VARIANTS SPORADIC CANCERS SER-151; PRO-156; LYS-174; ARG-194; CYS-220;
RP   GLN-248; LEU-248 AND HIS-273.
RX   PubMed=7682763;
RA   Caamano J., Zhang S.Y., Rosvold E.A., Bauer B., Klein-Szanto A.J.P.;
RT   "p53 alterations in human squamous cell carcinomas and carcinoma cell
RT   lines.";
RL   Am. J. Pathol. 142:1131-1139(1993).
RN   [190]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=8402617;
RA   Boyle J.O., Hakim J., Koch W., van der Riet P., Hruban R.H., Roa R.A.,
RA   Correo R., Eby Y.J., Ruppert J.M., Sidransky D.;
RT   "The incidence of p53 mutations increases with progression of head and neck
RT   cancer.";
RL   Cancer Res. 53:4477-4480(1993).
RN   [191]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=8336944;
RA   Hamelin R., Jego N., Laurent-Puig P., Vidaud M., Thomas G.;
RT   "Efficient screening of p53 mutations by denaturing gradient gel
RT   electrophoresis in colorectal tumors.";
RL   Oncogene 8:2213-2220(1993).
RN   [192]
RP   VARIANTS, AND INVOLVEMENT IN LFL.
RX   PubMed=8118819;
RA   Birch J.M., Hartley A.L., Tricker K.J., Prosser J., Condie A., Kelsey A.M.,
RA   Harris M., Jones P.H., Binchy A., Crowther D., Craft A.W., Eden O.B.,
RA   Evans D.G.R., Thompson E., Mann J.R., Martin J., Mitchell E.L.D.,
RA   Santibanez-Koref M.F.;
RT   "Prevalence and diversity of constitutional mutations in the p53 gene among
RT   21 Li-Fraumeni families.";
RL   Cancer Res. 54:1298-1304(1994).
RN   [193]
RP   CHARACTERIZATION OF VARIANT ALA-143.
RX   PubMed=8013454; DOI=10.1002/j.1460-2075.1994.tb06543.x;
RA   Zhang W., Guo X.-Y., Hu G.-Y., Liu W.-B., Shay J.W., Deisseroth A.B.;
RT   "A temperature-sensitive mutant of human p53.";
RL   EMBO J. 13:2535-2544(1994).
RN   [194]
RP   VARIANTS LFS HIS-175; ARG-193; GLN-248; CYS-273 AND TYR-275.
RX   PubMed=7887414;
RA   Frebourg T., Barbier N., Yan Y.-X., Garber J.E., Dreyfus M.,
RA   Fraumeni J.F. Jr., Li F.P., Friend S.H.;
RT   "Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome.";
RL   Am. J. Hum. Genet. 56:608-615(1995).
RN   [195]
RP   VARIANTS, AND INVOLVEMENT IN LFL.
RX   PubMed=8718514;
RA   Eeles R.A.;
RT   "Germline mutations in the TP53 gene.";
RL   Cancer Surv. 25:101-124(1995).
RN   [196]
RP   VARIANT LFS HIS-175.
RX   PubMed=8825920; DOI=10.1136/jmg.32.12.942;
RA   Varley J.M., McGrown G., Thorncroft M., Tricker K.J., Teare M.D.,
RA   Santibanez-Koref M.F., Houlston R.S., Martin J., Birch J.M., Evans D.G.R.;
RT   "An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175
RT   mutation in TP53.";
RL   J. Med. Genet. 32:942-945(1995).
RN   [197]
RP   VARIANTS SPORADIC CANCERS PHE-176; SER-245; TRP-248; TRP-282 AND GLN-286.
RX   PubMed=8829627;
RX   DOI=10.1002/(sici)1098-1004(1996)7:2<109::aid-humu4>3.0.co;2-7;
RA   Audrezet M.-P., Robaszkiewicz M., Mercier B., Nousbaum J.-B., Hardy E.,
RA   Bail J.-P., Volant A., Lozac'H P., Gouerou H., Ferec C.;
RT   "Molecular analysis of the TP53 gene in Barrett's adenocarcinoma.";
RL   Hum. Mutat. 7:109-113(1996).
RN   [198]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=9101296;
RX   DOI=10.1002/(sici)1098-1004(1997)9:4<348::aid-humu8>3.0.co;2-1;
RA   Guldberg P., Nedergaard T., Nielsen H.J., Olsen A.C., Ahrenkiel V.,
RA   Zeuthen J.;
RT   "Single-step DGGE-based mutation scanning of the p53 gene: application to
RT   genetic diagnosis of colorectal cancer.";
RL   Hum. Mutat. 9:348-355(1997).
RN   [199]
RP   VARIANT SPORADIC CANCER ILE-157.
RX   PubMed=9419979; DOI=10.1038/sj.onc.1201668;
RA   Miyaki M., Nishio J., Konishi M., Kikuchi-Yanoshita R., Tanaka K.,
RA   Muraoka M., Nagato M., Chong J.-M., Koike M., Terada T., Kawahara Y.,
RA   Fukutome A., Tomiyama J., Chuganji Y., Momoi M., Utsunomiya J.;
RT   "Drastic genetic instability of tumors and normal tissues in Turcot
RT   syndrome.";
RL   Oncogene 15:2877-2881(1997).
RN   [200]
RP   VARIANTS SER-152; ILE-169; PHE-176; THR-195; CYS-220; ILE-230; CYS-273 AND
RP   SER-278.
RX   PubMed=9450901;
RX   DOI=10.1002/(sici)1098-1004(1998)11:1<39::aid-humu6>3.0.co;2-g;
RA   van Rensburg E.J., Engelbrecht S., van Heerden W.F.P., Kotze M.J.,
RA   Raubenheimer E.J.;
RT   "Detection of p53 gene mutations in oral squamous cell carcinomas of a
RT   black African population sample.";
RL   Hum. Mutat. 11:39-44(1998).
RN   [201]
RP   VARIANT NON-CLASSICAL LFS CYS-337.
RX   PubMed=9452042; DOI=10.1002/humu.1380110121;
RA   Luca J.W., Strong L.C., Hansen M.F.;
RT   "A germline missense mutation R337C in exon 10 of the human p53 gene.";
RL   Hum. Mutat. Suppl. 1:S58-S61(1998).
RN   [202]
RP   VARIANT LFS ILE-292.
RX   PubMed=10484981; DOI=10.1016/s0165-4608(98)00276-3;
RA   Gueran S., Tunca Y., Imirzalioglu N.;
RT   "Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in a Li-
RT   Fraumeni syndrome family.";
RL   Cancer Genet. Cytogenet. 113:145-151(1999).
RN   [203]
RP   VARIANTS.
RX   PubMed=10549356; DOI=10.1016/s0065-230x(08)60785-x;
RA   Hainaut P., Hollstein M.;
RT   "p53 and human cancer: the first ten thousand mutations.";
RL   Adv. Cancer Res. 77:81-137(2000).
RN   [204]
RP   VARIANT ADCC HIS-337.
RX   PubMed=11481490; DOI=10.1073/pnas.161479898;
RA   Ribeiro R.C., Sandrini F., Figueiredo B., Zambetti G.P., Michalkiewicz E.,
RA   Lafferty A.R., DeLacerda L., Rabin M., Cadwell C., Sampaio G., Cat I.,
RA   Stratakis C.A., Sandrini R.;
RT   "An inherited p53 mutation that contributes in a tissue-specific manner to
RT   pediatric adrenal cortical carcinoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:9330-9335(2001).
RN   [205]
RP   INVOLVEMENT IN CPP.
RX   PubMed=12085209; DOI=10.1038/sj.bjc.6600269;
RA   Rutherford J., Chu C.E., Duddy P.M., Charlton R.S., Chumas P., Taylor G.R.,
RA   Lu X., Barnes D.M., Camplejohn R.S.;
RT   "Investigations on a clinically and functionally unusual and novel germline
RT   p53 mutation.";
RL   Br. J. Cancer 86:1592-1596(2002).
RN   [206]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-134; PHE-157; CYS-163; HIS-175;
RP   ARG-177; ARG-193; PRO-213; PHE-241; PHE-242; GLN-248; TRP-248; SER-249;
RP   TRP-267; LYS-271; CYS-273; HIS-273; LEU-273; SER-278; ILE-280 AND HIS-281.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [207]
RP   VARIANTS PRO-110; VAL-113; VAL-138; CYS-163; HIS-163; THR-195; MET-216;
RP   ALA-241; MET-249; SER-251; TYR-259 AND CYS-273.
RX   PubMed=17224074; DOI=10.1186/bcr1637;
RA   Chanock S.J., Burdett L., Yeager M., Llaca V., Langeroed A., Presswalla S.,
RA   Kaaresen R., Strausberg R.L., Gerhard D.S., Kristensen V., Perou C.M.,
RA   Boerresen-Dale A.-L.;
RT   "Somatic sequence alterations in twenty-one genes selected by expression
RT   profile analysis of breast carcinomas.";
RL   Breast Cancer Res. 9:R5-R5(2007).
RN   [208]
RP   VARIANTS.
RX   PubMed=17311302; DOI=10.1002/humu.20495;
RA   Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P.,
RA   Olivier M.;
RT   "Impact of mutant p53 functional properties on TP53 mutation patterns and
RT   tumor phenotype: lessons from recent developments in the IARC TP53
RT   database.";
RL   Hum. Mutat. 28:622-629(2007).
RN   [209]
RP   CHARACTERIZATION OF VARIANT SPORADIC CANCER LYS-280, UBIQUITINATION,
RP   PROTEASOMAL DEGRADATION, AND INTERACTION WITH CCAR2.
RX   PubMed=25732823; DOI=10.1016/j.celrep.2015.01.066;
RA   Qin B., Minter-Dykhouse K., Yu J., Zhang J., Liu T., Zhang H., Lee S.,
RA   Kim J., Wang L., Lou Z.;
RT   "DBC1 functions as a tumor suppressor by regulating p53 stability.";
RL   Cell Rep. 10:1324-1334(2015).
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological circumstances
CC       and cell type. Involved in cell cycle regulation as a trans-activator
CC       that acts to negatively regulate cell division by controlling a set of
CC       genes required for this process. One of the activated genes is an
CC       inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be
CC       mediated either by stimulation of BAX and FAS antigen expression, or by
CC       repression of Bcl-2 expression. Its pro-apoptotic activity is activated
CC       via its interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2
CC       (PubMed:12524540). However, this activity is inhibited when the
CC       interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 is displaced by
CC       PPP1R13L/iASPP (PubMed:12524540). In cooperation with mitochondrial
CC       PPIF is involved in activating oxidative stress-induced necrosis; the
CC       function is largely independent of transcription. Induces the
CC       transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and
CC       lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent
CC       transcriptional repression leading to apoptosis and seems to have an
CC       effect on cell-cycle regulation. Implicated in Notch signaling cross-
CC       over. Prevents CDK7 kinase activity when associated to CAK complex in
CC       response to DNA damage, thus stopping cell cycle progression. Isoform 2
CC       enhances the transactivation activity of isoform 1 from some but not
CC       all TP53-inducible promoters. Isoform 4 suppresses transactivation
CC       activity and impairs growth suppression mediated by isoform 1. Isoform
CC       7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock
CC       by repressing CLOCK-ARNTL/BMAL1-mediated transcriptional activation of
CC       PER2 (PubMed:24051492). {ECO:0000269|PubMed:11025664,
CC       ECO:0000269|PubMed:12524540, ECO:0000269|PubMed:12810724,
CC       ECO:0000269|PubMed:15186775, ECO:0000269|PubMed:15340061,
CC       ECO:0000269|PubMed:17317671, ECO:0000269|PubMed:17349958,
CC       ECO:0000269|PubMed:19556538, ECO:0000269|PubMed:20673990,
CC       ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:22726440,
CC       ECO:0000269|PubMed:24051492, ECO:0000269|PubMed:9840937}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC       Note=Binds 1 zinc ion per subunit.;
CC   -!- SUBUNIT: Forms homodimers and homotetramers (PubMed:19011621). Binds
CC       DNA as a homotetramer. Interacts with AXIN1. Probably part of a complex
CC       consisting of TP53, HIPK2 and AXIN1 (By similarity). Interacts with
CC       histone acetyltransferases EP300 and methyltransferases HRMT1L2 and
CC       CARM1, and recruits them to promoters. Interacts (via C-terminus) with
CC       TAF1; when TAF1 is part of the TFIID complex. Interacts with ING4; this
CC       interaction may be indirect. Found in a complex with CABLES1 and TP73.
CC       Interacts with HIPK1, HIPK2, and TP53INP1. Interacts with WWOX. May
CC       interact with HCV core protein. Interacts with USP7 and SYVN1.
CC       Interacts with HSP90AB1. Interacts with CHD8; leading to recruit
CC       histone H1 and prevent transactivation activity (By similarity).
CC       Interacts with ARMC10, BANP, CDKN2AIP, NUAK1, STK11/LKB1, UHRF2 and
CC       E4F1. Interacts with YWHAZ; the interaction enhances TP53
CC       transcriptional activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits
CC       this interaction. Interacts (via DNA-binding domain) with MAML1 (via N-
CC       terminus). Interacts with MKRN1. Interacts with PML (via C-terminus).
CC       Interacts with MDM2; leading to ubiquitination and proteasomal
CC       degradation of TP53. Directly interacts with FBXO42; leading to
CC       ubiquitination and degradation of TP53. Interacts (phosphorylated at
CC       Ser-15 by ATM) with the phosphatase PP2A-PPP2R5C holoenzyme; regulates
CC       stress-induced TP53-dependent inhibition of cell proliferation.
CC       Interacts with PPP2R2A. Interacts with AURKA, DAXX, BRD7 and TRIM24.
CC       Interacts (when monomethylated at Lys-382) with L3MBTL1. Isoform 1
CC       interacts with isoform 2 and with isoform 4. Interacts with GRK5. Binds
CC       to the CAK complex (CDK7, cyclin H and MAT1) in response to DNA damage.
CC       Interacts with CDK5 in neurons. Interacts with AURKB, SETD2, UHRF2 and
CC       NOC2L. Interacts (via N-terminus) with PTK2/FAK1; this promotes
CC       ubiquitination by MDM2. Interacts with PTK2B/PYK2; this promotes
CC       ubiquitination by MDM2. Interacts with PRKCG. Interacts with PPIF; the
CC       association implicates preferentially tetrameric TP53, is induced by
CC       oxidative stress and is impaired by cyclosporin A (CsA). Interacts with
CC       SNAI1; the interaction induces SNAI1 degradation via MDM2-mediated
CC       ubiquitination and inhibits SNAI1-induced cell invasion. Interacts with
CC       KAT6A. Interacts with UBC9. Interacts with ZNF385B; the interaction is
CC       direct. Interacts (via DNA-binding domain) with ZNF385A; the
CC       interaction is direct and enhances p53/TP53 transactivation functions
CC       on cell-cycle arrest target genes, resulting in growth arrest.
CC       Interacts with ANKRD2. Interacts with RFFL and RNF34; involved in
CC       p53/TP53 ubiquitination. Interacts with MTA1 and COP1. Interacts with
CC       CCAR2 (via N-terminus). Interacts with MORC3 (PubMed:17332504).
CC       Interacts (via C-terminus) with POU4F2 isoform 1 (via C-terminus)
CC       (PubMed:17145718). Interacts (via oligomerization region) with NOP53;
CC       the interaction is direct and may prevent the MDM2-mediated proteasomal
CC       degradation of TP53 (PubMed:22522597). Interacts with AFG1L; mediates
CC       mitochondrial translocation of TP53 (PubMed:27323408). Interacts with
CC       UBD (PubMed:25422469). Interacts with TAF6 isoform 1 and isoform 4
CC       (PubMed:20096117). Interacts with C10orf90/FATS; the interaction
CC       inhibits binding of TP53 and MDM2 (By similarity). Interacts with
CC       NUPR1; interaction is stress-dependent (PubMed:18690848). Forms a
CC       complex with EP300 and NUPR1; this complex binds CDKN1A promoter
CC       leading to transcriptional induction of CDKN1A (PubMed:18690848).
CC       Interacts with PRMT5 in response to DNA damage; the interaction is
CC       STRAP dependent (PubMed:19011621). Interacts with PPP1R13L (via SH3
CC       domain and ANK repeats); the interaction inhibits pro-apoptotic
CC       activity of p53/TP53 (PubMed:12524540). Interacts with PPP1R13B/ASPP1
CC       and TP53BP2/ASPP2; the interactions promotes pro-apoptotic activity
CC       (PubMed:12524540). When phosphorylated at Ser-15, interacts with DDX3X
CC       and gamma-tubulin (PubMed:28842590). Interacts with KAT7/HBO1; leading
CC       to inhibit histone acetyltransferase activity of KAT7/HBO1
CC       (PubMed:17954561). {ECO:0000250|UniProtKB:P02340,
CC       ECO:0000250|UniProtKB:P10361, ECO:0000269|PubMed:12524540,
CC       ECO:0000269|PubMed:12750254, ECO:0000269|PubMed:12810724,
CC       ECO:0000269|PubMed:12851404, ECO:0000269|PubMed:14534297,
CC       ECO:0000269|PubMed:14702041, ECO:0000269|PubMed:15053879,
CC       ECO:0000269|PubMed:15109303, ECO:0000269|PubMed:15136035,
CC       ECO:0000269|PubMed:15186775, ECO:0000269|PubMed:15701641,
CC       ECO:0000269|PubMed:15855171, ECO:0000269|PubMed:16219768,
CC       ECO:0000269|PubMed:16322561, ECO:0000269|PubMed:16376338,
CC       ECO:0000269|PubMed:16377624, ECO:0000269|PubMed:16402859,
CC       ECO:0000269|PubMed:16474402, ECO:0000269|PubMed:16793544,
CC       ECO:0000269|PubMed:16845383, ECO:0000269|PubMed:17015838,
CC       ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:17121812,
CC       ECO:0000269|PubMed:17145718, ECO:0000269|PubMed:17170702,
CC       ECO:0000269|PubMed:17245430, ECO:0000269|PubMed:17317671,
CC       ECO:0000269|PubMed:17332504, ECO:0000269|PubMed:17591690,
CC       ECO:0000269|PubMed:17719541, ECO:0000269|PubMed:17904127,
CC       ECO:0000269|PubMed:17954561, ECO:0000269|PubMed:17967874,
CC       ECO:0000269|PubMed:18585004, ECO:0000269|PubMed:18650397,
CC       ECO:0000269|PubMed:18690848, ECO:0000269|PubMed:18996393,
CC       ECO:0000269|PubMed:19011621, ECO:0000269|PubMed:19509332,
CC       ECO:0000269|PubMed:19515728, ECO:0000269|PubMed:19536131,
CC       ECO:0000269|PubMed:19556538, ECO:0000269|PubMed:19837670,
CC       ECO:0000269|PubMed:19880522, ECO:0000269|PubMed:20096117,
CC       ECO:0000269|PubMed:20124405, ECO:0000269|PubMed:20142040,
CC       ECO:0000269|PubMed:20228809, ECO:0000269|PubMed:20364130,
CC       ECO:0000269|PubMed:20385133, ECO:0000269|PubMed:20660729,
CC       ECO:0000269|PubMed:20870725, ECO:0000269|PubMed:20959462,
CC       ECO:0000269|PubMed:21317932, ECO:0000269|PubMed:21952639,
CC       ECO:0000269|PubMed:22214662, ECO:0000269|PubMed:22522597,
CC       ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:22945289,
CC       ECO:0000269|PubMed:23431171, ECO:0000269|PubMed:25422469,
CC       ECO:0000269|PubMed:25732823, ECO:0000269|PubMed:27323408,
CC       ECO:0000269|PubMed:28842590, ECO:0000269|PubMed:8875926,
CC       ECO:0000269|PubMed:8875929, ECO:0000269|PubMed:9840937}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with cancer-associated/HPV E6
CC       viral proteins leading to ubiquitination and degradation of TP53 giving
CC       a possible model for cell growth regulation. This complex formation
CC       requires an additional factor, E6-AP, which stably associates with TP53
CC       in the presence of E6. {ECO:0000269|PubMed:2175676}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human
CC       cytomegalovirus/HHV-5 protein UL123. {ECO:0000269|PubMed:19776115}.
CC   -!- SUBUNIT: (Microbial infection) Interacts (via N-terminus) with human
CC       adenovirus 5 E1B-55K protein; this interaction leads to the inhibition
CC       of TP53 function and/or its degradation. {ECO:0000269|PubMed:25772236}.
CC   -!- INTERACTION:
CC       P04637; Q13155: AIMP2; NbExp=6; IntAct=EBI-366083, EBI-745226;
CC       P04637; O95376: ARIH2; NbExp=5; IntAct=EBI-366083, EBI-711158;
CC       P04637; P49407: ARRB1; NbExp=5; IntAct=EBI-366083, EBI-743313;
CC       P04637; Q9UBL3: ASH2L; NbExp=7; IntAct=EBI-366083, EBI-540797;
CC       P04637; O95352-2: ATG7; NbExp=4; IntAct=EBI-366083, EBI-15980880;
CC       P04637; O15169: AXIN1; NbExp=4; IntAct=EBI-366083, EBI-710484;
CC       P04637; Q8N9N5: BANP; NbExp=3; IntAct=EBI-366083, EBI-744695;
CC       P04637; P10415: BCL2; NbExp=5; IntAct=EBI-366083, EBI-77694;
CC       P04637; Q07817-1: BCL2L1; NbExp=26; IntAct=EBI-366083, EBI-287195;
CC       P04637; P11274: BCR; NbExp=2; IntAct=EBI-366083, EBI-712838;
CC       P04637; O14503: BHLHE40; NbExp=11; IntAct=EBI-366083, EBI-711810;
CC       P04637; P51587: BRCA2; NbExp=7; IntAct=EBI-366083, EBI-79792;
CC       P04637; Q9NPI1: BRD7; NbExp=9; IntAct=EBI-366083, EBI-711221;
CC       P04637; Q9BX70: BTBD2; NbExp=2; IntAct=EBI-366083, EBI-710091;
CC       P04637; Q9Y297: BTRC; NbExp=2; IntAct=EBI-366083, EBI-307461;
CC       P04637; Q9BWC9: CCDC106; NbExp=3; IntAct=EBI-366083, EBI-711501;
CC       P04637; P38936: CDKN1A; NbExp=3; IntAct=EBI-366083, EBI-375077;
CC       P04637; P17676: CEBPB; NbExp=4; IntAct=EBI-366083, EBI-969696;
CC       P04637; Q92793: CREBBP; NbExp=11; IntAct=EBI-366083, EBI-81215;
CC       P04637; P55060: CSE1L; NbExp=5; IntAct=EBI-366083, EBI-286709;
CC       P04637; P68400: CSNK2A1; NbExp=2; IntAct=EBI-366083, EBI-347804;
CC       P04637; Q14999: CUL7; NbExp=5; IntAct=EBI-366083, EBI-308606;
CC       P04637; Q8IWT3: CUL9; NbExp=4; IntAct=EBI-366083, EBI-311123;
CC       P04637; Q9P0U4: CXXC1; NbExp=7; IntAct=EBI-366083, EBI-949911;
CC       P04637; Q9UER7: DAXX; NbExp=12; IntAct=EBI-366083, EBI-77321;
CC       P04637; Q92841: DDX17; NbExp=3; IntAct=EBI-366083, EBI-746012;
CC       P04637; P17844: DDX5; NbExp=6; IntAct=EBI-366083, EBI-351962;
CC       P04637; Q9NRR4: DROSHA; NbExp=5; IntAct=EBI-366083, EBI-528367;
CC       P04637; Q9BV47: DUSP26; NbExp=9; IntAct=EBI-366083, EBI-2924519;
CC       P04637; O14641: DVL2; NbExp=6; IntAct=EBI-366083, EBI-740850;
CC       P04637; Q09472: EP300; NbExp=20; IntAct=EBI-366083, EBI-447295;
CC       P04637; P15036: ETS2; NbExp=4; IntAct=EBI-366083, EBI-1646991;
CC       P04637; Q86XK2: FBXO11; NbExp=4; IntAct=EBI-366083, EBI-1047804;
CC       P04637; O43524: FOXO3; NbExp=2; IntAct=EBI-366083, EBI-1644164;
CC       P04637; P49841: GSK3B; NbExp=3; IntAct=EBI-366083, EBI-373586;
CC       P04637; P32780: GTF2H1; NbExp=12; IntAct=EBI-366083, EBI-715539;
CC       P04637; Q13547: HDAC1; NbExp=7; IntAct=EBI-366083, EBI-301834;
CC       P04637; Q86Z02: HIPK1; NbExp=2; IntAct=EBI-366083, EBI-692891;
CC       P04637; P09429: HMGB1; NbExp=9; IntAct=EBI-366083, EBI-389432;
CC       P04637; P61978: HNRNPK; NbExp=2; IntAct=EBI-366083, EBI-304185;
CC       P04637; P61978-2: HNRNPK; NbExp=2; IntAct=EBI-366083, EBI-7060731;
CC       P04637; P34931: HSPA1L; NbExp=2; IntAct=EBI-366083, EBI-354912;
CC       P04637; P38646: HSPA9; NbExp=6; IntAct=EBI-366083, EBI-354932;
CC       P04637; P04792: HSPB1; NbExp=3; IntAct=EBI-366083, EBI-352682;
CC       P04637; P42858: HTT; NbExp=4; IntAct=EBI-366083, EBI-466029;
CC       P04637; Q7Z6Z7: HUWE1; NbExp=3; IntAct=EBI-366083, EBI-625934;
CC       P04637; Q16666-2: IFI16; NbExp=6; IntAct=EBI-366083, EBI-6273540;
CC       P04637; O14920: IKBKB; NbExp=2; IntAct=EBI-366083, EBI-81266;
CC       P04637; Q9UHH9: IP6K2; NbExp=4; IntAct=EBI-366083, EBI-747509;
CC       P04637; Q6NYC1: JMJD6; NbExp=7; IntAct=EBI-366083, EBI-8464037;
CC       P04637; Q92993: KAT5; NbExp=3; IntAct=EBI-366083, EBI-399080;
CC       P04637; Q9H7Z6: KAT8; NbExp=2; IntAct=EBI-366083, EBI-896414;
CC       P04637; O60341-1: KDM1A; NbExp=6; IntAct=EBI-366083, EBI-15599570;
CC       P04637; Q8IZD2: KMT2E; NbExp=4; IntAct=EBI-366083, EBI-2689959;
CC       P04637; Q16363: LAMA4; NbExp=2; IntAct=EBI-366083, EBI-711505;
CC       P04637; P43356: MAGEA2B; NbExp=7; IntAct=EBI-366083, EBI-5650739;
CC       P04637; Q96M61: MAGEB18; NbExp=3; IntAct=EBI-366083, EBI-741835;
CC       P04637; Q9UBF1: MAGEC2; NbExp=3; IntAct=EBI-366083, EBI-5651487;
CC       P04637; P46821: MAP1B; NbExp=6; IntAct=EBI-366083, EBI-764611;
CC       P04637; Q15759: MAPK11; NbExp=2; IntAct=EBI-366083, EBI-298304;
CC       P04637; Q8IW41: MAPKAPK5; NbExp=2; IntAct=EBI-366083, EBI-1201460;
CC       P04637; Q00987: MDM2; NbExp=93; IntAct=EBI-366083, EBI-389668;
CC       P04637; O15151: MDM4; NbExp=19; IntAct=EBI-366083, EBI-398437;
CC       P04637; Q9UHC7: MKRN1; NbExp=8; IntAct=EBI-366083, EBI-373524;
CC       P04637; O75970: MPDZ; NbExp=3; IntAct=EBI-366083, EBI-821405;
CC       P04637; P04731: MT1A; NbExp=3; IntAct=EBI-366083, EBI-8045030;
CC       P04637; P19338: NCL; NbExp=2; IntAct=EBI-366083, EBI-346967;
CC       P04637; Q9Y618: NCOR2; NbExp=7; IntAct=EBI-366083, EBI-80830;
CC       P04637; P23511: NFYA; NbExp=11; IntAct=EBI-366083, EBI-389739;
CC       P04637; P25208: NFYB; NbExp=6; IntAct=EBI-366083, EBI-389728;
CC       P04637; Q9Y3T9: NOC2L; NbExp=8; IntAct=EBI-366083, EBI-751547;
CC       P04637; O60936: NOL3; NbExp=3; IntAct=EBI-366083, EBI-740992;
CC       P04637; P06748: NPM1; NbExp=6; IntAct=EBI-366083, EBI-78579;
CC       P04637; P06748-1: NPM1; NbExp=3; IntAct=EBI-366083, EBI-354150;
CC       P04637; Q15466: NR0B2; NbExp=3; IntAct=EBI-366083, EBI-3910729;
CC       P04637; P22736: NR4A1; NbExp=6; IntAct=EBI-366083, EBI-721550;
CC       P04637; O43847: NRDC; NbExp=6; IntAct=EBI-366083, EBI-2371631;
CC       P04637; O60285: NUAK1; NbExp=5; IntAct=EBI-366083, EBI-1046789;
CC       P04637; P49757: NUMB; NbExp=5; IntAct=EBI-366083, EBI-915016;
CC       P04637; Q96FW1: OTUB1; NbExp=8; IntAct=EBI-366083, EBI-1058491;
CC       P04637; Q8TEW0: PARD3; NbExp=3; IntAct=EBI-366083, EBI-81968;
CC       P04637; P09874: PARP1; NbExp=3; IntAct=EBI-366083, EBI-355676;
CC       P04637; Q96KB5: PBK; NbExp=7; IntAct=EBI-366083, EBI-536853;
CC       P04637; P35232: PHB; NbExp=6; IntAct=EBI-366083, EBI-354213;
CC       P04637; O75925: PIAS1; NbExp=4; IntAct=EBI-366083, EBI-629434;
CC       P04637; O75928: PIAS2; NbExp=2; IntAct=EBI-366083, EBI-348555;
CC       P04637; Q8N2W9: PIAS4; NbExp=2; IntAct=EBI-366083, EBI-473160;
CC       P04637; Q13526: PIN1; NbExp=12; IntAct=EBI-366083, EBI-714158;
CC       P04637; P53350: PLK1; NbExp=6; IntAct=EBI-366083, EBI-476768;
CC       P04637; P29590: PML; NbExp=4; IntAct=EBI-366083, EBI-295890;
CC       P04637; P30405: PPIF; NbExp=4; IntAct=EBI-366083, EBI-5544229;
CC       P04637; P36873-1: PPP1CC; NbExp=2; IntAct=EBI-366083, EBI-356289;
CC       P04637; Q8WUF5: PPP1R13L; NbExp=12; IntAct=EBI-366083, EBI-5550163;
CC       P04637; P30153: PPP2R1A; NbExp=3; IntAct=EBI-366083, EBI-302388;
CC       P04637; Q13362: PPP2R5C; NbExp=4; IntAct=EBI-366083, EBI-1266156;
CC       P04637; Q05655: PRKCD; NbExp=4; IntAct=EBI-366083, EBI-704279;
CC       P04637; P61289: PSME3; NbExp=7; IntAct=EBI-366083, EBI-355546;
CC       P04637; Q05397: PTK2; NbExp=13; IntAct=EBI-366083, EBI-702142;
CC       P04637; Q06609: RAD51; NbExp=2; IntAct=EBI-366083, EBI-297202;
CC       P04637; Q06330: RBPJ; NbExp=5; IntAct=EBI-366083, EBI-632552;
CC       P04637; Q96PM5: RCHY1; NbExp=11; IntAct=EBI-366083, EBI-947779;
CC       P04637; Q6PCD5: RFWD3; NbExp=5; IntAct=EBI-366083, EBI-2129159;
CC       P04637; Q06587: RING1; NbExp=7; IntAct=EBI-366083, EBI-752313;
CC       P04637; P23396: RPS3; NbExp=4; IntAct=EBI-366083, EBI-351193;
CC       P04637; Q8N488: RYBP; NbExp=3; IntAct=EBI-366083, EBI-752324;
CC       P04637; P23297: S100A1; NbExp=3; IntAct=EBI-366083, EBI-743686;
CC       P04637; P31949: S100A11; NbExp=2; IntAct=EBI-366083, EBI-701862;
CC       P04637; P29034: S100A2; NbExp=4; IntAct=EBI-366083, EBI-752230;
CC       P04637; P33764: S100A3; NbExp=2; IntAct=EBI-366083, EBI-1044747;
CC       P04637; P26447: S100A4; NbExp=9; IntAct=EBI-366083, EBI-717058;
CC       P04637; P33763: S100A5; NbExp=2; IntAct=EBI-366083, EBI-7211732;
CC       P04637; P06703: S100A6; NbExp=3; IntAct=EBI-366083, EBI-352877;
CC       P04637; P04271: S100B; NbExp=3; IntAct=EBI-366083, EBI-458391;
CC       P04637; P25815: S100P; NbExp=2; IntAct=EBI-366083, EBI-743700;
CC       P04637; Q15424: SAFB; NbExp=5; IntAct=EBI-366083, EBI-348298;
CC       P04637; Q8WTS6: SETD7; NbExp=11; IntAct=EBI-366083, EBI-1268586;
CC       P04637; P31947: SFN; NbExp=4; IntAct=EBI-366083, EBI-476295;
CC       P04637; Q96ST3: SIN3A; NbExp=2; IntAct=EBI-366083, EBI-347218;
CC       P04637; Q96EB6: SIRT1; NbExp=18; IntAct=EBI-366083, EBI-1802965;
CC       P04637; Q15796: SMAD2; NbExp=7; IntAct=EBI-366083, EBI-1040141;
CC       P04637; Q9NRG4: SMYD2; NbExp=6; IntAct=EBI-366083, EBI-1055671;
CC       P04637; O95863: SNAI1; NbExp=2; IntAct=EBI-366083, EBI-1045459;
CC       P04637; Q06945: SOX4; NbExp=4; IntAct=EBI-366083, EBI-6672525;
CC       P04637; P08047: SP1; NbExp=3; IntAct=EBI-366083, EBI-298336;
CC       P04637; Q12772: SREBF2; NbExp=3; IntAct=EBI-366083, EBI-465059;
CC       P04637; Q96SB4: SRPK1; NbExp=3; IntAct=EBI-366083, EBI-539478;
CC       P04637; P63165: SUMO1; NbExp=3; IntAct=EBI-366083, EBI-80140;
CC       P04637; Q86TM6: SYVN1; NbExp=5; IntAct=EBI-366083, EBI-947849;
CC       P04637; P20226: TBP; NbExp=2; IntAct=EBI-366083, EBI-355371;
CC       P04637; P15884: TCF4; NbExp=2; IntAct=EBI-366083, EBI-533224;
CC       P04637; Q96GM8: TOE1; NbExp=3; IntAct=EBI-366083, EBI-717460;
CC       P04637; P04637: TP53; NbExp=32; IntAct=EBI-366083, EBI-366083;
CC       P04637; Q12888: TP53BP1; NbExp=6; IntAct=EBI-366083, EBI-396540;
CC       P04637; Q12888-1: TP53BP1; NbExp=17; IntAct=EBI-366083, EBI-8022649;
CC       P04637; Q13625: TP53BP2; NbExp=9; IntAct=EBI-366083, EBI-77642;
CC       P04637; Q9H3D4: TP63; NbExp=5; IntAct=EBI-366083, EBI-2337775;
CC       P04637; P13693: TPT1; NbExp=7; IntAct=EBI-366083, EBI-1783169;
CC       P04637; O15164: TRIM24; NbExp=3; IntAct=EBI-366083, EBI-2130378;
CC       P04637; Q15672: TWIST1; NbExp=10; IntAct=EBI-366083, EBI-1797287;
CC       P04637; P0CG48: UBC; NbExp=15; IntAct=EBI-366083, EBI-3390054;
CC       P04637; P63279: UBE2I; NbExp=3; IntAct=EBI-366083, EBI-80168;
CC       P04637; Q05086: UBE3A; NbExp=6; IntAct=EBI-366083, EBI-954357;
CC       P04637; Q96PU4: UHRF2; NbExp=3; IntAct=EBI-366083, EBI-625304;
CC       P04637; Q9H9J4: USP42; NbExp=2; IntAct=EBI-366083, EBI-2513638;
CC       P04637; Q9H9J4-2: USP42; NbExp=2; IntAct=EBI-366083, EBI-9118105;
CC       P04637; Q93009: USP7; NbExp=18; IntAct=EBI-366083, EBI-302474;
CC       P04637; P11473: VDR; NbExp=6; IntAct=EBI-366083, EBI-286357;
CC       P04637; Q99986: VRK1; NbExp=11; IntAct=EBI-366083, EBI-1769146;
CC       P04637; Q14191: WRN; NbExp=5; IntAct=EBI-366083, EBI-368417;
CC       P04637; Q9NZC7: WWOX; NbExp=2; IntAct=EBI-366083, EBI-4320739;
CC       P04637; O14980: XPO1; NbExp=3; IntAct=EBI-366083, EBI-355867;
CC       P04637; P12956: XRCC6; NbExp=2; IntAct=EBI-366083, EBI-353208;
CC       P04637; P61981: YWHAG; NbExp=5; IntAct=EBI-366083, EBI-359832;
CC       P04637; P63104: YWHAZ; NbExp=2; IntAct=EBI-366083, EBI-347088;
CC       P04637; Q8TAQ5: ZNF420; NbExp=4; IntAct=EBI-366083, EBI-3923307;
CC       P04637; Q7L7W2; NbExp=2; IntAct=EBI-366083, EBI-7210801;
CC       P04637; P29066: Arrb1; Xeno; NbExp=3; IntAct=EBI-366083, EBI-4303019;
CC       P04637; Q9ESJ1: Cables1; Xeno; NbExp=3; IntAct=EBI-366083, EBI-604411;
CC       P04637; P45481: Crebbp; Xeno; NbExp=9; IntAct=EBI-366083, EBI-296306;
CC       P04637; P03126: E6; Xeno; NbExp=5; IntAct=EBI-366083, EBI-1177242;
CC       P04637; P06463: E6; Xeno; NbExp=3; IntAct=EBI-366083, EBI-1186926;
CC       P04637; P02829: HSP82; Xeno; NbExp=8; IntAct=EBI-366083, EBI-8659;
CC       P04637; Q08619: Ifi205b; Xeno; NbExp=2; IntAct=EBI-366083, EBI-8064290;
CC       P04637; P89055: NSP1; Xeno; NbExp=6; IntAct=EBI-366083, EBI-9522973;
CC       P04637; Q923E4: Sirt1; Xeno; NbExp=4; IntAct=EBI-366083, EBI-1802585;
CC       P04637; Q8R5A0: Smyd2; Xeno; NbExp=3; IntAct=EBI-366083, EBI-15612527;
CC       P04637; P32776: TFB1; Xeno; NbExp=7; IntAct=EBI-366083, EBI-19146;
CC       P04637; O88898: Tp63; Xeno; NbExp=2; IntAct=EBI-366083, EBI-2338025;
CC       P04637; P26687: Twist1; Xeno; NbExp=4; IntAct=EBI-366083, EBI-6123119;
CC       P04637; Q9PST7: znf585b; Xeno; NbExp=3; IntAct=EBI-366083, EBI-1782562;
CC       P04637; P03070; Xeno; NbExp=20; IntAct=EBI-366083, EBI-617698;
CC       P04637; PRO_0000037536 [P26663]; Xeno; NbExp=9; IntAct=EBI-366083, EBI-6838571;
CC       P04637; Q8QW27; Xeno; NbExp=2; IntAct=EBI-366083, EBI-6863726;
CC       P04637-1; P17844: DDX5; NbExp=2; IntAct=EBI-3895849, EBI-351962;
CC       P04637-7; P17844: DDX5; NbExp=2; IntAct=EBI-3895873, EBI-351962;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15340061,
CC       ECO:0000269|PubMed:15701641, ECO:0000269|PubMed:17170702,
CC       ECO:0000269|PubMed:19011621, ECO:0000269|PubMed:22726440}. Nucleus
CC       {ECO:0000269|PubMed:15340061, ECO:0000269|PubMed:15701641,
CC       ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:17591690,
CC       ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19011621}. Nucleus, PML
CC       body {ECO:0000269|PubMed:11025664, ECO:0000269|PubMed:12810724}.
CC       Endoplasmic reticulum {ECO:0000269|PubMed:17170702}. Mitochondrion
CC       matrix {ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:27323408}.
CC       Cytoplasm, cytoskeleton, microtubule organizing center, centrosome
CC       {ECO:0000269|PubMed:28842590}. Note=Interaction with BANP promotes
CC       nuclear localization (PubMed:15701641). Recruited into PML bodies
CC       together with CHEK2 (PubMed:12810724). Translocates to mitochondria
CC       upon oxidative stress (PubMed:22726440). Translocates to mitochondria
CC       in response to mitomycin C treatment (PubMed:27323408).
CC       {ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:15701641,
CC       ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:27323408}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Nucleus. Cytoplasm.
CC       Note=Predominantly nuclear but localizes to the cytoplasm when
CC       expressed with isoform 4.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus. Cytoplasm. Note=Localized
CC       mainly in the nucleus with minor staining in the cytoplasm.
CC   -!- SUBCELLULAR LOCATION: [Isoform 3]: Nucleus. Cytoplasm. Note=Localized
CC       in the nucleus in most cells but found in the cytoplasm in some cells.
CC   -!- SUBCELLULAR LOCATION: [Isoform 4]: Nucleus. Cytoplasm.
CC       Note=Predominantly nuclear but translocates to the cytoplasm following
CC       cell stress.
CC   -!- SUBCELLULAR LOCATION: [Isoform 7]: Nucleus. Cytoplasm. Note=Localized
CC       mainly in the nucleus with minor staining in the cytoplasm.
CC   -!- SUBCELLULAR LOCATION: [Isoform 8]: Nucleus. Cytoplasm. Note=Localized
CC       in both nucleus and cytoplasm in most cells. In some cells, forms foci
CC       in the nucleus that are different from nucleoli.
CC   -!- SUBCELLULAR LOCATION: [Isoform 9]: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=9;
CC       Name=1; Synonyms=p53, p53alpha;
CC         IsoId=P04637-1; Sequence=Displayed;
CC       Name=2; Synonyms=I9RET, p53beta;
CC         IsoId=P04637-2; Sequence=VSP_006535, VSP_006536;
CC       Name=3; Synonyms=p53gamma;
CC         IsoId=P04637-3; Sequence=VSP_040560, VSP_040561;
CC       Name=4; Synonyms=Del40-p53, Del40-p53alpha, p47;
CC         IsoId=P04637-4; Sequence=VSP_040832;
CC       Name=5; Synonyms=Del40-p53beta;
CC         IsoId=P04637-5; Sequence=VSP_040832, VSP_006535, VSP_006536;
CC       Name=6; Synonyms=Del40-p53gamma;
CC         IsoId=P04637-6; Sequence=VSP_040832, VSP_040560, VSP_040561;
CC       Name=7; Synonyms=Del133-p53, Del133-p53alpha;
CC         IsoId=P04637-7; Sequence=VSP_040833;
CC       Name=8; Synonyms=Del133-p53beta;
CC         IsoId=P04637-8; Sequence=VSP_040833, VSP_006535, VSP_006536;
CC       Name=9; Synonyms=Del133-p53gamma;
CC         IsoId=P04637-9; Sequence=VSP_040833, VSP_040560, VSP_040561;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Isoforms are expressed in a wide range
CC       of normal tissues but in a tissue-dependent manner. Isoform 2 is
CC       expressed in most normal tissues but is not detected in brain, lung,
CC       prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3
CC       is expressed in most normal tissues but is not detected in lung,
CC       spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is
CC       expressed in most normal tissues but is not detected in prostate,
CC       uterus, skeletal muscle and breast. Isoform 8 is detected only in
CC       colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is
CC       expressed in most normal tissues but is not detected in brain, heart,
CC       lung, fetal liver, salivary gland, breast or intestine.
CC       {ECO:0000269|PubMed:16131611}.
CC   -!- INDUCTION: Up-regulated in response to DNA damage. Isoform 2 is not
CC       induced in tumor cells in response to stress.
CC       {ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:16131611}.
CC   -!- DOMAIN: The nuclear export signal acts as a transcriptional repression
CC       domain. The TADI and TADII motifs (residues 17 to 25 and 48 to 56)
CC       correspond both to 9aaTAD motifs which are transactivation domains
CC       present in a large number of yeast and animal transcription factors.
CC       {ECO:0000269|PubMed:17467953}.
CC   -!- PTM: Acetylated. Acetylation of Lys-382 by CREBBP enhances
CC       transcriptional activity. Deacetylation of Lys-382 by SIRT1 impairs its
CC       ability to induce proapoptotic program and modulate cell senescence.
CC       Deacetylation by SIRT2 impairs its ability to induce transcription
CC       activation in a AKT-dependent manner. {ECO:0000269|PubMed:10656795,
CC       ECO:0000269|PubMed:20228809, ECO:0000269|PubMed:23431171}.
CC   -!- PTM: Phosphorylation on Ser residues mediates transcriptional
CC       activation. Phosphorylated by HIPK1 (By similarity). Phosphorylation at
CC       Ser-9 by HIPK4 increases repression activity on BIRC5 promoter.
CC       Phosphorylated on Thr-18 by VRK1. Phosphorylated on Ser-20 by CHEK2 in
CC       response to DNA damage, which prevents ubiquitination by MDM2.
CC       Phosphorylated on Ser-20 by PLK3 in response to reactive oxygen species
CC       (ROS), promoting p53/TP53-mediated apoptosis. Phosphorylated on Thr-55
CC       by TAF1, which promotes MDM2-mediated degradation. Phosphorylated on
CC       Ser-33 by CDK7 in a CAK complex in response to DNA damage.
CC       Phosphorylated on Ser-46 by HIPK2 upon UV irradiation. Phosphorylation
CC       on Ser-46 is required for acetylation by CREBBP. Phosphorylated on Ser-
CC       392 following UV but not gamma irradiation. Phosphorylated on Ser-15
CC       upon ultraviolet irradiation; which is enhanced by interaction with
CC       BANP. Phosphorylated by NUAK1 at Ser-15 and Ser-392; was initially
CC       thought to be mediated by STK11/LKB1 but it was later shown that it is
CC       indirect and that STK11/LKB1-dependent phosphorylation is probably
CC       mediated by downstream NUAK1 (PubMed:21317932). It is unclear whether
CC       AMP directly mediates phosphorylation at Ser-15. Phosphorylated on Thr-
CC       18 by isoform 1 and isoform 2 of VRK2. Phosphorylation on Thr-18 by
CC       isoform 2 of VRK2 results in a reduction in ubiquitination by MDM2 and
CC       an increase in acetylation by EP300. Stabilized by CDK5-mediated
CC       phosphorylation in response to genotoxic and oxidative stresses at Ser-
CC       15, Ser-33 and Ser-46, leading to accumulation of p53/TP53,
CC       particularly in the nucleus, thus inducing the transactivation of
CC       p53/TP53 target genes. Phosphorylated by DYRK2 at Ser-46 in response to
CC       genotoxic stress. Phosphorylated at Ser-315 and Ser-392 by CDK2 in
CC       response to DNA-damage. Phosphorylation at Ser-15 is required for
CC       interaction with DDX3X and gamma-tubulin (PubMed:28842590).
CC       {ECO:0000250, ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:10606744,
CC       ECO:0000269|PubMed:10884347, ECO:0000269|PubMed:10951572,
CC       ECO:0000269|PubMed:11239457, ECO:0000269|PubMed:11447225,
CC       ECO:0000269|PubMed:11546806, ECO:0000269|PubMed:11551930,
CC       ECO:0000269|PubMed:11554766, ECO:0000269|PubMed:11740489,
CC       ECO:0000269|PubMed:11780126, ECO:0000269|PubMed:12810724,
CC       ECO:0000269|PubMed:14702041, ECO:0000269|PubMed:15053879,
CC       ECO:0000269|PubMed:15701641, ECO:0000269|PubMed:15866171,
CC       ECO:0000269|PubMed:16377624, ECO:0000269|PubMed:16704422,
CC       ECO:0000269|PubMed:1705009, ECO:0000269|PubMed:17108107,
CC       ECO:0000269|PubMed:17254968, ECO:0000269|PubMed:17349958,
CC       ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:17967874,
CC       ECO:0000269|PubMed:18022393, ECO:0000269|PubMed:20041275,
CC       ECO:0000269|PubMed:20124405, ECO:0000269|PubMed:20959462,
CC       ECO:0000269|PubMed:21317932, ECO:0000269|PubMed:2141171,
CC       ECO:0000269|PubMed:22214662, ECO:0000269|PubMed:28842590,
CC       ECO:0000269|PubMed:9372954}.
CC   -!- PTM: Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40 small
CC       T antigen inhibits the dephosphorylation by the AC form of PP2A.
CC   -!- PTM: May be O-glycosylated in the C-terminal basic region. Studied in
CC       EB-1 cell line. {ECO:0000269|PubMed:8632915}.
CC   -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal
CC       degradation (PubMed:10722742, PubMed:12810724, PubMed:15340061,
CC       PubMed:17170702, PubMed:19880522). Ubiquitinated by RFWD3, which works
CC       in cooperation with MDM2 and may catalyze the formation of short
CC       polyubiquitin chains on p53/TP53 that are not targeted to the
CC       proteasome (PubMed:10722742, PubMed:12810724, PubMed:20173098).
CC       Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to
CC       proteasomal degradation (PubMed:19536131). Deubiquitinated by USP10,
CC       leading to its stabilization (PubMed:20096447). Ubiquitinated by
CC       TRIM24, RFFL, RNF34 and RNF125, which leads to proteasomal degradation
CC       (PubMed:19556538). Ubiquitination by TOPORS induces degradation
CC       (PubMed:19473992). Deubiquitination by USP7, leading to stabilization
CC       (PubMed:15053880). Isoform 4 is monoubiquitinated in an MDM2-
CC       independent manner (PubMed:15340061). Ubiquitinated by COP1, which
CC       leads to proteasomal degradation (PubMed:19837670). Ubiquitination and
CC       subsequent proteasomal degradation is negatively regulated by CCAR2
CC       (PubMed:25732823). Polyubiquitinated by C10orf90/FATS,
CC       polyubiquitination is 'Lys-48'-linkage independent and non-proteolytic,
CC       leading to TP53 stabilization (By similarity).
CC       {ECO:0000250|UniProtKB:P02340, ECO:0000269|PubMed:10722742,
CC       ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:15053880,
CC       ECO:0000269|PubMed:15340061, ECO:0000269|PubMed:17170702,
CC       ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:19473992,
CC       ECO:0000269|PubMed:19536131, ECO:0000269|PubMed:19556538,
CC       ECO:0000269|PubMed:19837670, ECO:0000269|PubMed:19880522,
CC       ECO:0000269|PubMed:20096447, ECO:0000269|PubMed:20173098,
CC       ECO:0000269|PubMed:25591766, ECO:0000269|PubMed:25732823}.
CC   -!- PTM: Monomethylated at Lys-372 by SETD7, leading to stabilization and
CC       increased transcriptional activation (PubMed:15525938,
CC       PubMed:16415881). Monomethylated at Lys-370 by SMYD2, leading to
CC       decreased DNA-binding activity and subsequent transcriptional
CC       regulation activity (PubMed:17108971). Lys-372 monomethylation prevents
CC       interaction with SMYD2 and subsequent monomethylation at Lys-370
CC       (PubMed:17108971). Dimethylated at Lys-373 by EHMT1 and EHMT2
CC       (PubMed:20118233). Monomethylated at Lys-382 by KMT5A, promoting
CC       interaction with L3MBTL1 and leading to repress transcriptional
CC       activity (PubMed:17707234). Dimethylation at Lys-370 and Lys-382
CC       diminishes p53 ubiquitination, through stabilizing association with the
CC       methyl reader PHF20 (PubMed:22864287). Demethylation of dimethylated
CC       Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53-
CC       mediated transcriptional activation (PubMed:17805299). Monomethylated
CC       at Arg-333 and dimethylated at Arg-335 and Arg-337 by PRMT5;
CC       methylation is increased after DNA damage and might possibly affect
CC       TP53 target gene specificity (PubMed:19011621).
CC       {ECO:0000269|PubMed:15525938, ECO:0000269|PubMed:16415881,
CC       ECO:0000269|PubMed:17108971, ECO:0000269|PubMed:17707234,
CC       ECO:0000269|PubMed:17805299, ECO:0000269|PubMed:19011621,
CC       ECO:0000269|PubMed:20118233, ECO:0000269|PubMed:22864287}.
CC   -!- PTM: Sumoylated with SUMO1. Sumoylated at Lys-386 by UBC9.
CC       {ECO:0000269|PubMed:11124955, ECO:0000269|PubMed:22214662,
CC       ECO:0000269|Ref.37}.
CC   -!- DISEASE: Note=TP53 is found in increased amounts in a wide variety of
CC       transformed cells. TP53 is frequently mutated or inactivated in about
CC       60% of cancers. TP53 defects are found in Barrett metaplasia a
CC       condition in which the normally stratified squamous epithelium of the
CC       lower esophagus is replaced by a metaplastic columnar epithelium. The
CC       condition develops as a complication in approximately 10% of patients
CC       with chronic gastroesophageal reflux disease and predisposes to the
CC       development of esophageal adenocarcinoma.
CC   -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the
CC       esophagus. The most common types are esophageal squamous cell carcinoma
CC       and adenocarcinoma. Cancer of the esophagus remains a devastating
CC       disease because it is usually not detected until it has progressed to
CC       an advanced incurable stage. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Li-Fraumeni syndrome (LFS) [MIM:151623]: An autosomal dominant
CC       familial cancer syndrome that in its classic form is defined by the
CC       existence of a proband affected by a sarcoma before 45 years with a
CC       first degree relative affected by any tumor before 45 years and another
CC       first degree relative with any tumor before 45 years or a sarcoma at
CC       any age. Other clinical definitions for LFS have been proposed and
CC       called Li-Fraumeni like syndrome (LFL). In these families affected
CC       relatives develop a diverse set of malignancies at unusually early
CC       ages. Four types of cancers account for 80% of tumors occurring in TP53
CC       germline mutation carriers: breast cancers, soft tissue and bone
CC       sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas.
CC       Less frequent tumors include choroid plexus carcinoma or papilloma
CC       before the age of 15, rhabdomyosarcoma before the age of 5, leukemia,
CC       Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers.
CC       {ECO:0000269|PubMed:10484981, ECO:0000269|PubMed:1565144,
CC       ECO:0000269|PubMed:1737852, ECO:0000269|PubMed:1933902,
CC       ECO:0000269|PubMed:1978757, ECO:0000269|PubMed:2259385,
CC       ECO:0000269|PubMed:7887414, ECO:0000269|PubMed:8825920,
CC       ECO:0000269|PubMed:9452042}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Squamous cell carcinoma of the head and neck (HNSCC)
CC       [MIM:275355]: A non-melanoma skin cancer affecting the head and neck.
CC       The hallmark of cutaneous SCC is malignant transformation of normal
CC       epidermal keratinocytes. Note=The gene represented in this entry is
CC       involved in disease pathogenesis.
CC   -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting
CC       tissues of the lung. The most common form of lung cancer is non-small
CC       cell lung cancer (NSCLC) that can be divided into 3 major histologic
CC       subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung
CC       cancer. NSCLC is often diagnosed at an advanced stage and has a poor
CC       prognosis. Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Papilloma of choroid plexus (CPP) [MIM:260500]: A benign tumor
CC       of neuroectodermal origin that generally occurs in childhood, but has
CC       also been reported in adults. Although generally found within the
CC       ventricular system, choroid plexus papillomas can arise ectopically in
CC       the brain parenchyma or disseminate throughout the neuraxis. Patients
CC       present with signs and symptoms of increased intracranial pressure
CC       including headache, hydrocephalus, papilledema, nausea, vomiting,
CC       cranial nerve deficits, gait impairment, and seizures.
CC       {ECO:0000269|PubMed:12085209}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Adrenocortical carcinoma (ADCC) [MIM:202300]: A malignant
CC       neoplasm of the adrenal cortex and a rare childhood tumor. It occurs
CC       with increased frequency in patients with Beckwith-Wiedemann syndrome
CC       and Li-Fraumeni syndrome. {ECO:0000269|PubMed:11481490}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Basal cell carcinoma 7 (BCC7) [MIM:614740]: A common malignant
CC       skin neoplasm that typically appears on hair-bearing skin, most
CC       commonly on sun-exposed areas. It is slow growing and rarely
CC       metastasizes, but has potentialities for local invasion and
CC       destruction. It usually develops as a flat, firm, pale area that is
CC       small, raised, pink or red, translucent, shiny, and waxy, and the area
CC       may bleed following minor injury. Tumor size can vary from a few
CC       millimeters to several centimeters in diameter.
CC       {ECO:0000269|PubMed:21946351}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Bone marrow failure syndrome 5 (BMFS5) [MIM:618165]: A form of
CC       bone marrow failure syndrome, a heterogeneous group of life-threatening
CC       disorders characterized by hematopoietic defects in association with a
CC       range of variable extra hematopoietic features. BMFS5 is an autosomal
CC       dominant form characterized by infantile onset of severe red cell
CC       anemia requiring transfusion. Additional features include
CC       hypogammaglobulinemia, poor growth with microcephaly, developmental
CC       delay, and seizures. {ECO:0000269|PubMed:30146126}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 2]: Expressed in quiescent lymphocytes. Seems
CC       to be non-functional. May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 3]: Expressed in quiescent lymphocytes. Seems
CC       to be non-functional. May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 7]: Produced by alternative promoter usage.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 8]: Produced by alternative promoter usage and
CC       alternative splicing. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 9]: Produced by alternative promoter usage and
CC       alternative splicing. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=IARC TP53 mutation database; Note=Somatic and
CC       germline TP53 mutations in human cancers;
CC       URL="https://p53.iarc.fr/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/P53ID88.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/tp53/";
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=TP53";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=P53 entry;
CC       URL="https://en.wikipedia.org/wiki/P53";
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=On the right track - Issue
CC       206 of August 2018;
CC       URL="https://web.expasy.org/spotlight/back_issues/206/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X02469; CAA26306.1; -; mRNA.
DR   EMBL; M13121; AAA59987.1; -; Genomic_DNA.
DR   EMBL; M13112; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13113; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13114; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13115; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13116; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13117; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13118; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13119; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13120; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; K03199; AAA59989.1; -; mRNA.
DR   EMBL; M14694; AAA61211.1; -; mRNA.
DR   EMBL; M14695; AAA61212.1; -; mRNA.
DR   EMBL; M22898; AAA59988.1; -; Genomic_DNA.
DR   EMBL; M22882; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22883; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22884; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22887; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22888; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22894; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22895; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22896; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22897; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; X01405; CAA25652.1; -; mRNA.
DR   EMBL; X60011; CAA42626.1; -; mRNA.
DR   EMBL; X60012; CAA42627.1; ALT_TERM; mRNA.
DR   EMBL; X60013; CAA42628.1; -; mRNA.
DR   EMBL; X60014; CAA42629.1; -; mRNA.
DR   EMBL; X60015; CAA42630.1; -; mRNA.
DR   EMBL; X60016; CAA42631.1; -; mRNA.
DR   EMBL; X60017; CAA42632.1; -; mRNA.
DR   EMBL; X60018; CAA42633.1; -; mRNA.
DR   EMBL; X60019; CAA42634.1; -; mRNA.
DR   EMBL; X60020; CAA42635.1; -; mRNA.
DR   EMBL; AF307851; AAG28785.1; -; mRNA.
DR   EMBL; DQ186648; ABA29753.1; -; mRNA.
DR   EMBL; DQ186649; ABA29754.1; -; mRNA.
DR   EMBL; DQ186650; ABA29755.1; -; mRNA.
DR   EMBL; DQ186651; ABA29756.1; -; mRNA.
DR   EMBL; DQ186652; ABA29757.1; -; mRNA.
DR   EMBL; DQ191317; ABB80262.1; -; mRNA.
DR   EMBL; DQ286964; ABB80266.1; -; mRNA.
DR   EMBL; X54156; CAA38095.1; -; Genomic_DNA.
DR   EMBL; U94788; AAC12971.1; -; Genomic_DNA.
DR   EMBL; AY838896; AAV80424.1; -; Genomic_DNA.
DR   EMBL; AF135121; AAD28535.1; -; Genomic_DNA.
DR   EMBL; AF135120; AAD28535.1; JOINED; Genomic_DNA.
DR   EMBL; AF136271; AAD28628.1; -; Genomic_DNA.
DR   EMBL; AF136270; AAD28628.1; JOINED; Genomic_DNA.
DR   EMBL; AB082923; BAC16799.1; -; mRNA.
DR   EMBL; AK312568; BAG35463.1; -; mRNA.
DR   EMBL; AC007421; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC087388; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471108; EAW90143.1; -; Genomic_DNA.
DR   EMBL; CH471108; EAW90144.1; -; Genomic_DNA.
DR   EMBL; BC003596; AAH03596.1; -; mRNA.
DR   EMBL; AY429684; AAR10356.1; -; mRNA.
DR   EMBL; AY390341; AAQ90158.1; -; Genomic_DNA.
DR   EMBL; AY359814; AAR13239.1; -; Genomic_DNA.
DR   EMBL; U63714; AAB39322.1; -; Genomic_DNA.
DR   EMBL; AF209136; AAF36362.1; -; Genomic_DNA.
DR   EMBL; AF209128; AAF36354.1; -; Genomic_DNA.
DR   EMBL; AF209129; AAF36355.1; -; Genomic_DNA.
DR   EMBL; AF209130; AAF36356.1; -; Genomic_DNA.
DR   EMBL; AF209131; AAF36357.1; -; Genomic_DNA.
DR   EMBL; AF209132; AAF36358.1; -; Genomic_DNA.
DR   EMBL; AF209133; AAF36359.1; -; Genomic_DNA.
DR   EMBL; AF209134; AAF36360.1; -; Genomic_DNA.
DR   EMBL; AF209135; AAF36361.1; -; Genomic_DNA.
DR   EMBL; AF209148; AAF36374.1; -; Genomic_DNA.
DR   EMBL; AF209149; AAF36375.1; -; Genomic_DNA.
DR   EMBL; AF209150; AAF36376.1; -; Genomic_DNA.
DR   EMBL; AF209151; AAF36377.1; -; Genomic_DNA.
DR   EMBL; AF209152; AAF36378.1; -; Genomic_DNA.
DR   EMBL; AF209153; AAF36379.1; -; Genomic_DNA.
DR   EMBL; AF209154; AAF36380.1; -; Genomic_DNA.
DR   EMBL; AF209155; AAF36381.1; -; Genomic_DNA.
DR   EMBL; AF209156; AAF36382.1; -; Genomic_DNA.
DR   EMBL; AF210309; AAF63442.1; -; Genomic_DNA.
DR   EMBL; AF210308; AAF63442.1; JOINED; Genomic_DNA.
DR   EMBL; AF210310; AAF63443.1; -; Genomic_DNA.
DR   EMBL; AF240684; AAK76358.1; -; Genomic_DNA.
DR   EMBL; AF240685; AAK76359.1; -; Genomic_DNA.
DR   EMBL; AY270155; AAP30003.1; -; Genomic_DNA.
DR   CCDS; CCDS11118.1; -. [P04637-1]
DR   CCDS; CCDS45605.1; -. [P04637-3]
DR   CCDS; CCDS45606.1; -. [P04637-2]
DR   CCDS; CCDS73966.1; -. [P04637-7]
DR   CCDS; CCDS73967.1; -. [P04637-9]
DR   CCDS; CCDS73968.1; -. [P04637-8]
DR   CCDS; CCDS73969.1; -. [P04637-4]
DR   CCDS; CCDS73970.1; -. [P04637-6]
DR   CCDS; CCDS73971.1; -. [P04637-5]
DR   PIR; A25224; DNHU53.
DR   RefSeq; NP_000537.3; NM_000546.5. [P04637-1]
DR   RefSeq; NP_001119584.1; NM_001126112.2. [P04637-1]
DR   RefSeq; NP_001119585.1; NM_001126113.2. [P04637-3]
DR   RefSeq; NP_001119586.1; NM_001126114.2. [P04637-2]
DR   RefSeq; NP_001119587.1; NM_001126115.1. [P04637-7]
DR   RefSeq; NP_001119588.1; NM_001126116.1. [P04637-8]
DR   RefSeq; NP_001119589.1; NM_001126117.1. [P04637-9]
DR   RefSeq; NP_001119590.1; NM_001126118.1. [P04637-4]
DR   RefSeq; NP_001263624.1; NM_001276695.1. [P04637-6]
DR   RefSeq; NP_001263625.1; NM_001276696.1. [P04637-5]
DR   RefSeq; NP_001263626.1; NM_001276697.1.
DR   RefSeq; NP_001263627.1; NM_001276698.1.
DR   RefSeq; NP_001263628.1; NM_001276699.1.
DR   RefSeq; NP_001263689.1; NM_001276760.1. [P04637-4]
DR   RefSeq; NP_001263690.1; NM_001276761.1. [P04637-4]
DR   PDB; 1A1U; NMR; -; A/C=324-358.
DR   PDB; 1AIE; X-ray; 1.50 A; A=326-356.
DR   PDB; 1C26; X-ray; 1.70 A; A=325-356.
DR   PDB; 1DT7; NMR; -; X/Y=367-388.
DR   PDB; 1GZH; X-ray; 2.60 A; A/C=95-292.
DR   PDB; 1H26; X-ray; 2.24 A; E=376-386.
DR   PDB; 1HS5; NMR; -; A/B=324-357.
DR   PDB; 1JSP; NMR; -; A=367-386.
DR   PDB; 1KZY; X-ray; 2.50 A; A/B=95-289.
DR   PDB; 1MA3; X-ray; 2.00 A; B=372-389.
DR   PDB; 1OLG; NMR; -; A/B/C/D=319-360.
DR   PDB; 1OLH; NMR; -; A/B/C/D=319-360.
DR   PDB; 1PES; NMR; -; A/B/C/D=325-355.
DR   PDB; 1PET; NMR; -; A/B/C/D=325-355.
DR   PDB; 1SAE; NMR; -; A/B/C/D=319-360.
DR   PDB; 1SAF; NMR; -; A/B/C/D=319-360.
DR   PDB; 1SAK; NMR; -; A/B/C/D=319-360.
DR   PDB; 1SAL; NMR; -; A/B/C/D=319-360.
DR   PDB; 1TSR; X-ray; 2.20 A; A/B/C=94-312.
DR   PDB; 1TUP; X-ray; 2.20 A; A/B/C=94-312.
DR   PDB; 1UOL; X-ray; 1.90 A; A/B=94-312.
DR   PDB; 1XQH; X-ray; 1.75 A; B/F=369-377.
DR   PDB; 1YC5; X-ray; 1.40 A; B=372-389.
DR   PDB; 1YCQ; X-ray; 2.30 A; B=13-29.
DR   PDB; 1YCR; X-ray; 2.60 A; B=15-29.
DR   PDB; 1YCS; X-ray; 2.20 A; A=94-292.
DR   PDB; 2AC0; X-ray; 1.80 A; A/B/C/D=94-293.
DR   PDB; 2ADY; X-ray; 2.50 A; A/B=94-293.
DR   PDB; 2AHI; X-ray; 1.85 A; A/B/C/D=94-293.
DR   PDB; 2ATA; X-ray; 2.20 A; A/B/C/D=94-293.
DR   PDB; 2B3G; X-ray; 1.60 A; B=33-60.
DR   PDB; 2BIM; X-ray; 1.98 A; A/B=94-312.
DR   PDB; 2BIN; X-ray; 1.90 A; A=94-312.
DR   PDB; 2BIO; X-ray; 1.90 A; A=94-312.
DR   PDB; 2BIP; X-ray; 1.80 A; A=94-312.
DR   PDB; 2BIQ; X-ray; 1.80 A; A=94-312.
DR   PDB; 2F1X; X-ray; 2.30 A; A/B=359-368.
DR   PDB; 2FEJ; NMR; -; A=94-297.
DR   PDB; 2FOJ; X-ray; 1.60 A; B=361-367.
DR   PDB; 2FOO; X-ray; 2.20 A; B=358-363.
DR   PDB; 2GS0; NMR; -; B=20-73.
DR   PDB; 2H1L; X-ray; 3.16 A; M/N/O/P/Q/R/S/T/U/V/W/X=92-292.
DR   PDB; 2H2D; X-ray; 1.70 A; B=372-389.
DR   PDB; 2H2F; X-ray; 2.20 A; B=372-389.
DR   PDB; 2H4F; X-ray; 2.00 A; D=372-389.
DR   PDB; 2H4H; X-ray; 1.99 A; B=372-389.
DR   PDB; 2H4J; X-ray; 2.10 A; D=372-389.
DR   PDB; 2H59; X-ray; 1.90 A; D/E=372-389.
DR   PDB; 2J0Z; NMR; -; A/B/C/D=326-356.
DR   PDB; 2J10; NMR; -; A/B/C/D=326-356.
DR   PDB; 2J11; NMR; -; A/B/C/D=326-356.
DR   PDB; 2J1W; X-ray; 1.80 A; A/B=94-312.
DR   PDB; 2J1X; X-ray; 1.65 A; A/B=94-312.
DR   PDB; 2J1Y; X-ray; 1.69 A; A/B/C/D=94-293.
DR   PDB; 2J1Z; X-ray; 1.80 A; A/B=94-312.
DR   PDB; 2J20; X-ray; 1.80 A; A/B=94-312.
DR   PDB; 2J21; X-ray; 1.60 A; A/B=94-312.
DR   PDB; 2K8F; NMR; -; B=1-39.
DR   PDB; 2L14; NMR; -; B=13-61.
DR   PDB; 2LY4; NMR; -; B=1-93.
DR   PDB; 2MEJ; NMR; -; B=96-312.
DR   PDB; 2MWO; NMR; -; B=363-377.
DR   PDB; 2MWP; NMR; -; B=376-387.
DR   PDB; 2MWY; NMR; -; B=15-29.
DR   PDB; 2MZD; NMR; -; B=35-59.
DR   PDB; 2OCJ; X-ray; 2.05 A; A/B/C/D=94-312.
DR   PDB; 2PCX; X-ray; 1.54 A; A=94-292.
DR   PDB; 2RUK; NMR; -; A=41-62.
DR   PDB; 2VUK; X-ray; 1.50 A; A/B=94-312.
DR   PDB; 2WGX; X-ray; 1.75 A; A/B=94-312.
DR   PDB; 2X0U; X-ray; 1.60 A; A/B=94-312.
DR   PDB; 2X0V; X-ray; 1.80 A; A/B=94-312.
DR   PDB; 2X0W; X-ray; 2.10 A; A/B=94-312.
DR   PDB; 2XWR; X-ray; 1.68 A; A/B=89-293.
DR   PDB; 2YBG; X-ray; 1.90 A; A/B/C/D=94-293.
DR   PDB; 2YDR; X-ray; 2.75 A; P=144-154.
DR   PDB; 2Z5S; X-ray; 2.30 A; P/Q/R=15-29.
DR   PDB; 2Z5T; X-ray; 2.30 A; P/Q/R=15-29.
DR   PDB; 3D05; X-ray; 1.70 A; A=94-293.
DR   PDB; 3D06; X-ray; 1.20 A; A=94-293.
DR   PDB; 3D07; X-ray; 2.20 A; A/B=94-293.
DR   PDB; 3D08; X-ray; 1.40 A; A=94-293.
DR   PDB; 3D09; X-ray; 1.90 A; A=94-293.
DR   PDB; 3D0A; X-ray; 1.80 A; A/B/C/D=94-293.
DR   PDB; 3DAB; X-ray; 1.90 A; B/D/F/H=15-29.
DR   PDB; 3DAC; X-ray; 1.80 A; B/P=17-37.
DR   PDB; 3IGK; X-ray; 1.70 A; A=94-293.
DR   PDB; 3IGL; X-ray; 1.80 A; A=94-293.
DR   PDB; 3KMD; X-ray; 2.15 A; A/B/C/D=92-291.
DR   PDB; 3KZ8; X-ray; 1.91 A; A/B=94-293.
DR   PDB; 3LW1; X-ray; 1.28 A; P=385-393.
DR   PDB; 3OQ5; X-ray; 2.50 A; D/E=377-386.
DR   PDB; 3PDH; X-ray; 1.80 A; D=372-389.
DR   PDB; 3Q01; X-ray; 2.10 A; A/B=94-356.
DR   PDB; 3Q05; X-ray; 2.40 A; A/B/C/D=94-356.
DR   PDB; 3Q06; X-ray; 3.20 A; A/B/C/D=96-354.
DR   PDB; 3SAK; NMR; -; A/B/C/D=319-360.
DR   PDB; 3TG5; X-ray; 2.30 A; B=365-375.
DR   PDB; 3TS8; X-ray; 2.80 A; A/B/C/D=94-356.
DR   PDB; 3ZME; X-ray; 1.35 A; A/B=94-312.
DR   PDB; 4AGL; X-ray; 1.70 A; A/B=94-312.
DR   PDB; 4AGM; X-ray; 1.52 A; A/B=94-312.
DR   PDB; 4AGN; X-ray; 1.60 A; A/B=94-312.
DR   PDB; 4AGO; X-ray; 1.45 A; A/B=94-312.
DR   PDB; 4AGP; X-ray; 1.50 A; A/B=94-312.
DR   PDB; 4AGQ; X-ray; 1.42 A; A/B=94-312.
DR   PDB; 4BUZ; X-ray; 1.90 A; P=379-386.
DR   PDB; 4BV2; X-ray; 3.30 A; E/H=376-388.
DR   PDB; 4HFZ; X-ray; 2.69 A; B/D=15-29.
DR   PDB; 4HJE; X-ray; 1.91 A; A/B/C/D=92-291.
DR   PDB; 4IBQ; X-ray; 1.80 A; A/B/C/D=94-293.
DR   PDB; 4IBS; X-ray; 1.78 A; A/B/C/D=94-293.
DR   PDB; 4IBT; X-ray; 1.70 A; A/B/C/D=94-293.
DR   PDB; 4IBU; X-ray; 1.70 A; A/B/C/D=94-293.
DR   PDB; 4IBV; X-ray; 2.10 A; A=94-293.
DR   PDB; 4IBW; X-ray; 1.79 A; A=94-293.
DR   PDB; 4IBY; X-ray; 1.45 A; A/B=94-293.
DR   PDB; 4IBZ; X-ray; 1.92 A; A/B/C/D=94-293.
DR   PDB; 4IJT; X-ray; 1.78 A; A=94-293.
DR   PDB; 4KVP; X-ray; 1.50 A; A/B/C/D=94-312.
DR   PDB; 4LO9; X-ray; 2.50 A; A/B/C/D=94-312.
DR   PDB; 4LOE; X-ray; 1.85 A; A/B/C/D=94-312.
DR   PDB; 4LOF; X-ray; 2.00 A; A=94-312.
DR   PDB; 4MZI; X-ray; 1.25 A; A=94-292.
DR   PDB; 4MZR; X-ray; 2.90 A; A/B/C/D=94-358.
DR   PDB; 4QO1; X-ray; 1.92 A; B=92-312.
DR   PDB; 4RP6; X-ray; 1.70 A; Z=252-258.
DR   PDB; 4RP7; X-ray; 1.58 A; Z=253-258.
DR   PDB; 4X34; X-ray; 1.80 A; C/D=377-386.
DR   PDB; 4XR8; X-ray; 2.25 A; C/D=94-292.
DR   PDB; 4ZZJ; X-ray; 2.74 A; B=379-383.
DR   PDB; 5A7B; X-ray; 1.40 A; A/B=94-312.
DR   PDB; 5AB9; X-ray; 1.36 A; A/B=94-312.
DR   PDB; 5ABA; X-ray; 1.62 A; A/B=94-312.
DR   PDB; 5AOI; X-ray; 1.78 A; A/B=94-312.
DR   PDB; 5AOJ; X-ray; 1.47 A; A/B=94-312.
DR   PDB; 5AOK; X-ray; 1.35 A; A/B=94-312.
DR   PDB; 5AOL; X-ray; 1.50 A; A/B=94-312.
DR   PDB; 5AOM; X-ray; 1.74 A; A/B=94-312.
DR   PDB; 5BUA; X-ray; 1.81 A; A=94-293.
DR   PDB; 5ECG; X-ray; 3.00 A; A/B=95-312.
DR   PDB; 5G4M; X-ray; 1.38 A; A/B=94-312.
DR   PDB; 5G4N; X-ray; 1.35 A; A/B=94-312.
DR   PDB; 5G4O; X-ray; 1.48 A; A/B=94-312.
DR   PDB; 5HOU; NMR; -; A=1-61.
DR   PDB; 5HP0; NMR; -; A=37-61.
DR   PDB; 5HPD; NMR; -; A=2-61.
DR   PDB; 5LAP; X-ray; 1.42 A; A/B=94-312.
DR   PDB; 5LGY; X-ray; 2.92 A; A/B/C/D=94-291.
DR   PDB; 5MCT; X-ray; 1.45 A; A/B=94-293.
DR   PDB; 5MCU; X-ray; 1.70 A; A/B=94-293.
DR   PDB; 5MCV; X-ray; 1.60 A; A/B=94-293.
DR   PDB; 5MCW; X-ray; 1.90 A; A/B=94-293.
DR   PDB; 5MF7; X-ray; 1.59 A; A/B=94-293.
DR   PDB; 5MG7; X-ray; 1.45 A; A/B=94-293.
DR   PDB; 5MHC; X-ray; 1.20 A; P=382-393.
DR   PDB; 5MOC; X-ray; 1.80 A; P=382-393.
DR   PDB; 5O1A; X-ray; 1.44 A; A/B=94-312.
DR   PDB; 5O1B; X-ray; 1.43 A; A/B=94-312.
DR   PDB; 5O1C; X-ray; 1.32 A; A/B=94-312.
DR   PDB; 5O1D; X-ray; 1.36 A; A/B=94-312.
DR   PDB; 5O1E; X-ray; 1.30 A; A/B=94-312.
DR   PDB; 5O1F; X-ray; 1.38 A; A/B=94-312.
DR   PDB; 5O1G; X-ray; 1.35 A; A/B=94-312.
DR   PDB; 5O1H; X-ray; 1.32 A; A/B=94-312.
DR   PDB; 5O1I; X-ray; 1.40 A; A/B=94-312.
DR   PDB; 5OL0; X-ray; 1.99 A; C/D=372-389.
DR   PDB; 5UN8; X-ray; 2.13 A; E/F/G/H=144-154.
DR   PDB; 5XZC; EM; 10.70 A; B/C/D/E=92-356.
DR   PDB; 6FF9; X-ray; 2.00 A; A/B/C/D=97-289.
DR   PDB; 6FJ5; X-ray; 2.05 A; A/B/C/D=94-293.
DR   PDB; 6GGA; X-ray; 1.55 A; A/B=94-312.
DR   PDB; 6GGB; X-ray; 1.32 A; A/B=94-312.
DR   PDB; 6GGC; X-ray; 1.24 A; A/B=94-312.
DR   PDB; 6GGD; X-ray; 1.40 A; A/B=94-312.
DR   PDB; 6GGE; X-ray; 1.25 A; A/B=94-312.
DR   PDB; 6GGF; X-ray; 1.32 A; A/B=94-312.
DR   PDB; 6R5L; X-ray; 1.88 A; P=382-393.
DR   PDB; 6RJZ; X-ray; 1.58 A; P=382-393.
DR   PDB; 6RK8; X-ray; 1.60 A; P=382-393.
DR   PDB; 6RKI; X-ray; 1.88 A; P=382-393.
DR   PDB; 6RKK; X-ray; 1.88 A; P=382-393.
DR   PDB; 6RKM; X-ray; 1.88 A; P=382-393.
DR   PDB; 6RL3; X-ray; 1.30 A; P=382-393.
DR   PDB; 6RL4; X-ray; 1.60 A; P=382-393.
DR   PDB; 6RL6; X-ray; 1.60 A; P=382-393.
DR   PDB; 6RM5; X-ray; 1.88 A; P=382-393.
DR   PDB; 6RM7; X-ray; 1.60 A; P=382-393.
DR   PDB; 6RWH; X-ray; 1.68 A; P=382-393.
DR   PDB; 6RWI; X-ray; 1.65 A; P=382-393.
DR   PDB; 6RWS; X-ray; 1.53 A; P=382-393.
DR   PDB; 6RWU; X-ray; 1.46 A; P=382-393.
DR   PDB; 6RX2; X-ray; 1.82 A; P=382-393.
DR   PDB; 6RZ3; X-ray; 4.23 A; A=62-292.
DR   PDB; 6S39; X-ray; 1.88 A; P=382-393.
DR   PDB; 6S3C; X-ray; 2.00 A; P=382-393.
DR   PDB; 6S40; X-ray; 1.90 A; P=382-393.
DR   PDB; 6S9Q; X-ray; 1.69 A; P=382-393.
DR   PDB; 6SHZ; X-ray; 1.24 A; A/B=94-311.
DR   PDB; 6SI0; X-ray; 1.53 A; A/B=94-312.
DR   PDB; 6SI1; X-ray; 1.44 A; A/B=94-312.
DR   PDB; 6SI2; X-ray; 1.50 A; A/B=94-312.
DR   PDB; 6SI3; X-ray; 1.40 A; A/B=94-312.
DR   PDB; 6SI4; X-ray; 1.80 A; A/B=94-312.
DR   PDB; 6SIN; X-ray; 1.64 A; P=382-393.
DR   PDB; 6SIO; X-ray; 1.60 A; P=382-393.
DR   PDB; 6SIP; X-ray; 1.60 A; P=382-393.
DR   PDB; 6SIQ; X-ray; 1.60 A; P=382-393.
DR   PDB; 6SL6; X-ray; 1.67 A; A=89-311.
DR   PDB; 6SLV; X-ray; 1.90 A; P=382-393.
DR   PDB; 6T58; X-ray; 3.10 A; A/B=17-56.
DR   PDB; 6V4F; X-ray; 1.35 A; B=14-29.
DR   PDB; 6V4H; X-ray; 1.53 A; B/D=14-29.
DR   PDB; 6VQO; X-ray; 3.00 A; P/Q=168-176.
DR   PDB; 6VR1; X-ray; 2.37 A; P/Q=168-176.
DR   PDB; 6VR5; X-ray; 2.38 A; P/Q=168-176.
DR   PDB; 6VRM; X-ray; 2.61 A; P=168-176.
DR   PDB; 6VRN; X-ray; 2.46 A; P=168-176.
DR   PDB; 7BWN; X-ray; 2.40 A; B/D/G/I/K/L/N/P=326-356.
DR   PDBsum; 1A1U; -.
DR   PDBsum; 1AIE; -.
DR   PDBsum; 1C26; -.
DR   PDBsum; 1DT7; -.
DR   PDBsum; 1GZH; -.
DR   PDBsum; 1H26; -.
DR   PDBsum; 1HS5; -.
DR   PDBsum; 1JSP; -.
DR   PDBsum; 1KZY; -.
DR   PDBsum; 1MA3; -.
DR   PDBsum; 1OLG; -.
DR   PDBsum; 1OLH; -.
DR   PDBsum; 1PES; -.
DR   PDBsum; 1PET; -.
DR   PDBsum; 1SAE; -.
DR   PDBsum; 1SAF; -.
DR   PDBsum; 1SAK; -.
DR   PDBsum; 1SAL; -.
DR   PDBsum; 1TSR; -.
DR   PDBsum; 1TUP; -.
DR   PDBsum; 1UOL; -.
DR   PDBsum; 1XQH; -.
DR   PDBsum; 1YC5; -.
DR   PDBsum; 1YCQ; -.
DR   PDBsum; 1YCR; -.
DR   PDBsum; 1YCS; -.
DR   PDBsum; 2AC0; -.
DR   PDBsum; 2ADY; -.
DR   PDBsum; 2AHI; -.
DR   PDBsum; 2ATA; -.
DR   PDBsum; 2B3G; -.
DR   PDBsum; 2BIM; -.
DR   PDBsum; 2BIN; -.
DR   PDBsum; 2BIO; -.
DR   PDBsum; 2BIP; -.
DR   PDBsum; 2BIQ; -.
DR   PDBsum; 2F1X; -.
DR   PDBsum; 2FEJ; -.
DR   PDBsum; 2FOJ; -.
DR   PDBsum; 2FOO; -.
DR   PDBsum; 2GS0; -.
DR   PDBsum; 2H1L; -.
DR   PDBsum; 2H2D; -.
DR   PDBsum; 2H2F; -.
DR   PDBsum; 2H4F; -.
DR   PDBsum; 2H4H; -.
DR   PDBsum; 2H4J; -.
DR   PDBsum; 2H59; -.
DR   PDBsum; 2J0Z; -.
DR   PDBsum; 2J10; -.
DR   PDBsum; 2J11; -.
DR   PDBsum; 2J1W; -.
DR   PDBsum; 2J1X; -.
DR   PDBsum; 2J1Y; -.
DR   PDBsum; 2J1Z; -.
DR   PDBsum; 2J20; -.
DR   PDBsum; 2J21; -.
DR   PDBsum; 2K8F; -.
DR   PDBsum; 2L14; -.
DR   PDBsum; 2LY4; -.
DR   PDBsum; 2MEJ; -.
DR   PDBsum; 2MWO; -.
DR   PDBsum; 2MWP; -.
DR   PDBsum; 2MWY; -.
DR   PDBsum; 2MZD; -.
DR   PDBsum; 2OCJ; -.
DR   PDBsum; 2PCX; -.
DR   PDBsum; 2RUK; -.
DR   PDBsum; 2VUK; -.
DR   PDBsum; 2WGX; -.
DR   PDBsum; 2X0U; -.
DR   PDBsum; 2X0V; -.
DR   PDBsum; 2X0W; -.
DR   PDBsum; 2XWR; -.
DR   PDBsum; 2YBG; -.
DR   PDBsum; 2YDR; -.
DR   PDBsum; 2Z5S; -.
DR   PDBsum; 2Z5T; -.
DR   PDBsum; 3D05; -.
DR   PDBsum; 3D06; -.
DR   PDBsum; 3D07; -.
DR   PDBsum; 3D08; -.
DR   PDBsum; 3D09; -.
DR   PDBsum; 3D0A; -.
DR   PDBsum; 3DAB; -.
DR   PDBsum; 3DAC; -.
DR   PDBsum; 3IGK; -.
DR   PDBsum; 3IGL; -.
DR   PDBsum; 3KMD; -.
DR   PDBsum; 3KZ8; -.
DR   PDBsum; 3LW1; -.
DR   PDBsum; 3OQ5; -.
DR   PDBsum; 3PDH; -.
DR   PDBsum; 3Q01; -.
DR   PDBsum; 3Q05; -.
DR   PDBsum; 3Q06; -.
DR   PDBsum; 3SAK; -.
DR   PDBsum; 3TG5; -.
DR   PDBsum; 3TS8; -.
DR   PDBsum; 3ZME; -.
DR   PDBsum; 4AGL; -.
DR   PDBsum; 4AGM; -.
DR   PDBsum; 4AGN; -.
DR   PDBsum; 4AGO; -.
DR   PDBsum; 4AGP; -.
DR   PDBsum; 4AGQ; -.
DR   PDBsum; 4BUZ; -.
DR   PDBsum; 4BV2; -.
DR   PDBsum; 4HFZ; -.
DR   PDBsum; 4HJE; -.
DR   PDBsum; 4IBQ; -.
DR   PDBsum; 4IBS; -.
DR   PDBsum; 4IBT; -.
DR   PDBsum; 4IBU; -.
DR   PDBsum; 4IBV; -.
DR   PDBsum; 4IBW; -.
DR   PDBsum; 4IBY; -.
DR   PDBsum; 4IBZ; -.
DR   PDBsum; 4IJT; -.
DR   PDBsum; 4KVP; -.
DR   PDBsum; 4LO9; -.
DR   PDBsum; 4LOE; -.
DR   PDBsum; 4LOF; -.
DR   PDBsum; 4MZI; -.
DR   PDBsum; 4MZR; -.
DR   PDBsum; 4QO1; -.
DR   PDBsum; 4RP6; -.
DR   PDBsum; 4RP7; -.
DR   PDBsum; 4X34; -.
DR   PDBsum; 4XR8; -.
DR   PDBsum; 4ZZJ; -.
DR   PDBsum; 5A7B; -.
DR   PDBsum; 5AB9; -.
DR   PDBsum; 5ABA; -.
DR   PDBsum; 5AOI; -.
DR   PDBsum; 5AOJ; -.
DR   PDBsum; 5AOK; -.
DR   PDBsum; 5AOL; -.
DR   PDBsum; 5AOM; -.
DR   PDBsum; 5BUA; -.
DR   PDBsum; 5ECG; -.
DR   PDBsum; 5G4M; -.
DR   PDBsum; 5G4N; -.
DR   PDBsum; 5G4O; -.
DR   PDBsum; 5HOU; -.
DR   PDBsum; 5HP0; -.
DR   PDBsum; 5HPD; -.
DR   PDBsum; 5LAP; -.
DR   PDBsum; 5LGY; -.
DR   PDBsum; 5MCT; -.
DR   PDBsum; 5MCU; -.
DR   PDBsum; 5MCV; -.
DR   PDBsum; 5MCW; -.
DR   PDBsum; 5MF7; -.
DR   PDBsum; 5MG7; -.
DR   PDBsum; 5MHC; -.
DR   PDBsum; 5MOC; -.
DR   PDBsum; 5O1A; -.
DR   PDBsum; 5O1B; -.
DR   PDBsum; 5O1C; -.
DR   PDBsum; 5O1D; -.
DR   PDBsum; 5O1E; -.
DR   PDBsum; 5O1F; -.
DR   PDBsum; 5O1G; -.
DR   PDBsum; 5O1H; -.
DR   PDBsum; 5O1I; -.
DR   PDBsum; 5OL0; -.
DR   PDBsum; 5UN8; -.
DR   PDBsum; 5XZC; -.
DR   PDBsum; 6FF9; -.
DR   PDBsum; 6FJ5; -.
DR   PDBsum; 6GGA; -.
DR   PDBsum; 6GGB; -.
DR   PDBsum; 6GGC; -.
DR   PDBsum; 6GGD; -.
DR   PDBsum; 6GGE; -.
DR   PDBsum; 6GGF; -.
DR   PDBsum; 6R5L; -.
DR   PDBsum; 6RJZ; -.
DR   PDBsum; 6RK8; -.
DR   PDBsum; 6RKI; -.
DR   PDBsum; 6RKK; -.
DR   PDBsum; 6RKM; -.
DR   PDBsum; 6RL3; -.
DR   PDBsum; 6RL4; -.
DR   PDBsum; 6RL6; -.
DR   PDBsum; 6RM5; -.
DR   PDBsum; 6RM7; -.
DR   PDBsum; 6RWH; -.
DR   PDBsum; 6RWI; -.
DR   PDBsum; 6RWS; -.
DR   PDBsum; 6RWU; -.
DR   PDBsum; 6RX2; -.
DR   PDBsum; 6RZ3; -.
DR   PDBsum; 6S39; -.
DR   PDBsum; 6S3C; -.
DR   PDBsum; 6S40; -.
DR   PDBsum; 6S9Q; -.
DR   PDBsum; 6SHZ; -.
DR   PDBsum; 6SI0; -.
DR   PDBsum; 6SI1; -.
DR   PDBsum; 6SI2; -.
DR   PDBsum; 6SI3; -.
DR   PDBsum; 6SI4; -.
DR   PDBsum; 6SIN; -.
DR   PDBsum; 6SIO; -.
DR   PDBsum; 6SIP; -.
DR   PDBsum; 6SIQ; -.
DR   PDBsum; 6SL6; -.
DR   PDBsum; 6SLV; -.
DR   PDBsum; 6T58; -.
DR   PDBsum; 6V4F; -.
DR   PDBsum; 6V4H; -.
DR   PDBsum; 6VQO; -.
DR   PDBsum; 6VR1; -.
DR   PDBsum; 6VR5; -.
DR   PDBsum; 6VRM; -.
DR   PDBsum; 6VRN; -.
DR   PDBsum; 7BWN; -.
DR   BMRB; P04637; -.
DR   PCDDB; P04637; -.
DR   SMR; P04637; -.
DR   BioGRID; 113010; 1230.
DR   CORUM; P04637; -.
DR   DIP; DIP-368N; -.
DR   ELM; P04637; -.
DR   IntAct; P04637; 498.
DR   MINT; P04637; -.
DR   STRING; 9606.ENSP00000269305; -.
DR   BindingDB; P04637; -.
DR   ChEMBL; CHEMBL4096; -.
DR   DrugBank; DB08363; 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine.
DR   DrugBank; DB00945; Acetylsalicylic acid.
DR   DrugBank; DB05404; AZD 3355.
DR   DrugBank; DB03347; Triethyl phosphate.
DR   DrugBank; DB01593; Zinc.
DR   DrugBank; DB14487; Zinc acetate.
DR   DrugBank; DB14533; Zinc chloride.
DR   DrugBank; DB14548; Zinc sulfate, unspecified form.
DR   MoonDB; P04637; Predicted.
DR   TCDB; 1.C.110.1.1; the pore-forming pnc-27 peptide of 32 aas from the p53 tumor suppressor protein (pnc-27) family.
DR   iPTMnet; P04637; -.
DR   MetOSite; P04637; -.
DR   PhosphoSitePlus; P04637; -.
DR   BioMuta; TP53; -.
DR   DMDM; 269849759; -.
DR   SWISS-2DPAGE; P04637; -.
DR   CPTAC; CPTAC-951; -.
DR   EPD; P04637; -.
DR   jPOST; P04637; -.
DR   MassIVE; P04637; -.
DR   MaxQB; P04637; -.
DR   PaxDb; P04637; -.
DR   PeptideAtlas; P04637; -.
DR   PRIDE; P04637; -.
DR   ProteomicsDB; 51728; -. [P04637-1]
DR   ProteomicsDB; 51729; -. [P04637-2]
DR   ProteomicsDB; 51730; -. [P04637-3]
DR   ProteomicsDB; 51731; -. [P04637-4]
DR   ProteomicsDB; 51732; -. [P04637-5]
DR   ProteomicsDB; 51733; -. [P04637-6]
DR   ProteomicsDB; 51734; -. [P04637-7]
DR   ProteomicsDB; 51735; -. [P04637-8]
DR   ProteomicsDB; 51736; -. [P04637-9]
DR   ABCD; P04637; 66 sequenced antibodies.
DR   Antibodypedia; 3525; 8937 antibodies.
DR   CPTC; P04637; 2 antibodies.
DR   DNASU; 7157; -.
DR   Ensembl; ENST00000269305; ENSP00000269305; ENSG00000141510. [P04637-1]
DR   Ensembl; ENST00000420246; ENSP00000391127; ENSG00000141510. [P04637-2]
DR   Ensembl; ENST00000445888; ENSP00000391478; ENSG00000141510. [P04637-1]
DR   Ensembl; ENST00000455263; ENSP00000398846; ENSG00000141510. [P04637-3]
DR   Ensembl; ENST00000504290; ENSP00000484409; ENSG00000141510. [P04637-9]
DR   Ensembl; ENST00000504937; ENSP00000481179; ENSG00000141510. [P04637-7]
DR   Ensembl; ENST00000510385; ENSP00000478499; ENSG00000141510. [P04637-8]
DR   Ensembl; ENST00000610292; ENSP00000478219; ENSG00000141510. [P04637-4]
DR   Ensembl; ENST00000610538; ENSP00000480868; ENSG00000141510. [P04637-6]
DR   Ensembl; ENST00000617185; ENSP00000482258; ENSG00000141510. [P04637-2]
DR   Ensembl; ENST00000619485; ENSP00000482537; ENSG00000141510. [P04637-4]
DR   Ensembl; ENST00000620739; ENSP00000481638; ENSG00000141510. [P04637-4]
DR   Ensembl; ENST00000622645; ENSP00000482222; ENSG00000141510. [P04637-5]
DR   GeneID; 7157; -.
DR   KEGG; hsa:7157; -.
DR   UCSC; uc002gij.4; human. [P04637-1]
DR   CTD; 7157; -.
DR   DisGeNET; 7157; -.
DR   EuPathDB; HostDB:ENSG00000141510.16; -.
DR   GeneCards; TP53; -.
DR   GeneReviews; TP53; -.
DR   HGNC; HGNC:11998; TP53.
DR   HPA; ENSG00000141510; Tissue enhanced (lymphoid).
DR   MalaCards; TP53; -.
DR   MIM; 133239; phenotype.
DR   MIM; 151623; phenotype.
DR   MIM; 191170; gene+phenotype.
DR   MIM; 202300; phenotype.
DR   MIM; 211980; phenotype.
DR   MIM; 260500; phenotype.
DR   MIM; 275355; phenotype.
DR   MIM; 614740; phenotype.
DR   MIM; 618165; phenotype.
DR   neXtProt; NX_P04637; -.
DR   OpenTargets; ENSG00000141510; -.
DR   Orphanet; 1501; Adrenocortical carcinoma.
DR   Orphanet; 210159; Adult hepatocellular carcinoma.
DR   Orphanet; 67038; B-cell chronic lymphocytic leukemia.
DR   Orphanet; 251899; Choroid plexus carcinoma.
DR   Orphanet; 3318; Essential thrombocythemia.
DR   Orphanet; 1333; Familial pancreatic carcinoma.
DR   Orphanet; 251579; Giant cell glioblastoma.
DR   Orphanet; 251576; Gliosarcoma.
DR   Orphanet; 145; Hereditary breast and ovarian cancer syndrome.
DR   Orphanet; 524; Li-Fraumeni syndrome.
DR   Orphanet; 668; Osteosarcoma.
DR   Orphanet; 2807; Papilloma of choroid plexus.
DR   Orphanet; 99860; Precursor B-cell acute lymphoblastic leukemia.
DR   Orphanet; 70573; Small cell lung cancer.
DR   PharmGKB; PA36679; -.
DR   eggNOG; ENOG502QVY3; Eukaryota.
DR   GeneTree; ENSGT00950000183153; -.
DR   InParanoid; P04637; -.
DR   OMA; FHKKGEP; -.
DR   OrthoDB; 233858at2759; -.
DR   PhylomeDB; P04637; -.
DR   TreeFam; TF106101; -.
DR   PathwayCommons; P04637; -.
DR   Reactome; R-HSA-111448; Activation of NOXA and translocation to mitochondria.
DR   Reactome; R-HSA-139915; Activation of PUMA and translocation to mitochondria.
DR   Reactome; R-HSA-1912408; Pre-NOTCH Transcription and Translation.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-2559584; Formation of Senescence-Associated Heterochromatin Foci (SAHF).
DR   Reactome; R-HSA-2559585; Oncogene Induced Senescence.
DR   Reactome; R-HSA-2559586; DNA Damage/Telomere Stress Induced Senescence.
DR   Reactome; R-HSA-3232118; SUMOylation of transcription factors.
DR   Reactome; R-HSA-349425; Autodegradation of the E3 ubiquitin ligase COP1.
DR   Reactome; R-HSA-390471; Association of TriC/CCT with target proteins during biosynthesis.
DR   Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-5689896; Ovarian tumor domain proteases.
DR   Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes.
DR   Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release.
DR   Reactome; R-HSA-6803205; TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain.
DR   Reactome; R-HSA-6803207; TP53 Regulates Transcription of Caspase Activators and Caspases.
DR   Reactome; R-HSA-6803211; TP53 Regulates Transcription of Death Receptors and Ligands.
DR   Reactome; R-HSA-6804114; TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest.
DR   Reactome; R-HSA-6804115; TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain.
DR   Reactome; R-HSA-6804116; TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest.
DR   Reactome; R-HSA-6804754; Regulation of TP53 Expression.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-HSA-6804757; Regulation of TP53 Degradation.
DR   Reactome; R-HSA-6804758; Regulation of TP53 Activity through Acetylation.
DR   Reactome; R-HSA-6804759; Regulation of TP53 Activity through Association with Co-factors.
DR   Reactome; R-HSA-6804760; Regulation of TP53 Activity through Methylation.
DR   Reactome; R-HSA-6811555; PI5P Regulates TP53 Acetylation.
DR   Reactome; R-HSA-69473; G2/M DNA damage checkpoint.
DR   Reactome; R-HSA-69481; G2/M Checkpoints.
DR   Reactome; R-HSA-69541; Stabilization of p53.
DR   Reactome; R-HSA-69895; Transcriptional activation of cell cycle inhibitor p21.
DR   Reactome; R-HSA-8852276; The role of GTSE1 in G2/M progression after G2 checkpoint.
DR   Reactome; R-HSA-8853884; Transcriptional Regulation by VENTX.
DR   Reactome; R-HSA-8941855; RUNX3 regulates CDKN1A transcription.
DR   Reactome; R-HSA-8943724; Regulation of PTEN gene transcription.
DR   Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
DR   SABIO-RK; P04637; -.
DR   SignaLink; P04637; -.
DR   SIGNOR; P04637; -.
DR   BioGRID-ORCS; 7157; 27 hits in 878 CRISPR screens.
DR   ChiTaRS; TP53; human.
DR   EvolutionaryTrace; P04637; -.
DR   GeneWiki; P53; -.
DR   GenomeRNAi; 7157; -.
DR   Pharos; P04637; Tchem.
DR   PRO; PR:P04637; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P04637; protein.
DR   Bgee; ENSG00000141510; Expressed in epithelium of mammary gland and 187 other tissues.
DR   ExpressionAtlas; P04637; baseline and differential.
DR   Genevisible; P04637; HS.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:BHF-UCL.
DR   GO; GO:0016363; C:nuclear matrix; IDA:UniProtKB.
DR   GO; GO:0031965; C:nuclear membrane; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:CAFA.
DR   GO; GO:0005657; C:replication fork; IEA:Ensembl.
DR   GO; GO:0035861; C:site of double-strand break; IEA:Ensembl.
DR   GO; GO:0005667; C:transcription regulator complex; IGI:ARUK-UCL.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0051087; F:chaperone binding; IPI:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0005507; F:copper ion binding; IDA:UniProtKB.
DR   GO; GO:0001046; F:core promoter sequence-specific DNA binding; IDA:CAFA.
DR   GO; GO:0097718; F:disordered domain specific binding; IPI:CAFA.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0001216; F:DNA-binding transcription activator activity; IDA:ARUK-UCL.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:ARUK-UCL.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0035035; F:histone acetyltransferase binding; IPI:UniProtKB.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:CAFA.
DR   GO; GO:0035033; F:histone deacetylase regulator activity; IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; IPI:UniProtKB.
DR   GO; GO:0097371; F:MDM2/MDM4 family protein binding; IEA:Ensembl.
DR   GO; GO:0003730; F:mRNA 3'-UTR binding; IDA:CAFA.
DR   GO; GO:0002039; F:p53 binding; IPI:CAFA.
DR   GO; GO:1990841; F:promoter-specific chromatin binding; IDA:UniProtKB.
DR   GO; GO:0002020; F:protease binding; IPI:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:UniProtKB.
DR   GO; GO:0051721; F:protein phosphatase 2A binding; IPI:UniProtKB.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0043621; F:protein self-association; IPI:AgBase.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:BHF-UCL.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0001085; F:RNA polymerase II transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0001094; F:TFIID-class transcription factor complex binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0000976; F:transcription regulatory region sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; TAS:UniProtKB.
DR   GO; GO:0006914; P:autophagy; IMP:CAFA.
DR   GO; GO:0002326; P:B cell lineage commitment; IEA:Ensembl.
DR   GO; GO:0048539; P:bone marrow development; IMP:UniProtKB.
DR   GO; GO:0060411; P:cardiac septum morphogenesis; IEA:Ensembl.
DR   GO; GO:0007569; P:cell aging; IMP:UniProtKB.
DR   GO; GO:0007050; P:cell cycle arrest; IDA:BHF-UCL.
DR   GO; GO:0034613; P:cellular protein localization; IDA:UniProtKB.
DR   GO; GO:0072717; P:cellular response to actinomycin D; IDA:CAFA.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0035690; P:cellular response to drug; IEP:UniProtKB.
DR   GO; GO:0071480; P:cellular response to gamma radiation; IDA:CAFA.
DR   GO; GO:0042149; P:cellular response to glucose starvation; IDA:UniProtKB.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEP:UniProtKB.
DR   GO; GO:0071479; P:cellular response to ionizing radiation; IMP:BHF-UCL.
DR   GO; GO:0034644; P:cellular response to UV; IDA:CAFA.
DR   GO; GO:0071494; P:cellular response to UV-C; IEA:Ensembl.
DR   GO; GO:0021549; P:cerebellum development; IEA:Ensembl.
DR   GO; GO:0031497; P:chromatin assembly; IDA:UniProtKB.
DR   GO; GO:0048512; P:circadian behavior; ISS:UniProtKB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0008340; P:determination of adult lifespan; ISS:BHF-UCL.
DR   GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; IDA:BHF-UCL.
DR   GO; GO:0006977; P:DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; IMP:CAFA.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IDA:CAFA.
DR   GO; GO:0000733; P:DNA strand renaturation; IDA:UniProtKB.
DR   GO; GO:0006302; P:double-strand break repair; IEA:Ensembl.
DR   GO; GO:0048568; P:embryonic organ development; IEA:Ensembl.
DR   GO; GO:0043153; P:entrainment of circadian clock by photoperiod; ISS:UniProtKB.
DR   GO; GO:0006983; P:ER overload response; IDA:MGI.
DR   GO; GO:0007369; P:gastrulation; IEA:Ensembl.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IMP:UniProtKB.
DR   GO; GO:0060218; P:hematopoietic stem cell differentiation; IMP:UniProtKB.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0097193; P:intrinsic apoptotic signaling pathway; TAS:HGNC-UCL.
DR   GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IMP:UniProtKB.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IDA:UniProtKB.
DR   GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; IEA:Ensembl.
DR   GO; GO:1990144; P:intrinsic apoptotic signaling pathway in response to hypoxia; IEA:Ensembl.
DR   GO; GO:0043504; P:mitochondrial DNA repair; IEA:Ensembl.
DR   GO; GO:0071850; P:mitotic cell cycle arrest; IEA:Ensembl.
DR   GO; GO:0031571; P:mitotic G1 DNA damage checkpoint; IMP:BHF-UCL.
DR   GO; GO:0009299; P:mRNA transcription; IMP:UniProtKB.
DR   GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0070266; P:necroptotic process; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; IMP:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:CACAO.
DR   GO; GO:0008156; P:negative regulation of DNA replication; IEA:Ensembl.
DR   GO; GO:0048147; P:negative regulation of fibroblast proliferation; IMP:UniProtKB.
DR   GO; GO:1904024; P:negative regulation of glucose catabolic process to lactate via pyruvate; IEA:Ensembl.
DR   GO; GO:0051097; P:negative regulation of helicase activity; TAS:UniProtKB.
DR   GO; GO:1901525; P:negative regulation of mitophagy; IEA:Ensembl.
DR   GO; GO:0007406; P:negative regulation of neuroblast proliferation; IEA:Ensembl.
DR   GO; GO:1905856; P:negative regulation of pentose-phosphate shunt; IMP:CACAO.
DR   GO; GO:1903799; P:negative regulation of production of miRNAs involved in gene silencing by miRNA; IEA:Ensembl.
DR   GO; GO:0045861; P:negative regulation of proteolysis; IEA:Ensembl.
DR   GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; IEA:Ensembl.
DR   GO; GO:0051974; P:negative regulation of telomerase activity; IDA:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0006289; P:nucleotide-excision repair; IMP:UniProtKB.
DR   GO; GO:0097252; P:oligodendrocyte apoptotic process; IDA:UniProtKB.
DR   GO; GO:0090403; P:oxidative stress-induced premature senescence; IMP:BHF-UCL.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0010666; P:positive regulation of cardiac muscle cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0090343; P:positive regulation of cell aging; IEA:Ensembl.
DR   GO; GO:0071158; P:positive regulation of cell cycle arrest; IDA:CAFA.
DR   GO; GO:1900119; P:positive regulation of execution phase of apoptosis; IMP:AgBase.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:CAFA.
DR   GO; GO:0031065; P:positive regulation of histone deacetylation; IEA:Ensembl.
DR   GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0035794; P:positive regulation of mitochondrial membrane permeability; IEA:Ensembl.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; ISS:BHF-UCL.
DR   GO; GO:1902895; P:positive regulation of pri-miRNA transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:1903800; P:positive regulation of production of miRNAs involved in gene silencing by miRNA; IDA:BHF-UCL.
DR   GO; GO:0062100; P:positive regulation of programmed necrotic cell death; IEA:Ensembl.
DR   GO; GO:0046827; P:positive regulation of protein export from nucleus; TAS:Reactome.
DR   GO; GO:1900740; P:positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IMP:BHF-UCL.
DR   GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; IDA:UniProtKB.
DR   GO; GO:0045899; P:positive regulation of RNA polymerase II transcription preinitiation complex assembly; IDA:BHF-UCL.
DR   GO; GO:0070245; P:positive regulation of thymocyte apoptotic process; ISS:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:1990440; P:positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0061419; P:positive regulation of transcription from RNA polymerase II promoter in response to hypoxia; IEA:Ensembl.
DR   GO; GO:0036003; P:positive regulation of transcription from RNA polymerase II promoter in response to stress; IDA:ARUK-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0006606; P:protein import into nucleus; IEA:Ensembl.
DR   GO; GO:0008104; P:protein localization; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IEA:Ensembl.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0065003; P:protein-containing complex assembly; IDA:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; IEP:BHF-UCL.
DR   GO; GO:0042981; P:regulation of apoptotic process; IDA:MGI.
DR   GO; GO:1902749; P:regulation of cell cycle G2/M phase transition; TAS:Reactome.
DR   GO; GO:2000772; P:regulation of cellular senescence; IEA:Ensembl.
DR   GO; GO:0043516; P:regulation of DNA damage response, signal transduction by p53 class mediator; IEA:Ensembl.
DR   GO; GO:2000269; P:regulation of fibroblast apoptotic process; IEA:Ensembl.
DR   GO; GO:1902253; P:regulation of intrinsic apoptotic signaling pathway by p53 class mediator; IEA:Ensembl.
DR   GO; GO:1902108; P:regulation of mitochondrial membrane permeability involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0034103; P:regulation of tissue remodeling; IEA:Ensembl.
DR   GO; GO:1990248; P:regulation of transcription from RNA polymerase II promoter in response to DNA damage; IDA:ARUK-UCL.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0001836; P:release of cytochrome c from mitochondria; IEA:Ensembl.
DR   GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL.
DR   GO; GO:0046677; P:response to antibiotic; IEP:UniProtKB.
DR   GO; GO:0010332; P:response to gamma radiation; IMP:BHF-UCL.
DR   GO; GO:0002931; P:response to ischemia; IEA:Ensembl.
DR   GO; GO:0009651; P:response to salt stress; IEA:Ensembl.
DR   GO; GO:0010165; P:response to X-ray; IEA:Ensembl.
DR   GO; GO:0009303; P:rRNA transcription; IEA:Ensembl.
DR   GO; GO:0072331; P:signal transduction by p53 class mediator; IDA:CAFA.
DR   GO; GO:0001756; P:somitogenesis; IEA:Ensembl.
DR   GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl.
DR   GO; GO:0002360; P:T cell lineage commitment; IEA:Ensembl.
DR   GO; GO:0002309; P:T cell proliferation involved in immune response; IEA:Ensembl.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IGI:BHF-UCL.
DR   GO; GO:0016032; P:viral process; IMP:CACAO.
DR   CDD; cd08367; P53; 1.
DR   DisProt; DP00086; -.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   IDEAL; IID00015; -.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR040926; p53_TAD2.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR013872; p53_transactivation_domain.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF08563; P53_TAD; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   Pfam; PF18521; TAD2; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative promoter usage;
KW   Alternative splicing; Apoptosis; Biological rhythms; Cell cycle; Cytoplasm;
KW   Cytoskeleton; Direct protein sequencing; Disease mutation; DNA-binding;
KW   Endoplasmic reticulum; Glycoprotein; Host-virus interaction;
KW   Isopeptide bond; Li-Fraumeni syndrome; Metal-binding; Methylation;
KW   Mitochondrion; Necrosis; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repressor; Transcription; Transcription regulation;
KW   Tumor suppressor; Ubl conjugation; Zinc.
FT   CHAIN           1..393
FT                   /note="Cellular tumor antigen p53"
FT                   /id="PRO_0000185703"
FT   DNA_BIND        102..292
FT   REGION          1..320
FT                   /note="Interaction with CCAR2"
FT                   /evidence="ECO:0000269|PubMed:25732823"
FT   REGION          1..83
FT                   /note="Interaction with HRMT1L2"
FT                   /evidence="ECO:0000269|PubMed:15186775"
FT   REGION          1..44
FT                   /note="Transcription activation (acidic)"
FT   REGION          66..110
FT                   /note="Interaction with WWOX"
FT   REGION          100..370
FT                   /note="Interaction with HIPK1"
FT                   /evidence="ECO:0000250"
FT   REGION          100..300
FT                   /note="Required for interaction with ZNF385A"
FT                   /evidence="ECO:0000269|PubMed:17719541"
FT   REGION          113..236
FT                   /note="Required for interaction with FBXO42"
FT                   /evidence="ECO:0000269|PubMed:19509332"
FT   REGION          116..292
FT                   /note="Interaction with AXIN1"
FT                   /evidence="ECO:0000250"
FT   REGION          241..248
FT                   /note="Interaction with the 53BP2 SH3 domain"
FT   REGION          256..294
FT                   /note="Interaction with E4F1"
FT                   /evidence="ECO:0000269|PubMed:10644996"
FT   REGION          273..280
FT                   /note="Interaction with DNA"
FT   REGION          300..393
FT                   /note="Interaction with CARM1"
FT                   /evidence="ECO:0000269|PubMed:15186775"
FT   REGION          319..360
FT                   /note="Interaction with HIPK2"
FT   REGION          325..356
FT                   /note="Oligomerization"
FT   REGION          359..363
FT                   /note="Interaction with USP7"
FT   REGION          368..387
FT                   /note="Basic (repression of DNA-binding)"
FT   MOTIF           17..25
FT                   /note="TADI"
FT   MOTIF           48..56
FT                   /note="TADII"
FT   MOTIF           305..321
FT                   /note="Bipartite nuclear localization signal"
FT   MOTIF           339..350
FT                   /note="Nuclear export signal"
FT   MOTIF           370..372
FT                   /note="[KR]-[STA]-K motif"
FT   METAL           176
FT                   /note="Zinc"
FT   METAL           179
FT                   /note="Zinc"
FT   METAL           238
FT                   /note="Zinc"
FT   METAL           242
FT                   /note="Zinc"
FT   SITE            120
FT                   /note="Interaction with DNA"
FT   MOD_RES         9
FT                   /note="Phosphoserine; by HIPK4"
FT                   /evidence="ECO:0000269|PubMed:18022393"
FT   MOD_RES         15
FT                   /note="Phosphoserine; by CDK5, PRPK, AMPK, NUAK1 and ATM"
FT                   /evidence="ECO:0000269|PubMed:10570149,
FT                   ECO:0000269|PubMed:11554766, ECO:0000269|PubMed:15701641,
FT                   ECO:0000269|PubMed:15866171, ECO:0000269|PubMed:17108107,
FT                   ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:17967874,
FT                   ECO:0000269|PubMed:21317932, ECO:0000269|PubMed:28842590"
FT   MOD_RES         18
FT                   /note="Phosphothreonine; by CK1, VRK1 and VRK2"
FT                   /evidence="ECO:0000269|PubMed:10606744,
FT                   ECO:0000269|PubMed:10951572, ECO:0000269|PubMed:16704422"
FT   MOD_RES         20
FT                   /note="Phosphoserine; by CHEK2, CK1 and PLK3"
FT                   /evidence="ECO:0000269|PubMed:10570149,
FT                   ECO:0000269|PubMed:11447225, ECO:0000269|PubMed:11551930,
FT                   ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:20041275"
FT   MOD_RES         33
FT                   /note="Phosphoserine; by CDK5 and CDK7"
FT                   /evidence="ECO:0000269|PubMed:17591690,
FT                   ECO:0000269|PubMed:9372954"
FT   MOD_RES         37
FT                   /note="Phosphoserine; by MAPKAPK5"
FT                   /evidence="ECO:0000269|PubMed:17254968"
FT   MOD_RES         46
FT                   /note="Phosphoserine; by CDK5, DYRK2, HIPK2 and PKC/PRKCG"
FT                   /evidence="ECO:0000269|PubMed:11740489,
FT                   ECO:0000269|PubMed:11780126, ECO:0000269|PubMed:16377624,
FT                   ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:17591690"
FT   MOD_RES         55
FT                   /note="Phosphothreonine; by TAF1 and GRK5"
FT                   /evidence="ECO:0000269|PubMed:15053879,
FT                   ECO:0000269|PubMed:20124405"
FT   MOD_RES         120
FT                   /note="N6-acetyllysine; by KAT6A"
FT                   /evidence="ECO:0000269|PubMed:23431171"
FT   MOD_RES         183
FT                   /note="Phosphoserine; by AURKB"
FT                   /evidence="ECO:0000269|PubMed:20959462"
FT   MOD_RES         269
FT                   /note="Phosphoserine; by AURKB"
FT                   /evidence="ECO:0000269|PubMed:20959462"
FT   MOD_RES         284
FT                   /note="Phosphothreonine; by AURKB"
FT                   /evidence="ECO:0000269|PubMed:20959462"
FT   MOD_RES         305
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:12724314"
FT   MOD_RES         315
FT                   /note="Phosphoserine; by AURKA, CDK1 and CDK2"
FT                   /evidence="ECO:0000269|PubMed:10884347,
FT                   ECO:0000269|PubMed:14702041"
FT   MOD_RES         321
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P02340"
FT   MOD_RES         333
FT                   /note="Omega-N-methylarginine; by PRMT5"
FT                   /evidence="ECO:0000269|PubMed:19011621"
FT   MOD_RES         335
FT                   /note="Symmetric dimethylarginine; by PRMT5"
FT                   /evidence="ECO:0000269|PubMed:19011621"
FT   MOD_RES         337
FT                   /note="Symmetric dimethylarginine; by PRMT5"
FT                   /evidence="ECO:0000269|PubMed:19011621"
FT   MOD_RES         370
FT                   /note="N6,N6-dimethyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:17108971,
FT                   ECO:0000269|PubMed:22864287"
FT   MOD_RES         370
FT                   /note="N6-methyllysine; by SMYD2; alternate"
FT                   /evidence="ECO:0000269|PubMed:17108971,
FT                   ECO:0000269|PubMed:22864287"
FT   MOD_RES         372
FT                   /note="N6-methyllysine; by SETD7"
FT                   /evidence="ECO:0000269|PubMed:15525938,
FT                   ECO:0000269|PubMed:16415881"
FT   MOD_RES         373
FT                   /note="N6,N6-dimethyllysine; by EHMT1 and EHMT2; alternate"
FT                   /evidence="ECO:0000269|PubMed:20118233"
FT   MOD_RES         373
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:10656795"
FT   MOD_RES         381
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         382
FT                   /note="N6,N6-dimethyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:17707234,
FT                   ECO:0000269|PubMed:20870725, ECO:0000269|PubMed:22864287"
FT   MOD_RES         382
FT                   /note="N6-acetyllysine; by KAT6A; alternate"
FT                   /evidence="ECO:0000244|PubMed:19608861,
FT                   ECO:0000269|PubMed:10656795, ECO:0000269|PubMed:20228809,
FT                   ECO:0000269|PubMed:23431171"
FT   MOD_RES         382
FT                   /note="N6-methyllysine; by KMT5A; alternate"
FT                   /evidence="ECO:0000269|PubMed:17707234,
FT                   ECO:0000269|PubMed:20870725, ECO:0000269|PubMed:22864287"
FT   MOD_RES         392
FT                   /note="Phosphoserine; by CK2, CDK2 and NUAK1"
FT                   /evidence="ECO:0000269|PubMed:10884347,
FT                   ECO:0000269|PubMed:11239457, ECO:0000269|PubMed:17108107,
FT                   ECO:0000269|PubMed:21317932, ECO:0000269|PubMed:22214662"
FT   CROSSLNK        291
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:19536131"
FT   CROSSLNK        292
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:19536131"
FT   CROSSLNK        386
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000269|PubMed:11124955,
FT                   ECO:0000269|PubMed:22214662, ECO:0000269|Ref.37"
FT   VAR_SEQ         1..132
FT                   /note="Missing (in isoform 7, isoform 8 and isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:16131611"
FT                   /id="VSP_040833"
FT   VAR_SEQ         1..39
FT                   /note="Missing (in isoform 4, isoform 5 and isoform 6)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_040832"
FT   VAR_SEQ         332..346
FT                   /note="IRGRERFEMFRELNE -> MLLDLRWCYFLINSS (in isoform 3,
FT                   isoform 6 and isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:16131611"
FT                   /id="VSP_040560"
FT   VAR_SEQ         332..341
FT                   /note="IRGRERFEMF -> DQTSFQKENC (in isoform 2, isoform 5
FT                   and isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:16131611"
FT                   /id="VSP_006535"
FT   VAR_SEQ         342..393
FT                   /note="Missing (in isoform 2, isoform 5 and isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:16131611"
FT                   /id="VSP_006536"
FT   VAR_SEQ         347..393
FT                   /note="Missing (in isoform 3, isoform 6 and isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:16131611"
FT                   /id="VSP_040561"
FT   VARIANT         5
FT                   /note="Q -> H (in a sporadic cancer; somatic mutation;
FT                   abolishes strongly phosphorylation)"
FT                   /id="VAR_044543"
FT   VARIANT         6
FT                   /note="S -> L (in a sporadic cancer; somatic mutation;
FT                   reduces interaction with ZNF385A)"
FT                   /id="VAR_044544"
FT   VARIANT         7
FT                   /note="D -> H (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs587782646)"
FT                   /id="VAR_005851"
FT   VARIANT         8
FT                   /note="P -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044545"
FT   VARIANT         10
FT                   /note="V -> I (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs535274413)"
FT                   /id="VAR_044546"
FT   VARIANT         11
FT                   /note="E -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs201382018)"
FT                   /id="VAR_044547"
FT   VARIANT         11
FT                   /note="E -> Q (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs201382018)"
FT                   /id="VAR_044548"
FT   VARIANT         15
FT                   /note="S -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044549"
FT   VARIANT         16
FT                   /note="Q -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044550"
FT   VARIANT         17
FT                   /note="E -> D (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044551"
FT   VARIANT         24
FT                   /note="K -> N (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044552"
FT   VARIANT         28
FT                   /note="E -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044553"
FT   VARIANT         29..30
FT                   /note="NN -> KD (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047158"
FT   VARIANT         31
FT                   /note="V -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs201753350)"
FT                   /id="VAR_044554"
FT   VARIANT         33
FT                   /note="S -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044555"
FT   VARIANT         34
FT                   /note="P -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044556"
FT   VARIANT         35
FT                   /note="L -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912661)"
FT                   /id="VAR_005852"
FT   VARIANT         36
FT                   /note="P -> L (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs587781866)"
FT                   /id="VAR_044557"
FT   VARIANT         37
FT                   /note="S -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044558"
FT   VARIANT         37
FT                   /note="S -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044559"
FT   VARIANT         39
FT                   /note="A -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044560"
FT   VARIANT         39
FT                   /note="A -> V (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1353016807)"
FT                   /id="VAR_044561"
FT   VARIANT         42
FT                   /note="D -> Y (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044562"
FT   VARIANT         43
FT                   /note="L -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_005853"
FT   VARIANT         44
FT                   /note="M -> I (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1060501190)"
FT                   /id="VAR_044563"
FT   VARIANT         44
FT                   /note="M -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044564"
FT   VARIANT         44
FT                   /note="M -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044565"
FT   VARIANT         45
FT                   /note="L -> M (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044566"
FT   VARIANT         46
FT                   /note="S -> F (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044567"
FT   VARIANT         46
FT                   /note="S -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876659630)"
FT                   /id="VAR_044568"
FT   VARIANT         47
FT                   /note="P -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044569"
FT   VARIANT         47
FT                   /note="P -> S (in dbSNP:rs1800371)"
FT                   /evidence="ECO:0000269|Ref.12"
FT                   /id="VAR_014632"
FT   VARIANT         48
FT                   /note="D -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044570"
FT   VARIANT         49
FT                   /note="D -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780728)"
FT                   /id="VAR_044571"
FT   VARIANT         49
FT                   /note="D -> N (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs587780728)"
FT                   /id="VAR_044572"
FT   VARIANT         49
FT                   /note="D -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044573"
FT   VARIANT         52
FT                   /note="Q -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044574"
FT   VARIANT         53
FT                   /note="W -> C (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005854"
FT   VARIANT         53
FT                   /note="W -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044575"
FT   VARIANT         54
FT                   /note="F -> L (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1555526742)"
FT                   /id="VAR_044576"
FT   VARIANT         54
FT                   /note="F -> Y (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044577"
FT   VARIANT         56
FT                   /note="E -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044578"
FT   VARIANT         56
FT                   /note="E -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044579"
FT   VARIANT         58
FT                   /note="P -> Q (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044580"
FT   VARIANT         58
FT                   /note="P -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044581"
FT   VARIANT         59
FT                   /note="G -> C (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1237722021)"
FT                   /id="VAR_044582"
FT   VARIANT         59
FT                   /note="G -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044583"
FT   VARIANT         59
FT                   /note="G -> N (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045783"
FT   VARIANT         60
FT                   /note="P -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044584"
FT   VARIANT         60
FT                   /note="P -> Q (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044585"
FT   VARIANT         60
FT                   /note="P -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_005855"
FT   VARIANT         61
FT                   /note="D -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1460793472)"
FT                   /id="VAR_044586"
FT   VARIANT         61
FT                   /note="D -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044587"
FT   VARIANT         62
FT                   /note="E -> D (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044588"
FT   VARIANT         63
FT                   /note="A -> T (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs876658902)"
FT                   /id="VAR_044589"
FT   VARIANT         63
FT                   /note="A -> V (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs372201428)"
FT                   /id="VAR_044590"
FT   VARIANT         65
FT                   /note="R -> T (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1060501210)"
FT                   /id="VAR_044591"
FT   VARIANT         66
FT                   /note="M -> I (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1555526711)"
FT                   /id="VAR_044592"
FT   VARIANT         66
FT                   /note="M -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044593"
FT   VARIANT         67
FT                   /note="P -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044594"
FT   VARIANT         67
FT                   /note="P -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044595"
FT   VARIANT         67
FT                   /note="P -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044596"
FT   VARIANT         68
FT                   /note="E -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044597"
FT   VARIANT         68
FT                   /note="E -> Q (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044598"
FT   VARIANT         69
FT                   /note="A -> D (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044599"
FT   VARIANT         69
FT                   /note="A -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs756233241)"
FT                   /id="VAR_044600"
FT   VARIANT         69
FT                   /note="A -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044601"
FT   VARIANT         69
FT                   /note="A -> V (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs756233241)"
FT                   /id="VAR_044602"
FT   VARIANT         70
FT                   /note="A -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044603"
FT   VARIANT         71
FT                   /note="P -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044604"
FT   VARIANT         72
FT                   /note="P -> C (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions; dbSNP:rs730882014)"
FT                   /id="VAR_045784"
FT   VARIANT         72
FT                   /note="P -> G (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045785"
FT   VARIANT         72
FT                   /note="P -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1042522)"
FT                   /id="VAR_045786"
FT   VARIANT         72
FT                   /note="P -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045787"
FT   VARIANT         72
FT                   /note="P -> R (in dbSNP:rs1042522)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:16131611, ECO:0000269|PubMed:1999338,
FT                   ECO:0000269|Ref.17"
FT                   /id="VAR_005856"
FT   VARIANT         73
FT                   /note="V -> E (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044605"
FT   VARIANT         73
FT                   /note="V -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044606"
FT   VARIANT         73
FT                   /note="V -> M (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782423)"
FT                   /id="VAR_044607"
FT   VARIANT         74
FT                   /note="A -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044608"
FT   VARIANT         75
FT                   /note="P -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044609"
FT   VARIANT         75
FT                   /note="P -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044610"
FT   VARIANT         75
FT                   /note="P -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044611"
FT   VARIANT         76
FT                   /note="A -> G (in a sporadic cancer; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:2946935"
FT                   /id="VAR_044612"
FT   VARIANT         76
FT                   /note="A -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044613"
FT   VARIANT         77
FT                   /note="P -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044614"
FT   VARIANT         78
FT                   /note="A -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044615"
FT   VARIANT         79
FT                   /note="A -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044616"
FT   VARIANT         79
FT                   /note="A -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_005857"
FT   VARIANT         79
FT                   /note="A -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044617"
FT   VARIANT         80
FT                   /note="P -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044618"
FT   VARIANT         80
FT                   /note="P -> S (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1060501204)"
FT                   /id="VAR_044619"
FT   VARIANT         81
FT                   /note="T -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044620"
FT   VARIANT         82
FT                   /note="P -> L (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs534447939)"
FT                   /id="VAR_044621"
FT   VARIANT         82
FT                   /note="P -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044622"
FT   VARIANT         83
FT                   /note="A -> E (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs201717599)"
FT                   /id="VAR_044623"
FT   VARIANT         83
FT                   /note="A -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs201717599)"
FT                   /id="VAR_044624"
FT   VARIANT         84
FT                   /note="A -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044625"
FT   VARIANT         84
FT                   /note="A -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044626"
FT   VARIANT         85
FT                   /note="P -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044627"
FT   VARIANT         85
FT                   /note="P -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044628"
FT   VARIANT         86
FT                   /note="A -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044629"
FT   VARIANT         87
FT                   /note="P -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005858"
FT   VARIANT         88
FT                   /note="A -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044630"
FT   VARIANT         88
FT                   /note="A -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555526631)"
FT                   /id="VAR_044631"
FT   VARIANT         89
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730881994)"
FT                   /id="VAR_044632"
FT   VARIANT         89
FT                   /note="P -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044633"
FT   VARIANT         90
FT                   /note="S -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555526625)"
FT                   /id="VAR_044634"
FT   VARIANT         90
FT                   /note="S -> Y (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044635"
FT   VARIANT         91
FT                   /note="W -> C (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044636"
FT   VARIANT         92
FT                   /note="P -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044637"
FT   VARIANT         92
FT                   /note="P -> L (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1210700121)"
FT                   /id="VAR_044638"
FT   VARIANT         92
FT                   /note="P -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044639"
FT   VARIANT         93
FT                   /note="L -> M (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044640"
FT   VARIANT         93
FT                   /note="L -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044641"
FT   VARIANT         94
FT                   /note="S -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044642"
FT   VARIANT         94
FT                   /note="S -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005859"
FT   VARIANT         95
FT                   /note="S -> F (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044643"
FT   VARIANT         95
FT                   /note="S -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044644"
FT   VARIANT         96
FT                   /note="S -> C (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044645"
FT   VARIANT         96
FT                   /note="S -> F (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044646"
FT   VARIANT         96
FT                   /note="S -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044647"
FT   VARIANT         97
FT                   /note="V -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044648"
FT   VARIANT         97
FT                   /note="V -> F (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044649"
FT   VARIANT         97
FT                   /note="V -> I (in familial cancer not matching LFS;
FT                   germline mutation and in a sporadic cancer; somatic
FT                   mutation; dbSNP:rs730882023)"
FT                   /id="VAR_044650"
FT   VARIANT         98
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1245723119)"
FT                   /id="VAR_044651"
FT   VARIANT         98
FT                   /note="P -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044652"
FT   VARIANT         99
FT                   /note="S -> F (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044653"
FT   VARIANT         99
FT                   /note="S -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044654"
FT   VARIANT         100
FT                   /note="Q -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044655"
FT   VARIANT         101
FT                   /note="K -> N (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs878854069)"
FT                   /id="VAR_044656"
FT   VARIANT         101
FT                   /note="K -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044657"
FT   VARIANT         102
FT                   /note="T -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786202717)"
FT                   /id="VAR_044658"
FT   VARIANT         104
FT                   /note="Q -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044659"
FT   VARIANT         104
FT                   /note="Q -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044660"
FT   VARIANT         105
FT                   /note="G -> C (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation)"
FT                   /id="VAR_044661"
FT   VARIANT         105
FT                   /note="G -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587781504)"
FT                   /id="VAR_044662"
FT   VARIANT         105
FT                   /note="G -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1060501195)"
FT                   /id="VAR_044663"
FT   VARIANT         105
FT                   /note="G -> S (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1060501195)"
FT                   /id="VAR_044664"
FT   VARIANT         105
FT                   /note="G -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044665"
FT   VARIANT         106
FT                   /note="S -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044666"
FT   VARIANT         106
FT                   /note="S -> R (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs1555526581)"
FT                   /id="VAR_044667"
FT   VARIANT         107
FT                   /note="Y -> C (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs587782447)"
FT                   /id="VAR_044668"
FT   VARIANT         107
FT                   /note="Y -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044669"
FT   VARIANT         107
FT                   /note="Y -> H (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs368771578)"
FT                   /id="VAR_044670"
FT   VARIANT         108
FT                   /note="G -> D (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044671"
FT   VARIANT         108
FT                   /note="G -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782461)"
FT                   /id="VAR_044672"
FT   VARIANT         109
FT                   /note="F -> C (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044673"
FT   VARIANT         109
FT                   /note="F -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044674"
FT   VARIANT         109
FT                   /note="F -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064796722)"
FT                   /id="VAR_044675"
FT   VARIANT         110
FT                   /note="R -> C (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587781371)"
FT                   /id="VAR_005860"
FT   VARIANT         110
FT                   /note="R -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044676"
FT   VARIANT         110
FT                   /note="R -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs11540654)"
FT                   /id="VAR_044677"
FT   VARIANT         110
FT                   /note="R -> L (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; does not induce SNAI1 degradation;
FT                   dbSNP:rs11540654)"
FT                   /evidence="ECO:0000269|PubMed:20385133"
FT                   /id="VAR_005861"
FT   VARIANT         110
FT                   /note="R -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs11540654)"
FT                   /evidence="ECO:0000269|PubMed:17224074"
FT                   /id="VAR_005862"
FT   VARIANT         110
FT                   /note="R -> S (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs587781371)"
FT                   /id="VAR_044678"
FT   VARIANT         111
FT                   /note="L -> M (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044679"
FT   VARIANT         111
FT                   /note="L -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519997)"
FT                   /id="VAR_044680"
FT   VARIANT         111
FT                   /note="L -> Q (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519997)"
FT                   /id="VAR_044681"
FT   VARIANT         111
FT                   /note="L -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519997)"
FT                   /id="VAR_044682"
FT   VARIANT         112
FT                   /note="G -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044683"
FT   VARIANT         112
FT                   /note="G -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1423803759)"
FT                   /id="VAR_044684"
FT   VARIANT         113
FT                   /note="F -> C (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005863"
FT   VARIANT         113
FT                   /note="F -> G (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045788"
FT   VARIANT         113
FT                   /note="F -> I (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044685"
FT   VARIANT         113
FT                   /note="F -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044686"
FT   VARIANT         113
FT                   /note="F -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044687"
FT   VARIANT         113
FT                   /note="F -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587781642)"
FT                   /evidence="ECO:0000269|PubMed:17224074"
FT                   /id="VAR_033033"
FT   VARIANT         115
FT                   /note="H -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044688"
FT   VARIANT         116
FT                   /note="S -> C (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044689"
FT   VARIANT         116
FT                   /note="S -> F (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044690"
FT   VARIANT         116
FT                   /note="S -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044691"
FT   VARIANT         117
FT                   /note="G -> E (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs755238756)"
FT                   /id="VAR_044692"
FT   VARIANT         117
FT                   /note="G -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555526518)"
FT                   /id="VAR_044693"
FT   VARIANT         118
FT                   /note="T -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044694"
FT   VARIANT         118
FT                   /note="T -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064794141)"
FT                   /id="VAR_044695"
FT   VARIANT         118
FT                   /note="T -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044696"
FT   VARIANT         119
FT                   /note="A -> D (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044697"
FT   VARIANT         119
FT                   /note="A -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044698"
FT   VARIANT         120
FT                   /note="K -> E (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912658)"
FT                   /id="VAR_044699"
FT   VARIANT         120
FT                   /note="K -> M (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044700"
FT   VARIANT         120
FT                   /note="K -> Q (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs121912658)"
FT                   /id="VAR_044701"
FT   VARIANT         120
FT                   /note="K -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044702"
FT   VARIANT         121
FT                   /note="S -> F (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044703"
FT   VARIANT         122
FT                   /note="V -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044704"
FT   VARIANT         123
FT                   /note="T -> I (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1555526486)"
FT                   /id="VAR_044705"
FT   VARIANT         123
FT                   /note="T -> N (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044706"
FT   VARIANT         124
FT                   /note="C -> G (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs730881997)"
FT                   /id="VAR_044707"
FT   VARIANT         124
FT                   /note="C -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044708"
FT   VARIANT         124
FT                   /note="C -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730881997)"
FT                   /id="VAR_044709"
FT   VARIANT         124
FT                   /note="C -> W (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044710"
FT   VARIANT         124
FT                   /note="C -> Y (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044711"
FT   VARIANT         125
FT                   /note="T -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044712"
FT   VARIANT         125
FT                   /note="T -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786201057)"
FT                   /id="VAR_044713"
FT   VARIANT         125
FT                   /note="T -> M (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786201057)"
FT                   /id="VAR_005864"
FT   VARIANT         125
FT                   /note="T -> P (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1057520003)"
FT                   /id="VAR_044714"
FT   VARIANT         125
FT                   /note="T -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786201057)"
FT                   /id="VAR_044715"
FT   VARIANT         126
FT                   /note="Y -> C (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs1555526335)"
FT                   /id="VAR_044716"
FT   VARIANT         126
FT                   /note="Y -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs886039483)"
FT                   /id="VAR_005865"
FT   VARIANT         126
FT                   /note="Y -> F (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044717"
FT   VARIANT         126
FT                   /note="Y -> G (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045789"
FT   VARIANT         126
FT                   /note="Y -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044718"
FT   VARIANT         126
FT                   /note="Y -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs886039483)"
FT                   /id="VAR_005866"
FT   VARIANT         126
FT                   /note="Y -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044719"
FT   VARIANT         127
FT                   /note="S -> C (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs730881999)"
FT                   /id="VAR_044720"
FT   VARIANT         127
FT                   /note="S -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730881999)"
FT                   /id="VAR_005867"
FT   VARIANT         127
FT                   /note="S -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044721"
FT   VARIANT         127
FT                   /note="S -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044722"
FT   VARIANT         127
FT                   /note="S -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044723"
FT   VARIANT         128
FT                   /note="P -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044724"
FT   VARIANT         128
FT                   /note="P -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044725"
FT   VARIANT         128
FT                   /note="P -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044726"
FT   VARIANT         128
FT                   /note="P -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005868"
FT   VARIANT         129
FT                   /note="A -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005869"
FT   VARIANT         129
FT                   /note="A -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044727"
FT   VARIANT         129
FT                   /note="A -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1438095083)"
FT                   /id="VAR_044728"
FT   VARIANT         129
FT                   /note="A -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs137852792)"
FT                   /id="VAR_044729"
FT   VARIANT         130
FT                   /note="L -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs863224683)"
FT                   /id="VAR_044730"
FT   VARIANT         130
FT                   /note="L -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044731"
FT   VARIANT         130
FT                   /note="L -> I (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044732"
FT   VARIANT         130
FT                   /note="L -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1131691013)"
FT                   /id="VAR_044733"
FT   VARIANT         130
FT                   /note="L -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005870"
FT   VARIANT         130
FT                   /note="L -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs863224683)"
FT                   /id="VAR_044734"
FT   VARIANT         131
FT                   /note="N -> D (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044735"
FT   VARIANT         131
FT                   /note="N -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044736"
FT   VARIANT         131
FT                   /note="N -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1131691037)"
FT                   /id="VAR_044737"
FT   VARIANT         131
FT                   /note="N -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs769270327)"
FT                   /id="VAR_005872"
FT   VARIANT         131
FT                   /note="N -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005871"
FT   VARIANT         131
FT                   /note="N -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044738"
FT   VARIANT         131
FT                   /note="N -> Y (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782160)"
FT                   /id="VAR_044739"
FT   VARIANT         132..133
FT                   /note="KM -> NL (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047159"
FT   VARIANT         132
FT                   /note="K -> E (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs747342068)"
FT                   /id="VAR_044740"
FT   VARIANT         132
FT                   /note="K -> L (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045790"
FT   VARIANT         132
FT                   /note="K -> M (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519996)"
FT                   /id="VAR_005873"
FT   VARIANT         132
FT                   /note="K -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs866775781)"
FT                   /id="VAR_044741"
FT   VARIANT         132
FT                   /note="K -> Q (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs747342068)"
FT                   /evidence="ECO:0000269|PubMed:1694291"
FT                   /id="VAR_005874"
FT   VARIANT         132
FT                   /note="K -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519996)"
FT                   /id="VAR_044742"
FT   VARIANT         132
FT                   /note="K -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519996)"
FT                   /id="VAR_044743"
FT   VARIANT         132
FT                   /note="K -> W (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045791"
FT   VARIANT         133
FT                   /note="M -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064795139)"
FT                   /id="VAR_044744"
FT   VARIANT         133
FT                   /note="M -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044745"
FT   VARIANT         133
FT                   /note="M -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044746"
FT   VARIANT         133
FT                   /note="M -> R (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation)"
FT                   /id="VAR_044747"
FT   VARIANT         133
FT                   /note="M -> T (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs28934873)"
FT                   /evidence="ECO:0000269|PubMed:1933902"
FT                   /id="VAR_005875"
FT   VARIANT         133
FT                   /note="M -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057280220)"
FT                   /id="VAR_044748"
FT   VARIANT         134
FT                   /note="F -> C (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs780442292)"
FT                   /id="VAR_044749"
FT   VARIANT         134
FT                   /note="F -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044750"
FT   VARIANT         134
FT                   /note="F -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs267605077)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036504"
FT   VARIANT         134
FT                   /note="F -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044751"
FT   VARIANT         134
FT                   /note="F -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044752"
FT   VARIANT         135
FT                   /note="C -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587781991)"
FT                   /id="VAR_005877"
FT   VARIANT         135
FT                   /note="C -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519975)"
FT                   /id="VAR_044753"
FT   VARIANT         135
FT                   /note="C -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519975)"
FT                   /id="VAR_044754"
FT   VARIANT         135
FT                   /note="C -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519975)"
FT                   /id="VAR_005876"
FT   VARIANT         135
FT                   /note="C -> T (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045792"
FT   VARIANT         135
FT                   /note="C -> W (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519976)"
FT                   /id="VAR_044755"
FT   VARIANT         135
FT                   /note="C -> Y (in sporadic cancers; somatic mutation;
FT                   decreased E6-mediated binding to E6-AP; dbSNP:rs587781991)"
FT                   /id="VAR_044756"
FT   VARIANT         136
FT                   /note="Q -> E (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555526268)"
FT                   /id="VAR_005878"
FT   VARIANT         136
FT                   /note="Q -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs758781593)"
FT                   /id="VAR_044757"
FT   VARIANT         136
FT                   /note="Q -> K (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_005879"
FT   VARIANT         136
FT                   /note="Q -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044758"
FT   VARIANT         136
FT                   /note="Q -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044759"
FT   VARIANT         137
FT                   /note="L -> M (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044760"
FT   VARIANT         137
FT                   /note="L -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044761"
FT   VARIANT         137
FT                   /note="L -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005880"
FT   VARIANT         137
FT                   /note="L -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044762"
FT   VARIANT         138
FT                   /note="A -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044763"
FT   VARIANT         138
FT                   /note="A -> P (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs28934875)"
FT                   /id="VAR_005881"
FT   VARIANT         138
FT                   /note="A -> S (in LFS; germline mutation)"
FT                   /id="VAR_044764"
FT   VARIANT         138
FT                   /note="A -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044765"
FT   VARIANT         138
FT                   /note="A -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs750600586)"
FT                   /evidence="ECO:0000269|PubMed:17224074"
FT                   /id="VAR_033034"
FT   VARIANT         139
FT                   /note="K -> E (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1212996409)"
FT                   /id="VAR_044766"
FT   VARIANT         139
FT                   /note="K -> N (in sporadic cancers; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:14660794"
FT                   /id="VAR_005882"
FT   VARIANT         139
FT                   /note="K -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044767"
FT   VARIANT         139
FT                   /note="K -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044768"
FT   VARIANT         139
FT                   /note="K -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044769"
FT   VARIANT         140
FT                   /note="T -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044770"
FT   VARIANT         140
FT                   /note="T -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044771"
FT   VARIANT         140
FT                   /note="T -> N (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs786202561)"
FT                   /id="VAR_044772"
FT   VARIANT         140
FT                   /note="T -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044773"
FT   VARIANT         140
FT                   /note="T -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044774"
FT   VARIANT         141
FT                   /note="C -> A (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045793"
FT   VARIANT         141
FT                   /note="C -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587781288)"
FT                   /id="VAR_005885"
FT   VARIANT         141
FT                   /note="C -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519978)"
FT                   /id="VAR_005884"
FT   VARIANT         141
FT                   /note="C -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519978)"
FT                   /id="VAR_044775"
FT   VARIANT         141
FT                   /note="C -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519978)"
FT                   /id="VAR_044776"
FT   VARIANT         141
FT                   /note="C -> W (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519977)"
FT                   /id="VAR_044777"
FT   VARIANT         141
FT                   /note="C -> Y (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs587781288)"
FT                   /id="VAR_005886"
FT   VARIANT         142
FT                   /note="P -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044778"
FT   VARIANT         142
FT                   /note="P -> F (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045794"
FT   VARIANT         142
FT                   /note="P -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044779"
FT   VARIANT         142
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs779196500)"
FT                   /id="VAR_044780"
FT   VARIANT         142
FT                   /note="P -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044781"
FT   VARIANT         142
FT                   /note="P -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044782"
FT   VARIANT         142
FT                   /note="P -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044783"
FT   VARIANT         143
FT                   /note="V -> A (in sporadic cancers; somatic mutation;
FT                   strong DNA binding ability at 32.5 degrees Celsius; strong
FT                   reduction of transcriptional activity at 37.5 degrees
FT                   Celsius; severely represses interaction with ZNF385A)"
FT                   /evidence="ECO:0000269|PubMed:17719541,
FT                   ECO:0000269|PubMed:8013454"
FT                   /id="VAR_005887"
FT   VARIANT         143
FT                   /note="V -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044784"
FT   VARIANT         143
FT                   /note="V -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555526241)"
FT                   /id="VAR_044785"
FT   VARIANT         143
FT                   /note="V -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782620)"
FT                   /id="VAR_044786"
FT   VARIANT         143
FT                   /note="V -> M (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782620)"
FT                   /id="VAR_044787"
FT   VARIANT         144
FT                   /note="Q -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786201419)"
FT                   /id="VAR_044788"
FT   VARIANT         144
FT                   /note="Q -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044789"
FT   VARIANT         144
FT                   /note="Q -> L (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs786203071)"
FT                   /id="VAR_044790"
FT   VARIANT         144
FT                   /note="Q -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786203071)"
FT                   /id="VAR_005888"
FT   VARIANT         144
FT                   /note="Q -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044791"
FT   VARIANT         145
FT                   /note="L -> M (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044792"
FT   VARIANT         145
FT                   /note="L -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782197)"
FT                   /id="VAR_005889"
FT   VARIANT         145
FT                   /note="L -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005890"
FT   VARIANT         145
FT                   /note="L -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044793"
FT   VARIANT         145
FT                   /note="L -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044794"
FT   VARIANT         146
FT                   /note="W -> C (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044795"
FT   VARIANT         146
FT                   /note="W -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786203064)"
FT                   /id="VAR_044796"
FT   VARIANT         146
FT                   /note="W -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044797"
FT   VARIANT         146
FT                   /note="W -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044798"
FT   VARIANT         146
FT                   /note="W -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044799"
FT   VARIANT         147
FT                   /note="V -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044800"
FT   VARIANT         147
FT                   /note="V -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005891"
FT   VARIANT         147
FT                   /note="V -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044801"
FT   VARIANT         147
FT                   /note="V -> F (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044802"
FT   VARIANT         147
FT                   /note="V -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1453167097)"
FT                   /id="VAR_005892"
FT   VARIANT         147
FT                   /note="V -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555526226)"
FT                   /id="VAR_044803"
FT   VARIANT         148
FT                   /note="D -> A (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1046611742)"
FT                   /id="VAR_044804"
FT   VARIANT         148
FT                   /note="D -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044805"
FT   VARIANT         148
FT                   /note="D -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044806"
FT   VARIANT         148
FT                   /note="D -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044807"
FT   VARIANT         148
FT                   /note="D -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044808"
FT   VARIANT         148
FT                   /note="D -> Y (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1131691007)"
FT                   /id="VAR_044809"
FT   VARIANT         149
FT                   /note="S -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555526214)"
FT                   /id="VAR_044810"
FT   VARIANT         149
FT                   /note="S -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005893"
FT   VARIANT         149
FT                   /note="S -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044811"
FT   VARIANT         150
FT                   /note="T -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044812"
FT   VARIANT         150
FT                   /note="T -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044813"
FT   VARIANT         150
FT                   /note="T -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044814"
FT   VARIANT         150
FT                   /note="T -> N (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044815"
FT   VARIANT         150
FT                   /note="T -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044816"
FT   VARIANT         150
FT                   /note="T -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044817"
FT   VARIANT         151
FT                   /note="P -> A (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs28934874)"
FT                   /id="VAR_005894"
FT   VARIANT         151
FT                   /note="P -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520000)"
FT                   /id="VAR_044818"
FT   VARIANT         151
FT                   /note="P -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044819"
FT   VARIANT         151
FT                   /note="P -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520000)"
FT                   /id="VAR_044820"
FT   VARIANT         151
FT                   /note="P -> S (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs28934874)"
FT                   /evidence="ECO:0000269|PubMed:7682763"
FT                   /id="VAR_005895"
FT   VARIANT         151
FT                   /note="P -> T (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs28934874)"
FT                   /id="VAR_005896"
FT   VARIANT         152
FT                   /note="P -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044821"
FT   VARIANT         152
FT                   /note="P -> L (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs587782705)"
FT                   /evidence="ECO:0000269|PubMed:1868473"
FT                   /id="VAR_005897"
FT   VARIANT         152
FT                   /note="P -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044822"
FT   VARIANT         152
FT                   /note="P -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044823"
FT   VARIANT         152
FT                   /note="P -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs767328513)"
FT                   /evidence="ECO:0000269|PubMed:9450901"
FT                   /id="VAR_005898"
FT   VARIANT         152
FT                   /note="P -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044824"
FT   VARIANT         153
FT                   /note="P -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044825"
FT   VARIANT         153
FT                   /note="P -> F (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045795"
FT   VARIANT         153
FT                   /note="P -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044826"
FT   VARIANT         153
FT                   /note="P -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044827"
FT   VARIANT         153
FT                   /note="P -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044828"
FT   VARIANT         153
FT                   /note="P -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064795860)"
FT                   /id="VAR_044829"
FT   VARIANT         153
FT                   /note="P -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005899"
FT   VARIANT         154
FT                   /note="G -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044830"
FT   VARIANT         154
FT                   /note="G -> C (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044831"
FT   VARIANT         154
FT                   /note="G -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs762846821)"
FT                   /id="VAR_044832"
FT   VARIANT         154
FT                   /note="G -> I (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045796"
FT   VARIANT         154
FT                   /note="G -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs137852789)"
FT                   /id="VAR_044833"
FT   VARIANT         154
FT                   /note="G -> V (in a brain tumor with no family history;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs762846821)"
FT                   /evidence="ECO:0000269|PubMed:2263646"
FT                   /id="VAR_005900"
FT   VARIANT         155
FT                   /note="T -> A (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs772683278)"
FT                   /evidence="ECO:0000269|PubMed:1868473"
FT                   /id="VAR_005901"
FT   VARIANT         155
FT                   /note="T -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044834"
FT   VARIANT         155
FT                   /note="T -> M (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044835"
FT   VARIANT         155
FT                   /note="T -> N (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs786202752)"
FT                   /id="VAR_044836"
FT   VARIANT         155
FT                   /note="T -> P (in sporadic cancers; somatic mutation; does
FT                   not induce SNAI1 degradation)"
FT                   /evidence="ECO:0000269|PubMed:14660794,
FT                   ECO:0000269|PubMed:20385133"
FT                   /id="VAR_044837"
FT   VARIANT         155
FT                   /note="T -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786202752)"
FT                   /id="VAR_044838"
FT   VARIANT         156
FT                   /note="R -> C (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs563378859)"
FT                   /id="VAR_044839"
FT   VARIANT         156
FT                   /note="R -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044840"
FT   VARIANT         156
FT                   /note="R -> H (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs371524413)"
FT                   /id="VAR_044841"
FT   VARIANT         156
FT                   /note="R -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044842"
FT   VARIANT         156
FT                   /note="R -> P (in sporadic cancers; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:7682763"
FT                   /id="VAR_005902"
FT   VARIANT         156
FT                   /note="R -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044843"
FT   VARIANT         157
FT                   /note="V -> A (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1131691023)"
FT                   /id="VAR_044844"
FT   VARIANT         157
FT                   /note="V -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005903"
FT   VARIANT         157
FT                   /note="V -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912654)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_005904"
FT   VARIANT         157
FT                   /note="V -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044845"
FT   VARIANT         157
FT                   /note="V -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912654)"
FT                   /evidence="ECO:0000269|PubMed:9419979"
FT                   /id="VAR_012977"
FT   VARIANT         157
FT                   /note="V -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044846"
FT   VARIANT         158
FT                   /note="R -> C (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780068)"
FT                   /id="VAR_005905"
FT   VARIANT         158
FT                   /note="R -> F (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045797"
FT   VARIANT         158
FT                   /note="R -> G (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation)"
FT                   /id="VAR_005906"
FT   VARIANT         158
FT                   /note="R -> H (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs587782144)"
FT                   /id="VAR_005907"
FT   VARIANT         158
FT                   /note="R -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044847"
FT   VARIANT         158
FT                   /note="R -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782144)"
FT                   /id="VAR_044848"
FT   VARIANT         158
FT                   /note="R -> Q (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044849"
FT   VARIANT         158
FT                   /note="R -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044850"
FT   VARIANT         158
FT                   /note="R -> Y (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045798"
FT   VARIANT         159
FT                   /note="A -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044851"
FT   VARIANT         159
FT                   /note="A -> F (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions; dbSNP:rs730882022)"
FT                   /id="VAR_045799"
FT   VARIANT         159
FT                   /note="A -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044852"
FT   VARIANT         159
FT                   /note="A -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882000)"
FT                   /id="VAR_044853"
FT   VARIANT         159
FT                   /note="A -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044854"
FT   VARIANT         159
FT                   /note="A -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882000)"
FT                   /id="VAR_044855"
FT   VARIANT         159
FT                   /note="A -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555526131)"
FT                   /id="VAR_044856"
FT   VARIANT         160..161
FT                   /note="MA -> IP (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047160"
FT   VARIANT         160..161
FT                   /note="MA -> IS (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_047161"
FT   VARIANT         160..161
FT                   /note="MA -> IT (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047162"
FT   VARIANT         160
FT                   /note="M -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs772354334)"
FT                   /id="VAR_005908"
FT   VARIANT         160
FT                   /note="M -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044857"
FT   VARIANT         160
FT                   /note="M -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044858"
FT   VARIANT         160
FT                   /note="M -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs377274728)"
FT                   /id="VAR_044859"
FT   VARIANT         161
FT                   /note="A -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064795691)"
FT                   /id="VAR_044860"
FT   VARIANT         161
FT                   /note="A -> F (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045800"
FT   VARIANT         161
FT                   /note="A -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044861"
FT   VARIANT         161
FT                   /note="A -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044862"
FT   VARIANT         161
FT                   /note="A -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005909"
FT   VARIANT         161
FT                   /note="A -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs193920817)"
FT                   /id="VAR_044863"
FT   VARIANT         161
FT                   /note="A -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044864"
FT   VARIANT         162
FT                   /note="I -> F (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044865"
FT   VARIANT         162
FT                   /note="I -> M (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044866"
FT   VARIANT         162
FT                   /note="I -> N (in a breast cancer with no family history;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation)"
FT                   /id="VAR_044867"
FT   VARIANT         162
FT                   /note="I -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780069)"
FT                   /id="VAR_005910"
FT   VARIANT         162
FT                   /note="I -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044868"
FT   VARIANT         162
FT                   /note="I -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005911"
FT   VARIANT         163
FT                   /note="Y -> C (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs148924904)"
FT                   /evidence="ECO:0000269|PubMed:16959974,
FT                   ECO:0000269|PubMed:17224074"
FT                   /id="VAR_033035"
FT   VARIANT         163
FT                   /note="Y -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786203436)"
FT                   /id="VAR_044869"
FT   VARIANT         163
FT                   /note="Y -> F (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044870"
FT   VARIANT         163
FT                   /note="Y -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786203436)"
FT                   /evidence="ECO:0000269|PubMed:17224074"
FT                   /id="VAR_005912"
FT   VARIANT         163
FT                   /note="Y -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786203436)"
FT                   /id="VAR_044871"
FT   VARIANT         163
FT                   /note="Y -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044872"
FT   VARIANT         164
FT                   /note="K -> E (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs879254249)"
FT                   /id="VAR_044873"
FT   VARIANT         164
FT                   /note="K -> M (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044874"
FT   VARIANT         164
FT                   /note="K -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1131691034)"
FT                   /id="VAR_005913"
FT   VARIANT         164
FT                   /note="K -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005914"
FT   VARIANT         164
FT                   /note="K -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044875"
FT   VARIANT         164
FT                   /note="K -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044876"
FT   VARIANT         165
FT                   /note="Q -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044877"
FT   VARIANT         165
FT                   /note="Q -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044878"
FT   VARIANT         165
FT                   /note="Q -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005915"
FT   VARIANT         165
FT                   /note="Q -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044879"
FT   VARIANT         165
FT                   /note="Q -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005916"
FT   VARIANT         166
FT                   /note="S -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044880"
FT   VARIANT         166
FT                   /note="S -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044881"
FT   VARIANT         166
FT                   /note="S -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555526101)"
FT                   /id="VAR_005917"
FT   VARIANT         166
FT                   /note="S -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044882"
FT   VARIANT         166
FT                   /note="S -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044883"
FT   VARIANT         167..168
FT                   /note="QH -> HD (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047163"
FT   VARIANT         167..168
FT                   /note="QH -> YL (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047164"
FT   VARIANT         167
FT                   /note="Q -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044884"
FT   VARIANT         167
FT                   /note="Q -> K (in LFS; germline mutation and in a sporadic
FT                   cancer; somatic mutation)"
FT                   /id="VAR_044885"
FT   VARIANT         167
FT                   /note="Q -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044886"
FT   VARIANT         167
FT                   /note="Q -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044887"
FT   VARIANT         168..169
FT                   /note="HM -> LI (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047165"
FT   VARIANT         168
FT                   /note="H -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044888"
FT   VARIANT         168
FT                   /note="H -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044889"
FT   VARIANT         168
FT                   /note="H -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044890"
FT   VARIANT         168
FT                   /note="H -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044891"
FT   VARIANT         168
FT                   /note="H -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044892"
FT   VARIANT         168
FT                   /note="H -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs867114783)"
FT                   /id="VAR_005918"
FT   VARIANT         168
FT                   /note="H -> V (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045801"
FT   VARIANT         168
FT                   /note="H -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044893"
FT   VARIANT         169..170
FT                   /note="MT -> IS (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047166"
FT   VARIANT         169
FT                   /note="M -> I (in sporadic cancers; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:9450901"
FT                   /id="VAR_005919"
FT   VARIANT         169
FT                   /note="M -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044894"
FT   VARIANT         169
FT                   /note="M -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005920"
FT   VARIANT         169
FT                   /note="M -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044895"
FT   VARIANT         170
FT                   /note="T -> A (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780729)"
FT                   /id="VAR_044896"
FT   VARIANT         170
FT                   /note="T -> K (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044897"
FT   VARIANT         170
FT                   /note="T -> M (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs779000871)"
FT                   /id="VAR_005921"
FT   VARIANT         170
FT                   /note="T -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044898"
FT   VARIANT         170
FT                   /note="T -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005922"
FT   VARIANT         171
FT                   /note="E -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044899"
FT   VARIANT         171
FT                   /note="E -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044900"
FT   VARIANT         171
FT                   /note="E -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044901"
FT   VARIANT         171
FT                   /note="E -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587781845)"
FT                   /id="VAR_044902"
FT   VARIANT         171
FT                   /note="E -> Q (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044903"
FT   VARIANT         171
FT                   /note="E -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044904"
FT   VARIANT         172
FT                   /note="V -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005923"
FT   VARIANT         172
FT                   /note="V -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044905"
FT   VARIANT         172
FT                   /note="V -> F (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs1131691043)"
FT                   /id="VAR_044906"
FT   VARIANT         172
FT                   /note="V -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1131691021)"
FT                   /id="VAR_044907"
FT   VARIANT         172
FT                   /note="V -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044908"
FT   VARIANT         173
FT                   /note="V -> A (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519747)"
FT                   /id="VAR_044909"
FT   VARIANT         173
FT                   /note="V -> E (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519747)"
FT                   /id="VAR_005924"
FT   VARIANT         173
FT                   /note="V -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519747)"
FT                   /id="VAR_044910"
FT   VARIANT         173
FT                   /note="V -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876660754)"
FT                   /id="VAR_005925"
FT   VARIANT         173
FT                   /note="V -> M (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs876660754)"
FT                   /id="VAR_005926"
FT   VARIANT         173
FT                   /note="V -> W (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045802"
FT   VARIANT         174
FT                   /note="R -> G (in LFS; germline mutation and in a sporadic
FT                   cancer; somatic mutation; dbSNP:rs864622115)"
FT                   /id="VAR_044911"
FT   VARIANT         174
FT                   /note="R -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064796681)"
FT                   /evidence="ECO:0000269|PubMed:7682763"
FT                   /id="VAR_005927"
FT   VARIANT         174
FT                   /note="R -> M (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044912"
FT   VARIANT         174
FT                   /note="R -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044913"
FT   VARIANT         174
FT                   /note="R -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044914"
FT   VARIANT         174
FT                   /note="R -> W (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044915"
FT   VARIANT         175
FT                   /note="R -> C (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs138729528)"
FT                   /id="VAR_005928"
FT   VARIANT         175
FT                   /note="R -> G (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs138729528)"
FT                   /id="VAR_005929"
FT   VARIANT         175
FT                   /note="R -> H (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; does not induce SNAI1
FT                   degradation; reduces interaction with ZNF385A;
FT                   dbSNP:rs28934578)"
FT                   /evidence="ECO:0000269|PubMed:16959974,
FT                   ECO:0000269|PubMed:17719541, ECO:0000269|PubMed:1868473,
FT                   ECO:0000269|PubMed:20385133, ECO:0000269|PubMed:7887414,
FT                   ECO:0000269|PubMed:8825920"
FT                   /id="VAR_005932"
FT   VARIANT         175
FT                   /note="R -> L (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs28934578)"
FT                   /id="VAR_005930"
FT   VARIANT         175
FT                   /note="R -> P (in sporadic cancers; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17719541"
FT                   /id="VAR_005931"
FT   VARIANT         175
FT                   /note="R -> Q (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044916"
FT   VARIANT         175
FT                   /note="R -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044917"
FT   VARIANT         176..177
FT                   /note="CP -> FS (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047167"
FT   VARIANT         176
FT                   /note="C -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786202962)"
FT                   /evidence="ECO:0000269|PubMed:1394225,
FT                   ECO:0000269|PubMed:1868473, ECO:0000269|PubMed:8829627,
FT                   ECO:0000269|PubMed:9450901"
FT                   /id="VAR_005933"
FT   VARIANT         176
FT                   /note="C -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044918"
FT   VARIANT         176
FT                   /note="C -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044919"
FT   VARIANT         176
FT                   /note="C -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs967461896)"
FT                   /id="VAR_044920"
FT   VARIANT         176
FT                   /note="C -> W (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519980)"
FT                   /id="VAR_005934"
FT   VARIANT         176
FT                   /note="C -> Y (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786202962)"
FT                   /id="VAR_044921"
FT   VARIANT         177
FT                   /note="P -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044922"
FT   VARIANT         177
FT                   /note="P -> F (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045803"
FT   VARIANT         177
FT                   /note="P -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044923"
FT   VARIANT         177
FT                   /note="P -> I (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045804"
FT   VARIANT         177
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs751477326)"
FT                   /id="VAR_005935"
FT   VARIANT         177
FT                   /note="P -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs751477326)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036505"
FT   VARIANT         177
FT                   /note="P -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs147002414)"
FT                   /id="VAR_044924"
FT   VARIANT         177
FT                   /note="P -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044925"
FT   VARIANT         178..179
FT                   /note="HH -> QS (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047168"
FT   VARIANT         178
FT                   /note="H -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044926"
FT   VARIANT         178
FT                   /note="H -> HPHP (in a Burkitt lymphoma)"
FT                   /evidence="ECO:0000269|PubMed:1303181"
FT                   /id="VAR_005936"
FT   VARIANT         178
FT                   /note="H -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044927"
FT   VARIANT         178
FT                   /note="H -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064795203)"
FT                   /id="VAR_044928"
FT   VARIANT         178
FT                   /note="H -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555526004)"
FT                   /id="VAR_044929"
FT   VARIANT         178
FT                   /note="H -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044930"
FT   VARIANT         178
FT                   /note="H -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044931"
FT   VARIANT         178
FT                   /note="H -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044932"
FT   VARIANT         179
FT                   /note="H -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780070)"
FT                   /id="VAR_044933"
FT   VARIANT         179
FT                   /note="H -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519991)"
FT                   /id="VAR_044934"
FT   VARIANT         179
FT                   /note="H -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780070)"
FT                   /id="VAR_044935"
FT   VARIANT         179
FT                   /note="H -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519991)"
FT                   /id="VAR_044936"
FT   VARIANT         179
FT                   /note="H -> Q (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876660821)"
FT                   /id="VAR_044937"
FT   VARIANT         179
FT                   /note="H -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519991)"
FT                   /id="VAR_044938"
FT   VARIANT         179
FT                   /note="H -> Y (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs587780070)"
FT                   /id="VAR_044939"
FT   VARIANT         180
FT                   /note="E -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044940"
FT   VARIANT         180
FT                   /note="E -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044941"
FT   VARIANT         180
FT                   /note="E -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044942"
FT   VARIANT         180
FT                   /note="E -> K (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs879253911)"
FT                   /id="VAR_044943"
FT   VARIANT         180
FT                   /note="E -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044944"
FT   VARIANT         180
FT                   /note="E -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044945"
FT   VARIANT         181
FT                   /note="R -> C (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs587782596)"
FT                   /id="VAR_044946"
FT   VARIANT         181
FT                   /note="R -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044947"
FT   VARIANT         181
FT                   /note="R -> H (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs397514495)"
FT                   /id="VAR_044948"
FT   VARIANT         181
FT                   /note="R -> L (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs397514495)"
FT                   /id="VAR_005937"
FT   VARIANT         181
FT                   /note="R -> P (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation)"
FT                   /id="VAR_044949"
FT   VARIANT         181
FT                   /note="R -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782596)"
FT                   /id="VAR_044950"
FT   VARIANT         182
FT                   /note="C -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044951"
FT   VARIANT         182
FT                   /note="C -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005938"
FT   VARIANT         182
FT                   /note="C -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044952"
FT   VARIANT         183
FT                   /note="S -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555525970)"
FT                   /id="VAR_044953"
FT   VARIANT         183
FT                   /note="S -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044954"
FT   VARIANT         184
FT                   /note="D -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1060501209)"
FT                   /id="VAR_044955"
FT   VARIANT         184
FT                   /note="D -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044956"
FT   VARIANT         184
FT                   /note="D -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs72661117)"
FT                   /id="VAR_047169"
FT   VARIANT         184
FT                   /note="D -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044957"
FT   VARIANT         184
FT                   /note="D -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005939"
FT   VARIANT         185
FT                   /note="S -> C (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044958"
FT   VARIANT         185
FT                   /note="S -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044959"
FT   VARIANT         185
FT                   /note="S -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044960"
FT   VARIANT         185
FT                   /note="S -> N (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs150607408)"
FT                   /id="VAR_044961"
FT   VARIANT         185
FT                   /note="S -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044962"
FT   VARIANT         185
FT                   /note="S -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044963"
FT   VARIANT         186
FT                   /note="D -> E (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs375275361)"
FT                   /id="VAR_044964"
FT   VARIANT         186
FT                   /note="D -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044965"
FT   VARIANT         186
FT                   /note="D -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044966"
FT   VARIANT         186
FT                   /note="D -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1060501206)"
FT                   /id="VAR_044967"
FT   VARIANT         186
FT                   /note="D -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044968"
FT   VARIANT         186
FT                   /note="D -> Y (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_005940"
FT   VARIANT         187
FT                   /note="G -> C (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005941"
FT   VARIANT         187
FT                   /note="G -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044969"
FT   VARIANT         187
FT                   /note="G -> N (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045805"
FT   VARIANT         187
FT                   /note="G -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044970"
FT   VARIANT         187
FT                   /note="G -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs776167460)"
FT                   /id="VAR_005942"
FT   VARIANT         187
FT                   /note="G -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044971"
FT   VARIANT         188
FT                   /note="L -> P (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1199893366)"
FT                   /id="VAR_044972"
FT   VARIANT         188
FT                   /note="L -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044973"
FT   VARIANT         189
FT                   /note="A -> D (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044974"
FT   VARIANT         189
FT                   /note="A -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044975"
FT   VARIANT         189
FT                   /note="A -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005943"
FT   VARIANT         189
FT                   /note="A -> S (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1555525921)"
FT                   /id="VAR_044976"
FT   VARIANT         189
FT                   /note="A -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044977"
FT   VARIANT         189
FT                   /note="A -> V (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs121912665)"
FT                   /id="VAR_044978"
FT   VARIANT         190
FT                   /note="P -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044979"
FT   VARIANT         190
FT                   /note="P -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044980"
FT   VARIANT         190
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876660825)"
FT                   /id="VAR_005944"
FT   VARIANT         190
FT                   /note="P -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876660825)"
FT                   /id="VAR_044981"
FT   VARIANT         190
FT                   /note="P -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044982"
FT   VARIANT         190
FT                   /note="P -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876660254)"
FT                   /id="VAR_044983"
FT   VARIANT         191
FT                   /note="P -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587778718)"
FT                   /id="VAR_044984"
FT   VARIANT         191
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587778718)"
FT                   /id="VAR_044985"
FT   VARIANT         191
FT                   /note="P -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587778718)"
FT                   /id="VAR_044986"
FT   VARIANT         191
FT                   /note="P -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs868590738)"
FT                   /id="VAR_044987"
FT   VARIANT         191
FT                   /note="P -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005945"
FT   VARIANT         192..193
FT                   /note="QH -> HN (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047170"
FT   VARIANT         192..193
FT                   /note="QH -> HY (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047171"
FT   VARIANT         192
FT                   /note="Q -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044988"
FT   VARIANT         192
FT                   /note="Q -> K (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_044989"
FT   VARIANT         192
FT                   /note="Q -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044990"
FT   VARIANT         192
FT                   /note="Q -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044991"
FT   VARIANT         192
FT                   /note="Q -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882002)"
FT                   /id="VAR_005946"
FT   VARIANT         193
FT                   /note="H -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876658468)"
FT                   /id="VAR_005947"
FT   VARIANT         193
FT                   /note="H -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786201838)"
FT                   /id="VAR_044992"
FT   VARIANT         193
FT                   /note="H -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876658468)"
FT                   /id="VAR_044993"
FT   VARIANT         193
FT                   /note="H -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786201838)"
FT                   /id="VAR_044994"
FT   VARIANT         193
FT                   /note="H -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044995"
FT   VARIANT         193
FT                   /note="H -> R (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs786201838)"
FT                   /evidence="ECO:0000269|PubMed:16959974,
FT                   ECO:0000269|PubMed:7887414"
FT                   /id="VAR_005948"
FT   VARIANT         193
FT                   /note="H -> Y (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876658468)"
FT                   /id="VAR_044996"
FT   VARIANT         194
FT                   /note="L -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780071)"
FT                   /id="VAR_044997"
FT   VARIANT         194
FT                   /note="L -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519998)"
FT                   /id="VAR_044998"
FT   VARIANT         194
FT                   /note="L -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_044999"
FT   VARIANT         194
FT                   /note="L -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519998)"
FT                   /id="VAR_005949"
FT   VARIANT         194
FT                   /note="L -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519998)"
FT                   /evidence="ECO:0000269|PubMed:7682763"
FT                   /id="VAR_005950"
FT   VARIANT         194
FT                   /note="L -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045000"
FT   VARIANT         195
FT                   /note="I -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs942158624)"
FT                   /id="VAR_045001"
FT   VARIANT         195
FT                   /note="I -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047172"
FT   VARIANT         195
FT                   /note="I -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs760043106)"
FT                   /id="VAR_045002"
FT   VARIANT         195
FT                   /note="I -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs760043106)"
FT                   /id="VAR_045003"
FT   VARIANT         195
FT                   /note="I -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs760043106)"
FT                   /evidence="ECO:0000269|PubMed:17224074,
FT                   ECO:0000269|PubMed:9450901"
FT                   /id="VAR_005951"
FT   VARIANT         195
FT                   /note="I -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045004"
FT   VARIANT         195
FT                   /note="I -> Y (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045806"
FT   VARIANT         196
FT                   /note="R -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs397516435)"
FT                   /id="VAR_045005"
FT   VARIANT         196
FT                   /note="R -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs483352697)"
FT                   /id="VAR_045006"
FT   VARIANT         196
FT                   /note="R -> P (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs483352697)"
FT                   /id="VAR_045007"
FT   VARIANT         196
FT                   /note="R -> Q (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs483352697)"
FT                   /id="VAR_045008"
FT   VARIANT         196
FT                   /note="R -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045009"
FT   VARIANT         197
FT                   /note="V -> E (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation)"
FT                   /id="VAR_045010"
FT   VARIANT         197
FT                   /note="V -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045011"
FT   VARIANT         197
FT                   /note="V -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786204041)"
FT                   /id="VAR_045012"
FT   VARIANT         197
FT                   /note="V -> M (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs786204041)"
FT                   /id="VAR_045013"
FT   VARIANT         198
FT                   /note="E -> D (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045014"
FT   VARIANT         198
FT                   /note="E -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045015"
FT   VARIANT         198
FT                   /note="E -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005952"
FT   VARIANT         198
FT                   /note="E -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045016"
FT   VARIANT         198
FT                   /note="E -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045017"
FT   VARIANT         199
FT                   /note="G -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045018"
FT   VARIANT         199
FT                   /note="G -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045019"
FT   VARIANT         199
FT                   /note="G -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045020"
FT   VARIANT         199
FT                   /note="G -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555525857)"
FT                   /id="VAR_045021"
FT   VARIANT         200
FT                   /note="N -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045022"
FT   VARIANT         200
FT                   /note="N -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045023"
FT   VARIANT         200
FT                   /note="N -> K (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045024"
FT   VARIANT         200
FT                   /note="N -> P (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045807"
FT   VARIANT         200
FT                   /note="N -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045025"
FT   VARIANT         200
FT                   /note="N -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045026"
FT   VARIANT         201..202
FT                   /note="LR -> FC (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047173"
FT   VARIANT         201
FT                   /note="L -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882024)"
FT                   /id="VAR_045027"
FT   VARIANT         201
FT                   /note="L -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045028"
FT   VARIANT         201
FT                   /note="L -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045029"
FT   VARIANT         202
FT                   /note="R -> C (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780072)"
FT                   /id="VAR_045030"
FT   VARIANT         202
FT                   /note="R -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780072)"
FT                   /id="VAR_045031"
FT   VARIANT         202
FT                   /note="R -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587778719)"
FT                   /id="VAR_045032"
FT   VARIANT         202
FT                   /note="R -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587778719)"
FT                   /id="VAR_045033"
FT   VARIANT         202
FT                   /note="R -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045034"
FT   VARIANT         202
FT                   /note="R -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045035"
FT   VARIANT         203..204
FT                   /note="VE -> LV (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047174"
FT   VARIANT         203
FT                   /note="V -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045036"
FT   VARIANT         203
FT                   /note="V -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045037"
FT   VARIANT         203
FT                   /note="V -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045038"
FT   VARIANT         203
FT                   /note="V -> M (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882003)"
FT                   /id="VAR_045039"
FT   VARIANT         203
FT                   /note="V -> W (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045808"
FT   VARIANT         204
FT                   /note="E -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045040"
FT   VARIANT         204
FT                   /note="E -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045041"
FT   VARIANT         204
FT                   /note="E -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1260903787)"
FT                   /id="VAR_045042"
FT   VARIANT         204
FT                   /note="E -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045043"
FT   VARIANT         204
FT                   /note="E -> Q (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045044"
FT   VARIANT         204
FT                   /note="E -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045045"
FT   VARIANT         205
FT                   /note="Y -> C (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520007)"
FT                   /evidence="ECO:0000269|PubMed:1459726"
FT                   /id="VAR_005953"
FT   VARIANT         205
FT                   /note="Y -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520008)"
FT                   /id="VAR_005954"
FT   VARIANT         205
FT                   /note="Y -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520007)"
FT                   /id="VAR_047175"
FT   VARIANT         205
FT                   /note="Y -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520008)"
FT                   /id="VAR_045046"
FT   VARIANT         205
FT                   /note="Y -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520008)"
FT                   /id="VAR_045047"
FT   VARIANT         205
FT                   /note="Y -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520007)"
FT                   /id="VAR_045048"
FT   VARIANT         206
FT                   /note="L -> F (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045049"
FT   VARIANT         206
FT                   /note="L -> M (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045050"
FT   VARIANT         207..208
FT                   /note="DD -> EY (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047176"
FT   VARIANT         207
FT                   /note="D -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045051"
FT   VARIANT         207
FT                   /note="D -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045052"
FT   VARIANT         207
FT                   /note="D -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045053"
FT   VARIANT         207
FT                   /note="D -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs923100890)"
FT                   /id="VAR_045054"
FT   VARIANT         207
FT                   /note="D -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045055"
FT   VARIANT         207
FT                   /note="D -> Y (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045056"
FT   VARIANT         208
FT                   /note="D -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045057"
FT   VARIANT         208
FT                   /note="D -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045058"
FT   VARIANT         208
FT                   /note="D -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045059"
FT   VARIANT         208
FT                   /note="D -> I (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045809"
FT   VARIANT         208
FT                   /note="D -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045060"
FT   VARIANT         208
FT                   /note="D -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1464727668)"
FT                   /id="VAR_045061"
FT   VARIANT         208
FT                   /note="D -> Y (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045062"
FT   VARIANT         209
FT                   /note="R -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045063"
FT   VARIANT         209
FT                   /note="R -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045064"
FT   VARIANT         209
FT                   /note="R -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045065"
FT   VARIANT         209
FT                   /note="R -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045066"
FT   VARIANT         210
FT                   /note="N -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045067"
FT   VARIANT         210
FT                   /note="N -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045068"
FT   VARIANT         210
FT                   /note="N -> I (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045069"
FT   VARIANT         210
FT                   /note="N -> K (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045070"
FT   VARIANT         210
FT                   /note="N -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045071"
FT   VARIANT         210
FT                   /note="N -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045072"
FT   VARIANT         210
FT                   /note="N -> Y (in a familial cancer not matching LFS;
FT                   germline mutation; dbSNP:rs1060501200)"
FT                   /id="VAR_045073"
FT   VARIANT         211
FT                   /note="T -> A (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1060501198)"
FT                   /id="VAR_045074"
FT   VARIANT         211
FT                   /note="T -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045075"
FT   VARIANT         211
FT                   /note="T -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045076"
FT   VARIANT         211
FT                   /note="T -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045077"
FT   VARIANT         211
FT                   /note="T -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045078"
FT   VARIANT         212
FT                   /note="F -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064795766)"
FT                   /id="VAR_045079"
FT   VARIANT         212
FT                   /note="F -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045080"
FT   VARIANT         212
FT                   /note="F -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045081"
FT   VARIANT         212
FT                   /note="F -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045082"
FT   VARIANT         212
FT                   /note="F -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045083"
FT   VARIANT         213
FT                   /note="R -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs397516436)"
FT                   /id="VAR_045084"
FT   VARIANT         213
FT                   /note="R -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587778720)"
FT                   /id="VAR_045085"
FT   VARIANT         213
FT                   /note="R -> P (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs587778720)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036506"
FT   VARIANT         213
FT                   /note="R -> Q (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs587778720)"
FT                   /id="VAR_005955"
FT   VARIANT         213
FT                   /note="R -> W (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045086"
FT   VARIANT         214
FT                   /note="H -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045087"
FT   VARIANT         214
FT                   /note="H -> P (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1057519992)"
FT                   /id="VAR_045088"
FT   VARIANT         214
FT                   /note="H -> Q (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587781386)"
FT                   /id="VAR_047177"
FT   VARIANT         214
FT                   /note="H -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519992)"
FT                   /id="VAR_045089"
FT   VARIANT         214
FT                   /note="H -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045090"
FT   VARIANT         215
FT                   /note="S -> C (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045091"
FT   VARIANT         215
FT                   /note="S -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs886039484)"
FT                   /id="VAR_045092"
FT   VARIANT         215
FT                   /note="S -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782177)"
FT                   /id="VAR_045093"
FT   VARIANT         215
FT                   /note="S -> K (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045810"
FT   VARIANT         215
FT                   /note="S -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782177)"
FT                   /id="VAR_045094"
FT   VARIANT         215
FT                   /note="S -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520001)"
FT                   /id="VAR_045095"
FT   VARIANT         215
FT                   /note="S -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782177)"
FT                   /id="VAR_045096"
FT   VARIANT         216
FT                   /note="V -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045097"
FT   VARIANT         216
FT                   /note="V -> E (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520004)"
FT                   /id="VAR_045098"
FT   VARIANT         216
FT                   /note="V -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520004)"
FT                   /id="VAR_045099"
FT   VARIANT         216
FT                   /note="V -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882025)"
FT                   /id="VAR_045100"
FT   VARIANT         216
FT                   /note="V -> M (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882025)"
FT                   /evidence="ECO:0000269|PubMed:17224074"
FT                   /id="VAR_005956"
FT   VARIANT         216
FT                   /note="V -> W (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045811"
FT   VARIANT         217
FT                   /note="V -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045101"
FT   VARIANT         217
FT                   /note="V -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045102"
FT   VARIANT         217
FT                   /note="V -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045103"
FT   VARIANT         217
FT                   /note="V -> I (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045104"
FT   VARIANT         217
FT                   /note="V -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045105"
FT   VARIANT         217
FT                   /note="V -> M (in dbSNP:rs35163653)"
FT                   /id="VAR_047178"
FT   VARIANT         218
FT                   /note="V -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045106"
FT   VARIANT         218
FT                   /note="V -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045107"
FT   VARIANT         218
FT                   /note="V -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555525743)"
FT                   /id="VAR_045108"
FT   VARIANT         218
FT                   /note="V -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045109"
FT   VARIANT         218
FT                   /note="V -> M (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs878854072)"
FT                   /id="VAR_045110"
FT   VARIANT         219
FT                   /note="P -> C (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045812"
FT   VARIANT         219
FT                   /note="P -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045111"
FT   VARIANT         219
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1420675064)"
FT                   /id="VAR_045112"
FT   VARIANT         219
FT                   /note="P -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045113"
FT   VARIANT         219
FT                   /note="P -> S (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs879253894)"
FT                   /id="VAR_045114"
FT   VARIANT         219
FT                   /note="P -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045115"
FT   VARIANT         220
FT                   /note="Y -> C (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs121912666)"
FT                   /evidence="ECO:0000269|PubMed:7682763,
FT                   ECO:0000269|PubMed:9450901"
FT                   /id="VAR_005957"
FT   VARIANT         220
FT                   /note="Y -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs530941076)"
FT                   /id="VAR_045116"
FT   VARIANT         220
FT                   /note="Y -> F (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045117"
FT   VARIANT         220
FT                   /note="Y -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs530941076)"
FT                   /id="VAR_005958"
FT   VARIANT         220
FT                   /note="Y -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs530941076)"
FT                   /id="VAR_045118"
FT   VARIANT         220
FT                   /note="Y -> S (in a brain tumor with no family history;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs121912666)"
FT                   /id="VAR_005959"
FT   VARIANT         221
FT                   /note="E -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045119"
FT   VARIANT         221
FT                   /note="E -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045120"
FT   VARIANT         221
FT                   /note="E -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045121"
FT   VARIANT         221
FT                   /note="E -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786201592)"
FT                   /id="VAR_045122"
FT   VARIANT         221
FT                   /note="E -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045123"
FT   VARIANT         222
FT                   /note="P -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045124"
FT   VARIANT         222
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs146340390)"
FT                   /id="VAR_045125"
FT   VARIANT         222
FT                   /note="P -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045126"
FT   VARIANT         222
FT                   /note="P -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045127"
FT   VARIANT         222
FT                   /note="P -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1060501203)"
FT                   /id="VAR_045128"
FT   VARIANT         222
FT                   /note="P -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045129"
FT   VARIANT         223
FT                   /note="P -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047179"
FT   VARIANT         223
FT                   /note="P -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs138983188)"
FT                   /id="VAR_045130"
FT   VARIANT         223
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs138983188)"
FT                   /id="VAR_045131"
FT   VARIANT         223
FT                   /note="P -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045132"
FT   VARIANT         223
FT                   /note="P -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045133"
FT   VARIANT         223
FT                   /note="P -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045134"
FT   VARIANT         224
FT                   /note="E -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs267605076)"
FT                   /id="VAR_045135"
FT   VARIANT         224
FT                   /note="E -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045136"
FT   VARIANT         224
FT                   /note="E -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555525707)"
FT                   /id="VAR_045137"
FT   VARIANT         224
FT                   /note="E -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045138"
FT   VARIANT         225
FT                   /note="V -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045139"
FT   VARIANT         225
FT                   /note="V -> D (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045140"
FT   VARIANT         225
FT                   /note="V -> F (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045141"
FT   VARIANT         225
FT                   /note="V -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045142"
FT   VARIANT         225
FT                   /note="V -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045143"
FT   VARIANT         225
FT                   /note="V -> L (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs746504075)"
FT                   /id="VAR_045144"
FT   VARIANT         226
FT                   /note="G -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045145"
FT   VARIANT         226
FT                   /note="G -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_047180"
FT   VARIANT         226
FT                   /note="G -> N (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045844"
FT   VARIANT         226
FT                   /note="G -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045146"
FT   VARIANT         226
FT                   /note="G -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs970212462)"
FT                   /id="VAR_045147"
FT   VARIANT         227
FT                   /note="S -> C (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045148"
FT   VARIANT         227
FT                   /note="S -> F (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045149"
FT   VARIANT         227
FT                   /note="S -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045150"
FT   VARIANT         227
FT                   /note="S -> T (in LFS; germline mutation and in a sporadic
FT                   cancer; somatic mutation)"
FT                   /id="VAR_045151"
FT   VARIANT         228
FT                   /note="D -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045152"
FT   VARIANT         228
FT                   /note="D -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005960"
FT   VARIANT         228
FT                   /note="D -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045153"
FT   VARIANT         228
FT                   /note="D -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045154"
FT   VARIANT         228
FT                   /note="D -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045155"
FT   VARIANT         228
FT                   /note="D -> P (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045845"
FT   VARIANT         228
FT                   /note="D -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045156"
FT   VARIANT         228
FT                   /note="D -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045157"
FT   VARIANT         229
FT                   /note="C -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045158"
FT   VARIANT         229
FT                   /note="C -> N (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045846"
FT   VARIANT         229
FT                   /note="C -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064794312)"
FT                   /id="VAR_045159"
FT   VARIANT         229
FT                   /note="C -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045160"
FT   VARIANT         229
FT                   /note="C -> Y (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064793603)"
FT                   /id="VAR_045161"
FT   VARIANT         230
FT                   /note="T -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045162"
FT   VARIANT         230
FT                   /note="T -> I (in sporadic cancers; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:9450901"
FT                   /id="VAR_005961"
FT   VARIANT         230
FT                   /note="T -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045163"
FT   VARIANT         230
FT                   /note="T -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045164"
FT   VARIANT         230
FT                   /note="T -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045165"
FT   VARIANT         231
FT                   /note="T -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045166"
FT   VARIANT         231
FT                   /note="T -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555525564)"
FT                   /id="VAR_045167"
FT   VARIANT         231
FT                   /note="T -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045168"
FT   VARIANT         231
FT                   /note="T -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045169"
FT   VARIANT         232
FT                   /note="I -> F (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045170"
FT   VARIANT         232
FT                   /note="I -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555525562)"
FT                   /id="VAR_045171"
FT   VARIANT         232
FT                   /note="I -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045172"
FT   VARIANT         232
FT                   /note="I -> S (in sporadic cancers; somatic mutation; does
FT                   not induce SNAI1 degradation)"
FT                   /evidence="ECO:0000269|PubMed:20385133"
FT                   /id="VAR_045173"
FT   VARIANT         232
FT                   /note="I -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587781589)"
FT                   /id="VAR_005962"
FT   VARIANT         232
FT                   /note="I -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045174"
FT   VARIANT         233
FT                   /note="H -> D (in LFS; germline mutation and in a sporadic
FT                   cancer; somatic mutation)"
FT                   /id="VAR_045175"
FT   VARIANT         233
FT                   /note="H -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045176"
FT   VARIANT         233
FT                   /note="H -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045177"
FT   VARIANT         233
FT                   /note="H -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045178"
FT   VARIANT         233
FT                   /note="H -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs879254233)"
FT                   /id="VAR_047181"
FT   VARIANT         233
FT                   /note="H -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045179"
FT   VARIANT         234
FT                   /note="Y -> C (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs587780073)"
FT                   /id="VAR_005963"
FT   VARIANT         234
FT                   /note="Y -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs864622237)"
FT                   /id="VAR_045180"
FT   VARIANT         234
FT                   /note="Y -> F (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045181"
FT   VARIANT         234
FT                   /note="Y -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs864622237)"
FT                   /id="VAR_005964"
FT   VARIANT         234
FT                   /note="Y -> K (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045847"
FT   VARIANT         234
FT                   /note="Y -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs864622237)"
FT                   /id="VAR_045182"
FT   VARIANT         234
FT                   /note="Y -> Q (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045848"
FT   VARIANT         234
FT                   /note="Y -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780073)"
FT                   /id="VAR_045183"
FT   VARIANT         235
FT                   /note="N -> D (in an adrenocortical carcinoma with no
FT                   family history; germline mutation and in sporadic cancers;
FT                   somatic mutation)"
FT                   /id="VAR_047182"
FT   VARIANT         235
FT                   /note="N -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045184"
FT   VARIANT         235
FT                   /note="N -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs144340710)"
FT                   /id="VAR_045185"
FT   VARIANT         235
FT                   /note="N -> M (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045849"
FT   VARIANT         235
FT                   /note="N -> S (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs144340710)"
FT                   /id="VAR_045186"
FT   VARIANT         235
FT                   /note="N -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045187"
FT   VARIANT         235
FT                   /note="N -> Y (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786204145)"
FT                   /id="VAR_045188"
FT   VARIANT         236
FT                   /note="Y -> C (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs730882026)"
FT                   /id="VAR_045189"
FT   VARIANT         236
FT                   /note="Y -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782289)"
FT                   /id="VAR_045190"
FT   VARIANT         236
FT                   /note="Y -> F (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045191"
FT   VARIANT         236
FT                   /note="Y -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782289)"
FT                   /id="VAR_045192"
FT   VARIANT         236
FT                   /note="Y -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782289)"
FT                   /id="VAR_045193"
FT   VARIANT         236
FT                   /note="Y -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882026)"
FT                   /id="VAR_045194"
FT   VARIANT         237
FT                   /note="M -> I (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs587782664)"
FT                   /id="VAR_005965"
FT   VARIANT         237
FT                   /note="M -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs765848205)"
FT                   /id="VAR_045195"
FT   VARIANT         237
FT                   /note="M -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045196"
FT   VARIANT         237
FT                   /note="M -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs765848205)"
FT                   /id="VAR_045197"
FT   VARIANT         237
FT                   /note="M -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045198"
FT   VARIANT         237
FT                   /note="M -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882004)"
FT                   /id="VAR_045199"
FT   VARIANT         238
FT                   /note="C -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882005)"
FT                   /id="VAR_005966"
FT   VARIANT         238
FT                   /note="C -> G (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs1057519981)"
FT                   /id="VAR_045200"
FT   VARIANT         238
FT                   /note="C -> H (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045850"
FT   VARIANT         238
FT                   /note="C -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519981)"
FT                   /id="VAR_045201"
FT   VARIANT         238
FT                   /note="C -> S (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs730882005)"
FT                   /id="VAR_045202"
FT   VARIANT         238
FT                   /note="C -> W (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs193920789)"
FT                   /id="VAR_045203"
FT   VARIANT         238
FT                   /note="C -> Y (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs730882005)"
FT                   /id="VAR_005967"
FT   VARIANT         239
FT                   /note="N -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876660807)"
FT                   /id="VAR_045204"
FT   VARIANT         239
FT                   /note="N -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045205"
FT   VARIANT         239
FT                   /note="N -> I (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045206"
FT   VARIANT         239
FT                   /note="N -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057522275)"
FT                   /id="VAR_045207"
FT   VARIANT         239
FT                   /note="N -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519999)"
FT                   /id="VAR_045208"
FT   VARIANT         239
FT                   /note="N -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519999)"
FT                   /id="VAR_045209"
FT   VARIANT         239
FT                   /note="N -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045210"
FT   VARIANT         240
FT                   /note="S -> C (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045211"
FT   VARIANT         240
FT                   /note="S -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045212"
FT   VARIANT         240
FT                   /note="S -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005968"
FT   VARIANT         240
FT                   /note="S -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045213"
FT   VARIANT         240
FT                   /note="S -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045214"
FT   VARIANT         240
FT                   /note="S -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045215"
FT   VARIANT         240
FT                   /note="S -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045216"
FT   VARIANT         241
FT                   /note="S -> A (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520002)"
FT                   /evidence="ECO:0000269|PubMed:17224074"
FT                   /id="VAR_033036"
FT   VARIANT         241
FT                   /note="S -> C (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs28934573)"
FT                   /id="VAR_045217"
FT   VARIANT         241
FT                   /note="S -> F (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs28934573)"
FT                   /evidence="ECO:0000269|PubMed:16959974,
FT                   ECO:0000269|PubMed:1699228"
FT                   /id="VAR_005969"
FT   VARIANT         241
FT                   /note="S -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520002)"
FT                   /id="VAR_045218"
FT   VARIANT         241
FT                   /note="S -> T (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation)"
FT                   /id="VAR_047183"
FT   VARIANT         241
FT                   /note="S -> Y (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs28934573)"
FT                   /id="VAR_045219"
FT   VARIANT         242
FT                   /note="C -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912655)"
FT                   /evidence="ECO:0000269|PubMed:1394225,
FT                   ECO:0000269|PubMed:16959974"
FT                   /id="VAR_005970"
FT   VARIANT         242
FT                   /note="C -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519982)"
FT                   /id="VAR_045220"
FT   VARIANT         242
FT                   /note="C -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045221"
FT   VARIANT         242
FT                   /note="C -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912655)"
FT                   /id="VAR_045222"
FT   VARIANT         242
FT                   /note="C -> W (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs375874539)"
FT                   /id="VAR_045223"
FT   VARIANT         242
FT                   /note="C -> Y (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs121912655)"
FT                   /id="VAR_045224"
FT   VARIANT         243..244
FT                   /note="MG -> IC (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047184"
FT   VARIANT         243..244
FT                   /note="MG -> IS (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047185"
FT   VARIANT         243
FT                   /note="M -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045225"
FT   VARIANT         243
FT                   /note="M -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045226"
FT   VARIANT         243
FT                   /note="M -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786203117)"
FT                   /id="VAR_045227"
FT   VARIANT         243
FT                   /note="M -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045228"
FT   VARIANT         243
FT                   /note="M -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882006)"
FT                   /id="VAR_045229"
FT   VARIANT         243
FT                   /note="M -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786203117)"
FT                   /id="VAR_045230"
FT   VARIANT         244
FT                   /note="G -> A (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs985033810)"
FT                   /id="VAR_047186"
FT   VARIANT         244
FT                   /note="G -> C (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519989)"
FT                   /id="VAR_045231"
FT   VARIANT         244
FT                   /note="G -> D (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs1057517983)"
FT                   /id="VAR_045232"
FT   VARIANT         244
FT                   /note="G -> E (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045233"
FT   VARIANT         244
FT                   /note="G -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519989)"
FT                   /id="VAR_045234"
FT   VARIANT         244
FT                   /note="G -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519989)"
FT                   /id="VAR_045235"
FT   VARIANT         244
FT                   /note="G -> V (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs985033810)"
FT                   /id="VAR_045236"
FT   VARIANT         245
FT                   /note="G -> A (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912656)"
FT                   /id="VAR_005971"
FT   VARIANT         245
FT                   /note="G -> C (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs28934575)"
FT                   /evidence="ECO:0000269|PubMed:1394225,
FT                   ECO:0000269|PubMed:1978757"
FT                   /id="VAR_005972"
FT   VARIANT         245
FT                   /note="G -> D (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs121912656)"
FT                   /evidence="ECO:0000269|PubMed:2259385"
FT                   /id="VAR_005973"
FT   VARIANT         245
FT                   /note="G -> E (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045237"
FT   VARIANT         245
FT                   /note="G -> F (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045851"
FT   VARIANT         245
FT                   /note="G -> H (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045852"
FT   VARIANT         245
FT                   /note="G -> L (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045853"
FT   VARIANT         245
FT                   /note="G -> N (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045854"
FT   VARIANT         245
FT                   /note="G -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs28934575)"
FT                   /id="VAR_045238"
FT   VARIANT         245
FT                   /note="G -> S (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs28934575)"
FT                   /evidence="ECO:0000269|PubMed:8829627"
FT                   /id="VAR_005974"
FT   VARIANT         245
FT                   /note="G -> V (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs121912656)"
FT                   /evidence="ECO:0000269|PubMed:2263646"
FT                   /id="VAR_005975"
FT   VARIANT         246
FT                   /note="M -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1019340046)"
FT                   /id="VAR_045239"
FT   VARIANT         246
FT                   /note="M -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045240"
FT   VARIANT         246
FT                   /note="M -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs483352695)"
FT                   /id="VAR_044020"
FT   VARIANT         246
FT                   /note="M -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780074)"
FT                   /id="VAR_005976"
FT   VARIANT         246
FT                   /note="M -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780074)"
FT                   /id="VAR_005977"
FT   VARIANT         246
FT                   /note="M -> V (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs483352695)"
FT                   /id="VAR_005978"
FT   VARIANT         247..248
FT                   /note="NR -> IP (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047187"
FT   VARIANT         247..248
FT                   /note="NR -> KW (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_047188"
FT   VARIANT         247
FT                   /note="N -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1452189221)"
FT                   /id="VAR_045241"
FT   VARIANT         247
FT                   /note="N -> F (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045855"
FT   VARIANT         247
FT                   /note="N -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786201762)"
FT                   /id="VAR_005980"
FT   VARIANT         247
FT                   /note="N -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045242"
FT   VARIANT         247
FT                   /note="N -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786201762)"
FT                   /id="VAR_045243"
FT   VARIANT         247
FT                   /note="N -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_047189"
FT   VARIANT         247
FT                   /note="N -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045244"
FT   VARIANT         248
FT                   /note="R -> C (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045245"
FT   VARIANT         248
FT                   /note="R -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912651)"
FT                   /id="VAR_005981"
FT   VARIANT         248
FT                   /note="R -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs11540652)"
FT                   /evidence="ECO:0000269|PubMed:1394225,
FT                   ECO:0000269|PubMed:7682763"
FT                   /id="VAR_005982"
FT   VARIANT         248
FT                   /note="R -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs11540652)"
FT                   /id="VAR_045246"
FT   VARIANT         248
FT                   /note="R -> Q (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs11540652)"
FT                   /evidence="ECO:0000269|PubMed:16959974,
FT                   ECO:0000269|PubMed:2263646, ECO:0000269|PubMed:7682763,
FT                   ECO:0000269|PubMed:7887414"
FT                   /id="VAR_005983"
FT   VARIANT         248
FT                   /note="R -> W (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs121912651)"
FT                   /evidence="ECO:0000269|PubMed:16959974,
FT                   ECO:0000269|PubMed:1978757, ECO:0000269|PubMed:8829627"
FT                   /id="VAR_005984"
FT   VARIANT         249..250
FT                   /note="RP -> SA (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047190"
FT   VARIANT         249..250
FT                   /note="RP -> SS (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_047191"
FT   VARIANT         249
FT                   /note="R -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782082)"
FT                   /id="VAR_005985"
FT   VARIANT         249
FT                   /note="R -> I (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045247"
FT   VARIANT         249
FT                   /note="R -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782329)"
FT                   /id="VAR_045248"
FT   VARIANT         249
FT                   /note="R -> M (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782329)"
FT                   /evidence="ECO:0000269|PubMed:17224074"
FT                   /id="VAR_033037"
FT   VARIANT         249
FT                   /note="R -> N (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045856"
FT   VARIANT         249
FT                   /note="R -> S (in sporadic cancers; somatic mutation; does
FT                   not induce SNAI1 degradation; dbSNP:rs28934571)"
FT                   /evidence="ECO:0000269|PubMed:1694291,
FT                   ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:20385133"
FT                   /id="VAR_005986"
FT   VARIANT         249
FT                   /note="R -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782329)"
FT                   /id="VAR_045249"
FT   VARIANT         249
FT                   /note="R -> W (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782082)"
FT                   /id="VAR_045250"
FT   VARIANT         250
FT                   /note="P -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045251"
FT   VARIANT         250
FT                   /note="P -> F (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045857"
FT   VARIANT         250
FT                   /note="P -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045252"
FT   VARIANT         250
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064794311)"
FT                   /id="VAR_047192"
FT   VARIANT         250
FT                   /note="P -> N (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045858"
FT   VARIANT         250
FT                   /note="P -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045253"
FT   VARIANT         250
FT                   /note="P -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045254"
FT   VARIANT         250
FT                   /note="P -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045255"
FT   VARIANT         251
FT                   /note="I -> F (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045256"
FT   VARIANT         251
FT                   /note="I -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882007)"
FT                   /id="VAR_045257"
FT   VARIANT         251
FT                   /note="I -> M (in LFS; germline mutation;
FT                   dbSNP:rs878854074)"
FT                   /id="VAR_045258"
FT   VARIANT         251
FT                   /note="I -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005987"
FT   VARIANT         251
FT                   /note="I -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882027)"
FT                   /evidence="ECO:0000269|PubMed:17224074"
FT                   /id="VAR_033038"
FT   VARIANT         251
FT                   /note="I -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045259"
FT   VARIANT         251
FT                   /note="I -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045260"
FT   VARIANT         252
FT                   /note="L -> F (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045261"
FT   VARIANT         252
FT                   /note="L -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045262"
FT   VARIANT         252
FT                   /note="L -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045263"
FT   VARIANT         252
FT                   /note="L -> P (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs121912653)"
FT                   /evidence="ECO:0000269|PubMed:1978757"
FT                   /id="VAR_005988"
FT   VARIANT         252
FT                   /note="L -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045264"
FT   VARIANT         253
FT                   /note="T -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045265"
FT   VARIANT         253
FT                   /note="T -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045266"
FT   VARIANT         253
FT                   /note="T -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555525465)"
FT                   /id="VAR_045267"
FT   VARIANT         253
FT                   /note="T -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_047193"
FT   VARIANT         253
FT                   /note="T -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045268"
FT   VARIANT         254
FT                   /note="I -> D (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045859"
FT   VARIANT         254
FT                   /note="I -> F (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045269"
FT   VARIANT         254
FT                   /note="I -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045270"
FT   VARIANT         254
FT                   /note="I -> M (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045271"
FT   VARIANT         254
FT                   /note="I -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_017908"
FT   VARIANT         254
FT                   /note="I -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1330865474)"
FT                   /id="VAR_045272"
FT   VARIANT         254
FT                   /note="I -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_017909"
FT   VARIANT         254
FT                   /note="I -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs746601313)"
FT                   /id="VAR_045273"
FT   VARIANT         255
FT                   /note="I -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519995)"
FT                   /id="VAR_045274"
FT   VARIANT         255
FT                   /note="I -> M (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045275"
FT   VARIANT         255
FT                   /note="I -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876659675)"
FT                   /id="VAR_045276"
FT   VARIANT         255
FT                   /note="I -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876659675)"
FT                   /id="VAR_045277"
FT   VARIANT         255
FT                   /note="I -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876659675)"
FT                   /id="VAR_045278"
FT   VARIANT         255
FT                   /note="I -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045279"
FT   VARIANT         256
FT                   /note="T -> I (in a brain tumor with no family history;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation)"
FT                   /id="VAR_045280"
FT   VARIANT         256
FT                   /note="T -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045281"
FT   VARIANT         256
FT                   /note="T -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045282"
FT   VARIANT         256
FT                   /note="T -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045283"
FT   VARIANT         257
FT                   /note="L -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005989"
FT   VARIANT         257
FT                   /note="L -> Q (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs28934577)"
FT                   /id="VAR_045284"
FT   VARIANT         257
FT                   /note="L -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs28934577)"
FT                   /id="VAR_045285"
FT   VARIANT         257
FT                   /note="L -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045286"
FT   VARIANT         258
FT                   /note="E -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045287"
FT   VARIANT         258
FT                   /note="E -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_005990"
FT   VARIANT         258
FT                   /note="E -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1060501201)"
FT                   /id="VAR_045288"
FT   VARIANT         258
FT                   /note="E -> K (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs121912652)"
FT                   /evidence="ECO:0000269|PubMed:1978757"
FT                   /id="VAR_005991"
FT   VARIANT         258
FT                   /note="E -> L (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045860"
FT   VARIANT         258
FT                   /note="E -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045289"
FT   VARIANT         258
FT                   /note="E -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045290"
FT   VARIANT         259
FT                   /note="D -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047194"
FT   VARIANT         259
FT                   /note="D -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045291"
FT   VARIANT         259
FT                   /note="D -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs745425759)"
FT                   /id="VAR_045292"
FT   VARIANT         259
FT                   /note="D -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045293"
FT   VARIANT         259
FT                   /note="D -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045294"
FT   VARIANT         259
FT                   /note="D -> P (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045861"
FT   VARIANT         259
FT                   /note="D -> S (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045862"
FT   VARIANT         259
FT                   /note="D -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045295"
FT   VARIANT         259
FT                   /note="D -> Y (in sporadic cancers; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17224074"
FT                   /id="VAR_033039"
FT   VARIANT         260
FT                   /note="S -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045296"
FT   VARIANT         260
FT                   /note="S -> C (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045297"
FT   VARIANT         260
FT                   /note="S -> F (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045298"
FT   VARIANT         260
FT                   /note="S -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045299"
FT   VARIANT         260
FT                   /note="S -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045300"
FT   VARIANT         260
FT                   /note="S -> Y (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876658916)"
FT                   /id="VAR_045301"
FT   VARIANT         261
FT                   /note="S -> C (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045302"
FT   VARIANT         261
FT                   /note="S -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045303"
FT   VARIANT         261
FT                   /note="S -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045304"
FT   VARIANT         261
FT                   /note="S -> N (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045305"
FT   VARIANT         261
FT                   /note="S -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045306"
FT   VARIANT         262..263
FT                   /note="GN -> PD (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047195"
FT   VARIANT         262
FT                   /note="G -> C (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs200579969)"
FT                   /id="VAR_045307"
FT   VARIANT         262
FT                   /note="G -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_047196"
FT   VARIANT         262
FT                   /note="G -> H (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045863"
FT   VARIANT         262
FT                   /note="G -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs200579969)"
FT                   /id="VAR_045308"
FT   VARIANT         262
FT                   /note="G -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1131691025)"
FT                   /evidence="ECO:0000269|Ref.23"
FT                   /id="VAR_045309"
FT   VARIANT         263
FT                   /note="N -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs72661119)"
FT                   /id="VAR_045310"
FT   VARIANT         263
FT                   /note="N -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045311"
FT   VARIANT         263
FT                   /note="N -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045312"
FT   VARIANT         263
FT                   /note="N -> K (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045313"
FT   VARIANT         263
FT                   /note="N -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045314"
FT   VARIANT         264
FT                   /note="L -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045315"
FT   VARIANT         264
FT                   /note="L -> P (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1555525353)"
FT                   /id="VAR_045316"
FT   VARIANT         264
FT                   /note="L -> Q (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045317"
FT   VARIANT         264
FT                   /note="L -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045318"
FT   VARIANT         264
FT                   /note="L -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045319"
FT   VARIANT         265
FT                   /note="L -> M (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045320"
FT   VARIANT         265
FT                   /note="L -> P (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs879253942)"
FT                   /id="VAR_045321"
FT   VARIANT         265
FT                   /note="L -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045322"
FT   VARIANT         265
FT                   /note="L -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_047197"
FT   VARIANT         266
FT                   /note="G -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045323"
FT   VARIANT         266
FT                   /note="G -> E (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs193920774)"
FT                   /id="VAR_045324"
FT   VARIANT         266
FT                   /note="G -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519990)"
FT                   /id="VAR_045325"
FT   VARIANT         266
FT                   /note="G -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs193920774)"
FT                   /id="VAR_045326"
FT   VARIANT         267
FT                   /note="R -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045327"
FT   VARIANT         267
FT                   /note="R -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045328"
FT   VARIANT         267
FT                   /note="R -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780075)"
FT                   /id="VAR_045329"
FT   VARIANT         267
FT                   /note="R -> Q (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs587780075)"
FT                   /id="VAR_045330"
FT   VARIANT         267
FT                   /note="R -> W (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs55832599)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036507"
FT   VARIANT         268
FT                   /note="N -> F (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045864"
FT   VARIANT         268
FT                   /note="N -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045331"
FT   VARIANT         268
FT                   /note="N -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045332"
FT   VARIANT         268
FT                   /note="N -> K (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045333"
FT   VARIANT         268
FT                   /note="N -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045334"
FT   VARIANT         268
FT                   /note="N -> Y (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045335"
FT   VARIANT         269
FT                   /note="S -> C (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045336"
FT   VARIANT         269
FT                   /note="S -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045337"
FT   VARIANT         269
FT                   /note="S -> I (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047198"
FT   VARIANT         269
FT                   /note="S -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045338"
FT   VARIANT         269
FT                   /note="S -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045339"
FT   VARIANT         269
FT                   /note="S -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045340"
FT   VARIANT         270
FT                   /note="F -> C (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519986)"
FT                   /id="VAR_045341"
FT   VARIANT         270
FT                   /note="F -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519988)"
FT                   /id="VAR_045342"
FT   VARIANT         270
FT                   /note="F -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519987)"
FT                   /id="VAR_045343"
FT   VARIANT         270
FT                   /note="F -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519986)"
FT                   /id="VAR_045344"
FT   VARIANT         270
FT                   /note="F -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519988)"
FT                   /id="VAR_045345"
FT   VARIANT         270
FT                   /note="F -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045346"
FT   VARIANT         271
FT                   /note="E -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045347"
FT   VARIANT         271
FT                   /note="E -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045348"
FT   VARIANT         271
FT                   /note="E -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045349"
FT   VARIANT         271
FT                   /note="E -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1060501191)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036508"
FT   VARIANT         271
FT                   /note="E -> P (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045865"
FT   VARIANT         271
FT                   /note="E -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045350"
FT   VARIANT         271
FT                   /note="E -> R (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045866"
FT   VARIANT         271
FT                   /note="E -> V (in an osteosarcoma with no family history;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation)"
FT                   /id="VAR_047199"
FT   VARIANT         272
FT                   /note="V -> A (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation)"
FT                   /id="VAR_045351"
FT   VARIANT         272
FT                   /note="V -> E (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876660333)"
FT                   /id="VAR_045352"
FT   VARIANT         272
FT                   /note="V -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876660333)"
FT                   /id="VAR_045353"
FT   VARIANT         272
FT                   /note="V -> L (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs121912657)"
FT                   /evidence="ECO:0000269|PubMed:1737852"
FT                   /id="VAR_005992"
FT   VARIANT         272
FT                   /note="V -> M (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912657)"
FT                   /id="VAR_045354"
FT   VARIANT         273
FT                   /note="R -> C (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs121913343)"
FT                   /evidence="ECO:0000269|PubMed:16959974,
FT                   ECO:0000269|PubMed:17224074, ECO:0000269|PubMed:7887414,
FT                   ECO:0000269|PubMed:9450901"
FT                   /id="VAR_005993"
FT   VARIANT         273
FT                   /note="R -> G (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation)"
FT                   /id="VAR_005994"
FT   VARIANT         273
FT                   /note="R -> H (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; abolishes sequence-specific DNA
FT                   binding; does not induce SNAI1 degradation;
FT                   dbSNP:rs28934576)"
FT                   /evidence="ECO:0000269|PubMed:10570149,
FT                   ECO:0000269|PubMed:1394225, ECO:0000269|PubMed:1565144,
FT                   ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:1699228,
FT                   ECO:0000269|PubMed:1868473, ECO:0000269|PubMed:20385133,
FT                   ECO:0000269|PubMed:7682763, ECO:0000269|Ref.14"
FT                   /id="VAR_005995"
FT   VARIANT         273
FT                   /note="R -> L (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs28934576)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036509"
FT   VARIANT         273
FT                   /note="R -> N (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045867"
FT   VARIANT         273
FT                   /note="R -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs28934576)"
FT                   /id="VAR_045355"
FT   VARIANT         273
FT                   /note="R -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045356"
FT   VARIANT         273
FT                   /note="R -> S (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs121913343)"
FT                   /id="VAR_045357"
FT   VARIANT         273
FT                   /note="R -> Y (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045868"
FT   VARIANT         274
FT                   /note="V -> A (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520006)"
FT                   /id="VAR_045358"
FT   VARIANT         274
FT                   /note="V -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520006)"
FT                   /id="VAR_045359"
FT   VARIANT         274
FT                   /note="V -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520005)"
FT                   /id="VAR_005997"
FT   VARIANT         274
FT                   /note="V -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520006)"
FT                   /id="VAR_047200"
FT   VARIANT         274
FT                   /note="V -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045360"
FT   VARIANT         274
FT                   /note="V -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057520005)"
FT                   /id="VAR_045361"
FT   VARIANT         275
FT                   /note="C -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs863224451)"
FT                   /id="VAR_045362"
FT   VARIANT         275
FT                   /note="C -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045363"
FT   VARIANT         275
FT                   /note="C -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519983)"
FT                   /id="VAR_045364"
FT   VARIANT         275
FT                   /note="C -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs863224451)"
FT                   /id="VAR_045365"
FT   VARIANT         275
FT                   /note="C -> W (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555525279)"
FT                   /id="VAR_005999"
FT   VARIANT         275
FT                   /note="C -> Y (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs863224451)"
FT                   /evidence="ECO:0000269|PubMed:7887414"
FT                   /id="VAR_005998"
FT   VARIANT         276
FT                   /note="A -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786202082)"
FT                   /id="VAR_045366"
FT   VARIANT         276
FT                   /note="A -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786202082)"
FT                   /id="VAR_045367"
FT   VARIANT         276
FT                   /note="A -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1131691029)"
FT                   /id="VAR_045368"
FT   VARIANT         276
FT                   /note="A -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045369"
FT   VARIANT         276
FT                   /note="A -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045370"
FT   VARIANT         276
FT                   /note="A -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045371"
FT   VARIANT         277
FT                   /note="C -> F (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs763098116)"
FT                   /id="VAR_045372"
FT   VARIANT         277
FT                   /note="C -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064795369)"
FT                   /id="VAR_006000"
FT   VARIANT         277
FT                   /note="C -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064795369)"
FT                   /id="VAR_045373"
FT   VARIANT         277
FT                   /note="C -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045374"
FT   VARIANT         277
FT                   /note="C -> W (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_047201"
FT   VARIANT         277
FT                   /note="C -> Y (in an osteosarcoma with no family history;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs763098116)"
FT                   /id="VAR_045375"
FT   VARIANT         278
FT                   /note="P -> A (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs17849781)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_006001"
FT   VARIANT         278
FT                   /note="P -> F (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045869"
FT   VARIANT         278
FT                   /note="P -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876659802)"
FT                   /id="VAR_006002"
FT   VARIANT         278
FT                   /note="P -> L (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs876659802)"
FT                   /evidence="ECO:0000269|PubMed:2263646"
FT                   /id="VAR_006003"
FT   VARIANT         278
FT                   /note="P -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876659802)"
FT                   /id="VAR_045376"
FT   VARIANT         278
FT                   /note="P -> S (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs17849781)"
FT                   /evidence="ECO:0000269|PubMed:16959974,
FT                   ECO:0000269|PubMed:2263646, ECO:0000269|PubMed:9450901"
FT                   /id="VAR_006004"
FT   VARIANT         278
FT                   /note="P -> T (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs17849781)"
FT                   /id="VAR_006005"
FT   VARIANT         279
FT                   /note="G -> E (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064793881)"
FT                   /id="VAR_006006"
FT   VARIANT         279
FT                   /note="G -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555525248)"
FT                   /id="VAR_045377"
FT   VARIANT         279
FT                   /note="G -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045378"
FT   VARIANT         279
FT                   /note="G -> W (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045379"
FT   VARIANT         280
FT                   /note="R -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs753660142)"
FT                   /id="VAR_045380"
FT   VARIANT         280
FT                   /note="R -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912660)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_006008"
FT   VARIANT         280
FT                   /note="R -> K (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; no effect on interaction with CCAR2;
FT                   dbSNP:rs121912660)"
FT                   /evidence="ECO:0000269|PubMed:1694291,
FT                   ECO:0000269|PubMed:25732823"
FT                   /id="VAR_006007"
FT   VARIANT         280
FT                   /note="R -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045381"
FT   VARIANT         280
FT                   /note="R -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045382"
FT   VARIANT         280
FT                   /note="R -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912660)"
FT                   /evidence="ECO:0000269|PubMed:1631151"
FT                   /id="VAR_006009"
FT   VARIANT         281..282
FT                   /note="DR -> EW (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_047203"
FT   VARIANT         281
FT                   /note="D -> A (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587781525)"
FT                   /id="VAR_006010"
FT   VARIANT         281
FT                   /note="D -> E (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519984)"
FT                   /evidence="ECO:0000269|PubMed:1459726"
FT                   /id="VAR_006011"
FT   VARIANT         281
FT                   /note="D -> G (in a brain tumor with no family history;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs587781525)"
FT                   /id="VAR_006012"
FT   VARIANT         281
FT                   /note="D -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs764146326)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_006013"
FT   VARIANT         281
FT                   /note="D -> N (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs764146326)"
FT                   /id="VAR_047202"
FT   VARIANT         281
FT                   /note="D -> R (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045870"
FT   VARIANT         281
FT                   /note="D -> V (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs587781525)"
FT                   /id="VAR_006014"
FT   VARIANT         281
FT                   /note="D -> Y (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs764146326)"
FT                   /id="VAR_045383"
FT   VARIANT         282
FT                   /note="R -> G (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs28934574)"
FT                   /id="VAR_045384"
FT   VARIANT         282
FT                   /note="R -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045385"
FT   VARIANT         282
FT                   /note="R -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882008)"
FT                   /id="VAR_006015"
FT   VARIANT         282
FT                   /note="R -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs730882008)"
FT                   /id="VAR_045386"
FT   VARIANT         282
FT                   /note="R -> Q (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs730882008)"
FT                   /evidence="ECO:0000269|PubMed:18453682, ECO:0000269|Ref.22"
FT                   /id="VAR_045387"
FT   VARIANT         282
FT                   /note="R -> W (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; does not induce SNAI1
FT                   degradation; dbSNP:rs28934574)"
FT                   /evidence="ECO:0000269|PubMed:20385133,
FT                   ECO:0000269|PubMed:8829627"
FT                   /id="VAR_006016"
FT   VARIANT         283
FT                   /note="R -> C (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs149633775)"
FT                   /id="VAR_006017"
FT   VARIANT         283
FT                   /note="R -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_006018"
FT   VARIANT         283
FT                   /note="R -> H (in a brain tumor with no family history;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs371409680)"
FT                   /id="VAR_006019"
FT   VARIANT         283
FT                   /note="R -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045388"
FT   VARIANT         283
FT                   /note="R -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_006020"
FT   VARIANT         283
FT                   /note="R -> S (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs149633775)"
FT                   /id="VAR_045389"
FT   VARIANT         284
FT                   /note="T -> A (in sporadic cancers; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:20959462"
FT                   /id="VAR_006021"
FT   VARIANT         284
FT                   /note="T -> I (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs863224685)"
FT                   /id="VAR_045390"
FT   VARIANT         284
FT                   /note="T -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045391"
FT   VARIANT         284
FT                   /note="T -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1204379654)"
FT                   /id="VAR_006022"
FT   VARIANT         285
FT                   /note="E -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045392"
FT   VARIANT         285
FT                   /note="E -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045393"
FT   VARIANT         285
FT                   /note="E -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045394"
FT   VARIANT         285
FT                   /note="E -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs112431538)"
FT                   /evidence="ECO:0000269|PubMed:1459726,
FT                   ECO:0000269|PubMed:1694291"
FT                   /id="VAR_006023"
FT   VARIANT         285
FT                   /note="E -> Q (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation)"
FT                   /id="VAR_006024"
FT   VARIANT         285
FT                   /note="E -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912667)"
FT                   /id="VAR_006025"
FT   VARIANT         286
FT                   /note="E -> A (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs1057519985)"
FT                   /id="VAR_006026"
FT   VARIANT         286
FT                   /note="E -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_006027"
FT   VARIANT         286
FT                   /note="E -> G (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519985)"
FT                   /id="VAR_006028"
FT   VARIANT         286
FT                   /note="E -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786201059)"
FT                   /evidence="ECO:0000269|PubMed:11023613,
FT                   ECO:0000269|PubMed:8316628"
FT                   /id="VAR_006029"
FT   VARIANT         286
FT                   /note="E -> L (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045871"
FT   VARIANT         286
FT                   /note="E -> Q (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs786201059)"
FT                   /evidence="ECO:0000269|PubMed:8829627"
FT                   /id="VAR_006030"
FT   VARIANT         286
FT                   /note="E -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1057519985)"
FT                   /id="VAR_045395"
FT   VARIANT         287
FT                   /note="E -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047204"
FT   VARIANT         287
FT                   /note="E -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs748891343)"
FT                   /id="VAR_045396"
FT   VARIANT         287
FT                   /note="E -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045397"
FT   VARIANT         287
FT                   /note="E -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782006)"
FT                   /id="VAR_045398"
FT   VARIANT         287
FT                   /note="E -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045399"
FT   VARIANT         288
FT                   /note="N -> D (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045400"
FT   VARIANT         288
FT                   /note="N -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045401"
FT   VARIANT         288
FT                   /note="N -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045402"
FT   VARIANT         288
FT                   /note="N -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045403"
FT   VARIANT         288
FT                   /note="N -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045404"
FT   VARIANT         289
FT                   /note="L -> F (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045405"
FT   VARIANT         289
FT                   /note="L -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045406"
FT   VARIANT         289
FT                   /note="L -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045407"
FT   VARIANT         289
FT                   /note="L -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045408"
FT   VARIANT         289
FT                   /note="L -> V (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555525154)"
FT                   /id="VAR_045409"
FT   VARIANT         290
FT                   /note="R -> C (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs770374782)"
FT                   /id="VAR_045410"
FT   VARIANT         290
FT                   /note="R -> H (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs55819519)"
FT                   /id="VAR_045411"
FT   VARIANT         290
FT                   /note="R -> L (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation)"
FT                   /id="VAR_045412"
FT   VARIANT         291
FT                   /note="K -> E (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555525126)"
FT                   /id="VAR_045413"
FT   VARIANT         291
FT                   /note="K -> M (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045414"
FT   VARIANT         291
FT                   /note="K -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs372613518)"
FT                   /id="VAR_045415"
FT   VARIANT         291
FT                   /note="K -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_047205"
FT   VARIANT         291
FT                   /note="K -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs781490101)"
FT                   /id="VAR_045416"
FT   VARIANT         291
FT                   /note="K -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045417"
FT   VARIANT         292
FT                   /note="K -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045418"
FT   VARIANT         292
FT                   /note="K -> G (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045872"
FT   VARIANT         292
FT                   /note="K -> I (in LFS; germline mutation and in a sporadic
FT                   cancer; somatic mutation; dbSNP:rs121912663)"
FT                   /evidence="ECO:0000269|PubMed:10484981"
FT                   /id="VAR_015819"
FT   VARIANT         292
FT                   /note="K -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045419"
FT   VARIANT         292
FT                   /note="K -> Q (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045420"
FT   VARIANT         292
FT                   /note="K -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912663)"
FT                   /id="VAR_045421"
FT   VARIANT         292
FT                   /note="K -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045422"
FT   VARIANT         293
FT                   /note="G -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045423"
FT   VARIANT         293
FT                   /note="G -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587780076)"
FT                   /id="VAR_045424"
FT   VARIANT         293
FT                   /note="G -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045425"
FT   VARIANT         293
FT                   /note="G -> W (in a brain tumor with no family history;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs587780076)"
FT                   /id="VAR_045426"
FT   VARIANT         294
FT                   /note="E -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045427"
FT   VARIANT         294
FT                   /note="E -> D (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1305324490)"
FT                   /id="VAR_045428"
FT   VARIANT         294
FT                   /note="E -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045429"
FT   VARIANT         294
FT                   /note="E -> K (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_047206"
FT   VARIANT         294
FT                   /note="E -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045430"
FT   VARIANT         294
FT                   /note="E -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045431"
FT   VARIANT         295
FT                   /note="P -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045432"
FT   VARIANT         295
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs751713111)"
FT                   /id="VAR_045433"
FT   VARIANT         295
FT                   /note="P -> R (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs751713111)"
FT                   /id="VAR_045434"
FT   VARIANT         295
FT                   /note="P -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1131691006)"
FT                   /id="VAR_045435"
FT   VARIANT         296
FT                   /note="H -> C (in sporadic cancers; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045873"
FT   VARIANT         296
FT                   /note="H -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045436"
FT   VARIANT         296
FT                   /note="H -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_047207"
FT   VARIANT         296
FT                   /note="H -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045437"
FT   VARIANT         296
FT                   /note="H -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_006031"
FT   VARIANT         296
FT                   /note="H -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045438"
FT   VARIANT         296
FT                   /note="H -> R (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs483352696)"
FT                   /id="VAR_045439"
FT   VARIANT         296
FT                   /note="H -> Y (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs672601296)"
FT                   /id="VAR_045440"
FT   VARIANT         297
FT                   /note="H -> D (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045441"
FT   VARIANT         297
FT                   /note="H -> N (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045442"
FT   VARIANT         297
FT                   /note="H -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045443"
FT   VARIANT         297
FT                   /note="H -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876659477)"
FT                   /id="VAR_045444"
FT   VARIANT         297
FT                   /note="H -> Y (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045445"
FT   VARIANT         298
FT                   /note="E -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045446"
FT   VARIANT         298
FT                   /note="E -> D (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045447"
FT   VARIANT         298
FT                   /note="E -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs201744589)"
FT                   /id="VAR_045448"
FT   VARIANT         298
FT                   /note="E -> Q (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs201744589)"
FT                   /id="VAR_045449"
FT   VARIANT         298
FT                   /note="E -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045450"
FT   VARIANT         299
FT                   /note="L -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045451"
FT   VARIANT         299
FT                   /note="L -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045452"
FT   VARIANT         299
FT                   /note="L -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045453"
FT   VARIANT         299
FT                   /note="L -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045454"
FT   VARIANT         300
FT                   /note="P -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045455"
FT   VARIANT         300
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs909643864)"
FT                   /id="VAR_045456"
FT   VARIANT         300
FT                   /note="P -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_006032"
FT   VARIANT         300
FT                   /note="P -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045457"
FT   VARIANT         301
FT                   /note="P -> A (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045458"
FT   VARIANT         301
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555525067)"
FT                   /id="VAR_006033"
FT   VARIANT         301
FT                   /note="P -> Q (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045459"
FT   VARIANT         301
FT                   /note="P -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045460"
FT   VARIANT         301
FT                   /note="P -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047208"
FT   VARIANT         302
FT                   /note="G -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045461"
FT   VARIANT         302
FT                   /note="G -> E (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1060501202)"
FT                   /id="VAR_006034"
FT   VARIANT         302
FT                   /note="G -> R (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs863224686)"
FT                   /id="VAR_045462"
FT   VARIANT         302
FT                   /note="G -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_006035"
FT   VARIANT         303
FT                   /note="S -> C (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045463"
FT   VARIANT         303
FT                   /note="S -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045464"
FT   VARIANT         303
FT                   /note="S -> N (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs876658714)"
FT                   /id="VAR_045465"
FT   VARIANT         303
FT                   /note="S -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045466"
FT   VARIANT         304
FT                   /note="T -> A (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs587782654)"
FT                   /id="VAR_045467"
FT   VARIANT         304
FT                   /note="T -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045468"
FT   VARIANT         304
FT                   /note="T -> N (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045469"
FT   VARIANT         304
FT                   /note="T -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047209"
FT   VARIANT         305
FT                   /note="K -> E (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045470"
FT   VARIANT         305
FT                   /note="K -> M (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation)"
FT                   /id="VAR_045471"
FT   VARIANT         305
FT                   /note="K -> N (in sporadic cancers; somatic mutation; loss
FT                   of nuclear localization)"
FT                   /evidence="ECO:0000269|PubMed:10551826"
FT                   /id="VAR_045472"
FT   VARIANT         305
FT                   /note="K -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045473"
FT   VARIANT         305
FT                   /note="K -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045474"
FT   VARIANT         306
FT                   /note="R -> P (in LFS; germline mutation and in a sporadic
FT                   cancer; somatic mutation)"
FT                   /id="VAR_045475"
FT   VARIANT         306
FT                   /note="R -> Q (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1048095040)"
FT                   /id="VAR_006036"
FT   VARIANT         307
FT                   /note="A -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045476"
FT   VARIANT         307
FT                   /note="A -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045477"
FT   VARIANT         307
FT                   /note="A -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_006037"
FT   VARIANT         308
FT                   /note="L -> M (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045478"
FT   VARIANT         308
FT                   /note="L -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045479"
FT   VARIANT         309
FT                   /note="P -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045480"
FT   VARIANT         309
FT                   /note="P -> S (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs1555525012)"
FT                   /evidence="ECO:0000269|Ref.14"
FT                   /id="VAR_006038"
FT   VARIANT         310
FT                   /note="N -> I (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045481"
FT   VARIANT         310
FT                   /note="N -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045482"
FT   VARIANT         311
FT                   /note="N -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555525007)"
FT                   /id="VAR_045483"
FT   VARIANT         311
FT                   /note="N -> K (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045484"
FT   VARIANT         311
FT                   /note="N -> S (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs56184981)"
FT                   /id="VAR_045485"
FT   VARIANT         311
FT                   /note="N -> T (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs56184981)"
FT                   /id="VAR_045486"
FT   VARIANT         312
FT                   /note="T -> I (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045487"
FT   VARIANT         312
FT                   /note="T -> S (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs145151284)"
FT                   /id="VAR_045488"
FT   VARIANT         313
FT                   /note="S -> C (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045489"
FT   VARIANT         313
FT                   /note="S -> I (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045490"
FT   VARIANT         313
FT                   /note="S -> N (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045491"
FT   VARIANT         313
FT                   /note="S -> R (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1367492395)"
FT                   /id="VAR_045492"
FT   VARIANT         314
FT                   /note="S -> F (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs751440465)"
FT                   /id="VAR_045493"
FT   VARIANT         315
FT                   /note="S -> C (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045494"
FT   VARIANT         315
FT                   /note="S -> F (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045495"
FT   VARIANT         315
FT                   /note="S -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045496"
FT   VARIANT         316
FT                   /note="P -> L (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1555524979)"
FT                   /id="VAR_045497"
FT   VARIANT         316
FT                   /note="P -> T (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs772773208)"
FT                   /id="VAR_045498"
FT   VARIANT         317
FT                   /note="Q -> H (in a kidney cancer with no family history;
FT                   germline mutation and in a sporadic cancer; somatic
FT                   mutation; dbSNP:rs1060501199)"
FT                   /id="VAR_045499"
FT   VARIANT         317
FT                   /note="Q -> K (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs764735889)"
FT                   /id="VAR_045500"
FT   VARIANT         317
FT                   /note="Q -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047210"
FT   VARIANT         317
FT                   /note="Q -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045501"
FT   VARIANT         317
FT                   /note="Q -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1159579789)"
FT                   /id="VAR_045502"
FT   VARIANT         318
FT                   /note="P -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1555524975)"
FT                   /id="VAR_045503"
FT   VARIANT         319
FT                   /note="K -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045504"
FT   VARIANT         319
FT                   /note="K -> N (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045505"
FT   VARIANT         319
FT                   /note="K -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045506"
FT   VARIANT         320
FT                   /note="K -> N (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045507"
FT   VARIANT         321
FT                   /note="K -> E (in kidney cancer; germline mutation)"
FT                   /id="VAR_045508"
FT   VARIANT         321
FT                   /note="K -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045509"
FT   VARIANT         322
FT                   /note="P -> L (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045510"
FT   VARIANT         322
FT                   /note="P -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045511"
FT   VARIANT         323
FT                   /note="L -> G (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045874"
FT   VARIANT         323
FT                   /note="L -> M (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045512"
FT   VARIANT         323
FT                   /note="L -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045513"
FT   VARIANT         323
FT                   /note="L -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045514"
FT   VARIANT         323
FT                   /note="L -> V (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1432281680)"
FT                   /id="VAR_047211"
FT   VARIANT         324
FT                   /note="D -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045515"
FT   VARIANT         324
FT                   /note="D -> S (in a sporadic cancer; somatic mutation;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_045875"
FT   VARIANT         324
FT                   /note="D -> Y (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045516"
FT   VARIANT         325
FT                   /note="G -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045517"
FT   VARIANT         325
FT                   /note="G -> E (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045518"
FT   VARIANT         325
FT                   /note="G -> V (in LFS; germline mutation;
FT                   dbSNP:rs121912659)"
FT                   /evidence="ECO:0000269|PubMed:1565144"
FT                   /id="VAR_006039"
FT   VARIANT         326
FT                   /note="E -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045519"
FT   VARIANT         327
FT                   /note="Y -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045520"
FT   VARIANT         327
FT                   /note="Y -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045521"
FT   VARIANT         328
FT                   /note="F -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045522"
FT   VARIANT         328
FT                   /note="F -> S (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045523"
FT   VARIANT         328
FT                   /note="F -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045524"
FT   VARIANT         329
FT                   /note="T -> I (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs969930693)"
FT                   /id="VAR_045525"
FT   VARIANT         329
FT                   /note="T -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045526"
FT   VARIANT         330
FT                   /note="L -> H (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045527"
FT   VARIANT         330
FT                   /note="L -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047212"
FT   VARIANT         330
FT                   /note="L -> R (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045528"
FT   VARIANT         331
FT                   /note="Q -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs11575996)"
FT                   /id="VAR_045529"
FT   VARIANT         331
FT                   /note="Q -> P (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045530"
FT   VARIANT         331
FT                   /note="Q -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs1064795056)"
FT                   /id="VAR_045531"
FT   VARIANT         332
FT                   /note="I -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045532"
FT   VARIANT         334
FT                   /note="G -> V (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_006040"
FT   VARIANT         334
FT                   /note="G -> W (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs730882028)"
FT                   /id="VAR_045533"
FT   VARIANT         335
FT                   /note="R -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045534"
FT   VARIANT         335
FT                   /note="R -> H (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs771939956)"
FT                   /id="VAR_045535"
FT   VARIANT         335
FT                   /note="R -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045536"
FT   VARIANT         337
FT                   /note="R -> C (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs587782529)"
FT                   /evidence="ECO:0000269|PubMed:9452042"
FT                   /id="VAR_006041"
FT   VARIANT         337
FT                   /note="R -> H (in LFS; germline mutation and in sporadic
FT                   cancers; somatic mutation; dbSNP:rs121912664)"
FT                   /evidence="ECO:0000269|PubMed:11481490"
FT                   /id="VAR_035016"
FT   VARIANT         337
FT                   /note="R -> L (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912664)"
FT                   /id="VAR_045537"
FT   VARIANT         337
FT                   /note="R -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs121912664)"
FT                   /id="VAR_045538"
FT   VARIANT         338
FT                   /note="F -> I (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045539"
FT   VARIANT         338
FT                   /note="F -> L (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs150293825)"
FT                   /id="VAR_045540"
FT   VARIANT         339
FT                   /note="E -> K (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs17882252)"
FT                   /evidence="ECO:0000269|Ref.12"
FT                   /id="VAR_022316"
FT   VARIANT         339
FT                   /note="E -> Q (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs17882252)"
FT                   /id="VAR_045541"
FT   VARIANT         341
FT                   /note="F -> C (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045542"
FT   VARIANT         342
FT                   /note="R -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045543"
FT   VARIANT         342
FT                   /note="R -> P (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs375338359)"
FT                   /id="VAR_045544"
FT   VARIANT         342
FT                   /note="R -> Q (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs375338359)"
FT                   /id="VAR_047213"
FT   VARIANT         343
FT                   /note="E -> G (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045545"
FT   VARIANT         344
FT                   /note="L -> P (in LFS; germline mutation and in a sporadic
FT                   cancer; somatic mutation; dbSNP:rs121912662)"
FT                   /id="VAR_045546"
FT   VARIANT         344
FT                   /note="L -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045547"
FT   VARIANT         346
FT                   /note="E -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045548"
FT   VARIANT         347
FT                   /note="A -> G (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045549"
FT   VARIANT         347
FT                   /note="A -> T (in sporadic cancers; somatic mutation)"
FT                   /id="VAR_045550"
FT   VARIANT         348
FT                   /note="L -> F (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045551"
FT   VARIANT         348
FT                   /note="L -> S (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045552"
FT   VARIANT         349
FT                   /note="E -> D (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045553"
FT   VARIANT         352
FT                   /note="D -> H (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045554"
FT   VARIANT         353
FT                   /note="A -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045555"
FT   VARIANT         354
FT                   /note="Q -> E (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045556"
FT   VARIANT         354
FT                   /note="Q -> K (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs755394212)"
FT                   /id="VAR_045557"
FT   VARIANT         354
FT                   /note="Q -> R (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs752142489)"
FT                   /id="VAR_047214"
FT   VARIANT         356
FT                   /note="G -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045558"
FT   VARIANT         356
FT                   /note="G -> W (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045559"
FT   VARIANT         358
FT                   /note="E -> D (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045560"
FT   VARIANT         358
FT                   /note="E -> K (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs587782237)"
FT                   /id="VAR_045561"
FT   VARIANT         360
FT                   /note="G -> A (in dbSNP:rs35993958)"
FT                   /id="VAR_045562"
FT   VARIANT         360
FT                   /note="G -> V (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs35993958)"
FT                   /id="VAR_045563"
FT   VARIANT         363
FT                   /note="R -> K (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs876660285)"
FT                   /id="VAR_045564"
FT   VARIANT         364
FT                   /note="A -> P (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045565"
FT   VARIANT         364
FT                   /note="A -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045566"
FT   VARIANT         364
FT                   /note="A -> V (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045567"
FT   VARIANT         365
FT                   /note="H -> R (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_047215"
FT   VARIANT         365
FT                   /note="H -> Y (in a familial cancer not matching LFS;
FT                   germline mutation and in a sporadic cancer; somatic
FT                   mutation; dbSNP:rs267605075)"
FT                   /id="VAR_045568"
FT   VARIANT         366
FT                   /note="S -> A (in a familial cancer not matching LFS;
FT                   germline mutation and in sporadic cancers; somatic
FT                   mutation; dbSNP:rs17881470)"
FT                   /evidence="ECO:0000269|Ref.12"
FT                   /id="VAR_022317"
FT   VARIANT         370
FT                   /note="K -> Q (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045569"
FT   VARIANT         376
FT                   /note="S -> A (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045570"
FT   VARIANT         376
FT                   /note="S -> T (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045571"
FT   VARIANT         379
FT                   /note="R -> H (in sporadic cancers; somatic mutation;
FT                   dbSNP:rs863224682)"
FT                   /id="VAR_045572"
FT   VARIANT         385
FT                   /note="F -> L (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs1555524094)"
FT                   /id="VAR_045573"
FT   VARIANT         389
FT                   /note="G -> W (in a sporadic cancer; somatic mutation;
FT                   dbSNP:rs587783064)"
FT                   /id="VAR_045574"
FT   VARIANT         392
FT                   /note="S -> L (in a sporadic cancer; somatic mutation)"
FT                   /id="VAR_045575"
FT   MUTAGEN         15
FT                   /note="S->A: Loss of interaction with PPP2R5C, PPP2CA AND
FT                   PPP2R1A."
FT                   /evidence="ECO:0000269|PubMed:17967874"
FT   MUTAGEN         18
FT                   /note="T->A: No effect on interaction with MDM2 and
FT                   increase in protein levels after DNA damage."
FT                   /evidence="ECO:0000269|PubMed:10570149"
FT   MUTAGEN         20
FT                   /note="S->A: Abolishes phosphorylation site. Abolishes
FT                   increase in protein levels after DNA damage."
FT                   /evidence="ECO:0000269|PubMed:10570149"
FT   MUTAGEN         20
FT                   /note="S->D: Constitutively increased TP53 protein levels."
FT                   /evidence="ECO:0000269|PubMed:10570149"
FT   MUTAGEN         22..23
FT                   /note="LW->QS: Loss of interaction with MDM2, leading to
FT                   constitutively increased TP53 protein levels."
FT                   /evidence="ECO:0000269|PubMed:10570149"
FT   MUTAGEN         37
FT                   /note="S->D: Abolihes phosphorylation by MAPKAPK5."
FT                   /evidence="ECO:0000269|PubMed:17254968"
FT   MUTAGEN         46
FT                   /note="S->A: Abolishes phosphorylation by DYRK2 and HIPK2
FT                   and acetylation of K-382 by CREBBP."
FT                   /evidence="ECO:0000269|PubMed:11740489,
FT                   ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:17349958"
FT   MUTAGEN         46
FT                   /note="Missing: Alters interaction with WWOX."
FT                   /evidence="ECO:0000269|PubMed:11740489,
FT                   ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:17349958"
FT   MUTAGEN         55
FT                   /note="T->A: Blocks phosphorylation by TAF1."
FT                   /evidence="ECO:0000269|PubMed:15053879"
FT   MUTAGEN         183
FT                   /note="S->A: Abolishes strongly phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:20959462"
FT   MUTAGEN         183
FT                   /note="S->E: Inhibits slightly its transcriptional
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:20959462"
FT   MUTAGEN         248
FT                   /note="R->S: Does not induce SNAI1 degradation."
FT                   /evidence="ECO:0000269|PubMed:20385133"
FT   MUTAGEN         269
FT                   /note="S->A: Abolishes phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:20959462"
FT   MUTAGEN         269
FT                   /note="S->E: Inhibits strongly its transcriptional
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:20959462"
FT   MUTAGEN         284
FT                   /note="T->E: Inhibits strongly its transcriptional
FT                   activity."
FT   MUTAGEN         291..292
FT                   /note="KK->RR: Abolishes polyubiquitination by MKRN1."
FT                   /evidence="ECO:0000269|PubMed:19536131"
FT   MUTAGEN         319
FT                   /note="K->A: Loss of nuclear localization; when associated
FT                   with A-320 and A-321."
FT                   /evidence="ECO:0000269|PubMed:2156209"
FT   MUTAGEN         320
FT                   /note="K->A: Loss of nuclear localization; when associated
FT                   with A-319 and A-321."
FT                   /evidence="ECO:0000269|PubMed:2156209"
FT   MUTAGEN         321
FT                   /note="K->A: Loss of nuclear localization; when associated
FT                   with A-319 and A-320."
FT                   /evidence="ECO:0000269|PubMed:2156209"
FT   MUTAGEN         333..337
FT                   /note="RGRER->KGKEK: Reduced methylation by PRMT5. Reduced
FT                   nuclear localization. Decreased binding to promoters of
FT                   target genes. Reduced transcriptional activity. Decrease in
FT                   cell cycle arrest."
FT                   /evidence="ECO:0000269|PubMed:19011621"
FT   MUTAGEN         359
FT                   /note="P->D: Abolishes binding to USP7."
FT                   /evidence="ECO:0000269|PubMed:16402859"
FT   MUTAGEN         361
FT                   /note="G->E: Abolishes binding to USP7."
FT                   /evidence="ECO:0000269|PubMed:16402859"
FT   MUTAGEN         362
FT                   /note="S->A: Abolishes binding to USP7."
FT                   /evidence="ECO:0000269|PubMed:16402859"
FT   MUTAGEN         370
FT                   /note="K->R: Induces a decrease in methylation by SMYD2."
FT                   /evidence="ECO:0000269|PubMed:17108971"
FT   MUTAGEN         372
FT                   /note="K->R: Induces a decrease in protein stabilization."
FT                   /evidence="ECO:0000269|PubMed:15525938"
FT   MUTAGEN         373
FT                   /note="K->R: Abolishes dimethylation by EHMT1 and EHMT2."
FT                   /evidence="ECO:0000269|PubMed:20118233"
FT   MUTAGEN         382
FT                   /note="K->A: Abolishes acetylation by CREBBP."
FT                   /evidence="ECO:0000269|PubMed:10884347,
FT                   ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:17707234,
FT                   ECO:0000269|PubMed:20870725"
FT   MUTAGEN         382
FT                   /note="K->R: Abolishes monomethylation by KMT5A."
FT                   /evidence="ECO:0000269|PubMed:10884347,
FT                   ECO:0000269|PubMed:11740489, ECO:0000269|PubMed:17707234,
FT                   ECO:0000269|PubMed:20870725"
FT   MUTAGEN         383
FT                   /note="L->A: Abolishes S-315 phosphorylation by CDK2/cyclin
FT                   A."
FT                   /evidence="ECO:0000269|PubMed:10884347"
FT   MUTAGEN         385
FT                   /note="F->A: Reduced SUMO1 conjugation."
FT                   /evidence="ECO:0000269|PubMed:10884347,
FT                   ECO:0000269|PubMed:11124955"
FT   MUTAGEN         386
FT                   /note="K->A: Abolishes SUMO1 conjugation, in vitro and in
FT                   vivo."
FT                   /evidence="ECO:0000269|PubMed:11124955, ECO:0000269|Ref.37"
FT   MUTAGEN         387
FT                   /note="T->A: No effect SUMO1 conjugation."
FT                   /evidence="ECO:0000269|PubMed:11124955"
FT   MUTAGEN         388
FT                   /note="E->A: Abolishes SUMO1 conjugation."
FT                   /evidence="ECO:0000269|PubMed:11124955"
FT   HELIX           3..6
FT                   /evidence="ECO:0000244|PDB:5HOU"
FT   TURN            8..10
FT                   /evidence="ECO:0000244|PDB:5HOU"
FT   HELIX           19..21
FT                   /evidence="ECO:0000244|PDB:6T58"
FT   HELIX           22..27
FT                   /evidence="ECO:0000244|PDB:6V4F"
FT   STRAND          29..31
FT                   /evidence="ECO:0000244|PDB:2LY4"
FT   STRAND          33..35
FT                   /evidence="ECO:0000244|PDB:2L14"
FT   HELIX           36..38
FT                   /evidence="ECO:0000244|PDB:2B3G"
FT   HELIX           41..44
FT                   /evidence="ECO:0000244|PDB:2B3G"
FT   HELIX           47..55
FT                   /evidence="ECO:0000244|PDB:2B3G"
FT   TURN            105..108
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   STRAND          110..112
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   STRAND          118..120
FT                   /evidence="ECO:0000244|PDB:3Q05"
FT   TURN            121..123
FT                   /evidence="ECO:0000244|PDB:3Q05"
FT   STRAND          124..127
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   TURN            128..131
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   STRAND          132..135
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   STRAND          141..146
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   STRAND          148..150
FT                   /evidence="ECO:0000244|PDB:5UN8"
FT   STRAND          156..165
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   HELIX           166..168
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   HELIX           177..180
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   STRAND          181..183
FT                   /evidence="ECO:0000244|PDB:4KVP"
FT   STRAND          187..189
FT                   /evidence="ECO:0000244|PDB:6GGC"
FT   STRAND          194..199
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   STRAND          204..207
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   TURN            209..211
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   STRAND          214..219
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   TURN            225..227
FT                   /evidence="ECO:0000244|PDB:2FEJ"
FT   STRAND          228..236
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   HELIX           240..242
FT                   /evidence="ECO:0000244|PDB:3D07"
FT   TURN            243..248
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   STRAND          251..258
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   STRAND          260..262
FT                   /evidence="ECO:0000244|PDB:2ADY"
FT   STRAND          264..274
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   HELIX           278..287
FT                   /evidence="ECO:0000244|PDB:3D06"
FT   HELIX           288..290
FT                   /evidence="ECO:0000244|PDB:4HJE"
FT   HELIX           322..324
FT                   /evidence="ECO:0000244|PDB:3Q01"
FT   STRAND          327..334
FT                   /evidence="ECO:0000244|PDB:3Q01"
FT   HELIX           335..354
FT                   /evidence="ECO:0000244|PDB:1AIE"
FT   HELIX           375..380
FT                   /evidence="ECO:0000244|PDB:1YC5"
SQ   SEQUENCE   393 AA;  43653 MW;  AD5C149FD8106131 CRC64;
     MEEPQSDPSV EPPLSQETFS DLWKLLPENN VLSPLPSQAM DDLMLSPDDI EQWFTEDPGP
     DEAPRMPEAA PPVAPAPAAP TPAAPAPAPS WPLSSSVPSQ KTYQGSYGFR LGFLHSGTAK
     SVTCTYSPAL NKMFCQLAKT CPVQLWVDST PPPGTRVRAM AIYKQSQHMT EVVRRCPHHE
     RCSDSDGLAP PQHLIRVEGN LRVEYLDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS
     SCMGGMNRRP ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENLR KKGEPHHELP
     PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL KDAQAGKEPG
     GSRAHSSHLK SKKGQSTSRH KKLMFKTEGP DSD
//
ID   MITF_HUMAN              Reviewed;         526 AA.
AC   O75030; B4DJL2; D3K197; E9PFN0; Q14841; Q9P2V0; Q9P2V1; Q9P2V2; Q9P2Y8;
DT   21-FEB-2001, integrated into UniProtKB/Swiss-Prot.
DT   21-FEB-2001, sequence version 2.
DT   02-DEC-2020, entry version 208.
DE   RecName: Full=Microphthalmia-associated transcription factor;
DE   AltName: Full=Class E basic helix-loop-helix protein 32;
DE            Short=bHLHe32;
GN   Name=MITF; Synonyms=BHLHE32;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A2), NUCLEOTIDE SEQUENCE [MRNA] OF 1-35
RP   (ISOFORMS H1/H2), FUNCTION, TISSUE SPECIFICITY, AND INVOLVEMENT IN WS2-OA.
RC   TISSUE=Kidney;
RX   PubMed=9647758; DOI=10.1006/bbrc.1998.8838;
RA   Amae S., Fuse N., Yasumoto K., Sato S., Yajima I., Yamamoto H., Udono T.,
RA   Durlu Y.K., Tamai M., Takahashi K., Shibahara S.;
RT   "Identification of a novel isoform of microphthalmia-associated
RT   transcription factor that is enriched in retinal pigment epithelium.";
RL   Biochem. Biophys. Res. Commun. 247:710-715(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM M1).
RC   TISSUE=Skin;
RX   PubMed=8069297; DOI=10.1093/hmg/3.4.553;
RA   Tachibana M., Perez-Jurado L.A., Nakayama A., Hodgkinson C.A., Li X.,
RA   Schneider M., Miki T., Fex J., Francke U., Arnheiter H.;
RT   "Cloning of MITF, the human homolog of the mouse microphthalmia gene and
RT   assignment to chromosome 3p14.1-p12.3.";
RL   Hum. Mol. Genet. 3:553-557(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM MDEL), AND TISSUE SPECIFICITY.
RX   PubMed=20163701; DOI=10.1186/1741-7015-8-14;
RA   Wang Y., Radfar S., Liu S., Riker A.I., Khong H.T.;
RT   "Mitf-Mdel, a novel melanocyte/melanoma-specific isoform of microphthalmia-
RT   associated transcription factor-M, as a candidate biomarker for melanoma.";
RL   BMC Med. 8:14-14(2010).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM A2).
RC   TISSUE=Uterus;
RX   PubMed=11230166; DOI=10.1101/gr.gr1547r;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H., Lauber J.,
RA   Duesterhoeft A., Beyer A., Koehrer K., Strack N., Mewes H.-W.,
RA   Ottenwaelder B., Obermaier B., Tampe J., Heubner D., Wambutt R., Korn B.,
RA   Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and analysis of
RT   500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 12).
RC   TISSUE=Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS M1 AND M2).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PARTIAL NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS A1/A2; B1/B2; H1/H2 AND
RP   M1/M2).
RX   PubMed=10760582; DOI=10.1016/s0167-4781(00)00051-8;
RA   Udono T., Yasumoto K., Takeda K., Amae S., Watanabe K., Saito H., Fuse N.,
RA   Tachibana M., Takahashi K., Tamai M., Shibahara S.;
RT   "Structural organization of the human microphthalmia-associated
RT   transcription factor gene containing four alternative promoters.";
RL   Biochim. Biophys. Acta 1491:205-219(2000).
RN   [9]
RP   ALTERNATIVE SPLICING (ISOFORM C1/C2), AND TISSUE SPECIFICITY.
RC   TISSUE=Kidney;
RX   PubMed=10578055; DOI=10.1093/oxfordjournals.jbchem.a022548;
RA   Fuse N., Yasumoto K., Takeda K., Amae S., Yoshizawa M., Udono T.,
RA   Takahashi K., Tamai M., Tomita Y., Tachibana M., Shibahara S.;
RT   "Molecular cloning of cDNA encoding a novel microphthalmia-associated
RT   transcription factor isoform with a distinct amino-terminus.";
RL   J. Biochem. 126:1043-1051(1999).
RN   [10]
RP   PHOSPHORYLATION AT SER-180 AND SER-516, UBIQUITINATION, AND MUTAGENESIS OF
RP   SER-180 AND SER-516.
RX   PubMed=10673502;
RA   Wu M., Hemesath T.J., Takemoto C.M., Horstmann M.A., Wells A.G.,
RA   Price E.R., Fisher D.Z., Fisher D.E.;
RT   "c-Kit triggers dual phosphorylations, which couple activation and
RT   degradation of the essential melanocyte factor Mi.";
RL   Genes Dev. 14:301-312(2000).
RN   [11]
RP   FUNCTION, MUTAGENESIS OF SER-405, AND PHOSPHORYLATION AT SER-405.
RX   PubMed=10587587; DOI=10.1093/hmg/9.1.125;
RA   Takeda K., Takemoto C., Kobayashi I., Watanabe A., Nobukuni Y.,
RA   Fisher D.E., Tachibana M.;
RT   "Ser298 of MITF, a mutation site in Waardenburg syndrome type 2, is a
RT   phosphorylation site with functional significance.";
RL   Hum. Mol. Genet. 9:125-132(2000).
RN   [12]
RP   INTERACTION WITH KARS1.
RX   PubMed=14975237; DOI=10.1016/s1074-7613(04)00020-2;
RA   Lee Y.N., Nechushtan H., Figov N., Razin E.;
RT   "The function of lysyl-tRNA synthetase and Ap4A as signaling regulators of
RT   MITF activity in FcepsilonRI-activated mast cells.";
RL   Immunity 20:145-151(2004).
RN   [13]
RP   SUBUNIT, SUMOYLATION AT LYS-289 AND LYS-423, AND MUTAGENESIS OF LYS-289 AND
RP   LYS-423.
RX   PubMed=15507434; DOI=10.1074/jbc.m411757200;
RA   Miller A.J., Levy C., Davis I.J., Razin E., Fisher D.E.;
RT   "Sumoylation of MITF and its related family members TFE3 and TFEB.";
RL   J. Biol. Chem. 280:146-155(2005).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-414, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-414, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-491, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   FUNCTION, AND IDENTIFICATION IN A COMPLEX WITH HINT1 AND CTNNB1.
RX   PubMed=22647378; DOI=10.4161/cc.20765;
RA   Genovese G., Ghosh P., Li H., Rettino A., Sioletic S., Cittadini A.,
RA   Sgambato A.;
RT   "The tumor suppressor HINT1 regulates MITF and beta-catenin transcriptional
RT   activity in melanoma cells.";
RL   Cell Cycle 11:2206-2215(2012).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-414, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [19]
RP   FUNCTION, SUBCELLULAR LOCATION, INVOLVEMENT IN COMMAD, VARIANTS COMMAD
RP   ASN-313; ARG-324 DEL AND GLY-324, AND CHARACTERIZATION OF VARIANTS COMMAD
RP   ASN-313 AND ARG-324 DEL.
RX   PubMed=27889061; DOI=10.1016/j.ajhg.2016.11.004;
RA   George A., Zand D.J., Hufnagel R.B., Sharma R., Sergeev Y.V., Legare J.M.,
RA   Rice G.M., Scott Schwoerer J.A., Rius M., Tetri L., Gamm D.M., Bharti K.,
RA   Brooks B.P.;
RT   "Biallelic mutations in MITF cause coloboma, osteopetrosis, microphthalmia,
RT   macrocephaly, albinism, and deafness.";
RL   Am. J. Hum. Genet. 99:1388-1394(2016).
RN   [20]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND PHOSPHORYLATION.
RX   PubMed=28842328; DOI=10.1016/j.jid.2017.07.833;
RA   Regazzetti C., Sormani L., Debayle D., Bernerd F., Tulic M.K.,
RA   De Donatis G.M., Chignon-Sicard B., Rocchi S., Passeron T.;
RT   "Melanocytes Sense Blue Light and Regulate Pigmentation through Opsin-3.";
RL   J. Invest. Dermatol. 138:171-178(2018).
RN   [21]
RP   INVOLVEMENT IN DISEASE, AND VARIANT LYS-425.
RX   PubMed=27680874; DOI=10.1210/jc.2016-2103;
RA   Castro-Vega L.J., Kiando S.R., Burnichon N., Buffet A., Amar L., Simian C.,
RA   Berdelou A., Galan P., Schlumberger M., Bouatia-Naji N., Favier J.,
RA   Bressac-de Paillerets B., Gimenez-Roqueplo A.P.;
RT   "The MITF, p.E318K Variant, as a Risk Factor for Pheochromocytoma and
RT   Paraganglioma.";
RL   J. Clin. Endocrinol. Metab. 101:4764-4768(2016).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 357-403, SUBUNIT, AND COILED
RP   COIL.
RX   PubMed=24631970; DOI=10.1016/j.jsb.2014.03.002;
RA   Kukenshoner T., Wohlwend D., Niemoller C., Dondapati P., Speck J.,
RA   Adeniran A.V., Nieth A., Gerhardt S., Einsle O., Muller K.M., Arndt K.M.;
RT   "Improving coiled coil stability while maintaining specificity by a
RT   bacterial hitchhiker selection system.";
RL   J. Struct. Biol. 186:335-348(2014).
RN   [23]
RP   VARIANTS WS2A LYS-310; ARG-324 DEL; PRO-357; ASP-385 AND PRO-405.
RX   PubMed=8589691; DOI=10.1093/hmg/4.11.2131;
RA   Tassabehji M., Newton V.E., Liu X.-Z., Brady A., Donnai D.,
RA   Krajewska-Walasek M., Murday V., Norman A., Obersztyn E., Reardon W.,
RA   Rice J.C., Trembath R., Wieacker P., Whiteford M., Winter R., Read A.P.;
RT   "The mutational spectrum in Waardenburg syndrome.";
RL   Hum. Mol. Genet. 4:2131-2137(1995).
RN   [24]
RP   VARIANT TADS LYS-317.
RC   TISSUE=Blood;
RX   PubMed=10851256; DOI=10.1136/jmg.37.6.446;
RA   Smith S.D., Kelley P.M., Kenyon J.B., Hoover D.;
RT   "Tietz syndrome (hypopigmentation/deafness) caused by mutation of MITF.";
RL   J. Med. Genet. 37:446-448(2000).
RN   [25]
RP   INVOLVEMENT IN CMM8, AND VARIANT CMM8 LYS-425.
RX   PubMed=22012259; DOI=10.1038/nature10539;
RA   Bertolotto C., Lesueur F., Giuliano S., Strub T., de Lichy M., Bille K.,
RA   Dessen P., d'Hayer B., Mohamdi H., Remenieras A., Maubec E.,
RA   de la Fouchardiere A., Molinie V., Vabres P., Dalle S., Poulalhon N.,
RA   Martin-Denavit T., Thomas L., Andry-Benzaquen P., Dupin N., Boitier F.,
RA   Rossi A., Perrot J.L., Labeille B., Robert C., Escudier B., Caron O.,
RA   Brugieres L., Saule S., Gardie B., Gad S., Richard S., Couturier J.,
RA   Teh B.T., Ghiorzo P., Pastorino L., Puig S., Badenas C., Olsson H.,
RA   Ingvar C., Rouleau E., Lidereau R., Bahadoran P., Vielh P., Corda E.,
RA   Blanche H., Zelenika D., Galan P., Aubin F., Bachollet B., Becuwe C.,
RA   Berthet P., Bignon Y.J., Bonadona V., Bonafe J.L., Bonnet-Dupeyron M.N.,
RA   Cambazard F., Chevrant-Breton J., Coupier I., Dalac S., Demange L.,
RA   d'Incan M., Dugast C., Faivre L., Vincent-Fetita L., Gauthier-Villars M.,
RA   Gilbert B., Grange F., Grob J.J., Humbert P., Janin N., Joly P., Kerob D.,
RA   Lasset C., Leroux D., Levang J., Limacher J.M., Livideanu C., Longy M.,
RA   Lortholary A., Stoppa-Lyonnet D., Mansard S., Mansuy L., Marrou K.,
RA   Mateus C., Maugard C., Meyer N., Nogues C., Souteyrand P., Venat-Bouvet L.,
RA   Zattara H., Chaudru V., Lenoir G.M., Lathrop M., Davidson I., Avril M.F.,
RA   Demenais F., Ballotti R., Bressac-de Paillerets B.;
RT   "A SUMOylation-defective MITF germline mutation predisposes to melanoma and
RT   renal carcinoma.";
RL   Nature 480:94-98(2011).
RN   [26]
RP   INVOLVEMENT IN CMM8, VARIANT CMM8 LYS-425, AND CHARACTERIZATION OF VARIANT
RP   CMM8 LYS-425.
RX   PubMed=22080950; DOI=10.1038/nature10630;
RA   Yokoyama S., Woods S.L., Boyle G.M., Aoude L.G., MacGregor S., Zismann V.,
RA   Gartside M., Cust A.E., Haq R., Harland M., Taylor J.C., Duffy D.L.,
RA   Holohan K., Dutton-Regester K., Palmer J.M., Bonazzi V., Stark M.S.,
RA   Symmons J., Law M.H., Schmidt C., Lanagan C., O'Connor L., Holland E.A.,
RA   Schmid H., Maskiell J.A., Jetann J., Ferguson M., Jenkins M.A.,
RA   Kefford R.F., Giles G.G., Armstrong B.K., Aitken J.F., Hopper J.L.,
RA   Whiteman D.C., Pharoah P.D., Easton D.F., Dunning A.M., Newton-Bishop J.A.,
RA   Montgomery G.W., Martin N.G., Mann G.J., Bishop D.T., Tsao H., Trent J.M.,
RA   Fisher D.E., Hayward N.K., Brown K.M.;
RT   "A novel recurrent mutation in MITF predisposes to familial and sporadic
RT   melanoma.";
RL   Nature 480:99-103(2011).
RN   [27]
RP   VARIANT WS2A THR-294.
RX   PubMed=28236341; DOI=10.1002/humu.23206;
RA   Issa S., Bondurand N., Faubert E., Poisson S., Lecerf L., Nitschke P.,
RA   Deggouj N., Loundon N., Jonard L., David A., Sznajer Y., Blanchet P.,
RA   Marlin S., Pingault V.;
RT   "EDNRB mutations cause Waardenburg syndrome type II in the heterozygous
RT   state.";
RL   Hum. Mutat. 38:581-593(2017).
CC   -!- FUNCTION: Transcription factor that regulates the expression of genes
CC       with essential roles in cell differentiation, proliferation and
CC       survival. Binds to M-boxes (5'-TCATGTG-3') and symmetrical DNA
CC       sequences (E-boxes) (5'-CACGTG-3') found in the promoters of target
CC       genes, such as BCL2 and tyrosinase (TYR). Plays an important role in
CC       melanocyte development by regulating the expression of tyrosinase (TYR)
CC       and tyrosinase-related protein 1 (TYRP1). Plays a critical role in the
CC       differentiation of various cell types, such as neural crest-derived
CC       melanocytes, mast cells, osteoclasts and optic cup-derived retinal
CC       pigment epithelium. {ECO:0000269|PubMed:10587587,
CC       ECO:0000269|PubMed:22647378, ECO:0000269|PubMed:27889061,
CC       ECO:0000269|PubMed:9647758}.
CC   -!- SUBUNIT: Homodimer or heterodimer; dimerization is mediated via the
CC       coiled coil region (PubMed:24631970). Efficient DNA binding requires
CC       dimerization with another bHLH protein (PubMed:14975237). Binds DNA in
CC       the form of homodimer or heterodimer with either TFE3, TFEB or TFEC
CC       (PubMed:15507434). Interacts with KARS1 (PubMed:14975237). Identified
CC       in a complex with HINT1 and CTNNB1 (PubMed:22647378). Interacts with
CC       VSX2 (By similarity). {ECO:0000250|UniProtKB:Q08874,
CC       ECO:0000269|PubMed:14975237, ECO:0000269|PubMed:15507434,
CC       ECO:0000269|PubMed:22647378, ECO:0000269|PubMed:24631970}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:27889061,
CC       ECO:0000269|PubMed:28842328}. Cytoplasm {ECO:0000269|PubMed:28842328}.
CC       Note=Found exclusively in the nucleus upon phosphorylation.
CC       {ECO:0000269|PubMed:28842328}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=12;
CC         Comment=The X2-type isoforms differ from the X1-type isoforms by the
CC         absence of a 6 residue insert.;
CC       Name=A1;
CC         IsoId=O75030-1; Sequence=Displayed;
CC       Name=A2;
CC         IsoId=O75030-2; Sequence=VSP_002128;
CC       Name=B1;
CC         IsoId=O75030-3; Sequence=VSP_002124;
CC       Name=B2;
CC         IsoId=O75030-4; Sequence=VSP_002124, VSP_002128;
CC       Name=C1;
CC         IsoId=O75030-5; Sequence=VSP_002125;
CC       Name=C2;
CC         IsoId=O75030-6; Sequence=VSP_002125, VSP_002128;
CC       Name=H1;
CC         IsoId=O75030-7; Sequence=VSP_002126;
CC       Name=H2;
CC         IsoId=O75030-8; Sequence=VSP_002126, VSP_002128;
CC       Name=M1;
CC         IsoId=O75030-9; Sequence=VSP_002127;
CC       Name=M2;
CC         IsoId=O75030-10; Sequence=VSP_002127, VSP_002128;
CC       Name=Mdel;
CC         IsoId=O75030-11; Sequence=VSP_002127, VSP_045178, VSP_045179;
CC       Name=12;
CC         IsoId=O75030-12; Sequence=VSP_046438, VSP_045179;
CC   -!- TISSUE SPECIFICITY: Expressed in melanocytes (at protein level).
CC       {ECO:0000269|PubMed:28842328}.
CC   -!- TISSUE SPECIFICITY: [Isoform A2]: Expressed in the retinal pigment
CC       epithelium, brain, and placenta (PubMed:9647758). Expressed in the
CC       kidney (PubMed:9647758, PubMed:10578055). {ECO:0000269|PubMed:10578055,
CC       ECO:0000269|PubMed:9647758}.
CC   -!- TISSUE SPECIFICITY: [Isoform C2]: Expressed in the kidney and retinal
CC       pigment epithelium. {ECO:0000269|PubMed:10578055}.
CC   -!- TISSUE SPECIFICITY: [Isoform H1]: Expressed in the kidney.
CC       {ECO:0000269|PubMed:10578055, ECO:0000269|PubMed:9647758}.
CC   -!- TISSUE SPECIFICITY: [Isoform H2]: Expressed in the kidney.
CC       {ECO:0000269|PubMed:10578055, ECO:0000269|PubMed:9647758}.
CC   -!- TISSUE SPECIFICITY: [Isoform M1]: Expressed in melanocytes.
CC       {ECO:0000269|PubMed:20163701}.
CC   -!- TISSUE SPECIFICITY: [Isoform Mdel]: Expressed in melanocytes.
CC       {ECO:0000269|PubMed:20163701}.
CC   -!- DOMAIN: The leucine zipper region is part of a larger coiled coil.
CC       {ECO:0000305|PubMed:24631970}.
CC   -!- PTM: Phosphorylation at Ser-405 significantly enhances the ability to
CC       bind the tyrosinase promoter (PubMed:10587587). Phosphorylated at Ser-
CC       180 and Ser-516 following KIT signaling, triggering a short live
CC       activation: Phosphorylation at Ser-180 and Ser-516 by MAPK and RPS6KA1,
CC       respectively, activate the transcription factor activity but also
CC       promote ubiquitination and subsequent degradation by the proteasome
CC       (PubMed:10673502). Phosphorylated in response to blue light (415nm)
CC       (PubMed:28842328). {ECO:0000269|PubMed:10587587,
CC       ECO:0000269|PubMed:10673502, ECO:0000269|PubMed:28842328}.
CC   -!- PTM: Ubiquitinated following phosphorylation at Ser-180, leading to
CC       subsequent degradation by the proteasome. Deubiquitinated by USP13,
CC       preventing its degradation. {ECO:0000269|PubMed:10673502}.
CC   -!- DISEASE: Waardenburg syndrome 2A (WS2A) [MIM:193510]: WS2 is a
CC       genetically heterogeneous, autosomal dominant disorder characterized by
CC       sensorineural deafness, pigmentary disturbances, and absence of
CC       dystopia canthorum. The frequency of deafness is higher in WS2 than in
CC       WS1. {ECO:0000269|PubMed:28236341, ECO:0000269|PubMed:8589691}.
CC       Note=The disease is caused by mutations affecting the gene represented
CC       in this entry.
CC   -!- DISEASE: Waardenburg syndrome 2, with ocular albinism, autosomal
CC       recessive (WS2-OA) [MIM:103470]: A disorder characterized by the
CC       association of features typical of Waardenburg syndrome type 2 with
CC       ocular albinism. Patients manifest reduced visual acuity, albinotic
CC       fundus, deafness, hypomelanosis. {ECO:0000269|PubMed:9647758}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Tietz albinism-deafness syndrome (TADS) [MIM:103500]: An
CC       autosomal dominant disorder characterized by generalized
CC       hypopigmentation and congenital, bilateral, profound sensorineural
CC       deafness. {ECO:0000269|PubMed:10851256}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Melanoma, cutaneous malignant 8 (CMM8) [MIM:614456]: A
CC       malignant neoplasm of melanocytes, arising de novo or from a pre-
CC       existing benign nevus, which occurs most often in the skin but also may
CC       involve other sites. {ECO:0000269|PubMed:22012259,
CC       ECO:0000269|PubMed:22080950}. Note=Disease susceptibility is associated
CC       with variations affecting the gene represented in this entry.
CC   -!- DISEASE: Coloboma, osteopetrosis, microphthalmia, macrocephaly,
CC       albinism, and deafness (COMMAD) [MIM:617306]: An autosomal recessive
CC       syndrome characterized by severe microphthalmia, profound congenital
CC       sensorineural hearing loss, lack of pigment in the hair, skin, and
CC       eyes, macrocephaly, facial dysmorphism, and osteopetrosis.
CC       {ECO:0000269|PubMed:27889061}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry. An allelic combination
CC       involving at least one dominant-negative mutation, inherited in a
CC       recessive manner, represents the underlying molecular mechanism leading
CC       to COMMAD syndrome. {ECO:0000269|PubMed:27889061}.
CC   -!- DISEASE: Note=Variations affecting this gene are associated with
CC       susceptibility to pheochromocytomas and paragangliomas, rare neural
CC       crest-derived tumors with an approximate incidence of 1:300,000/year.
CC       {ECO:0000269|PubMed:27680874}.
CC   -!- SIMILARITY: Belongs to the MiT/TFE family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB006909; BAA32288.1; -; mRNA.
DR   EMBL; AB006989; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; Z29678; CAA82775.1; -; mRNA.
DR   EMBL; GU355676; ADB90411.1; -; mRNA.
DR   EMBL; AL110195; CAB53672.1; -; mRNA.
DR   EMBL; AK296129; BAG58874.1; -; mRNA.
DR   EMBL; AC099326; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC104445; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC104449; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC124915; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC026961; AAH26961.1; -; mRNA.
DR   EMBL; BC065243; AAH65243.1; -; mRNA.
DR   EMBL; AF034755; AAC39639.1; -; Genomic_DNA.
DR   EMBL; AB032359; BAA95208.1; -; Genomic_DNA.
DR   EMBL; AB032358; BAA95207.1; -; Genomic_DNA.
DR   EMBL; AB032357; BAA95206.1; -; Genomic_DNA.
DR   EMBL; AB009608; BAA95209.1; ALT_TERM; Genomic_DNA.
DR   CCDS; CCDS2913.1; -. [O75030-9]
DR   CCDS; CCDS43106.1; -. [O75030-2]
DR   CCDS; CCDS43107.1; -. [O75030-10]
DR   CCDS; CCDS46865.1; -. [O75030-8]
DR   CCDS; CCDS46866.2; -. [O75030-11]
DR   CCDS; CCDS54607.1; -. [O75030-12]
DR   CCDS; CCDS87108.1; -. [O75030-1]
DR   PIR; I38024; I38024.
DR   PIR; T14752; T14752.
DR   RefSeq; NP_000239.1; NM_000248.3. [O75030-9]
DR   RefSeq; NP_001171896.1; NM_001184967.1. [O75030-12]
DR   RefSeq; NP_006713.1; NM_006722.2. [O75030-6]
DR   RefSeq; NP_937801.1; NM_198158.2. [O75030-10]
DR   RefSeq; NP_937802.1; NM_198159.2. [O75030-2]
DR   RefSeq; NP_937820.1; NM_198177.2. [O75030-8]
DR   RefSeq; NP_937821.2; NM_198178.2. [O75030-11]
DR   RefSeq; XP_005264811.1; XM_005264754.1.
DR   RefSeq; XP_005264812.1; XM_005264755.3.
DR   RefSeq; XP_016861933.1; XM_017006444.1.
DR   RefSeq; XP_016861937.1; XM_017006448.1.
DR   PDB; 4C7N; X-ray; 2.10 A; A=357-403.
DR   PDBsum; 4C7N; -.
DR   SMR; O75030; -.
DR   BioGRID; 110432; 32.
DR   DIP; DIP-59573N; -.
DR   IntAct; O75030; 14.
DR   MINT; O75030; -.
DR   STRING; 9606.ENSP00000295600; -.
DR   ChEMBL; CHEMBL1741165; -.
DR   iPTMnet; O75030; -.
DR   PhosphoSitePlus; O75030; -.
DR   BioMuta; MITF; -.
DR   jPOST; O75030; -.
DR   MassIVE; O75030; -.
DR   MaxQB; O75030; -.
DR   PaxDb; O75030; -.
DR   PeptideAtlas; O75030; -.
DR   PRIDE; O75030; -.
DR   ProteomicsDB; 12779; -.
DR   ProteomicsDB; 20138; -.
DR   ProteomicsDB; 49704; -. [O75030-1]
DR   ProteomicsDB; 49705; -. [O75030-10]
DR   ProteomicsDB; 49706; -. [O75030-2]
DR   ProteomicsDB; 49707; -. [O75030-3]
DR   ProteomicsDB; 49708; -. [O75030-4]
DR   ProteomicsDB; 49709; -. [O75030-5]
DR   ProteomicsDB; 49710; -. [O75030-6]
DR   ProteomicsDB; 49711; -. [O75030-7]
DR   ProteomicsDB; 49712; -. [O75030-8]
DR   ProteomicsDB; 49713; -. [O75030-9]
DR   Antibodypedia; 923; 876 antibodies.
DR   Ensembl; ENST00000314557; ENSP00000324246; ENSG00000187098. [O75030-10]
DR   Ensembl; ENST00000314589; ENSP00000324443; ENSG00000187098. [O75030-8]
DR   Ensembl; ENST00000328528; ENSP00000327867; ENSG00000187098. [O75030-6]
DR   Ensembl; ENST00000352241; ENSP00000295600; ENSG00000187098. [O75030-2]
DR   Ensembl; ENST00000394351; ENSP00000377880; ENSG00000187098. [O75030-9]
DR   Ensembl; ENST00000448226; ENSP00000391803; ENSG00000187098. [O75030-1]
DR   Ensembl; ENST00000472437; ENSP00000418845; ENSG00000187098. [O75030-12]
DR   Ensembl; ENST00000531774; ENSP00000435909; ENSG00000187098. [O75030-11]
DR   Ensembl; ENST00000642352; ENSP00000494105; ENSG00000187098. [O75030-2]
DR   GeneID; 4286; -.
DR   KEGG; hsa:4286; -.
DR   UCSC; uc003dnz.4; human. [O75030-1]
DR   CTD; 4286; -.
DR   DisGeNET; 4286; -.
DR   EuPathDB; HostDB:ENSG00000187098.14; -.
DR   GeneCards; MITF; -.
DR   HGNC; HGNC:7105; MITF.
DR   HPA; ENSG00000187098; Low tissue specificity.
DR   MalaCards; MITF; -.
DR   MIM; 103470; phenotype.
DR   MIM; 103500; phenotype.
DR   MIM; 156845; gene.
DR   MIM; 193510; phenotype.
DR   MIM; 614456; phenotype.
DR   MIM; 617306; phenotype.
DR   neXtProt; NX_O75030; -.
DR   OpenTargets; ENSG00000187098; -.
DR   Orphanet; 404511; Clear cell papillary renal cell carcinoma.
DR   Orphanet; 618; Familial melanoma.
DR   Orphanet; 293822; MITF-related melanoma and renal cell carcinoma predisposition syndrome.
DR   Orphanet; 352740; Ocular albinism with congenital sensorineural deafness.
DR   Orphanet; 319298; Papillary renal cell carcinoma.
DR   Orphanet; 42665; Tietz syndrome.
DR   Orphanet; 895; Waardenburg syndrome type 2.
DR   Orphanet; 897; Waardenburg-Shah syndrome.
DR   PharmGKB; PA30823; -.
DR   eggNOG; KOG1318; Eukaryota.
DR   GeneTree; ENSGT00940000156326; -.
DR   HOGENOM; CLU_031638_2_0_1; -.
DR   InParanoid; O75030; -.
DR   OMA; MANTXCI; -.
DR   OrthoDB; 1211990at2759; -.
DR   PhylomeDB; O75030; -.
DR   TreeFam; TF317174; -.
DR   PathwayCommons; O75030; -.
DR   Reactome; R-HSA-3232118; SUMOylation of transcription factors.
DR   SignaLink; O75030; -.
DR   SIGNOR; O75030; -.
DR   BioGRID-ORCS; 4286; 22 hits in 871 CRISPR screens.
DR   ChiTaRS; MITF; human.
DR   GeneWiki; Microphthalmia-associated_transcription_factor; -.
DR   GenomeRNAi; 4286; -.
DR   Pharos; O75030; Tbio.
DR   PRO; PR:O75030; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; O75030; protein.
DR   Bgee; ENSG00000187098; Expressed in pigmented layer of retina and 248 other tissues.
DR   ExpressionAtlas; O75030; baseline and differential.
DR   Genevisible; O75030; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; ISA:NTNU_SB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IEA:Ensembl.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; NAS:BHF-UCL.
DR   GO; GO:0070888; F:E-box binding; IDA:UniProtKB.
DR   GO; GO:0046983; F:protein dimerization activity; IEA:Ensembl.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0046849; P:bone remodeling; IEA:Ensembl.
DR   GO; GO:0043010; P:camera-type eye development; IEA:Ensembl.
DR   GO; GO:0044336; P:canonical Wnt signaling pathway involved in negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0045165; P:cell fate commitment; IEA:Ensembl.
DR   GO; GO:0030318; P:melanocyte differentiation; IBA:GO_Central.
DR   GO; GO:0030336; P:negative regulation of cell migration; IMP:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:0030316; P:osteoclast differentiation; IEA:Ensembl.
DR   GO; GO:2000144; P:positive regulation of DNA-templated transcription, initiation; IDA:CACAO.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:CACAO.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0065003; P:protein-containing complex assembly; IDA:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0045670; P:regulation of osteoclast differentiation; IEA:Ensembl.
DR   GO; GO:2001141; P:regulation of RNA biosynthetic process; IDA:CACAO.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IMP:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:Ensembl.
DR   CDD; cd00083; HLH; 1.
DR   Gene3D; 4.10.280.10; -; 1.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR036638; HLH_DNA-bd_sf.
DR   InterPro; IPR021802; MiT/TFE_C.
DR   InterPro; IPR031867; MiT/TFE_N.
DR   InterPro; IPR030532; MITF.
DR   PANTHER; PTHR45776:SF4; PTHR45776:SF4; 1.
DR   Pfam; PF11851; DUF3371; 1.
DR   Pfam; PF00010; HLH; 1.
DR   Pfam; PF15951; MITF_TFEB_C_3_N; 1.
DR   SMART; SM00353; HLH; 1.
DR   SUPFAM; SSF47459; SSF47459; 1.
DR   PROSITE; PS50888; BHLH; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Albinism; Alternative splicing; Coiled coil;
KW   Cytoplasm; Deafness; Developmental protein; Disease mutation; DNA-binding;
KW   Isopeptide bond; Microphthalmia; Nucleus; Osteopetrosis; Phosphoprotein;
KW   Polymorphism; Reference proteome; Transcription; Transcription regulation;
KW   Ubl conjugation; Waardenburg syndrome.
FT   CHAIN           1..526
FT                   /note="Microphthalmia-associated transcription factor"
FT                   /id="PRO_0000127276"
FT   DOMAIN          311..364
FT                   /note="bHLH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00981"
FT   REGION          224..295
FT                   /note="Transactivation"
FT   REGION          374..395
FT                   /note="Leucine-zipper"
FT                   /evidence="ECO:0000305|PubMed:24631970"
FT   REGION          401..431
FT                   /note="DNA binding regulation"
FT   COILED          355..402
FT                   /evidence="ECO:0000305|PubMed:24631970"
FT   MOD_RES         180
FT                   /note="Phosphoserine; by MAPK"
FT                   /evidence="ECO:0000269|PubMed:10673502"
FT   MOD_RES         405
FT                   /note="Phosphoserine; by GSK3"
FT                   /evidence="ECO:0000269|PubMed:10587587"
FT   MOD_RES         414
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18220336,
FT                   ECO:0000244|PubMed:18669648, ECO:0000244|PubMed:23186163"
FT   MOD_RES         491
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:20068231"
FT   MOD_RES         516
FT                   /note="Phosphoserine; by RPS6KA1"
FT                   /evidence="ECO:0000269|PubMed:10673502"
FT   CROSSLNK        289
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000269|PubMed:15507434"
FT   CROSSLNK        423
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000269|PubMed:15507434"
FT   VAR_SEQ         1..118
FT                   /note="MQSESGIVPDFEVGEEFHEEPKTYYELKSQPLKSSSSAEHPGASKPPISSSS
FT                   MTSRILLRQQLMREQMQEQERREQQQKLQAAQFMQQRVPVSQTPAINVSVPTTLPSATQ
FT                   VPMEVLK -> MLEMLEYNHYQ (in isoform M1, isoform M2 and
FT                   isoform Mdel)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:20163701, ECO:0000303|PubMed:8069297"
FT                   /id="VSP_002127"
FT   VAR_SEQ         1..52
FT                   /note="Missing (in isoform 12)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_046438"
FT   VAR_SEQ         1..35
FT                   /note="MQSESGIVPDFEVGEEFHEEPKTYYELKSQPLKSS -> MEALRVQMFMPCS
FT                   FESLYL (in isoform H1 and isoform H2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_002126"
FT   VAR_SEQ         1..34
FT                   /note="MQSESGIVPDFEVGEEFHEEPKTYYELKSQPLKS -> MLYAFWFSH (in
FT                   isoform B1 and isoform B2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_002124"
FT   VAR_SEQ         1..34
FT                   /note="MQSESGIVPDFEVGEEFHEEPKTYYELKSQPLKS -> MGHLENTSVVFPRA
FT                   IFSLCEKETRKLTLCLFSR (in isoform C1 and isoform C2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_002125"
FT   VAR_SEQ         139..194
FT                   /note="Missing (in isoform Mdel)"
FT                   /evidence="ECO:0000303|PubMed:20163701"
FT                   /id="VSP_045178"
FT   VAR_SEQ         293..298
FT                   /note="Missing (in isoform Mdel and isoform 12)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:20163701"
FT                   /id="VSP_045179"
FT   VAR_SEQ         294..299
FT                   /note="Missing (in isoform A2, isoform B2, isoform C2,
FT                   isoform H2 and isoform M2)"
FT                   /evidence="ECO:0000303|PubMed:11230166,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:9647758"
FT                   /id="VSP_002128"
FT   VARIANT         294
FT                   /note="A -> T (in WS2A; unknown pathological significance;
FT                   dbSNP:rs1559742541)"
FT                   /evidence="ECO:0000269|PubMed:28236341"
FT                   /id="VAR_078311"
FT   VARIANT         310
FT                   /note="R -> K (in WS2A; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:8589691"
FT                   /id="VAR_010297"
FT   VARIANT         313
FT                   /note="K -> N (in COMMAD; has both cytoplasmic and nuclear
FT                   localization; decreased binding to M-box or E-box DNA
FT                   sequences; dbSNP:rs1057519325)"
FT                   /evidence="ECO:0000269|PubMed:27889061"
FT                   /id="VAR_077922"
FT   VARIANT         317
FT                   /note="N -> K (in TADS; dbSNP:rs104893745)"
FT                   /evidence="ECO:0000269|PubMed:10851256"
FT                   /id="VAR_010298"
FT   VARIANT         324
FT                   /note="R -> G (in COMMAD; dbSNP:rs1057519326)"
FT                   /evidence="ECO:0000269|PubMed:27889061"
FT                   /id="VAR_077923"
FT   VARIANT         324
FT                   /note="Missing (in WS2A and COMMAD; does not localize to
FT                   the nucleus; does not bind M-box or E-box DNA sequences;
FT                   loss of function in transcriptional regulation; dominant
FT                   negative effect)"
FT                   /evidence="ECO:0000269|PubMed:27889061,
FT                   ECO:0000269|PubMed:8589691"
FT                   /id="VAR_010299"
FT   VARIANT         357
FT                   /note="S -> P (in WS2A; dbSNP:rs104893744)"
FT                   /evidence="ECO:0000269|PubMed:8589691"
FT                   /id="VAR_010300"
FT   VARIANT         385
FT                   /note="N -> D (in WS2A)"
FT                   /evidence="ECO:0000269|PubMed:8589691"
FT                   /id="VAR_010301"
FT   VARIANT         405
FT                   /note="S -> P (in WS2A; dbSNP:rs104893747)"
FT                   /evidence="ECO:0000269|PubMed:8589691"
FT                   /id="VAR_010302"
FT   VARIANT         425
FT                   /note="E -> K (in CMM8; associated with disease
FT                   susceptibility; also associated with pheochromocytomas and
FT                   paragangliomas susceptibility; results in impaired
FT                   sumoylation; dbSNP:rs149617956)"
FT                   /evidence="ECO:0000269|PubMed:22012259,
FT                   ECO:0000269|PubMed:22080950, ECO:0000269|PubMed:27680874"
FT                   /id="VAR_067367"
FT   MUTAGEN         180
FT                   /note="S->A: Abolishes both transcription factor activity
FT                   and ubiquitination, leading to an inert and stable protein;
FT                   when associated with A-516."
FT                   /evidence="ECO:0000269|PubMed:10673502"
FT   MUTAGEN         289
FT                   /note="K->R: Loss of sumoylation; when associated with R-
FT                   423."
FT                   /evidence="ECO:0000269|PubMed:15507434"
FT   MUTAGEN         405
FT                   /note="S->A,P: Loss of phosphorylation and function."
FT                   /evidence="ECO:0000269|PubMed:10587587"
FT   MUTAGEN         423
FT                   /note="K->R: Loss of sumoylation; when associated with R-
FT                   289."
FT                   /evidence="ECO:0000269|PubMed:15507434"
FT   MUTAGEN         516
FT                   /note="S->A: Abolishes both transcription factor activity
FT                   and ubiquitination, leading to an inert and stable protein;
FT                   when associated with A-180."
FT                   /evidence="ECO:0000269|PubMed:10673502"
FT   CONFLICT        241
FT                   /note="I -> T (in Ref. 5; BAG58874)"
FT                   /evidence="ECO:0000305"
FT   HELIX           357..401
FT                   /evidence="ECO:0000244|PDB:4C7N"
SQ   SEQUENCE   526 AA;  58795 MW;  136EBED3044C1986 CRC64;
     MQSESGIVPD FEVGEEFHEE PKTYYELKSQ PLKSSSSAEH PGASKPPISS SSMTSRILLR
     QQLMREQMQE QERREQQQKL QAAQFMQQRV PVSQTPAINV SVPTTLPSAT QVPMEVLKVQ
     THLENPTKYH IQQAQRQQVK QYLSTTLANK HANQVLSLPC PNQPGDHVMP PVPGSSAPNS
     PMAMLTLNSN CEKEGFYKFE EQNRAESECP GMNTHSRASC MQMDDVIDDI ISLESSYNEE
     ILGLMDPALQ MANTLPVSGN LIDLYGNQGL PPPGLTISNS CPANLPNIKR ELTACIFPTE
     SEARALAKER QKKDNHNLIE RRRRFNINDR IKELGTLIPK SNDPDMRWNK GTILKASVDY
     IRKLQREQQR AKELENRQKK LEHANRHLLL RIQELEMQAR AHGLSLIPST GLCSPDLVNR
     IIKQEPVLEN CSQDLLQHHA DLTCTTTLDL TDGTITFNNN LGTGTEANQA YSVPTKMGSK
     LEDILMDDTL SPVGVTDPLL SSVSPGASKT SSRRSSMSME ETEHTC
//
ID   MTAP_HUMAN              Reviewed;         283 AA.
AC   Q13126; I2G7M5; I2G7M6; I2G7M7; I2G7M8; I2G7M9; I2G7N0; Q5T3P3; Q9H010;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2007, sequence version 2.
DT   02-DEC-2020, entry version 208.
DE   RecName: Full=S-methyl-5'-thioadenosine phosphorylase {ECO:0000255|HAMAP-Rule:MF_03155};
DE            EC=2.4.2.28 {ECO:0000255|HAMAP-Rule:MF_03155};
DE   AltName: Full=5'-methylthioadenosine phosphorylase {ECO:0000255|HAMAP-Rule:MF_03155};
DE            Short=MTA phosphorylase {ECO:0000255|HAMAP-Rule:MF_03155};
DE            Short=MTAP {ECO:0000255|HAMAP-Rule:MF_03155};
DE            Short=MTAPase {ECO:0000255|HAMAP-Rule:MF_03155};
GN   Name=MTAP {ECO:0000255|HAMAP-Rule:MF_03155}; Synonyms=MSAP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ILE-56.
RC   TISSUE=Epidermis;
RX   PubMed=7604019; DOI=10.1073/pnas.92.14.6489;
RA   Olopade O.I., Pomykala H.M., Hagos F., Sveen L.W., Espinosa R. III,
RA   Dreyling M.H., Gursky S., Stadler W.M., le Beau M.M., Bohlander S.K.;
RT   "Construction of a 2.8-megabase yeast artificial chromosome contig and
RT   cloning of the human methylthioadenosine phosphorylase gene from the tumor
RT   suppressor region on 9p21.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:6489-6493(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RC   TISSUE=Placenta;
RX   PubMed=8650244; DOI=10.1073/pnas.93.12.6203;
RA   Nobori T., Takabayashi K., Tran P., Orvis L., Batova A., Yu A.L.,
RA   Carson D.A.;
RT   "Genomic cloning of methylthioadenosine phosphorylase: a purine metabolic
RT   enzyme deficient in multiple different cancers.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:6203-6208(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3; 4; 5; 6 AND 7), AND INVOLVEMENT
RP   IN DMSMFH.
RX   PubMed=22464254; DOI=10.1016/j.ajhg.2012.02.024;
RA   Camacho-Vanegas O., Camacho S.C., Till J., Miranda-Lorenzo I., Terzo E.,
RA   Ramirez M.C., Schramm V., Cordovano G., Watts G., Mehta S., Kimonis V.,
RA   Hoch B., Philibert K.D., Raabe C.A., Bishop D.F., Glucksman M.J.,
RA   Martignetti J.A.;
RT   "Primate genome gain and loss: a bone dysplasia, muscular dystrophy, and
RT   bone cancer syndrome resulting from mutated retroviral-derived MTAP
RT   transcripts.";
RL   Am. J. Hum. Genet. 90:614-627(2012).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ILE-56.
RC   TISSUE=Colon;
RA   Li Q., Cao W.-X., Zhang Y., Shi M.-M., Liu B.-Y., Zhu Z.-G., Lin Y.-Z.;
RT   "Identification of human methylthioadenosine phosphorylase (MTAP) mRNA
RT   mutation in colon cancer cell line COLO 205.";
RL   Submitted (AUG-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ILE-56.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBUNIT.
RX   PubMed=3091600;
RA   Della Ragione F., Carteni-Farina M., Gragnaniello V., Schettino M.I.,
RA   Zappia V.;
RT   "Purification and characterization of 5'-deoxy-5'-methylthioadenosine
RT   phosphorylase from human placenta.";
RL   J. Biol. Chem. 261:12324-12329(1986).
RN   [9]
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND SUBUNIT.
RX   PubMed=8687427; DOI=10.1006/bbrc.1996.0926;
RA   Ragione F.D., Takabayashi K., Mastropietro S., Mercurio C., Oliva A.,
RA   Russo G.L., Pietra V.D., Borriello A., Nobori T., Carson D.A., Zappia V.;
RT   "Purification and characterization of recombinant human 5'-
RT   methylthioadenosine phosphorylase: definite identification of coding
RT   cDNA.";
RL   Biochem. Biophys. Res. Commun. 223:514-519(1996).
RN   [10]
RP   INVOLVEMENT IN OSTEOSARCOMA.
RX   PubMed=11895909;
RA   Garcia-Castellano J.M., Villanueva A., Healey J.H., Sowers R.,
RA   Cordon-Cardo C., Huvos A., Bertino J.R., Meyers P., Gorlick R.;
RT   "Methylthioadenosine phosphorylase gene deletions are common in
RT   osteosarcoma.";
RL   Clin. Cancer Res. 8:782-787(2002).
RN   [11]
RP   INVOLVEMENT IN OSTEOSARCOMA.
RX   PubMed=17912432;
RA   Miyazaki S., Nishioka J., Shiraishi T., Matsumine A., Uchida A., Nobori T.;
RT   "Methylthioadenosine phosphorylase deficiency in Japanese osteosarcoma
RT   patients.";
RL   Int. J. Oncol. 31:1069-1076(2007).
RN   [12]
RP   INVOLVEMENT IN MALIGNANT MELANOMA.
RX   PubMed=19097084; DOI=10.1002/jcb.21984;
RA   Stevens A.P., Spangler B., Wallner S., Kreutz M., Dettmer K., Oefner P.J.,
RA   Bosserhoff A.K.;
RT   "Direct and tumor microenvironment mediated influences of 5'-deoxy-5'-
RT   (methylthio)adenosine on tumor progression of malignant melanoma.";
RL   J. Cell. Biochem. 106:210-219(2009).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   INVOLVEMENT IN GASTRIC CANCER.
RX   PubMed=21412930; DOI=10.1002/gcc.20867;
RA   Kim J., Kim M.A., Min S.Y., Jee C.D., Lee H.E., Kim W.H.;
RT   "Downregulation of methylthioadenosine phosphorylase by homozygous deletion
RT   in gastric carcinoma.";
RL   Genes Chromosomes Cancer 50:421-433(2011).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) IN COMPLEX WITH MTA.
RX   PubMed=10404592; DOI=10.1016/s0969-2126(99)80084-7;
RA   Appleby T.C., Erion M.D., Ealick S.E.;
RT   "The structure of human 5'-deoxy-5'-methylthioadenosine phosphorylase at
RT   1.7-A resolution provides insights into substrate binding and catalysis.";
RL   Structure 7:629-641(1999).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.03 ANGSTROMS) IN COMPLEX WITH SUBSTRATE ANALOGS.
RX   PubMed=15122881; DOI=10.1021/bi035492h;
RA   Lee J.E., Settembre E.C., Cornell K.A., Riscoe M.K., Sufrin J.R.,
RA   Ealick S.E., Howell P.L.;
RT   "Structural comparison of MTA phosphorylase and MTA/AdoHcy nucleosidase
RT   explains substrate preferences and identifies regions exploitable for
RT   inhibitor design.";
RL   Biochemistry 43:5159-5169(2004).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) IN COMPLEX WITH INHIBITORS.
RX   PubMed=14705926; DOI=10.1021/bi0358420;
RA   Singh V., Shi W., Evans G.B., Tyler P.C., Furneaux R.H., Almo S.C.,
RA   Schramm V.L.;
RT   "Picomolar transition state analogue inhibitors of human 5'-
RT   methylthioadenosine phosphorylase and X-ray structure with MT-immucillin-
RT   A.";
RL   Biochemistry 43:9-18(2004).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 227-237.
RX   PubMed=20934997; DOI=10.3324/haematol.2010.030924;
RA   Bade-Doding C., Theodossis A., Gras S., Kjer-Nielsen L., Eiz-Vesper B.,
RA   Seltsam A., Huyton T., Rossjohn J., McCluskey J., Blasczyk R.;
RT   "The impact of human leukocyte antigen (HLA) micropolymorphism on ligand
RT   specificity within the HLA-B*41 allotypic family.";
RL   Haematologica 96:110-118(2011).
CC   -!- FUNCTION: Catalyzes the reversible phosphorylation of S-methyl-5'-
CC       thioadenosine (MTA) to adenine and 5-methylthioribose-1-phosphate.
CC       Involved in the breakdown of MTA, a major by-product of polyamine
CC       biosynthesis. Responsible for the first step in the methionine salvage
CC       pathway after MTA has been generated from S-adenosylmethionine. Has
CC       broad substrate specificity with 6-aminopurine nucleosides as preferred
CC       substrates. {ECO:0000255|HAMAP-Rule:MF_03155,
CC       ECO:0000269|PubMed:3091600}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=phosphate + S-methyl-5'-thioadenosine = adenine + S-methyl-5-
CC         thio-alpha-D-ribose 1-phosphate; Xref=Rhea:RHEA:11852,
CC         ChEBI:CHEBI:16708, ChEBI:CHEBI:17509, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:58533; EC=2.4.2.28; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_03155};
CC   -!- ACTIVITY REGULATION: Inhibited by 5'-methylthiotubercin and 5'-
CC       chloroformycin.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=5 uM for S-methyl-5'-thioadenosine {ECO:0000269|PubMed:3091600,
CC         ECO:0000269|PubMed:8687427};
CC         KM=580 uM for phosphate {ECO:0000269|PubMed:3091600,
CC         ECO:0000269|PubMed:8687427};
CC         KM=23 uM for adenine {ECO:0000269|PubMed:3091600,
CC         ECO:0000269|PubMed:8687427};
CC         KM=8 uM for S-methyl-5-thio-alpha-D-ribose 1-phosphate
CC         {ECO:0000269|PubMed:3091600, ECO:0000269|PubMed:8687427};
CC       pH dependence:
CC         Optimum pH is 7.2-7.6. {ECO:0000269|PubMed:3091600,
CC         ECO:0000269|PubMed:8687427};
CC   -!- PATHWAY: Amino-acid biosynthesis; L-methionine biosynthesis via salvage
CC       pathway; S-methyl-5-thio-alpha-D-ribose 1-phosphate from S-methyl-5'-
CC       thioadenosine (phosphorylase route): step 1/1. {ECO:0000255|HAMAP-
CC       Rule:MF_03155}.
CC   -!- SUBUNIT: Homotrimer. {ECO:0000255|HAMAP-Rule:MF_03155,
CC       ECO:0000269|PubMed:10404592, ECO:0000269|PubMed:14705926,
CC       ECO:0000269|PubMed:15122881, ECO:0000269|PubMed:3091600,
CC       ECO:0000269|PubMed:8687427}.
CC   -!- INTERACTION:
CC       Q13126; Q9H3R5: CENPH; NbExp=3; IntAct=EBI-2547776, EBI-1003700;
CC       Q13126; Q9P0I2: EMC3; NbExp=3; IntAct=EBI-2547776, EBI-1054670;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus {ECO:0000255|HAMAP-
CC       Rule:MF_03155}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC       Name=1;
CC         IsoId=Q13126-1; Sequence=Displayed;
CC       Name=2; Synonyms=MTAP_v1;
CC         IsoId=Q13126-2; Sequence=VSP_044074;
CC       Name=3; Synonyms=MTAP_v2;
CC         IsoId=Q13126-3; Sequence=VSP_044075;
CC       Name=4; Synonyms=MTAP_v3;
CC         IsoId=Q13126-4; Sequence=VSP_044076;
CC       Name=5; Synonyms=MTAP_v4;
CC         IsoId=Q13126-5; Sequence=VSP_044071;
CC       Name=6; Synonyms=MTAP_v5;
CC         IsoId=Q13126-6; Sequence=VSP_044072;
CC       Name=7; Synonyms=MTAP_v6;
CC         IsoId=Q13126-7; Sequence=VSP_044073;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed.
CC   -!- DISEASE: Diaphyseal medullary stenosis with malignant fibrous
CC       histiocytoma (DMSMFH) [MIM:112250]: An autosomal dominant bone
CC       dysplasia characterized by pathologic fractures due to abnormal
CC       cortical growth and diaphyseal medullary stenosis. The fractures heal
CC       poorly, and there is progressive bowing of the lower extremities. Some
CC       patients show a limb-girdle myopathy, with muscle weakness and atrophy.
CC       Approximately 35% of affected individuals develop an aggressive form of
CC       bone sarcoma consistent with malignant fibrous histiocytoma or
CC       osteosarcoma. {ECO:0000269|PubMed:22464254}. Note=The disease is caused
CC       by mutations affecting the gene represented in this entry. DMSMFH
CC       causing mutations found in MTAP exon 9 result in exon skipping and
CC       dysregulated alternative splicing of all MTAP isoforms
CC       (PubMed:22464254). {ECO:0000269|PubMed:22464254}.
CC   -!- DISEASE: Note=Loss of MTAP activity may play a role in human cancer.
CC       MTAP loss has been reported in a number of cancers, including
CC       osteosarcoma, malignant melanoma and gastric cancer.
CC   -!- SIMILARITY: Belongs to the PNP/MTAP phosphorylase family. MTAP
CC       subfamily. {ECO:0000255|HAMAP-Rule:MF_03155}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U22233; AAA81646.1; -; mRNA.
DR   EMBL; L40432; AAG38871.1; -; mRNA.
DR   EMBL; L42634; AAR24607.2; -; Genomic_DNA.
DR   EMBL; L42627; AAR24607.2; JOINED; Genomic_DNA.
DR   EMBL; L42628; AAR24607.2; JOINED; Genomic_DNA.
DR   EMBL; L42629; AAR24607.2; JOINED; Genomic_DNA.
DR   EMBL; L42630; AAR24607.2; JOINED; Genomic_DNA.
DR   EMBL; L42631; AAR24607.2; JOINED; Genomic_DNA.
DR   EMBL; L42632; AAR24607.2; JOINED; Genomic_DNA.
DR   EMBL; L42633; AAR24607.2; JOINED; Genomic_DNA.
DR   EMBL; HE654772; CCF77345.1; -; mRNA.
DR   EMBL; HE654773; CCF77346.1; -; mRNA.
DR   EMBL; HE654774; CCF77347.1; -; mRNA.
DR   EMBL; HE654775; CCF77348.1; -; mRNA.
DR   EMBL; HE654776; CCF77349.1; -; mRNA.
DR   EMBL; HE654777; CCF77350.1; -; mRNA.
DR   EMBL; AY712791; AAU04442.1; -; mRNA.
DR   EMBL; AL359922; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471071; EAW58606.1; -; Genomic_DNA.
DR   EMBL; BC026106; AAH26106.1; -; mRNA.
DR   CCDS; CCDS6509.1; -. [Q13126-1]
DR   PIR; I38969; I38969.
DR   RefSeq; NP_002442.2; NM_002451.3. [Q13126-1]
DR   PDB; 1CB0; X-ray; 1.70 A; A=1-283.
DR   PDB; 1CG6; X-ray; 1.70 A; A=1-283.
DR   PDB; 1K27; X-ray; 1.95 A; A=1-283.
DR   PDB; 1SD1; X-ray; 2.03 A; A=1-283.
DR   PDB; 1SD2; X-ray; 2.10 A; A=1-283.
DR   PDB; 3LN5; X-ray; 1.90 A; C=227-237.
DR   PDB; 3OZC; X-ray; 1.93 A; A=1-283.
DR   PDB; 3OZD; X-ray; 2.10 A; A/B=1-283.
DR   PDB; 3OZE; X-ray; 2.00 A; A/B/C/D/E/F=1-283.
DR   PDB; 5EUB; X-ray; 1.81 A; A=1-283.
DR   PDB; 5TC5; X-ray; 1.96 A; A/B/C=1-283.
DR   PDB; 5TC6; X-ray; 1.48 A; A=1-283.
DR   PDB; 5TC7; X-ray; 1.75 A; A=1-283.
DR   PDB; 5TC8; X-ray; 1.80 A; A=1-283.
DR   PDB; 6DYZ; X-ray; 1.62 A; A=1-283.
DR   PDB; 6DZ0; X-ray; 1.62 A; A=1-283.
DR   PDB; 6DZ2; X-ray; 1.99 A; A/B/C=1-283.
DR   PDB; 6DZ3; X-ray; 1.91 A; A/B/C=1-283.
DR   PDBsum; 1CB0; -.
DR   PDBsum; 1CG6; -.
DR   PDBsum; 1K27; -.
DR   PDBsum; 1SD1; -.
DR   PDBsum; 1SD2; -.
DR   PDBsum; 3LN5; -.
DR   PDBsum; 3OZC; -.
DR   PDBsum; 3OZD; -.
DR   PDBsum; 3OZE; -.
DR   PDBsum; 5EUB; -.
DR   PDBsum; 5TC5; -.
DR   PDBsum; 5TC6; -.
DR   PDBsum; 5TC7; -.
DR   PDBsum; 5TC8; -.
DR   PDBsum; 6DYZ; -.
DR   PDBsum; 6DZ0; -.
DR   PDBsum; 6DZ2; -.
DR   PDBsum; 6DZ3; -.
DR   SMR; Q13126; -.
DR   BioGRID; 110611; 59.
DR   IntAct; Q13126; 17.
DR   MINT; Q13126; -.
DR   STRING; 9606.ENSP00000369519; -.
DR   BindingDB; Q13126; -.
DR   ChEMBL; CHEMBL4941; -.
DR   DrugBank; DB02158; (2S,3S,4R,5S)-2-(4-Amino-4,5-dihydro-1H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-[(methylsulfanyl)methyl]-3,4-pyrrolidinediol.
DR   DrugBank; DB02933; 5'-Deoxy-5'-(Methylthio)-Tubercidin.
DR   DrugBank; DB02282; 5'-S-methyl-5'-thioadenosine.
DR   DrugBank; DB00173; Adenine.
DR   DrugBank; DB02281; Formycin.
DR   iPTMnet; Q13126; -.
DR   MetOSite; Q13126; -.
DR   PhosphoSitePlus; Q13126; -.
DR   BioMuta; MTAP; -.
DR   DMDM; 143811423; -.
DR   REPRODUCTION-2DPAGE; Q13126; -.
DR   UCD-2DPAGE; Q13126; -.
DR   EPD; Q13126; -.
DR   jPOST; Q13126; -.
DR   MassIVE; Q13126; -.
DR   MaxQB; Q13126; -.
DR   PaxDb; Q13126; -.
DR   PeptideAtlas; Q13126; -.
DR   PRIDE; Q13126; -.
DR   ProteomicsDB; 59174; -. [Q13126-1]
DR   Antibodypedia; 35188; 255 antibodies.
DR   DNASU; 4507; -.
DR   Ensembl; ENST00000580900; ENSP00000463424; ENSG00000099810. [Q13126-3]
DR   Ensembl; ENST00000644715; ENSP00000494373; ENSG00000099810. [Q13126-1]
DR   GeneID; 4507; -.
DR   KEGG; hsa:4507; -.
DR   UCSC; uc003zph.4; human. [Q13126-1]
DR   CTD; 4507; -.
DR   DisGeNET; 4507; -.
DR   EuPathDB; HostDB:ENSG00000099810.18; -.
DR   GeneCards; MTAP; -.
DR   HGNC; HGNC:7413; MTAP.
DR   HPA; ENSG00000099810; Low tissue specificity.
DR   MalaCards; MTAP; -.
DR   MIM; 112250; phenotype.
DR   MIM; 156540; gene.
DR   neXtProt; NX_Q13126; -.
DR   OpenTargets; ENSG00000099810; -.
DR   Orphanet; 85182; Diaphyseal medullary stenosis-bone malignancy syndrome.
DR   PharmGKB; PA31220; -.
DR   eggNOG; KOG3985; Eukaryota.
DR   GeneTree; ENSGT00950000182991; -.
DR   OrthoDB; 1616485at2759; -.
DR   PhylomeDB; Q13126; -.
DR   TreeFam; TF312883; -.
DR   BioCyc; MetaCyc:HS01913-MONOMER; -.
DR   BRENDA; 2.4.2.28; 2681.
DR   PathwayCommons; Q13126; -.
DR   Reactome; R-HSA-1237112; Methionine salvage pathway.
DR   Reactome; R-HSA-8950505; Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation.
DR   SABIO-RK; Q13126; -.
DR   SignaLink; Q13126; -.
DR   UniPathway; UPA00904; UER00873.
DR   BioGRID-ORCS; 4507; 30 hits in 848 CRISPR screens.
DR   ChiTaRS; MTAP; human.
DR   EvolutionaryTrace; Q13126; -.
DR   GeneWiki; MTAP; -.
DR   GenomeRNAi; 4507; -.
DR   Pharos; Q13126; Tchem.
DR   PRO; PR:Q13126; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; Q13126; protein.
DR   Bgee; ENSG00000099810; Expressed in adrenal tissue and 207 other tissues.
DR   ExpressionAtlas; Q13126; baseline and differential.
DR   Genevisible; Q13126; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0004645; F:1,4-alpha-oligoglucan phosphorylase activity; TAS:ProtInc.
DR   GO; GO:0004731; F:purine-nucleoside phosphorylase activity; IBA:GO_Central.
DR   GO; GO:0017061; F:S-methyl-5-thioadenosine phosphorylase activity; IBA:GO_Central.
DR   GO; GO:0035722; P:interleukin-12-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0019509; P:L-methionine salvage from methylthioadenosine; IBA:GO_Central.
DR   GO; GO:0032259; P:methylation; IEA:Ensembl.
DR   GO; GO:0006139; P:nucleobase-containing compound metabolic process; TAS:ProtInc.
DR   GO; GO:0006166; P:purine ribonucleoside salvage; IEA:UniProtKB-KW.
DR   GO; GO:0033574; P:response to testosterone; IEA:Ensembl.
DR   Gene3D; 3.40.50.1580; -; 1.
DR   HAMAP; MF_01963; MTAP; 1.
DR   InterPro; IPR010044; MTAP.
DR   InterPro; IPR000845; Nucleoside_phosphorylase_d.
DR   InterPro; IPR035994; Nucleoside_phosphorylase_sf.
DR   InterPro; IPR018099; Purine_phosphorylase-2_CS.
DR   PANTHER; PTHR42679; PTHR42679; 1.
DR   Pfam; PF01048; PNP_UDP_1; 1.
DR   SUPFAM; SSF53167; SSF53167; 1.
DR   TIGRFAMs; TIGR01694; MTAP; 1.
DR   PROSITE; PS01240; PNP_MTAP_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cytoplasm;
KW   Glycosyltransferase; Nucleus; Polymorphism; Purine salvage;
KW   Reference proteome; Transferase.
FT   CHAIN           1..283
FT                   /note="S-methyl-5'-thioadenosine phosphorylase"
FT                   /id="PRO_0000184545"
FT   REGION          60..61
FT                   /note="Phosphate binding"
FT   REGION          93..94
FT                   /note="Phosphate binding"
FT   REGION          220..222
FT                   /note="Substrate binding"
FT   BINDING         18
FT                   /note="Phosphate"
FT   BINDING         196
FT                   /note="Substrate; via amide nitrogen"
FT   BINDING         197
FT                   /note="Phosphate"
FT   SITE            178
FT                   /note="Important for substrate specificity"
FT   SITE            233
FT                   /note="Important for substrate specificity"
FT   MOD_RES         51
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9CQ65"
FT   VAR_SEQ         231..283
FT                   /note="VSVDRVLKTLKENANKAKSLLLTTIPQIGSTEWSETLHNLKNMAQFSVLLPR
FT                   H -> MIKFQMILSEGYHPFNIQESPFYRGLLDFPSVGHGRGKKCLSAPAIILRPPQPR
FT                   GTVTTFKVSWSKDQTYICMKS (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:22464254"
FT                   /id="VSP_044071"
FT   VAR_SEQ         231..283
FT                   /note="VSVDRVLKTLKENANKAKSLLLTTIPQIGSTEWSETLHNLKNMAQFSVLLPR
FT                   H -> MIKFQMILSEGYHPFNIQESPFYRGLLDFPSVGHGRGEILPLSPLDLAGYCFQQ
FT                   PMQPPCPDS (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:22464254"
FT                   /id="VSP_044072"
FT   VAR_SEQ         232..283
FT                   /note="SVDRVLKTLKENANKAKSLLLTTIPQIGSTEWSETLHNLKNMAQFSVLLPRH
FT                   -> RSAFQLPP (in isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:22464254"
FT                   /id="VSP_044073"
FT   VAR_SEQ         272..283
FT                   /note="NMAQFSVLLPRH -> MIKFQMILSEGYHPFNIQESPFYRGLLDFPSVGHGR
FT                   GKKCLSAPAIILRPPQPRGTVTTFKVSWSKDQTYICMKS (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:22464254"
FT                   /id="VSP_044074"
FT   VAR_SEQ         272..283
FT                   /note="NMAQFSVLLPRH -> MIKFQMILSEGYHPFNIQESPFYRGLLDFPSVGHGR
FT                   GEILPLSPLDLAGYCFQQPMQPPCPDS (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:22464254"
FT                   /id="VSP_044075"
FT   VAR_SEQ         272..283
FT                   /note="NMAQFSVLLPRH -> VRSAFQLPP (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:22464254"
FT                   /id="VSP_044076"
FT   VARIANT         56
FT                   /note="V -> I (in dbSNP:rs7023954)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:7604019, ECO:0000269|Ref.4"
FT                   /id="VAR_031470"
FT   CONFLICT        218
FT                   /note="A -> G (in Ref. 2; AAG38871/AAR24607)"
FT                   /evidence="ECO:0000305"
FT   STRAND          11..17
FT                   /evidence="ECO:0000244|PDB:5TC6"
FT   HELIX           18..20
FT                   /evidence="ECO:0000244|PDB:6DZ3"
FT   HELIX           23..25
FT                   /evidence="ECO:0000244|PDB:5TC6"
FT   STRAND          26..32
FT                   /evidence="ECO:0000244|PDB:5TC6"
FT   STRAND          45..50
FT                   /evidence="ECO:0000244|PDB:5TC6"
FT   STRAND          53..59
FT                   /evidence="ECO:0000244|PDB:5TC6"
FT   TURN            60..65
FT                   /evidence="ECO:0000244|PDB:5TC6"
FT   HELIX           69..71
FT                   /evidence="ECO:0000244|PDB:5TC6"
FT   HELIX           74..83
FT                   /evidence="ECO:0000244|PDB:5TC6"
FT   STRAND          87..97
FT                   /evidence="ECO:0000244|PDB:5TC6"
FT   STRAND          107..109
FT                   /evidence="ECO:0000244|PDB:5TC6"
FT   STRAND          112..116
FT                   /evidence="ECO:0000244|PDB:5TC6"
FT   STRAND          126..128
FT                   /evidence="ECO:0000244|PDB:5TC6"
FT   STRAND          134..136
FT                   /evidence="ECO:0000244|PDB:5TC6"
FT   STRAND          140..142
FT                   /evidence="ECO:0000244|PDB:6DZ3"
FT   HELIX           146..158
FT                   /evidence="ECO:0000244|PDB:5TC6"
FT   STRAND          163..165
FT                   /evidence="ECO:0000244|PDB:5TC6"
FT   STRAND          168..172
FT                   /evidence="ECO:0000244|PDB:5TC6"
FT   HELIX           180..188
FT                   /evidence="ECO:0000244|PDB:5TC6"
FT   STRAND          193..197
FT                   /evidence="ECO:0000244|PDB:5TC6"
FT   HELIX           198..207
FT                   /evidence="ECO:0000244|PDB:5TC6"
FT   STRAND          211..220
FT                   /evidence="ECO:0000244|PDB:5TC6"
FT   TURN            222..224
FT                   /evidence="ECO:0000244|PDB:6DYZ"
FT   STRAND          226..228
FT                   /evidence="ECO:0000244|PDB:5TC7"
FT   HELIX           233..259
FT                   /evidence="ECO:0000244|PDB:5TC6"
FT   HELIX           264..276
FT                   /evidence="ECO:0000244|PDB:5TC6"
SQ   SEQUENCE   283 AA;  31236 MW;  3B34C565EB5B99DA CRC64;
     MASGTTTTAV KIGIIGGTGL DDPEILEGRT EKYVDTPFGK PSDALILGKI KNVDCVLLAR
     HGRQHTIMPS KVNYQANIWA LKEEGCTHVI VTTACGSLRE EIQPGDIVII DQFIDRTTMR
     PQSFYDGSHS CARGVCHIPM AEPFCPKTRE VLIETAKKLG LRCHSKGTMV TIEGPRFSSR
     AESFMFRTWG ADVINMTTVP EVVLAKEAGI CYASIAMATD YDCWKEHEEA VSVDRVLKTL
     KENANKAKSL LLTTIPQIGS TEWSETLHNL KNMAQFSVLL PRH
//
ID   ING1_HUMAN              Reviewed;         422 AA.
AC   Q9UK53; O00532; O43658; Q53ZR3; Q5T9G8; Q5T9G9; Q5T9H0; Q5T9H1; Q9H007;
AC   Q9HD98; Q9HD99; Q9NS83; Q9P0U6; Q9UBC6; Q9UIJ1; Q9UIJ2; Q9UIJ3; Q9UIJ4;
AC   Q9UK52;
DT   16-JAN-2004, integrated into UniProtKB/Swiss-Prot.
DT   04-NOV-2008, sequence version 2.
DT   02-DEC-2020, entry version 174.
DE   RecName: Full=Inhibitor of growth protein 1;
GN   Name=ING1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND VARIANT ARG-125.
RX   PubMed=8944021; DOI=10.1038/ng1296-415;
RA   Garkavtsev I.A., Kazarov A.R., Gudkov A.V., Riabowol K.;
RT   "Suppression of the novel growth inhibitor p33ING1 promotes neoplastic
RT   transformation.";
RL   Nat. Genet. 14:415-420(1996).
RN   [2]
RP   ERRATUM OF PUBMED:8944021.
RA   Garkavtsev I.A., Kazarov A.R., Gudkov A.V., Riabowol K.;
RL   Nat. Genet. 23:373-373(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3 AND 4), AND TISSUE SPECIFICITY.
RC   TISSUE=Mammary cancer, and Testis;
RX   PubMed=10626813;
RA   Jaeger D., Stockert E., Scanlan M.J., Guere A.O., Jaeger E., Knuth A.,
RA   Old L.J., Chen Y.-T.;
RT   "Cancer-testis antigens and ING1 tumor suppressor gene product are breast
RT   cancer antigens: characterization of tissue-specific ING1 transcripts and a
RT   homologue gene.";
RL   Cancer Res. 59:6197-6204(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE (ISOFORMS 1 AND 2).
RX   PubMed=10779953;
RA   Baranova A.V., Ivanov D.V., Makeeva N.V., Corcoran M., Nikitin E.A.,
RA   Borodina T.A., Poltaraus A.B., Glinshchikova O.A., Sudarikov A.B.,
RA   Oscier D., Iankovskii N.K.;
RT   "Genomic organization of the suppressor gene for tumor growth ING1.";
RL   Mol. Biol. (Mosk.) 34:263-269(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1; 2; 3 AND 5), AND VARIANTS
RP   HNSCC ARG-125; ASP-335; SER-358 AND SER-359.
RX   PubMed=10866301;
RA   Gunduz M., Ouchida M., Fukushima K., Hanafusa H., Etani T., Nishioka S.,
RA   Nishizaki K., Shimizu K.;
RT   "Genomic structure of the human ING1 gene and tumor-specific mutations
RT   detected in head and neck squamous cell carcinomas.";
RL   Cancer Res. 60:3143-3146(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1; 2 AND 3), AND VARIANT
RP   ARG-125.
RX   PubMed=10807544; DOI=10.1007/s100380050206;
RA   Saito A., Furukawa T., Fukushige S., Koyama S., Hoshi M., Hayashi Y.,
RA   Horii A.;
RT   "p24/ING1-ALT1 and p47/ING1-ALT2, distinct alternative transcripts of
RT   p33/ING1.";
RL   J. Hum. Genet. 45:177-181(2000).
RN   [7]
RP   NUCLEOTIDE SEQUENCE (ISOFORM 2).
RC   TISSUE=Brain;
RA   Nouman G.S., Anderson J.J., Angus B., Lunec J.;
RT   "Supplement: sequencing of ING1 tumour suppressor gene cDNAs generated from
RT   mRNA recovered from normal and neoplastic cell lines.";
RL   J. Pathol. 192:266-266(2000).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 2).
RX   PubMed=11481424; DOI=10.1073/pnas.161151798;
RA   Nagashima M., Shiseki M., Miura K., Hagiwara K., Linke S.P., Pedeux R.,
RA   Wang X.W., Yokota J., Riabowol K., Harris C.C.;
RT   "DNA damage-inducible gene p33ING2 negatively regulates cell proliferation
RT   through acetylation of p53.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:9671-9676(2001).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S.,
RA   Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C.,
RA   Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P.,
RA   Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L.,
RA   Frankish A.G., Frankland J., French L., Garner P., Garnett J.,
RA   Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M.,
RA   Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D.,
RA   Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D.,
RA   Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S.,
RA   Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R.,
RA   Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W.,
RA   Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L.,
RA   Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R.,
RA   Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH TP53.
RX   PubMed=9440695; DOI=10.1038/34675;
RA   Garkavtsev I.A., Grigorian I.A., Ossovskaya V.S., Chernov M.V.,
RA   Chumakov P.M., Gudkov A.V.;
RT   "The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth
RT   control.";
RL   Nature 391:295-298(1998).
RN   [14]
RP   DOMAIN PHD-TYPE ZINC-FINGER, AND INTERACTION WITH HISTONES H3K4ME3 AND
RP   H3K4ME2.
RX   PubMed=16728974; DOI=10.1038/nature04835;
RA   Shi X., Hong T., Walter K.L., Ewalt M., Michishita E., Hung T., Carney D.,
RA   Pena P., Lan F., Kaadige M.R., Lacoste N., Cayrou C., Davrazou F., Saha A.,
RA   Cairns B.R., Ayer D.E., Kutateladze T.G., Shi Y., Cote J., Chua K.F.,
RA   Gozani O.;
RT   "ING2 PHD domain links histone H3 lysine 4 methylation to active gene
RT   repression.";
RL   Nature 442:96-99(2006).
RN   [15]
RP   INTERACTION WITH RSL1D1.
RX   PubMed=22419112; DOI=10.1038/cddis.2012.22;
RA   Li N., Zhao G., Chen T., Xue L., Ma L., Niu J., Tong T.;
RT   "Nucleolar protein CSIG is required for p33ING1 function in UV-induced
RT   apoptosis.";
RL   Cell Death Dis. 3:E283-E283(2012).
RN   [16]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-278, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 345-404 IN COMPLEX WITH H3K4ME3
RP   AND ZINC, AND MUTAGENESIS OF TRP-378.
RX   PubMed=18533182; DOI=10.1016/j.jmb.2008.04.061;
RA   Pena P.V., Hom R.A., Hung T., Lin H., Kuo A.J., Wong R.P., Subach O.M.,
RA   Champagne K.S., Zhao R., Verkhusha V.V., Li G., Gozani O.,
RA   Kutateladze T.G.;
RT   "Histone H3K4me3 binding is required for the DNA repair and apoptotic
RT   activities of ING1 tumor suppressor.";
RL   J. Mol. Biol. 380:303-312(2008).
CC   -!- FUNCTION: Cooperates with p53/TP53 in the negative regulatory pathway
CC       of cell growth by modulating p53-dependent transcriptional activation.
CC       Implicated as a tumor suppressor gene. {ECO:0000269|PubMed:9440695}.
CC   -!- SUBUNIT: Interacts with H3K4me3 and to a lesser extent with H3K4me2.
CC       Interacts with TP53. Isoform 2 interacts with RSL1D1.
CC       {ECO:0000269|PubMed:16728974, ECO:0000269|PubMed:18533182,
CC       ECO:0000269|PubMed:22419112, ECO:0000269|PubMed:9440695}.
CC   -!- INTERACTION:
CC       Q9UK53; P15559: NQO1; NbExp=3; IntAct=EBI-399198, EBI-3989435;
CC       Q9UK53-2; Q96A65-2: EXOC4; NbExp=3; IntAct=EBI-8068204, EBI-17869840;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=p47ING1a, ING1-ALT2;
CC         IsoId=Q9UK53-1; Sequence=Displayed;
CC       Name=2; Synonyms=p33ING1b, Variant A;
CC         IsoId=Q9UK53-2; Sequence=VSP_009126;
CC       Name=3; Synonyms=p24ING1c, ING1-ALT1, Variant B;
CC         IsoId=Q9UK53-3; Sequence=VSP_009129;
CC       Name=4; Synonyms=Variant C;
CC         IsoId=Q9UK53-4; Sequence=VSP_009127;
CC       Name=5;
CC         IsoId=Q9UK53-5; Sequence=VSP_009128;
CC   -!- TISSUE SPECIFICITY: Isoform 2 was expressed in all normal tissues and
CC       cells examined, as well as in all breast cancer and melanoma cell lines
CC       examined. Isoform 3 was expressed in testis, liver, and kidney, weakly
CC       expressed in colon and brain and not expressed in breast and cultured
CC       melanocytes. Isoform 4 was highly expressed in testis and weakly
CC       expressed in brain, but not expressed in breast, colon, kidney,
CC       melanocytes, breast cancer or melanoma cell lines.
CC       {ECO:0000269|PubMed:10626813}.
CC   -!- DOMAIN: The PHD-type zinc finger mediates the binding to H3K4me3.
CC       {ECO:0000269|PubMed:16728974}.
CC   -!- DOMAIN: The polybasic region (PBR) is responsive to the binding to
CC       phosphoinositides (PtdInsPs), including phosphatidylinositol 5-
CC       phosphate (PtdIns(5)P). {ECO:0000250|UniProtKB:Q9H160}.
CC   -!- DISEASE: Squamous cell carcinoma of the head and neck (HNSCC)
CC       [MIM:275355]: A non-melanoma skin cancer affecting the head and neck.
CC       The hallmark of cutaneous SCC is malignant transformation of normal
CC       epidermal keratinocytes. {ECO:0000269|PubMed:10866301}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the ING family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB60879.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AAG02579.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF181849; AAF07920.1; -; mRNA.
DR   EMBL; AF181850; AAF07921.1; -; mRNA.
DR   EMBL; AF001954; AAB60879.1; ALT_FRAME; mRNA.
DR   EMBL; AF044076; AAC00501.1; -; mRNA.
DR   EMBL; AF149721; AAF37421.1; -; mRNA.
DR   EMBL; AF149722; AAF37422.1; -; mRNA.
DR   EMBL; AF149723; AAF37423.1; -; mRNA.
DR   EMBL; AF167551; AAG02578.1; -; Genomic_DNA.
DR   EMBL; AF167550; AAG02578.1; JOINED; Genomic_DNA.
DR   EMBL; AF167551; AAG02579.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AF167549; AAG02579.1; JOINED; Genomic_DNA.
DR   EMBL; AB037387; BAB08101.1; -; Genomic_DNA.
DR   EMBL; AB037387; BAB08102.1; -; Genomic_DNA.
DR   EMBL; AB037387; BAB08103.1; -; Genomic_DNA.
DR   EMBL; AB037594; BAB20992.2; -; mRNA.
DR   EMBL; AB031269; BAA83496.1; -; mRNA.
DR   EMBL; AB024401; BAA82886.1; -; mRNA.
DR   EMBL; AB024402; BAA82887.1; -; mRNA.
DR   EMBL; AB024403; BAA82888.1; -; Genomic_DNA.
DR   EMBL; AB024404; BAA82889.1; -; Genomic_DNA.
DR   EMBL; AB024404; BAA83462.1; -; Genomic_DNA.
DR   EMBL; AB024405; BAA82890.1; -; Genomic_DNA.
DR   EMBL; AJ310392; CAC38067.1; -; mRNA.
DR   EMBL; AF078835; AAG12174.1; -; mRNA.
DR   EMBL; AF078837; AAG12175.1; -; Genomic_DNA.
DR   EMBL; AF078836; AAG12175.1; JOINED; Genomic_DNA.
DR   EMBL; AK302353; BAG63679.1; -; mRNA.
DR   EMBL; AL157820; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471085; EAX09127.1; -; Genomic_DNA.
DR   EMBL; CH471085; EAX09130.1; -; Genomic_DNA.
DR   EMBL; BC093942; AAH93942.1; -; mRNA.
DR   EMBL; BC093944; AAH93944.1; -; mRNA.
DR   CCDS; CCDS9515.1; -. [Q9UK53-4]
DR   CCDS; CCDS9516.1; -. [Q9UK53-2]
DR   CCDS; CCDS9517.1; -. [Q9UK53-1]
DR   CCDS; CCDS9518.1; -. [Q9UK53-3]
DR   RefSeq; NP_001254657.1; NM_001267728.1. [Q9UK53-5]
DR   RefSeq; NP_005528.4; NM_005537.5.
DR   RefSeq; NP_937860.1; NM_198217.2. [Q9UK53-4]
DR   RefSeq; NP_937861.1; NM_198218.2. [Q9UK53-3]
DR   RefSeq; NP_937862.1; NM_198219.2. [Q9UK53-2]
DR   PDB; 2QIC; X-ray; 2.10 A; A=345-404.
DR   PDBsum; 2QIC; -.
DR   SMR; Q9UK53; -.
DR   BioGRID; 109833; 84.
DR   ComplexPortal; CPX-3321; SIN3A histone deacetylase complex.
DR   ComplexPortal; CPX-3322; SIN3B histone deacetylase complex.
DR   ComplexPortal; CPX-3323; SIN3A histone deacetylase complex, ES cell-specific variant.
DR   CORUM; Q9UK53; -.
DR   DIP; DIP-24256N; -.
DR   DIP; DIP-24257N; -.
DR   DIP; DIP-24258N; -.
DR   IntAct; Q9UK53; 21.
DR   MINT; Q9UK53; -.
DR   STRING; 9606.ENSP00000364929; -.
DR   iPTMnet; Q9UK53; -.
DR   PhosphoSitePlus; Q9UK53; -.
DR   BioMuta; ING1; -.
DR   DMDM; 212276438; -.
DR   EPD; Q9UK53; -.
DR   jPOST; Q9UK53; -.
DR   MassIVE; Q9UK53; -.
DR   PaxDb; Q9UK53; -.
DR   PeptideAtlas; Q9UK53; -.
DR   PRIDE; Q9UK53; -.
DR   ProteomicsDB; 84718; -. [Q9UK53-1]
DR   ProteomicsDB; 84719; -. [Q9UK53-2]
DR   ProteomicsDB; 84720; -. [Q9UK53-3]
DR   ProteomicsDB; 84721; -. [Q9UK53-4]
DR   ProteomicsDB; 84722; -. [Q9UK53-5]
DR   Antibodypedia; 4248; 480 antibodies.
DR   Ensembl; ENST00000333219; ENSP00000328436; ENSG00000153487. [Q9UK53-2]
DR   Ensembl; ENST00000338450; ENSP00000345202; ENSG00000153487. [Q9UK53-4]
DR   Ensembl; ENST00000375775; ENSP00000364930; ENSG00000153487. [Q9UK53-3]
DR   GeneID; 3621; -.
DR   KEGG; hsa:3621; -.
DR   UCSC; uc001vrf.5; human. [Q9UK53-1]
DR   CTD; 3621; -.
DR   DisGeNET; 3621; -.
DR   EuPathDB; HostDB:ENSG00000153487.12; -.
DR   GeneCards; ING1; -.
DR   HGNC; HGNC:6062; ING1.
DR   HPA; ENSG00000153487; Low tissue specificity.
DR   MalaCards; ING1; -.
DR   MIM; 275355; phenotype.
DR   MIM; 601566; gene.
DR   neXtProt; NX_Q9UK53; -.
DR   OpenTargets; ENSG00000153487; -.
DR   Orphanet; 500481; Squamous cell carcinoma of salivary glands.
DR   Orphanet; 494547; Squamous cell carcinoma of the hypopharynx.
DR   Orphanet; 494550; Squamous cell carcinoma of the larynx.
DR   Orphanet; 502366; Squamous cell carcinoma of the lip.
DR   Orphanet; 500464; Squamous cell carcinoma of the nasal cavity and paranasal sinuses.
DR   Orphanet; 502363; Squamous cell carcinoma of the oral cavity.
DR   Orphanet; 500478; Squamous cell carcinoma of the oropharynx.
DR   PharmGKB; PA29872; -.
DR   eggNOG; KOG1973; Eukaryota.
DR   GeneTree; ENSGT00940000155401; -.
DR   HOGENOM; CLU_031900_5_1_1; -.
DR   InParanoid; Q9UK53; -.
DR   OMA; YCVCNQI; -.
DR   OrthoDB; 1434088at2759; -.
DR   PhylomeDB; Q9UK53; -.
DR   TreeFam; TF352014; -.
DR   PathwayCommons; Q9UK53; -.
DR   SIGNOR; Q9UK53; -.
DR   BioGRID-ORCS; 3621; 7 hits in 857 CRISPR screens.
DR   ChiTaRS; ING1; human.
DR   EvolutionaryTrace; Q9UK53; -.
DR   GeneWiki; ING1; -.
DR   GenomeRNAi; 3621; -.
DR   Pharos; Q9UK53; Tbio.
DR   PRO; PR:Q9UK53; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   RNAct; Q9UK53; protein.
DR   Bgee; ENSG00000153487; Expressed in decidua and 217 other tissues.
DR   ExpressionAtlas; Q9UK53; baseline and differential.
DR   Genevisible; Q9UK53; HS.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0035064; F:methylated histone binding; IDA:UniProtKB.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0030308; P:negative regulation of cell growth; NAS:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; TAS:ProtInc.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IBA:GO_Central.
DR   GO; GO:0010941; P:regulation of cell death; IEA:InterPro.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR028643; ING1.
DR   InterPro; IPR028651; ING_fam.
DR   InterPro; IPR024610; ING_N_histone-binding.
DR   InterPro; IPR019786; Zinc_finger_PHD-type_CS.
DR   InterPro; IPR011011; Znf_FYVE_PHD.
DR   InterPro; IPR001965; Znf_PHD.
DR   InterPro; IPR019787; Znf_PHD-finger.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR10333; PTHR10333; 1.
DR   PANTHER; PTHR10333:SF85; PTHR10333:SF85; 1.
DR   Pfam; PF12998; ING; 1.
DR   SMART; SM01408; ING; 1.
DR   SMART; SM00249; PHD; 1.
DR   SUPFAM; SSF57903; SSF57903; 1.
DR   PROSITE; PS01359; ZF_PHD_1; 1.
DR   PROSITE; PS50016; ZF_PHD_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell cycle; Disease mutation;
KW   Isopeptide bond; Metal-binding; Nucleus; Reference proteome;
KW   Tumor suppressor; Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN           1..422
FT                   /note="Inhibitor of growth protein 1"
FT                   /id="PRO_0000212661"
FT   ZN_FING         353..402
FT                   /note="PHD-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00146"
FT   REGION          405..422
FT                   /note="PBR"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H160"
FT   METAL           356
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000244|PDB:2QIC,
FT                   ECO:0000269|PubMed:18533182"
FT   METAL           358
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000244|PDB:2QIC,
FT                   ECO:0000269|PubMed:18533182"
FT   METAL           369
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000244|PDB:2QIC,
FT                   ECO:0000269|PubMed:18533182"
FT   METAL           374
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000244|PDB:2QIC,
FT                   ECO:0000269|PubMed:18533182"
FT   METAL           380
FT                   /note="Zinc 1; via pros nitrogen"
FT                   /evidence="ECO:0000244|PDB:2QIC,
FT                   ECO:0000269|PubMed:18533182"
FT   METAL           383
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000244|PDB:2QIC,
FT                   ECO:0000269|PubMed:18533182"
FT   METAL           396
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000244|PDB:2QIC,
FT                   ECO:0000269|PubMed:18533182"
FT   METAL           399
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000244|PDB:2QIC,
FT                   ECO:0000269|PubMed:18533182"
FT   BINDING         355
FT                   /note="Histone H3K4me3"
FT                   /evidence="ECO:0000244|PDB:2QIC,
FT                   ECO:0000269|PubMed:18533182"
FT   BINDING         366
FT                   /note="Histone H3K4me3"
FT                   /evidence="ECO:0000244|PDB:2QIC,
FT                   ECO:0000269|PubMed:18533182"
FT   BINDING         370
FT                   /note="Histone H3K4me3"
FT                   /evidence="ECO:0000244|PDB:2QIC,
FT                   ECO:0000269|PubMed:18533182"
FT   BINDING         378
FT                   /note="Histone H3K4me3"
FT                   /evidence="ECO:0000244|PDB:2QIC,
FT                   ECO:0000269|PubMed:18533182"
FT   CROSSLNK        278
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   VAR_SEQ         1..212
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:10626813,
FT                   ECO:0000303|PubMed:10807544"
FT                   /id="VSP_009129"
FT   VAR_SEQ         1..189
FT                   /note="MSFVECPYHSPAERLVAEADEGGPSAITGMGLCFRCLLFSFSGRSGVEGGRV
FT                   DLNVFGSLGLQPWIGSSRCWGGPCSSALRCGWFSSWPPPSKSAIPIGGGSRGAGRVSRW
FT                   PPPHWLEAWRVSPLPLSPLSPATFGRGFIAVAVIPGLWARGRGCSSDRLPRPAGPARRQ
FT                   FQAASLLTRGWGRAWPWKQ -> MLSPANGEQLHLVNYVEDYLDSIESLPFDLQRNVSL
FT                   MREIDAKYQE (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10626813,
FT                   ECO:0000303|PubMed:10807544, ECO:0000303|PubMed:11481424,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8944021"
FT                   /id="VSP_009126"
FT   VAR_SEQ         1..189
FT                   /note="MSFVECPYHSPAERLVAEADEGGPSAITGMGLCFRCLLFSFSGRSGVEGGRV
FT                   DLNVFGSLGLQPWIGSSRCWGGPCSSALRCGWFSSWPPPSKSAIPIGGGSRGAGRVSRW
FT                   PPPHWLEAWRVSPLPLSPLSPATFGRGFIAVAVIPGLWARGRGCSSDRLPRPAGPARRQ
FT                   FQAASLLTRGWGRAWPWKQ -> ME (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:10626813,
FT                   ECO:0000303|PubMed:14702039"
FT                   /id="VSP_009127"
FT   VAR_SEQ         1..189
FT                   /note="MSFVECPYHSPAERLVAEADEGGPSAITGMGLCFRCLLFSFSGRSGVEGGRV
FT                   DLNVFGSLGLQPWIGSSRCWGGPCSSALRCGWFSSWPPPSKSAIPIGGGSRGAGRVSRW
FT                   PPPHWLEAWRVSPLPLSPLSPATFGRGFIAVAVIPGLWARGRGCSSDRLPRPAGPARRQ
FT                   FQAASLLTRGWGRAWPWKQ -> MSFVECPYHSPAERLVAEADEGGPSAITE (in
FT                   isoform 5)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_009128"
FT   VARIANT         125
FT                   /note="L -> R (in dbSNP:rs7338333)"
FT                   /evidence="ECO:0000269|PubMed:10807544,
FT                   ECO:0000269|PubMed:10866301, ECO:0000269|PubMed:8944021"
FT                   /id="VAR_047097"
FT   VARIANT         335
FT                   /note="A -> D (in HNSCC)"
FT                   /evidence="ECO:0000269|PubMed:10866301"
FT                   /id="VAR_017420"
FT   VARIANT         358
FT                   /note="C -> S (in HNSCC)"
FT                   /evidence="ECO:0000269|PubMed:10866301"
FT                   /id="VAR_017421"
FT   VARIANT         359
FT                   /note="N -> S (in HNSCC)"
FT                   /evidence="ECO:0000269|PubMed:10866301"
FT                   /id="VAR_017422"
FT   MUTAGEN         378
FT                   /note="W->A: Unable to stimulate DNA repair after UV
FT                   irradiation or promote DNA-damage-induced apoptosis."
FT                   /evidence="ECO:0000269|PubMed:18533182"
FT   CONFLICT        266
FT                   /note="A -> V (in Ref. 1; AAC00501/AAB60879, 3 and 6)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        272
FT                   /note="A -> V (in Ref. 1; AAC00501/AAB60879, 3 and 6)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        278
FT                   /note="K -> N (in Ref. 1; AAC00501/AAB60879, 3 and 6)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        280
FT                   /note="E -> D (in Ref. 1; AAC00501/AAB60879, 3 and 6)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        282
FT                   /note="A -> V (in Ref. 1; AAC00501/AAB60879, 3 and 6)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        285
FT                   /note="A -> S (in Ref. 1; AAC00501/AAB60879, 3 and 6)"
FT                   /evidence="ECO:0000305"
FT   TURN            356..359
FT                   /evidence="ECO:0000244|PDB:2QIC"
FT   STRAND          364..368
FT                   /evidence="ECO:0000244|PDB:2QIC"
FT   STRAND          378..380
FT                   /evidence="ECO:0000244|PDB:2QIC"
FT   HELIX           382..384
FT                   /evidence="ECO:0000244|PDB:2QIC"
FT   HELIX           397..400
FT                   /evidence="ECO:0000244|PDB:2QIC"
SQ   SEQUENCE   422 AA;  46738 MW;  03D6AEEAA6E39090 CRC64;
     MSFVECPYHS PAERLVAEAD EGGPSAITGM GLCFRCLLFS FSGRSGVEGG RVDLNVFGSL
     GLQPWIGSSR CWGGPCSSAL RCGWFSSWPP PSKSAIPIGG GSRGAGRVSR WPPPHWLEAW
     RVSPLPLSPL SPATFGRGFI AVAVIPGLWA RGRGCSSDRL PRPAGPARRQ FQAASLLTRG
     WGRAWPWKQI LKELDECYER FSRETDGAQK RRMLHCVQRA LIRSQELGDE KIQIVSQMVE
     LVENRTRQVD SHVELFEAQQ ELGDTAGNSG KAGADRPKGE AAAQADKPNS KRSRRQRNNE
     NRENASSNHD HDDGASGTPK EKKAKTSKKK KRSKAKAERE ASPADLPIDP NEPTYCLCNQ
     VSYGEMIGCD NDECPIEWFH FSCVGLNHKP KGKWYCPKCR GENEKTMDKA LEKSKKERAY
     NR
//
ID   EWS_HUMAN               Reviewed;         656 AA.
AC   Q01844; B0QYK1; Q5THL0; Q92635; Q96FE8; Q96MN4; Q96MX4; Q9BWA2;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   02-DEC-2020, entry version 229.
DE   RecName: Full=RNA-binding protein EWS;
DE   AltName: Full=EWS oncogene;
DE   AltName: Full=Ewing sarcoma breakpoint region 1 protein;
GN   Name=EWSR1; Synonyms=EWS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM EWS), INVOLVEMENT IN EWS, AND
RP   CHROMOSOMAL TRANSLOCATION WITH FLI.
RC   TISSUE=Fetal brain;
RX   PubMed=1522903; DOI=10.1038/359162a0;
RA   Delattre O., Zucman J., Plougastel B., Desmaze C., Melot T., Peter M.,
RA   Kovar H., Joubert I., de Jong P., Rouleau G., Aurias A., Thomas G.;
RT   "Gene fusion with an ETS DNA-binding domain caused by chromosome
RT   translocation in human tumours.";
RL   Nature 359:162-165(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8307570; DOI=10.1016/s0888-7543(05)80363-5;
RA   Plougastel B., Zucman J., Peter M., Thomas G., Delattre O.;
RT   "Genomic structure of the EWS gene and its relationship to EWSR1, a site of
RT   tumor-associated chromosome translocation.";
RL   Genomics 18:609-615(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Zucman-Rossi J., Legoix P., Thomas G.;
RT   "Genomic sequence of the human EWS gene with the 5' flanking region.";
RL   Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 5 AND 6).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M., Clamp M.,
RA   Smink L.J., Ainscough R., Almeida J.P., Babbage A.K., Bagguley C.,
RA   Bailey J., Barlow K.F., Bates K.N., Beasley O.P., Bird C.P., Blakey S.E.,
RA   Bridgeman A.M., Buck D., Burgess J., Burrill W.D., Burton J., Carder C.,
RA   Carter N.P., Chen Y., Clark G., Clegg S.M., Cobley V.E., Cole C.G.,
RA   Collier R.E., Connor R., Conroy D., Corby N.R., Coville G.J., Cox A.V.,
RA   Davis J., Dawson E., Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M.,
RA   Ellington A.G., Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S., Hunt S.E.,
RA   Jones M.C., Kershaw J., Kimberley A.M., King A., Laird G.K., Langford C.F.,
RA   Leversha M.A., Lloyd C., Lloyd D.M., Martyn I.D., Mashreghi-Mohammadi M.,
RA   Matthews L.H., Mccann O.T., Mcclay J., Mclaren S., McMurray A.A.,
RA   Milne S.A., Mortimore B.J., Odell C.N., Pavitt R., Pearce A.V., Pearson D.,
RA   Phillimore B.J.C.T., Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y.,
RA   Rogers L., Ross M.T., Scott C.E., Sehra H.K., Skuce C.D., Smalley S.,
RA   Smith M.L., Soderlund C., Spragon L., Steward C.A., Sulston J.E.,
RA   Swann R.M., Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J., Shintani A.,
RA   Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S., Roe B.A., Chen F., Chu L.,
RA   Crabtree J., Deschamps S., Do A., Do T., Dorman A., Fang F., Fu Y., Hu P.,
RA   Hua A., Kenton S., Lai H., Lao H.I., Lewis J., Lewis S., Lin S.-P., Loh P.,
RA   Malaj E., Nguyen T., Pan H., Phan S., Qi S., Qian Y., Ray L., Ren Q.,
RA   Shaull S., Sloan D., Song L., Wang Q., Wang Y., Wang Z., White J.,
RA   Willingham D., Wu H., Yao Z., Zhan M., Zhang G., Chissoe S., Murray J.,
RA   Miller N., Minx P., Fulton R., Johnson D., Bemis G., Bentley D.,
RA   Bradshaw H., Bourne S., Cordes M., Du Z., Fulton L., Goela D., Graves T.,
RA   Hawkins J., Hinds K., Kemp K., Latreille P., Layman D., Ozersky P.,
RA   Rohlfing T., Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K.,
RA   Nelson J., Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S., Budarf M.L.,
RA   McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E., Edelmann L., Kim U.J.,
RA   Shizuya H., Simon M.I., Dumanski J.P., Peyrard M., Kedra D., Seroussi E.,
RA   Fransson I., Tapia I., Bruder C.E., O'Brien K.P., Wilkinson P.,
RA   Bodenteich A., Hartman K., Hu X., Khan A.S., Lane L., Tilahun Y.,
RA   Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS EWS; 3 AND 4).
RC   TISSUE=Lymph, Muscle, Placenta, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-345.
RX   PubMed=8975699; DOI=10.1006/geno.1996.0625;
RA   Zucman-Rossi J., Legoix P., Thomas G.;
RT   "Identification of new members of the Gas2 and Ras families in the 22q12
RT   chromosome region.";
RL   Genomics 38:247-254(1996).
RN   [10]
RP   PROTEIN SEQUENCE OF 128-158; 233-247; 268-324; 334-364; 393-439; 447-518
RP   AND 551-641, METHYLATION AT ARG-300; ARG-302; ARG-304; ARG-309; ARG-314;
RP   ARG-317; ARG-321; ARG-455; ARG-464; ARG-471; ARG-490; ARG-494; ARG-500;
RP   ARG-503; ARG-506; ARG-563; ARG-565; ARG-572; ARG-575; ARG-581; ARG-589;
RP   ARG-592; ARG-596; ARG-600; ARG-603; ARG-607; ARG-615; ARG-633 AND ARG-636,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=11278906; DOI=10.1074/jbc.m011446200;
RA   Belyanskaya L.L., Gehrig P.M., Gehring H.;
RT   "Exposure on cell surface and extensive arginine methylation of Ewing
RT   sarcoma (EWS) protein.";
RL   J. Biol. Chem. 276:18681-18687(2001).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 241-268.
RC   TISSUE=Placenta;
RX   PubMed=7542907; DOI=10.1002/gcc.2870130209;
RA   Bhagirath T., Abe S., Nojima T., Yoshida M.C.;
RT   "Molecular analysis of a t(11;22) translocation junction in a case of
RT   Ewing's sarcoma.";
RL   Genes Chromosomes Cancer 13:126-132(1995).
RN   [12]
RP   PROTEIN SEQUENCE OF 269-292; 393-404; 411-439; 491-500 AND 615-632,
RP   METHYLATION AT ARG-494 AND ARG-615, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Colon carcinoma, and Ovarian carcinoma;
RA   Bienvenut W.V., Lilla S., von Kriegsheim A., Lempens A., Zebisch A.,
RA   Kolch W.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [13]
RP   PARTIAL PROTEIN SEQUENCE, AND PHOSPHORYLATION AT SER-266.
RX   PubMed=9341188; DOI=10.1074/jbc.272.43.27369;
RA   Deloulme J.C., Prichard L., Delattre O., Storm D.R.;
RT   "The prooncoprotein EWS binds calmodulin and is phosphorylated by protein
RT   kinase C through an IQ domain.";
RL   J. Biol. Chem. 272:27369-27377(1997).
RN   [14]
RP   CHROMOSOMAL TRANSLOCATION WITH ATF1.
RX   PubMed=8401579; DOI=10.1038/ng0893-341;
RA   Zucman J., Delattre O., Desmaze C., Epstein A.L., Stenman G., Speleman F.,
RA   Fletchers C.D., Aurias A., Thomas G.;
RT   "EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant
RT   melanoma of soft parts.";
RL   Nat. Genet. 4:341-345(1993).
RN   [15]
RP   ALTERNATIVE SPLICING, AND RNA-BINDING.
RX   PubMed=8084618;
RA   Ohno T., Ouchida M., Lee L., Gatalica Z., Rao V.N., Reddy E.S.P.;
RT   "The EWS gene, involved in Ewing family of tumors, malignant melanoma of
RT   soft parts and desmoplastic small round cell tumors, codes for an RNA
RT   binding protein with novel regulatory domains.";
RL   Oncogene 9:3087-3097(1994).
RN   [16]
RP   CHROMOSOMAL TRANSLOCATION WITH NR4A3.
RX   PubMed=7539287; DOI=10.1002/gcc.2870120412;
RA   Gill S., McManus A.P., Crew A.J., Benjamin H., Sheer D., Gusterson B.A.,
RA   Pinkerton C.R., Patel K., Cooper C.S., Shipley J.M.;
RT   "Fusion of the EWS gene to a DNA segment from 9q22-31 in a human myxoid
RT   chondrosarcoma.";
RL   Genes Chromosomes Cancer 12:307-310(1995).
RN   [17]
RP   CHROMOSOMAL TRANSLOCATION WITH ETV1.
RX   PubMed=7700648;
RA   Jeon I.-S., Davis J.N., Braun B.S., Sublett J.E., Roussel M.F., Denny C.T.,
RA   Shapiro D.N.;
RT   "A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the
RT   ETS gene ETV1.";
RL   Oncogene 10:1229-1234(1995).
RN   [18]
RP   CHROMOSOMAL TRANSLOCATION WITH WT1.
RX   PubMed=7862627; DOI=10.1073/pnas.92.4.1028;
RA   Gerald W.L., Rosai J., Ladanyi M.;
RT   "Characterization of the genomic breakpoint and chimeric transcripts in the
RT   EWS-WT1 gene fusion of desmoplastic small round cell tumor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:1028-1032(1995).
RN   [19]
RP   INVOLVEMENT IN EWS, AND CHROMOSOMAL TRANSLOCATION WITH FEV.
RX   PubMed=9121764; DOI=10.1038/sj.onc.1200933;
RA   Peter M., Couturier J., Pacquement H., Michon J., Thomas G., Magdelenat H.,
RA   Delattre O.;
RT   "A new member of the ETS family fused to EWS in Ewing tumors.";
RL   Oncogene 14:1159-1164(1997).
RN   [20]
RP   INTERACTION WITH SF1.
RX   PubMed=9660765; DOI=10.1074/jbc.273.29.18086;
RA   Zhang D., Paley A.J., Childs G.;
RT   "The transcriptional repressor ZFM1 interacts with and modulates the
RT   ability of EWS to activate transcription.";
RL   J. Biol. Chem. 273:18086-18091(1998).
RN   [21]
RP   CHARACTERIZATION.
RX   PubMed=10767297; DOI=10.1074/jbc.m002961200;
RA   Li K.K.C., Lee K.A.W.;
RT   "Transcriptional activation by the Ewing's sarcoma (EWS) oncogene can be
RT   cis-repressed by the EWS RNA-binding domain.";
RL   J. Biol. Chem. 275:23053-23058(2000).
RN   [22]
RP   CHROMOSOMAL TRANSLOCATION WITH PATZ1.
RX   PubMed=10949935; DOI=10.1038/sj.onc.1203762;
RA   Mastrangelo T., Modena P., Tornielli S., Bullrich F., Testi A.,
RA   Mezzelani A., Radice P., Azzarelli A., Pilotti S., Croce C., Pierotti M.,
RA   Sozzi G.;
RT   "A novel zinc finger gene is fused to EWS in small round cell tumor.";
RL   Oncogene 19:3799-3804(2000).
RN   [23]
RP   CHROMOSOMAL TRANSLOCATION WITH ERG, CHROMOSOMAL TRANSLOCATION WITH FLI1,
RP   AND INVOLVEMENT IN EWS.
RX   PubMed=15044653; DOI=10.1056/nejmc032965;
RA   Bielack S.S., Paulussen M., Koehler G.;
RT   "A patient with two Ewing's sarcomas with distinct EWS fusion
RT   transcripts.";
RL   N. Engl. J. Med. 350:1364-1365(2004).
RN   [24]
RP   CHARACTERIZATION OF THE EWSR1-FEV FUSION PROTEIN.
RX   PubMed=17172842; DOI=10.4161/cc.5.23.3505;
RA   Braunreiter C.L., Hancock J.D., Coffin C.M., Boucher K.M., Lessnick S.L.;
RT   "Expression of EWS-ETS fusions in NIH3T3 cells reveals significant
RT   differences to Ewing's sarcoma.";
RL   Cell Cycle 5:2753-2759(2006).
RN   [25]
RP   SUBCELLULAR LOCATION, NUCLEAR LOCALIZATION SIGNAL, AND MUTAGENESIS OF
RP   ARG-648; ARG-651; ARG-652; ASP-653; ARG-654; PRO-655 AND TYR-656.
RX   PubMed=16965792; DOI=10.1016/j.jmb.2006.08.018;
RA   Zakaryan R.P., Gehring H.;
RT   "Identification and characterization of the nuclear localization/retention
RT   signal in the EWS proto-oncoprotein.";
RL   J. Mol. Biol. 363:27-38(2006).
RN   [26]
RP   INTERACTION WITH TDRD3.
RX   PubMed=18632687; DOI=10.1093/hmg/ddn203;
RA   Goulet I., Boisvenue S., Mokas S., Mazroui R., Cote J.;
RT   "TDRD3, a novel Tudor domain-containing protein, localizes to cytoplasmic
RT   stress granules.";
RL   Hum. Mol. Genet. 17:3055-3074(2008).
RN   [27]
RP   METHYLATION AT ARG-490; ARG-572; ARG-596; ARG-603 AND ARG-607.
RX   PubMed=18320585; DOI=10.1002/prot.22004;
RA   Pahlich S., Zakaryan R.P., Gehring H.;
RT   "Identification of proteins interacting with protein arginine
RT   methyltransferase 8: the Ewing sarcoma (EWS) protein binds independent of
RT   its methylation state.";
RL   Proteins 72:1125-1137(2008).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [31]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-471; ARG-486 AND ARG-615, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [32]
RP   STRUCTURE BY NMR OF 353-453.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the RNA recognition motif of Ewing sarcoma (EWS)
RT   protein.";
RL   Submitted (NOV-2005) to the PDB data bank.
RN   [33]
RP   CHROMOSOMAL TRANSLOCATION WITH ATF1, AND INVOLVEMENT IN AFH.
RX   PubMed=15884099; DOI=10.1002/gcc.20201;
RA   Hallor K.H., Mertens F., Jin Y., Meis-Kindblom J.M., Kindblom L.-G.,
RA   Behrendtz M., Kalen A., Mandahl N., Panagopoulos I.;
RT   "Fusion of the EWSR1 and ATF1 genes without expression of the MITF-M
RT   transcript in angiomatoid fibrous histiocytoma.";
RL   Genes Chromosomes Cancer 44:97-102(2005).
RN   [34]
RP   CHROMOSOMAL TRANSLOCATION WITH CREB1, AND INVOLVEMENT IN AFH.
RX   PubMed=17724745; DOI=10.1002/gcc.20491;
RA   Antonescu C.R., Dal Cin P., Nafa K., Teot L.A., Surti U., Fletcher C.D.,
RA   Ladanyi M.;
RT   "EWSR1-CREB1 is the predominant gene fusion in angiomatoid fibrous
RT   histiocytoma.";
RL   Genes Chromosomes Cancer 46:1051-1060(2007).
CC   -!- FUNCTION: Might normally function as a transcriptional repressor. EWS-
CC       fusion-proteins (EFPS) may play a role in the tumorigenic process. They
CC       may disturb gene expression by mimicking, or interfering with the
CC       normal function of CTD-POLII within the transcription initiation
CC       complex. They may also contribute to an aberrant activation of the
CC       fusion protein target genes.
CC   -!- SUBUNIT: Binds POLR2C, SF1, calmodulin and RNA. Interacts with
CC       PTK2B/FAK2 and TDRD3. Binds calmodulin in the presence, but not in the
CC       absence, of calcium ion. Forms a complex with REC8, PRDM9, SYCP3 and
CC       SYCP1; complex formation is dependent of phosphorylated form of REC8
CC       and requires PRDM9 bound to hotspot DNA; EWSR1 joins PRDM9 with the
CC       chromosomal axis through REC8 (By similarity).
CC       {ECO:0000250|UniProtKB:Q61545, ECO:0000269|PubMed:18632687,
CC       ECO:0000269|PubMed:9660765}.
CC   -!- INTERACTION:
CC       Q01844; Q8N5M1: ATPAF2; NbExp=7; IntAct=EBI-739737, EBI-1166928;
CC       Q01844; Q09472: EP300; NbExp=2; IntAct=EBI-739737, EBI-447295;
CC       Q01844; Q01844: EWSR1; NbExp=3; IntAct=EBI-739737, EBI-739737;
CC       Q01844; P35637: FUS; NbExp=5; IntAct=EBI-739737, EBI-400434;
CC       Q01844; Q92993: KAT5; NbExp=2; IntAct=EBI-739737, EBI-399080;
CC       Q01844; Q8NDC0: MAPK1IP1L; NbExp=5; IntAct=EBI-739737, EBI-741424;
CC       Q01844; Q9UBV8: PEF1; NbExp=3; IntAct=EBI-739737, EBI-724639;
CC       Q01844; O15162: PLSCR1; NbExp=4; IntAct=EBI-739737, EBI-740019;
CC       Q01844; Q99873: PRMT1; NbExp=2; IntAct=EBI-739737, EBI-78738;
CC       Q01844; Q9NZ81: PRR13; NbExp=3; IntAct=EBI-739737, EBI-740924;
CC       Q01844; Q9NS23-2: RASSF1; NbExp=3; IntAct=EBI-739737, EBI-438698;
CC       Q01844; O95486: SEC24A; NbExp=3; IntAct=EBI-739737, EBI-749911;
CC       Q01844; O94855: SEC24D; NbExp=3; IntAct=EBI-739737, EBI-748817;
CC       Q01844; Q13485: SMAD4; NbExp=3; IntAct=EBI-739737, EBI-347263;
CC       Q01844; Q9BWW4: SSBP3; NbExp=3; IntAct=EBI-739737, EBI-2902395;
CC       Q01844; Q92734: TFG; NbExp=3; IntAct=EBI-739737, EBI-357061;
CC       Q01844; Q13077: TRAF1; NbExp=3; IntAct=EBI-739737, EBI-359224;
CC       Q01844; Q12933: TRAF2; NbExp=3; IntAct=EBI-739737, EBI-355744;
CC       Q01844; P49910: ZNF165; NbExp=2; IntAct=EBI-739737, EBI-741694;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:16965792}. Cytoplasm
CC       {ECO:0000269|PubMed:16965792}. Cell membrane
CC       {ECO:0000269|PubMed:16965792}. Note=Relocates from cytoplasm to
CC       ribosomes upon PTK2B/FAK2 activation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=EWS;
CC         IsoId=Q01844-1; Sequence=Displayed;
CC       Name=EWS-B;
CC         IsoId=Q01844-2; Sequence=VSP_005793;
CC       Name=3;
CC         IsoId=Q01844-3; Sequence=VSP_043453;
CC       Name=4;
CC         IsoId=Q01844-4; Sequence=VSP_043452, VSP_043454;
CC       Name=5;
CC         IsoId=Q01844-5; Sequence=VSP_043451, VSP_043453;
CC       Name=6;
CC         IsoId=Q01844-6; Sequence=VSP_045412;
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- DOMAIN: EWS activation domain (EAD) functions as a potent activation
CC       domain in EFPS. EWSR1 binds POLR2C but not POLR2E or POLR2G, whereas
CC       the isolated EAD binds POLR2E and POLR2G but not POLR2C. Cis-linked
CC       RNA-binding domain (RBD) can strongly and specifically repress trans-
CC       activation by the EAD.
CC   -!- PTM: Phosphorylated; calmodulin-binding inhibits phosphorylation of
CC       Ser-266. {ECO:0000269|PubMed:9341188}.
CC   -!- PTM: Highly methylated on arginine residues. Methylation is mediated by
CC       PRMT1 and, at lower level by PRMT8. {ECO:0000269|PubMed:11278906,
CC       ECO:0000269|PubMed:18320585, ECO:0000269|Ref.12}.
CC   -!- DISEASE: Ewing sarcoma (ES) [MIM:612219]: A highly malignant,
CC       metastatic, primitive small round cell tumor of bone and soft tissue
CC       that affects children and adolescents. It belongs to the Ewing sarcoma
CC       family of tumors, a group of morphologically heterogeneous neoplasms
CC       that share the same cytogenetic features. They are considered neural
CC       tumors derived from cells of the neural crest. Ewing sarcoma represents
CC       the less differentiated form of the tumors.
CC       {ECO:0000269|PubMed:15044653, ECO:0000269|PubMed:1522903,
CC       ECO:0000269|PubMed:7700648, ECO:0000269|PubMed:9121764}. Note=The
CC       protein represented in this entry is involved in disease pathogenesis.
CC       Chromosomal aberrations involving EWSR1 are found in patients with
CC       Ewing sarcoma. Translocation t(11;22)(q24;q12) with FLI1
CC       (PubMed:1522903, PubMed:15044653). Translocation t(7;22)(p22;q12) with
CC       ETV1 (PubMed:7700648). Translocation t(21;22)(q22;q21) with ERG
CC       (PubMed:15044653). Translocation t(2;21;22)(q23;q22;q12) that forms a
CC       EWSR1-FEV fusion protein with potential oncogenic activity
CC       (PubMed:9121764). {ECO:0000269|PubMed:15044653,
CC       ECO:0000269|PubMed:1522903, ECO:0000269|PubMed:7700648,
CC       ECO:0000269|PubMed:9121764}.
CC   -!- DISEASE: Note=A chromosomal aberration involving EWSR1 has been found
CC       in extraskeletal myxoid chondrosarcoma. Translocation t(9;22)(q22-
CC       31;q11-12) with NR4A3. {ECO:0000269|PubMed:7539287}.
CC   -!- DISEASE: Note=A chromosomal aberration involving EWSR1 is associated
CC       with desmoplastic small round cell tumor (DSRCT). Translocation
CC       t(11;22)(p13;q12) with WT1. {ECO:0000269|PubMed:7862627}.
CC   -!- DISEASE: Note=A chromosomal aberration involving EWSR1 is associated
CC       with malignant melanoma of soft parts (MMSP). Translocation
CC       t(12;22)(q13;q12) with ATF1. Malignant melanoma of soft parts, also
CC       known as soft tissue clear cell sarcoma, is a rare tumor developing in
CC       tendons and aponeuroses. {ECO:0000269|PubMed:8401579}.
CC   -!- DISEASE: Note=A chromosomal aberration involving EWSR1 is associated
CC       with small round cell sarcoma. Translocation t(11;22)(p36.1;q12) with
CC       PATZ1. {ECO:0000269|PubMed:10949935}.
CC   -!- DISEASE: Angiomatoid fibrous histiocytoma (AFH) [MIM:612160]: A
CC       distinct variant of malignant fibrous histiocytoma that typically
CC       occurs in children and adolescents and is manifest by nodular
CC       subcutaneous growth. Characteristic microscopic features include
CC       lobulated sheets of histiocyte-like cells intimately associated with
CC       areas of hemorrhage and cystic pseudovascular spaces, as well as a
CC       striking cuffing of inflammatory cells, mimicking a lymph node
CC       metastasis. {ECO:0000269|PubMed:15884099, ECO:0000269|PubMed:17724745}.
CC       Note=The gene represented in this entry is involved in disease
CC       pathogenesis. Chromosomal aberrations involving EWSR1 are found in
CC       patients with angiomatoid fibrous histiocytoma. Translocation
CC       t(12;22)(q13;q12) with ATF1 generates a chimeric EWSR1/ATF1 protein
CC       (PubMed:15884099). Translocation t(2;22)(q33;q12) with CREB1 generates
CC       a EWSR1/CREB1 fusion gene that is most common genetic abnormality in
CC       this tumor type (PubMed:17724745). {ECO:0000269|PubMed:15884099,
CC       ECO:0000269|PubMed:17724745}.
CC   -!- DISEASE: Note=EFPS arise due to chromosomal translocations in which
CC       EWSR1 is fused to a variety of cellular transcription factors. EFPS are
CC       very potent transcriptional activators dependent on the EAD and a C-
CC       terminal DNA-binding domain contributed by the fusion partner. The
CC       spectrum of malignancies associated with EFPS are thought to arise via
CC       EFP-induced transcriptional deregulation, with the tumor phenotype
CC       specified by the EWSR1 fusion partner and cell type. Transcriptional
CC       repression of the transforming growth factor beta type II receptor (TGF
CC       beta RII) is an important target of the EWS-FLI1, EWS-ERG, or EWS-ETV1
CC       oncogene. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the RRM TET family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA70044.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/EWSR1ID85.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X66899; CAA47350.1; -; mRNA.
DR   EMBL; X72990; CAA51489.1; -; Genomic_DNA.
DR   EMBL; X72991; CAA51489.1; JOINED; Genomic_DNA.
DR   EMBL; X72992; CAA51489.1; JOINED; Genomic_DNA.
DR   EMBL; X72993; CAA51489.1; JOINED; Genomic_DNA.
DR   EMBL; X72994; CAA51489.1; JOINED; Genomic_DNA.
DR   EMBL; X72995; CAA51489.1; JOINED; Genomic_DNA.
DR   EMBL; X72996; CAA51489.1; JOINED; Genomic_DNA.
DR   EMBL; X72997; CAA51489.1; JOINED; Genomic_DNA.
DR   EMBL; X72998; CAA51489.1; JOINED; Genomic_DNA.
DR   EMBL; X72999; CAA51489.1; JOINED; Genomic_DNA.
DR   EMBL; X73000; CAA51489.1; JOINED; Genomic_DNA.
DR   EMBL; X73001; CAA51489.1; JOINED; Genomic_DNA.
DR   EMBL; X73002; CAA51489.1; JOINED; Genomic_DNA.
DR   EMBL; X73003; CAA51489.1; JOINED; Genomic_DNA.
DR   EMBL; X73004; CAA51489.1; JOINED; Genomic_DNA.
DR   EMBL; Y07848; CAA69177.1; -; Genomic_DNA.
DR   EMBL; CR456490; CAG30376.1; -; mRNA.
DR   EMBL; AK056309; BAB71145.1; -; mRNA.
DR   EMBL; AK056681; BAB71252.1; -; mRNA.
DR   EMBL; AL031186; CAI18001.1; -; Genomic_DNA.
DR   EMBL; AC000026; CAI18001.1; JOINED; Genomic_DNA.
DR   EMBL; AC002059; CAI18001.1; JOINED; Genomic_DNA.
DR   EMBL; AL031186; CAQ10937.1; -; Genomic_DNA.
DR   EMBL; AC000026; CAQ10937.1; JOINED; Genomic_DNA.
DR   EMBL; AC002059; CAQ10937.1; JOINED; Genomic_DNA.
DR   EMBL; AL031186; CAQ10938.1; -; Genomic_DNA.
DR   EMBL; AC000026; CAQ10938.1; JOINED; Genomic_DNA.
DR   EMBL; AC002059; CAQ10938.1; JOINED; Genomic_DNA.
DR   EMBL; AL031186; CAQ10940.1; -; Genomic_DNA.
DR   EMBL; AC000026; CAQ10940.1; JOINED; Genomic_DNA.
DR   EMBL; AC002059; CAQ10940.1; JOINED; Genomic_DNA.
DR   EMBL; CH471095; EAW59780.1; -; Genomic_DNA.
DR   EMBL; CH471095; EAW59781.1; -; Genomic_DNA.
DR   EMBL; CH471095; EAW59785.1; -; Genomic_DNA.
DR   EMBL; CH471095; EAW59786.1; -; Genomic_DNA.
DR   EMBL; CH471095; EAW59787.1; -; Genomic_DNA.
DR   EMBL; BC000527; AAH00527.1; -; mRNA.
DR   EMBL; BC004817; AAH04817.1; -; mRNA.
DR   EMBL; BC011048; AAH11048.1; -; mRNA.
DR   EMBL; BC072442; AAH72442.1; -; mRNA.
DR   EMBL; Y08806; CAA70044.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AB016435; BAA31990.1; -; Genomic_DNA.
DR   CCDS; CCDS13851.1; -. [Q01844-1]
DR   CCDS; CCDS13852.2; -. [Q01844-5]
DR   CCDS; CCDS54512.1; -. [Q01844-4]
DR   CCDS; CCDS54513.1; -. [Q01844-3]
DR   CCDS; CCDS54514.1; -. [Q01844-6]
DR   PIR; A49358; A49358.
DR   RefSeq; NP_001156757.1; NM_001163285.1. [Q01844-3]
DR   RefSeq; NP_001156758.1; NM_001163286.1. [Q01844-6]
DR   RefSeq; NP_001156759.1; NM_001163287.1. [Q01844-4]
DR   RefSeq; NP_005234.1; NM_005243.3. [Q01844-1]
DR   RefSeq; NP_053733.2; NM_013986.3. [Q01844-5]
DR   PDB; 2CPE; NMR; -; A=353-453.
DR   PDBsum; 2CPE; -.
DR   BMRB; Q01844; -.
DR   SMR; Q01844; -.
DR   BioGRID; 108431; 755.
DR   CORUM; Q01844; -.
DR   DIP; DIP-34449N; -.
DR   IntAct; Q01844; 181.
DR   MINT; Q01844; -.
DR   STRING; 9606.ENSP00000400142; -.
DR   ChEMBL; CHEMBL3351202; -.
DR   GlyGen; Q01844; 8 sites, 1 O-linked glycan (8 sites).
DR   iPTMnet; Q01844; -.
DR   MetOSite; Q01844; -.
DR   PhosphoSitePlus; Q01844; -.
DR   SwissPalm; Q01844; -.
DR   BioMuta; EWSR1; -.
DR   DMDM; 544261; -.
DR   EPD; Q01844; -.
DR   jPOST; Q01844; -.
DR   MassIVE; Q01844; -.
DR   MaxQB; Q01844; -.
DR   PaxDb; Q01844; -.
DR   PeptideAtlas; Q01844; -.
DR   PRIDE; Q01844; -.
DR   ProteomicsDB; 2658; -.
DR   ProteomicsDB; 58004; -. [Q01844-1]
DR   ProteomicsDB; 58005; -. [Q01844-2]
DR   ProteomicsDB; 58006; -. [Q01844-3]
DR   ProteomicsDB; 58007; -. [Q01844-4]
DR   ProteomicsDB; 58008; -. [Q01844-5]
DR   Antibodypedia; 3786; 542 antibodies.
DR   DNASU; 2130; -.
DR   Ensembl; ENST00000332035; ENSP00000331699; ENSG00000182944. [Q01844-6]
DR   Ensembl; ENST00000333395; ENSP00000327456; ENSG00000182944. [Q01844-4]
DR   Ensembl; ENST00000397938; ENSP00000381031; ENSG00000182944. [Q01844-1]
DR   Ensembl; ENST00000406548; ENSP00000385726; ENSG00000182944. [Q01844-3]
DR   Ensembl; ENST00000414183; ENSP00000400142; ENSG00000182944. [Q01844-5]
DR   GeneID; 2130; -.
DR   KEGG; hsa:2130; -.
DR   UCSC; uc003aes.5; human. [Q01844-1]
DR   CTD; 2130; -.
DR   DisGeNET; 2130; -.
DR   EuPathDB; HostDB:ENSG00000182944.17; -.
DR   GeneCards; EWSR1; -.
DR   HGNC; HGNC:3508; EWSR1.
DR   HPA; ENSG00000182944; Low tissue specificity.
DR   MalaCards; EWSR1; -.
DR   MIM; 133450; gene.
DR   MIM; 612160; phenotype.
DR   MIM; 612219; phenotype.
DR   neXtProt; NX_Q01844; -.
DR   OpenTargets; ENSG00000182944; -.
DR   Orphanet; 83469; Desmoplastic small round cell tumor.
DR   Orphanet; 370334; Extraskeletal Ewing sarcoma.
DR   Orphanet; 209916; Extraskeletal myxoid chondrosarcoma.
DR   Orphanet; 97338; Melanoma of soft tissue.
DR   Orphanet; 319; Skeletal Ewing sarcoma.
DR   PharmGKB; PA27921; -.
DR   eggNOG; KOG1995; Eukaryota.
DR   GeneTree; ENSGT00940000154191; -.
DR   HOGENOM; CLU_025609_1_1_1; -.
DR   InParanoid; Q01844; -.
DR   OMA; NYGSYTQ; -.
DR   OrthoDB; 1539664at2759; -.
DR   PhylomeDB; Q01844; -.
DR   TreeFam; TF322599; -.
DR   PathwayCommons; Q01844; -.
DR   SIGNOR; Q01844; -.
DR   BioGRID-ORCS; 2130; 631 hits in 861 CRISPR screens.
DR   ChiTaRS; EWSR1; human.
DR   EvolutionaryTrace; Q01844; -.
DR   GeneWiki; Ewing_sarcoma_breakpoint_region_1; -.
DR   GenomeRNAi; 2130; -.
DR   Pharos; Q01844; Tbio.
DR   PRO; PR:Q01844; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   RNAct; Q01844; protein.
DR   Bgee; ENSG00000182944; Expressed in testis and 243 other tissues.
DR   ExpressionAtlas; Q01844; baseline and differential.
DR   Genevisible; Q01844; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005516; F:calmodulin binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0003712; F:transcription coregulator activity; IBA:GO_Central.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:InterPro.
DR   CDD; cd12533; RRM_EWS; 1.
DR   DisProt; DP00632; -.
DR   Gene3D; 3.30.70.330; -; 1.
DR   InterPro; IPR034869; EWS_RRM.
DR   InterPro; IPR033109; EWSR1.
DR   InterPro; IPR012677; Nucleotide-bd_a/b_plait_sf.
DR   InterPro; IPR035979; RBD_domain_sf.
DR   InterPro; IPR000504; RRM_dom.
DR   InterPro; IPR034870; TET_fam.
DR   InterPro; IPR001876; Znf_RanBP2.
DR   InterPro; IPR036443; Znf_RanBP2_sf.
DR   PANTHER; PTHR23238; PTHR23238; 1.
DR   PANTHER; PTHR23238:SF3; PTHR23238:SF3; 1.
DR   Pfam; PF00076; RRM_1; 1.
DR   Pfam; PF00641; zf-RanBP; 1.
DR   SMART; SM00360; RRM; 1.
DR   SMART; SM00547; ZnF_RBZ; 1.
DR   SUPFAM; SSF54928; SSF54928; 1.
DR   SUPFAM; SSF90209; SSF90209; 1.
DR   PROSITE; PS50102; RRM; 1.
DR   PROSITE; PS01358; ZF_RANBP2_1; 1.
DR   PROSITE; PS50199; ZF_RANBP2_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Calmodulin-binding;
KW   Cell membrane; Chromosomal rearrangement; Cytoplasm;
KW   Direct protein sequencing; Membrane; Metal-binding; Methylation; Nucleus;
KW   Phosphoprotein; Proto-oncogene; Reference proteome; Repeat; Repressor;
KW   RNA-binding; Transcription; Transcription regulation; Zinc; Zinc-finger.
FT   CHAIN           1..656
FT                   /note="RNA-binding protein EWS"
FT                   /id="PRO_0000081586"
FT   REPEAT          8..16
FT                   /note="1"
FT   REPEAT          17..27
FT                   /note="2"
FT   REPEAT          28..34
FT                   /note="3"
FT   REPEAT          35..42
FT                   /note="4"
FT   REPEAT          43..50
FT                   /note="5"
FT   REPEAT          51..59
FT                   /note="6"
FT   REPEAT          60..68
FT                   /note="7"
FT   REPEAT          69..75
FT                   /note="8"
FT   REPEAT          76..84
FT                   /note="9"
FT   REPEAT          85..91
FT                   /note="10"
FT   REPEAT          92..110
FT                   /note="11"
FT   REPEAT          111..116
FT                   /note="12"
FT   REPEAT          117..125
FT                   /note="13"
FT   REPEAT          126..156
FT                   /note="14"
FT   REPEAT          157..163
FT                   /note="15"
FT   REPEAT          164..170
FT                   /note="16"
FT   REPEAT          171..177
FT                   /note="17"
FT   REPEAT          178..188
FT                   /note="18"
FT   REPEAT          189..193
FT                   /note="19"
FT   REPEAT          194..201
FT                   /note="20"
FT   REPEAT          202..206
FT                   /note="21"
FT   REPEAT          207..212
FT                   /note="22"
FT   REPEAT          213..218
FT                   /note="23"
FT   REPEAT          219..224
FT                   /note="24"
FT   REPEAT          225..230
FT                   /note="25"
FT   REPEAT          231..238
FT                   /note="26"
FT   REPEAT          239..245
FT                   /note="27"
FT   REPEAT          246..252
FT                   /note="28"
FT   REPEAT          253..259
FT                   /note="29"
FT   DOMAIN          256..285
FT                   /note="IQ"
FT   REPEAT          260..276
FT                   /note="30"
FT   REPEAT          277..285
FT                   /note="31"
FT   DOMAIN          361..447
FT                   /note="RRM"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00176"
FT   ZN_FING         518..549
FT                   /note="RanBP2-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00322"
FT   REGION          1..285
FT                   /note="EAD (Gln/Pro/Thr-rich)"
FT   REGION          8..285
FT                   /note="31 X approximate tandem repeats"
FT   MOTIF           639..656
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000269|PubMed:16965792"
FT   COMPBIAS        300..340
FT                   /note="Arg/Gly/Pro-rich"
FT   COMPBIAS        454..513
FT                   /note="Arg/Gly/Pro-rich"
FT   COMPBIAS        559..640
FT                   /note="Arg/Gly/Pro-rich"
FT   SITE            265
FT                   /note="Breakpoint for translocation to form chimeric
FT                   EWSR1/ATF1 protein"
FT   SITE            348..349
FT                   /note="Breakpoint for insertion to form EWSR1-FEV fusion
FT                   protein"
FT   MOD_RES         266
FT                   /note="Phosphoserine; by PKC"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         300
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000269|PubMed:11278906"
FT   MOD_RES         302
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000269|PubMed:11278906"
FT   MOD_RES         304
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000269|PubMed:11278906"
FT   MOD_RES         309
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000269|PubMed:11278906"
FT   MOD_RES         314
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000269|PubMed:11278906"
FT   MOD_RES         317
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000269|PubMed:11278906"
FT   MOD_RES         321
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000269|PubMed:11278906"
FT   MOD_RES         439
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61545"
FT   MOD_RES         455
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000269|PubMed:11278906"
FT   MOD_RES         464
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000269|PubMed:11278906"
FT   MOD_RES         471
FT                   /note="Asymmetric dimethylarginine; alternate"
FT                   /evidence="ECO:0000269|PubMed:11278906"
FT   MOD_RES         471
FT                   /note="Omega-N-methylarginine; alternate"
FT                   /evidence="ECO:0000244|PubMed:24129315,
FT                   ECO:0000269|PubMed:11278906"
FT   MOD_RES         486
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000244|PubMed:24129315"
FT   MOD_RES         490
FT                   /note="Asymmetric dimethylarginine; by PRMT8"
FT                   /evidence="ECO:0000269|PubMed:11278906,
FT                   ECO:0000269|PubMed:18320585"
FT   MOD_RES         494
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000269|PubMed:11278906, ECO:0000269|Ref.12"
FT   MOD_RES         500
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000269|PubMed:11278906"
FT   MOD_RES         503
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000269|PubMed:11278906"
FT   MOD_RES         506
FT                   /note="Asymmetric dimethylarginine; alternate"
FT                   /evidence="ECO:0000269|PubMed:11278906"
FT   MOD_RES         506
FT                   /note="Omega-N-methylarginine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q61545"
FT   MOD_RES         563
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000269|PubMed:11278906"
FT   MOD_RES         565
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000269|PubMed:11278906"
FT   MOD_RES         572
FT                   /note="Asymmetric dimethylarginine; alternate; by PRMT8"
FT                   /evidence="ECO:0000269|PubMed:11278906,
FT                   ECO:0000269|PubMed:18320585"
FT   MOD_RES         572
FT                   /note="Omega-N-methylarginine; alternate; by PRMT8"
FT                   /evidence="ECO:0000269|PubMed:11278906,
FT                   ECO:0000269|PubMed:18320585"
FT   MOD_RES         575
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000269|PubMed:11278906"
FT   MOD_RES         581
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000269|PubMed:11278906"
FT   MOD_RES         589
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000269|PubMed:11278906"
FT   MOD_RES         592
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000269|PubMed:11278906"
FT   MOD_RES         596
FT                   /note="Asymmetric dimethylarginine; alternate; by PRMT8"
FT                   /evidence="ECO:0000269|PubMed:11278906,
FT                   ECO:0000269|PubMed:18320585"
FT   MOD_RES         596
FT                   /note="Omega-N-methylarginine; alternate; by PRMT8"
FT                   /evidence="ECO:0000269|PubMed:11278906,
FT                   ECO:0000269|PubMed:18320585"
FT   MOD_RES         600
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000269|PubMed:11278906"
FT   MOD_RES         603
FT                   /note="Asymmetric dimethylarginine; by PRMT8"
FT                   /evidence="ECO:0000269|PubMed:11278906,
FT                   ECO:0000269|PubMed:18320585"
FT   MOD_RES         607
FT                   /note="Asymmetric dimethylarginine; alternate; by PRMT8"
FT                   /evidence="ECO:0000269|PubMed:11278906,
FT                   ECO:0000269|PubMed:18320585"
FT   MOD_RES         607
FT                   /note="Omega-N-methylarginine; alternate; by PRMT8"
FT                   /evidence="ECO:0000269|PubMed:11278906,
FT                   ECO:0000269|PubMed:18320585"
FT   MOD_RES         615
FT                   /note="Asymmetric dimethylarginine; alternate"
FT                   /evidence="ECO:0000269|PubMed:11278906, ECO:0000269|Ref.12"
FT   MOD_RES         615
FT                   /note="Omega-N-methylarginine; alternate"
FT                   /evidence="ECO:0000244|PubMed:24129315"
FT   MOD_RES         633
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000269|PubMed:11278906"
FT   MOD_RES         636
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000269|PubMed:11278906"
FT   VAR_SEQ         74
FT                   /note="P -> PTVEGTS (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_043451"
FT   VAR_SEQ         136..191
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045412"
FT   VAR_SEQ         266..338
FT                   /note="Missing (in isoform EWS-B)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_005793"
FT   VAR_SEQ         326..354
FT                   /note="SAGERGGFNKPGGPMDEGPDLDLGPPVDP -> LQSESLVYTSILKKYPYSV
FT                   LSRQHNEKWD (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_043452"
FT   VAR_SEQ         326
FT                   /note="Missing (in isoform 3 and isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15461802, ECO:0000303|PubMed:15489334"
FT                   /id="VSP_043453"
FT   VAR_SEQ         355..656
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_043454"
FT   MUTAGEN         648
FT                   /note="R->A: Cytoplasmic localization."
FT                   /evidence="ECO:0000269|PubMed:16965792"
FT   MUTAGEN         648
FT                   /note="R->K: No effect on nuclear targeting."
FT                   /evidence="ECO:0000269|PubMed:16965792"
FT   MUTAGEN         651
FT                   /note="R->A: No effect on nuclear targeting."
FT                   /evidence="ECO:0000269|PubMed:16965792"
FT   MUTAGEN         652
FT                   /note="R->A: Cytoplasmic localization."
FT                   /evidence="ECO:0000269|PubMed:16965792"
FT   MUTAGEN         652
FT                   /note="R->K: No effect on nuclear targeting."
FT                   /evidence="ECO:0000269|PubMed:16965792"
FT   MUTAGEN         653
FT                   /note="D->A: No effect on nuclear targeting."
FT                   /evidence="ECO:0000269|PubMed:16965792"
FT   MUTAGEN         654
FT                   /note="R->A: No effect on nuclear targeting."
FT                   /evidence="ECO:0000269|PubMed:16965792"
FT   MUTAGEN         655
FT                   /note="P->A: Cytoplasmic localization."
FT                   /evidence="ECO:0000269|PubMed:16965792"
FT   MUTAGEN         656
FT                   /note="Y->A: Cytoplasmic localization."
FT                   /evidence="ECO:0000269|PubMed:16965792"
FT   CONFLICT        224
FT                   /note="S -> G (in Ref. 5; BAB71252)"
FT                   /evidence="ECO:0000305"
FT   STRAND          362..366
FT                   /evidence="ECO:0000244|PDB:2CPE"
FT   HELIX           374..381
FT                   /evidence="ECO:0000244|PDB:2CPE"
FT   TURN            382..384
FT                   /evidence="ECO:0000244|PDB:2CPE"
FT   STRAND          391..393
FT                   /evidence="ECO:0000244|PDB:2CPE"
FT   STRAND          396..399
FT                   /evidence="ECO:0000244|PDB:2CPE"
FT   TURN            404..406
FT                   /evidence="ECO:0000244|PDB:2CPE"
FT   STRAND          411..419
FT                   /evidence="ECO:0000244|PDB:2CPE"
FT   HELIX           420..430
FT                   /evidence="ECO:0000244|PDB:2CPE"
FT   STRAND          441..443
FT                   /evidence="ECO:0000244|PDB:2CPE"
SQ   SEQUENCE   656 AA;  68478 MW;  0DA02CEE146720BB CRC64;
     MASTDYSTYS QAAAQQGYSA YTAQPTQGYA QTTQAYGQQS YGTYGQPTDV SYTQAQTTAT
     YGQTAYATSY GQPPTGYTTP TAPQAYSQPV QGYGTGAYDT TTATVTTTQA SYAAQSAYGT
     QPAYPAYGQQ PAATAPTRPQ DGNKPTETSQ PQSSTGGYNQ PSLGYGQSNY SYPQVPGSYP
     MQPVTAPPSY PPTSYSSTQP TSYDQSSYSQ QNTYGQPSSY GQQSSYGQQS SYGQQPPTSY
     PPQTGSYSQA PSQYSQQSSS YGQQSSFRQD HPSSMGVYGQ ESGGFSGPGE NRSMSGPDNR
     GRGRGGFDRG GMSRGGRGGG RGGMGSAGER GGFNKPGGPM DEGPDLDLGP PVDPDEDSDN
     SAIYVQGLND SVTLDDLADF FKQCGVVKMN KRTGQPMIHI YLDKETGKPK GDATVSYEDP
     PTAKAAVEWF DGKDFQGSKL KVSLARKKPP MNSMRGGLPP REGRGMPPPL RGGPGGPGGP
     GGPMGRMGGR GGDRGGFPPR GPRGSRGNPS GGGNVQHRAG DWQCPNPGCG NQNFAWRTEC
     NQCKAPKPEG FLPPPFPPPG GDRGRGGPGG MRGGRGGLMD RGGPGGMFRG GRGGDRGGFR
     GGRGMDRGGF GGGRRGGPGG PPGPLMEQMG GRRGGRGGPG KMDKGEHRQE RRDRPY
//
ID   POTE1_HUMAN             Reviewed;         634 AA.
AC   Q9NUX5; O95018; Q5MJ36; Q9H662; Q9NW19; Q9UG95;
DT   19-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   02-DEC-2020, entry version 186.
DE   RecName: Full=Protection of telomeres protein 1;
DE            Short=hPot1;
DE   AltName: Full=POT1-like telomere end-binding protein;
GN   Name=POT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   SINGLE-STRANDED TELOMERE DNA-BINDING.
RC   TISSUE=Ovary;
RX   PubMed=11349150; DOI=10.1126/science.1060036;
RA   Baumann P., Cech T.R.;
RT   "Pot1, the putative telomere end-binding protein in fission yeast and
RT   humans.";
RL   Science 292:1171-1175(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ALTERNATIVE SPLICING (ISOFORMS 1
RP   AND 2), TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND SINGLE-STRANDED
RP   TELOMERE DNA-BINDING.
RX   PubMed=12391173; DOI=10.1128/mcb.22.22.8079-8087.2002;
RA   Baumann P., Podell E., Cech T.R.;
RT   "Human Pot1 (protection of telomeres) protein: cytolocalization, gene
RT   structure, and alternative splicing.";
RL   Mol. Cell. Biol. 22:8079-8087(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta, Small intestine, and Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 499-634 (ISOFORM 1).
RC   TISSUE=Uterus;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [8]
RP   FUNCTION IN TELOMERE REGULATION, ALTERNATIVE SPLICING (ISOFORMS 1 AND 2),
RP   AND SINGLE-STRANDED TELOMERE DNA-BINDING.
RX   PubMed=12781132; DOI=10.1016/s0960-9822(03)00339-7;
RA   Colgin L.M., Baran K., Baumann P., Cech T.R., Reddel R.R.;
RT   "Human POT1 facilitates telomere elongation by telomerase.";
RL   Curr. Biol. 13:942-946(2003).
RN   [9]
RP   FUNCTION IN TELOMERE REGULATION, IDENTIFICATION IN A COMPLEX WITH TERF1;
RP   TINF2 AND TNKS1, AND INTERACTION WITH TNKS1.
RX   PubMed=12768206; DOI=10.1038/nature01688;
RA   Loayza D., De Lange T.;
RT   "POT1 as a terminal transducer of TRF1 telomere length control.";
RL   Nature 423:1013-1018(2003).
RN   [10]
RP   SINGLE-STRANDED TELOMERE DNA-BINDING.
RX   PubMed=14715659; DOI=10.1074/jbc.m312309200;
RA   Loayza D., Parsons H., Donigian J., Hoke K., de Lange T.;
RT   "DNA binding features of human POT1: a nonamer 5'-TAGGGTTAG-3' minimal
RT   binding site, sequence specificity, and internal binding to multimeric
RT   sites.";
RL   J. Biol. Chem. 279:13241-13248(2004).
RN   [11]
RP   INTERACTION WITH ACD.
RX   PubMed=15231715; DOI=10.1101/gad.1215404;
RA   Ye J.Z.-S., Hockemeyer D., Krutchinsky A.N., Loayza D., Hooper S.M.,
RA   Chait B.T., de Lange T.;
RT   "POT1-interacting protein PIP1: a telomere length regulator that recruits
RT   POT1 to the TIN2/TRF1 complex.";
RL   Genes Dev. 18:1649-1654(2004).
RN   [12]
RP   IDENTIFICATION IN THE SHELTERIN COMPLEX.
RX   PubMed=15316005; DOI=10.1074/jbc.m409047200;
RA   Ye J.Z.-S., Donigian J.R., van Overbeek M., Loayza D., Luo Y.,
RA   Krutchinsky A.N., Chait B.T., de Lange T.;
RT   "TIN2 binds TRF1 and TRF2 simultaneously and stabilizes the TRF2 complex on
RT   telomeres.";
RL   J. Biol. Chem. 279:47264-47271(2004).
RN   [13]
RP   IDENTIFICATION IN THE SHELTERIN COMPLEX.
RX   PubMed=15383534; DOI=10.1074/jbc.m409293200;
RA   Liu D., O'Connor M.S., Qin J., Songyang Z.;
RT   "Telosome, a mammalian telomere-associated complex formed by multiple
RT   telomeric proteins.";
RL   J. Biol. Chem. 279:51338-51342(2004).
RN   [14]
RP   FUNCTION OF THE SHELTERIN COMPLEX.
RX   PubMed=16166375; DOI=10.1101/gad.1346005;
RA   de Lange T.;
RT   "Shelterin: the protein complex that shapes and safeguards human
RT   telomeres.";
RL   Genes Dev. 19:2100-2110(2005).
RN   [15]
RP   FUNCTION, SUBUNIT, AND IDENTIFICATION IN A COMPLEX WITH ACD AND
RP   SINGLE-STRANDED TELOMERIC DNA.
RX   PubMed=17237768; DOI=10.1038/nature05454;
RA   Wang F., Podell E.R., Zaug A.J., Yang Y., Baciu P., Cech T.R., Lei M.;
RT   "The POT1-TPP1 telomere complex is a telomerase processivity factor.";
RL   Nature 445:506-510(2007).
RN   [16]
RP   IDENTIFICATION IN THE TELOMERASE HOLOENZYME COMPLEX.
RX   PubMed=19179534; DOI=10.1126/science.1165357;
RA   Venteicher A.S., Abreu E.B., Meng Z., McCann K.E., Terns R.M.,
RA   Veenstra T.D., Terns M.P., Artandi S.E.;
RT   "A human telomerase holoenzyme protein required for Cajal body localization
RT   and telomere synthesis.";
RL   Science 323:644-648(2009).
RN   [17]
RP   FUNCTION.
RX   PubMed=20231318; DOI=10.1101/gad.1881810;
RA   Zaug A.J., Podell E.R., Nandakumar J., Cech T.R.;
RT   "Functional interaction between telomere protein TPP1 and telomerase.";
RL   Genes Dev. 24:613-622(2010).
RN   [18]
RP   INVOLVEMENT IN GLM9, AND VARIANT GLM9 CYS-95.
RX   PubMed=25482530; DOI=10.1093/jnci/dju384;
RG   Gliogene Consortium;
RA   Bainbridge M.N., Armstrong G.N., Gramatges M.M., Bertuch A.A.,
RA   Jhangiani S.N., Doddapaneni H., Lewis L., Tombrello J., Tsavachidis S.,
RA   Liu Y., Jalali A., Plon S.E., Lau C.C., Parsons D.W., Claus E.B.,
RA   Barnholtz-Sloan J., Il'yasova D., Schildkraut J., Ali-Osman F.,
RA   Sadetzki S., Johansen C., Houlston R.S., Jenkins R.B., Lachance D.,
RA   Olson S.H., Bernstein J.L., Merrell R.T., Wrensch M.R., Walsh K.M.,
RA   Davis F.G., Lai R., Shete S., Aldape K., Amos C.I., Thompson P.A.,
RA   Muzny D.M., Gibbs R.A., Melin B.S., Bondy M.L.;
RT   "Germline mutations in shelterin complex genes are associated with familial
RT   glioma.";
RL   J. Natl. Cancer Inst. 107:384-384(2015).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.73 ANGSTROMS) OF 6-299 IN COMPLEX WITH
RP   SINGLE-STRANDED TELOMERIC DNA.
RX   PubMed=15558049; DOI=10.1038/nsmb867;
RA   Lei M., Podell E.R., Cech T.R.;
RT   "Structure of human POT1 bound to telomeric single-stranded DNA provides a
RT   model for chromosome end-protection.";
RL   Nat. Struct. Mol. Biol. 11:1223-1229(2004).
RN   [20]
RP   INVOLVEMENT IN CMM10, VARIANTS CMM10 CYS-89; GLU-94 AND LEU-273, AND
RP   CHARACTERIZATION OF VARIANTS CMM10 CYS-89; GLU-94 AND LEU-273.
RX   PubMed=24686849; DOI=10.1038/ng.2947;
RA   Robles-Espinoza C.D., Harland M., Ramsay A.J., Aoude L.G., Quesada V.,
RA   Ding Z., Pooley K.A., Pritchard A.L., Tiffen J.C., Petljak M., Palmer J.M.,
RA   Symmons J., Johansson P., Stark M.S., Gartside M.G., Snowden H.,
RA   Montgomery G.W., Martin N.G., Liu J.Z., Choi J., Makowski M., Brown K.M.,
RA   Dunning A.M., Keane T.M., Lopez-Otin C., Gruis N.A., Hayward N.K.,
RA   Bishop D.T., Newton-Bishop J.A., Adams D.J.;
RT   "POT1 loss-of-function variants predispose to familial melanoma.";
RL   Nat. Genet. 46:478-481(2014).
RN   [21]
RP   VARIANTS CMM10 HIS-137; ASN-224; ASN-270; PRO-532 AND HIS-623, AND
RP   CHARACTERIZATION OF VARIANTS CMM10 HIS-137; ASN-270 AND HIS-623.
RX   PubMed=24686846; DOI=10.1038/ng.2941;
RA   Shi J., Yang X.R., Ballew B., Rotunno M., Calista D., Fargnoli M.C.,
RA   Ghiorzo P., Bressac-de Paillerets B., Nagore E., Avril M.F., Caporaso N.E.,
RA   McMaster M.L., Cullen M., Wang Z., Zhang X., Bruno W., Pastorino L.,
RA   Queirolo P., Banuls-Roca J., Garcia-Casado Z., Vaysse A., Mohamdi H.,
RA   Riazalhosseini Y., Foglio M., Jouenne F., Hua X., Hyland P.L., Yin J.,
RA   Vallabhaneni H., Chai W., Minghetti P., Pellegrini C., Ravichandran S.,
RA   Eggermont A., Lathrop M., Peris K., Scarra G.B., Landi G., Savage S.A.,
RA   Sampson J.N., He J., Yeager M., Goldin L.R., Demenais F., Chanock S.J.,
RA   Tucker M.A., Goldstein A.M., Liu Y., Landi M.T.;
RT   "Rare missense variants in POT1 predispose to familial cutaneous malignant
RT   melanoma.";
RL   Nat. Genet. 46:482-486(2014).
CC   -!- FUNCTION: Component of the telomerase ribonucleoprotein (RNP) complex
CC       that is essential for the replication of chromosome termini. Is a
CC       component of the double-stranded telomeric DNA-binding TRF1 complex
CC       which is involved in the regulation of telomere length by cis-
CC       inhibition of telomerase. Also acts as a single-stranded telomeric DNA-
CC       binding protein and thus may act as a downstream effector of the TRF1
CC       complex and may transduce information about telomere maintenance and/or
CC       length to the telomere terminus. Component of the shelterin complex
CC       (telosome) that is involved in the regulation of telomere length and
CC       protection. Shelterin associates with arrays of double-stranded TTAGGG
CC       repeats added by telomerase and protects chromosome ends; without its
CC       protective activity, telomeres are no longer hidden from the DNA damage
CC       surveillance and chromosome ends are inappropriately processed by DNA
CC       repair pathways. Binds to two or more telomeric single-stranded 5'-
CC       TTAGGG-3' repeats (G-strand) and with high specificity to a minimal
CC       telomeric single-stranded 5'-TAGGGTTAG-3' sequence. Binds telomeric
CC       single-stranded sequences internally or at proximity of a 3'-end. Its
CC       activity is TERT dependent but it does not increase TERT activity by
CC       itself. In contrast, the ACD-POT1 heterodimer enhances telomere
CC       elongation by increasing telomerase processivity.
CC       {ECO:0000269|PubMed:12768206, ECO:0000269|PubMed:12781132,
CC       ECO:0000269|PubMed:16166375, ECO:0000269|PubMed:17237768,
CC       ECO:0000269|PubMed:20231318}.
CC   -!- SUBUNIT: Homodimer or homooligomer (PubMed:17237768). Component of the
CC       shelterin complex (telosome) composed of TERF1, TERF2, TINF2, TERF2IP,
CC       ACD and POT1 (PubMed:15316005, PubMed:15383534). Binds single-stranded
CC       telomeric DNA as a monomer (PubMed:15558049). Associated component of
CC       the telomerase holoenzyme complex (PubMed:19179534). Found in a complex
CC       with TERF1, TINF2 and TNKS1 (PubMed:12768206). Interacts with TNKS1.
CC       Forms heterodimers with ACD (PubMed:15231715). Identified in a complex
CC       with ACD and single-stranded telomeric DNA (PubMed:17237768).
CC       {ECO:0000269|PubMed:12768206, ECO:0000269|PubMed:15231715,
CC       ECO:0000269|PubMed:15316005, ECO:0000269|PubMed:15383534,
CC       ECO:0000269|PubMed:15558049, ECO:0000269|PubMed:17237768,
CC       ECO:0000269|PubMed:19179534}.
CC   -!- INTERACTION:
CC       Q9NUX5; Q96AP0: ACD; NbExp=9; IntAct=EBI-752420, EBI-717666;
CC       Q9NUX5; P30838: ALDH3A1; NbExp=2; IntAct=EBI-752420, EBI-3905126;
CC       Q9NUX5; P07355: ANXA2; NbExp=2; IntAct=EBI-752420, EBI-352622;
CC       Q9NUX5; Q9BV29: CCDC32; NbExp=2; IntAct=EBI-752420, EBI-2874058;
CC       Q9NUX5; Q549N0: CFL2; NbExp=3; IntAct=EBI-752420, EBI-10201319;
CC       Q9NUX5; Q9Y281: CFL2; NbExp=3; IntAct=EBI-752420, EBI-351218;
CC       Q9NUX5; O95833: CLIC3; NbExp=2; IntAct=EBI-752420, EBI-10192241;
CC       Q9NUX5; Q6PJW8: CNST; NbExp=2; IntAct=EBI-752420, EBI-750390;
CC       Q9NUX5; O60496: DOK2; NbExp=2; IntAct=EBI-752420, EBI-1046024;
CC       Q9NUX5; O94808: GFPT2; NbExp=2; IntAct=EBI-752420, EBI-6916534;
CC       Q9NUX5; Q99795: GPA33; NbExp=2; IntAct=EBI-752420, EBI-4289554;
CC       Q9NUX5; P46952: HAAO; NbExp=2; IntAct=EBI-752420, EBI-743215;
CC       Q9NUX5; P50747: HLCS; NbExp=2; IntAct=EBI-752420, EBI-3915568;
CC       Q9NUX5; P09601: HMOX1; NbExp=2; IntAct=EBI-752420, EBI-2806151;
CC       Q9NUX5; P0DMV8: HSPA1A; NbExp=2; IntAct=EBI-752420, EBI-11052499;
CC       Q9NUX5; Q9NPH2: ISYNA1; NbExp=2; IntAct=EBI-752420, EBI-720563;
CC       Q9NUX5; Q96A73: KIAA1191; NbExp=2; IntAct=EBI-752420, EBI-725897;
CC       Q9NUX5; Q8WXG6: MADD; NbExp=2; IntAct=EBI-752420, EBI-310528;
CC       Q9NUX5; P43358: MAGEA4; NbExp=2; IntAct=EBI-752420, EBI-743122;
CC       Q9NUX5; Q12851: MAP4K2; NbExp=2; IntAct=EBI-752420, EBI-49783;
CC       Q9NUX5; Q03426: MVK; NbExp=2; IntAct=EBI-752420, EBI-740630;
CC       Q9NUX5; Q9BY11: PACSIN1; NbExp=2; IntAct=EBI-752420, EBI-721769;
CC       Q9NUX5; Q96GU1: PAGE5; NbExp=2; IntAct=EBI-752420, EBI-11305258;
CC       Q9NUX5; Q01064: PDE1B; NbExp=2; IntAct=EBI-752420, EBI-7413304;
CC       Q9NUX5; Q5SRE7: PHYHD1; NbExp=2; IntAct=EBI-752420, EBI-2623130;
CC       Q9NUX5; Q8IUZ5: PHYKPL; NbExp=2; IntAct=EBI-752420, EBI-751947;
CC       Q9NUX5; Q9P0Z9: PIPOX; NbExp=2; IntAct=EBI-752420, EBI-725582;
CC       Q9NUX5; Q86WR7: PROSER2; NbExp=2; IntAct=EBI-752420, EBI-2880603;
CC       Q9NUX5; Q9BRP8: PYM1; NbExp=2; IntAct=EBI-752420, EBI-2352802;
CC       Q9NUX5; Q9BWH6: RPAP1; NbExp=2; IntAct=EBI-752420, EBI-1048085;
CC       Q9NUX5; O43704: SULT1B1; NbExp=2; IntAct=EBI-752420, EBI-10179062;
CC       Q9NUX5; Q9BR01: SULT4A1; NbExp=2; IntAct=EBI-752420, EBI-6690555;
CC       Q9NUX5; Q96A49: SYAP1; NbExp=2; IntAct=EBI-752420, EBI-10770179;
CC       Q9NUX5; Q15554: TERF2; NbExp=7; IntAct=EBI-752420, EBI-706637;
CC       Q9NUX5; Q9BSI4: TINF2; NbExp=3; IntAct=EBI-752420, EBI-717399;
CC       Q9NUX5; P63313: TMSB10; NbExp=2; IntAct=EBI-752420, EBI-2688673;
CC       Q9NUX5; Q9Y4P8: WIPI2; NbExp=2; IntAct=EBI-752420, EBI-719396;
CC       Q9NUX5-1; Q96AP0: ACD; NbExp=4; IntAct=EBI-15593881, EBI-717666;
CC       Q9NUX5-2; Q96AP0: ACD; NbExp=3; IntAct=EBI-752435, EBI-717666;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12391173}.
CC       Chromosome, telomere {ECO:0000269|PubMed:12391173}. Note=Colocalizes
CC       with telomeric DNA.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC         Comment=A number of isoforms are produced.;
CC       Name=1; Synonyms=Variant 1;
CC         IsoId=Q9NUX5-1; Sequence=Displayed;
CC       Name=2; Synonyms=Variant 3;
CC         IsoId=Q9NUX5-2; Sequence=VSP_010846, VSP_010847;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. {ECO:0000269|PubMed:11349150,
CC       ECO:0000269|PubMed:12391173}.
CC   -!- DISEASE: Melanoma, cutaneous malignant 10 (CMM10) [MIM:615848]: A
CC       malignant neoplasm of melanocytes, arising de novo or from a pre-
CC       existing benign nevus, which occurs most often in the skin but also may
CC       involve other sites. {ECO:0000269|PubMed:24686846,
CC       ECO:0000269|PubMed:24686849}. Note=Disease susceptibility is associated
CC       with variations affecting the gene represented in this entry.
CC   -!- DISEASE: Glioma 9 (GLM9) [MIM:616568]: Gliomas are benign or malignant
CC       central nervous system neoplasms derived from glial cells. They
CC       comprise astrocytomas and glioblastoma multiforme that are derived from
CC       astrocytes, oligodendrogliomas derived from oligodendrocytes and
CC       ependymomas derived from ependymocytes. {ECO:0000269|PubMed:25482530}.
CC       Note=Disease susceptibility is associated with variations affecting the
CC       gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the telombin family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB15404.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY823520; AAW22613.1; -; mRNA.
DR   EMBL; AK001230; BAA91568.1; -; mRNA.
DR   EMBL; AK001935; BAA91988.1; -; mRNA.
DR   EMBL; AK022580; BAB14110.1; -; mRNA.
DR   EMBL; AK026234; BAB15404.1; ALT_INIT; mRNA.
DR   EMBL; AC004925; AAD08852.1; -; Genomic_DNA.
DR   EMBL; AC096665; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC110791; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471070; EAW83616.1; -; Genomic_DNA.
DR   EMBL; BC002923; AAH02923.1; -; mRNA.
DR   EMBL; AL050120; CAB43281.1; -; mRNA.
DR   CCDS; CCDS5793.1; -. [Q9NUX5-1]
DR   PIR; T08766; T08766.
DR   RefSeq; NP_001036059.1; NM_001042594.1.
DR   RefSeq; NP_056265.2; NM_015450.2. [Q9NUX5-1]
DR   RefSeq; XP_006715980.1; XM_006715917.3.
DR   PDB; 1XJV; X-ray; 1.73 A; A=6-299.
DR   PDB; 3KJO; X-ray; 1.80 A; A=1-299.
DR   PDB; 3KJP; X-ray; 1.80 A; A=1-299.
DR   PDB; 5H65; X-ray; 2.10 A; A=341-634.
DR   PDB; 5UN7; X-ray; 2.10 A; A=330-634.
DR   PDBsum; 1XJV; -.
DR   PDBsum; 3KJO; -.
DR   PDBsum; 3KJP; -.
DR   PDBsum; 5H65; -.
DR   PDBsum; 5UN7; -.
DR   SMR; Q9NUX5; -.
DR   BioGRID; 117417; 219.
DR   ComplexPortal; CPX-152; Shelterin complex.
DR   CORUM; Q9NUX5; -.
DR   DIP; DIP-29610N; -.
DR   IntAct; Q9NUX5; 183.
DR   STRING; 9606.ENSP00000350249; -.
DR   BindingDB; Q9NUX5; -.
DR   ChEMBL; CHEMBL5908; -.
DR   MoonDB; Q9NUX5; Predicted.
DR   iPTMnet; Q9NUX5; -.
DR   PhosphoSitePlus; Q9NUX5; -.
DR   BioMuta; POT1; -.
DR   DMDM; 50401179; -.
DR   EPD; Q9NUX5; -.
DR   jPOST; Q9NUX5; -.
DR   MassIVE; Q9NUX5; -.
DR   MaxQB; Q9NUX5; -.
DR   PaxDb; Q9NUX5; -.
DR   PeptideAtlas; Q9NUX5; -.
DR   PRIDE; Q9NUX5; -.
DR   ProteomicsDB; 82726; -. [Q9NUX5-1]
DR   ProteomicsDB; 82727; -. [Q9NUX5-2]
DR   Antibodypedia; 31798; 302 antibodies.
DR   DNASU; 25913; -.
DR   Ensembl; ENST00000357628; ENSP00000350249; ENSG00000128513. [Q9NUX5-1]
DR   Ensembl; ENST00000653241; ENSP00000499476; ENSG00000128513. [Q9NUX5-1]
DR   Ensembl; ENST00000655761; ENSP00000499635; ENSG00000128513. [Q9NUX5-1]
DR   Ensembl; ENST00000664366; ENSP00000499290; ENSG00000128513. [Q9NUX5-1]
DR   Ensembl; ENST00000668382; ENSP00000499546; ENSG00000128513. [Q9NUX5-1]
DR   GeneID; 25913; -.
DR   KEGG; hsa:25913; -.
DR   UCSC; uc003vlm.4; human. [Q9NUX5-1]
DR   CTD; 25913; -.
DR   DisGeNET; 25913; -.
DR   EuPathDB; HostDB:ENSG00000128513.14; -.
DR   GeneCards; POT1; -.
DR   HGNC; HGNC:17284; POT1.
DR   HPA; ENSG00000128513; Low tissue specificity.
DR   MalaCards; POT1; -.
DR   MIM; 606478; gene.
DR   MIM; 615848; phenotype.
DR   MIM; 616568; phenotype.
DR   neXtProt; NX_Q9NUX5; -.
DR   OpenTargets; ENSG00000128513; -.
DR   Orphanet; 251630; Anaplastic oligodendroglioma.
DR   Orphanet; 67038; B-cell chronic lymphocytic leukemia.
DR   Orphanet; 618; Familial melanoma.
DR   Orphanet; 251627; Oligodendroglioma.
DR   PharmGKB; PA134934904; -.
DR   eggNOG; KOG4757; Eukaryota.
DR   GeneTree; ENSGT00390000018285; -.
DR   HOGENOM; CLU_019567_0_0_1; -.
DR   InParanoid; Q9NUX5; -.
DR   OMA; DSQNMES; -.
DR   PhylomeDB; Q9NUX5; -.
DR   TreeFam; TF328398; -.
DR   PathwayCommons; Q9NUX5; -.
DR   Reactome; R-HSA-110328; Recognition and association of DNA glycosylase with site containing an affected pyrimidine.
DR   Reactome; R-HSA-110329; Cleavage of the damaged pyrimidine.
DR   Reactome; R-HSA-110330; Recognition and association of DNA glycosylase with site containing an affected purine.
DR   Reactome; R-HSA-110331; Cleavage of the damaged purine.
DR   Reactome; R-HSA-1221632; Meiotic synapsis.
DR   Reactome; R-HSA-171306; Packaging Of Telomere Ends.
DR   Reactome; R-HSA-171319; Telomere Extension By Telomerase.
DR   Reactome; R-HSA-174411; Polymerase switching on the C-strand of the telomere.
DR   Reactome; R-HSA-174414; Processive synthesis on the C-strand of the telomere.
DR   Reactome; R-HSA-174417; Telomere C-strand (Lagging Strand) Synthesis.
DR   Reactome; R-HSA-174430; Telomere C-strand synthesis initiation.
DR   Reactome; R-HSA-174437; Removal of the Flap Intermediate from the C-strand.
DR   Reactome; R-HSA-2559586; DNA Damage/Telomere Stress Induced Senescence.
DR   Reactome; R-HSA-9670095; Inhibition of DNA recombination at telomere.
DR   SIGNOR; Q9NUX5; -.
DR   BioGRID-ORCS; 25913; 341 hits in 858 CRISPR screens.
DR   ChiTaRS; POT1; human.
DR   EvolutionaryTrace; Q9NUX5; -.
DR   GeneWiki; POT1; -.
DR   GenomeRNAi; 25913; -.
DR   Pharos; Q9NUX5; Tbio.
DR   PRO; PR:Q9NUX5; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; Q9NUX5; protein.
DR   Bgee; ENSG00000128513; Expressed in stomach and 229 other tissues.
DR   ExpressionAtlas; Q9NUX5; baseline and differential.
DR   Genevisible; Q9NUX5; HS.
DR   GO; GO:0000781; C:chromosome, telomeric region; IDA:UniProtKB.
DR   GO; GO:0000784; C:nuclear chromosome, telomeric region; IDA:BHF-UCL.
DR   GO; GO:0000783; C:nuclear telomere cap complex; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0070187; C:shelterin complex; IDA:BHF-UCL.
DR   GO; GO:1905773; F:8-hydroxy-2'-deoxyguanosine DNA binding; IDA:BHF-UCL.
DR   GO; GO:0017151; F:DEAD/H-box RNA helicase binding; IPI:BHF-UCL.
DR   GO; GO:1990955; F:G-rich single-stranded DNA binding; IDA:BHF-UCL.
DR   GO; GO:0098505; F:G-rich strand telomeric DNA binding; IDA:BHF-UCL.
DR   GO; GO:0043047; F:single-stranded telomeric DNA binding; IDA:BHF-UCL.
DR   GO; GO:0010521; F:telomerase inhibitor activity; IDA:BHF-UCL.
DR   GO; GO:0061821; F:telomeric D-loop binding; IDA:BHF-UCL.
DR   GO; GO:0042162; F:telomeric DNA binding; IDA:BHF-UCL.
DR   GO; GO:0032508; P:DNA duplex unwinding; IDA:BHF-UCL.
DR   GO; GO:0070200; P:establishment of protein localization to telomere; IMP:BHF-UCL.
DR   GO; GO:0051974; P:negative regulation of telomerase activity; IDA:BHF-UCL.
DR   GO; GO:0032211; P:negative regulation of telomere maintenance via telomerase; IGI:BHF-UCL.
DR   GO; GO:1905776; P:positive regulation of DNA helicase activity; IDA:BHF-UCL.
DR   GO; GO:0060383; P:positive regulation of DNA strand elongation; IDA:BHF-UCL.
DR   GO; GO:0051096; P:positive regulation of helicase activity; IDA:BHF-UCL.
DR   GO; GO:0051973; P:positive regulation of telomerase activity; IDA:BHF-UCL.
DR   GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; IDA:BHF-UCL.
DR   GO; GO:1905774; P:regulation of DNA helicase activity; IDA:BHF-UCL.
DR   GO; GO:2001032; P:regulation of double-strand break repair via nonhomologous end joining; IDA:CACAO.
DR   GO; GO:0032210; P:regulation of telomere maintenance via telomerase; IGI:BHF-UCL.
DR   GO; GO:0032202; P:telomere assembly; IDA:BHF-UCL.
DR   GO; GO:0016233; P:telomere capping; IMP:BHF-UCL.
DR   GO; GO:0007004; P:telomere maintenance via telomerase; IDA:UniProtKB.
DR   GO; GO:0061820; P:telomeric D-loop disassembly; IGI:BHF-UCL.
DR   InterPro; IPR012340; NA-bd_OB-fold.
DR   InterPro; IPR028389; POT1.
DR   InterPro; IPR032042; POT1PC.
DR   InterPro; IPR011564; Telomer_end-bd_POT1/Cdc13.
DR   PANTHER; PTHR14513; PTHR14513; 1.
DR   Pfam; PF02765; POT1; 1.
DR   Pfam; PF16686; POT1PC; 1.
DR   SMART; SM00976; Telo_bind; 1.
DR   SUPFAM; SSF50249; SSF50249; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Chromosome; Disease mutation;
KW   DNA-binding; Nucleus; Polymorphism; Reference proteome; Telomere.
FT   CHAIN           1..634
FT                   /note="Protection of telomeres protein 1"
FT                   /id="PRO_0000121728"
FT   REGION          33..48
FT                   /note="DNA binding"
FT   REGION          270..273
FT                   /note="DNA binding"
FT   SITE            243
FT                   /note="DNA binding"
FT   VAR_SEQ         532..538
FT                   /note="ALGIVPL -> DVNSVLV (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_010846"
FT   VAR_SEQ         539..634
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_010847"
FT   VARIANT         89
FT                   /note="Y -> C (in CMM10; complete abolition of POT1-DNA
FT                   complex formation, thus disrupting the interaction with
FT                   telomeres and leading to elongated telomeres;
FT                   dbSNP:rs587777472)"
FT                   /evidence="ECO:0000269|PubMed:24686849"
FT                   /id="VAR_071390"
FT   VARIANT         94
FT                   /note="Q -> E (in CMM10; complete abolition of POT1-DNA
FT                   complex formation, thus disrupting the interaction with
FT                   telomeres and leading to elongated telomeres;
FT                   dbSNP:rs587777474)"
FT                   /evidence="ECO:0000269|PubMed:24686849"
FT                   /id="VAR_071391"
FT   VARIANT         95
FT                   /note="G -> C (in GLM9; dbSNP:rs797045168)"
FT                   /evidence="ECO:0000269|PubMed:25482530"
FT                   /id="VAR_075717"
FT   VARIANT         137
FT                   /note="R -> H (in CMM10; increased telomere intensity
FT                   signals and telomere fragility; dbSNP:rs587777475)"
FT                   /evidence="ECO:0000269|PubMed:24686846"
FT                   /id="VAR_071392"
FT   VARIANT         224
FT                   /note="D -> N (in CMM10; dbSNP:rs202187871)"
FT                   /evidence="ECO:0000269|PubMed:24686846"
FT                   /id="VAR_071393"
FT   VARIANT         270
FT                   /note="S -> N (in CMM10; significantly increased telomere
FT                   length and numbers of fragile telomeres;
FT                   dbSNP:rs587777477)"
FT                   /evidence="ECO:0000269|PubMed:24686846"
FT                   /id="VAR_071394"
FT   VARIANT         273
FT                   /note="R -> L (in CMM10; complete abolition of POT1-DNA
FT                   complex formation, thus disrupting the interaction with
FT                   telomeres and leading to elongated telomeres;
FT                   dbSNP:rs587777476)"
FT                   /evidence="ECO:0000269|PubMed:24686849"
FT                   /id="VAR_071395"
FT   VARIANT         529
FT                   /note="V -> M (in dbSNP:rs34973253)"
FT                   /id="VAR_034393"
FT   VARIANT         532
FT                   /note="A -> P (in CMM10; dbSNP:rs537377921)"
FT                   /evidence="ECO:0000269|PubMed:24686846"
FT                   /id="VAR_071396"
FT   VARIANT         623
FT                   /note="Q -> H (in CMM10; increased telomere intensity
FT                   signals and telomere fragility; dbSNP:rs587777478)"
FT                   /evidence="ECO:0000269|PubMed:24686846"
FT                   /id="VAR_071397"
FT   CONFLICT        410
FT                   /note="D -> V (in Ref. 3; BAA91568)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        412
FT                   /note="K -> Q (in Ref. 3; BAB15404)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        499
FT                   /note="H -> D (in Ref. 7; CAB43281)"
FT                   /evidence="ECO:0000305"
FT   HELIX           14..16
FT                   /evidence="ECO:0000244|PDB:1XJV"
FT   STRAND          19..37
FT                   /evidence="ECO:0000244|PDB:1XJV"
FT   STRAND          39..50
FT                   /evidence="ECO:0000244|PDB:1XJV"
FT   STRAND          56..65
FT                   /evidence="ECO:0000244|PDB:1XJV"
FT   HELIX           66..68
FT                   /evidence="ECO:0000244|PDB:1XJV"
FT   STRAND          78..89
FT                   /evidence="ECO:0000244|PDB:1XJV"
FT   STRAND          92..106
FT                   /evidence="ECO:0000244|PDB:1XJV"
FT   HELIX           127..143
FT                   /evidence="ECO:0000244|PDB:1XJV"
FT   HELIX           153..155
FT                   /evidence="ECO:0000244|PDB:1XJV"
FT   STRAND          161..173
FT                   /evidence="ECO:0000244|PDB:1XJV"
FT   STRAND          175..184
FT                   /evidence="ECO:0000244|PDB:1XJV"
FT   TURN            200..202
FT                   /evidence="ECO:0000244|PDB:3KJP"
FT   HELIX           207..213
FT                   /evidence="ECO:0000244|PDB:1XJV"
FT   HELIX           214..216
FT                   /evidence="ECO:0000244|PDB:1XJV"
FT   STRAND          217..223
FT                   /evidence="ECO:0000244|PDB:1XJV"
FT   HELIX           226..232
FT                   /evidence="ECO:0000244|PDB:1XJV"
FT   STRAND          238..251
FT                   /evidence="ECO:0000244|PDB:1XJV"
FT   STRAND          257..265
FT                   /evidence="ECO:0000244|PDB:1XJV"
FT   HELIX           270..272
FT                   /evidence="ECO:0000244|PDB:1XJV"
FT   STRAND          274..278
FT                   /evidence="ECO:0000244|PDB:1XJV"
FT   HELIX           283..297
FT                   /evidence="ECO:0000244|PDB:1XJV"
FT   STRAND          334..339
FT                   /evidence="ECO:0000244|PDB:5UN7"
FT   HELIX           348..352
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   STRAND          359..370
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   HELIX           374..377
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   STRAND          378..381
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   TURN            383..385
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   STRAND          388..390
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   HELIX           394..404
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   HELIX           411..413
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   STRAND          417..425
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   STRAND          427..429
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   STRAND          433..439
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   HELIX           448..450
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   STRAND          452..457
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   HELIX           460..469
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   STRAND          470..478
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   STRAND          480..486
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   STRAND          492..495
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   STRAND          498..500
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   TURN            504..506
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   HELIX           512..517
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   STRAND          521..523
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   HELIX           526..532
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   STRAND          539..549
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   STRAND          554..563
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   TURN            564..566
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   HELIX           570..573
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   HELIX           577..590
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   STRAND          593..595
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   HELIX           597..599
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   STRAND          603..611
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   STRAND          620..626
FT                   /evidence="ECO:0000244|PDB:5H65"
FT   TURN            630..632
FT                   /evidence="ECO:0000244|PDB:5H65"
SQ   SEQUENCE   634 AA;  71442 MW;  123A12CABE708C91 CRC64;
     MSLVPATNYI YTPLNQLKGG TIVNVYGVVK FFKPPYLSKG TDYCSVVTIV DQTNVKLTCL
     LFSGNYEALP IIYKNGDIVR FHRLKIQVYK KETQGITSSG FASLTFEGTL GAPIIPRTSS
     KYFNFTTEDH KMVEALRVWA STHMSPSWTL LKLCDVQPMQ YFDLTCQLLG KAEVDGASFL
     LKVWDGTRTP FPSWRVLIQD LVLEGDLSHI HRLQNLTIDI LVYDNHVHVA RSLKVGSFLR
     IYSLHTKLQS MNSENQTMLS LEFHLHGGTS YGRGIRVLPE SNSDVDQLKK DLESANLTAN
     QHSDVICQSE PDDSFPSSGS VSLYEVERCQ QLSATILTDH QYLERTPLCA ILKQKAPQQY
     RIRAKLRSYK PRRLFQSVKL HCPKCHLLQE VPHEGDLDII FQDGATKTPD VKLQNTSLYD
     SKIWTTKNQK GRKVAVHFVK NNGILPLSNE CLLLIEGGTL SEICKLSNKF NSVIPVRSGH
     EDLELLDLSA PFLIQGTIHH YGCKQCSSLR SIQNLNSLVD KTSWIPSSVA EALGIVPLQY
     VFVMTFTLDD GTGVLEAYLM DSDKFFQIPA SEVLMDDDLQ KSVDMIMDMF CPPGIKIDAY
     PWLECFIKSY NVTNGTDNQI CYQIFDTTVA EDVI
//
ID   PTEN_HUMAN              Reviewed;         403 AA.
AC   P60484; B2R904; F2YHV0; O00633; O02679; Q6ICT7;
DT   16-FEB-2004, integrated into UniProtKB/Swiss-Prot.
DT   16-FEB-2004, sequence version 1.
DT   02-DEC-2020, entry version 200.
DE   RecName: Full=Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN;
DE            EC=3.1.3.16 {ECO:0000269|PubMed:9256433};
DE            EC=3.1.3.48 {ECO:0000269|PubMed:9187108, ECO:0000269|PubMed:9256433};
DE            EC=3.1.3.67 {ECO:0000269|PubMed:16824732, ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9811831};
DE   AltName: Full=Mutated in multiple advanced cancers 1;
DE   AltName: Full=Phosphatase and tensin homolog;
GN   Name=PTEN; Synonyms=MMAC1, TEP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY,
RP   SUBCELLULAR LOCATION, AND INDUCTION.
RC   TISSUE=Epithelium;
RX   PubMed=9187108;
RA   Li D.M., Sun H.;
RT   "TEP1, encoded by a candidate tumor suppressor locus, is a novel protein
RT   tyrosine phosphatase regulated by transforming growth factor beta.";
RL   Cancer Res. 57:2124-2129(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANTS
RP   GLIOMA SER-15; GLU-36; ARG-42; TRP-57 AND THR-319 DEL.
RX   PubMed=9090379; DOI=10.1038/ng0497-356;
RA   Steck P.A., Pershouse M.A., Jasser S.A., Lin H., Yung W.K.A., Ligon A.H.,
RA   Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R.,
RA   Swedlund B., Teng D.H.-F., Tavtigian S.V.;
RT   "Identification of a candidate tumour suppressor gene, MMAC1, at chromosome
RT   10q23.3 that is mutated in multiple advanced cancers.";
RL   Nat. Genet. 15:356-363(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS GLIOBLASTOMA ARG-129
RP   AND PROSTATE CANCER LEU-134.
RX   PubMed=9072974; DOI=10.1126/science.275.5308.1943;
RA   Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J.,
RA   Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C.,
RA   Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R.;
RT   "PTEN, a putative protein tyrosine phosphatase gene mutated in human brain,
RT   breast, and prostate cancer.";
RL   Science 275:1943-1947(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10817502; DOI=10.1054/bjoc.2000.1211;
RA   Hamilton J.A., Stewart L.M.D., Ajayi L., Gray I.C., Gray N.E.,
RA   Roberts K.G., Watson G.J., Kaisary A.V., Snary D.;
RT   "The expression profile for the tumour suppressor gene PTEN and associated
RT   polymorphic markers.";
RL   Br. J. Cancer 82:1671-1676(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Wang S., Li J., Liaw D., Bose S., Podsypanina K., Parsons R.;
RL   Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Jensen K., de la Bastide M., Parsons R., Parnell L.D., Dedhia N.,
RA   Gottesman T., Gnoj L., Kaplan N., Lodhi M., Johnson A.F., Shohdy N.,
RA   Hasegawa A., Haberman K., Huang E.N., Schutz K., Calma C., Granat S.,
RA   Wigler M.H., McCombie W.R.;
RT   "Genomic sequence of PTEN/MMAC1.";
RL   Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Yang C.-W., Hsu Y.-F.;
RT   "Homo sapiens phosphatase and tensin homolog mRNA splicing variants.";
RL   Submitted (JAN-2011) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Spleen;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-290.
RG   NIEHS SNPs program;
RL   Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   FUNCTION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANTS GLIOMA
RP   TRP-57; ENDOMETRIAL CANCER TYR-123; GLIOBLASTOMA ARG-129; CWS1 ARG-129;
RP   PROSTATE CANCER LEU-134; GLIOBLASTOMA ARG-165; BREAST CANCER PRO-167 AND BZ
RP   ARG-170.
RX   PubMed=9256433; DOI=10.1073/pnas.94.17.9052;
RA   Myers M.P., Stolarov J.P., Eng C., Li J., Wang S.I., Wigler M.H.,
RA   Parsons R., Tonks N.K.;
RT   "P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-
RT   specificity phosphatase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:9052-9057(1997).
RN   [14]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=9593664; DOI=10.1074/jbc.273.22.13375;
RA   Maehama T., Dixon J.E.;
RT   "The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second
RT   messenger, phosphatidylinositol 3,4,5-trisphosphate.";
RL   J. Biol. Chem. 273:13375-13378(1998).
RN   [15]
RP   FUNCTION, CATALYTIC ACTIVITY, MUTAGENESIS OF ARG-130, AND CHARACTERIZATION
RP   OF VARIANTS CWS1 SER-124 AND CWS1 GLU-129.
RX   PubMed=9811831; DOI=10.1073/pnas.95.23.13513;
RA   Myers M.P., Pass I., Batty I.H., Van der Kaay J., Stolarov J.P.,
RA   Hemmings B.A., Wigler M.H., Downes C.P., Tonks N.K.;
RT   "The lipid phosphatase activity of PTEN is critical for its tumor
RT   suppressor function.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:13513-13518(1998).
RN   [16]
RP   FUNCTION, MUTAGENESIS OF ASP-92 AND CYS-124, AND CHARACTERIZATION OF
RP   VARIANT GLU-129.
RX   PubMed=9616126; DOI=10.1126/science.280.5369.1614;
RA   Tamura M., Gu J., Matsumoto K., Aota S., Parsons R., Yamada K.M.;
RT   "Inhibition of cell migration, spreading, and focal adhesions by tumor
RT   suppressor PTEN.";
RL   Science 280:1614-1617(1998).
RN   [17]
RP   FUNCTION, DOMAIN, AND CHARACTERIZATION OF VARIANTS THR-319 DEL; GLN-345 AND
RP   ILE-348.
RX   PubMed=10468583; DOI=10.1073/pnas.96.18.10182;
RA   Georgescu M.-M., Kirsch K.H., Akagi T., Shishido T., Hanafusa H.;
RT   "The tumor-suppressor activity of PTEN is regulated by its carboxyl-
RT   terminal region.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:10182-10187(1999).
RN   [18]
RP   INTERACTION WITH DLG1 AND MAST2, AND PHOSPHORYLATION AT THR-401.
RX   PubMed=10646847;
RA   Adey N.B., Huang L., Ormonde P.A., Baumgard M.L., Pero R., Byreddy D.V.,
RA   Tavtigian S.V., Bartel P.L.;
RT   "Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both
RT   inhibits and stimulates PDZ binding.";
RL   Cancer Res. 60:35-37(2000).
RN   [19]
RP   INTERACTION WITH MAGI3.
RX   PubMed=10748157; DOI=10.1074/jbc.m909741199;
RA   Wu Y., Dowbenko D., Spencer S., Laura R., Lee J., Gu Q., Lasky L.A.;
RT   "Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3,
RT   a novel membrane-associated guanylate kinase.";
RL   J. Biol. Chem. 275:21477-21485(2000).
RN   [20]
RP   INTERACTION WITH AIP1.
RX   PubMed=10760291; DOI=10.1073/pnas.97.8.4233;
RA   Wu X., Hepner K., Castelino-Prabhu S., Do D., Kaye M.B., Yuan X.-J.,
RA   Wood J., Ross C., Sawyers C.L., Whang Y.E.;
RT   "Evidence for regulation of the PTEN tumor suppressor by a membrane-
RT   localized multi-PDZ domain containing scaffold protein MAGI-2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:4233-4238(2000).
RN   [21]
RP   PHOSPHORYLATION AT SER-370; SER-380; THR-382; THR-383 AND SER-385.
RX   PubMed=11035045; DOI=10.1074/jbc.m009134200;
RA   Torres J., Pulido R.;
RT   "The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at
RT   its C terminus. Implications for PTEN stability to proteasome-mediated
RT   degradation.";
RL   J. Biol. Chem. 276:993-998(2001).
RN   [22]
RP   FUNCTION, PHOSPHORYLATION, AND INTERACTION WITH AIP1.
RX   PubMed=11707428; DOI=10.1074/jbc.c100556200;
RA   Vazquez F., Grossman S.R., Takahashi Y., Rokas M.V., Nakamura N.,
RA   Sellers W.R.;
RT   "Phosphorylation of the PTEN tail acts as an inhibitory switch by
RT   preventing its recruitment into a protein complex.";
RL   J. Biol. Chem. 276:48627-48630(2001).
RN   [23]
RP   PHOSPHORYLATION AT THR-366; SER-370 AND SER-385.
RX   PubMed=12297295; DOI=10.1016/s0014-5793(02)03274-x;
RA   Miller S., Lou D., Seldin D., Lane W., Neel B.;
RT   "Direct identification of PTEN phosphorylation sites.";
RL   FEBS Lett. 528:145-153(2002).
RN   [24]
RP   INTERACTION WITH NOP53, REGION, AND CHARACTERIZATION OF VARIANTS CWS1
RP   VAL-341; GLU-343 AND GLN-345.
RX   PubMed=15355975; DOI=10.1074/jbc.c400377200;
RA   Okahara F., Ikawa H., Kanaho Y., Maehama T.;
RT   "Regulation of PTEN phosphorylation and stability by a tumor suppressor
RT   candidate protein.";
RL   J. Biol. Chem. 279:45300-45303(2004).
RN   [25]
RP   INTERACTION WITH STK11, SUBCELLULAR LOCATION, AND PHOSPHORYLATION BY STK11.
RX   PubMed=15987703; DOI=10.1093/hmg/ddi225;
RA   Mehenni H., Lin-Marq N., Buchet-Poyau K., Reymond A., Collart M.A.,
RA   Picard D., Antonarakis S.E.;
RT   "LKB1 interacts with and phosphorylates PTEN: a functional link between two
RT   proteins involved in cancer predisposing syndromes.";
RL   Hum. Mol. Genet. 14:2209-2219(2005).
RN   [26]
RP   INTERACTION WITH MAGI2; MAGI3; MAST1; MAST2 AND MAST3, MUTAGENESIS OF
RP   VAL-403, AND PHOSPHORYLATION.
RX   PubMed=15951562; DOI=10.1074/jbc.m504761200;
RA   Valiente M., Andres-Pons A., Gomar B., Torres J., Gil A., Tapparel C.,
RA   Antonarakis S.E., Pulido R.;
RT   "Binding of PTEN to specific PDZ domains contributes to PTEN protein
RT   stability and phosphorylation by microtubule-associated serine/threonine
RT   kinases.";
RL   J. Biol. Chem. 280:28936-28943(2005).
RN   [27]
RP   CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND FUNCTION.
RX   PubMed=16824732; DOI=10.1016/j.cellsig.2006.05.010;
RA   Vandeput F., Backers K., Villeret V., Pesesse X., Erneux C.;
RT   "The influence of anionic lipids on SHIP2 phosphatidylinositol 3,4,5-
RT   trisphosphate 5-phosphatase activity.";
RL   Cell. Signal. 18:2193-2199(2006).
RN   [28]
RP   INTERACTION WITH NEDD4.
RX   PubMed=17218260; DOI=10.1016/j.cell.2006.11.039;
RA   Wang X., Trotman L.C., Koppie T., Alimonti A., Chen Z., Gao Z., Wang J.,
RA   Erdjument-Bromage H., Tempst P., Cordon-Cardo C., Pandolfi P.P., Jiang X.;
RT   "NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN.";
RL   Cell 128:129-139(2007).
RN   [29]
RP   FUNCTION, INTERACTION WITH USP7, UBIQUITINATION AT LYS-13 AND LYS-289,
RP   DEUBIQUITINATION BY USP7, SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-13 AND
RP   LYS-289, AND CHARACTERIZATION OF VARIANT CWS1 GLU-289.
RX   PubMed=18716620; DOI=10.1038/nature07290;
RA   Song M.S., Salmena L., Carracedo A., Egia A., Lo-Coco F.,
RA   Teruya-Feldstein J., Pandolfi P.P.;
RT   "The deubiquitinylation and localization of PTEN are regulated by a HAUSP-
RT   PML network.";
RL   Nature 455:813-817(2008).
RN   [30]
RP   INTERACTION WITH FRK, PHOSPHORYLATION AT TYR-336, AND MUTAGENESIS OF
RP   TYR-336.
RX   PubMed=19345329; DOI=10.1016/j.ccr.2009.02.012;
RA   Yim E.-K., Peng G., Dai H., Hu R., Li K., Lu Y., Mills G.B.,
RA   Meric-Bernstam F., Hennessy B.T., Craven R.J., Lin S.-Y.;
RT   "Rak functions as a tumor suppressor by regulating PTEN protein stability
RT   and function.";
RL   Cancer Cell 15:304-314(2009).
RN   [31]
RP   UBIQUITINATION BY XIAP/BIRC4, SUBCELLULAR LOCATION, AND INTERACTION WITH
RP   XIAP/BIRC4.
RX   PubMed=19473982; DOI=10.1074/jbc.c109.009522;
RA   Van Themsche C., Leblanc V., Parent S., Asselin E.;
RT   "X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN
RT   ubiquitination, content, and compartmentalization.";
RL   J. Biol. Chem. 284:20462-20466(2009).
RN   [32]
RP   PHOSPHORYLATION AT THR-366 AND SER-370, AND MUTAGENESIS OF THR-366 AND
RP   SER-370.
RX   PubMed=20940307; DOI=10.1074/jbc.m110.166462;
RA   Xu D., Yao Y., Jiang X., Lu L., Dai W.;
RT   "Regulation of PTEN stability and activity by Plk3.";
RL   J. Biol. Chem. 285:39935-39942(2010).
RN   [33]
RP   INTERACTION WITH NDFIP1 AND NDFIP2.
RX   PubMed=20534535; DOI=10.1073/pnas.0911714107;
RA   Mund T., Pelham H.R.;
RT   "Regulation of PTEN/Akt and MAP kinase signaling pathways by the ubiquitin
RT   ligase activators Ndfip1 and Ndfip2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:11429-11434(2010).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [35]
RP   FUNCTION IN CELL MIGRATION.
RX   PubMed=22279049; DOI=10.1101/gad.177642.111;
RA   Stohr N., Kohn M., Lederer M., Glass M., Reinke C., Singer R.H.,
RA   Huttelmaier S.;
RT   "IGF2BP1 promotes cell migration by regulating MK5 and PTEN signaling.";
RL   Genes Dev. 26:176-189(2012).
RN   [36]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT THR-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [37]
RP   ALTERNATIVE INITIATION (ISOFORM ALPHA), CTG START CODON, FUNCTION (ISOFORM
RP   ALPHA), AND SUBCELLULAR LOCATION (ISOFORM ALPHA).
RX   PubMed=23744781; DOI=10.1126/science.1234907;
RA   Hopkins B.D., Fine B., Steinbach N., Dendy M., Rapp Z., Shaw J., Pappas K.,
RA   Yu J.S., Hodakoski C., Mense S., Klein J., Pegno S., Sulis M.L.,
RA   Goldstein H., Amendolara B., Lei L., Maurer M., Bruce J., Canoll P.,
RA   Hibshoosh H., Parsons R.;
RT   "A secreted PTEN phosphatase that enters cells to alter signaling and
RT   survival.";
RL   Science 341:399-402(2013).
RN   [38]
RP   INTERACTION WITH PPP1R16B.
RX   PubMed=25007873; DOI=10.1152/ajprenal.00070.2014;
RA   Obeidat M., Li L., Ballermann B.J.;
RT   "TIMAP promotes angiogenesis by suppressing PTEN-mediated Akt inhibition in
RT   human glomerular endothelial cells.";
RL   Am. J. Physiol. 307:F623-F633(2014).
RN   [39]
RP   ALTERNATIVE INITIATION (ISOFORM ALPHA), CTG START CODON, SUBCELLULAR
RP   LOCATION (ISOFORM ALPHA), AND MUTAGENESIS OF MET-1.
RX   PubMed=24768297; DOI=10.1016/j.cmet.2014.03.023;
RA   Liang H., He S., Yang J., Jia X., Wang P., Chen X., Zhang Z., Zou X.,
RA   McNutt M.A., Shen W.H., Yin Y.;
RT   "PTENalpha, a PTEN isoform translated through alternative initiation,
RT   regulates mitochondrial function and energy metabolism.";
RL   Cell Metab. 19:836-848(2014).
RN   [40]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-366, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [41]
RP   INTERACTION WITH NDFIP1, AND SUBCELLULAR LOCATION.
RX   PubMed=25801959; DOI=10.1093/jmcb/mjv020;
RA   Howitt J., Low L.H., Putz U., Doan A., Lackovic J., Goh C.P., Gunnersen J.,
RA   Silke J., Tan S.S.;
RT   "Ndfip1 represses cell proliferation by controlling Pten localization and
RT   signaling specificity.";
RL   J. Mol. Cell Biol. 7:119-131(2015).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 8-353 IN COMPLEX WITH
RP   L(+)-TARTRATE, SUBUNIT, DOMAIN, MUTAGENESIS OF ASP-92; HIS-93; LYS-125;
RP   LYS-128; THR-167; GLN-171; 263-LYS--ALA-269 AND 327-LYS--ALA-335, AND
RP   CATALYTIC ACTIVITY.
RX   PubMed=10555148; DOI=10.1016/s0092-8674(00)81663-3;
RA   Lee J.-O., Yang H., Georgescu M.-M., Di Cristofano A., Maehama T., Shi Y.,
RA   Dixon J.E., Pandolfi P., Pavletich N.P.;
RT   "Crystal structure of the PTEN tumor suppressor: implications for its
RT   phosphoinositide phosphatase activity and membrane association.";
RL   Cell 99:323-334(1999).
RN   [43]
RP   VARIANT CWS1 ASN-137 INS.
RX   PubMed=9345101; DOI=10.1086/301607;
RA   Tsou H.C., Teng D.H.-F., Ping X.L., Brancolini V., Davis T., Hu R.,
RA   Xie X.X., Gruener A.C., Schrager C.A., Christiano A.M., Eng C., Steck P.,
RA   Ott J., Tavtigian S.V., Peacocke M.;
RT   "The role of MMAC1 mutations in early-onset breast cancer: causative in
RT   association with Cowden syndrome and excluded in BRCA1-negative cases.";
RL   Am. J. Hum. Genet. 61:1036-1043(1997).
RN   [44]
RP   VARIANTS CWS1 GLU-343 AND LEU-347.
RX   PubMed=9399897; DOI=10.1086/301639;
RA   Lynch E.D., Ostermeyer E.A., Lee M.K., Arena J.F., Ji H., Dann J.,
RA   Swisshelm K., Suchard D., MacLeod P.M., Kvinnsland S., Gjertsen B.T.,
RA   Heimdal K., Lubs H., Moeller P., King M.-C.;
RT   "Inherited mutations in PTEN that are associated with breast cancer, Cowden
RT   disease, and juvenile polyposis.";
RL   Am. J. Hum. Genet. 61:1254-1260(1997).
RN   [45]
RP   VARIANTS GLIOBLASTOMA TYR-107; PRO-121; ARG-129; ARG-165 AND GLN-345.
RX   PubMed=9331071;
RA   Wang S.I., Puc J., Li J., Bruce J.N., Cairns P., Sidransky D., Parsons R.;
RT   "Somatic mutations of PTEN in glioblastoma multiforme.";
RL   Cancer Res. 57:4183-4186(1997).
RN   [46]
RP   VARIANTS CWS1 ARG-123 AND ARG-124.
RX   PubMed=9259288; DOI=10.1093/hmg/6.8.1383;
RA   Nelen M.R., van Staveren W.C.G., Peeters E.A.J., Ben-Hassel M.,
RA   Gorlin R.J., Hamm H., Lindboe C.F., Fryns J.-P., Sijmons R.H., Woods D.G.,
RA   Mariman E.C.M., Padberg G.W., Kremer H.;
RT   "Germline mutations in the PTEN/MMAC1 gene in patients with Cowden
RT   disease.";
RL   Hum. Mol. Genet. 6:1383-1387(1997).
RN   [47]
RP   VARIANT CWS1 GLU-129.
RX   PubMed=9140396; DOI=10.1038/ng0597-64;
RA   Liaw D., Marsh D.J., Li J., Dahia P.L.M., Wang S.I., Zheng Z., Bose S.,
RA   Call K.M., Tsou H.C., Peacocke M., Eng C., Parsons R.;
RT   "Germline mutations of the PTEN gene in Cowden disease, an inherited breast
RT   and thyroid cancer syndrome.";
RL   Nat. Genet. 16:64-67(1997).
RN   [48]
RP   VARIANT CWS1 ARG-170.
RX   PubMed=9241266; DOI=10.1038/ng0897-333;
RA   Marsh D.J., Dahia P.L.M., Zheng Z., Liaw D., Parsons R., Gorlin R.J.,
RA   Eng C.;
RT   "Germline mutations in PTEN are present in Bannayan-Zonana syndrome.";
RL   Nat. Genet. 16:333-334(1997).
RN   [49]
RP   VARIANTS ENDOMETRIAL HYPERPLASIA ARG-36; LEU-130; CYS-173; ALA-191 AND
RP   ILE-348.
RX   PubMed=9635567;
RA   Maxwell G.L., Risinger J.I., Gumbs C., Shaw H., Bentley R.C., Barrett J.C.,
RA   Berchuck A., Futreal P.A.;
RT   "Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias.";
RL   Cancer Res. 58:2500-2503(1998).
RN   [50]
RP   VARIANT CWS1 GLU-289.
RX   PubMed=9797362; DOI=10.1016/s0016-5085(98)70078-2;
RA   Chi S.-G., Kim H.-J., Park B.-J., Min H.-J., Park J.-H., Kim Y.-W.,
RA   Dong S.-H., Kim B.-H., Lee J.-I., Chang Y.-W., Chang R., Kim W.-K.,
RA   Yang M.-H.;
RT   "Mutational abrogation of the PTEN/MMAC1 gene in gastrointestinal polyps in
RT   patients with Cowden disease.";
RL   Gastroenterology 115:1084-1089(1998).
RN   [51]
RP   VARIANTS CWS1 HIS-68 AND PRO-112.
RX   PubMed=9600246; DOI=10.1007/s004390050723;
RA   Tsou H.C., Ping X.L., Xie X.X., Gruener A.C., Zhang H., Nini R.,
RA   Swisshelm K., Sybert V., Diamond T.M., Sutphen R., Peacocke M.;
RT   "The genetic basis of Cowden's syndrome: three novel mutations in
RT   PTEN/MMAC1/TEP1.";
RL   Hum. Genet. 102:467-473(1998).
RN   [52]
RP   VARIANTS CWS1.
RX   PubMed=9467011; DOI=10.1093/hmg/7.3.507;
RA   Marsh D.J., Coulon V., Lunetta K.L., Rocca-Serra P., Dahia P.L.M.,
RA   Zheng Z., Liaw D., Caron S., Duboue B., Lin A.Y., Richardson A.-L.,
RA   Bonnetblanc J.-M., Bressieux J.-M., Cabarrot-Moreau A., Chompret A.,
RA   Demange L., Eeles R.A., Yahanda A.M., Fearon E.R., Fricker J.-P.,
RA   Gorlin R.J., Hodgson S.V., Huson S., Lacombe D., Leprat F., Odent S.,
RA   Toulouse C., Olopade O.I., Sobol H., Tishler S., Woods C.G., Robinson B.G.,
RA   Weber H.C., Parsons R., Peacocke M., Longy M., Eng C.;
RT   "Mutation spectrum and genotype-phenotype analyses in Cowden disease and
RT   Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN
RT   mutation.";
RL   Hum. Mol. Genet. 7:507-515(1998).
RN   [53]
RP   VARIANT CWS1 TYR-136.
RX   PubMed=9735393; DOI=10.3892/ijo.13.4.665;
RA   Scala S., Bruni P., Lo Muzio L., Mignogna M., Viglietto G., Fusco A.;
RT   "Novel mutation of the PTEN gene in an Italian Cowden's disease kindred.";
RL   Int. J. Oncol. 13:665-668(1998).
RN   [54]
RP   VARIANT CWS1 PRO-70.
RX   PubMed=9832031; DOI=10.1136/jmg.35.11.881;
RA   Marsh D.J., Dahia P.L.M., Caron S., Kum J.B., Frayling I.M.,
RA   Tomlinson I.P.M., Hughes K.S., Eeles R.A., Hodgson S.V., Murday V.A.,
RA   Houlston R., Eng C.;
RT   "Germline PTEN mutations in Cowden syndrome-like families.";
RL   J. Med. Genet. 35:881-885(1998).
RN   [55]
RP   VARIANT CWS1 ARG-35.
RX   PubMed=9425889; DOI=10.1038/ng0198-12;
RA   Olschwang S., Serova-Sinilnikova O.M., Lenoir G.M., Thomas G.;
RT   "PTEN germ-line mutations in juvenile polyposis coli.";
RL   Nat. Genet. 18:12-14(1998).
RN   [56]
RP   VARIANT CWS1 GLN-130.
RX   PubMed=9915974; DOI=10.1086/302207;
RA   Kurose K., Araki T., Matsunaka T., Takada Y., Emi M.;
RT   "Variant manifestation of Cowden disease in Japan: hamartomatous polyposis
RT   of the digestive tract with mutation of the PTEN gene.";
RL   Am. J. Hum. Genet. 64:308-310(1999).
RN   [57]
RP   VARIANT CWS1/LDD PRO-112.
RX   PubMed=10051160;
RX   DOI=10.1002/(sici)1096-8628(19990212)82:4<290::aid-ajmg3>3.0.co;2-0;
RA   Sutphen R., Diamond T.M., Minton S.E., Peacocke M., Tsou H.C., Root A.W.;
RT   "Severe Lhermitte-Duclos disease with unique germline mutation of PTEN.";
RL   Am. J. Med. Genet. 82:290-293(1999).
RN   [58]
RP   VARIANTS CWS1 ILE-33 DEL; ARG-123; ARG-124 AND GLU-165.
RX   PubMed=10234502; DOI=10.1038/sj.ejhg.5200289;
RA   Nelen M.R., Kremer H., Konings I.B.M., Schoute F., van Essen A.J., Koch R.,
RA   Woods C.G., Fryns J.-P., Hamel B.C.J., Hoefsloot L.H., Peeters E.A.J.,
RA   Padberg G.W.;
RT   "Novel PTEN mutations in patients with Cowden disease: absence of clear
RT   genotype-phenotype correlations.";
RL   Eur. J. Hum. Genet. 7:267-273(1999).
RN   [59]
RP   VARIANTS CWS1 ASP-34; HIS-68; TYR-105; VAL-135; ARG-170 AND LEU-246.
RX   PubMed=10400993; DOI=10.1093/hmg/8.8.1461;
RA   Marsh D.J., Kum J.B., Lunetta K.L., Bennett M.J., Gorlin R.J., Ahmed S.F.,
RA   Bodurtha J., Crowe C., Curtis M.A., Dasouki M., Dunn T., Feit H.,
RA   Geraghty M.T., Graham J.M. Jr., Hodgson S.V., Hunter A., Korf B.R.,
RA   Manchester D., Miesfeldt S., Murday V.A., Nathanson K.L., Parisi M.,
RA   Pober B., Romano C., Tolmie J.L., Trembath R., Winter R.M., Zackai E.H.,
RA   Zori R.T., Weng L.-P., Dahia P.L.M., Eng C.;
RT   "PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-
RT   Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.";
RL   Hum. Mol. Genet. 8:1461-1472(1999).
RN   [60]
RP   CHARACTERIZATION OF VARIANTS ASN-10; CYS-16; GLU-20; SER-27; ARG-61;
RP   HIS-68; ARG-112; PRO-121; ARG-129; GLY-130; ILE-133; LEU-134; ARG-165;
RP   ASN-170; CYS-173; HIS-173; PRO-173; ASN-174; PHE-227; CYS-251; GLN-345;
RP   GLY-369 AND ILE-401, AND CHARACTERIZATION OF VARIANTS CWS1 TYR-71; TYR-93;
RP   PHE-105; TYR-107; PRO-112; ARG-124; GLU-129; LEU-130; GLN-130; TYR-136;
RP   CYS-155; ARG-170; GLU-289; GLY-331; VAL-341; ASN-342; GLU-343 AND LEU-347.
RX   PubMed=10866302;
RA   Han S.-Y., Kato H., Kato S., Suzuki T., Shibata H., Ishii S., Shiiba K.,
RA   Matsuno S., Kanamaru R., Ishioka C.;
RT   "Functional evaluation of PTEN missense mutations using in vitro
RT   phosphoinositide phosphatase assay.";
RL   Cancer Res. 60:3147-3151(2000).
RN   [61]
RP   VARIANTS MULTIPLE CANCERS LEU-119 AND LEU-158.
RX   PubMed=10807691; DOI=10.1136/jmg.37.5.336;
RA   De Vivo I., Gertig D.M., Nagase S., Hankinson S.E., O'Brien R.,
RA   Speizer F.E., Parsons R., Hunter D.J.;
RT   "Novel germline mutations in the PTEN tumour suppressor gene found in women
RT   with multiple cancers.";
RL   J. Med. Genet. 37:336-341(2000).
RN   [62]
RP   VARIANTS MALIGNANT MELANOMA ASN-19 AND ILE-217.
RX   PubMed=10978354; DOI=10.1136/jmg.37.9.653;
RA   Celebi J.T., Shendrik I., Silvers D.N., Peacocke M.;
RT   "Identification of PTEN mutations in metastatic melanoma specimens.";
RL   J. Med. Genet. 37:653-657(2000).
RN   [63]
RP   CHARACTERIZATION OF VARIANTS CWS1 SER-124 AND GLU-129.
RX   PubMed=11230179; DOI=10.1093/hmg/10.6.599;
RA   Weng L.-P., Brown J.L., Eng C.;
RT   "PTEN coordinates G1 arrest by down-regulating cyclin D1 via its protein
RT   phosphatase activity and up-regulating p27 via its lipid phosphatase
RT   activity in a breast cancer model.";
RL   Hum. Mol. Genet. 10:599-604(2001).
RN   [64]
RP   VARIANT ASP-61.
RX   PubMed=11748304; DOI=10.1136/jmg.38.12.820;
RA   Reardon W., Zhou X.-P., Eng C.;
RT   "A novel germline mutation of the PTEN gene in a patient with macrocephaly,
RT   ventricular dilatation, and features of VATER association.";
RL   J. Med. Genet. 38:820-823(2001).
RN   [65]
RP   VARIANTS CWS1 ASP-34; GLY-47; HIS-68; TYR-105; VAL-135 AND ARG-170.
RX   PubMed=11494117; DOI=10.1038/sj/neo/7900154;
RA   Marsh D.J., Theodosopoulos G., Howell V., Richardson A.-L., Benn D.E.,
RA   Proos A.L., Eng C., Robinson B.G.;
RT   "Rapid mutation scanning of genes associated with familial cancer syndromes
RT   using denaturing high-performance liquid chromatography.";
RL   Neoplasia 3:236-244(2001).
RN   [66]
RP   VARIANT GLM2 GLN-234, AND CHARACTERIZATION OF VARIANT GLM2 GLN-234.
RX   PubMed=12085208; DOI=10.1038/sj.bjc.6600206;
RA   Staal F.J.T., van der Luijt R.B., Baert M.R.M., van Drunen J.,
RA   van Bakel H., Peters E., de Valk I., van Amstel H.K.P., Taphoorn M.J.B.,
RA   Jansen G.H., van Veelen C.W.M., Burgering B., Staal G.E.J.;
RT   "A novel germline mutation of PTEN associated with brain tumours of
RT   multiple lineages.";
RL   Br. J. Cancer 86:1586-1591(2002).
RN   [67]
RP   VARIANT HNSCC GLY-121.
RX   PubMed=11801303; DOI=10.1016/s0165-4608(01)00509-x;
RA   Poetsch M., Lorenz G., Kleist B.;
RT   "Detection of new PTEN/MMAC1 mutations in head and neck squamous cell
RT   carcinomas with loss of chromosome 10.";
RL   Cancer Genet. Cytogenet. 132:20-24(2002).
RN   [68]
RP   DISCUSSION OF PTEN INVOLVEMENT IN PROTEUS SYNDROME.
RX   PubMed=12471211; DOI=10.1136/jmg.39.12.937;
RA   Smith J.M., Kirk E.P.E., Theodosopoulos G., Marshall G.M., Walker J.,
RA   Rogers M., Field M., Brereton J.J., Marsh D.J.;
RT   "Germline mutation of the tumour suppressor PTEN in Proteus syndrome.";
RL   J. Med. Genet. 39:937-940(2002).
RN   [69]
RP   VARIANTS MCEPHAS ARG-93; SER-241 AND GLY-252.
RX   PubMed=15805158; DOI=10.1136/jmg.2004.024646;
RA   Butler M.G., Dasouki M.J., Zhou X.-P., Talebizadeh Z., Brown M.,
RA   Takahashi T.N., Miles J.H., Wang C.H., Stratton R., Pilarski R., Eng C.;
RT   "Subset of individuals with autism spectrum disorders and extreme
RT   macrocephaly associated with germline PTEN tumour suppressor gene
RT   mutations.";
RL   J. Med. Genet. 42:318-321(2005).
RN   [70]
RP   INVOLVEMENT IN CHROMOSOME 10Q23 DELETION SYNDROME.
RX   PubMed=17436248; DOI=10.1086/513607;
RA   Balciuniene J., Feng N., Iyadurai K., Hirsch B., Charnas L., Bill B.R.,
RA   Easterday M.C., Staaf J., Oseth L., Czapansky-Beilman D., Avramopoulos D.,
RA   Thomas G.H., Borg A., Valle D., Schimmenti L.A., Selleck S.B.;
RT   "Recurrent 10q22-q23 deletions: a genomic disorder on 10q associated with
RT   cognitive and behavioral abnormalities.";
RL   Am. J. Hum. Genet. 80:938-947(2007).
RN   [71]
RP   VARIANT VAL-132.
RX   PubMed=16752378; DOI=10.1002/ajmg.a.31273;
RA   Tekin M., Hismi B.O., Fitoz S., Yalcinkaya F., Ekim M., Kansu A., Ertem M.,
RA   Deda G., Tutar E., Arsan S., Zhou X.-P., Pilarski R., Eng C., Akar N.;
RT   "A germline PTEN mutation with manifestations of prenatal onset and
RT   verrucous epidermal nevus.";
RL   Am. J. Med. Genet. A 140:1472-1475(2006).
RN   [72]
RP   VARIANTS MCEPHAS ILE-131 AND ASN-167.
RX   PubMed=23160955; DOI=10.1126/science.1227764;
RA   O'Roak B.J., Vives L., Fu W., Egertson J.D., Stanaway I.B., Phelps I.G.,
RA   Carvill G., Kumar A., Lee C., Ankenman K., Munson J., Hiatt J.B.,
RA   Turner E.H., Levy R., O'Day D.R., Krumm N., Coe B.P., Martin B.K.,
RA   Borenstein E., Nickerson D.A., Mefford H.C., Doherty D., Akey J.M.,
RA   Bernier R., Eichler E.E., Shendure J.;
RT   "Multiplex targeted sequencing identifies recurrently mutated genes in
RT   autism spectrum disorders.";
RL   Science 338:1619-1622(2012).
RN   [73]
RP   VARIANT MCEPHAS 65-TYR--VAL-403 DEL.
RX   PubMed=26637798; DOI=10.1016/j.neuron.2015.11.009;
RA   D'Gama A.M., Pochareddy S., Li M., Jamuar S.S., Reiff R.E., Lam A.T.,
RA   Sestan N., Walsh C.A.;
RT   "Targeted DNA Sequencing from Autism Spectrum Disorder Brains Implicates
RT   Multiple Genetic Mechanisms.";
RL   Neuron 88:910-917(2015).
RN   [74]
RP   VARIANT PROSTATE CANCER GLY-126, CHARACTERIZATION OF VARIANT GLY-126,
RP   MUTAGENESIS OF ALA-126, AND FUNCTION.
RX   PubMed=26504226; DOI=10.1073/pnas.1422504112;
RA   Costa H.A., Leitner M.G., Sos M.L., Mavrantoni A., Rychkova A.,
RA   Johnson J.R., Newton B.W., Yee M.C., De La Vega F.M., Ford J.M.,
RA   Krogan N.J., Shokat K.M., Oliver D., Halaszovich C.R., Bustamante C.D.;
RT   "Discovery and functional characterization of a neomorphic PTEN mutation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 112:13976-13981(2015).
CC   -!- FUNCTION: Tumor suppressor. Acts as a dual-specificity protein
CC       phosphatase, dephosphorylating tyrosine-, serine- and threonine-
CC       phosphorylated proteins. Also acts as a lipid phosphatase, removing the
CC       phosphate in the D3 position of the inositol ring from
CC       phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-
CC       diphosphate, phosphatidylinositol 3-phosphate and inositol 1,3,4,5-
CC       tetrakisphosphate with order of substrate preference in vitro
CC       PtdIns(3,4,5)P3 > PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4
CC       (PubMed:26504226, PubMed:16824732). The lipid phosphatase activity is
CC       critical for its tumor suppressor function. Antagonizes the PI3K-
CC       AKT/PKB signaling pathway by dephosphorylating phosphoinositides and
CC       thereby modulating cell cycle progression and cell survival. The
CC       unphosphorylated form cooperates with AIP1 to suppress AKT1 activation.
CC       Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and
CC       inhibits cell migration and integrin-mediated cell spreading and focal
CC       adhesion formation. Plays a role as a key modulator of the AKT-mTOR
CC       signaling pathway controlling the tempo of the process of newborn
CC       neurons integration during adult neurogenesis, including correct neuron
CC       positioning, dendritic development and synapse formation. May be a
CC       negative regulator of insulin signaling and glucose metabolism in
CC       adipose tissue. The nuclear monoubiquitinated form possesses greater
CC       apoptotic potential, whereas the cytoplasmic nonubiquitinated form
CC       induces less tumor suppressive ability. In motile cells, suppresses the
CC       formation of lateral pseudopods and thereby promotes cell polarization
CC       and directed movement. {ECO:0000269|PubMed:16824732,
CC       ECO:0000269|PubMed:26504226}.
CC   -!- FUNCTION: [Isoform alpha]: Functional kinase, like isoform 1 it
CC       antagonizes the PI3K-AKT/PKB signaling pathway. Plays a role in
CC       mitochondrial energetic metabolism by promoting COX activity and ATP
CC       production, via collaboration with isoform 1 in increasing protein
CC       levels of PINK1.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-
CC         trisphosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
CC         inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:25017,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57836,
CC         ChEBI:CHEBI:58456; EC=3.1.3.67;
CC         Evidence={ECO:0000269|PubMed:16824732, ECO:0000269|PubMed:9593664,
CC         ECO:0000269|PubMed:9811831};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + O-phospho-L-seryl-[protein] = L-seryl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:20629, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15377, ChEBI:CHEBI:29999, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:83421; EC=3.1.3.16;
CC         Evidence={ECO:0000269|PubMed:9256433};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + O-phospho-L-threonyl-[protein] = L-threonyl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:47004, Rhea:RHEA-COMP:11060, Rhea:RHEA-
CC         COMP:11605, ChEBI:CHEBI:15377, ChEBI:CHEBI:30013, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:61977; EC=3.1.3.16;
CC         Evidence={ECO:0000269|PubMed:9256433};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + O-phospho-L-tyrosyl-[protein] = L-tyrosyl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:10684, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620; EC=3.1.3.48; Evidence={ECO:0000269|PubMed:9187108,
CC         ECO:0000269|PubMed:9256433};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-
CC         trisphosphate) + H2O = 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-
CC         inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:43552,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:83416,
CC         ChEBI:CHEBI:83419; Evidence={ECO:0000269|PubMed:16824732};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43553;
CC         Evidence={ECO:0000305|PubMed:16824732};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-
CC         3,4,5-trisphosphate) + H2O = 1,2-dihexadecanoyl-sn-glycero-3-phospho-
CC         (1D-myo-inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:43560,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:83420,
CC         ChEBI:CHEBI:83423; Evidence={ECO:0000269|PubMed:16824732};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43561;
CC         Evidence={ECO:0000305|PubMed:16824732};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ACTIVITY REGULATION: Enzymatic activity is enhanced in the presence of
CC       phosphatidylserine. {ECO:0000269|PubMed:16824732}.
CC   -!- SUBUNIT: Monomer. The unphosphorylated form interacts with the second
CC       PDZ domain of AIP1 and with DLG1 and MAST2 in vitro (PubMed:10646847,
CC       PubMed:10760291, PubMed:11707428). Interacts with MAGI2, MAGI3, MAST1
CC       and MAST3, but neither with MAST4 nor with DLG5; interaction with MAGI2
CC       increases protein stability (PubMed:10748157, PubMed:15951562).
CC       Interacts with NEDD4 (PubMed:17218260). Interacts with NDFIP1 and
CC       NDFIP2; in the presence of NEDD4 or ITCH, this interaction promotes
CC       PTEN ubiquitination (PubMed:25801959, PubMed:20534535). Interacts (via
CC       C2 domain) with FRK (PubMed:19345329). Interacts with USP7; the
CC       interaction is direct (PubMed:18716620). Interacts with ROCK1 (By
CC       similarity). Interacts with XIAP/BIRC4 (PubMed:19473982). Interacts
CC       with STK11; the interaction phosphorylates PTEN (PubMed:15987703).
CC       Interacts with PPP1R16B (PubMed:25007873). Interacts with NOP53;
CC       regulates PTEN phosphorylation and increases its stability
CC       (PubMed:15355975). {ECO:0000250|UniProtKB:O08586,
CC       ECO:0000269|PubMed:10555148, ECO:0000269|PubMed:10646847,
CC       ECO:0000269|PubMed:10748157, ECO:0000269|PubMed:10760291,
CC       ECO:0000269|PubMed:11707428, ECO:0000269|PubMed:15355975,
CC       ECO:0000269|PubMed:15951562, ECO:0000269|PubMed:15987703,
CC       ECO:0000269|PubMed:17218260, ECO:0000269|PubMed:18716620,
CC       ECO:0000269|PubMed:19345329, ECO:0000269|PubMed:19473982,
CC       ECO:0000269|PubMed:20534535, ECO:0000269|PubMed:25007873,
CC       ECO:0000269|PubMed:25801959}.
CC   -!- INTERACTION:
CC       P60484; P35226: BMI1; NbExp=7; IntAct=EBI-696162, EBI-2341576;
CC       P60484; P30260: CDC27; NbExp=7; IntAct=EBI-696162, EBI-994813;
CC       P60484; Q16643: DBN1; NbExp=5; IntAct=EBI-696162, EBI-351394;
CC       P60484; P42685: FRK; NbExp=7; IntAct=EBI-696162, EBI-1383583;
CC       P60484; O60307: MAST3; NbExp=3; IntAct=EBI-696162, EBI-311420;
CC       P60484; Q9Y6Q9: NCOA3; NbExp=2; IntAct=EBI-696162, EBI-81196;
CC       P60484; P46934: NEDD4; NbExp=4; IntAct=EBI-696162, EBI-726944;
CC       P60484; P09619: PDGFRB; NbExp=3; IntAct=EBI-696162, EBI-641237;
CC       P60484; P62136: PPP1CA; NbExp=2; IntAct=EBI-696162, EBI-357253;
CC       P60484; Q06830: PRDX1; NbExp=7; IntAct=EBI-696162, EBI-353193;
CC       P60484; P60484: PTEN; NbExp=9; IntAct=EBI-696162, EBI-696162;
CC       P60484; O14745: SLC9A3R1; NbExp=7; IntAct=EBI-696162, EBI-349787;
CC       P60484; Q15599: SLC9A3R2; NbExp=5; IntAct=EBI-696162, EBI-1149760;
CC       P60484; O43791: SPOP; NbExp=4; IntAct=EBI-696162, EBI-743549;
CC       P60484; Q62696: Dlg1; Xeno; NbExp=2; IntAct=EBI-696162, EBI-389325;
CC       P60484; O88382: Magi2; Xeno; NbExp=3; IntAct=EBI-696162, EBI-696179;
CC       P60484; Q9JK71: Magi3; Xeno; NbExp=3; IntAct=EBI-696162, EBI-696226;
CC       P60484; Q9R1L5: Mast1; Xeno; NbExp=3; IntAct=EBI-696162, EBI-491771;
CC       P60484; Q60592: Mast2; Xeno; NbExp=4; IntAct=EBI-696162, EBI-493888;
CC       P60484; Q9JHL1: Slc9a3r2; Xeno; NbExp=2; IntAct=EBI-696162, EBI-538451;
CC       P60484-1; Q19T08: ECSCR; NbExp=4; IntAct=EBI-15722967, EBI-15778214;
CC       P60484-1; Q5T2D3: OTUD3; NbExp=9; IntAct=EBI-15722967, EBI-16170539;
CC       P60484-1; P60484-1: PTEN; NbExp=3; IntAct=EBI-15722967, EBI-15722967;
CC       P60484-1; Q93009: USP7; NbExp=5; IntAct=EBI-15722967, EBI-302474;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15987703,
CC       ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:19473982,
CC       ECO:0000269|PubMed:25801959, ECO:0000269|PubMed:9187108}. Nucleus
CC       {ECO:0000269|PubMed:15987703, ECO:0000269|PubMed:18716620,
CC       ECO:0000269|PubMed:19473982, ECO:0000269|PubMed:25801959}. Nucleus, PML
CC       body {ECO:0000269|PubMed:18716620}. Note=Monoubiquitinated form is
CC       nuclear. Nonubiquitinated form is cytoplasmic. Colocalized with PML and
CC       USP7 in PML nuclear bodies (PubMed:18716620). XIAP/BIRC4 promotes its
CC       nuclear localization (PubMed:19473982). {ECO:0000269|PubMed:18716620,
CC       ECO:0000269|PubMed:19473982}.
CC   -!- SUBCELLULAR LOCATION: [Isoform alpha]: Secreted
CC       {ECO:0000269|PubMed:23744781, ECO:0000269|PubMed:24768297}. Note=May be
CC       secreted via a classical signal peptide and reenter into cells with the
CC       help of a poly-Arg motif.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=3;
CC       Name=1; Synonyms=55kDa;
CC         IsoId=P60484-1; Sequence=Displayed;
CC       Name=alpha; Synonyms=70kDa, PTEN-long;
CC         IsoId=P60484-2; Sequence=VSP_055420;
CC       Name=3;
CC         IsoId=P60484-3; Sequence=VSP_055421, VSP_055422, VSP_055423;
CC   -!- TISSUE SPECIFICITY: Expressed at a relatively high level in all adult
CC       tissues, including heart, brain, placenta, lung, liver, muscle, kidney
CC       and pancreas. {ECO:0000269|PubMed:9090379}.
CC   -!- INDUCTION: Down-regulated by TGFB1. {ECO:0000269|PubMed:9187108}.
CC   -!- DOMAIN: The C2 domain binds phospholipid membranes in vitro in a
CC       Ca(2+)-independent manner; this binding is important for its tumor
CC       suppressor function. {ECO:0000269|PubMed:10468583,
CC       ECO:0000269|PubMed:10555148}.
CC   -!- PTM: Constitutively phosphorylated by CK2 under normal conditions.
CC       Phosphorylated in vitro by MAST1, MAST2, MAST3 and STK11.
CC       Phosphorylation results in an inhibited activity towards PIP3.
CC       Phosphorylation can both inhibit or promote PDZ-binding.
CC       Phosphorylation at Tyr-336 by FRK/PTK5 protects this protein from
CC       ubiquitin-mediated degradation probably by inhibiting its binding to
CC       NEDD4. Phosphorylation by ROCK1 is essential for its stability and
CC       activity. Phosphorylation by PLK3 promotes its stability and prevents
CC       its degradation by the proteasome. {ECO:0000269|PubMed:10646847,
CC       ECO:0000269|PubMed:11035045, ECO:0000269|PubMed:11707428,
CC       ECO:0000269|PubMed:12297295, ECO:0000269|PubMed:15951562,
CC       ECO:0000269|PubMed:15987703, ECO:0000269|PubMed:18716620,
CC       ECO:0000269|PubMed:19345329, ECO:0000269|PubMed:20940307}.
CC   -!- PTM: Monoubiquitinated; monoubiquitination is increased in presence of
CC       retinoic acid. Deubiquitinated by USP7; leading to its nuclear
CC       exclusion. Monoubiquitination of one of either Lys-13 and Lys-289 amino
CC       acid is sufficient to modulate PTEN compartmentalization. Ubiquitinated
CC       by XIAP/BIRC4. {ECO:0000269|PubMed:18716620,
CC       ECO:0000269|PubMed:19473982}.
CC   -!- DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant
CC       hamartomatous polyposis syndrome with age-related penetrance. Cowden
CC       syndrome is characterized by hamartomatous lesions affecting
CC       derivatives of ectodermal, mesodermal and endodermal layers,
CC       macrocephaly, facial trichilemmomas (benign tumors of the hair follicle
CC       infundibulum), acral keratoses, papillomatous papules, and elevated
CC       risk for development of several types of malignancy, particularly
CC       breast carcinoma in women and thyroid carcinoma in both men and women.
CC       Colon cancer and renal cell carcinoma have also been reported.
CC       Hamartomas can be found in virtually every organ, but most commonly in
CC       the skin, gastrointestinal tract, breast and thyroid.
CC       {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502,
CC       ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:10866302,
CC       ECO:0000269|PubMed:11230179, ECO:0000269|PubMed:11494117,
CC       ECO:0000269|PubMed:15355975, ECO:0000269|PubMed:18716620,
CC       ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9241266,
CC       ECO:0000269|PubMed:9259288, ECO:0000269|PubMed:9345101,
CC       ECO:0000269|PubMed:9399897, ECO:0000269|PubMed:9425889,
CC       ECO:0000269|PubMed:9467011, ECO:0000269|PubMed:9600246,
CC       ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362,
CC       ECO:0000269|PubMed:9811831, ECO:0000269|PubMed:9832031,
CC       ECO:0000269|PubMed:9915974}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease
CC       characterized by the occurrence of a slowly enlarging mass within the
CC       cerebellar cortex corresponding histologically to a cerebellar
CC       hamartoma. It manifests, most commonly in the third and fourth decades
CC       of life, with increased intracranial pressure, headache, nausea,
CC       cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual
CC       disturbances and other cranial nerve palsies. Various associated
CC       abnormalities may be present such as megalencephaly, microgyria,
CC       hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part
CC       of the PTEN hamartoma tumor syndromes spectrum that also includes
CC       Cowden syndrome. Note=The disease is caused by mutations affecting the
CC       gene represented in this entry.
CC   -!- DISEASE: Squamous cell carcinoma of the head and neck (HNSCC)
CC       [MIM:275355]: A non-melanoma skin cancer affecting the head and neck.
CC       The hallmark of cutaneous SCC is malignant transformation of normal
CC       epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of
CC       endometrium, the mucous lining of the uterus. Most endometrial cancers
CC       are adenocarcinomas, cancers that begin in cells that make and release
CC       mucus and other fluids. Note=Disease susceptibility is associated with
CC       variations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=PTEN mutations are found in a subset of patients with
CC       Proteus syndrome, a genetically heterogeneous condition. The molecular
CC       diagnosis of PTEN mutation positive cases classifies Proteus syndrome
CC       patients as part of the PTEN hamartoma syndrome spectrum. As such,
CC       patients surviving the early years of Proteus syndrome are likely at a
CC       greater risk of developing malignancies.
CC   -!- DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant
CC       central nervous system neoplasms derived from glial cells. They
CC       comprise astrocytomas and glioblastoma multiforme that are derived from
CC       astrocytes, oligodendrogliomas derived from oligodendrocytes and
CC       ependymomas derived from ependymocytes. {ECO:0000269|PubMed:12085208}.
CC       Note=Disease susceptibility is associated with variations affecting the
CC       gene represented in this entry.
CC   -!- DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in
CC       tissues of the prostate. Most prostate cancers are adenocarcinomas that
CC       develop in the acini of the prostatic ducts. Other rare histopathologic
CC       types of prostate cancer that occur in approximately 5% of patients
CC       include small cell carcinoma, mucinous carcinoma, prostatic ductal
CC       carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal
CC       cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell
CC       carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:26504226,
CC       ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated
CC       with variations affecting the gene represented in this entry.
CC   -!- DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients
CC       have autism spectrum disorders and macrocephaly, with head
CC       circumferences ranging from +2.5 to +8 SD for age and sex (average head
CC       circumference +4.0 SD). {ECO:0000269|PubMed:15805158,
CC       ECO:0000269|PubMed:23160955, ECO:0000269|PubMed:26637798}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and
CC       PTEN is a cause of chromosome 10q23 deletion syndrome, which shows
CC       overlapping features of the following three disorders: Bannayan-Zonana
CC       syndrome, Cowden disease and juvenile polyposis syndrome.
CC   -!- MISCELLANEOUS: [Isoform alpha]: Produced by alternative initiation at a
CC       CTG start codon of isoform 1. May contain a signal peptide at positions
CC       1-21. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the PTEN phosphatase protein family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PTENID158.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/pten/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U96180; AAB66902.1; -; mRNA.
DR   EMBL; U92436; AAC51182.1; -; mRNA.
DR   EMBL; U93051; AAC51183.1; -; mRNA.
DR   EMBL; AF143315; AAD38372.1; -; Genomic_DNA.
DR   EMBL; AF143312; AAD38372.1; JOINED; Genomic_DNA.
DR   EMBL; AF143313; AAD38372.1; JOINED; Genomic_DNA.
DR   EMBL; AF143314; AAD38372.1; JOINED; Genomic_DNA.
DR   EMBL; AF000734; AAC08699.1; -; Genomic_DNA.
DR   EMBL; AF000726; AAC08699.1; JOINED; Genomic_DNA.
DR   EMBL; AF000727; AAC08699.1; JOINED; Genomic_DNA.
DR   EMBL; AF000728; AAC08699.1; JOINED; Genomic_DNA.
DR   EMBL; AF000729; AAC08699.1; JOINED; Genomic_DNA.
DR   EMBL; AF000730; AAC08699.1; JOINED; Genomic_DNA.
DR   EMBL; AF000731; AAC08699.1; JOINED; Genomic_DNA.
DR   EMBL; AF000732; AAC08699.1; JOINED; Genomic_DNA.
DR   EMBL; AF000733; AAC08699.1; JOINED; Genomic_DNA.
DR   EMBL; AF067844; AAD13528.1; -; Genomic_DNA.
DR   EMBL; JF268690; ADZ48535.1; -; mRNA.
DR   EMBL; CR450306; CAG29302.1; -; mRNA.
DR   EMBL; AK313581; BAG36351.1; -; mRNA.
DR   EMBL; DQ073384; AAY57327.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW50174.1; -; Genomic_DNA.
DR   EMBL; BC005821; AAH05821.1; -; mRNA.
DR   CCDS; CCDS31238.1; -. [P60484-1]
DR   RefSeq; NP_000305.3; NM_000314.6. [P60484-1]
DR   RefSeq; NP_001291646.2; NM_001304717.2.
DR   RefSeq; NP_001291647.1; NM_001304718.1.
DR   PDB; 1D5R; X-ray; 2.10 A; A=8-353.
DR   PDB; 2KYL; NMR; -; B=391-403.
DR   PDB; 4O1V; X-ray; 2.00 A; B=354-368.
DR   PDB; 5BUG; X-ray; 2.40 A; A/B/C/D=14-351.
DR   PDB; 5BZX; X-ray; 2.50 A; A/B/C/D=14-351.
DR   PDB; 5BZZ; X-ray; 2.20 A; A/B/C/D=14-351.
DR   PDBsum; 1D5R; -.
DR   PDBsum; 2KYL; -.
DR   PDBsum; 4O1V; -.
DR   PDBsum; 5BUG; -.
DR   PDBsum; 5BZX; -.
DR   PDBsum; 5BZZ; -.
DR   SMR; P60484; -.
DR   BioGRID; 111700; 739.
DR   ComplexPortal; CPX-3153; PTEN phosphatase complex.
DR   CORUM; P60484; -.
DR   DIP; DIP-35019N; -.
DR   ELM; P60484; -.
DR   IntAct; P60484; 58.
DR   MINT; P60484; -.
DR   STRING; 9606.ENSP00000361021; -.
DR   BindingDB; P60484; -.
DR   ChEMBL; CHEMBL2052032; -.
DR   DrugBank; DB04327; Phosphatidylethanolamine.
DR   GuidetoPHARMACOLOGY; 2497; -.
DR   SwissLipids; SLP:000000849; -.
DR   CarbonylDB; P60484; -.
DR   DEPOD; PTEN; -.
DR   iPTMnet; P60484; -.
DR   MetOSite; P60484; -.
DR   PhosphoSitePlus; P60484; -.
DR   BioMuta; PTEN; -.
DR   DMDM; 42560209; -.
DR   EPD; P60484; -.
DR   jPOST; P60484; -.
DR   MassIVE; P60484; -.
DR   MaxQB; P60484; -.
DR   PaxDb; P60484; -.
DR   PeptideAtlas; P60484; -.
DR   PRIDE; P60484; -.
DR   ProteomicsDB; 57209; -. [P60484-1]
DR   Antibodypedia; 3420; 1693 antibodies.
DR   CPTC; P60484; 8 antibodies.
DR   DNASU; 5728; -.
DR   Ensembl; ENST00000371953; ENSP00000361021; ENSG00000171862. [P60484-1]
DR   GeneID; 5728; -.
DR   KEGG; hsa:5728; -.
DR   UCSC; uc001kfb.4; human. [P60484-1]
DR   CTD; 5728; -.
DR   DisGeNET; 5728; -.
DR   EuPathDB; HostDB:ENSG00000171862.9; -.
DR   GeneCards; PTEN; -.
DR   GeneReviews; PTEN; -.
DR   HGNC; HGNC:9588; PTEN.
DR   HPA; ENSG00000171862; Low tissue specificity.
DR   MalaCards; PTEN; -.
DR   MIM; 137800; phenotype.
DR   MIM; 158350; phenotype.
DR   MIM; 176807; phenotype.
DR   MIM; 275355; phenotype.
DR   MIM; 601728; gene.
DR   MIM; 605309; phenotype.
DR   MIM; 608089; phenotype.
DR   MIM; 612242; phenotype.
DR   MIM; 613028; phenotype.
DR   neXtProt; NX_P60484; -.
DR   OpenTargets; ENSG00000171862; -.
DR   Orphanet; 397596; Activated PI3K-delta syndrome.
DR   Orphanet; 109; Bannayan-Riley-Ruvalcaba syndrome.
DR   Orphanet; 201; Cowden syndrome.
DR   Orphanet; 145; Hereditary breast and ovarian cancer syndrome.
DR   Orphanet; 79076; Juvenile polyposis of infancy.
DR   Orphanet; 65285; Lhermitte-Duclos disease.
DR   Orphanet; 210548; Macrocephaly-intellectual disability-autism syndrome.
DR   Orphanet; 744; Proteus syndrome.
DR   Orphanet; 2969; Proteus-like syndrome.
DR   Orphanet; 137608; Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome.
DR   Orphanet; 500481; Squamous cell carcinoma of salivary glands.
DR   Orphanet; 494547; Squamous cell carcinoma of the hypopharynx.
DR   Orphanet; 494550; Squamous cell carcinoma of the larynx.
DR   Orphanet; 502366; Squamous cell carcinoma of the lip.
DR   Orphanet; 500464; Squamous cell carcinoma of the nasal cavity and paranasal sinuses.
DR   Orphanet; 502363; Squamous cell carcinoma of the oral cavity.
DR   Orphanet; 500478; Squamous cell carcinoma of the oropharynx.
DR   PharmGKB; PA33942; -.
DR   eggNOG; KOG2283; Eukaryota.
DR   GeneTree; ENSGT00940000154335; -.
DR   HOGENOM; CLU_020105_5_2_1; -.
DR   InParanoid; P60484; -.
DR   OMA; PKMKRKE; -.
DR   OrthoDB; 639380at2759; -.
DR   PhylomeDB; P60484; -.
DR   TreeFam; TF324513; -.
DR   BioCyc; MetaCyc:HS10404-MONOMER; -.
DR   BRENDA; 3.1.3.16; 2681.
DR   PathwayCommons; P60484; -.
DR   Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane.
DR   Reactome; R-HSA-1855204; Synthesis of IP3 and IP4 in the cytosol.
DR   Reactome; R-HSA-199418; Negative regulation of the PI3K/AKT network.
DR   Reactome; R-HSA-202424; Downstream TCR signaling.
DR   Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes.
DR   Reactome; R-HSA-5674404; PTEN Loss of Function in Cancer.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-5689896; Ovarian tumor domain proteases.
DR   Reactome; R-HSA-8943723; Regulation of PTEN mRNA translation.
DR   Reactome; R-HSA-8948747; Regulation of PTEN localization.
DR   Reactome; R-HSA-8948751; Regulation of PTEN stability and activity.
DR   Reactome; R-HSA-8986944; Transcriptional Regulation by MECP2.
DR   SignaLink; P60484; -.
DR   SIGNOR; P60484; -.
DR   BioGRID-ORCS; 5728; 36 hits in 833 CRISPR screens.
DR   ChiTaRS; PTEN; human.
DR   EvolutionaryTrace; P60484; -.
DR   GeneWiki; PTEN_(gene); -.
DR   GenomeRNAi; 5728; -.
DR   Pharos; P60484; Tchem.
DR   PRO; PR:P60484; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; P60484; protein.
DR   Bgee; ENSG00000171862; Expressed in calcaneal tendon and 218 other tissues.
DR   ExpressionAtlas; P60484; baseline and differential.
DR   Genevisible; P60484; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IMP:UniProtKB.
DR   GO; GO:0042995; C:cell projection; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0043197; C:dendritic spine; IEA:Ensembl.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0035749; C:myelin sheath adaxonal region; ISS:BHF-UCL.
DR   GO; GO:0043005; C:neuron projection; ISS:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:Ensembl.
DR   GO; GO:0043220; C:Schmidt-Lanterman incisure; ISS:BHF-UCL.
DR   GO; GO:0010997; F:anaphase-promoting complex binding; IPI:BHF-UCL.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0051717; F:inositol-1,3,4,5-tetrakisphosphate 3-phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0035255; F:ionotropic glutamate receptor binding; IEA:Ensembl.
DR   GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW.
DR   GO; GO:0030165; F:PDZ domain binding; IPI:UniProtKB.
DR   GO; GO:0016314; F:phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0051800; F:phosphatidylinositol-3,4-bisphosphate 3-phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0004438; F:phosphatidylinositol-3-phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0004721; F:phosphoprotein phosphatase activity; IDA:BHF-UCL.
DR   GO; GO:0005161; F:platelet-derived growth factor receptor binding; IEA:Ensembl.
DR   GO; GO:0004722; F:protein serine/threonine phosphatase activity; IDA:UniProtKB.
DR   GO; GO:1990782; F:protein tyrosine kinase binding; IEA:Ensembl.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0008138; F:protein tyrosine/serine/threonine phosphatase activity; IEA:InterPro.
DR   GO; GO:1990381; F:ubiquitin-specific protease binding; IPI:MGI.
DR   GO; GO:0030534; P:adult behavior; IEA:Ensembl.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0001525; P:angiogenesis; IEA:Ensembl.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0048854; P:brain morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0048738; P:cardiac muscle tissue development; IEA:Ensembl.
DR   GO; GO:0016477; P:cell migration; ISS:UniProtKB.
DR   GO; GO:0048870; P:cell motility; IBA:GO_Central.
DR   GO; GO:0071257; P:cellular response to electrical stimulus; IMP:BHF-UCL.
DR   GO; GO:0071361; P:cellular response to ethanol; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IEA:Ensembl.
DR   GO; GO:1990314; P:cellular response to insulin-like growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0044320; P:cellular response to leptin stimulus; IEA:Ensembl.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0007417; P:central nervous system development; ISS:UniProtKB.
DR   GO; GO:0032286; P:central nervous system myelin maintenance; ISS:BHF-UCL.
DR   GO; GO:0021955; P:central nervous system neuron axonogenesis; ISS:BHF-UCL.
DR   GO; GO:0060997; P:dendritic spine morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0021542; P:dentate gyrus development; ISS:BHF-UCL.
DR   GO; GO:0016311; P:dephosphorylation; IBA:GO_Central.
DR   GO; GO:0043542; P:endothelial cell migration; IEA:Ensembl.
DR   GO; GO:0048853; P:forebrain morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0007507; P:heart development; ISS:UniProtKB.
DR   GO; GO:0046855; P:inositol phosphate dephosphorylation; IDA:UniProtKB.
DR   GO; GO:0043647; P:inositol phosphate metabolic process; TAS:Reactome.
DR   GO; GO:0007611; P:learning or memory; ISS:BHF-UCL.
DR   GO; GO:0045475; P:locomotor rhythm; ISS:BHF-UCL.
DR   GO; GO:0007626; P:locomotory behavior; ISS:BHF-UCL.
DR   GO; GO:0060292; P:long-term synaptic depression; IEA:Ensembl.
DR   GO; GO:0060291; P:long-term synaptic potentiation; IEA:Ensembl.
DR   GO; GO:0060179; P:male mating behavior; IEA:Ensembl.
DR   GO; GO:0042711; P:maternal behavior; IEA:Ensembl.
DR   GO; GO:0007613; P:memory; IEA:Ensembl.
DR   GO; GO:0033555; P:multicellular organismal response to stress; ISS:BHF-UCL.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0048681; P:negative regulation of axon regeneration; IEA:Ensembl.
DR   GO; GO:0050771; P:negative regulation of axonogenesis; ISS:BHF-UCL.
DR   GO; GO:0060044; P:negative regulation of cardiac muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0090344; P:negative regulation of cell aging; IEA:Ensembl.
DR   GO; GO:1902807; P:negative regulation of cell cycle G1/S phase transition; IDA:UniProtKB.
DR   GO; GO:0030336; P:negative regulation of cell migration; IMP:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:BHF-UCL.
DR   GO; GO:0045792; P:negative regulation of cell size; ISS:BHF-UCL.
DR   GO; GO:0045736; P:negative regulation of cyclin-dependent protein serine/threonine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0061002; P:negative regulation of dendritic spine morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; IMP:BHF-UCL.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IMP:BHF-UCL.
DR   GO; GO:0090394; P:negative regulation of excitatory postsynaptic potential; ISS:BHF-UCL.
DR   GO; GO:0051895; P:negative regulation of focal adhesion assembly; IMP:UniProtKB.
DR   GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IDA:BHF-UCL.
DR   GO; GO:0051548; P:negative regulation of keratinocyte migration; IMP:BHF-UCL.
DR   GO; GO:0031642; P:negative regulation of myelination; IEA:Ensembl.
DR   GO; GO:0010977; P:negative regulation of neuron projection development; ISS:ARUK-UCL.
DR   GO; GO:0046621; P:negative regulation of organ growth; ISS:BHF-UCL.
DR   GO; GO:0033137; P:negative regulation of peptidyl-serine phosphorylation; IMP:UniProtKB.
DR   GO; GO:0050765; P:negative regulation of phagocytosis; IEA:Ensembl.
DR   GO; GO:0014067; P:negative regulation of phosphatidylinositol 3-kinase signaling; TAS:BHF-UCL.
DR   GO; GO:1901017; P:negative regulation of potassium ion transmembrane transporter activity; IEA:Ensembl.
DR   GO; GO:0051898; P:negative regulation of protein kinase B signaling; IMP:UniProtKB.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0090071; P:negative regulation of ribosome biogenesis; IEA:Ensembl.
DR   GO; GO:2000272; P:negative regulation of signaling receptor activity; IEA:Ensembl.
DR   GO; GO:2000808; P:negative regulation of synaptic vesicle clustering; ISS:BHF-UCL.
DR   GO; GO:1904706; P:negative regulation of vascular associated smooth muscle cell proliferation; IMP:BHF-UCL.
DR   GO; GO:1903690; P:negative regulation of wound healing, spreading of epidermal cells; IMP:BHF-UCL.
DR   GO; GO:0007270; P:neuron-neuron synaptic transmission; ISS:BHF-UCL.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IBA:GO_Central.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome.
DR   GO; GO:0046856; P:phosphatidylinositol dephosphorylation; IDA:UniProtKB.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0010666; P:positive regulation of cardiac muscle cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; ISS:BHF-UCL.
DR   GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; IMP:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; ISS:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:1903984; P:positive regulation of TRAIL-activated apoptotic signaling pathway; IMP:BHF-UCL.
DR   GO; GO:1904668; P:positive regulation of ubiquitin protein ligase activity; IDA:BHF-UCL.
DR   GO; GO:2000060; P:positive regulation of ubiquitin-dependent protein catabolic process; IDA:BHF-UCL.
DR   GO; GO:0097107; P:postsynaptic density assembly; ISS:BHF-UCL.
DR   GO; GO:0060134; P:prepulse inhibition; ISS:BHF-UCL.
DR   GO; GO:0097105; P:presynaptic membrane assembly; ISS:BHF-UCL.
DR   GO; GO:0060736; P:prostate gland growth; IEA:Ensembl.
DR   GO; GO:0006470; P:protein dephosphorylation; IDA:UniProtKB.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0043491; P:protein kinase B signaling; ISS:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IDA:BHF-UCL.
DR   GO; GO:0002902; P:regulation of B cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0032535; P:regulation of cellular component size; ISS:BHF-UCL.
DR   GO; GO:0033032; P:regulation of myeloid cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0010975; P:regulation of neuron projection development; ISS:UniProtKB.
DR   GO; GO:0051896; P:regulation of protein kinase B signaling; IBA:GO_Central.
DR   GO; GO:0031647; P:regulation of protein stability; IMP:UniProtKB.
DR   GO; GO:0032228; P:regulation of synaptic transmission, GABAergic; IEA:Ensembl.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0046685; P:response to arsenic-containing substance; IEA:Ensembl.
DR   GO; GO:0033198; P:response to ATP; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0009749; P:response to glucose; IEA:Ensembl.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0010043; P:response to zinc ion; IEA:Ensembl.
DR   GO; GO:0060024; P:rhythmic synaptic transmission; ISS:BHF-UCL.
DR   GO; GO:0035176; P:social behavior; ISS:BHF-UCL.
DR   GO; GO:0007416; P:synapse assembly; ISS:BHF-UCL.
DR   GO; GO:0060074; P:synapse maturation; ISS:BHF-UCL.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; TAS:Reactome.
DR   Gene3D; 3.90.190.10; -; 1.
DR   InterPro; IPR017361; Bifunc_PIno_P3_Pase/Pase_PTEN.
DR   InterPro; IPR000340; Dual-sp_phosphatase_cat-dom.
DR   InterPro; IPR029021; Prot-tyrosine_phosphatase-like.
DR   InterPro; IPR014020; Tensin_C2-dom.
DR   InterPro; IPR029023; Tensin_phosphatase.
DR   InterPro; IPR016130; Tyr_Pase_AS.
DR   InterPro; IPR003595; Tyr_Pase_cat.
DR   Pfam; PF00782; DSPc; 1.
DR   Pfam; PF10409; PTEN_C2; 1.
DR   PIRSF; PIRSF038025; PTEN; 1.
DR   SMART; SM01326; PTEN_C2; 1.
DR   SMART; SM00404; PTPc_motif; 1.
DR   SUPFAM; SSF52799; SSF52799; 1.
DR   PROSITE; PS51182; C2_TENSIN; 1.
DR   PROSITE; PS51181; PPASE_TENSIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative initiation; Alternative splicing;
KW   Apoptosis; Autism spectrum disorder; Cytoplasm; Disease mutation;
KW   Hydrolase; Isopeptide bond; Lipid metabolism; Lipid-binding; Neurogenesis;
KW   Nucleus; Phosphoprotein; Polymorphism; Protein phosphatase;
KW   Reference proteome; Secreted; Tumor suppressor; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000244|PubMed:22814378"
FT   CHAIN           2..403
FT                   /note="Phosphatidylinositol 3,4,5-trisphosphate 3-
FT                   phosphatase and dual-specificity protein phosphatase PTEN"
FT                   /id="PRO_0000215904"
FT   DOMAIN          14..185
FT                   /note="Phosphatase tensin-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00590"
FT   DOMAIN          190..350
FT                   /note="C2 tensin-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00589"
FT   REGION          338..348
FT                   /note="Required for interaction with NOP53"
FT                   /evidence="ECO:0000269|PubMed:15355975"
FT   REGION          401..403
FT                   /note="PDZ domain-binding"
FT   ACT_SITE        124
FT                   /note="Phosphocysteine intermediate"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00590"
FT   MOD_RES         2
FT                   /note="N-acetylthreonine"
FT                   /evidence="ECO:0000244|PubMed:22814378"
FT   MOD_RES         294
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O08586"
FT   MOD_RES         336
FT                   /note="Phosphotyrosine; by FRK"
FT                   /evidence="ECO:0000269|PubMed:19345329"
FT   MOD_RES         366
FT                   /note="Phosphothreonine; by GSK3-beta and PLK3"
FT                   /evidence="ECO:0000244|PubMed:24275569,
FT                   ECO:0000269|PubMed:12297295, ECO:0000269|PubMed:20940307"
FT   MOD_RES         370
FT                   /note="Phosphoserine; by CK2 and PLK3"
FT                   /evidence="ECO:0000269|PubMed:11035045,
FT                   ECO:0000269|PubMed:12297295, ECO:0000269|PubMed:20940307"
FT   MOD_RES         380
FT                   /note="Phosphoserine; by ROCK1 and CK2"
FT                   /evidence="ECO:0000269|PubMed:11035045"
FT   MOD_RES         382
FT                   /note="Phosphothreonine; by ROCK1 and CK2"
FT                   /evidence="ECO:0000269|PubMed:11035045"
FT   MOD_RES         383
FT                   /note="Phosphothreonine; by ROCK1 and CK2"
FT                   /evidence="ECO:0000269|PubMed:11035045"
FT   MOD_RES         385
FT                   /note="Phosphoserine; by CK2"
FT                   /evidence="ECO:0000269|PubMed:11035045,
FT                   ECO:0000269|PubMed:12297295"
FT   MOD_RES         401
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:10646847"
FT   CROSSLNK        13
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:18716620"
FT   CROSSLNK        289
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:18716620"
FT   VAR_SEQ         1
FT                   /note="M -> MERGGEAAAAAAAAAAAPGRGSESPVTISRAGNAGELVSPLLLPPTR
FT                   RRRRRHIQGPGPVLNLPSAAAAPPVARAPEAAGGGSRSEDYSSSPHSAAAAARPLAAEE
FT                   KQAQSLQPSSSRRSSHYPAAVQSQAAAERGASATAKSRAISILQKKPRHQQLLPSLSSF
FT                   FFSHRLPDM (in isoform alpha)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_055420"
FT   VAR_SEQ         55..70
FT                   /note="RFLDSKHKNHYKIYNL -> S (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.7"
FT                   /id="VSP_055421"
FT   VAR_SEQ         165..190
FT                   /note="GVTIPSQRRYVYYYSYLLKNHLDYRP -> ADPTGGIPDKGIIVIGDGSSMD
FT                   VIAP (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.7"
FT                   /id="VSP_055422"
FT   VAR_SEQ         191..403
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.7"
FT                   /id="VSP_055423"
FT   VARIANT         10
FT                   /note="S -> N (retains phosphatase activity towards
FT                   Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the ability to
FT                   bind phospholipid membranes)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026248"
FT   VARIANT         15
FT                   /note="R -> S (in glioma; dbSNP:rs1064794096)"
FT                   /evidence="ECO:0000269|PubMed:9090379"
FT                   /id="VAR_007457"
FT   VARIANT         16
FT                   /note="Y -> C (loss of phosphatase activity towards
FT                   Ins(1,3,4,5)P4; retains the ability to bind phospholipid
FT                   membranes)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026249"
FT   VARIANT         19
FT                   /note="D -> N (in malignant melanoma; somatic mutation;
FT                   dbSNP:rs121909233)"
FT                   /evidence="ECO:0000269|PubMed:10978354"
FT                   /id="VAR_018100"
FT   VARIANT         20
FT                   /note="G -> E (reduced phosphatase activity towards
FT                   Ins(1,3,4,5)P4; retains phosphatase activity towards
FT                   PtdIns(3,4,5)P3; dbSNP:rs1064795967)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026250"
FT   VARIANT         27
FT                   /note="Y -> S (loss of phosphatase activity towards
FT                   Ins(1,3,4,5)P4; dbSNP:rs886041877)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026251"
FT   VARIANT         33
FT                   /note="Missing (in CWS1)"
FT                   /evidence="ECO:0000269|PubMed:10234502"
FT                   /id="VAR_008733"
FT   VARIANT         34
FT                   /note="A -> D (in CWS1)"
FT                   /evidence="ECO:0000269|PubMed:10400993,
FT                   ECO:0000269|PubMed:11494117"
FT                   /id="VAR_008734"
FT   VARIANT         35
FT                   /note="M -> R (in CWS1; dbSNP:rs121909225)"
FT                   /evidence="ECO:0000269|PubMed:9425889"
FT                   /id="VAR_008036"
FT   VARIANT         36
FT                   /note="G -> E (in glioma; dbSNP:rs1554893792)"
FT                   /evidence="ECO:0000269|PubMed:9090379"
FT                   /id="VAR_007458"
FT   VARIANT         36
FT                   /note="G -> R (in endometrial hyperplasia;
FT                   dbSNP:rs786204854)"
FT                   /evidence="ECO:0000269|PubMed:9635567"
FT                   /id="VAR_026252"
FT   VARIANT         42
FT                   /note="L -> R (in glioma; retains phosphatase activity
FT                   towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the
FT                   ability to bind phospholipid membranes)"
FT                   /evidence="ECO:0000269|PubMed:9090379"
FT                   /id="VAR_007459"
FT   VARIANT         47
FT                   /note="R -> G (in CWS1; dbSNP:rs786204855)"
FT                   /evidence="ECO:0000269|PubMed:11494117"
FT                   /id="VAR_011587"
FT   VARIANT         57
FT                   /note="L -> W (in glioma; loss of protein phosphatase
FT                   activity; dbSNP:rs786202398)"
FT                   /evidence="ECO:0000269|PubMed:9090379,
FT                   ECO:0000269|PubMed:9256433"
FT                   /id="VAR_007460"
FT   VARIANT         61
FT                   /note="H -> D (foun in a patient with macrocephaly,
FT                   ventriculomegaly, vertebral anomalies, anal atresia,
FT                   congenital cardiac disease, tracheoesophageal fistula,
FT                   renal anomalies, radial dysplasia and other limb defects;
FT                   unknown pathological significance; dbSNP:rs121909236)"
FT                   /evidence="ECO:0000269|PubMed:11748304"
FT                   /id="VAR_018101"
FT   VARIANT         61
FT                   /note="H -> R (loss of phosphatase activity towards
FT                   Ins(1,3,4,5)P4; dbSNP:rs398123316)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026253"
FT   VARIANT         65..403
FT                   /note="Missing (in MCEPHAS)"
FT                   /evidence="ECO:0000269|PubMed:26637798"
FT                   /id="VAR_078705"
FT   VARIANT         67
FT                   /note="I -> R (in CWS1)"
FT                   /id="VAR_007461"
FT   VARIANT         68
FT                   /note="Y -> H (in CWS1; loss of phosphatase activity
FT                   towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the
FT                   ability to bind phospholipid membranes; dbSNP:rs398123317)"
FT                   /evidence="ECO:0000269|PubMed:10400993,
FT                   ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11494117,
FT                   ECO:0000269|PubMed:9600246"
FT                   /id="VAR_007462"
FT   VARIANT         70
FT                   /note="L -> P (in CWS1; dbSNP:rs121909226)"
FT                   /evidence="ECO:0000269|PubMed:9832031"
FT                   /id="VAR_018102"
FT   VARIANT         71
FT                   /note="C -> Y (in CWS1; loss of phosphatase activity
FT                   towards Ins(1,3,4,5)P4)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026254"
FT   VARIANT         93
FT                   /note="H -> R (in MCEPHAS; dbSNP:rs121909238)"
FT                   /evidence="ECO:0000269|PubMed:15805158"
FT                   /id="VAR_032634"
FT   VARIANT         93
FT                   /note="H -> Y (in CWS1)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026255"
FT   VARIANT         105
FT                   /note="C -> F (in CWS1; loss of phosphatase activity
FT                   towards Ins(1,3,4,5)P4)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026256"
FT   VARIANT         105
FT                   /note="C -> Y (in CWS1; dbSNP:rs587782343)"
FT                   /evidence="ECO:0000269|PubMed:10400993,
FT                   ECO:0000269|PubMed:11494117"
FT                   /id="VAR_008735"
FT   VARIANT         107
FT                   /note="D -> Y (in CWS1 and glioblastoma; loss of
FT                   phosphatase activity towards Ins(1,3,4,5)P4;
FT                   dbSNP:rs57374291)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:9331071"
FT                   /id="VAR_026257"
FT   VARIANT         112
FT                   /note="L -> P (in CWS1 and LDD; loss of phosphatase
FT                   activity towards Ins(1,3,4,5)P4; dbSNP:rs121909230)"
FT                   /evidence="ECO:0000269|PubMed:10051160,
FT                   ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:9600246"
FT                   /id="VAR_007807"
FT   VARIANT         112
FT                   /note="L -> R (loss of phosphatase activity towards
FT                   Ins(1,3,4,5)P4)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026258"
FT   VARIANT         119
FT                   /note="V -> L (in multiple cancers; dbSNP:rs139767111)"
FT                   /evidence="ECO:0000269|PubMed:10807691"
FT                   /id="VAR_011588"
FT   VARIANT         121
FT                   /note="A -> G (in HNSCC; dbSNP:rs121909237)"
FT                   /evidence="ECO:0000269|PubMed:11801303"
FT                   /id="VAR_018103"
FT   VARIANT         121
FT                   /note="A -> P (in glioblastoma; loss of phosphatase
FT                   activity towards Ins(1,3,4,5)P4)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:9331071"
FT                   /id="VAR_026259"
FT   VARIANT         123
FT                   /note="H -> R (in CWS1; dbSNP:rs121909222)"
FT                   /evidence="ECO:0000269|PubMed:10234502,
FT                   ECO:0000269|PubMed:9259288"
FT                   /id="VAR_007463"
FT   VARIANT         123
FT                   /note="H -> Y (in endometrial cancer; loss of protein
FT                   phosphatase activity; dbSNP:rs786204931)"
FT                   /evidence="ECO:0000269|PubMed:9256433"
FT                   /id="VAR_026260"
FT   VARIANT         124
FT                   /note="C -> R (in CWS1; dbSNP:rs121909223)"
FT                   /evidence="ECO:0000269|PubMed:10234502,
FT                   ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:9259288"
FT                   /id="VAR_007464"
FT   VARIANT         124
FT                   /note="C -> S (in CWS1; phosphatase-dead protein with
FT                   neither lipid nor protein phosphatase activity)"
FT                   /evidence="ECO:0000269|PubMed:11230179,
FT                   ECO:0000269|PubMed:9811831"
FT                   /id="VAR_018104"
FT   VARIANT         126
FT                   /note="A -> G (in a patient with prostate cancer; reduced
FT                   phosphatase activity towards PtdIns(3,4,5); shifts its
FT                   activity from phosphatidylinositol phosphate 3-phosphatase
FT                   to phosphatidylinositol phosphate 5-phosphatase; disrupts
FT                   PI3K/ATK signaling; reduced cell migration)"
FT                   /evidence="ECO:0000269|PubMed:26504226"
FT                   /id="VAR_076551"
FT   VARIANT         129
FT                   /note="G -> E (in CWS1; no lipid phosphatase activity but
FT                   retains protein phosphatase activity; retains ability to
FT                   inhibit focal adhesion formation; dbSNP:rs121909218)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:11230179, ECO:0000269|PubMed:9140396,
FT                   ECO:0000269|PubMed:9616126, ECO:0000269|PubMed:9811831"
FT                   /id="VAR_007465"
FT   VARIANT         129
FT                   /note="G -> R (in glioblastoma; severely reduced protein
FT                   phosphatase activity; loss of phosphatase activity towards
FT                   Ins(1,3,4,5)P4; dbSNP:rs786204929)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:9072974, ECO:0000269|PubMed:9256433,
FT                   ECO:0000269|PubMed:9331071"
FT                   /id="VAR_007466"
FT   VARIANT         130
FT                   /note="R -> G (loss of phosphatase activity towards
FT                   Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; dbSNP:rs121909224)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026261"
FT   VARIANT         130
FT                   /note="R -> L (in CWS1 and endometrial hyperplasia; loss of
FT                   phosphatase activity towards Ins(1,3,4,5)P4; retains
FT                   ability to bind phospholipid membranes; dbSNP:rs121909229)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:9635567"
FT                   /id="VAR_007467"
FT   VARIANT         130
FT                   /note="R -> Q (in CWS1; loss of phosphatase activity
FT                   towards Ins(1,3,4,5)P4; retains ability to bind
FT                   phospholipid membranes; dbSNP:rs121909229)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:9915974"
FT                   /id="VAR_007468"
FT   VARIANT         131
FT                   /note="T -> I (in MCEPHAS; dbSNP:rs397514560)"
FT                   /evidence="ECO:0000269|PubMed:23160955"
FT                   /id="VAR_076762"
FT   VARIANT         132
FT                   /note="G -> V (in one patient with clinical findings
FT                   suggesting hamartoma tumor syndrome; dbSNP:rs121909241)"
FT                   /evidence="ECO:0000269|PubMed:16752378"
FT                   /id="VAR_032635"
FT   VARIANT         133
FT                   /note="V -> I (loss of phosphatase activity towards
FT                   Ins(1,3,4,5)P3)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026262"
FT   VARIANT         134
FT                   /note="M -> L (in prostate cancer; no effect on protein
FT                   phosphatase activity; reduced phosphatase activity towards
FT                   Ins(1,3,4,5)P3 but retains PtdIns(3,4,5)P3 phosphatase
FT                   activity)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:9072974, ECO:0000269|PubMed:9256433"
FT                   /id="VAR_007469"
FT   VARIANT         135
FT                   /note="I -> V (in CWS1; dbSNP:rs587782360)"
FT                   /evidence="ECO:0000269|PubMed:10400993,
FT                   ECO:0000269|PubMed:11494117"
FT                   /id="VAR_008736"
FT   VARIANT         136
FT                   /note="C -> Y (in CWS1; loss of phosphatase activity
FT                   towards Ins(1,3,4,5)P3; dbSNP:rs786204859)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:9735393"
FT                   /id="VAR_007808"
FT   VARIANT         137
FT                   /note="A -> AN (in CWS1)"
FT                   /evidence="ECO:0000269|PubMed:9345101"
FT                   /id="VAR_008737"
FT   VARIANT         155
FT                   /note="Y -> C (in CWS1; loss of phosphatase activity
FT                   towards Ins(1,3,4,5)P4; dbSNP:rs1060500126)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026263"
FT   VARIANT         158
FT                   /note="V -> L (in multiple cancers)"
FT                   /evidence="ECO:0000269|PubMed:10807691"
FT                   /id="VAR_011589"
FT   VARIANT         165
FT                   /note="G -> E (in CWS1)"
FT                   /evidence="ECO:0000269|PubMed:10234502"
FT                   /id="VAR_008739"
FT   VARIANT         165
FT                   /note="G -> R (in glioblastoma; severely reduced protein
FT                   phosphatase activity; loss of phosphatase activity towards
FT                   Ins(1,3,4,5)P4; retains ability to bind phospholipid
FT                   membranes; dbSNP:rs587782603)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:9256433, ECO:0000269|PubMed:9331071"
FT                   /id="VAR_026264"
FT   VARIANT         165
FT                   /note="G -> V (in CWS1; dbSNP:rs786204863)"
FT                   /id="VAR_008738"
FT   VARIANT         167
FT                   /note="T -> N (in MCEPHAS; dbSNP:rs397514559)"
FT                   /evidence="ECO:0000269|PubMed:23160955"
FT                   /id="VAR_076763"
FT   VARIANT         167
FT                   /note="T -> P (in breast cancer; severely reduced protein
FT                   phosphatase activity)"
FT                   /evidence="ECO:0000269|PubMed:9256433"
FT                   /id="VAR_026265"
FT   VARIANT         170
FT                   /note="S -> N (loss of phosphatase activity towards
FT                   Ins(1,3,4,5)P4; retains ability to bind phospholipid
FT                   membranes)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026266"
FT   VARIANT         170
FT                   /note="S -> R (in CWS1; severely reduced protein
FT                   phosphatase activity; loss of phosphatase activity towards
FT                   Ins(1,3,4,5)P4; dbSNP:rs121909221)"
FT                   /evidence="ECO:0000269|PubMed:10400993,
FT                   ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11494117,
FT                   ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9256433"
FT                   /id="VAR_007470"
FT   VARIANT         173
FT                   /note="R -> C (in endometrial hyperplasia; loss of
FT                   phosphatase activity towards Ins(1,3,4,5)P4 and
FT                   PtdIns(3,4,5)P3; retains ability to bind phospholipid
FT                   membranes; dbSNP:rs121913293)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:9635567"
FT                   /id="VAR_026267"
FT   VARIANT         173
FT                   /note="R -> H (loss of phosphatase activity towards
FT                   Ins(1,3,4,5)P4; dbSNP:rs121913294)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026268"
FT   VARIANT         173
FT                   /note="R -> P (loss of phosphatase activity towards
FT                   Ins(1,3,4,5)P4; dbSNP:rs121913294)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026269"
FT   VARIANT         174
FT                   /note="Y -> N (loss of phosphatase activity towards
FT                   Ins(1,3,4,5)P4; dbSNP:rs587782316)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026270"
FT   VARIANT         191
FT                   /note="V -> A (in endometrial hyperplasia)"
FT                   /evidence="ECO:0000269|PubMed:9635567"
FT                   /id="VAR_026271"
FT   VARIANT         217
FT                   /note="V -> I (in malignant melanoma; somatic mutation;
FT                   dbSNP:rs121909234)"
FT                   /evidence="ECO:0000269|PubMed:10978354"
FT                   /id="VAR_018105"
FT   VARIANT         227
FT                   /note="S -> F (reduced phosphatase activity towards
FT                   Ins(1,3,4,5)P4 but retains PtdIns(3,4,5)P3 phosphatase
FT                   activity; dbSNP:rs905615413)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026272"
FT   VARIANT         234
FT                   /note="R -> Q (in GLM2; the patient also suffered from
FT                   benign meningioma; not capable of inducing apoptosis;
FT                   induced increased cell proliferation; led to high
FT                   constitutive AKT1 activation which could not be increased
FT                   further by stimulation with insulin; dbSNP:rs121909235)"
FT                   /evidence="ECO:0000269|PubMed:12085208"
FT                   /id="VAR_018106"
FT   VARIANT         241
FT                   /note="F -> S (in MCEPHAS; dbSNP:rs121909240)"
FT                   /evidence="ECO:0000269|PubMed:15805158"
FT                   /id="VAR_032636"
FT   VARIANT         246
FT                   /note="P -> L (in CWS1; dbSNP:rs587782350)"
FT                   /evidence="ECO:0000269|PubMed:10400993"
FT                   /id="VAR_008740"
FT   VARIANT         251
FT                   /note="G -> C (loss of phosphatase activity towards
FT                   Ins(1,3,4,5)P4; retains ability to bind phospholipid
FT                   membranes)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026273"
FT   VARIANT         252
FT                   /note="D -> G (in MCEPHAS; dbSNP:rs121909239)"
FT                   /evidence="ECO:0000269|PubMed:15805158"
FT                   /id="VAR_032637"
FT   VARIANT         289
FT                   /note="K -> E (in CWS1; reduced phosphatase activity
FT                   towards Ins(1,3,4,5)P4; retains ability to bind
FT                   phospholipid membranes; predominantly nuclear;
FT                   dbSNP:rs562015640)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:9797362"
FT                   /id="VAR_008741"
FT   VARIANT         290
FT                   /note="V -> L (in dbSNP:rs35600253)"
FT                   /evidence="ECO:0000269|Ref.10"
FT                   /id="VAR_025167"
FT   VARIANT         319
FT                   /note="Missing (in glioma; reduced tumor suppressor
FT                   activity; fails to inactivate AKT/PKB)"
FT                   /evidence="ECO:0000269|PubMed:10468583,
FT                   ECO:0000269|PubMed:9090379"
FT                   /id="VAR_026274"
FT   VARIANT         331
FT                   /note="D -> G (in CWS1; reduced phosphatase activity
FT                   towards Ins(1,3,4,5)P4; retains ability to bind
FT                   phospholipid membranes)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026275"
FT   VARIANT         341
FT                   /note="F -> V (in CWS1; loss of interaction with NOP53;
FT                   decreased phosphorylation at S-380; decreased stability;
FT                   loss of phosphatase activity towards Ins(1,3,4,5)P4;
FT                   dbSNP:rs1554825652)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:15355975"
FT                   /id="VAR_026276"
FT   VARIANT         342
FT                   /note="K -> N (in CWS1; reduced phosphatase activity
FT                   towards Ins(1,3,4,5)P4 but PtdIns(3,4,5)P3 phosphatase
FT                   activity is similar to wild-type; dbSNP:rs398123314)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026277"
FT   VARIANT         343
FT                   /note="V -> E (in CWS1; loss of interaction with NOP53;
FT                   decreased phosphorylation at S-380; decreased stability;
FT                   loss of phosphatase activity towards Ins(1,3,4,5)P4)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:15355975, ECO:0000269|PubMed:9399897"
FT                   /id="VAR_008742"
FT   VARIANT         345
FT                   /note="L -> Q (in glioblastoma; reduced tumor suppressor
FT                   activity; loss of interaction with NOP53; decreased
FT                   phosphorylation at S-380; decreased stability; loss of
FT                   phosphatase activity towards Ins(1,3,4,5)P4; reduced
FT                   ability to inactivate AKT/PKB; retains ability to bind
FT                   phospholipid membranes)"
FT                   /evidence="ECO:0000269|PubMed:10468583,
FT                   ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:15355975,
FT                   ECO:0000269|PubMed:9331071"
FT                   /id="VAR_026278"
FT   VARIANT         347
FT                   /note="F -> L (in CWS1; reduced phosphatase activity
FT                   towards Ins(1,3,4,5)P4)"
FT                   /evidence="ECO:0000269|PubMed:10866302,
FT                   ECO:0000269|PubMed:9399897"
FT                   /id="VAR_008743"
FT   VARIANT         348
FT                   /note="T -> I (in endometrial hyperplasia; reduced
FT                   phosphatase activity towards PtdIns(3,4,5)P3; mildly
FT                   reduced tumor suppressor activity; reduced ability to
FT                   inactivate AKT/PKB)"
FT                   /evidence="ECO:0000269|PubMed:10468583,
FT                   ECO:0000269|PubMed:9635567"
FT                   /id="VAR_026279"
FT   VARIANT         369
FT                   /note="V -> G (retains Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3
FT                   phosphatase activity; retains ability to bind phospholipid
FT                   membranes)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026280"
FT   VARIANT         401
FT                   /note="T -> I (retains Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3
FT                   phosphatase activity; retains ability to bind phospholipid
FT                   membranes)"
FT                   /evidence="ECO:0000269|PubMed:10866302"
FT                   /id="VAR_026281"
FT   MUTAGEN         1
FT                   /note="M->I: Expression is restricted to isoform alpha."
FT                   /evidence="ECO:0000269|PubMed:24768297"
FT   MUTAGEN         13
FT                   /note="K->E: Nuclear. Cytoplasmic; when associated with E-
FT                   289. Shows less tumor suppressive ability; when associated
FT                   with E-289."
FT                   /evidence="ECO:0000269|PubMed:18716620"
FT   MUTAGEN         92
FT                   /note="D->A: 700-fold reduction in phosphatase activity
FT                   towards PtdIns(3,4,5)P3. Loss of protein phosphatase
FT                   activity. Unable to inhibit focal adhesion formation."
FT                   /evidence="ECO:0000269|PubMed:10555148,
FT                   ECO:0000269|PubMed:9616126"
FT   MUTAGEN         93
FT                   /note="H->A: 75% reduction in phosphatase activity towards
FT                   PtdIns(3,4,5)P3. Modest reduction in phosphatase activity
FT                   towards PtdIns(3,4)P2."
FT                   /evidence="ECO:0000269|PubMed:10555148"
FT   MUTAGEN         124
FT                   /note="C->A: Loss of protein phosphatase activity. Unable
FT                   to inhibit focal adhesion formation."
FT                   /evidence="ECO:0000269|PubMed:9616126"
FT   MUTAGEN         125
FT                   /note="K->M: Reduced phosphatase activity towards
FT                   PtdIns(3,4,5)P3, PtdIns(3,4)P2 and PtdIns(3)P."
FT                   /evidence="ECO:0000269|PubMed:10555148"
FT   MUTAGEN         126
FT                   /note="A->P: Does not reduce phosphatase activity towards
FT                   PtdIns(3,4,5)P3 and PtdIns(3,4)P2."
FT                   /evidence="ECO:0000269|PubMed:26504226"
FT   MUTAGEN         126
FT                   /note="A->S: Does not reduce phosphatase activity towards
FT                   PtdIns(3,4,5)P3 and PtdIns(3,4)P2."
FT                   /evidence="ECO:0000269|PubMed:26504226"
FT   MUTAGEN         126
FT                   /note="A->V: Does not reduce phosphatase activity towards
FT                   PtdIns(3,4,5)P3 and PtdIns(3,4)P2."
FT                   /evidence="ECO:0000269|PubMed:26504226"
FT   MUTAGEN         128
FT                   /note="K->M: 85% reduction in phosphatase activity towards
FT                   PtdIns(3,4,5)P3."
FT                   /evidence="ECO:0000269|PubMed:10555148"
FT   MUTAGEN         128
FT                   /note="K->R: Does not reduce phosphatase activity towards
FT                   PtdIns(3,4,5)P3."
FT                   /evidence="ECO:0000269|PubMed:10555148"
FT   MUTAGEN         130
FT                   /note="R->M: Does not affect the ability to inhibit AKT/PKB
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:9811831"
FT   MUTAGEN         167
FT                   /note="T->A,D: 60% reduction in phosphatase activity
FT                   towards PtdIns(3,4,5)P3."
FT                   /evidence="ECO:0000269|PubMed:10555148"
FT   MUTAGEN         171
FT                   /note="Q->A,E: 75% reduction in phosphatase activity
FT                   towards PtdIns(3,4,5)P3."
FT                   /evidence="ECO:0000269|PubMed:10555148"
FT   MUTAGEN         263..269
FT                   /note="KMLKKDK->AAGAADA: Reduces the growth suppression
FT                   activity and cells show anchorage-independent growth.
FT                   Reduces binding to phospholipid membranes in vitro.
FT                   Phosphatase activity towards PtdIns(3,4,5)P3 is not
FT                   affected."
FT                   /evidence="ECO:0000269|PubMed:10555148"
FT   MUTAGEN         289
FT                   /note="K->E: Cytoplasmic; when associated with E-13. Shows
FT                   less tumor suppressive ability; when associated with E-13."
FT                   /evidence="ECO:0000269|PubMed:18716620"
FT   MUTAGEN         327..335
FT                   /note="KANKDKANR->AAGADAANA: Reduces growth suppression
FT                   activity and promotes anchorage-independent growth. Reduces
FT                   binding to phospholipid membranes in vitro; phosphatase
FT                   activity towards PtdIns(3,4,5)P3 is not affected."
FT                   /evidence="ECO:0000269|PubMed:10555148"
FT   MUTAGEN         336
FT                   /note="Y->F: Significantly lower phosphatase activity,
FT                   reduced protein stability and decreased growth-inhibitory
FT                   effect."
FT                   /evidence="ECO:0000269|PubMed:19345329"
FT   MUTAGEN         366
FT                   /note="T->A: Decreased stability."
FT                   /evidence="ECO:0000269|PubMed:20940307"
FT   MUTAGEN         370
FT                   /note="S->A: Decreased stability."
FT                   /evidence="ECO:0000269|PubMed:20940307"
FT   MUTAGEN         401
FT                   /note="T->A: Loss of DLG1-binding. No effect on MAGI2- and
FT                   MAST2-binding."
FT   MUTAGEN         402
FT                   /note="K->A: No effect on MAGI2-, MAST2- and DLG1-binding."
FT   MUTAGEN         402
FT                   /note="K->W: Loss of DLG1-, MAGI2-, MAGI3- and MAST2-
FT                   binding. Decrease of protein stability."
FT   MUTAGEN         403
FT                   /note="V->A: Loss of DLG1-, MAGI2-, MAGI3-, MAST1-,
FT                   MAST2- and MAST3-binding."
FT                   /evidence="ECO:0000269|PubMed:15951562"
FT   TURN            19..22
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   STRAND          23..29
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   STRAND          32..35
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   STRAND          39..41
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   STRAND          44..47
FT                   /evidence="ECO:0000244|PDB:5BZZ"
FT   HELIX           50..60
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   STRAND          61..63
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   STRAND          65..73
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   HELIX           78..80
FT                   /evidence="ECO:0000244|PDB:5BZZ"
FT   STRAND          81..83
FT                   /evidence="ECO:0000244|PDB:5BZZ"
FT   STRAND          85..90
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   HELIX           98..100
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   HELIX           101..112
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   TURN            113..115
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   STRAND          118..123
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   STRAND          125..128
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   HELIX           129..141
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   HELIX           148..159
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   STRAND          161..163
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   HELIX           169..184
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   STRAND          192..202
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   STRAND          206..209
FT                   /evidence="ECO:0000244|PDB:5BZZ"
FT   STRAND          213..219
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   STRAND          222..226
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   STRAND          232..235
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   STRAND          238..259
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   STRAND          262..264
FT                   /evidence="ECO:0000244|PDB:5BZZ"
FT   STRAND          268..276
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   HELIX           277..279
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   STRAND          280..284
FT                   /evidence="ECO:0000244|PDB:5BZZ"
FT   STRAND          310..312
FT                   /evidence="ECO:0000244|PDB:5BZX"
FT   STRAND          315..321
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   HELIX           322..324
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   HELIX           328..330
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   STRAND          335..337
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   STRAND          342..349
FT                   /evidence="ECO:0000244|PDB:1D5R"
FT   STRAND          395..403
FT                   /evidence="ECO:0000244|PDB:2KYL"
SQ   SEQUENCE   403 AA;  47166 MW;  75F97C3DD6802BA9 CRC64;
     MTAIIKEIVS RNKRRYQEDG FDLDLTYIYP NIIAMGFPAE RLEGVYRNNI DDVVRFLDSK
     HKNHYKIYNL CAERHYDTAK FNCRVAQYPF EDHNPPQLEL IKPFCEDLDQ WLSEDDNHVA
     AIHCKAGKGR TGVMICAYLL HRGKFLKAQE ALDFYGEVRT RDKKGVTIPS QRRYVYYYSY
     LLKNHLDYRP VALLFHKMMF ETIPMFSGGT CNPQFVVCQL KVKIYSSNSG PTRREDKFMY
     FEFPQPLPVC GDIKVEFFHK QNKMLKKDKM FHFWVNTFFI PGPEETSEKV ENGSLCDQEI
     DSICSIERAD NDKEYLVLTL TKNDLDKANK DKANRYFSPN FKVKLYFTKT VEEPSNPEAS
     SSTSVTPDVS DNEPDHYRYS DTTDSDPENE PFDEDQHTQI TKV
//
ID   CDK4_HUMAN              Reviewed;         303 AA.
AC   P11802; B2R9A0; B4DNF9; O00576; Q6FG61;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 2.
DT   02-DEC-2020, entry version 241.
DE   RecName: Full=Cyclin-dependent kinase 4;
DE            EC=2.7.11.22;
DE   AltName: Full=Cell division protein kinase 4;
DE   AltName: Full=PSK-J3;
GN   Name=CDK4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Hanks S.K.;
RL   Submitted (FEB-1987) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9192850; DOI=10.1006/geno.1997.4727;
RA   Elkahloun A.G., Krizman D.B., Wang Z., Hofmann T.A., Roe B.A.,
RA   Meltzer P.S.;
RT   "Transcript mapping in a 46-kb sequenced region at the core of 12q13.3
RT   amplification in human cancers.";
RL   Genomics 42:295-301(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT CMM3 CYS-24, AND
RP   CHARACTERIZATION OF VARIANT CYS-24.
RX   PubMed=7652577; DOI=10.1126/science.7652577;
RA   Wolfel T., Hauer M., Schneider J., Serrano M., Wolfel C., Klehmann-Hieb E.,
RA   De Plaen E., Hankeln T., Meyer Zum Bueschenfelde K.-H., Beach D.;
RT   "A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in
RT   a human melanoma.";
RL   Science 269:1281-1284(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANT CMM3 CYS-24, AND
RP   CHARACTERIZATION OF VARIANT CYS-24.
RX   PubMed=8528263; DOI=10.1038/ng0196-97;
RA   Zuo L., Weger J., Yang Q., Goldstein A.M., Tucker M.A., Walker G.J.,
RA   Hayward N., Dracopoli N.C.;
RT   "Germline mutations in the p16INK4a binding domain of CDK4 in familial
RT   melanoma.";
RL   Nat. Genet. 12:97-99(1996).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLN-82.
RG   NIEHS SNPs program;
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Embryo;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA   Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA   Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA   Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA   Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA   Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA   Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA   Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA   Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA   Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA   Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA   Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA   Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA   David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA   D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA   Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA   Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA   Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA   LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA   Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA   Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA   Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA   Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA   Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA   Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA   Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA   Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA   Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA   Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA   Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 88-188 (ISOFORM 1).
RX   PubMed=2948189; DOI=10.1073/pnas.84.2.388;
RA   Hanks S.K.;
RT   "Homology probing: identification of cDNA clones encoding members of the
RT   protein-serine kinase family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:388-392(1987).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 95-182.
RX   PubMed=8221695;
RA   Khatib Z.A., Matsushime H., Valentine M., Shapiro D.N., Sherr C.J.,
RA   Look A.T.;
RT   "Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas.";
RL   Cancer Res. 53:5535-5541(1993).
RN   [13]
RP   FUNCTION.
RX   PubMed=9003781; DOI=10.1002/j.1460-2075.1996.tb01097.x;
RA   Kitagawa M., Higashi H., Jung H.K., Suzuki-Takahashi I., Ikeda M.,
RA   Tamai K., Kato J., Segawa K., Yoshida E., Nishimura S., Taya Y.;
RT   "The consensus motif for phosphorylation by cyclin D1-Cdk4 is different
RT   from that for phosphorylation by cyclin A/E-Cdk2.";
RL   EMBO J. 15:7060-7069(1996).
RN   [14]
RP   INTERACTION WITH CDKN1A; CCND1 AND CCND3, SUBCELLULAR LOCATION, AND
RP   CATALYTIC ACTIVITY.
RX   PubMed=9106657; DOI=10.1101/gad.11.7.847;
RA   LaBaer J., Garrett M.D., Stevenson L.F., Slingerland J.M., Sandhu C.,
RA   Chou H.S., Fattaey A., Harlow E.;
RT   "New functional activities for the p21 family of CDK inhibitors.";
RL   Genes Dev. 11:847-862(1997).
RN   [15]
RP   INTERACTION WITH SEI1.
RX   PubMed=10580009; DOI=10.1101/gad.13.22.3027;
RA   Sugimoto M., Nakamura T., Ohtani N., Hampson L., Hampson I.N.,
RA   Shimamoto A., Furuichi Y., Okumura K., Niwa S., Taya Y., Hara E.;
RT   "Regulation of CDK4 activity by a novel CDK4-binding protein, p34(SEI-1).";
RL   Genes Dev. 13:3027-3033(1999).
RN   [16]
RP   INTERACTION WITH CEBPA.
RX   PubMed=15107404; DOI=10.1101/gad.1183304;
RA   Wang G.L., Iakova P., Wilde M., Awad S., Timchenko N.A.;
RT   "Liver tumors escape negative control of proliferation via PI3K/Akt-
RT   mediated block of C/EBP alpha growth inhibitory activity.";
RL   Genes Dev. 18:912-925(2004).
RN   [17]
RP   FUNCTION.
RX   PubMed=15241418; DOI=10.1038/nature02650;
RA   Matsuura I., Denissova N.G., Wang G., He D., Long J., Liu F.;
RT   "Cyclin-dependent kinases regulate the antiproliferative function of
RT   Smads.";
RL   Nature 430:226-231(2004).
RN   [18]
RP   INTERACTION WITH ZNF655.
RX   PubMed=15558030; DOI=10.1038/sj.onc.1208043;
RA   Houlard M., Romero-Portillo F., Germani A., Depaux A., Regnier-Ricard F.,
RA   Gisselbrecht S., Varin-Blank N.;
RT   "Characterization of VIK-1: a new Vav-interacting Kruppel-like protein.";
RL   Oncogene 24:28-38(2005).
RN   [19]
RP   PHOSPHORYLATION AT THR-172, INTERACTION WITH CCND1; CCND3; CDKN2A AND
RP   CDKN1B, AND MUTAGENESIS OF THR-172.
RX   PubMed=16782892; DOI=10.1128/mcb.02006-05;
RA   Bockstaele L., Kooken H., Libert F., Paternot S., Dumont J.E.,
RA   de Launoit Y., Roger P.P., Coulonval K.;
RT   "Regulated activating Thr172 phosphorylation of cyclin-dependent kinase
RT   4(CDK4): its relationship with cyclins and CDK 'inhibitors'.";
RL   Mol. Cell. Biol. 26:5070-5085(2006).
RN   [20]
RP   SUBCELLULAR LOCATION, FUNCTION, AND INTERACTION WITH CCND2.
RX   PubMed=18827403; DOI=10.1247/csf.08019;
RA   Wang Z., Xie Y., Zhang L., Zhang H., An X., Wang T., Meng A.;
RT   "Migratory localization of cyclin D2-Cdk4 complex suggests a spatial
RT   regulation of the G1-S transition.";
RL   Cell Struct. Funct. 33:171-183(2008).
RN   [21]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [22]
RP   INTERACTION WITH CCND1.
RX   PubMed=19124461; DOI=10.1074/jbc.m808843200;
RA   Zhang T., Liu W.D., Saunee N.A., Breslin M.B., Lan M.S.;
RT   "Zinc finger transcription factor INSM1 interrupts cyclin D1 and CDK4
RT   binding and induces cell cycle arrest.";
RL   J. Biol. Chem. 284:5574-5581(2009).
RN   [23]
RP   INTERACTION WITH CDKN1B, PHOSPHORYLATION, AND CATALYTIC ACTIVITY.
RX   PubMed=19075005; DOI=10.1128/mcb.00898-08;
RA   Ray A., James M.K., Larochelle S., Fisher R.P., Blain S.W.;
RT   "p27Kip1 inhibits cyclin D-cyclin-dependent kinase 4 by two independent
RT   modes.";
RL   Mol. Cell. Biol. 29:986-999(2009).
RN   [24]
RP   PHOSPHORYLATION AT THR-172, ACTIVITY REGULATION, AND MUTAGENESIS OF
RP   PRO-173.
RX   PubMed=19487459; DOI=10.1128/mcb.01823-08;
RA   Bockstaele L., Bisteau X., Paternot S., Roger P.P.;
RT   "Differential regulation of cyclin-dependent kinase 4 (CDK4) and CDK6,
RT   evidence that CDK4 might not be activated by CDK7, and design of a CDK6
RT   activating mutation.";
RL   Mol. Cell. Biol. 29:4188-4200(2009).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-172, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [26]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH CCND1.
RX   PubMed=20399237; DOI=10.1016/j.bbamcr.2010.04.001;
RA   Kim H., Kang M., Lee S.A., Kwak T.K., Jung O., Lee H.J., Kim S.H.,
RA   Lee J.W.;
RT   "TM4SF5 accelerates G1/S phase progression via cytosolic p27Kip1 expression
RT   and RhoA activity.";
RL   Biochim. Biophys. Acta 1803:975-982(2010).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [28]
RP   INTERACTION WITH FNIP1 AND FNIP2.
RX   PubMed=27353360; DOI=10.1038/ncomms12037;
RA   Woodford M.R., Dunn D.M., Blanden A.R., Capriotti D., Loiselle D.,
RA   Prodromou C., Panaretou B., Hughes P.F., Smith A., Ackerman W.,
RA   Haystead T.A., Loh S.N., Bourboulia D., Schmidt L.S., Marston Linehan W.,
RA   Bratslavsky G., Mollapour M.;
RT   "The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance
RT   drug binding.";
RL   Nat. Commun. 7:12037-12037(2016).
RN   [29]
RP   IDENTIFICATION IN A COMPLEX WITH HSP90; HSP70; CDC37; PPP5C; TSC1; TSC2;
RP   AKT; RAF1 AND NR3C1.
RX   PubMed=29127155; DOI=10.15252/embj.201796700;
RA   Woodford M.R., Sager R.A., Marris E., Dunn D.M., Blanden A.R., Murphy R.L.,
RA   Rensing N., Shapiro O., Panaretou B., Prodromou C., Loh S.N., Gutmann D.H.,
RA   Bourboulia D., Bratslavsky G., Wong M., Mollapour M.;
RT   "Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding
RT   of kinase and non-kinase clients.";
RL   EMBO J. 36:3650-3665(2017).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF THR-172-PHOSPHORYLATED WILD TYPE
RP   AND MUTANTS ALA-172; PHE-172 AND ASP-172 IN COMPLEX WITH CCND1,
RP   IDENTIFICATION BY MASS SPECTROMETRY, PHOSPHORYLATION AT THR-172, AND
RP   CATALYTIC ACTIVITY.
RX   PubMed=19237565; DOI=10.1073/pnas.0809645106;
RA   Day P.J., Cleasby A., Tickle I.J., O'Reilly M., Coyle J.E., Holding F.P.,
RA   McMenamin R.L., Yon J., Chopra R., Lengauer C., Jhoti H.;
RT   "Crystal structure of human CDK4 in complex with a D-type cyclin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:4166-4170(2009).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF NONPHOSPHORYLATED FORM IN COMPLEX
RP   WITH CCND3, PHOSPHORYLATION AT THR-172, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=19237555; DOI=10.1073/pnas.0809674106;
RA   Takaki T., Echalier A., Brown N.R., Hunt T., Endicott J.A., Noble M.E.;
RT   "The structure of CDK4/cyclin D3 has implications for models of CDK
RT   activation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:4171-4176(2009).
RN   [32]
RP   VARIANT CMM3 SER-41.
RX   PubMed=9311594;
RX   DOI=10.1002/(sici)1097-0215(19970904)72:5<780::aid-ijc13>3.0.co;2-d;
RA   Guldberg P., Kirkin A.F., Gronbaek K., thor Straten P., Ahrenkiel V.,
RA   Zeuthen J.;
RT   "Complete scanning of the CDK4 gene by denaturing gradient gel
RT   electrophoresis: a novel missense mutation but low overall frequency of
RT   mutations in sporadic metastatic malignant melanoma.";
RL   Int. J. Cancer 72:780-783(1997).
RN   [33]
RP   VARIANT CMM3 HIS-24.
RX   PubMed=9425228; DOI=10.1093/hmg/7.2.209;
RA   Soufir N., Avril M.-F., Chompret A., Demenais F., Bombled J., Spatz A.,
RA   Stoppa-Lyonnet D., Benard J., Bressac-De Paillerets B.;
RT   "Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone
RT   families in France.";
RL   Hum. Mol. Genet. 7:209-216(1998).
RN   [34]
RP   ERRATUM OF PUBMED:9425228.
RA   Soufir N., Avril M.-F., Chompret A., Demenais F., Bombled J., Spatz A.,
RA   Stoppa-Lyonnet D., Benard J., Bressac-De Paillerets B.;
RL   Hum. Mol. Genet. 7:941-941(1998).
RN   [35]
RP   VARIANT [LARGE SCALE ANALYSIS] HIS-122.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes that
CC       phosphorylate and inhibit members of the retinoblastoma (RB) protein
CC       family including RB1 and regulate the cell-cycle during G(1)/S
CC       transition. Phosphorylation of RB1 allows dissociation of the
CC       transcription factor E2F from the RB/E2F complexes and the subsequent
CC       transcription of E2F target genes which are responsible for the
CC       progression through the G(1) phase. Hypophosphorylates RB1 in early
CC       G(1) phase. Cyclin D-CDK4 complexes are major integrators of various
CC       mitogenenic and antimitogenic signals. Also phosphorylates SMAD3 in a
CC       cell-cycle-dependent manner and represses its transcriptional activity.
CC       Component of the ternary complex, cyclin D/CDK4/CDKN1B, required for
CC       nuclear translocation and activity of the cyclin D-CDK4 complex.
CC       {ECO:0000269|PubMed:15241418, ECO:0000269|PubMed:18827403,
CC       ECO:0000269|PubMed:9003781}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.22;
CC         Evidence={ECO:0000269|PubMed:19075005, ECO:0000269|PubMed:19237565,
CC         ECO:0000269|PubMed:9106657};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.22; Evidence={ECO:0000269|PubMed:19075005,
CC         ECO:0000269|PubMed:19237565, ECO:0000269|PubMed:9106657};
CC   -!- ACTIVITY REGULATION: Both phosphorylation at Thr-172 and binding of a
CC       D-type cyclin are necessary for enzymatic activity. Full activation of
CC       the cyclin-D-CDK4 complex appears to require other factors such as
CC       recruitment of the substrate via a substrate recruitment motif, and/or
CC       formation of the CDKN1B ternary complex. Inhibited by INK4 family
CC       members. In resting cells, the non-tyrosine-phosphorylated form of
CC       CDKN1B prevents phosphorylation at Thr-172 and inactivation, while, in
CC       proliferating cells, tyrosine phosphorylation of CDKN1B allows
CC       phosphorylation of Thr-172 of CDK4 and subsequent activation.
CC       {ECO:0000269|PubMed:19487459}.
CC   -!- SUBUNIT: Component of the D-CDK4 complex, composed of CDK4 and some D-
CC       type G1 cyclin (CCND1, CCND2 or CCND3). Interacts directly in the
CC       complex with CCND1, CCND2 or CCND3. Interacts with SEI1 and ZNF655.
CC       Forms a ternary complex, cyclin D-CDK4-CDKN1B, involved in modulating
CC       CDK4 enzymatic activity. Interacts directly with CDKN1B (phosphorylated
CC       on 'Tyr-88' and 'Tyr-89'); the interaction allows assembly of the
CC       cyclin D-CDK4 complex, Thr-172 phosphorylation, nuclear translocation
CC       and enhances the cyclin D-CDK4 complex activity. CDK4 activity is
CC       either inhibited or enhanced depending on stoichiometry of complex. The
CC       non-tyrosine-phosphorylated form of CDKN1B prevents T-loop
CC       phosphorylation of CDK4 producing inactive CDK4. Interacts
CC       (unphosphorylated form) with CDK2. Also forms ternary complexes with
CC       CDKN1A or CDKN2A. Interacts directly with CDKN1A (via its N-terminal);
CC       the interaction promotes the assembly of the cyclin D-CDK4 complex, its
CC       nuclear translocation and promotes the cyclin D-dependent enzyme
CC       activity of CDK4. Interacts with CCND1; the interaction is prevented
CC       with the binding of CCND1 to INSM1 during cell cycle progression.
CC       Probably forms a complex composed of chaperones HSP90 and HSP70, co-
CC       chaperones CDC37, PPP5C, TSC1 and client protein TSC2, CDK4, AKT, RAF1
CC       and NR3C1; this complex does not contain co-chaperones STIP1/HOP and
CC       PTGES3/p23 (PubMed:29127155). Interacts with CEBPA (when
CC       phosphorylated) (PubMed:15107404). Interacts with FNIP1 and FNIP2
CC       (PubMed:27353360). {ECO:0000250|UniProtKB:P30285,
CC       ECO:0000269|PubMed:10580009, ECO:0000269|PubMed:15107404,
CC       ECO:0000269|PubMed:15558030, ECO:0000269|PubMed:16782892,
CC       ECO:0000269|PubMed:18827403, ECO:0000269|PubMed:19075005,
CC       ECO:0000269|PubMed:19124461, ECO:0000269|PubMed:19237555,
CC       ECO:0000269|PubMed:19237565, ECO:0000269|PubMed:20399237,
CC       ECO:0000269|PubMed:27353360, ECO:0000269|PubMed:29127155,
CC       ECO:0000269|PubMed:9106657}.
CC   -!- INTERACTION:
CC       P11802; Q9UH17: APOBEC3B; NbExp=9; IntAct=EBI-295644, EBI-2967317;
CC       P11802; P24385: CCND1; NbExp=36; IntAct=EBI-295644, EBI-375001;
CC       P11802; P30279: CCND2; NbExp=15; IntAct=EBI-295644, EBI-748789;
CC       P11802; P30281: CCND3; NbExp=35; IntAct=EBI-295644, EBI-375013;
CC       P11802; Q16543: CDC37; NbExp=12; IntAct=EBI-295644, EBI-295634;
CC       P11802; P50613: CDK7; NbExp=2; IntAct=EBI-295644, EBI-1245958;
CC       P11802; P38936: CDKN1A; NbExp=7; IntAct=EBI-295644, EBI-375077;
CC       P11802; P46527: CDKN1B; NbExp=7; IntAct=EBI-295644, EBI-519280;
CC       P11802; P42771: CDKN2A; NbExp=14; IntAct=EBI-295644, EBI-375053;
CC       P11802; P42772: CDKN2B; NbExp=18; IntAct=EBI-295644, EBI-711280;
CC       P11802; P42773: CDKN2C; NbExp=21; IntAct=EBI-295644, EBI-711290;
CC       P11802; P55273: CDKN2D; NbExp=23; IntAct=EBI-295644, EBI-745859;
CC       P11802; Q9UJC3: HOOK1; NbExp=14; IntAct=EBI-295644, EBI-746704;
CC       P11802; P08238: HSP90AB1; NbExp=4; IntAct=EBI-295644, EBI-352572;
CC       P11802; Q9UKT9: IKZF3; NbExp=6; IntAct=EBI-295644, EBI-747204;
CC       P11802; Q0VD86: INCA1; NbExp=3; IntAct=EBI-295644, EBI-6509505;
CC       P11802; P01106: MYC; NbExp=2; IntAct=EBI-295644, EBI-447544;
CC       P11802; Q9ULD0: OGDHL; NbExp=3; IntAct=EBI-295644, EBI-3940481;
CC       P11802; P28749: RBL1; NbExp=2; IntAct=EBI-295644, EBI-971402;
CC       P11802; Q8N720: ZNF655; NbExp=6; IntAct=EBI-295644, EBI-625509;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:18827403}. Nucleus
CC       {ECO:0000269|PubMed:18827403, ECO:0000269|PubMed:20399237,
CC       ECO:0000269|PubMed:9106657}. Nucleus membrane
CC       {ECO:0000269|PubMed:18827403}. Note=Cytoplasmic when non-complexed.
CC       Forms a cyclin D-CDK4 complex in the cytoplasm as cells progress
CC       through G(1) phase. The complex accumulates on the nuclear membrane and
CC       enters the nucleus on transition from G(1) to S phase. Also present in
CC       nucleoli and heterochromatin lumps. Colocalizes with RB1 after release
CC       into the nucleus. {ECO:0000269|PubMed:18827403}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P11802-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P11802-2; Sequence=VSP_056487;
CC   -!- PTM: Phosphorylation at Thr-172 is required for enzymatic activity.
CC       Phosphorylated, in vitro, at this site by CCNH-CDK7, but, in vivo,
CC       appears to be phosphorylated by a proline-directed kinase. In the
CC       cyclin D-CDK4-CDKN1B complex, this phosphorylation and consequent CDK4
CC       enzyme activity, is dependent on the tyrosine phosphorylation state of
CC       CDKN1B. Thus, in proliferating cells, CDK4 within the complex is
CC       phosphorylated on Thr-172 in the T-loop. In resting cells,
CC       phosphorylation on Thr-172 is prevented by the non-tyrosine-
CC       phosphorylated form of CDKN1B. {ECO:0000269|PubMed:16782892,
CC       ECO:0000269|PubMed:19075005, ECO:0000269|PubMed:19237555,
CC       ECO:0000269|PubMed:19237565, ECO:0000269|PubMed:19487459}.
CC   -!- DISEASE: Melanoma, cutaneous malignant 3 (CMM3) [MIM:609048]: A
CC       malignant neoplasm of melanocytes, arising de novo or from a pre-
CC       existing benign nevus, which occurs most often in the skin but also may
CC       involve other sites. {ECO:0000269|PubMed:7652577,
CC       ECO:0000269|PubMed:8528263, ECO:0000269|PubMed:9311594,
CC       ECO:0000269|PubMed:9425228}. Note=Disease susceptibility is associated
CC       with variations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr
CC       protein kinase family. CDC2/CDKX subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CDK4ID238ch12q14.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/cdk4/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M14505; AAA35673.1; -; mRNA.
DR   EMBL; U81031; AAC39521.2; -; Genomic_DNA.
DR   EMBL; Z48970; CAA88834.1; -; mRNA.
DR   EMBL; U37022; AAC50506.1; -; Genomic_DNA.
DR   EMBL; AF507942; AAM23014.1; -; Genomic_DNA.
DR   EMBL; AK297901; BAG60221.1; -; mRNA.
DR   EMBL; AK313701; BAG36447.1; -; mRNA.
DR   EMBL; CR407668; CAG28596.1; -; mRNA.
DR   EMBL; CR542247; CAG47043.1; -; mRNA.
DR   EMBL; AC025165; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471054; EAW97058.1; -; Genomic_DNA.
DR   EMBL; BC003644; AAH03644.1; -; mRNA.
DR   EMBL; BC005864; AAH05864.1; -; mRNA.
DR   EMBL; BC010153; AAH10153.1; -; mRNA.
DR   EMBL; S67448; AAD13991.1; -; Genomic_DNA.
DR   CCDS; CCDS8953.1; -. [P11802-1]
DR   PIR; I52695; I52695.
DR   PIR; S52841; S52841.
DR   RefSeq; NP_000066.1; NM_000075.3. [P11802-1]
DR   PDB; 1LD2; Model; -; A=1-303.
DR   PDB; 2W96; X-ray; 2.30 A; B=1-303.
DR   PDB; 2W99; X-ray; 2.80 A; B=1-303.
DR   PDB; 2W9F; X-ray; 2.85 A; B=1-303.
DR   PDB; 2W9Z; X-ray; 2.45 A; B=1-303.
DR   PDB; 3G33; X-ray; 3.00 A; A/C=1-303.
DR   PDB; 5FWK; EM; 3.90 A; K=1-303.
DR   PDB; 5FWL; EM; 9.00 A; K=1-303.
DR   PDB; 5FWM; EM; 8.00 A; K=1-303.
DR   PDB; 5FWP; EM; 7.20 A; K=1-303.
DR   PDB; 6P8E; X-ray; 2.30 A; B=2-303.
DR   PDB; 6P8F; X-ray; 2.89 A; B=2-303.
DR   PDB; 6P8G; X-ray; 2.80 A; B=2-303.
DR   PDB; 6P8H; X-ray; 3.19 A; B=2-303.
DR   PDBsum; 1LD2; -.
DR   PDBsum; 2W96; -.
DR   PDBsum; 2W99; -.
DR   PDBsum; 2W9F; -.
DR   PDBsum; 2W9Z; -.
DR   PDBsum; 3G33; -.
DR   PDBsum; 5FWK; -.
DR   PDBsum; 5FWL; -.
DR   PDBsum; 5FWM; -.
DR   PDBsum; 5FWP; -.
DR   PDBsum; 6P8E; -.
DR   PDBsum; 6P8F; -.
DR   PDBsum; 6P8G; -.
DR   PDBsum; 6P8H; -.
DR   SMR; P11802; -.
DR   BioGRID; 107454; 235.
DR   ComplexPortal; CPX-2010; Cyclin D1-CDK4 complex.
DR   ComplexPortal; CPX-2011; Cyclin D2-CDK4 complex.
DR   ComplexPortal; CPX-2012; Cyclin D3-CDK4 complex.
DR   CORUM; P11802; -.
DR   DIP; DIP-875N; -.
DR   ELM; P11802; -.
DR   IntAct; P11802; 115.
DR   MINT; P11802; -.
DR   STRING; 9606.ENSP00000257904; -.
DR   BindingDB; P11802; -.
DR   ChEMBL; CHEMBL331; -.
DR   DrugBank; DB12001; Abemaciclib.
DR   DrugBank; DB03496; Alvocidib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB09073; Palbociclib.
DR   DrugBank; DB02733; Purvalanol.
DR   DrugBank; DB11730; Ribociclib.
DR   DrugCentral; P11802; -.
DR   GuidetoPHARMACOLOGY; 1976; -.
DR   iPTMnet; P11802; -.
DR   MetOSite; P11802; -.
DR   PhosphoSitePlus; P11802; -.
DR   BioMuta; CDK4; -.
DR   DMDM; 1168867; -.
DR   EPD; P11802; -.
DR   jPOST; P11802; -.
DR   MassIVE; P11802; -.
DR   MaxQB; P11802; -.
DR   PaxDb; P11802; -.
DR   PeptideAtlas; P11802; -.
DR   PRIDE; P11802; -.
DR   ProteomicsDB; 4694; -.
DR   ProteomicsDB; 52805; -. [P11802-1]
DR   Antibodypedia; 4190; 1056 antibodies.
DR   DNASU; 1019; -.
DR   Ensembl; ENST00000257904; ENSP00000257904; ENSG00000135446. [P11802-1]
DR   GeneID; 1019; -.
DR   KEGG; hsa:1019; -.
DR   UCSC; uc001spv.4; human. [P11802-1]
DR   CTD; 1019; -.
DR   DisGeNET; 1019; -.
DR   EuPathDB; HostDB:ENSG00000135446.16; -.
DR   GeneCards; CDK4; -.
DR   HGNC; HGNC:1773; CDK4.
DR   HPA; ENSG00000135446; Low tissue specificity.
DR   MalaCards; CDK4; -.
DR   MIM; 123829; gene.
DR   MIM; 609048; phenotype.
DR   neXtProt; NX_P11802; -.
DR   OpenTargets; ENSG00000135446; -.
DR   Orphanet; 99970; Dedifferentiated liposarcoma.
DR   Orphanet; 618; Familial melanoma.
DR   Orphanet; 99971; Well-differentiated liposarcoma.
DR   PharmGKB; PA102; -.
DR   eggNOG; KOG0594; Eukaryota.
DR   GeneTree; ENSGT00940000154770; -.
DR   InParanoid; P11802; -.
DR   OMA; FEMFNRK; -.
DR   PhylomeDB; P11802; -.
DR   TreeFam; TF101022; -.
DR   BRENDA; 2.7.11.22; 2681.
DR   PathwayCommons; P11802; -.
DR   Reactome; R-HSA-187577; SCF(Skp2)-mediated degradation of p27/p21.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP).
DR   Reactome; R-HSA-2559585; Oncogene Induced Senescence.
DR   Reactome; R-HSA-3214858; RMTs methylate histone arginines.
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-69231; Cyclin D associated events in G1.
DR   Reactome; R-HSA-75815; Ubiquitin-dependent degradation of Cyclin D.
DR   Reactome; R-HSA-8849470; PTK6 Regulates Cell Cycle.
DR   Reactome; R-HSA-8878166; Transcriptional regulation by RUNX2.
DR   Reactome; R-HSA-912446; Meiotic recombination.
DR   Reactome; R-HSA-9616222; Transcriptional regulation of granulopoiesis.
DR   Reactome; R-HSA-9630791; Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4.
DR   Reactome; R-HSA-9630794; Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6.
DR   Reactome; R-HSA-9632697; Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4.
DR   Reactome; R-HSA-9632700; Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6.
DR   Reactome; R-HSA-9661069; Defective binding of RB1 mutants to E2F1,(E2F2, E2F3).
DR   SignaLink; P11802; -.
DR   SIGNOR; P11802; -.
DR   BioGRID-ORCS; 1019; 271 hits in 879 CRISPR screens.
DR   ChiTaRS; CDK4; human.
DR   EvolutionaryTrace; P11802; -.
DR   GeneWiki; Cyclin-dependent_kinase_4; -.
DR   GenomeRNAi; 1019; -.
DR   Pharos; P11802; Tclin.
DR   PRO; PR:P11802; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; P11802; protein.
DR   Bgee; ENSG00000135446; Expressed in subventricular zone (inner) (primate) and 237 other tissues.
DR   ExpressionAtlas; P11802; baseline and differential.
DR   Genevisible; P11802; HS.
DR   GO; GO:0005923; C:bicellular tight junction; IEA:Ensembl.
DR   GO; GO:0000785; C:chromatin; IDA:UniProtKB.
DR   GO; GO:0097129; C:cyclin D2-CDK4 complex; IEA:Ensembl.
DR   GO; GO:0000307; C:cyclin-dependent protein kinase holoenzyme complex; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0016592; C:mediator complex; IBA:GO_Central.
DR   GO; GO:0031965; C:nuclear membrane; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005667; C:transcription regulator complex; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0030332; F:cyclin binding; IPI:UniProtKB.
DR   GO; GO:0004693; F:cyclin-dependent protein serine/threonine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0016538; F:cyclin-dependent protein serine/threonine kinase regulator activity; TAS:Reactome.
DR   GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl.
DR   GO; GO:0008353; F:RNA polymerase II CTD heptapeptide repeat kinase activity; IBA:GO_Central.
DR   GO; GO:0060612; P:adipose tissue development; IEA:Ensembl.
DR   GO; GO:0031100; P:animal organ regeneration; IEA:Ensembl.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IEA:Ensembl.
DR   GO; GO:0071353; P:cellular response to interleukin-4; IEA:Ensembl.
DR   GO; GO:1904637; P:cellular response to ionomycin; IEA:Ensembl.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:1904628; P:cellular response to phorbol 13-acetate 12-myristate; IEA:Ensembl.
DR   GO; GO:0007623; P:circadian rhythm; IEA:Ensembl.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IMP:BHF-UCL.
DR   GO; GO:0002088; P:lens development in camera-type eye; IEA:Ensembl.
DR   GO; GO:0071157; P:negative regulation of cell cycle arrest; IDA:UniProtKB.
DR   GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0045787; P:positive regulation of cell cycle; TAS:Reactome.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:BHF-UCL.
DR   GO; GO:0045793; P:positive regulation of cell size; IEA:Ensembl.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IMP:BHF-UCL.
DR   GO; GO:0010971; P:positive regulation of G2/M transition of mitotic cell cycle; IDA:UniProtKB.
DR   GO; GO:0045727; P:positive regulation of translation; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0051726; P:regulation of cell cycle; IBA:GO_Central.
DR   GO; GO:0010468; P:regulation of gene expression; IMP:BHF-UCL.
DR   GO; GO:0046626; P:regulation of insulin receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0046890; P:regulation of lipid biosynthetic process; IEA:Ensembl.
DR   GO; GO:0050994; P:regulation of lipid catabolic process; IEA:Ensembl.
DR   GO; GO:0040014; P:regulation of multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEP:UniProtKB.
DR   GO; GO:0055093; P:response to hyperoxia; IEA:Ensembl.
DR   GO; GO:0010288; P:response to lead ion; IEA:Ensembl.
DR   GO; GO:0033574; P:response to testosterone; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; IEA:Ensembl.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; TAS:Reactome.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding; Cell cycle;
KW   Cell division; Cytoplasm; Disease mutation; Kinase; Membrane;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000244|PubMed:19413330"
FT   CHAIN           2..303
FT                   /note="Cyclin-dependent kinase 4"
FT                   /id="PRO_0000085778"
FT   DOMAIN          6..295
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   NP_BIND         12..20
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          50..56
FT                   /note="Required for binding D-type cyclins"
FT   COMPBIAS        42..48
FT                   /note="Poly-Gly"
FT   ACT_SITE        140
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         35
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000244|PubMed:19413330"
FT   MOD_RES         172
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:19369195,
FT                   ECO:0000269|PubMed:16782892, ECO:0000269|PubMed:19237555,
FT                   ECO:0000269|PubMed:19237565, ECO:0000269|PubMed:19487459"
FT   VAR_SEQ         1..120
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056487"
FT   VARIANT         24
FT                   /note="R -> C (in CMM3; somatic and familial; generates a
FT                   dominant oncogene resistant to inhibition by p16(INK4a);
FT                   dbSNP:rs11547328)"
FT                   /evidence="ECO:0000269|PubMed:7652577,
FT                   ECO:0000269|PubMed:8528263"
FT                   /id="VAR_006200"
FT   VARIANT         24
FT                   /note="R -> H (in CMM3; dbSNP:rs104894340)"
FT                   /evidence="ECO:0000269|PubMed:9425228"
FT                   /id="VAR_006201"
FT   VARIANT         41
FT                   /note="N -> S (in CMM3; sporadic; dbSNP:rs144890720)"
FT                   /evidence="ECO:0000269|PubMed:9311594"
FT                   /id="VAR_021152"
FT   VARIANT         82
FT                   /note="R -> Q (in dbSNP:rs3211612)"
FT                   /evidence="ECO:0000269|Ref.5"
FT                   /id="VAR_029153"
FT   VARIANT         122
FT                   /note="R -> H (in dbSNP:rs34386532)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041976"
FT   MUTAGEN         172
FT                   /note="T->A: Weak enzyme activity towards RB1, but no
FT                   effect on binding of CCDN1 nor CCDN3."
FT                   /evidence="ECO:0000269|PubMed:16782892"
FT   MUTAGEN         172
FT                   /note="T->E: Retains moderate enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:16782892"
FT   MUTAGEN         173
FT                   /note="P->S: No effect on in vitro phosphorylation by CDK7.
FT                   Greatly reduced T-172 phosphorylation and enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:19487459"
FT   CONFLICT        117
FT                   /note="I -> L (in Ref. 6; BAG36447)"
FT                   /evidence="ECO:0000305"
FT   STRAND          7..13
FT                   /evidence="ECO:0000244|PDB:2W96"
FT   STRAND          15..17
FT                   /evidence="ECO:0000244|PDB:3G33"
FT   STRAND          20..24
FT                   /evidence="ECO:0000244|PDB:2W96"
FT   TURN            26..28
FT                   /evidence="ECO:0000244|PDB:2W96"
FT   STRAND          31..40
FT                   /evidence="ECO:0000244|PDB:2W96"
FT   STRAND          47..49
FT                   /evidence="ECO:0000244|PDB:6P8G"
FT   HELIX           51..63
FT                   /evidence="ECO:0000244|PDB:2W96"
FT   HELIX           64..66
FT                   /evidence="ECO:0000244|PDB:2W96"
FT   STRAND          74..82
FT                   /evidence="ECO:0000244|PDB:2W96"
FT   STRAND          84..94
FT                   /evidence="ECO:0000244|PDB:2W96"
FT   STRAND          97..99
FT                   /evidence="ECO:0000244|PDB:2W9Z"
FT   HELIX           100..105
FT                   /evidence="ECO:0000244|PDB:2W96"
FT   TURN            109..111
FT                   /evidence="ECO:0000244|PDB:2W9F"
FT   HELIX           114..133
FT                   /evidence="ECO:0000244|PDB:2W96"
FT   TURN            143..145
FT                   /evidence="ECO:0000244|PDB:2W96"
FT   STRAND          146..148
FT                   /evidence="ECO:0000244|PDB:2W96"
FT   TURN            150..152
FT                   /evidence="ECO:0000244|PDB:2W9Z"
FT   STRAND          154..156
FT                   /evidence="ECO:0000244|PDB:2W96"
FT   HELIX           162..169
FT                   /evidence="ECO:0000244|PDB:2W96"
FT   HELIX           172..175
FT                   /evidence="ECO:0000244|PDB:3G33"
FT   TURN            183..185
FT                   /evidence="ECO:0000244|PDB:2W96"
FT   STRAND          186..189
FT                   /evidence="ECO:0000244|PDB:2W96"
FT   HELIX           195..208
FT                   /evidence="ECO:0000244|PDB:2W96"
FT   STRAND          209..211
FT                   /evidence="ECO:0000244|PDB:2W96"
FT   HELIX           219..230
FT                   /evidence="ECO:0000244|PDB:2W96"
FT   HELIX           235..237
FT                   /evidence="ECO:0000244|PDB:6P8E"
FT   STRAND          242..244
FT                   /evidence="ECO:0000244|PDB:2W99"
FT   HELIX           246..248
FT                   /evidence="ECO:0000244|PDB:6P8E"
FT   HELIX           257..259
FT                   /evidence="ECO:0000244|PDB:6P8E"
FT   HELIX           266..275
FT                   /evidence="ECO:0000244|PDB:2W96"
FT   HELIX           280..282
FT                   /evidence="ECO:0000244|PDB:2W96"
FT   HELIX           286..290
FT                   /evidence="ECO:0000244|PDB:2W96"
FT   HELIX           293..295
FT                   /evidence="ECO:0000244|PDB:6P8E"
SQ   SEQUENCE   303 AA;  33730 MW;  0916A0C07403A33A CRC64;
     MATSRYEPVA EIGVGAYGTV YKARDPHSGH FVALKSVRVP NGGGGGGGLP ISTVREVALL
     RRLEAFEHPN VVRLMDVCAT SRTDREIKVT LVFEHVDQDL RTYLDKAPPP GLPAETIKDL
     MRQFLRGLDF LHANCIVHRD LKPENILVTS GGTVKLADFG LARIYSYQMA LTPVVVTLWY
     RAPEVLLQST YATPVDMWSV GCIFAEMFRR KPLFCGNSEA DQLGKIFDLI GLPPEDDWPR
     DVSLPRGAFP PRGPRPVQSV VPEMEESGAQ LLLEMLTFNP HKRISAFRAL QHSYLHKDEG
     NPE
//
ID   CDN2A_HUMAN             Reviewed;         156 AA.
AC   P42771; A5X2G7; D3DRK1; G3XAG3; O95440; Q15191; Q5VVJ5; Q96B52; Q9NP05;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 2.
DT   02-DEC-2020, entry version 226.
DE   RecName: Full=Cyclin-dependent kinase inhibitor 2A {ECO:0000312|HGNC:HGNC:1787};
DE   AltName: Full=Cyclin-dependent kinase 4 inhibitor A;
DE            Short=CDK4I;
DE   AltName: Full=Multiple tumor suppressor 1;
DE            Short=MTS-1;
DE   AltName: Full=p16-INK4a;
DE            Short=p16-INK4;
DE            Short=p16INK4A;
GN   Name=CDKN2A {ECO:0000312|HGNC:HGNC:1787}; Synonyms=CDKN2, MTS1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=8259215; DOI=10.1038/366704a0;
RA   Serrano M., Hannon G.J., Beach D.;
RT   "A new regulatory motif in cell-cycle control causing specific inhibition
RT   of cyclin D/CDK4.";
RL   Nature 366:704-707(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND TISSUE SPECIFICITY.
RX   PubMed=10445844; DOI=10.1038/sj.onc.1202737;
RA   Robertson K.D., Jones P.A.;
RT   "Tissue-specific alternative splicing in the human INK4a/ARF cell cycle
RT   regulatory locus.";
RL   Oncogene 18:3810-3820(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=12228235; DOI=10.1074/jbc.m208353200;
RA   Kitagawa Y., Inoue K., Sasaki S., Hayashi Y., Matsuo Y., Lieber M.R.,
RA   Mizoguchi H., Yokota J., Kohno T.;
RT   "Prevalent involvement of illegitimate V(D)J recombination in chromosome
RT   9p21 deletions in lymphoid leukemia.";
RL   J. Biol. Chem. 277:46289-46297(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), AND ALTERNATIVE SPLICING.
RX   PubMed=17486064; DOI=10.1038/sj.onc.1210507;
RA   Lin Y.C., Diccianni M.B., Kim Y., Lin H.H., Lee C.H., Lin R.J., Joo S.H.,
RA   Li J., Chuang T.J., Yang A.S., Kuo H.H., Tsai M.D., Yu A.L.;
RT   "Human p16gamma, a novel transcriptional variant of p16(INK4A), coexpresses
RT   with p16(INK4A) in cancer cells and inhibits cell-cycle progression.";
RL   Oncogene 26:7017-7027(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-20.
RX   PubMed=8622687; DOI=10.1128/mcb.16.3.859;
RA   Hara E., Smith R., Parry D., Tahara H., Stone S., Peters G.;
RT   "Regulation of p16CDKN2 expression and its implications for cell
RT   immortalization and senescence.";
RL   Mol. Cell. Biol. 16:859-867(1996).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 51-156.
RX   PubMed=8152487; DOI=10.1038/368753a0;
RA   Nobori T., Miura K., Wu D.J., Lois A., Takabayashi K., Carson D.A.;
RT   "Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple
RT   human cancers.";
RL   Nature 368:753-756(1994).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 51-152.
RX   PubMed=8153634; DOI=10.1126/science.8153634;
RA   Kamb A., Gruis N.A., Weaver-Feldhaus J., Liu Q., Harshman K.,
RA   Tavtigian S.V., Stockert E., Day R.S. III, Johnson B.E., Skolnick M.H.;
RT   "A cell cycle regulator potentially involved in genesis of many tumor
RT   types.";
RL   Science 264:436-440(1994).
RN   [11]
RP   FUNCTION.
RX   PubMed=7972006; DOI=10.1073/pnas.91.23.11045;
RA   Okamoto A., Demetrick D.J., Spillare E.A., Hagiwara K., Hussain S.P.,
RA   Bennett W.P., Forrester K., Gerwin B., Serrano M., Beach D.H., Harris C.C.;
RT   "Mutations and altered expression of p16INK4 in human cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994).
RN   [12]
RP   PHOSPHORYLATION AT SER-7; SER-8; SER-140 AND SER-152.
RX   PubMed=12529334; DOI=10.1074/jbc.c200622200;
RA   Gump J., Stokoe D., McCormick F.;
RT   "Phosphorylation of p16INK4A correlates with Cdk4 association.";
RL   J. Biol. Chem. 278:6619-6622(2003).
RN   [13]
RP   INTERACTION WITH CDK4, AND FUNCTION.
RX   PubMed=16782892; DOI=10.1128/mcb.02006-05;
RA   Bockstaele L., Kooken H., Libert F., Paternot S., Dumont J.E.,
RA   de Launoit Y., Roger P.P., Coulonval K.;
RT   "Regulated activating Thr172 phosphorylation of cyclin-dependent kinase
RT   4(CDK4): its relationship with cyclins and CDK 'inhibitors'.";
RL   Mol. Cell. Biol. 26:5070-5085(2006).
RN   [14]
RP   INTERACTION WITH ISOC2, AND SUBCELLULAR LOCATION.
RX   PubMed=17658461; DOI=10.1016/j.bbrc.2007.06.181;
RA   Huang X., Shi Z., Wang W., Bai J., Chen Z., Xu J., Zhang D., Fu S.;
RT   "Identification and characterization of a novel protein ISOC2 that
RT   interacts with p16INK4a.";
RL   Biochem. Biophys. Res. Commun. 361:287-293(2007).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF COMPLEX WITH CDK6.
RX   PubMed=9751050; DOI=10.1038/26155;
RA   Russo A.A., Tong L., Lee J.O., Jeffrey P.D., Pavletich N.P.;
RT   "Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the
RT   tumour suppressor p16INK4a.";
RL   Nature 395:237-243(1998).
RN   [19]
RP   STRUCTURE BY NMR.
RX   PubMed=10556039; DOI=10.1006/jmbi.1999.3231;
RA   Yuan C., Li J., Selby T.L., Byeon I.-J., Tsai M.-D.;
RT   "Tumor suppressor INK4: comparisons of conformational properties between
RT   p16(INK4A) and p18(INK4C).";
RL   J. Mol. Biol. 294:201-211(1999).
RN   [20]
RP   STRUCTURE BY NMR.
RX   PubMed=10892805; DOI=10.1110/ps.9.6.1120;
RA   Yuan C., Selby T.L., Li J., Byeon I.J., Tsai M.D.;
RT   "Tumor suppressor INK4: refinement of p16INK4A structure and determination
RT   of p15INK4B structure by comparative modeling and NMR data.";
RL   Protein Sci. 9:1120-1128(2000).
RN   [21]
RP   REVIEW ON MELANOMA VARIANTS.
RX   PubMed=8783570;
RA   Dracopoli N.C., Fountain J.W.;
RT   "CDKN2 mutations in melanoma.";
RL   Cancer Surv. 26:115-132(1996).
RN   [22]
RP   REVIEW ON VARIANTS.
RX   PubMed=8723678;
RX   DOI=10.1002/(sici)1098-1004(1996)7:4<294::aid-humu2>3.0.co;2-9;
RA   Smith-Soerensen B., Hovig E.;
RT   "CDKN2A (p16INK4A) somatic and germline mutations.";
RL   Hum. Mutat. 7:294-303(1996).
RN   [23]
RP   VARIANTS NON-SMALL CELL LUNG CARCINOMA TYR-66; HIS-84; ALA-93; ALA-95;
RP   GLN-99; LEU-114; ALA-120; LYS-120; PRO-132; VAL-134; TYR-142 AND VAL-150.
RX   PubMed=8060323; DOI=10.1006/bbrc.1994.2090;
RA   Hayashi N., Sugimoto Y., Tsuchiya E., Ogawa M., Nakamura Y.;
RT   "Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4l (cyclin-
RT   dependent kinase-4 inhibitor) gene in human primary non-small cell lung
RT   carcinomas.";
RL   Biochem. Biophys. Res. Commun. 202:1426-1430(1994).
RN   [24]
RP   VARIANTS CMM2 PRO-87; TRP-101 AND ASP-126, AND VARIANTS THR-49; SER-71 AND
RP   THR-148.
RX   PubMed=7987387; DOI=10.1038/ng0994-15;
RA   Hussussian C.J., Struewing J.P., Goldstein A.M., Higgins P.A.T., Ally D.S.,
RA   Sheahan M.D., Clark W.H. Jr., Tucker M.A., Dracopoli N.C.;
RT   "Germline p16 mutations in familial melanoma.";
RL   Nat. Genet. 8:15-21(1994).
RN   [25]
RP   VARIANTS SQUAMOUS CELL CARCINOMA SER-127 AND CYS-144.
RX   PubMed=7970734;
RA   Zhou X., Tarmin L., Yin J., Jiang H.-Y., Suzuki H., Rhyu M.-G.,
RA   Abraham J.M., Meltzer S.J.;
RT   "The MTS1 gene is frequently mutated in primary human esophageal tumors.";
RL   Oncogene 9:3737-3741(1994).
RN   [26]
RP   VARIANTS.
RX   PubMed=7882351;
RA   Okamoto A., Hussain S.P., Hagiwara K., Spillare E.A., Rusin M.R.,
RA   Demetrick D.J., Serrano M., Hannon G.J., Shiseki M., Zariwala M., Xiong Y.,
RA   Beach D.H., Yokota J., Harris C.C.;
RT   "Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in
RT   primary and metastatic lung cancer.";
RL   Cancer Res. 55:1448-1451(1995).
RN   [27]
RP   VARIANTS CMM2 PRO-32; ALA-35; GLU-35; ARG-50 AND ILE-53, AND VARIANT
RP   THR-148.
RX   PubMed=8595405; DOI=10.1093/hmg/4.10.1845;
RA   Walker G.J., Hussussian C.J., Flores J.F., Glendening J.M., Haluska F.G.,
RA   Dracopoli N.C., Hayward N.K., Fountain J.W.;
RT   "Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds.";
RL   Hum. Mol. Genet. 4:1845-1852(1995).
RN   [28]
RP   CHARACTERIZATION OF VARIANTS THR-49; SER-71; LEU-81; PRO-87; TRP-101;
RP   ASP-126 AND THR-148.
RX   PubMed=7647780; DOI=10.1038/ng0595-114;
RA   Ranade K., Hussussian C.J., Sikorski R.S., Varmus H.E., Goldstein A.M.,
RA   Tucker M.A., Serrano M., Hannon G.J., Beach D., Dracopoli N.C.;
RT   "Mutations associated with familial melanoma impair p16INK4 function.";
RL   Nat. Genet. 10:114-116(1995).
RN   [29]
RP   VARIANT CMM2 ARG-112 INS, AND VARIANT THR-148.
RX   PubMed=8653684;
RA   Borg A., Johannsson U., Johannsson O., Haakansson S., Westerdahl J.,
RA   Maasbaeck A., Olsson H., Ingvar C.;
RT   "Novel germline p16 mutation in familial malignant melanoma in southern
RT   Sweden.";
RL   Cancer Res. 56:2497-2500(1996).
RN   [30]
RP   VARIANTS CMM2 ILE-53 AND CYS-107, AND VARIANTS VAL-68; THR-85 AND THR-148.
RX   PubMed=8710906; DOI=10.1073/pnas.93.16.8541;
RA   Fitzgerald M.G., Harkin D.P., Silva-Arrieta S., Macdonald D.J.,
RA   Lucchina L.C., Unsal H., O'Neill E., Koh J., Finkelstein D.M.,
RA   Isselbacher K.J., Sober A.J., Haber D.A.;
RT   "Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial
RT   melanoma: analysis of a clinic-based population.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:8541-8545(1996).
RN   [31]
RP   VARIANTS CMM2 PRO-24; ILE-53 AND THR-118, AND VARIANT THR-148.
RX   PubMed=9328469; DOI=10.1093/hmg/6.12.2061;
RA   Harland M., Meloni R., Gruis N., Pinney E., Brookes S., Spurr N.K.,
RA   Frischauf A.-M., Bataille V., Peters G., Cuzick J., Selby P., Bishop D.T.,
RA   Bishop J.N.;
RT   "Germline mutations of the CDKN2 gene in UK melanoma families.";
RL   Hum. Mol. Genet. 6:2061-2067(1997).
RN   [32]
RP   VARIANTS CMM2.
RX   PubMed=9425228; DOI=10.1093/hmg/7.2.209;
RA   Soufir N., Avril M.-F., Chompret A., Demenais F., Bombled J., Spatz A.,
RA   Stoppa-Lyonnet D., Benard J., Bressac-De Paillerets B.;
RT   "Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone
RT   families in France.";
RL   Hum. Mol. Genet. 7:209-216(1998).
RN   [33]
RP   ERRATUM OF PUBMED:9425228.
RA   Soufir N., Avril M.-F., Chompret A., Demenais F., Bombled J., Spatz A.,
RA   Stoppa-Lyonnet D., Benard J., Bressac-De Paillerets B.;
RL   Hum. Mol. Genet. 7:941-941(1998).
RN   [34]
RP   VARIANTS CMM2 LEU-48; ASP-89 AND MET-117, VARIANT PANCREAS CARCINOMA
RP   VAL-57, AND VARIANT THR-148.
RX   PubMed=10651484;
RA   Gretarsdottir S., Olafsdottir G.H., Borg A.;
RT   "Five novel somatic CDKN2/p16 mutations identified in melanoma, glioma and
RT   carcinoma of the pancreas.";
RL   Hum. Mutat. 12:212-212(1998).
RN   [35]
RP   VARIANT GLU-102.
RX   PubMed=10484981; DOI=10.1016/s0165-4608(98)00276-3;
RA   Gueran S., Tunca Y., Imirzalioglu N.;
RT   "Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in a Li-
RT   Fraumeni syndrome family.";
RL   Cancer Genet. Cytogenet. 113:145-151(1999).
RN   [36]
RP   VARIANT CMM2 ASP-126.
RX   PubMed=11506491; DOI=10.1054/bjoc.2001.1944;
RA   Goldstein A.M., Liu L., Shennan M.G., Hogg D., Tucker M.A., Struewing J.P.;
RT   "A common founder for the V126D CDKN2A mutation in seven North American
RT   melanoma-prone families.";
RL   Br. J. Cancer 85:527-530(2001).
RN   [37]
RP   INVOLVEMENT IN MASTS.
RX   PubMed=11136714; DOI=10.1093/hmg/10.1.55;
RA   Randerson-Moor J.A., Harland M., Williams S., Cuthbert-Heavens D.,
RA   Sheridan E., Aveyard J., Sibley K., Whitaker L., Knowles M., Bishop J.N.,
RA   Bishop D.T.;
RT   "A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system
RT   tumour syndrome family.";
RL   Hum. Mol. Genet. 10:55-62(2001).
RN   [38]
RP   VARIANT CMM2 ARG-122.
RX   PubMed=12019208; DOI=10.1093/hmg/11.11.1273;
RA   Hewitt C., Lee Wu C., Evans G., Howell A., Elles R.G., Jordan R., Sloan P.,
RA   Read A.P., Thakker N.;
RT   "Germline mutation of ARF in a melanoma kindred.";
RL   Hum. Mol. Genet. 11:1273-1279(2002).
RN   [39]
RP   VARIANTS CMM2 GLY-59; TYR-84; TRP-87 AND TRP-101.
RX   PubMed=10874641;
RA   Ruiz A., Puig S., Malvehy J., Lazaro C., Lynch M., Gimenez-Arnau A.M.,
RA   Puig L., Sanchez-Conejo J., Estivill X., Castel T.;
RT   "CDKN2A mutations in Spanish cutaneous malignant melanoma families and
RT   patients with multiple melanomas and other neoplasia.";
RL   J. Med. Genet. 36:490-493(1999).
RN   [40]
RP   POSSIBLE INVOLVEMENT IN SUSCEPTIBILITY TO UVEAL MELANOMA.
RX   PubMed=12556369; DOI=10.1167/iovs.02-0026;
RA   Hearle N., Damato B.E., Humphreys J., Wixey J., Green H., Stone J.,
RA   Easton D.F., Houlston R.S.;
RT   "Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15
RT   to uveal melanoma.";
RL   Invest. Ophthalmol. Vis. Sci. 44:458-462(2003).
RN   [41]
RP   VARIANT CMM2 GLN-94.
RX   PubMed=14646619; DOI=10.1097/01.cmr.0000056289.15046.c0;
RA   Avbelj M., Hocevar M., Trebusak-Podkrajsek K., Krzisnik C., Battelino T.;
RT   "A novel L94Q mutation in the CDKN2A gene in a melanoma kindred.";
RL   Melanoma Res. 13:567-570(2003).
RN   [42]
RP   VARIANTS CMM2 THR-ALA-19 INS; VAL-35; ARG-67; 67-GLY--ASN-71 DEL; TYR-74;
RP   PRO-77; PRO-80; THR-81 AND ARG-97, VARIANTS GLN-24; GLY-69 AND SER-114, AND
RP   CHARACTERIZATION OF VARIANTS.
RX   PubMed=19260062; DOI=10.1002/humu.20845;
RA   Kannengiesser C., Brookes S., del Arroyo A.G., Pham D., Bombled J.,
RA   Barrois M., Mauffret O., Avril M.F., Chompret A., Lenoir G.M., Sarasin A.,
RA   Peters G., Bressac-de Paillerets B.;
RT   "Functional, structural, and genetic evaluation of 20 CDKN2A germ line
RT   mutations identified in melanoma-prone families or patients.";
RL   Hum. Mutat. 30:564-574(2009).
CC   -!- FUNCTION: Acts as a negative regulator of the proliferation of normal
CC       cells by interacting strongly with CDK4 and CDK6. This inhibits their
CC       ability to interact with cyclins D and to phosphorylate the
CC       retinoblastoma protein. {ECO:0000269|PubMed:16782892,
CC       ECO:0000269|PubMed:7972006}.
CC   -!- SUBUNIT: Heterodimer with CDK4 or CDK6. Predominant p16 complexes
CC       contained CDK6. Interacts with CDK4 (both 'T-172'-phosphorylated and
CC       non-phosphorylated forms); the interaction inhibits cyclin D-CDK4
CC       kinase activity. Interacts with ISCO2. {ECO:0000269|PubMed:16782892,
CC       ECO:0000269|PubMed:17658461}.
CC   -!- INTERACTION:
CC       P42771; P11802: CDK4; NbExp=14; IntAct=EBI-375053, EBI-295644;
CC       P42771; Q00534: CDK6; NbExp=15; IntAct=EBI-375053, EBI-295663;
CC       P42771; Q6UXH1: CRELD2; NbExp=2; IntAct=EBI-375053, EBI-3935314;
CC       P42771; O75398: DEAF1; NbExp=2; IntAct=EBI-375053, EBI-718185;
CC       P42771; Q00839: HNRNPU; NbExp=2; IntAct=EBI-375053, EBI-351126;
CC       P42771; Q14566: MCM6; NbExp=4; IntAct=EBI-375053, EBI-374900;
CC       P42771; P12004: PCNA; NbExp=8; IntAct=EBI-375053, EBI-358311;
CC       P42771; Q8NHU6: TDRD7; NbExp=2; IntAct=EBI-375053, EBI-624505;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17658461}. Nucleus
CC       {ECO:0000269|PubMed:17658461}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC         Comment=Isoform 1 and isoform tumor suppressor ARF arise due to the
CC         use of two alternative first exons joined to a common exon 2 at the
CC         same acceptor site but in different reading frames, resulting in two
CC         completely different isoforms.;
CC       Name=1; Synonyms=p16INK4a;
CC         IsoId=P42771-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P42771-2; Sequence=VSP_015864;
CC       Name=3; Synonyms=p12;
CC         IsoId=P42771-3; Sequence=VSP_015865, VSP_015866;
CC       Name=tumor suppressor ARF; Synonyms=p14ARF, p19ARF;
CC         IsoId=Q8N726-1; Sequence=External;
CC       Name=5; Synonyms=p16gamma;
CC         IsoId=P42771-4; Sequence=VSP_043577;
CC       Name=smARF;
CC         IsoId=Q8N726-2; Sequence=External;
CC   -!- TISSUE SPECIFICITY: Widely expressed but not detected in brain or
CC       skeletal muscle. Isoform 3 is pancreas-specific.
CC       {ECO:0000269|PubMed:10445844}.
CC   -!- PTM: Phosphorylation seems to increase interaction with CDK4.
CC       {ECO:0000269|PubMed:12529334}.
CC   -!- DISEASE: Note=The association between cutaneous and uveal melanomas in
CC       some families suggests that mutations in CDKN2A may account for a
CC       proportion of uveal melanomas. However, CDKN2A mutations are rarely
CC       found in uveal melanoma patients.
CC   -!- DISEASE: Melanoma, cutaneous malignant 2 (CMM2) [MIM:155601]: A
CC       malignant neoplasm of melanocytes, arising de novo or from a pre-
CC       existing benign nevus, which occurs most often in the skin but also may
CC       involve other sites. {ECO:0000269|PubMed:10651484,
CC       ECO:0000269|PubMed:10874641, ECO:0000269|PubMed:11506491,
CC       ECO:0000269|PubMed:12019208, ECO:0000269|PubMed:14646619,
CC       ECO:0000269|PubMed:19260062, ECO:0000269|PubMed:7987387,
CC       ECO:0000269|PubMed:8595405, ECO:0000269|PubMed:8653684,
CC       ECO:0000269|PubMed:8710906, ECO:0000269|PubMed:9328469,
CC       ECO:0000269|PubMed:9425228}. Note=Disease susceptibility is associated
CC       with variations affecting the gene represented in this entry.
CC   -!- DISEASE: Familial atypical multiple mole melanoma-pancreatic carcinoma
CC       syndrome (FAMMMPC) [MIM:606719]: An inherited cancer predisposition
CC       syndrome characterized by an increased risk of developing malignant
CC       melanoma and/or pancreatic cancer. Mutation carriers within families
CC       may develop either or both types of cancer. Note=The disease is caused
CC       by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Melanoma-astrocytoma syndrome (MASTS) [MIM:155755]:
CC       Characterized by a dual predisposition to melanoma and neural system
CC       tumors, commonly astrocytoma. {ECO:0000269|PubMed:11136714}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: [Isoform 5]: Barely detectable in non-tumor cells.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the CDKN2 cyclin-dependent kinase inhibitor
CC       family. {ECO:0000305}.
CC   -!- CAUTION: The proteins described here are encoded by the gene CDKN2A,
CC       but are completely unrelated in terms of sequence and function to tumor
CC       suppressor ARF (AC Q8N726) which is encoded by the same gene.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB60645.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=CDKN2A Database; Note=Database of CDKN2A germline
CC       and somatic variants;
CC       URL="https://biodesktop.uvm.edu/perl/p16";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/cdkn2a/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=P16INK4a entry;
CC       URL="https://en.wikipedia.org/wiki/P16INK4a";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L27211; AAA92554.1; -; mRNA.
DR   EMBL; AF115544; AAD11437.1; -; mRNA.
DR   EMBL; AB060808; BAB91133.1; -; Genomic_DNA.
DR   EMBL; AF527803; AAR05391.1; -; Genomic_DNA.
DR   EMBL; DQ318021; ABC47036.1; -; mRNA.
DR   EMBL; AL449423; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471071; EAW58598.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58599.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58603.1; -; Genomic_DNA.
DR   EMBL; X94154; CAA63870.1; -; Genomic_DNA.
DR   EMBL; AH007355; AAD14050.1; -; Genomic_DNA.
DR   EMBL; S69804; AAD14048.1; -; Genomic_DNA.
DR   EMBL; U12820; AAB60645.1; ALT_INIT; Genomic_DNA.
DR   EMBL; U12818; AAB60645.1; JOINED; Genomic_DNA.
DR   EMBL; U12819; AAB60645.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS56565.1; -. [P42771-4]
DR   CCDS; CCDS6510.1; -. [P42771-1]
DR   CCDS; CCDS87644.1; -. [P42771-2]
DR   PIR; JE0141; JE0141.
DR   RefSeq; NP_000068.1; NM_000077.4. [P42771-1]
DR   RefSeq; NP_001182061.1; NM_001195132.1. [P42771-4]
DR   RefSeq; NP_478104.2; NM_058197.4. [P42771-3]
DR   RefSeq; XP_005251400.1; XM_005251343.1. [P42771-2]
DR   RefSeq; XP_011515981.1; XM_011517679.1.
DR   PDB; 1A5E; NMR; -; A=1-156.
DR   PDB; 1BI7; X-ray; 3.40 A; B=1-156.
DR   PDB; 1DC2; NMR; -; A=1-156.
DR   PDB; 2A5E; NMR; -; A=1-156.
DR   PDBsum; 1A5E; -.
DR   PDBsum; 1BI7; -.
DR   PDBsum; 1DC2; -.
DR   PDBsum; 2A5E; -.
DR   BMRB; P42771; -.
DR   SMR; P42771; -.
DR   BioGRID; 107463; 235.
DR   CORUM; P42771; -.
DR   DIP; DIP-6108N; -.
DR   IntAct; P42771; 63.
DR   MINT; P42771; -.
DR   STRING; 9606.ENSP00000418915; -.
DR   iPTMnet; P42771; -.
DR   PhosphoSitePlus; P42771; -.
DR   BioMuta; CDKN2A; -.
DR   DMDM; 3041660; -.
DR   CPTAC; CPTAC-333; -.
DR   CPTAC; CPTAC-334; -.
DR   EPD; P42771; -.
DR   jPOST; P42771; -.
DR   MassIVE; P42771; -.
DR   PaxDb; P42771; -.
DR   PeptideAtlas; P42771; -.
DR   PRIDE; P42771; -.
DR   ProteomicsDB; 33740; -.
DR   ProteomicsDB; 55551; -. [P42771-1]
DR   ProteomicsDB; 55552; -. [P42771-2]
DR   ProteomicsDB; 55553; -. [P42771-3]
DR   ProteomicsDB; 55554; -. [P42771-4]
DR   TopDownProteomics; P42771-1; -. [P42771-1]
DR   ABCD; P42771; 8 sequenced antibodies.
DR   Antibodypedia; 3608; 1402 antibodies.
DR   DNASU; 1029; -.
DR   Ensembl; ENST00000304494; ENSP00000307101; ENSG00000147889. [P42771-1]
DR   Ensembl; ENST00000380151; ENSP00000369496; ENSG00000147889. [P42771-3]
DR   Ensembl; ENST00000494262; ENSP00000464952; ENSG00000147889. [P42771-2]
DR   Ensembl; ENST00000498124; ENSP00000418915; ENSG00000147889. [P42771-4]
DR   Ensembl; ENST00000498628; ENSP00000467857; ENSG00000147889. [P42771-2]
DR   Ensembl; ENST00000578845; ENSP00000467390; ENSG00000147889. [P42771-2]
DR   GeneID; 1029; -.
DR   KEGG; hsa:1029; -.
DR   UCSC; uc003zpj.4; human.
DR   UCSC; uc003zpk.4; human. [P42771-1]
DR   CTD; 1029; -.
DR   DisGeNET; 1029; -.
DR   EuPathDB; HostDB:ENSG00000147889.16; -.
DR   GeneCards; CDKN2A; -.
DR   HGNC; HGNC:1787; CDKN2A.
DR   HPA; ENSG00000147889; Tissue enhanced (blood, pituitary gland).
DR   MalaCards; CDKN2A; -.
DR   MIM; 155601; phenotype.
DR   MIM; 155755; phenotype.
DR   MIM; 600160; gene.
DR   MIM; 606719; phenotype.
DR   neXtProt; NX_P42771; -.
DR   OpenTargets; ENSG00000147889; -.
DR   Orphanet; 404560; Familial atypical multiple mole melanoma syndrome.
DR   Orphanet; 618; Familial melanoma.
DR   Orphanet; 1333; Familial pancreatic carcinoma.
DR   Orphanet; 524; Li-Fraumeni syndrome.
DR   Orphanet; 252206; Melanoma and neural system tumor syndrome.
DR   Orphanet; 99860; Precursor B-cell acute lymphoblastic leukemia.
DR   Orphanet; 99861; Precursor T-cell acute lymphoblastic leukemia.
DR   PharmGKB; PA106; -.
DR   eggNOG; KOG0504; Eukaryota.
DR   GeneTree; ENSGT00940000163078; -.
DR   HOGENOM; CLU_2229116_0_0_1; -.
DR   InParanoid; P42771; -.
DR   OMA; RDEDKGM; -.
DR   OrthoDB; 1435166at2759; -.
DR   TreeFam; TF352389; -.
DR   PathwayCommons; P42771; -.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP).
DR   Reactome; R-HSA-2559585; Oncogene Induced Senescence.
DR   Reactome; R-HSA-69231; Cyclin D associated events in G1.
DR   Reactome; R-HSA-8853884; Transcriptional Regulation by VENTX.
DR   Reactome; R-HSA-9630791; Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4.
DR   Reactome; R-HSA-9630794; Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6.
DR   Reactome; R-HSA-9632697; Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4.
DR   Reactome; R-HSA-9632700; Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6.
DR   SIGNOR; P42771; -.
DR   BioGRID-ORCS; 1029; 10 hits in 855 CRISPR screens.
DR   ChiTaRS; CDKN2A; human.
DR   EvolutionaryTrace; P42771; -.
DR   GeneWiki; P16_(gene); -.
DR   GenomeRNAi; 1029; -.
DR   Pharos; P42771; Tbio.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; P42771; protein.
DR   Bgee; ENSG00000147889; Expressed in adenohypophysis and 208 other tissues.
DR   ExpressionAtlas; P42771; baseline and differential.
DR   Genevisible; P42771; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:HGNC-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:HGNC-UCL.
DR   GO; GO:0035985; C:senescence-associated heterochromatin focus; IDA:UniProtKB.
DR   GO; GO:0004861; F:cyclin-dependent protein serine/threonine kinase inhibitor activity; IDA:BHF-UCL.
DR   GO; GO:0051059; F:NF-kappaB binding; IDA:BHF-UCL.
DR   GO; GO:0019901; F:protein kinase binding; IPI:BHF-UCL.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0007050; P:cell cycle arrest; IDA:BHF-UCL.
DR   GO; GO:0090398; P:cellular senescence; IMP:BHF-UCL.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IDA:BHF-UCL.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:BHF-UCL.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:BHF-UCL.
DR   GO; GO:0001953; P:negative regulation of cell-matrix adhesion; IMP:BHF-UCL.
DR   GO; GO:0045736; P:negative regulation of cyclin-dependent protein serine/threonine kinase activity; IDA:BHF-UCL.
DR   GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; IDA:BHF-UCL.
DR   GO; GO:0042326; P:negative regulation of phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IMP:UniProtKB.
DR   GO; GO:2000774; P:positive regulation of cellular senescence; IMP:UniProtKB.
DR   GO; GO:2000111; P:positive regulation of macrophage apoptotic process; ISS:BHF-UCL.
DR   GO; GO:0034393; P:positive regulation of smooth muscle cell apoptotic process; ISS:BHF-UCL.
DR   GO; GO:0007265; P:Ras protein signal transduction; IEP:BHF-UCL.
DR   GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL.
DR   GO; GO:0035986; P:senescence-associated heterochromatin focus assembly; IMP:UniProtKB.
DR   Gene3D; 1.25.40.20; -; 1.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ANK repeat; Cell cycle;
KW   Cytoplasm; Disease mutation; Li-Fraumeni syndrome; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; Tumor suppressor.
FT   CHAIN           1..156
FT                   /note="Cyclin-dependent kinase inhibitor 2A"
FT                   /id="PRO_0000144177"
FT   REPEAT          11..40
FT                   /note="ANK 1"
FT   REPEAT          44..72
FT                   /note="ANK 2"
FT   REPEAT          77..106
FT                   /note="ANK 3"
FT   REPEAT          110..139
FT                   /note="ANK 4"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000244|PubMed:19413330,
FT                   ECO:0000244|PubMed:22814378"
FT   MOD_RES         7
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:12529334"
FT   MOD_RES         8
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:12529334"
FT   MOD_RES         140
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:12529334"
FT   MOD_RES         152
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:12529334"
FT   VAR_SEQ         1..51
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_015864"
FT   VAR_SEQ         52..116
FT                   /note="MMMGSARVAELLLLHGAEPNCADPATLTRPVHDAAREGFLDTLVVLHRAGAR
FT                   LDVRDAWGRLPVD -> GRGSAAGAGDGGRLWRTKFAGELESGSASILRKKGRLPGEFS
FT                   EGVCNHRPPPGDALGAWEAKEEE (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:10445844"
FT                   /id="VSP_015865"
FT   VAR_SEQ         117..156
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:10445844"
FT                   /id="VSP_015866"
FT   VAR_SEQ         153..156
FT                   /note="DIPD -> EMIGNHLWVCRSRHA (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:17486064"
FT                   /id="VSP_043577"
FT   VARIANT         14
FT                   /note="D -> E (in a biliary tract tumor)"
FT                   /id="VAR_001408"
FT   VARIANT         16
FT                   /note="L -> P (in a biliary tract tumor and a familial
FT                   melanoma)"
FT                   /id="VAR_001409"
FT   VARIANT         19
FT                   /note="A -> ATA (in CMM2; loss of CDK4 binding)"
FT                   /id="VAR_058549"
FT   VARIANT         20
FT                   /note="A -> P (in a lung tumor and melanoma;
FT                   dbSNP:rs760065045)"
FT                   /id="VAR_001410"
FT   VARIANT         20
FT                   /note="A -> S (in a biliary tract tumor;
FT                   dbSNP:rs760065045)"
FT                   /id="VAR_001411"
FT   VARIANT         23
FT                   /note="G -> D (in a pancreas tumor and a melanoma; loss of
FT                   CDK4 binding; dbSNP:rs1064794292)"
FT                   /id="VAR_001412"
FT   VARIANT         24
FT                   /note="R -> C (in CMM2)"
FT                   /id="VAR_001413"
FT   VARIANT         24
FT                   /note="R -> P (in CMM2; dbSNP:rs104894097)"
FT                   /evidence="ECO:0000269|PubMed:9328469"
FT                   /id="VAR_001414"
FT   VARIANT         24
FT                   /note="R -> Q (found in a patient with multiple primary
FT                   melanoma; partial loss of CDK4 binding; dbSNP:rs104894097)"
FT                   /evidence="ECO:0000269|PubMed:19260062"
FT                   /id="VAR_058550"
FT   VARIANT         26
FT                   /note="E -> D (in a biliary tract tumor)"
FT                   /id="VAR_001415"
FT   VARIANT         32
FT                   /note="L -> P (in CMM2; dbSNP:rs878853650)"
FT                   /evidence="ECO:0000269|PubMed:8595405"
FT                   /id="VAR_001416"
FT   VARIANT         33
FT                   /note="E -> D (in a biliary tract tumor)"
FT                   /id="VAR_001417"
FT   VARIANT         35
FT                   /note="G -> A (in CMM2; also found in a biliary tract tumor
FT                   and a patient with uveal melanoma; partial loss of CDK4
FT                   binding; dbSNP:rs746834149)"
FT                   /evidence="ECO:0000269|PubMed:8595405"
FT                   /id="VAR_001418"
FT   VARIANT         35
FT                   /note="G -> E (in CMM2; dbSNP:rs746834149)"
FT                   /evidence="ECO:0000269|PubMed:8595405"
FT                   /id="VAR_001419"
FT   VARIANT         35
FT                   /note="G -> V (in CMM2; loss of CDK4 binding;
FT                   dbSNP:rs746834149)"
FT                   /evidence="ECO:0000269|PubMed:19260062"
FT                   /id="VAR_058551"
FT   VARIANT         48
FT                   /note="P -> L (in CMM2; also found in head and neck tumor;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:10651484"
FT                   /id="VAR_001420"
FT   VARIANT         49
FT                   /note="I -> S (in a biliary tract tumor;
FT                   dbSNP:rs199907548)"
FT                   /id="VAR_001421"
FT   VARIANT         49
FT                   /note="I -> T (in dbSNP:rs199907548)"
FT                   /evidence="ECO:0000269|PubMed:7647780,
FT                   ECO:0000269|PubMed:7987387"
FT                   /id="VAR_001422"
FT   VARIANT         50
FT                   /note="Q -> R (in CMM2; dbSNP:rs587778189)"
FT                   /evidence="ECO:0000269|PubMed:8595405"
FT                   /id="VAR_001423"
FT   VARIANT         53
FT                   /note="M -> I (in CMM2; dbSNP:rs104894095)"
FT                   /evidence="ECO:0000269|PubMed:8595405,
FT                   ECO:0000269|PubMed:8710906, ECO:0000269|PubMed:9328469"
FT                   /id="VAR_001424"
FT   VARIANT         56
FT                   /note="S -> I (possible polymorphism; dbSNP:rs104894109)"
FT                   /id="VAR_001425"
FT   VARIANT         57
FT                   /note="A -> V (in pancreas carcinoma; somatic mutation;
FT                   partial loss of CDK4 binding; dbSNP:rs372266620)"
FT                   /evidence="ECO:0000269|PubMed:10651484"
FT                   /id="VAR_001426"
FT   VARIANT         59
FT                   /note="V -> G (in CMM2; dbSNP:rs104894099)"
FT                   /evidence="ECO:0000269|PubMed:10874641"
FT                   /id="VAR_001427"
FT   VARIANT         60
FT                   /note="A -> T (in dbSNP:rs769382085)"
FT                   /id="VAR_001428"
FT   VARIANT         60
FT                   /note="A -> V (in melanoma; loss of CDK4 binding;
FT                   dbSNP:rs36204594)"
FT                   /id="VAR_053028"
FT   VARIANT         61..62
FT                   /note="EL -> DV"
FT                   /id="VAR_001429"
FT   VARIANT         62
FT                   /note="L -> P (in CMM2)"
FT                   /id="VAR_001430"
FT   VARIANT         66
FT                   /note="H -> Y (in non-small cell lung carcinoma)"
FT                   /evidence="ECO:0000269|PubMed:8060323"
FT                   /id="VAR_001431"
FT   VARIANT         67..71
FT                   /note="Missing (in melanoma; loss of CDK4 binding)"
FT                   /evidence="ECO:0000269|PubMed:19260062"
FT                   /id="VAR_058552"
FT   VARIANT         67
FT                   /note="G -> R (in CMM2; partial loss of CDK4 binding;
FT                   dbSNP:rs758389471)"
FT                   /evidence="ECO:0000269|PubMed:19260062"
FT                   /id="VAR_058553"
FT   VARIANT         68
FT                   /note="A -> L (in CMM2; requires 2 nucleotide
FT                   substitutions; dbSNP:rs876658534)"
FT                   /id="VAR_001432"
FT   VARIANT         68
FT                   /note="A -> T (in an esophagus tumor)"
FT                   /id="VAR_001433"
FT   VARIANT         68
FT                   /note="A -> V (in dbSNP:rs1060501260)"
FT                   /evidence="ECO:0000269|PubMed:8710906"
FT                   /id="VAR_001434"
FT   VARIANT         69
FT                   /note="E -> G (found in some patients with melanoma;
FT                   partial loss of CDK4 binding; dbSNP:rs372670098)"
FT                   /evidence="ECO:0000269|PubMed:19260062"
FT                   /id="VAR_058554"
FT   VARIANT         69
FT                   /note="E -> K (in a bladder tumor)"
FT                   /id="VAR_001435"
FT   VARIANT         69
FT                   /note="E -> V (in a lung tumor)"
FT                   /id="VAR_001436"
FT   VARIANT         71
FT                   /note="N -> K (in CMM2)"
FT                   /id="VAR_001437"
FT   VARIANT         71
FT                   /note="N -> S (in dbSNP:rs559848002)"
FT                   /evidence="ECO:0000269|PubMed:7647780,
FT                   ECO:0000269|PubMed:7987387"
FT                   /id="VAR_001438"
FT   VARIANT         72
FT                   /note="C -> G (in an esophagus tumor)"
FT                   /id="VAR_001439"
FT   VARIANT         74
FT                   /note="D -> N (in a bladder tumor; dbSNP:rs760640852)"
FT                   /id="VAR_001440"
FT   VARIANT         74
FT                   /note="D -> V (in a biliary tract tumor)"
FT                   /id="VAR_001441"
FT   VARIANT         74
FT                   /note="D -> Y (in CMM2; loss of CDK4 binding;
FT                   dbSNP:rs760640852)"
FT                   /evidence="ECO:0000269|PubMed:19260062"
FT                   /id="VAR_058555"
FT   VARIANT         77
FT                   /note="T -> P (in CMM2; loss of CDK4 binding)"
FT                   /evidence="ECO:0000269|PubMed:19260062"
FT                   /id="VAR_058556"
FT   VARIANT         80
FT                   /note="R -> L (in a head and neck tumor)"
FT                   /id="VAR_001442"
FT   VARIANT         80
FT                   /note="R -> P (in CMM2; loss of CDK4 binding;
FT                   dbSNP:rs1057519883)"
FT                   /evidence="ECO:0000269|PubMed:19260062"
FT                   /id="VAR_058557"
FT   VARIANT         81
FT                   /note="P -> L (in some patients with melanoma; impairs the
FT                   function; dbSNP:rs11552823)"
FT                   /evidence="ECO:0000269|PubMed:7647780"
FT                   /id="VAR_001443"
FT   VARIANT         81
FT                   /note="P -> T (in CMM2; loss of CDK4 binding;
FT                   dbSNP:rs1334828764)"
FT                   /evidence="ECO:0000269|PubMed:19260062"
FT                   /id="VAR_058558"
FT   VARIANT         83
FT                   /note="H -> N (in a lung tumor)"
FT                   /id="VAR_001445"
FT   VARIANT         83
FT                   /note="H -> Q (in dbSNP:rs34968276)"
FT                   /id="VAR_053029"
FT   VARIANT         83
FT                   /note="H -> Y (in a pancreas tumor; also found in head and
FT                   neck tumor; dbSNP:rs121913385)"
FT                   /id="VAR_001444"
FT   VARIANT         84
FT                   /note="D -> E (in a bladder tumor)"
FT                   /id="VAR_001446"
FT   VARIANT         84
FT                   /note="D -> H (in non-small cell lung carcinoma)"
FT                   /evidence="ECO:0000269|PubMed:8060323"
FT                   /id="VAR_001447"
FT   VARIANT         84
FT                   /note="D -> N (in an esophagus tumor; also found in head
FT                   and neck tumor; also found in a lung tumor;
FT                   dbSNP:rs11552822)"
FT                   /id="VAR_001448"
FT   VARIANT         84
FT                   /note="D -> Y (in CMM2; also found in a lung tumor and a
FT                   prostate tumor; dbSNP:rs11552822)"
FT                   /evidence="ECO:0000269|PubMed:10874641"
FT                   /id="VAR_001449"
FT   VARIANT         85
FT                   /note="A -> T (in dbSNP:rs878853646)"
FT                   /evidence="ECO:0000269|PubMed:8710906"
FT                   /id="VAR_001450"
FT   VARIANT         87
FT                   /note="R -> P (in CMM2; impairs the function;
FT                   dbSNP:rs878853647)"
FT                   /evidence="ECO:0000269|PubMed:7647780,
FT                   ECO:0000269|PubMed:7987387"
FT                   /id="VAR_001451"
FT   VARIANT         87
FT                   /note="R -> W (in CMM2; partial loss of CDK4 binding;
FT                   dbSNP:rs749714198)"
FT                   /evidence="ECO:0000269|PubMed:10874641"
FT                   /id="VAR_012317"
FT   VARIANT         88
FT                   /note="E -> D (in a biliary tract tumor)"
FT                   /id="VAR_001452"
FT   VARIANT         89
FT                   /note="G -> D (in CMM2; somatic mutation;
FT                   dbSNP:rs137854599)"
FT                   /evidence="ECO:0000269|PubMed:10651484"
FT                   /id="VAR_001453"
FT   VARIANT         89
FT                   /note="G -> S (in CMM2; dbSNP:rs137854597)"
FT                   /id="VAR_001454"
FT   VARIANT         93
FT                   /note="T -> A (in non-small cell lung carcinoma)"
FT                   /evidence="ECO:0000269|PubMed:8060323"
FT                   /id="VAR_001455"
FT   VARIANT         94
FT                   /note="L -> Q (in CMM2)"
FT                   /evidence="ECO:0000269|PubMed:14646619"
FT                   /id="VAR_023604"
FT   VARIANT         95
FT                   /note="V -> A (in non-small cell lung carcinoma)"
FT                   /evidence="ECO:0000269|PubMed:8060323"
FT                   /id="VAR_001456"
FT   VARIANT         97
FT                   /note="L -> R (in CMM2; loss of CDK4 binding)"
FT                   /evidence="ECO:0000269|PubMed:19260062"
FT                   /id="VAR_001457"
FT   VARIANT         98
FT                   /note="H -> P (in CMM2)"
FT                   /id="VAR_001458"
FT   VARIANT         98
FT                   /note="H -> Q (in CMM2)"
FT                   /id="VAR_001459"
FT   VARIANT         99
FT                   /note="R -> P (in CMM2; loss of CDK4 binding;
FT                   dbSNP:rs754806883)"
FT                   /id="VAR_001460"
FT   VARIANT         99
FT                   /note="R -> Q (in non-small cell lung carcinoma;
FT                   dbSNP:rs754806883)"
FT                   /evidence="ECO:0000269|PubMed:8060323"
FT                   /id="VAR_001461"
FT   VARIANT         99
FT                   /note="R -> W (in dbSNP:rs34886500)"
FT                   /id="VAR_053030"
FT   VARIANT         100
FT                   /note="A -> L (in CMM2; requires 2 nucleotide
FT                   substitutions)"
FT                   /id="VAR_001462"
FT   VARIANT         100
FT                   /note="A -> P"
FT                   /id="VAR_001463"
FT   VARIANT         101
FT                   /note="G -> W (in CMM2 and FAMMMPC; impairs the function;
FT                   dbSNP:rs104894094)"
FT                   /evidence="ECO:0000269|PubMed:10874641,
FT                   ECO:0000269|PubMed:7647780, ECO:0000269|PubMed:7987387"
FT                   /id="VAR_001464"
FT   VARIANT         102
FT                   /note="A -> E (found in seminoma and medulloblastoma
FT                   tissues from Li-Fraumeni syndrome patients carrying a
FT                   mutation in TP53; somatic mutation; dbSNP:rs137854598)"
FT                   /evidence="ECO:0000269|PubMed:10484981"
FT                   /id="VAR_015818"
FT   VARIANT         102
FT                   /note="A -> T (in dbSNP:rs35741010)"
FT                   /id="VAR_053031"
FT   VARIANT         104..105
FT                   /note="Missing"
FT                   /id="VAR_001465"
FT   VARIANT         107
FT                   /note="R -> C (in CMM2; dbSNP:rs1554654024)"
FT                   /evidence="ECO:0000269|PubMed:8710906"
FT                   /id="VAR_001466"
FT   VARIANT         107
FT                   /note="R -> H (in dbSNP:rs370823171)"
FT                   /id="VAR_001467"
FT   VARIANT         108
FT                   /note="D -> H (in a bladder tumor)"
FT                   /id="VAR_001469"
FT   VARIANT         108
FT                   /note="D -> Y (in a head and neck tumor;
FT                   dbSNP:rs121913381)"
FT                   /id="VAR_001468"
FT   VARIANT         112
FT                   /note="R -> RR (in CMM2)"
FT                   /evidence="ECO:0000269|PubMed:8653684"
FT                   /id="VAR_035068"
FT   VARIANT         114
FT                   /note="P -> L (in non-small cell lung carcinoma;
FT                   dbSNP:rs121913386)"
FT                   /evidence="ECO:0000269|PubMed:8060323"
FT                   /id="VAR_001470"
FT   VARIANT         114
FT                   /note="P -> S (found in some patients with melanoma; loss
FT                   of CDK4 binding; dbSNP:rs104894104)"
FT                   /evidence="ECO:0000269|PubMed:19260062"
FT                   /id="VAR_058559"
FT   VARIANT         117
FT                   /note="L -> M (in CMM2; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:10651484"
FT                   /id="VAR_001471"
FT   VARIANT         118
FT                   /note="A -> T (in CMM2; dbSNP:rs1554653960)"
FT                   /evidence="ECO:0000269|PubMed:9328469"
FT                   /id="VAR_001472"
FT   VARIANT         119
FT                   /note="E -> Q (in a biliary tract tumor)"
FT                   /id="VAR_001473"
FT   VARIANT         120
FT                   /note="E -> A (in non-small cell lung carcinoma)"
FT                   /evidence="ECO:0000269|PubMed:8060323"
FT                   /id="VAR_001474"
FT   VARIANT         120
FT                   /note="E -> K (in non-small cell lung carcinoma)"
FT                   /evidence="ECO:0000269|PubMed:8060323"
FT                   /id="VAR_001475"
FT   VARIANT         122
FT                   /note="G -> R (in CMM2; dbSNP:rs113798404)"
FT                   /evidence="ECO:0000269|PubMed:12019208"
FT                   /id="VAR_035069"
FT   VARIANT         122
FT                   /note="G -> S (in a biliary tract tumor;
FT                   dbSNP:rs113798404)"
FT                   /id="VAR_001476"
FT   VARIANT         123
FT                   /note="H -> Q (in leukemia; dbSNP:rs6413463)"
FT                   /id="VAR_001477"
FT   VARIANT         124
FT                   /note="R -> C (in dbSNP:rs34170727)"
FT                   /id="VAR_053032"
FT   VARIANT         124
FT                   /note="R -> H (in an esophagus tumor; dbSNP:rs747621669)"
FT                   /id="VAR_001478"
FT   VARIANT         126
FT                   /note="V -> D (in CMM2; impairs the function;
FT                   dbSNP:rs104894098)"
FT                   /evidence="ECO:0000269|PubMed:11506491,
FT                   ECO:0000269|PubMed:7647780, ECO:0000269|PubMed:7987387"
FT                   /id="VAR_001479"
FT   VARIANT         127
FT                   /note="A -> S (in squamous cell carcinoma;
FT                   dbSNP:rs6413464)"
FT                   /evidence="ECO:0000269|PubMed:7970734"
FT                   /id="VAR_001480"
FT   VARIANT         132
FT                   /note="A -> P (in non-small cell lung carcinoma)"
FT                   /evidence="ECO:0000269|PubMed:8060323"
FT                   /id="VAR_001481"
FT   VARIANT         134
FT                   /note="A -> V (in non-small cell lung carcinoma;
FT                   dbSNP:rs757497674)"
FT                   /evidence="ECO:0000269|PubMed:8060323"
FT                   /id="VAR_001482"
FT   VARIANT         142
FT                   /note="H -> Y (in non-small cell lung carcinoma)"
FT                   /evidence="ECO:0000269|PubMed:8060323"
FT                   /id="VAR_001483"
FT   VARIANT         144
FT                   /note="R -> C (in squamous cell carcinoma;
FT                   dbSNP:rs116150891)"
FT                   /evidence="ECO:0000269|PubMed:7970734"
FT                   /id="VAR_001484"
FT   VARIANT         148
FT                   /note="A -> T (in dbSNP:rs3731249)"
FT                   /evidence="ECO:0000269|PubMed:10651484,
FT                   ECO:0000269|PubMed:7647780, ECO:0000269|PubMed:7987387,
FT                   ECO:0000269|PubMed:8595405, ECO:0000269|PubMed:8653684,
FT                   ECO:0000269|PubMed:8710906, ECO:0000269|PubMed:9328469"
FT                   /id="VAR_001486"
FT   VARIANT         150
FT                   /note="G -> V (in non-small cell lung carcinoma)"
FT                   /evidence="ECO:0000269|PubMed:8060323"
FT                   /id="VAR_001487"
FT   STRAND          4..6
FT                   /evidence="ECO:0000244|PDB:2A5E"
FT   HELIX           15..22
FT                   /evidence="ECO:0000244|PDB:1BI7"
FT   HELIX           25..32
FT                   /evidence="ECO:0000244|PDB:1BI7"
FT   TURN            33..35
FT                   /evidence="ECO:0000244|PDB:1BI7"
FT   STRAND          43..45
FT                   /evidence="ECO:0000244|PDB:1BI7"
FT   TURN            48..50
FT                   /evidence="ECO:0000244|PDB:1BI7"
FT   HELIX           57..64
FT                   /evidence="ECO:0000244|PDB:1BI7"
FT   TURN            65..67
FT                   /evidence="ECO:0000244|PDB:1BI7"
FT   TURN            75..77
FT                   /evidence="ECO:0000244|PDB:1BI7"
FT   HELIX           81..88
FT                   /evidence="ECO:0000244|PDB:1BI7"
FT   HELIX           91..100
FT                   /evidence="ECO:0000244|PDB:1BI7"
FT   STRAND          109..111
FT                   /evidence="ECO:0000244|PDB:1A5E"
FT   HELIX           114..121
FT                   /evidence="ECO:0000244|PDB:1BI7"
FT   HELIX           124..130
FT                   /evidence="ECO:0000244|PDB:1BI7"
FT   TURN            133..135
FT                   /evidence="ECO:0000244|PDB:2A5E"
FT   TURN            141..143
FT                   /evidence="ECO:0000244|PDB:1DC2"
FT   STRAND          145..147
FT                   /evidence="ECO:0000244|PDB:1DC2"
FT   STRAND          150..153
FT                   /evidence="ECO:0000244|PDB:1A5E"
FT   CONFLICT        P42771-3:54
FT                   /note="G -> R (in Ref. 2; AAD11437)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        P42771-3:112
FT                   /note="A -> T (in Ref. 2; AAD11437)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   156 AA;  16533 MW;  E59C0E6174B48255 CRC64;
     MEPAAGSSME PSADWLATAA ARGRVEEVRA LLEAGALPNA PNSYGRRPIQ VMMMGSARVA
     ELLLLHGAEP NCADPATLTR PVHDAAREGF LDTLVVLHRA GARLDVRDAW GRLPVDLAEE
     LGHRDVARYL RAAAGGTRGS NHARIDAAEG PSDIPD
//
ID   BAP1_HUMAN              Reviewed;         729 AA.
AC   Q92560; A8K993; Q6LEM0; Q7Z5E8;
DT   05-JUL-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1998, sequence version 2.
DT   02-DEC-2020, entry version 170.
DE   RecName: Full=Ubiquitin carboxyl-terminal hydrolase BAP1 {ECO:0000305};
DE            EC=3.4.19.12 {ECO:0000269|PubMed:20436459, ECO:0000269|PubMed:9528852};
DE   AltName: Full=BRCA1-associated protein 1 {ECO:0000303|PubMed:9528852};
DE   AltName: Full=Cerebral protein 6 {ECO:0000303|Ref.2};
GN   Name=BAP1 {ECO:0000303|PubMed:9528852, ECO:0000312|HGNC:HGNC:950};
GN   Synonyms=KIAA0272 {ECO:0000303|PubMed:9039502};
GN   ORFNames=hucep-6 {ECO:0000303|Ref.2};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], ENZYME ACTIVITY, FUNCTION, MUTAGENESIS OF
RP   CYS-91 AND LEU-691, INTERACTION WITH BRCA1, TISSUE SPECIFICITY, AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=B-cell;
RX   PubMed=9528852; DOI=10.1038/sj.onc.1201861;
RA   Jensen D.E., Proctor M., Marquis S.T., Gardner H.P., Ha S.I., Chodosh L.A.,
RA   Ishov A.M., Tommerup N., Vissing H., Sekido Y., Minna J., Borodovsky A.,
RA   Schultz D.C., Wilkinson K.D., Maul G.G., Barlev N., Berger S.,
RA   Prendergast G.C., Rauscher F.J. III;
RT   "BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and
RT   enhances BRCA1-mediated cell growth suppression.";
RL   Oncogene 16:1097-1112(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RA   Yoshimoto M., Yazaki M., Takayama K., Matsumoto K.;
RT   "Biological functions of a novel human gene, hucep-6, which is specifically
RT   expressed in the central nervous system.";
RL   Submitted (NOV-1996) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=9039502; DOI=10.1093/dnares/3.5.321;
RA   Nagase T., Seki N., Ishikawa K., Ohira M., Kawarabayasi Y., Ohara O.,
RA   Tanaka A., Kotani H., Miyajima N., Nomura N.;
RT   "Prediction of the coding sequences of unidentified human genes. VI. The
RT   coding sequences of 80 new genes (KIAA0201-KIAA0280) deduced by analysis of
RT   cDNA clones from cell line KG-1 and brain.";
RL   DNA Res. 3:321-329(1996).
RN   [4]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 164-729.
RC   TISSUE=Medulloblastoma;
RX   PubMed=12800201; DOI=10.1002/ijc.11208;
RA   Behrends U., Schneider I., Roessler S., Frauenknecht H., Golbeck A.,
RA   Lechner B., Eigenstetter G., Zobywalski C., Mueller-Weihrich S.,
RA   Graubner U., Schmid I., Sackerer D., Spaeth M., Goetz C., Prantl F.,
RA   Asmuss H.-P., Bise K., Mautner J.;
RT   "Novel tumor antigens identified by autologous antibody screening of
RT   childhood medulloblastoma cDNA libraries.";
RL   Int. J. Cancer 106:244-251(2003).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   INVOLVEMENT IN MESOM, AND VARIANTS CYS-63; VAL-81; TRP-91; ASP-95; ALA-315
RP   AND VAL-685.
RX   PubMed=21642991; DOI=10.1038/ng.855;
RA   Bott M., Brevet M., Taylor B.S., Shimizu S., Ito T., Wang L., Creaney J.,
RA   Lake R.A., Zakowski M.F., Reva B., Sander C., Delsite R., Powell S.,
RA   Zhou Q., Shen R., Olshen A., Rusch V., Ladanyi M.;
RT   "The nuclear deubiquitinase BAP1 is commonly inactivated by somatic
RT   mutations and 3p21.1 losses in malignant pleural mesothelioma.";
RL   Nat. Genet. 43:668-672(2011).
RN   [14]
RP   INVOLVEMENT IN TPDS.
RX   PubMed=21874003; DOI=10.1038/ng.910;
RA   Wiesner T., Obenauf A.C., Murali R., Fried I., Griewank K.G., Ulz P.,
RA   Windpassinger C., Wackernagel W., Loy S., Wolf I., Viale A., Lash A.E.,
RA   Pirun M., Socci N.D., Rutten A., Palmedo G., Abramson D., Offit K., Ott A.,
RA   Becker J.C., Cerroni L., Kutzner H., Bastian B.C., Speicher M.R.;
RT   "Germline mutations in BAP1 predispose to melanocytic tumors.";
RL   Nat. Genet. 43:1018-1021(2011).
RN   [15]
RP   INVOLVEMENT IN TPDS AND MESOM.
RX   PubMed=21874000; DOI=10.1038/ng.912;
RA   Testa J.R., Cheung M., Pei J., Below J.E., Tan Y., Sementino E., Cox N.J.,
RA   Dogan A.U., Pass H.I., Trusa S., Hesdorffer M., Nasu M., Powers A.,
RA   Rivera Z., Comertpay S., Tanji M., Gaudino G., Yang H., Carbone M.;
RT   "Germline BAP1 mutations predispose to malignant mesothelioma.";
RL   Nat. Genet. 43:1022-1025(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-292; SER-369; SER-521;
RP   SER-537; SER-585 AND SER-597, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   VARIANTS ASP-95 AND VAL-178.
RX   PubMed=10546591; DOI=10.1016/s0304-3835(99)90004-6;
RA   Jensen D.E., Rauscher F.J. III;
RT   "Defining biochemical functions for the BRCA1 tumor suppressor protein:
RT   analysis of the BRCA1 binding protein BAP1.";
RL   Cancer Lett. 143:S13-S17(1999).
RN   [19]
RP   FUNCTION.
RX   PubMed=12485996; DOI=10.1093/emboj/cdf691;
RA   Mallery D.L., Vandenberg C.J., Hiom K.;
RT   "Activation of the E3 ligase function of the BRCA1/BARD1 complex by
RT   polyubiquitin chains.";
RL   EMBO J. 21:6755-6762(2002).
RN   [20]
RP   FUNCTION, SUBCELLULAR LOCATION, NUCLEAR LOCALIZATION SIGNAL, MUTAGENESIS OF
RP   CYS-91; 656-LYS--ARG-661 AND 717-ARG--ARG-722, AND CHARACTERIZATION OF
RP   VARIANTS ASP-95 AND VAL-178.
RX   PubMed=18757409; DOI=10.1158/0008-5472.can-08-0365;
RA   Ventii K.H., Devi N.S., Friedrich K.L., Chernova T.A., Tighiouart M.,
RA   Van Meir E.G., Wilkinson K.D.;
RT   "BRCA1-associated protein-1 is a tumor suppressor that requires
RT   deubiquitinating activity and nuclear localization.";
RL   Cancer Res. 68:6953-6962(2008).
RN   [21]
RP   FUNCTION, INTERACTION WITH BARD1 AND BRCA1, AND MUTAGENESIS OF CYS-91.
RX   PubMed=19117993; DOI=10.1158/0008-5472.can-08-3355;
RA   Nishikawa H., Wu W., Koike A., Kojima R., Gomi H., Fukuda M., Ohta T.;
RT   "BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer
RT   activity.";
RL   Cancer Res. 69:111-119(2009).
RN   [22]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH HCFC1, AND MUTAGENESIS OF
RP   CYS-91 AND 363-ASN--TYR-366.
RX   PubMed=19815555; DOI=10.1074/jbc.m109.046755;
RA   Machida Y.J., Machida Y., Vashisht A.A., Wohlschlegel J.A., Dutta A.;
RT   "The deubiquitinating enzyme BAP1 regulates cell growth via interaction
RT   with HCF-1.";
RL   J. Biol. Chem. 284:34179-34188(2009).
RN   [23]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH HCFC1, AND MUTAGENESIS OF
RP   CYS-91 AND 363-ASN--TYR-366.
RX   PubMed=19188440; DOI=10.1128/mcb.01517-08;
RA   Misaghi S., Ottosen S., Izrael-Tomasevic A., Arnott D., Lamkanfi M.,
RA   Lee J., Liu J., O'Rourke K., Dixit V.M., Wilson A.C.;
RT   "Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1
RT   with cell cycle regulator host cell factor 1.";
RL   Mol. Cell. Biol. 29:2181-2192(2009).
RN   [24]
RP   FUNCTION, CATALYTIC ACTIVITY, IDENTIFICATION IN THE PR-DUB COMPLEX, AND
RP   INTERACTION WITH ASXL1.
RX   PubMed=20436459; DOI=10.1038/nature08966;
RA   Scheuermann J.C., de Ayala Alonso A.G., Oktaba K., Ly-Hartig N.,
RA   McGinty R.K., Fraterman S., Wilm M., Muir T.W., Muller J.;
RT   "Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-
RT   DUB.";
RL   Nature 465:243-247(2010).
RN   [25]
RP   FUNCTION, SUBCELLULAR LOCATION, UBIQUITINATION, NUCLEAR LOCALIZATION
RP   SIGNAL, AND MUTAGENESIS OF 691-LEU--LYS-711.
RX   PubMed=24703950; DOI=10.1016/j.molcel.2014.03.002;
RA   Mashtalir N., Daou S., Barbour H., Sen N.N., Gagnon J., Hammond-Martel I.,
RA   Dar H.H., Therrien M., Affar E.B.;
RT   "Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic
RT   sequestration mediated by the atypical ubiquitin ligase UBE2O.";
RL   Mol. Cell 54:392-406(2014).
RN   [26]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH FOXK2.
RX   PubMed=24748658; DOI=10.1093/nar/gku274;
RA   Ji Z., Mohammed H., Webber A., Ridsdale J., Han N., Carroll J.S.,
RA   Sharrocks A.D.;
RT   "The forkhead transcription factor FOXK2 acts as a chromatin targeting
RT   factor for the BAP1-containing histone deubiquitinase complex.";
RL   Nucleic Acids Res. 42:6232-6242(2014).
RN   [27]
RP   FUNCTION, INTERACTION WITH FOXK1 AND FOXK2, PHOSPHORYLATION AT THR-493, AND
RP   MUTAGENESIS OF CYS-91; SER-489; SER-492; THR-493 AND THR-495.
RX   PubMed=25451922; DOI=10.1074/jbc.m114.609834;
RA   Okino Y., Machida Y., Frankland-Searby S., Machida Y.J.;
RT   "BRCA1-associated protein 1 (BAP1) deubiquitinase antagonizes the
RT   ubiquitin-mediated activation of FoxK2 target genes.";
RL   J. Biol. Chem. 290:1580-1591(2015).
RN   [28]
RP   VARIANT PHE-47.
RX   PubMed=25080371; DOI=10.1111/cge.12472;
RA   de la Fouchardiere A., Cabaret O., Savin L., Combemale P., Schvartz H.,
RA   Penet C., Bonadona V., Soufir N., Bressac-de Paillerets B.;
RT   "Germline BAP1 mutations predispose also to multiple basal cell
RT   carcinomas.";
RL   Clin. Genet. 88:273-277(2015).
RN   [29]
RP   CHARACTERIZATION OF VARIANTS PHE-47; VAL-81; ASP-95 AND VAL-178.
RX   PubMed=26680512; DOI=10.1038/srep18462;
RA   Bhattacharya S., Hanpude P., Maiti T.K.;
RT   "Cancer associated missense mutations in BAP1 catalytic domain induce
RT   amyloidogenic aggregation: A new insight in enzymatic inactivation.";
RL   Sci. Rep. 5:18462-18462(2015).
CC   -!- FUNCTION: Deubiquitinating enzyme that plays a key role in chromatin by
CC       mediating deubiquitination of histone H2A and HCFC1 (PubMed:12485996,
CC       PubMed:18757409, PubMed:20436459, PubMed:25451922). Catalytic component
CC       of the PR-DUB complex, a complex that specifically mediates
CC       deubiquitination of histone H2A monoubiquitinated at 'Lys-119'
CC       (H2AK119ub1) (PubMed:20436459, PubMed:25451922). Does not
CC       deubiquitinate monoubiquitinated histone H2B (PubMed:20436459). Acts as
CC       a regulator of cell growth by mediating deubiquitination of HCFC1 N-
CC       terminal and C-terminal chains, with some specificity toward 'Lys-48'-
CC       linked polyubiquitin chains compared to 'Lys-63'-linked polyubiquitin
CC       chains (PubMed:19188440, PubMed:19815555). Deubiquitination of HCFC1
CC       does not lead to increase stability of HCFC1 (PubMed:19188440,
CC       PubMed:19815555). Interferes with the BRCA1 and BARD1 heterodimer
CC       activity by inhibiting their ability to mediate ubiquitination and
CC       autoubiquitination (PubMed:19117993). It however does not mediate
CC       deubiquitination of BRCA1 and BARD1 (PubMed:19117993). Able to mediate
CC       autodeubiquitination via intramolecular interactions to couteract
CC       monoubiquitination at the nuclear localization signal (NLS), thereby
CC       protecting it from cytoplasmic sequestration (PubMed:24703950). Acts as
CC       a tumor suppressor (PubMed:9528852). {ECO:0000269|PubMed:12485996,
CC       ECO:0000269|PubMed:18757409, ECO:0000269|PubMed:19117993,
CC       ECO:0000269|PubMed:19188440, ECO:0000269|PubMed:19815555,
CC       ECO:0000269|PubMed:20436459, ECO:0000269|PubMed:24703950,
CC       ECO:0000269|PubMed:25451922, ECO:0000269|PubMed:9528852}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide
CC         and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-
CC         residue protein attached to proteins as an intracellular targeting
CC         signal).; EC=3.4.19.12; Evidence={ECO:0000269|PubMed:20436459,
CC         ECO:0000269|PubMed:9528852};
CC   -!- SUBUNIT: Component of the PR-DUB complex, at least composed of BAP1 and
CC       ASXL1 (PubMed:20436459). Interacts with BRCA1 (via the RING finger)
CC       (PubMed:19117993, PubMed:9528852). Interacts (via HBM-like motif) with
CC       HCFC1 (PubMed:19188440, PubMed:19815555). Interacts (when
CC       phosphorylated at Thr-493) with FOXK1 (PubMed:25451922). Interacts
CC       (when phosphorylated at Thr-493) with FOXK2; leading to recruit the PR-
CC       DUB complex and repress FOXK2 target genes (PubMed:24748658,
CC       PubMed:25451922). {ECO:0000269|PubMed:19117993,
CC       ECO:0000269|PubMed:19188440, ECO:0000269|PubMed:19815555,
CC       ECO:0000269|PubMed:20436459, ECO:0000269|PubMed:24748658,
CC       ECO:0000269|PubMed:25451922, ECO:0000269|PubMed:9528852}.
CC   -!- INTERACTION:
CC       Q92560; Q8IXJ9: ASXL1; NbExp=7; IntAct=EBI-1791447, EBI-1646500;
CC       Q92560; P38398: BRCA1; NbExp=3; IntAct=EBI-1791447, EBI-349905;
CC       Q92560; P38398-5: BRCA1; NbExp=2; IntAct=EBI-1791447, EBI-2015072;
CC       Q92560; P51610: HCFC1; NbExp=4; IntAct=EBI-1791447, EBI-396176;
CC       Q92560; Q14573: ITPR3; NbExp=12; IntAct=EBI-1791447, EBI-351055;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:18757409,
CC       ECO:0000269|PubMed:19188440, ECO:0000269|PubMed:19815555,
CC       ECO:0000269|PubMed:24703950}. Nucleus {ECO:0000269|PubMed:18757409,
CC       ECO:0000269|PubMed:19188440, ECO:0000269|PubMed:19815555,
CC       ECO:0000269|PubMed:24703950, ECO:0000269|PubMed:24748658,
CC       ECO:0000269|PubMed:9528852}. Note=Mainly nuclear. Binds to chromatin.
CC       Localizes to the cytoplasm when monoubiquitinated by the E2/E3 hybrid
CC       ubiquitin-protein ligase UBE2O (PubMed:24703950).
CC       {ECO:0000269|PubMed:24703950}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in testis, placenta and ovary.
CC       Expressed in breast. {ECO:0000269|PubMed:9528852}.
CC   -!- PTM: Ubiquitinated: monoubiquitinated at multiple site of its nuclear
CC       localization signal (NLS) BY UBE2O, leading to cytoplasmic retention.
CC       Able to mediate autodeubiquitination via intramolecular interactions to
CC       couteract cytoplasmic retention. {ECO:0000269|PubMed:24703950}.
CC   -!- DISEASE: Mesothelioma, malignant (MESOM) [MIM:156240]: An aggressive
CC       neoplasm of the serosal lining of the chest. It appears as broad sheets
CC       of cells, with some regions containing spindle-shaped, sarcoma-like
CC       cells and other regions showing adenomatous patterns. Pleural
CC       mesotheliomas have been linked to exposure to asbestos.
CC       {ECO:0000269|PubMed:21642991, ECO:0000269|PubMed:21874000}. Note=The
CC       gene represented in this entry is involved in disease pathogenesis.
CC   -!- DISEASE: Tumor predisposition syndrome (TPDS) [MIM:614327]: A condition
CC       characterized by predisposition to develop a variety of tumors,
CC       including benign melanocytic tumors as well as several malignant
CC       tumors, including uveal melanoma, cutaneous melanoma, malignant
CC       mesothelioma on exposure to asbestos, lung adenocarcinoma and
CC       meningioma. {ECO:0000269|PubMed:21874000, ECO:0000269|PubMed:21874003}.
CC       Note=The disease is caused by mutations affecting the gene represented
CC       in this entry.
CC   -!- SIMILARITY: Belongs to the peptidase C12 family. BAP1 subfamily.
CC       {ECO:0000305}.
CC   -!- CAUTION: According to a report, interaction with FOXK2 is not dependent
CC       on phosphorylation of BAP1 (PubMed:24748658). However, it was later
CC       shown that phosphorylation at Thr-493 promotes interaction with FOXK2
CC       (PubMed:25451922). {ECO:0000269|PubMed:24748658,
CC       ECO:0000269|PubMed:25451922}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA13401.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/BAP1ID755ch3p21.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF045581; AAC15970.1; -; mRNA.
DR   EMBL; D88812; BAB46921.1; -; mRNA.
DR   EMBL; D87462; BAA13401.2; ALT_INIT; mRNA.
DR   EMBL; AK292608; BAF85297.1; -; mRNA.
DR   EMBL; CH471055; EAW65220.1; -; Genomic_DNA.
DR   EMBL; BC001596; AAH01596.1; -; mRNA.
DR   EMBL; AY130008; AAN05092.1; -; mRNA.
DR   CCDS; CCDS2853.1; -.
DR   RefSeq; NP_004647.1; NM_004656.3.
DR   SMR; Q92560; -.
DR   BioGRID; 113911; 104.
DR   ComplexPortal; CPX-414; PR-DUB complex.
DR   DIP; DIP-47004N; -.
DR   IntAct; Q92560; 59.
DR   MINT; Q92560; -.
DR   STRING; 9606.ENSP00000417132; -.
DR   BindingDB; Q92560; -.
DR   ChEMBL; CHEMBL1293314; -.
DR   MEROPS; C12.004; -.
DR   iPTMnet; Q92560; -.
DR   MetOSite; Q92560; -.
DR   PhosphoSitePlus; Q92560; -.
DR   BioMuta; BAP1; -.
DR   DMDM; 68565074; -.
DR   EPD; Q92560; -.
DR   jPOST; Q92560; -.
DR   MassIVE; Q92560; -.
DR   MaxQB; Q92560; -.
DR   PaxDb; Q92560; -.
DR   PeptideAtlas; Q92560; -.
DR   PRIDE; Q92560; -.
DR   ProteomicsDB; 75316; -.
DR   Antibodypedia; 3812; 427 antibodies.
DR   Ensembl; ENST00000460680; ENSP00000417132; ENSG00000163930.
DR   GeneID; 8314; -.
DR   KEGG; hsa:8314; -.
DR   UCSC; uc003ddx.5; human.
DR   CTD; 8314; -.
DR   DisGeNET; 8314; -.
DR   EuPathDB; HostDB:ENSG00000163930.9; -.
DR   GeneCards; BAP1; -.
DR   GeneReviews; BAP1; -.
DR   HGNC; HGNC:950; BAP1.
DR   HPA; ENSG00000163930; Low tissue specificity.
DR   MalaCards; BAP1; -.
DR   MIM; 156240; phenotype.
DR   MIM; 603089; gene.
DR   MIM; 614327; phenotype.
DR   neXtProt; NX_Q92560; -.
DR   OpenTargets; ENSG00000163930; -.
DR   Orphanet; 289539; BAP1-related tumor predisposition syndrome.
DR   Orphanet; 618; Familial melanoma.
DR   Orphanet; 2495; Meningioma.
DR   Orphanet; 39044; Uveal melanoma.
DR   PharmGKB; PA25254; -.
DR   eggNOG; KOG2778; Eukaryota.
DR   GeneTree; ENSGT00940000156388; -.
DR   HOGENOM; CLU_018316_5_0_1; -.
DR   InParanoid; Q92560; -.
DR   OMA; HDKKQQD; -.
DR   OrthoDB; 1363547at2759; -.
DR   PhylomeDB; Q92560; -.
DR   TreeFam; TF313976; -.
DR   BRENDA; 3.4.19.12; 2681.
DR   PathwayCommons; Q92560; -.
DR   Reactome; R-HSA-5689603; UCH proteinases.
DR   Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks.
DR   SIGNOR; Q92560; -.
DR   BioGRID-ORCS; 8314; 421 hits in 852 CRISPR screens.
DR   ChiTaRS; BAP1; human.
DR   GeneWiki; BAP1; -.
DR   GenomeRNAi; 8314; -.
DR   Pharos; Q92560; Tbio.
DR   PRO; PR:Q92560; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q92560; protein.
DR   Bgee; ENSG00000163930; Expressed in testis and 207 other tissues.
DR   ExpressionAtlas; Q92560; baseline and differential.
DR   Genevisible; Q92560; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0035517; C:PR-DUB complex; IDA:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0008234; F:cysteine-type peptidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0008233; F:peptidase activity; NAS:UniProtKB.
DR   GO; GO:0004843; F:thiol-dependent ubiquitin-specific protease activity; IDA:UniProtKB.
DR   GO; GO:0006464; P:cellular protein modification process; NAS:UniProtKB.
DR   GO; GO:0061519; P:macrophage homeostasis; IEA:Ensembl.
DR   GO; GO:0035522; P:monoubiquitinated histone H2A deubiquitination; IDA:UniProtKB.
DR   GO; GO:0035520; P:monoubiquitinated protein deubiquitination; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; TAS:ProtInc.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:1903955; P:positive regulation of protein targeting to mitochondrion; HMP:ParkinsonsUK-UCL.
DR   GO; GO:0016579; P:protein deubiquitination; IDA:UniProtKB.
DR   GO; GO:0071108; P:protein K48-linked deubiquitination; IMP:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; IMP:UniProtKB.
DR   GO; GO:0001558; P:regulation of cell growth; IMP:UniProtKB.
DR   GO; GO:1900015; P:regulation of cytokine production involved in inflammatory response; IEA:Ensembl.
DR   GO; GO:0010035; P:response to inorganic substance; IEA:Ensembl.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IEA:InterPro.
DR   Gene3D; 3.40.532.10; -; 1.
DR   InterPro; IPR038765; Papain-like_cys_pep_sf.
DR   InterPro; IPR001578; Peptidase_C12_UCH.
DR   InterPro; IPR036959; Peptidase_C12_UCH_sf.
DR   InterPro; IPR041507; UCH_C.
DR   PANTHER; PTHR10589; PTHR10589; 1.
DR   Pfam; PF01088; Peptidase_C12; 1.
DR   Pfam; PF18031; UCH_C; 1.
DR   PRINTS; PR00707; UBCTHYDRLASE.
DR   SUPFAM; SSF54001; SSF54001; 1.
PE   1: Evidence at protein level;
KW   Chromatin regulator; Coiled coil; Cytoplasm; Hydrolase; Nucleus;
KW   Phosphoprotein; Polymorphism; Protease; Reference proteome; Thiol protease;
KW   Ubl conjugation; Ubl conjugation pathway.
FT   CHAIN           1..729
FT                   /note="Ubiquitin carboxyl-terminal hydrolase BAP1"
FT                   /id="PRO_0000211069"
FT   REGION          596..721
FT                   /note="Interaction with BRCA1"
FT   COILED          630..661
FT                   /evidence="ECO:0000255"
FT   MOTIF           363..366
FT                   /note="HBM-like motif"
FT                   /evidence="ECO:0000269|PubMed:19188440,
FT                   ECO:0000269|PubMed:19815555, ECO:0000269|PubMed:25451922"
FT   MOTIF           717..722
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000269|PubMed:18757409,
FT                   ECO:0000269|PubMed:24703950"
FT   ACT_SITE        91
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000269|PubMed:18757409,
FT                   ECO:0000269|PubMed:19117993, ECO:0000269|PubMed:19188440,
FT                   ECO:0000269|PubMed:19815555, ECO:0000269|PubMed:25451922,
FT                   ECO:0000269|PubMed:9528852"
FT   ACT_SITE        169
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000250|UniProtKB:P09936"
FT   SITE            184
FT                   /note="Important for enzyme activity"
FT                   /evidence="ECO:0000250|UniProtKB:P09936"
FT   MOD_RES         292
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         369
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         395
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q99PU7"
FT   MOD_RES         493
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:25451922"
FT   MOD_RES         521
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         537
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         585
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         597
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   VARIANT         47
FT                   /note="I -> F (found in a primary uveal melanoma; somatic
FT                   mutation; induces cytoplasmic accumulation; loss of
FT                   deubiquitinase activity; upregulates heat shock response;
FT                   induces formation of amyloid-beta aggregates)"
FT                   /evidence="ECO:0000269|PubMed:25080371,
FT                   ECO:0000269|PubMed:26680512"
FT                   /id="VAR_075251"
FT   VARIANT         63
FT                   /note="S -> C (found in a malignant pleural mesothelioma
FT                   sample; somatic mutation; dbSNP:rs747311942)"
FT                   /evidence="ECO:0000269|PubMed:21642991"
FT                   /id="VAR_065976"
FT   VARIANT         81
FT                   /note="F -> V (found in a malignant pleural mesothelioma
FT                   sample; somatic mutation; induces cytoplasmic accumulation;
FT                   loss of deubiquitinase activity; upregulates heat shock
FT                   response; induces formation of amyloid-beta aggregates)"
FT                   /evidence="ECO:0000269|PubMed:21642991,
FT                   ECO:0000269|PubMed:26680512"
FT                   /id="VAR_065977"
FT   VARIANT         91
FT                   /note="C -> W (found in a malignant pleural mesothelioma
FT                   sample)"
FT                   /evidence="ECO:0000269|PubMed:21642991"
FT                   /id="VAR_065978"
FT   VARIANT         95
FT                   /note="A -> D (in a lung cancer sample; also found in a
FT                   malignant pleural mesothelioma cell line; induces
FT                   cytoplasmic accumulation; loss of deubiquitinase activity;
FT                   upregulates heat shock response; induces formation of
FT                   amyloid-beta aggregates)"
FT                   /evidence="ECO:0000269|PubMed:10546591,
FT                   ECO:0000269|PubMed:18757409, ECO:0000269|PubMed:21642991,
FT                   ECO:0000269|PubMed:26680512"
FT                   /id="VAR_063498"
FT   VARIANT         178
FT                   /note="G -> V (in a lung cancer sample; induces cytoplasmic
FT                   accumulation; impairs deubiquitinase activity; upregulates
FT                   heat shock response; induces formation of beta-amyloid
FT                   aggregates)"
FT                   /evidence="ECO:0000269|PubMed:10546591,
FT                   ECO:0000269|PubMed:18757409, ECO:0000269|PubMed:26680512"
FT                   /id="VAR_063499"
FT   VARIANT         315
FT                   /note="E -> A (found in a malignant pleural mesothelioma
FT                   sample; dbSNP:rs149974450)"
FT                   /evidence="ECO:0000269|PubMed:21642991"
FT                   /id="VAR_065979"
FT   VARIANT         616
FT                   /note="V -> E (in dbSNP:rs35353781)"
FT                   /id="VAR_051517"
FT   VARIANT         685
FT                   /note="E -> V (found in a malignant pleural mesothelioma
FT                   cell line)"
FT                   /evidence="ECO:0000269|PubMed:21642991"
FT                   /id="VAR_065980"
FT   MUTAGEN         91
FT                   /note="C->A,S: Abolishes enzymatic activity without
FT                   affecting its ability to interfere with BRCA1 E3 ligase
FT                   activity. Does not affect interaction with FOXK1 and
FT                   FOXK2."
FT                   /evidence="ECO:0000269|PubMed:18757409,
FT                   ECO:0000269|PubMed:19117993, ECO:0000269|PubMed:19188440,
FT                   ECO:0000269|PubMed:19815555, ECO:0000269|PubMed:25451922,
FT                   ECO:0000269|PubMed:9528852"
FT   MUTAGEN         363..366
FT                   /note="NHNY->AAAA: Abolishes interaction with HCFC1 without
FT                   affecting interaction with FOXK1 and FOXK2."
FT                   /evidence="ECO:0000269|PubMed:19188440,
FT                   ECO:0000269|PubMed:19815555, ECO:0000269|PubMed:25451922"
FT   MUTAGEN         489
FT                   /note="S->A: Does not affect interaction with FOXK1 and
FT                   FOXK2."
FT                   /evidence="ECO:0000269|PubMed:25451922"
FT   MUTAGEN         492
FT                   /note="S->A: Does not affect interaction with FOXK1 and
FT                   FOXK2."
FT                   /evidence="ECO:0000269|PubMed:25451922"
FT   MUTAGEN         493
FT                   /note="T->A,L: Abolished interaction with FOXK1 and FOXK2."
FT                   /evidence="ECO:0000269|PubMed:25451922"
FT   MUTAGEN         495
FT                   /note="T->A: Does not affect interaction with FOXK1 and
FT                   FOXK2."
FT                   /evidence="ECO:0000269|PubMed:25451922"
FT   MUTAGEN         656..661
FT                   /note="KRKKFK->AAAAAA: Does not affect nuclear
FT                   localization."
FT                   /evidence="ECO:0000269|PubMed:18757409"
FT   MUTAGEN         691..711
FT                   /note="Missing: Abolishes ubiquitination by UBE2O."
FT                   /evidence="ECO:0000269|PubMed:24703950"
FT   MUTAGEN         691
FT                   /note="L->P: Abolishes interaction with BRCA1."
FT                   /evidence="ECO:0000269|PubMed:9528852"
FT   MUTAGEN         717..722
FT                   /note="RRKRSR->AAAAAA: Abolishes nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:18757409"
SQ   SEQUENCE   729 AA;  80362 MW;  031DA03AE1841D85 CRC64;
     MNKGWLELES DPGLFTLLVE DFGVKGVQVE EIYDLQSKCQ GPVYGFIFLF KWIEERRSRR
     KVSTLVDDTS VIDDDIVNNM FFAHQLIPNS CATHALLSVL LNCSSVDLGP TLSRMKDFTK
     GFSPESKGYA IGNAPELAKA HNSHARPEPR HLPEKQNGLS AVRTMEAFHF VSYVPITGRL
     FELDGLKVYP IDHGPWGEDE EWTDKARRVI MERIGLATAG EPYHDIRFNL MAVVPDRRIK
     YEARLHVLKV NRQTVLEALQ QLIRVTQPEL IQTHKSQESQ LPEESKSASN KSPLVLEANR
     APAASEGNHT DGAEEAAGSC AQAPSHSPPN KPKLVVKPPG SSLNGVHPNP TPIVQRLPAF
     LDNHNYAKSP MQEEEDLAAG VGRSRVPVRP PQQYSDDEDD YEDDEEDDVQ NTNSALRYKG
     KGTGKPGALS GSADGQLSVL QPNTINVLAE KLKESQKDLS IPLSIKTSSG AGSPAVAVPT
     HSQPSPTPSN ESTDTASEIG SAFNSPLRSP IRSANPTRPS SPVTSHISKV LFGEDDSLLR
     VDCIRYNRAV RDLGPVISTG LLHLAEDGVL SPLALTEGGK GSSPSIRPIQ GSQGSSSPVE
     KEVVEATDSR EKTGMVRPGE PLSGEKYSPK ELLALLKCVE AEIANYEACL KEEVEKRKKF
     KIDDQRRTHN YDEFICTFIS MLAQEGMLAN LVEQNISVRR RQGVSIGRLH KQRKPDRRKR
     SRPYKAKRQ
//
ID   ING3_HUMAN              Reviewed;         418 AA.
AC   Q9NXR8; A8K790; O60394; Q567P3; Q6GMT3; Q7Z762; Q969G0; Q96DT4; Q9HC99;
AC   Q9P081;
DT   15-FEB-2005, integrated into UniProtKB/Swiss-Prot.
DT   15-FEB-2005, sequence version 2.
DT   02-DEC-2020, entry version 175.
DE   RecName: Full=Inhibitor of growth protein 3;
DE   AltName: Full=p47ING3;
GN   Name=ING3; ORFNames=HSPC301;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND ROLE IN P53 MEDIATED GROWTH
RP   SUPPRESSION.
RX   PubMed=12545155; DOI=10.1038/sj.onc.1206115;
RA   Nagashima M., Shiseki M., Pedeux R.M., Okamura S., Kitahama-Shiseki M.,
RA   Miura K., Yokota J., Harris C.C.;
RT   "A novel PHD-finger motif protein, p47ING3, modulates p53-mediated
RT   transcription, cell cycle control, and apoptosis.";
RL   Oncogene 22:343-350(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Zenklusen J.C., Green E.D.;
RT   "Cloning and characterization of p47ING3, a new member of the p33ING1
RT   family of p53 regulators.";
RL   Submitted (SEP-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Skeletal muscle;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Umbilical cord blood;
RA   Ye M., Zhang Q.-H., Zhou J., Shen Y., Wu X.-Y., Guan Z.Q., Wang L.,
RA   Fan H.-Y., Mao Y.-F., Dai M., Huang Q.-H., Chen S.-J., Chen Z.;
RT   "Human partial CDS from CD34+ stem cells.";
RL   Submitted (MAY-1999) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Uterus;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Blood, Liver, Lung, Pancreas, and Urinary bladder;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 80-92, IDENTIFICATION IN NUA4 COMPLEX, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=12963728; DOI=10.1074/jbc.c300389200;
RA   Cai Y., Jin J., Tomomori-Sato C., Sato S., Sorokina I., Parmely T.J.,
RA   Conaway R.C., Conaway J.W.;
RT   "Identification of new subunits of the multiprotein mammalian TRRAP/TIP60-
RT   containing histone acetyltransferase complex.";
RL   J. Biol. Chem. 278:42733-42736(2003).
RN   [9]
RP   REVIEW ON NUA4 COMPLEX.
RX   PubMed=15196461; DOI=10.1016/j.gde.2004.02.009;
RA   Doyon Y., Cote J.;
RT   "The highly conserved and multifunctional NuA4 HAT complex.";
RL   Curr. Opin. Genet. Dev. 14:147-154(2004).
RN   [10]
RP   FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN NUA4
RP   COMPLEX.
RX   PubMed=14966270; DOI=10.1128/mcb.24.5.1884-1896.2004;
RA   Doyon Y., Selleck W., Lane W.S., Tan S., Cote J.;
RT   "Structural and functional conservation of the NuA4 histone
RT   acetyltransferase complex from yeast to humans.";
RL   Mol. Cell. Biol. 24:1884-1896(2004).
RN   [11]
RP   IDENTIFICATION IN NUA4 COMPLEX.
RX   PubMed=16387653; DOI=10.1016/j.molcel.2005.12.007;
RA   Doyon Y., Cayrou C., Ullah M., Landry A.-J., Cote V., Selleck W.,
RA   Lane W.S., Tan S., Yang X.-J., Cote J.;
RT   "ING tumor suppressor proteins are critical regulators of chromatin
RT   acetylation required for genome expression and perpetuation.";
RL   Mol. Cell 21:51-64(2006).
RN   [12]
RP   DOMAIN PHD-TYPE ZINC-FINGER, AND INTERACTION WITH HISTONES H3K4ME3 AND
RP   H3K4ME2.
RX   PubMed=16728974; DOI=10.1038/nature04835;
RA   Shi X., Hong T., Walter K.L., Ewalt M., Michishita E., Hung T., Carney D.,
RA   Pena P., Lan F., Kaadige M.R., Lacoste N., Cayrou C., Davrazou F., Saha A.,
RA   Cairns B.R., Ayer D.E., Kutateladze T.G., Shi Y., Cote J., Chua K.F.,
RA   Gozani O.;
RT   "ING2 PHD domain links histone H3 lysine 4 methylation to active gene
RT   repression.";
RL   Nature 442:96-99(2006).
RN   [13]
RP   DOMAIN PHD-TYPE ZINC-FINGER, AND INTERACTION WITH HISTONES H3K4ME3 AND
RP   H3K4ME2.
RX   PubMed=19154204; DOI=10.1111/j.1365-313x.2009.03795.x;
RA   Lee W.Y., Lee D., Chung W.I., Kwon C.S.;
RT   "Arabidopsis ING and Alfin1-like protein families localize to the nucleus
RT   and bind to H3K4me3/2 via plant homeodomain fingers.";
RL   Plant J. 58:511-524(2009).
RN   [14]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-264, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [15]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-167, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [16]
RP   FUNCTION, AND IDENTIFICATION IN THE SWR1-LIKE COMPLEX.
RX   PubMed=24463511; DOI=10.1038/nature12922;
RA   Obri A., Ouararhni K., Papin C., Diebold M.L., Padmanabhan K., Marek M.,
RA   Stoll I., Roy L., Reilly P.T., Mak T.W., Dimitrov S., Romier C.,
RA   Hamiche A.;
RT   "ANP32E is a histone chaperone that removes H2A.Z from chromatin.";
RL   Nature 505:648-653(2014).
RN   [17]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-167, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [18]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-148; LYS-165; LYS-167 AND
RP   LYS-256, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [19]
RP   STRUCTURE BY NMR OF 362-418.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of PHD domain in inhibitor of growth protein 3 (ING3)
RT   antigen 7.";
RL   Submitted (NOV-2006) to the PDB data bank.
RN   [20]
RP   VARIANT HNSCC GLY-20.
RX   PubMed=12080476; DOI=10.1038/sj.onc.1205540;
RA   Gunduz M., Ouchida M., Fukushima K., Ito S., Jitsumori Y., Nakashima T.,
RA   Nagai N., Nishizaki K., Shimizu K.;
RT   "Allelic loss and reduced expression of the ING3, a candidate tumor
RT   suppressor gene at 7q31, in human head and neck cancers.";
RL   Oncogene 21:4462-4470(2002).
CC   -!- FUNCTION: Component of the NuA4 histone acetyltransferase (HAT) complex
CC       which is involved in transcriptional activation of select genes
CC       principally by acetylation of nucleosomal histones H4 and H2A. This
CC       modification may both alter nucleosome - DNA interactions and promote
CC       interaction of the modified histones with other proteins which
CC       positively regulate transcription. This complex may be required for the
CC       activation of transcriptional programs associated with oncogene and
CC       proto-oncogene mediated growth induction, tumor suppressor mediated
CC       growth arrest and replicative senescence, apoptosis, and DNA repair.
CC       NuA4 may also play a direct role in DNA repair when directly recruited
CC       to sites of DNA damage. Component of a SWR1-like complex that
CC       specifically mediates the removal of histone H2A.Z/H2AZ1 from the
CC       nucleosome. {ECO:0000269|PubMed:12545155, ECO:0000269|PubMed:14966270,
CC       ECO:0000269|PubMed:24463511}.
CC   -!- SUBUNIT: Interacts with H3K4me3 and to a lesser extent with H3K4me2.
CC       Component of the NuA4 histone acetyltransferase complex which contains
CC       the catalytic subunit KAT5/TIP60 and the subunits EP400, TRRAP/PAF400,
CC       BRD8/SMAP, EPC1, DMAP1/DNMAP1, RUVBL1/TIP49, RUVBL2, ING3, actin,
CC       ACTL6A/BAF53A, MORF4L1/MRG15, MORF4L2/MRGX, MRGBP, YEATS4/GAS41,
CC       VPS72/YL1 and MEAF6. The NuA4 complex interacts with MYC and the
CC       adenovirus E1A protein. HTATTIP/TIP60, EPC1, and ING3 together
CC       constitute a minimal HAT complex termed Piccolo NuA4. Component of a
CC       SWR1-like complex. {ECO:0000269|PubMed:12963728,
CC       ECO:0000269|PubMed:14966270, ECO:0000269|PubMed:16387653,
CC       ECO:0000269|PubMed:16728974, ECO:0000269|PubMed:19154204,
CC       ECO:0000269|PubMed:24463511}.
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9NXR8-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NXR8-2; Sequence=VSP_012885, VSP_012886;
CC       Name=3;
CC         IsoId=Q9NXR8-3; Sequence=VSP_012887, VSP_012888;
CC   -!- TISSUE SPECIFICITY: Expressed in brain, heart, kidney, liver, lung,
CC       ovaries, placenta, prostate, skeletal muscle, small intestine, spleen,
CC       testis and thymus.
CC   -!- DOMAIN: The PHD-type zinc finger mediates the binding to H3K4me3.
CC       {ECO:0000269|PubMed:16728974, ECO:0000269|PubMed:19154204}.
CC   -!- DISEASE: Squamous cell carcinoma of the head and neck (HNSCC)
CC       [MIM:275355]: A non-melanoma skin cancer affecting the head and neck.
CC       The hallmark of cutaneous SCC is malignant transformation of normal
CC       epidermal keratinocytes. {ECO:0000269|PubMed:12080476}. Note=The
CC       disease may be caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- MISCELLANEOUS: [Isoform 2]: May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 3]: May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the ING family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF28979.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AAH73865.1; Type=Miscellaneous discrepancy; Note=Intron retention.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF074968; AAG12172.1; -; mRNA.
DR   EMBL; AY007790; AAG23285.1; -; mRNA.
DR   EMBL; AK000096; BAA90942.1; -; mRNA.
DR   EMBL; AK291905; BAF84594.1; -; mRNA.
DR   EMBL; AF161419; AAF28979.1; ALT_FRAME; mRNA.
DR   EMBL; AL603623; CAC48260.2; -; Transcribed_RNA.
DR   EMBL; AC004537; AAQ93373.1; -; Genomic_DNA.
DR   EMBL; BC009777; AAH09777.1; -; mRNA.
DR   EMBL; BC009777; AAQ93374.1; -; mRNA.
DR   EMBL; BC010851; AAH10851.1; -; mRNA.
DR   EMBL; BC062634; AAH09776.1; -; mRNA.
DR   EMBL; BC062634; AAH62634.1; -; mRNA.
DR   EMBL; BC073865; AAH73865.1; ALT_SEQ; mRNA.
DR   EMBL; BC093091; AAH93091.1; -; mRNA.
DR   EMBL; BC093689; AAH93689.1; -; mRNA.
DR   EMBL; BC101609; AAI01610.1; -; mRNA.
DR   CCDS; CCDS35497.1; -. [Q9NXR8-2]
DR   CCDS; CCDS5778.1; -. [Q9NXR8-1]
DR   RefSeq; NP_061944.2; NM_019071.2. [Q9NXR8-1]
DR   RefSeq; NP_938008.1; NM_198267.1. [Q9NXR8-2]
DR   PDB; 1X4I; NMR; -; A=362-418.
DR   PDBsum; 1X4I; -.
DR   SMR; Q9NXR8; -.
DR   BioGRID; 120041; 63.
DR   ComplexPortal; CPX-709; Piccolo NuA4 histone acetyltransferase complex.
DR   ComplexPortal; CPX-978; NuA4 histone acetyltransferase complex.
DR   CORUM; Q9NXR8; -.
DR   DIP; DIP-34303N; -.
DR   IntAct; Q9NXR8; 39.
DR   MINT; Q9NXR8; -.
DR   STRING; 9606.ENSP00000320566; -.
DR   iPTMnet; Q9NXR8; -.
DR   PhosphoSitePlus; Q9NXR8; -.
DR   BioMuta; ING3; -.
DR   EPD; Q9NXR8; -.
DR   jPOST; Q9NXR8; -.
DR   MassIVE; Q9NXR8; -.
DR   MaxQB; Q9NXR8; -.
DR   PaxDb; Q9NXR8; -.
DR   PeptideAtlas; Q9NXR8; -.
DR   PRIDE; Q9NXR8; -.
DR   ProteomicsDB; 83128; -. [Q9NXR8-1]
DR   ProteomicsDB; 83129; -. [Q9NXR8-2]
DR   ProteomicsDB; 83130; -. [Q9NXR8-3]
DR   Antibodypedia; 31689; 227 antibodies.
DR   DNASU; 54556; -.
DR   Ensembl; ENST00000315870; ENSP00000320566; ENSG00000071243. [Q9NXR8-1]
DR   Ensembl; ENST00000339121; ENSP00000341697; ENSG00000071243. [Q9NXR8-2]
DR   Ensembl; ENST00000427726; ENSP00000410406; ENSG00000071243. [Q9NXR8-3]
DR   GeneID; 54556; -.
DR   KEGG; hsa:54556; -.
DR   UCSC; uc003vjl.4; human. [Q9NXR8-1]
DR   CTD; 54556; -.
DR   DisGeNET; 54556; -.
DR   EuPathDB; HostDB:ENSG00000071243.15; -.
DR   GeneCards; ING3; -.
DR   HGNC; HGNC:14587; ING3.
DR   HPA; ENSG00000071243; Tissue enhanced (bone).
DR   MalaCards; ING3; -.
DR   MIM; 275355; phenotype.
DR   MIM; 607493; gene.
DR   neXtProt; NX_Q9NXR8; -.
DR   OpenTargets; ENSG00000071243; -.
DR   PharmGKB; PA29875; -.
DR   eggNOG; KOG1973; Eukaryota.
DR   GeneTree; ENSGT00940000156619; -.
DR   HOGENOM; CLU_031900_0_0_1; -.
DR   InParanoid; Q9NXR8; -.
DR   OMA; DNCPYEW; -.
DR   OrthoDB; 1434088at2759; -.
DR   PhylomeDB; Q9NXR8; -.
DR   TreeFam; TF106497; -.
DR   PathwayCommons; Q9NXR8; -.
DR   Reactome; R-HSA-3214847; HATs acetylate histones.
DR   BioGRID-ORCS; 54556; 345 hits in 859 CRISPR screens.
DR   ChiTaRS; ING3; human.
DR   EvolutionaryTrace; Q9NXR8; -.
DR   GeneWiki; ING3; -.
DR   GenomeRNAi; 54556; -.
DR   Pharos; Q9NXR8; Tbio.
DR   PRO; PR:Q9NXR8; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; Q9NXR8; protein.
DR   Bgee; ENSG00000071243; Expressed in secondary oocyte and 242 other tissues.
DR   ExpressionAtlas; Q9NXR8; baseline and differential.
DR   Genevisible; Q9NXR8; HS.
DR   GO; GO:0035267; C:NuA4 histone acetyltransferase complex; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0032777; C:Piccolo NuA4 histone acetyltransferase complex; IDA:UniProtKB.
DR   GO; GO:0000812; C:Swr1 complex; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0035064; F:methylated histone binding; IDA:UniProtKB.
DR   GO; GO:0043968; P:histone H2A acetylation; IDA:UniProtKB.
DR   GO; GO:0043967; P:histone H4 acetylation; IDA:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0040008; P:regulation of growth; IEA:UniProtKB-KW.
DR   CDD; cd15585; PHD_ING3; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR042020; ING3_PHD.
DR   InterPro; IPR028651; ING_fam.
DR   InterPro; IPR024610; ING_N_histone-binding.
DR   InterPro; IPR019786; Zinc_finger_PHD-type_CS.
DR   InterPro; IPR011011; Znf_FYVE_PHD.
DR   InterPro; IPR001965; Znf_PHD.
DR   InterPro; IPR019787; Znf_PHD-finger.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR10333; PTHR10333; 1.
DR   Pfam; PF12998; ING; 1.
DR   SMART; SM01408; ING; 1.
DR   SMART; SM00249; PHD; 1.
DR   SUPFAM; SSF57903; SSF57903; 1.
DR   PROSITE; PS01359; ZF_PHD_1; 1.
DR   PROSITE; PS50016; ZF_PHD_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Chromatin regulator;
KW   Direct protein sequencing; Disease mutation; Growth regulation;
KW   Isopeptide bond; Metal-binding; Nucleus; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN           1..418
FT                   /note="Inhibitor of growth protein 3"
FT                   /id="PRO_0000212665"
FT   ZN_FING         360..409
FT                   /note="PHD-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00146"
FT   COMPBIAS        313..329
FT                   /note="Poly-Ser"
FT   METAL           363
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UK53"
FT   METAL           365
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UK53"
FT   METAL           376
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UK53"
FT   METAL           381
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UK53"
FT   METAL           387
FT                   /note="Zinc 1; via pros nitrogen"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UK53"
FT   METAL           390
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UK53"
FT   METAL           403
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UK53"
FT   METAL           406
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UK53"
FT   BINDING         362
FT                   /note="Histone H3K4me3"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UK53"
FT   BINDING         373
FT                   /note="Histone H3K4me3"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UK53"
FT   BINDING         377
FT                   /note="Histone H3K4me3"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UK53"
FT   BINDING         385
FT                   /note="Histone H3K4me3"
FT                   /evidence="ECO:0000250|UniProtKB:Q9UK53"
FT   MOD_RES         181
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VEK6"
FT   MOD_RES         264
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   CROSSLNK        148
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        165
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   CROSSLNK        167
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:25218447,
FT                   ECO:0000244|PubMed:25772364, ECO:0000244|PubMed:28112733"
FT   CROSSLNK        256
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:28112733"
FT   VAR_SEQ         90..93
FT                   /note="VDRH -> DLWN (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_012887"
FT   VAR_SEQ         90..92
FT                   /note="VDR -> QHF (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.4"
FT                   /id="VSP_012885"
FT   VAR_SEQ         93..418
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.4"
FT                   /id="VSP_012886"
FT   VAR_SEQ         94..418
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_012888"
FT   VARIANT         20
FT                   /note="D -> G (in HNSCC)"
FT                   /evidence="ECO:0000269|PubMed:12080476"
FT                   /id="VAR_021263"
FT   CONFLICT        325
FT                   /note="C -> S (in Ref. 2 and 3)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        367
FT                   /note="Q -> QV (in Ref. 5; CAC48260)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        380
FT                   /note="Missing (in Ref. 5; CAC48260)"
FT                   /evidence="ECO:0000305"
FT   STRAND          371..374
FT                   /evidence="ECO:0000244|PDB:1X4I"
FT   HELIX           388..391
FT                   /evidence="ECO:0000244|PDB:1X4I"
FT   HELIX           404..414
FT                   /evidence="ECO:0000244|PDB:1X4I"
SQ   SEQUENCE   418 AA;  46743 MW;  AA127416912D87F5 CRC64;
     MLYLEDYLEM IEQLPMDLRD RFTEMREMDL QVQNAMDQLE QRVSEFFMNA KKNKPEWREE
     QMASIKKDYY KALEDADEKV QLANQIYDLV DRHLRKLDQE LAKFKMELEA DNAGITEILE
     RRSLELDTPS QPVNNHHAHS HTPVEKRKYN PTSHHTTTDH IPEKKFKSEA LLSTLTSDAS
     KENTLGCRNN NSTASSNNAY NVNSSQPLGS YNIGSLSSGT GAGAITMAAA QAVQATAQMK
     EGRRTSSLKA SYEAFKNNDF QLGKEFSMAR ETVGYSSSSA LMTTLTQNAS SSAADSRSGR
     KSKNNNKSSS QQSSSSSSSS SLSSCSSSST VVQEISQQTT VVPESDSNSQ VDWTYDPNEP
     RYCICNQVSY GEMVGCDNQD CPIEWFHYGC VGLTEAPKGK WYCPQCTAAM KRRGSRHK
//
ID   AKT3_HUMAN              Reviewed;         479 AA.
AC   Q9Y243; Q0VAA6; Q5VTI1; Q5VTI2; Q96QV3; Q9UFP5;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   02-DEC-2020, entry version 213.
DE   RecName: Full=RAC-gamma serine/threonine-protein kinase;
DE            EC=2.7.11.1;
DE   AltName: Full=Protein kinase Akt-3;
DE   AltName: Full=Protein kinase B gamma;
DE            Short=PKB gamma;
DE   AltName: Full=RAC-PK-gamma;
DE   AltName: Full=STK-2;
GN   Name=AKT3; Synonyms=PKBG;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND MUTAGENESIS.
RX   PubMed=10092583; DOI=10.1074/jbc.274.14.9133;
RA   Brodbeck D., Cron P., Hemmings B.A.;
RT   "A human protein kinase B gamma with regulatory phosphorylation sites in
RT   the activation loop and in the C-terminal hydrophobic domain.";
RL   J. Biol. Chem. 274:9133-9136(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=10208883; DOI=10.1006/bbrc.1999.0559;
RA   Nakatani K., Sakaue H., Thompson D.A., Weigel R.J., Roth R.A.;
RT   "Identification of a human Akt3 (protein kinase B gamma) which contains the
RT   regulatory serine phosphorylation site.";
RL   Biochem. Biophys. Res. Commun. 257:906-910(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=10491192; DOI=10.1046/j.1432-1327.1999.00774.x;
RA   Masure S., Haefner B., Wesselink J.-J., Hoefnagel E., Mortier E.,
RA   Verhasselt P., Tuytelaars A., Gordon R., Richardson A.;
RT   "Molecular cloning, expression and characterization of the human
RT   serine/threonine kinase Akt-3.";
RL   Eur. J. Biochem. 265:353-360(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Li X., Yu L., Huang H., Zhang M., Zhao Y., Zhao S.;
RT   "Cloning of a novel human cDNA, STK-2, which encodes a rat serine-threonine
RT   protein kinase (STK) homolog.";
RL   Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=11230166; DOI=10.1101/gr.gr1547r;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H., Lauber J.,
RA   Duesterhoeft A., Beyer A., Koehrer K., Strack N., Mewes H.-W.,
RA   Ottenwaelder B., Obermaier B., Tampe J., Heubner D., Wambutt R., Korn B.,
RA   Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and analysis of
RT   500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND MUTAGENESIS OF THR-305
RP   AND THR-447.
RX   PubMed=11387345; DOI=10.1074/jbc.m104633200;
RA   Brodbeck D., Hill M.M., Hemmings B.A.;
RT   "Two splice variants of PKB gamma have different regulatory capacity
RT   depending on the presence or absence of the regulatory phosphorylation site
RT   Ser-472 in the C-terminal hydrophobic domain.";
RL   J. Biol. Chem. 276:29550-29558(2001).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   CHARACTERIZATION, AND PHOSPHORYLATION AT THR-305 BY PDPK1.
RX   PubMed=9512493; DOI=10.1042/bj3310299;
RA   Walker K.S., Deak M., Paterson A., Hudson K., Cohen P., Alessi D.R.;
RT   "Activation of protein kinase B beta and gamma isoforms by insulin in vivo
RT   and by 3-phosphoinositide-dependent protein kinase-1 in vitro: comparison
RT   with protein kinase B alpha.";
RL   Biochem. J. 331:299-308(1998).
RN   [11]
RP   PHOSPHORYLATION AT SER-472.
RX   PubMed=12162751; DOI=10.1021/bi026065r;
RA   Hodgkinson C.P., Sale E.M., Sale G.J.;
RT   "Characterization of PDK2 activity against protein kinase B gamma.";
RL   Biochemistry 41:10351-10359(2002).
RN   [12]
RP   INTERACTION WITH TCL1A.
RX   PubMed=11707444; DOI=10.1074/jbc.m107069200;
RA   Laine J., Kuenstle G., Obata T., Noguchi M.;
RT   "Differential regulation of Akt kinase isoforms by the members of the TCL1
RT   oncogene family.";
RL   J. Biol. Chem. 277:3743-3751(2002).
RN   [13]
RP   INTERACTION WITH TCL1A.
RX   PubMed=11839817; DOI=10.1128/mcb.22.5.1513-1525.2002;
RA   Kuenstle G., Laine J., Pierron G., Kagami S., Nakajima H., Hoh F.,
RA   Roumestand C., Stern M.H., Noguchi M.;
RT   "Identification of Akt association and oligomerization domains of the Akt
RT   kinase coactivator TCL1.";
RL   Mol. Cell. Biol. 22:1513-1525(2002).
RN   [14]
RP   INVOLVEMENT IN TUMORS.
RX   PubMed=15466193; DOI=10.1158/0008-5472.can-04-1399;
RA   Stahl J.M., Sharma A., Cheung M., Zimmerman M., Cheng J.Q., Bosenberg M.W.,
RA   Kester M., Sandirasegarane L., Robertson G.P.;
RT   "Deregulated Akt3 activity promotes development of malignant melanoma.";
RL   Cancer Res. 64:7002-7010(2004).
RN   [15]
RP   INVOLVEMENT IN CANCER.
RX   PubMed=17178867; DOI=10.1158/0008-5472.can-06-1968;
RA   Cristiano B.E., Chan J.C., Hannan K.M., Lundie N.A., Marmy-Conus N.J.,
RA   Campbell I.G., Phillips W.A., Robbie M., Hannan R.D., Pearson R.B.;
RT   "A specific role for AKT3 in the genesis of ovarian cancer through
RT   modulation of G(2)-M phase transition.";
RL   Cancer Res. 66:11718-11725(2006).
RN   [16]
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=16540465; DOI=10.1074/jbc.m601384200;
RA   Zhang X., Zhang S., Yamane H., Wahl R., Ali A., Lofgren J.A., Kendall R.L.;
RT   "Kinetic mechanism of AKT/PKB enzyme family.";
RL   J. Biol. Chem. 281:13949-13956(2006).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [18]
RP   FUNCTION.
RX   PubMed=18524868; DOI=10.1096/fj.08-106468;
RA   Wright G.L., Maroulakou I.G., Eldridge J., Liby T.L., Sridharan V.,
RA   Tsichlis P.N., Muise-Helmericks R.C.;
RT   "VEGF stimulation of mitochondrial biogenesis: requirement of AKT3
RT   kinase.";
RL   FASEB J. 22:3264-3275(2008).
RN   [19]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [20]
RP   UBIQUITINATION BY TTC3.
RX   PubMed=20059950; DOI=10.1016/j.devcel.2009.09.007;
RA   Suizu F., Hiramuki Y., Okumura F., Matsuda M., Okumura A.J., Hirata N.,
RA   Narita M., Kohno T., Yokota J., Bohgaki M., Obuse C., Hatakeyama S.,
RA   Obata T., Noguchi M.;
RT   "The E3 ligase TTC3 facilitates ubiquitination and degradation of
RT   phosphorylated Akt.";
RL   Dev. Cell 17:800-810(2009).
RN   [21]
RP   INTERACTION WITH TRAF6.
RX   PubMed=19713527; DOI=10.1126/science.1175065;
RA   Yang W.-L., Wang J., Chan C.-H., Lee S.-W., Campos A.D., Lamothe B.,
RA   Hur L., Grabiner B.C., Lin X., Darnay B.G., Lin H.-K.;
RT   "The E3 ligase TRAF6 regulates Akt ubiquitination and activation.";
RL   Science 325:1134-1138(2009).
RN   [22]
RP   SUBCELLULAR LOCATION.
RX   PubMed=20018949; DOI=10.1152/ajpcell.00375.2009;
RA   Santi S.A., Lee H.;
RT   "The Akt isoforms are present at distinct subcellular locations.";
RL   Am. J. Physiol. 298:C580-C591(2010).
RN   [23]
RP   INVOLVEMENT IN TUMORS.
RX   PubMed=20167810; DOI=10.1093/neuonc/nop026;
RA   Mure H., Matsuzaki K., Kitazato K.T., Mizobuchi Y., Kuwayama K., Kageji T.,
RA   Nagahiro S.;
RT   "Akt2 and Akt3 play a pivotal role in malignant gliomas.";
RL   Neuro-oncol. 12:221-232(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   FUNCTION.
RX   PubMed=21191416; DOI=10.1038/jid.2010.361;
RA   Moriya C., Jinnin M., Yamane K., Maruo K., Muchemwa F.C., Igata T.,
RA   Makino T., Fukushima S., Ihn H.;
RT   "Expression of matrix metalloproteinase-13 is controlled by IL-13 via
RT   PI3K/Akt3 and PKC-delta in normal human dermal fibroblasts.";
RL   J. Invest. Dermatol. 131:655-661(2011).
RN   [26]
RP   REVIEW ON FUNCTION.
RX   PubMed=21620960; DOI=10.1016/j.cellsig.2011.05.004;
RA   Hers I., Vincent E.E., Tavare J.M.;
RT   "Akt signalling in health and disease.";
RL   Cell. Signal. 23:1515-1527(2011).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-447, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (1.46 ANGSTROMS) OF 1-118.
RA   Vollmar M., Wang J., Zhang Y., Elkins J.M., Burgess-Brown N., Chaikuad A.,
RA   Pike A.C.W., Von Delft F., Bountra C., Arrowsmith C.H., Weigelt J.,
RA   Edwards A., Knapp S.;
RT   "The crystal structure of the PH domain of human Akt3 protein kinase.";
RL   Submitted (DEC-2009) to the PDB data bank.
RN   [29]
RP   VARIANT [LARGE SCALE ANALYSIS] ARG-171.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [30]
RP   VARIANT MELANOMA LYS-17, AND CHARACTERIZATION OF VARIANT MELANOMA LYS-17.
RX   PubMed=18813315; DOI=10.1038/sj.bjc.6604637;
RA   Davies M.A., Stemke-Hale K., Tellez C., Calderone T.L., Deng W.,
RA   Prieto V.G., Lazar A.J., Gershenwald J.E., Mills G.B.;
RT   "A novel AKT3 mutation in melanoma tumours and cell lines.";
RL   Br. J. Cancer 99:1265-1268(2008).
RN   [31]
RP   VARIANTS MPPH2 SER-229 AND TRP-465.
RX   PubMed=22729224; DOI=10.1038/ng.2331;
RA   Riviere J.B., Mirzaa G.M., O'Roak B.J., Beddaoui M., Alcantara D.,
RA   Conway R.L., St-Onge J., Schwartzentruber J.A., Gripp K.W., Nikkel S.M.,
RA   Worthylake T., Sullivan C.T., Ward T.R., Butler H.E., Kramer N.A.,
RA   Albrecht B., Armour C.M., Armstrong L., Caluseriu O., Cytrynbaum C.,
RA   Drolet B.A., Innes A.M., Lauzon J.L., Lin A.E., Mancini G.M.,
RA   Meschino W.S., Reggin J.D., Saggar A.K., Lerman-Sagie T., Uyanik G.,
RA   Weksberg R., Zirn B., Beaulieu C.L., Majewski J., Bulman D.E.,
RA   O'Driscoll M., Shendure J., Graham J.M. Jr., Boycott K.M., Dobyns W.B.;
RT   "De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA
RT   cause a spectrum of related megalencephaly syndromes.";
RL   Nat. Genet. 44:934-940(2012).
RN   [32]
RP   VARIANT MPPH2 LYS-17.
RX   PubMed=22729223; DOI=10.1038/ng.2329;
RA   Lee J.H., Huynh M., Silhavy J.L., Kim S., Dixon-Salazar T., Heiberg A.,
RA   Scott E., Bafna V., Hill K.J., Collazo A., Funari V., Russ C.,
RA   Gabriel S.B., Mathern G.W., Gleeson J.G.;
RT   "De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway
RT   cause hemimegalencephaly.";
RL   Nat. Genet. 44:941-945(2012).
RN   [33]
RP   VARIANT MPPH2 LYS-17.
RX   PubMed=22500628; DOI=10.1016/j.neuron.2012.03.010;
RA   Poduri A., Evrony G.D., Cai X., Elhosary P.C., Beroukhim R., Lehtinen M.K.,
RA   Hills L.B., Heinzen E.L., Hill A., Hill R.S., Barry B.J., Bourgeois B.F.,
RA   Riviello J.J., Barkovich A.J., Black P.M., Ligon K.L., Walsh C.A.;
RT   "Somatic activation of AKT3 causes hemispheric developmental brain
RT   malformations.";
RL   Neuron 74:41-48(2012).
RN   [34]
RP   VARIANT MPPH2 SER-229.
RX   PubMed=23745724; DOI=10.1111/cge.12188;
RA   Nakamura K., Kato M., Tohyama J., Shiohama T., Hayasaka K., Nishiyama K.,
RA   Kodera H., Nakashima M., Tsurusaki Y., Miyake N., Matsumoto N., Saitsu H.;
RT   "AKT3 and PIK3R2 mutations in two patients with megalencephaly-related
RT   syndromes: MCAP and MPPH.";
RL   Clin. Genet. 85:396-398(2014).
CC   -!- FUNCTION: AKT3 is one of 3 closely related serine/threonine-protein
CC       kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate
CC       many processes including metabolism, proliferation, cell survival,
CC       growth and angiogenesis. This is mediated through serine and/or
CC       threonine phosphorylation of a range of downstream substrates. Over 100
CC       substrate candidates have been reported so far, but for most of them,
CC       no isoform specificity has been reported. AKT3 is the least studied AKT
CC       isoform. It plays an important role in brain development and is crucial
CC       for the viability of malignant glioma cells. AKT3 isoform may also be
CC       the key molecule in up-regulation and down-regulation of MMP13 via
CC       IL13. Required for the coordination of mitochondrial biogenesis with
CC       growth factor-induced increases in cellular energy demands. Down-
CC       regulation by RNA interference reduces the expression of the
CC       phosphorylated form of BAD, resulting in the induction of caspase-
CC       dependent apoptosis. {ECO:0000269|PubMed:18524868,
CC       ECO:0000269|PubMed:21191416}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- ACTIVITY REGULATION: Two specific sites, one in the kinase domain (Thr-
CC       305) and the other in the C-terminal regulatory region (Ser-472), need
CC       to be phosphorylated for its full activation (By similarity). IGF-1
CC       leads to the activation of AKT3, which may play a role in regulating
CC       cell survival. {ECO:0000250}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=87.9 uM for ATP (for purified and in vitro activated AKT3)
CC         {ECO:0000269|PubMed:16540465};
CC         KM=12.4 uM for peptide substrate (for purified and in vitro activated
CC         AKT3) {ECO:0000269|PubMed:16540465};
CC         KM=118.7 uM for ATP (for recombinant myristoylated AKT3 expressed and
CC         immunoprecipitated from Rat-1 cells) {ECO:0000269|PubMed:16540465};
CC         KM=2.3 uM for peptide substrate (for recombinant myristoylated AKT3
CC         expressed and immunoprecipitated from Rat-1 cells)
CC         {ECO:0000269|PubMed:16540465};
CC   -!- SUBUNIT: Interacts (via PH domain) with TCL1A; this enhances AKT3
CC       phosphorylation and activation. Interacts with TRAF6. Interacts with
CC       KCTD20 (By similarity). Interacts with BTBD10 (By similarity).
CC       {ECO:0000250|UniProtKB:Q9WUA6, ECO:0000269|PubMed:11707444,
CC       ECO:0000269|PubMed:11839817, ECO:0000269|PubMed:19713527}.
CC   -!- INTERACTION:
CC       Q9Y243; P42574: CASP3; NbExp=2; IntAct=EBI-296115, EBI-524064;
CC       Q9Y243; Q16543: CDC37; NbExp=2; IntAct=EBI-296115, EBI-295634;
CC       Q9Y243; P53804: TTC3; NbExp=2; IntAct=EBI-296115, EBI-2681313;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:20018949}. Cytoplasm
CC       {ECO:0000269|PubMed:20018949}. Membrane {ECO:0000269|PubMed:20018949};
CC       Peripheral membrane protein {ECO:0000269|PubMed:20018949}.
CC       Note=Membrane-associated after cell stimulation leading to its
CC       translocation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=PKB gamma;
CC         IsoId=Q9Y243-1; Sequence=Displayed;
CC       Name=2; Synonyms=PKB gamma 1;
CC         IsoId=Q9Y243-2; Sequence=VSP_004947;
CC   -!- TISSUE SPECIFICITY: In adult tissues, it is highly expressed in brain,
CC       lung and kidney, but weakly in heart, testis and liver. In fetal
CC       tissues, it is highly expressed in heart, liver and brain and not at
CC       all in kidney.
CC   -!- DOMAIN: Binding of the PH domain to the phosphatidylinositol 3-kinase
CC       alpha (PI(3)K) results in its targeting to the plasma membrane.
CC   -!- PTM: Phosphorylation on Thr-305 and Ser-472 is required for full
CC       activity. {ECO:0000250}.
CC   -!- PTM: Ubiquitinated. When fully phosphorylated and translocated into the
CC       nucleus, undergoes 'Lys-48'-polyubiquitination catalyzed by TTC3,
CC       leading to its degradation by the proteasome.
CC       {ECO:0000269|PubMed:12162751, ECO:0000269|PubMed:20059950,
CC       ECO:0000269|PubMed:9512493}.
CC   -!- PTM: O-GlcNAcylation at Thr-302 and Thr-309 inhibits activating
CC       phosphorylation at Thr-305 via disrupting the interaction between AKT
CC       and PDK1. {ECO:0000250}.
CC   -!- DISEASE: Note=AKT3 is a key modulator of several tumors like melanoma,
CC       glioma and ovarian cancer. Active AKT3 increases progressively during
CC       melanoma tumor progression with highest levels present in advanced-
CC       stage metastatic melanomas. Promotes melanoma tumorigenesis by
CC       decreasing apoptosis. Plays a key role in the genesis of ovarian
CC       cancers through modulation of G2/M phase transition. With AKT2, plays a
CC       pivotal role in the biology of glioblastoma.
CC   -!- DISEASE: Megalencephaly-polymicrogyria-polydactyly-hydrocephalus
CC       syndrome 2 (MPPH2) [MIM:615937]: A syndrome characterized by
CC       megalencephaly, hydrocephalus, and polymicrogyria; polydactyly may also
CC       be seen. There is considerable phenotypic similarity between this
CC       disorder and the megalencephaly-capillary malformation syndrome.
CC       {ECO:0000269|PubMed:22500628, ECO:0000269|PubMed:22729223,
CC       ECO:0000269|PubMed:22729224, ECO:0000269|PubMed:23745724}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. RAC subfamily. {ECO:0000305}.
CC   -!- CAUTION: In light of strong homologies in the primary amino acid
CC       sequence, the 3 AKT kinases were long surmised to play redundant and
CC       overlapping roles. More recent studies has brought into question the
CC       redundancy within AKT kinase isoforms and instead pointed to isoform
CC       specific functions in different cellular events and diseases. AKT1 is
CC       more specifically involved in cellular survival pathways, by inhibiting
CC       apoptotic processes; whereas AKT2 is more specific for the insulin
CC       receptor signaling pathway. Moreover, while AKT1 and AKT2 are often
CC       implicated in many aspects of cellular transformation, the 2 isoforms
CC       act in a complementary opposing manner. The role of AKT3 is less clear,
CC       though it appears to be predominantly expressed in brain.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/AKT3ID615ch1q44.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF124141; AAD29089.1; -; mRNA.
DR   EMBL; AF135794; AAD24196.1; -; mRNA.
DR   EMBL; AF085234; AAL40392.1; -; mRNA.
DR   EMBL; AJ245709; CAB53537.1; -; mRNA.
DR   EMBL; AL117525; CAB55977.1; ALT_TERM; mRNA.
DR   EMBL; AY005799; AAF91073.1; -; mRNA.
DR   EMBL; AC096539; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL591721; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL592151; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL662889; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471148; EAW77093.1; -; Genomic_DNA.
DR   EMBL; CH471148; EAW77094.1; -; Genomic_DNA.
DR   EMBL; BC121154; AAI21155.1; -; mRNA.
DR   CCDS; CCDS31076.1; -. [Q9Y243-2]
DR   CCDS; CCDS31077.1; -. [Q9Y243-1]
DR   PIR; A59380; A59380.
DR   PIR; T17287; T17287.
DR   RefSeq; NP_001193658.1; NM_001206729.1. [Q9Y243-2]
DR   RefSeq; NP_005456.1; NM_005465.4. [Q9Y243-1]
DR   RefSeq; NP_859029.1; NM_181690.2. [Q9Y243-2]
DR   RefSeq; XP_005273051.1; XM_005272994.4.
DR   RefSeq; XP_005273052.1; XM_005272995.2.
DR   PDB; 2X18; X-ray; 1.46 A; A/B/C/D/E/F/G/H=1-118.
DR   PDBsum; 2X18; -.
DR   SMR; Q9Y243; -.
DR   BioGRID; 115318; 53.
DR   DIP; DIP-32584N; -.
DR   IntAct; Q9Y243; 40.
DR   MINT; Q9Y243; -.
DR   STRING; 9606.ENSP00000263826; -.
DR   BindingDB; Q9Y243; -.
DR   ChEMBL; CHEMBL4816; -.
DR   DrugCentral; Q9Y243; -.
DR   GuidetoPHARMACOLOGY; 2286; -.
DR   GlyGen; Q9Y243; 2 sites.
DR   iPTMnet; Q9Y243; -.
DR   PhosphoSitePlus; Q9Y243; -.
DR   BioMuta; AKT3; -.
DR   DMDM; 12643943; -.
DR   EPD; Q9Y243; -.
DR   jPOST; Q9Y243; -.
DR   MassIVE; Q9Y243; -.
DR   PaxDb; Q9Y243; -.
DR   PeptideAtlas; Q9Y243; -.
DR   PRIDE; Q9Y243; -.
DR   ProteomicsDB; 85641; -. [Q9Y243-1]
DR   ProteomicsDB; 85642; -. [Q9Y243-2]
DR   ABCD; Q9Y243; 3 sequenced antibodies.
DR   Antibodypedia; 3402; 1116 antibodies.
DR   CPTC; Q9Y243; 7 antibodies.
DR   DNASU; 10000; -.
DR   Ensembl; ENST00000263826; ENSP00000263826; ENSG00000117020. [Q9Y243-1]
DR   Ensembl; ENST00000336199; ENSP00000336943; ENSG00000117020. [Q9Y243-2]
DR   Ensembl; ENST00000366540; ENSP00000355498; ENSG00000117020. [Q9Y243-2]
DR   Ensembl; ENST00000613395; ENSP00000479922; ENSG00000275199. [Q9Y243-2]
DR   Ensembl; ENST00000619536; ENSP00000483054; ENSG00000275199. [Q9Y243-2]
DR   Ensembl; ENST00000621586; ENSP00000479081; ENSG00000275199. [Q9Y243-1]
DR   Ensembl; ENST00000673466; ENSP00000500582; ENSG00000117020. [Q9Y243-1]
DR   GeneID; 10000; -.
DR   KEGG; hsa:10000; -.
DR   UCSC; uc001hzz.2; human. [Q9Y243-1]
DR   CTD; 10000; -.
DR   DisGeNET; 10000; -.
DR   EuPathDB; HostDB:ENSG00000117020.16; -.
DR   GeneCards; AKT3; -.
DR   GeneReviews; AKT3; -.
DR   HGNC; HGNC:393; AKT3.
DR   HPA; ENSG00000117020; Low tissue specificity.
DR   MalaCards; AKT3; -.
DR   MIM; 611223; gene.
DR   MIM; 615937; phenotype.
DR   neXtProt; NX_Q9Y243; -.
DR   OpenTargets; ENSG00000117020; -.
DR   Orphanet; 99802; Hemimegalencephaly.
DR   Orphanet; 83473; Megalencephaly-polymicrogyria-postaxial polydactyly-hydrocephalus syndrome.
DR   PharmGKB; PA24686; -.
DR   eggNOG; KOG0690; Eukaryota.
DR   GeneTree; ENSGT00940000157060; -.
DR   HOGENOM; CLU_000288_11_0_1; -.
DR   InParanoid; Q9Y243; -.
DR   OMA; CQIMSVD; -.
DR   OrthoDB; 787710at2759; -.
DR   PhylomeDB; Q9Y243; -.
DR   TreeFam; TF102004; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   PathwayCommons; Q9Y243; -.
DR   Reactome; R-HSA-111447; Activation of BAD and translocation to mitochondria.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1358803; Downregulation of ERBB2:ERBB3 signaling.
DR   Reactome; R-HSA-198323; AKT phosphorylates targets in the cytosol.
DR   Reactome; R-HSA-198693; AKT phosphorylates targets in the nucleus.
DR   Reactome; R-HSA-199418; Negative regulation of the PI3K/AKT network.
DR   Reactome; R-HSA-211163; AKT-mediated inactivation of FOXO1A.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-389513; CTLA4 inhibitory signaling.
DR   Reactome; R-HSA-392451; G beta:gamma signalling through PI3Kgamma.
DR   Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes.
DR   Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer.
DR   Reactome; R-HSA-6804757; Regulation of TP53 Degradation.
DR   Reactome; R-HSA-6804758; Regulation of TP53 Activity through Acetylation.
DR   Reactome; R-HSA-6804759; Regulation of TP53 Activity through Association with Co-factors.
DR   Reactome; R-HSA-69202; Cyclin E associated events during G1/S transition.
DR   Reactome; R-HSA-69656; Cyclin A:Cdk2-associated events at S phase entry.
DR   Reactome; R-HSA-8876198; RAB GEFs exchange GTP for GDP on RABs.
DR   Reactome; R-HSA-8941332; RUNX2 regulates genes involved in cell migration.
DR   Reactome; R-HSA-8948751; Regulation of PTEN stability and activity.
DR   Reactome; R-HSA-9614399; Regulation of localization of FOXO transcription factors.
DR   Reactome; R-HSA-9634638; Estrogen-dependent nuclear events downstream of ESR-membrane signaling.
DR   SABIO-RK; Q9Y243; -.
DR   SignaLink; Q9Y243; -.
DR   SIGNOR; Q9Y243; -.
DR   BioGRID-ORCS; 10000; 4 hits in 875 CRISPR screens.
DR   ChiTaRS; AKT3; human.
DR   GeneWiki; AKT3; -.
DR   GenomeRNAi; 10000; -.
DR   Pharos; Q9Y243; Tchem.
DR   PRO; PR:Q9Y243; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q9Y243; protein.
DR   Bgee; ENSG00000117020; Expressed in neocortex and 244 other tissues.
DR   ExpressionAtlas; Q9Y243; baseline and differential.
DR   Genevisible; Q9Y243; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0048854; P:brain morphogenesis; IEA:Ensembl.
DR   GO; GO:0048873; P:homeostasis of number of cells within a tissue; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0000002; P:mitochondrial genome maintenance; IMP:UniProtKB.
DR   GO; GO:2000773; P:negative regulation of cellular senescence; IMP:BHF-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:1905653; P:positive regulation of artery morphogenesis; IEA:Ensembl.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IDA:BHF-UCL.
DR   GO; GO:0090050; P:positive regulation of cell migration involved in sprouting angiogenesis; IMP:BHF-UCL.
DR   GO; GO:0045793; P:positive regulation of cell size; IEA:Ensembl.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0032008; P:positive regulation of TOR signaling; IEA:Ensembl.
DR   GO; GO:1905564; P:positive regulation of vascular endothelial cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0007165; P:signal transduction; IMP:UniProtKB.
DR   CDD; cd01241; PH_PKB; 1.
DR   CDD; cd05593; STKc_PKB_gamma; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR034675; Akt3.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR039026; PH_PKB.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR039029; RAC_gamma-like.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR24351:SF199; PTHR24351:SF199; 1.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding; Cytoplasm;
KW   Disease mutation; Disulfide bond; Glycoprotein; Kinase; Membrane;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase;
KW   Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000244|PubMed:19413330"
FT   CHAIN           2..479
FT                   /note="RAC-gamma serine/threonine-protein kinase"
FT                   /id="PRO_0000085611"
FT   DOMAIN          5..107
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          148..405
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          406..479
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   NP_BIND         154..162
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   ACT_SITE        271
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         177
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0000244|PubMed:19413330"
FT   MOD_RES         305
FT                   /note="Phosphothreonine; by PDPK1"
FT                   /evidence="ECO:0000269|PubMed:9512493"
FT   MOD_RES         447
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   MOD_RES         472
FT                   /note="Phosphoserine; by PKC/PRKCZ"
FT                   /evidence="ECO:0000269|PubMed:12162751"
FT   CARBOHYD        302
FT                   /note="O-linked (GlcNAc) threonine"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        309
FT                   /note="O-linked (GlcNAc) threonine"
FT                   /evidence="ECO:0000250"
FT   DISULFID        59..76
FT                   /evidence="ECO:0000250"
FT   DISULFID        293..307
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         452..479
FT                   /note="YDEDGMDCMDNERRPHFPQFSYSASGRE -> CQQSDCGMLGNWKK (in
FT                   isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11230166,
FT                   ECO:0000303|PubMed:11387345, ECO:0000303|PubMed:15489334"
FT                   /id="VSP_004947"
FT   VARIANT         17
FT                   /note="E -> K (in MPPH2 and melanoma; results in activation
FT                   of AKT; dbSNP:rs397514606)"
FT                   /evidence="ECO:0000269|PubMed:18813315,
FT                   ECO:0000269|PubMed:22500628, ECO:0000269|PubMed:22729223"
FT                   /id="VAR_065830"
FT   VARIANT         171
FT                   /note="G -> R (in a glioblastoma multiforme sample; somatic
FT                   mutation; dbSNP:rs1402272180)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040358"
FT   VARIANT         229
FT                   /note="N -> S (in MPPH2; dbSNP:rs397514605)"
FT                   /evidence="ECO:0000269|PubMed:22729224,
FT                   ECO:0000269|PubMed:23745724"
FT                   /id="VAR_069260"
FT   VARIANT         465
FT                   /note="R -> W (in MPPH2; disease phenotype overlaps with
FT                   megalencephaly-capillary malformation syndrome;
FT                   dbSNP:rs587776935)"
FT                   /evidence="ECO:0000269|PubMed:22729224"
FT                   /id="VAR_069261"
FT   MUTAGEN         305
FT                   /note="T->A: No activation after pervanadate treatment."
FT                   /evidence="ECO:0000269|PubMed:11387345"
FT   MUTAGEN         305
FT                   /note="T->D: 2-fold increase of phosphorylation steady
FT                   state level, no activation after pervanadate treatment."
FT                   /evidence="ECO:0000269|PubMed:11387345"
FT   MUTAGEN         447
FT                   /note="T->A: No effect."
FT                   /evidence="ECO:0000269|PubMed:11387345"
FT   MUTAGEN         447
FT                   /note="T->D: No effect."
FT                   /evidence="ECO:0000269|PubMed:11387345"
FT   MUTAGEN         472
FT                   /note="S->A: 67% decrease of activity after pervanadate
FT                   treatment."
FT                   /evidence="ECO:0000269|PubMed:10092583"
FT   MUTAGEN         472
FT                   /note="S->D: 1.4-fold increase of phosphorylation steady
FT                   state level, 50% decrease of activity after pervanadate
FT                   treatment."
FT                   /evidence="ECO:0000269|PubMed:10092583"
FT   CONFLICT        279
FT                   /note="L -> R (in Ref. 9; AAI21155)"
FT                   /evidence="ECO:0000305"
FT   STRAND          6..15
FT                   /evidence="ECO:0000244|PDB:2X18"
FT   STRAND          17..30
FT                   /evidence="ECO:0000244|PDB:2X18"
FT   STRAND          33..41
FT                   /evidence="ECO:0000244|PDB:2X18"
FT   HELIX           44..46
FT                   /evidence="ECO:0000244|PDB:2X18"
FT   STRAND          51..55
FT                   /evidence="ECO:0000244|PDB:2X18"
FT   STRAND          60..64
FT                   /evidence="ECO:0000244|PDB:2X18"
FT   STRAND          66..68
FT                   /evidence="ECO:0000244|PDB:2X18"
FT   STRAND          71..75
FT                   /evidence="ECO:0000244|PDB:2X18"
FT   TURN            80..82
FT                   /evidence="ECO:0000244|PDB:2X18"
FT   STRAND          84..88
FT                   /evidence="ECO:0000244|PDB:2X18"
FT   HELIX           92..113
FT                   /evidence="ECO:0000244|PDB:2X18"
SQ   SEQUENCE   479 AA;  55775 MW;  F08BDDE6502E78FB CRC64;
     MSDVTIVKEG WVQKRGEYIK NWRPRYFLLK TDGSFIGYKE KPQDVDLPYP LNNFSVAKCQ
     LMKTERPKPN TFIIRCLQWT TVIERTFHVD TPEEREEWTE AIQAVADRLQ RQEEERMNCS
     PTSQIDNIGE EEMDASTTHH KRKTMNDFDY LKLLGKGTFG KVILVREKAS GKYYAMKILK
     KEVIIAKDEV AHTLTESRVL KNTRHPFLTS LKYSFQTKDR LCFVMEYVNG GELFFHLSRE
     RVFSEDRTRF YGAEIVSALD YLHSGKIVYR DLKLENLMLD KDGHIKITDF GLCKEGITDA
     ATMKTFCGTP EYLAPEVLED NDYGRAVDWW GLGVVMYEMM CGRLPFYNQD HEKLFELILM
     EDIKFPRTLS SDAKSLLSGL LIKDPNKRLG GGPDDAKEIM RHSFFSGVNW QDVYDKKLVP
     PFKPQVTSET DTRYFDEEFT AQTITITPPE KYDEDGMDCM DNERRPHFPQ FSYSASGRE
//
